<SEC-DOCUMENT>0001161697-23-000158.txt : 20230308
<SEC-HEADER>0001161697-23-000158.hdr.sgml : 20230308
<ACCEPTANCE-DATETIME>20230308163823
ACCESSION NUMBER:		0001161697-23-000158
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		65
CONFORMED PERIOD OF REPORT:	20221231
FILED AS OF DATE:		20230308
DATE AS OF CHANGE:		20230308

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			KORU Medical Systems, Inc.
		CENTRAL INDEX KEY:			0000704440
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		IRS NUMBER:				133044880
		STATE OF INCORPORATION:			NY
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39086
		FILM NUMBER:		23716657

	BUSINESS ADDRESS:	
		STREET 1:		100 CORPORATE DRIVE
		CITY:			MAHWAH
		STATE:			NJ
		ZIP:			07430
		BUSINESS PHONE:		845-469-2042

	MAIL ADDRESS:	
		STREET 1:		100 CORPORATE DRIVE
		CITY:			MAHWAH
		STATE:			NJ
		ZIP:			07430

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	REPRO MED SYSTEMS INC
		DATE OF NAME CHANGE:	19920703
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>form_10-k.htm
<DESCRIPTION>FORM 10-K ANNUAL REPORT FOR 12-31-2022
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:us-gaap-supplement="http://fasb.org/us-gaap-sup/2022q3" xmlns:srt-supplement="http://fasb.org/srt-sup/2022q3" xmlns:us-roles="http://fasb.org/us-roles/2022" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:country="http://xbrl.sec.gov/country/2022" xmlns:srt="http://fasb.org/srt/2022" xmlns:krmd="http://korumedical.com/20221231">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html" />
</head>
<!-- Field: Set; Name: xdx; ID: xdx_02B_US%2DGAAP%2D2022 -->
<!-- Field: Set; Name: xdx; ID: xdx_03B_krmd_korumedical.com_20221231 -->
<!-- Field: Set; Name: xdx; ID: xdx_048_20220101_20221231 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DEntityCentralIndexKey_0000704440 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_051_edei%2D%2DCurrentFiscalYearEndDate_%2D%2DLS0xMi0zMQ== -->
<!-- Field: Set; Name: xdx; ID: xdx_050_edei%2D%2DDocumentFiscalYearFocus_2022 -->
<!-- Field: Set; Name: xdx; ID: xdx_05A_edei%2D%2DDocumentFiscalPeriodFocus_FY -->
<!-- Field: Set; Name: xdx; ID: xdx_078_XDX_D%2D%2D\EDGARbiz\Clients (D)\KORU (fka Repro%2DMed)\10%2DK 2022%2D12%2D31 KORU\KORU__Med__10k__12%2D31%2D2022.xdx -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_069_Pure_4_xbrli%2D%2Dpure -->
<!-- Field: Set; Name: xdx; ID: xdx_064_N_0_Number -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="dei:EntityCentralIndexKey">0000704440</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="dei:AmendmentFlag">false</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="dei:CurrentFiscalYearEndDate">--12-31</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="dei:DocumentFiscalYearFocus">2022</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="dei:DocumentFiscalPeriodFocus">FY</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2022-01-01to2022-12-31" id="xdx2ixbrl0019" name="dei:EntityRegistrantName">KORU MEDICAL SYSTEMS, INC</ix:nonNumeric>
  <ix:nonFraction name="us-gaap:FinanceLeaseLiabilityCurrent" contextRef="AsOf2021-12-31" id="xdx2ixbrl0120" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:FinanceLeaseLiabilityNoncurrent" contextRef="AsOf2021-12-31" id="xdx2ixbrl0129" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="AsOf2021-12-31" id="xdx2ixbrl0132" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" contextRef="From2022-01-01to2022-12-31" id="xdx2ixbrl0211" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherIncome" contextRef="From2022-01-01to2022-12-31" id="xdx2ixbrl0214" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2021-01-012021-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0260" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2021-01-012021-12-31_us-gaap_TreasuryStockMember" id="xdx2ixbrl0261" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0266" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="From2021-01-012021-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0268" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="From2021-01-012021-12-31_us-gaap_TreasuryStockMember" id="xdx2ixbrl0269" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0272" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" contextRef="From2021-01-012021-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0274" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" contextRef="From2021-01-012021-12-31_us-gaap_TreasuryStockMember" id="xdx2ixbrl0275" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="krmd:NewIssuanceLitigationSettlementAmountIssuance" contextRef="From2021-01-012021-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0280" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="krmd:NewIssuanceLitigationSettlementAmountIssuance" contextRef="From2021-01-012021-12-31_us-gaap_TreasuryStockMember" id="xdx2ixbrl0281" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2021-01-012021-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0288" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2021-01-012021-12-31_us-gaap_TreasuryStockMember" id="xdx2ixbrl0289" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0294" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-01-012021-12-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0295" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-01-012021-12-31_us-gaap_TreasuryStockMember" id="xdx2ixbrl0297" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0310" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2022-01-012022-12-31_us-gaap_TreasuryStockMember" id="xdx2ixbrl0311" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0316" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0318" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="From2022-01-012022-12-31_us-gaap_TreasuryStockMember" id="xdx2ixbrl0319" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0324" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" contextRef="From2022-01-012022-12-31_us-gaap_TreasuryStockMember" id="xdx2ixbrl0325" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0332" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2022-01-012022-12-31_us-gaap_TreasuryStockMember" id="xdx2ixbrl0333" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0338" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0339" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-01-012022-12-31_us-gaap_TreasuryStockMember" id="xdx2ixbrl0341" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:GainLossOnSaleOfOtherAssets" contextRef="From2022-01-01to2022-12-31" id="xdx2ixbrl0367" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProceedsFromSaleOfProductiveAssets" contextRef="From2022-01-01to2022-12-31" id="xdx2ixbrl0415" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="krmd:CommonStockIssuanceAsSettlementForLitigation" contextRef="From2022-01-01to2022-12-31" id="xdx2ixbrl0427" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:IncomeTaxesPaidNet" contextRef="From2022-01-01to2022-12-31" id="xdx2ixbrl0460" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssued1" contextRef="From2022-01-01to2022-12-31" id="xdx2ixbrl0469" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NumberOfReportableSegments" contextRef="From2022-01-01to2022-12-31" id="xdx2ixbrl0476" decimals="INF" unitRef="N">1</ix:nonFraction>
  <ix:nonNumeric contextRef="From2022-01-012022-12-31_custom_PatentsAndTrademarksMember_srt_MinimumMember" id="xdx2ixbrl0488" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife">P6Y</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2022-01-012022-12-31_custom_PatentsAndTrademarksMember_srt_MaximumMember" id="xdx2ixbrl0490" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife">P20Y</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2022-01-012022-12-31_srt_MinimumMember_custom_FurnitureAndOfficeEquipmentMember" id="xdx2ixbrl0517" name="us-gaap:PropertyPlantAndEquipmentUsefulLife">P3Y</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2022-01-012022-12-31_srt_MaximumMember_custom_FurnitureAndOfficeEquipmentMember" id="xdx2ixbrl0518" name="us-gaap:PropertyPlantAndEquipmentUsefulLife">P10Y0M0D</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2022-01-012022-12-31_srt_MinimumMember_custom_EquipmentAndToolingMember" id="xdx2ixbrl0519" name="us-gaap:PropertyPlantAndEquipmentUsefulLife">P3Y</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2022-01-012022-12-31_srt_MaximumMember_custom_EquipmentAndToolingMember" id="xdx2ixbrl0520" name="us-gaap:PropertyPlantAndEquipmentUsefulLife">P12Y</ix:nonNumeric>
  <ix:nonFraction name="us-gaap:IncrementalCommonSharesAttributableToCallOptionsAndWarrants" contextRef="From2022-01-01to2022-12-31" id="xdx2ixbrl0541" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:IncrementalCommonSharesAttributableToCallOptionsAndWarrants" contextRef="From2021-01-012021-12-31" id="xdx2ixbrl0542" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="krmd:IncrementalCommonSharesAttributableToRestrictedStock" contextRef="From2022-01-01to2022-12-31" id="xdx2ixbrl0544" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="krmd:IncrementalCommonSharesAttributableToRestrictedStock" contextRef="From2021-01-012021-12-31" id="xdx2ixbrl0545" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2022-01-012022-12-31_us-gaap_EmployeeStockMember" id="xdx2ixbrl0560" decimals="INF" unitRef="Shares">0</ix:nonFraction>
  <ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2022-12-31" id="xdx2ixbrl0640" decimals="0" unitRef="USD">3886975</ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" contextRef="From2021-01-012021-12-31_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember" id="xdx2ixbrl0697" unitRef="Pure" xs:nil="true"></ix:nonFraction>
  <ix:nonNumeric contextRef="From2022-01-012022-12-31_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember" id="xdx2ixbrl0703" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">P10Y</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2021-01-012021-12-31_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember" id="xdx2ixbrl0705" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">P10Y</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2022-01-012022-12-31_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember_custom_ExercisePrice1Member" id="xdx2ixbrl0782" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2">P8Y9M18D</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2022-01-012022-12-31_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember" id="xdx2ixbrl0792" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">P45M</ix:nonNumeric>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" contextRef="From2022-01-012022-12-31_custom_StockOptionPlan2021Member_custom_TimeBasedSharesOptionsMember" id="xdx2ixbrl0817" unitRef="Pure" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" contextRef="From2021-01-012021-12-31_custom_StockOptionPlan2021Member_custom_TimeBasedSharesOptionsMember" id="xdx2ixbrl0819" unitRef="Pure" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments" contextRef="From2021-01-012021-12-31_custom_StockOptionPlan2021Member_custom_TimeBasedSharesOptionsMember" id="xdx2ixbrl0823" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonNumeric contextRef="From2022-01-012022-12-31_custom_StockOptionPlan2021Member_custom_TimeBasedSharesOptionsMember" id="xdx2ixbrl0825" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">P10Y</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2021-01-012021-12-31_custom_StockOptionPlan2021Member_custom_TimeBasedSharesOptionsMember" id="xdx2ixbrl0827" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">P0Y</ix:nonNumeric>
  <ix:nonFraction name="krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber2" contextRef="AsOf2020-12-31_custom_StockOptionPlan2021Member" id="xdx2ixbrl0840" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice2" contextRef="AsOf2020-12-31_custom_StockOptionPlan2021Member" id="xdx2ixbrl0841" unitRef="USDPShares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross2" contextRef="From2021-01-012021-12-31_custom_StockOptionPlan2021Member" id="xdx2ixbrl0846" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="krmd:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice2" contextRef="From2021-01-012021-12-31_custom_StockOptionPlan2021Member" id="xdx2ixbrl0847" unitRef="USDPShares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="krmd:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice2" contextRef="From2022-01-012022-12-31_custom_StockOptionPlan2021Member" id="xdx2ixbrl0851" unitRef="USDPShares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="krmd:StockIssuedDuringPeriodSharesStockOptionsExercised2" contextRef="From2021-01-012021-12-31_custom_StockOptionPlan2021Member" id="xdx2ixbrl0852" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="krmd:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice2" contextRef="From2021-01-012021-12-31_custom_StockOptionPlan2021Member" id="xdx2ixbrl0853" unitRef="USDPShares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="krmd:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice2" contextRef="From2022-01-012022-12-31_custom_StockOptionPlan2021Member" id="xdx2ixbrl0857" unitRef="USDPShares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod2" contextRef="From2021-01-012021-12-31_custom_StockOptionPlan2021Member" id="xdx2ixbrl0858" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="krmd:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice2" contextRef="From2021-01-012021-12-31_custom_StockOptionPlan2021Member" id="xdx2ixbrl0859" unitRef="USDPShares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice2" contextRef="AsOf2022-12-31_custom_StockOptionPlan2021Member" id="xdx2ixbrl0869" unitRef="USDPShares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="AsOf2021-12-31_custom_StockOptionPlan2021Member" id="xdx2ixbrl0870" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice2" contextRef="AsOf2021-12-31_custom_StockOptionPlan2021Member" id="xdx2ixbrl0871" unitRef="USDPShares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue2" contextRef="From2021-01-012021-12-31_custom_StockOptionPlan2021Member" id="xdx2ixbrl0874" unitRef="USDPShares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2021-01-012021-12-31_custom_StockOptionPlan2021Member" id="xdx2ixbrl0877" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2021-01-012021-12-31_custom_StockOptionPlan2021Member" id="xdx2ixbrl0881" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonNumeric contextRef="From2022-01-012022-12-31_custom_StockOptionPlan2021Member_custom_TimeBasedSharesOptionsMember_custom_ExercisePrice1Member" id="xdx2ixbrl0891" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2">P9Y3M19D</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2022-01-012022-12-31_custom_StockOptionPlan2021Member_custom_TimeBasedSharesOptionsMember" id="xdx2ixbrl0901" name="krmd:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm3">P48M</ix:nonNumeric>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" contextRef="AsOf2022-12-31_custom_StockOptionPlan2021Member" id="xdx2ixbrl0903" decimals="0" unitRef="USD">0</ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" contextRef="AsOf2021-12-31_custom_StockOptionPlan2021Member" id="xdx2ixbrl0905" decimals="0" unitRef="USD">0</ix:nonFraction>
  <ix:nonFraction name="krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber1" contextRef="AsOf2021-12-31_us-gaap_PerformanceSharesMember" id="xdx2ixbrl0910" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice1" contextRef="AsOf2021-12-31_us-gaap_PerformanceSharesMember" id="xdx2ixbrl0912" unitRef="USDPShares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="krmd:AllocatedShareBasedCompensationExpense1" contextRef="From2022-01-012022-12-31_us-gaap_PerformanceSharesMember" id="xdx2ixbrl0953" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2022-01-012022-12-31_custom_StockOptionPlan2021Member_us-gaap_StockOptionMember" id="xdx2ixbrl0957" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberUnvested" contextRef="AsOf2020-12-31_custom_RestrictedStockAwardsMember_custom_StockOptionPlan2021Member" id="xdx2ixbrl0970" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceUnvested" contextRef="AsOf2020-12-31_custom_RestrictedStockAwardsMember_custom_StockOptionPlan2021Member" id="xdx2ixbrl0971" unitRef="USDPShares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrossUnvested" contextRef="From2022-01-012022-12-31_custom_StockOptionPlan2021Member_custom_RestrictedStockAwardsMember" id="xdx2ixbrl0973" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="krmd:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePriceUnvested" contextRef="From2022-01-012022-12-31_custom_StockOptionPlan2021Member_custom_RestrictedStockAwardsMember" id="xdx2ixbrl0975" unitRef="USDPShares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodGross" contextRef="From2021-01-012021-12-31_custom_RestrictedStockAwardsMember_custom_StockOptionPlan2021Member" id="xdx2ixbrl0982" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="krmd:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice" contextRef="From2021-01-012021-12-31_custom_RestrictedStockAwardsMember_custom_StockOptionPlan2021Member" id="xdx2ixbrl0983" unitRef="USDPShares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodUnvested" contextRef="From2022-01-012022-12-31_custom_StockOptionPlan2021Member_custom_RestrictedStockAwardsMember" id="xdx2ixbrl0985" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="krmd:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePriceUnvested" contextRef="From2022-01-012022-12-31_custom_StockOptionPlan2021Member_custom_RestrictedStockAwardsMember" id="xdx2ixbrl0987" unitRef="USDPShares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodUnvested" contextRef="From2021-01-012021-12-31_custom_RestrictedStockAwardsMember_custom_StockOptionPlan2021Member" id="xdx2ixbrl0988" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="krmd:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePriceUnvested" contextRef="From2021-01-012021-12-31_custom_RestrictedStockAwardsMember_custom_StockOptionPlan2021Member" id="xdx2ixbrl0989" unitRef="USDPShares" xs:nil="true"></ix:nonFraction>
  <ix:nonNumeric contextRef="From2022-01-012022-12-31_custom_StockOptionPlan2021Member_custom_RestrictedStockAwardsMember" id="xdx2ixbrl0999" name="krmd:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm4">P21M</ix:nonNumeric>
  <ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="AsOf2021-12-31" id="xdx2ixbrl1057" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentOtherNet" contextRef="AsOf2021-12-31" id="xdx2ixbrl1072" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:FinanceLeaseLiabilityCurrent" contextRef="AsOf2021-12-31" id="xdx2ixbrl1075" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:FinanceLeaseLiabilityNoncurrent" contextRef="AsOf2021-12-31" id="xdx2ixbrl1078" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:FinanceLeaseLiability" contextRef="AsOf2021-12-31" id="xdx2ixbrl1081" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonNumeric contextRef="AsOf2022-12-31" id="xdx2ixbrl1083" name="us-gaap:LesseeOperatingLeaseRenewalTerm">P9Y8M12D</ix:nonNumeric>
  <ix:nonNumeric contextRef="AsOf2021-12-31" id="xdx2ixbrl1085" name="us-gaap:LesseeOperatingLeaseRenewalTerm">P0Y7M6D</ix:nonNumeric>
  <ix:nonNumeric contextRef="AsOf2022-12-31" id="xdx2ixbrl1087" name="us-gaap:LesseeFinanceLeaseRenewalTerm1">P4Y0M22D</ix:nonNumeric>
  <ix:nonNumeric contextRef="AsOf2021-12-31" id="xdx2ixbrl1089" name="us-gaap:LesseeFinanceLeaseRenewalTerm1">P0Y0M0D</ix:nonNumeric>
  <ix:nonFraction name="us-gaap:FinanceLeaseLiabilityPaymentsDueAfterYearFive" contextRef="AsOf2022-12-31" id="xdx2ixbrl1123" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:CurrentFederalTaxExpenseBenefit" contextRef="From2022-01-01to2022-12-31" id="xdx2ixbrl1153" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:CurrentFederalTaxExpenseBenefit" contextRef="From2021-01-012021-12-31" id="xdx2ixbrl1154" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="From2022-01-01to2022-12-31" id="xdx2ixbrl1156" decimals="0" sign="-" unitRef="USD">2014018</ix:nonFraction>
  <ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="From2022-01-01to2022-12-31" id="xdx2ixbrl1175" decimals="0" sign="-" unitRef="USD">2014018</ix:nonFraction>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="krmd-20221231.xsd" xlink:type="simple" />
  </ix:references>
 <ix:resources>
    <xbrli:context id="From2022-01-01to2022-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-03-08">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-03-08</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_TreasuryStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_TreasuryStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_us-gaap_TreasuryStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_TreasuryStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_TreasuryStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_PatentsAndTrademarksMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">krmd:PatentsAndTrademarksMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_PatentsAndTrademarksMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">krmd:PatentsAndTrademarksMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_srt_MinimumMember_custom_FurnitureAndOfficeEquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">krmd:FurnitureAndOfficeEquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_srt_MaximumMember_custom_FurnitureAndOfficeEquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">krmd:FurnitureAndOfficeEquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_srt_MinimumMember_custom_EquipmentAndToolingMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">krmd:EquipmentAndToolingMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_srt_MaximumMember_custom_EquipmentAndToolingMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">krmd:EquipmentAndToolingMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_PropertyPlantAndEquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:PropertyPlantAndEquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_us-gaap_PropertyPlantAndEquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:PropertyPlantAndEquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_EmployeeStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_us-gaap_EmployeeStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_country_US">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_country_US">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_NonUsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_us-gaap_NonUsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_FurnitureAndOfficeEquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">krmd:FurnitureAndOfficeEquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_FurnitureAndOfficeEquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">krmd:FurnitureAndOfficeEquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_LeaseholdImprovementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_LeaseholdImprovementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_ManufacturingEquipmentAndToolingMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">krmd:ManufacturingEquipmentAndToolingMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_ManufacturingEquipmentAndToolingMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">krmd:ManufacturingEquipmentAndToolingMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_StockOptionPlan2015Member_custom_ExecutiveskeyEmployeesAndConsultantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">krmd:StockOptionPlan2015Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">krmd:ExecutiveskeyEmployeesAndConsultantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_StockOptionPlan2015Member_custom_ExecutiveskeyEmployeesAndConsultantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">krmd:StockOptionPlan2015Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">krmd:ExecutiveskeyEmployeesAndConsultantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_StockOptionPlan2015Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">krmd:StockOptionPlan2015Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_StockOptionPlan2021Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">krmd:StockOptionPlan2021Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_StockOptionPlan2021Member_srt_DirectorMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">krmd:StockOptionPlan2021Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_StockOptionPlan2021Member_custom_ExecutiveMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">krmd:StockOptionPlan2021Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">krmd:ExecutiveMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-12-302021-01-02_custom_NonEmployeeDirectorAndBoardAdvisorMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">krmd:NonEmployeeDirectorAndBoardAdvisorMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-12-30</xbrli:startDate>
        <xbrli:endDate>2021-01-02</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-12-302021-01-02_srt_BoardOfDirectorsChairmanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-12-30</xbrli:startDate>
        <xbrli:endDate>2021-01-02</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-05-162021-05-18_custom_NonEmployeeDirectorAndBoardAdvisorMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">krmd:NonEmployeeDirectorAndBoardAdvisorMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-05-16</xbrli:startDate>
        <xbrli:endDate>2021-05-18</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-05-162021-05-18_srt_BoardOfDirectorsChairmanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-05-16</xbrli:startDate>
        <xbrli:endDate>2021-05-18</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-112021-04-12_custom_ChiefExecutiveOfficerLindaTharbyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">krmd:ChiefExecutiveOfficerLindaTharbyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-11</xbrli:startDate>
        <xbrli:endDate>2021-04-12</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_custom_StockOptionPlan2015Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">krmd:StockOptionPlan2015Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">krmd:StockOptionPlan2015Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">krmd:TimeBasedSharesOptionsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">krmd:StockOptionPlan2015Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">krmd:TimeBasedSharesOptionsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">krmd:StockOptionPlan2015Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">krmd:TimeBasedSharesOptionsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">krmd:StockOptionPlan2015Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">krmd:TimeBasedSharesOptionsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_custom_StockOptionPlan2021Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">krmd:StockOptionPlan2021Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_StockOptionPlan2021Member_custom_TimeBasedSharesOptionsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">krmd:StockOptionPlan2021Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">krmd:TimeBasedSharesOptionsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_custom_StockOptionPlan2021Member_custom_TimeBasedSharesOptionsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">krmd:StockOptionPlan2021Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">krmd:TimeBasedSharesOptionsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_StockOptionPlan2021Member_custom_TimeBasedSharesOptionsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">krmd:StockOptionPlan2021Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">krmd:TimeBasedSharesOptionsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_StockOptionPlan2021Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">krmd:StockOptionPlan2021Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_StockOptionPlan2021Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">krmd:StockOptionPlan2021Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_StockOptionPlan2021Member_us-gaap_StockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">krmd:StockOptionPlan2021Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_custom_StockOptionPlan2021Member_us-gaap_StockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">krmd:StockOptionPlan2021Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-04-12_custom_EmploymentAgreementMember_srt_ChiefExecutiveOfficerMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">krmd:EmploymentAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-04-12</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_StockOptionPlan2021Member_custom_RestrictedStockAwardsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">krmd:StockOptionPlan2021Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">krmd:RestrictedStockAwardsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_custom_RestrictedStockAwardsMember_custom_StockOptionPlan2021Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">krmd:RestrictedStockAwardsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">krmd:StockOptionPlan2021Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">krmd:StockOptionPlan2015Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">krmd:TimeBasedSharesOptionsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">krmd:StockOptionPlan2015Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">krmd:TimeBasedSharesOptionsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">krmd:StockOptionPlan2015Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">krmd:TimeBasedSharesOptionsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">krmd:StockOptionPlan2015Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">krmd:TimeBasedSharesOptionsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_custom_StockOptionPlan2021Member_custom_TimeBasedSharesOptionsMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">krmd:StockOptionPlan2021Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">krmd:TimeBasedSharesOptionsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_StockOptionPlan2021Member_custom_TimeBasedSharesOptionsMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">krmd:StockOptionPlan2021Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">krmd:TimeBasedSharesOptionsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_StockOptionPlan2015Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">krmd:StockOptionPlan2015Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_StockOptionPlan2015Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">krmd:StockOptionPlan2015Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_StockOptionPlan2015Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">krmd:StockOptionPlan2015Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_StockOptionPlan2021Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">krmd:StockOptionPlan2021Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember_custom_ExercisePrice1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">krmd:StockOptionPlan2015Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">krmd:TimeBasedSharesOptionsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">krmd:ExercisePrice1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember_custom_ExercisePrice1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">krmd:StockOptionPlan2015Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">krmd:TimeBasedSharesOptionsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">krmd:ExercisePrice1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_StockOptionPlan2021Member_custom_TimeBasedSharesOptionsMember_custom_ExercisePrice1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">krmd:StockOptionPlan2021Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">krmd:TimeBasedSharesOptionsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">krmd:ExercisePrice1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_StockOptionPlan2021Member_custom_TimeBasedSharesOptionsMember_custom_ExercisePrice1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">krmd:StockOptionPlan2021Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">krmd:TimeBasedSharesOptionsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">krmd:ExercisePrice1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_PerformanceSharesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_PerformanceSharesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_PerformanceSharesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_us-gaap_PerformanceSharesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_PerformanceSharesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_RestrictedStockAwardsMember_custom_StockOptionPlan2021Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">krmd:RestrictedStockAwardsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">krmd:StockOptionPlan2021Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_RestrictedStockAwardsMember_custom_StockOptionPlan2021Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">krmd:RestrictedStockAwardsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">krmd:StockOptionPlan2021Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_RestrictedStockAwardsMember_custom_StockOptionPlan2021Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">krmd:RestrictedStockAwardsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">krmd:StockOptionPlan2021Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">krmd:CustomerOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">krmd:CustomerOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-08-05_custom_AONPremiumFinanceLLCMember_custom_PromissoryNoteMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">krmd:AONPremiumFinanceLLCMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">krmd:PromissoryNoteMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-08-05</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-08-032022-08-05_custom_AONPremiumFinanceLLCMember_custom_PromissoryNoteMember_us-gaap_LineOfCreditMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">krmd:AONPremiumFinanceLLCMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">krmd:PromissoryNoteMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-08-03</xbrli:startDate>
        <xbrli:endDate>2022-08-05</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
    <xbrli:unit id="Pure">
      <xbrli:measure>xbrli:pure</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="N">
      <xbrli:measure>krmd:Number</xbrli:measure>
    </xbrli:unit>
  </ix:resources>
 </ix:header>
</div>


<div style="width: 7.5in">

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>UNITED STATES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>SECURITIES AND EXCHANGE COMMISSION</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Washington, DC 20549</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>FORM <span id="xdx_903_edei--DocumentType_c20220101__20221231_zmc9xMIGRfk4"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="dei:DocumentType">10-K</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_909_edei--DocumentAnnualReport_c20220101__20221231_zVLWfREJRcV5"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" format="ixt:booleantrue" name="dei:DocumentAnnualReport">&#9746;</ix:nonNumeric></span></span>&#160;&#160;ANNUAL
REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>For the fiscal year ended <span id="xdx_90D_edei--DocumentPeriodEndDate_c20220101__20221231_zQZmaBTFPcQ3"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate">December 31, 2022</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">OR</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_907_edei--DocumentTransitionReport_c20220101__20221231_zzJ0aFxy1XH2"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" format="ixt:booleanfalse" name="dei:DocumentTransitionReport">&#9744;</ix:nonNumeric></span></span>&#160;&#160;TRANSITION
REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">For the transition period from ____________ to __________</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Commission file number <span id="xdx_908_edei--EntityFileNumber_c20220101__20221231_zbpT7tjIl1Ea"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="dei:EntityFileNumber">0-12305</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b><span style="text-decoration: underline"><span id="xdx_908_edei--EntityRegistrantName_dxL_c20220101__20221231_zyOmCW2ZwE3" title="::XDX::KORU%20MEDICAL%20SYSTEMS%2C%20INC"><span style="-sec-ix-hidden: xdx2ixbrl0019">KORU MEDICAL SYSTEMS, INC.</span></span></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">(Exact name of registrant as specified in its charter)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; width: 7.5in; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td style="width: 3.5in; text-align: center"><b><span style="text-decoration: underline"><span id="xdx_90B_edei--EntityIncorporationStateCountryCode_c20220101__20221231_zKoLuj0ESsS4"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode">New York</ix:nonNumeric></span></span></b></td>
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 3.5in; text-align: center"><b><span style="text-decoration: underline"><span id="xdx_909_edei--EntityTaxIdentificationNumber_c20220101__20221231_zCqEeGVJs5r7"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="dei:EntityTaxIdentificationNumber">13-3044880</ix:nonNumeric></span></span></b></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">(State or other jurisdiction of incorporation or organization)</td>
    <td>&#160;</td>
    <td style="text-align: center">(I.R.S. Employer Identification No.)</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><b><span style="text-decoration: underline"><span id="xdx_903_edei--EntityAddressAddressLine1_c20220101__20221231_zulAdC6pZf42"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="dei:EntityAddressAddressLine1">100 Corporate Drive</ix:nonNumeric></span>, <span id="xdx_904_edei--EntityAddressCityOrTown_c20220101__20221231_zFVXkboYdHa1"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="dei:EntityAddressCityOrTown">Mahwah</ix:nonNumeric></span>, <span id="xdx_902_edei--EntityAddressStateOrProvince_c20220101__20221231_zSukAEtD9Njg"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" format="ixt-sec:stateprovnameen" name="dei:EntityAddressStateOrProvince">New Jersey</ix:nonNumeric></span></span></b></td>
    <td>&#160;</td>
    <td style="text-align: center"><b><span style="text-decoration: underline"><span id="xdx_902_edei--EntityAddressPostalZipCode_c20220101__20221231_zaiwW0iW3N6"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="dei:EntityAddressPostalZipCode">07430</ix:nonNumeric></span></span></b></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">(Address of principal executive offices)</td>
    <td>&#160;</td>
    <td style="text-align: center">(Zip Code)</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b><span style="text-decoration: underline">(<span id="xdx_90D_edei--CityAreaCode_c20220101__20221231_zn450KD0y6Mi"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="dei:CityAreaCode">845</ix:nonNumeric></span>)-<span id="xdx_90D_edei--LocalPhoneNumber_c20220101__20221231_zDKDBU5zBWF4"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="dei:LocalPhoneNumber">469-2042</ix:nonNumeric></span></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">Registrant&#8217;s telephone number, including area
code</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Securities registered pursuant to Section 12(b) of the Act:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; width: 7.5in; margin-right: auto">
  <tr style="vertical-align: top">
    <td style="width: 2.5in"><span style="text-decoration: underline">Title of each class</span></td>
    <td style="width: 2.5in"><span style="text-decoration: underline">Trading Symbol(s)</span></td>
    <td style="width: 2.5in"><span style="text-decoration: underline">Name of each exchange on which registered</span></td></tr>
  <tr style="vertical-align: top">
    <td><b><span id="xdx_90A_edei--Security12bTitle_c20220101__20221231_zHpdJa6tIQU8"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="dei:Security12bTitle">common stock, $0.01 par value</ix:nonNumeric></span> </b></td>
    <td><b><span id="xdx_902_edei--TradingSymbol_c20220101__20221231_zeJBY3ujleG9"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="dei:TradingSymbol">KRMD</ix:nonNumeric></span></b></td>
    <td><b><span id="xdx_908_edei--SecurityExchangeName_c20220101__20221231_zCtsZxRcJ7mg"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName">The Nasdaq Stock Market</ix:nonNumeric></span></b></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Securities registered pursuant to Section 12(g) of the Act:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b><span style="text-decoration: underline">COMMON STOCK, $.01 PAR VALUE</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">(Title of Class)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Indicate by check mark if the registrant is a well-known seasoned issuer,
as defined in Rule 405 of the Securities Act. Yes&#160;<span style="font-family: Times New Roman, Times, Serif">&#9744;</span>&#160;&#160;<span id="xdx_90E_edei--EntityWellKnownSeasonedIssuer_c20220101__20221231_z75WxcRT4Fef"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="dei:EntityWellKnownSeasonedIssuer">No</ix:nonNumeric></span>&#160;<span style="font-family: Times New Roman, Times, Serif">&#9746;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Indicate by check mark if the registrant is not required to file reports
pursuant to Section 13 or Section 15(d) of the Act. Yes&#160;<span style="font-family: Times New Roman, Times, Serif">&#9744;</span>&#160;&#160;<span id="xdx_904_edei--EntityVoluntaryFilers_c20220101__20221231_z4lEzN3Ep00b"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="dei:EntityVoluntaryFilers">No</ix:nonNumeric></span>&#160;<span style="font-family: Times New Roman, Times, Serif">&#9746;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Indicate by check mark whether the registrant (1) has filed all reports
required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter
period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.
<span id="xdx_90F_edei--EntityCurrentReportingStatus_c20220101__20221231_zHA32cpmQ4Ed"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="dei:EntityCurrentReportingStatus">Yes</ix:nonNumeric></span>&#160;<span style="font-family: Times New Roman, Times, Serif">&#9746;</span>&#160;&#160;No&#160;<span style="font-family: Times New Roman, Times, Serif">&#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Indicate by check mark whether the registrant has submitted electronically
every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T &#160;(&#167; 232.405 of this chapter) during
the preceding 12 months (or for such shorter period that the registrant was required to submit such files.) <span id="xdx_90A_edei--EntityInteractiveDataCurrent_c20220101__20221231_zhJO51ZIMdri"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="dei:EntityInteractiveDataCurrent">Yes</ix:nonNumeric></span>&#160;<span style="font-family: Times New Roman, Times, Serif">&#9746;</span>&#160;&#160;No&#160;<span style="font-family: Times New Roman, Times, Serif">&#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Indicate by check mark whether the registrant is a large accelerated filer,
an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of &#8220;large
accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221;
in Rule 12b-2 of the Exchange Act.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; width: 7.5in; margin-right: auto">
  <tr style="vertical-align: top">
    <td style="width: 3.75in">Large accelerated filer <span style="font-family: Times New Roman, Times, Serif">&#9744;</span></td>
    <td style="width: 3.75in">Accelerated filer <span style="font-family: Times New Roman, Times, Serif">&#9744;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span id="xdx_90E_edei--EntityFilerCategory_c20220101__20221231_zikAtn23Ogc7"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" format="ixt-sec:entityfilercategoryen" name="dei:EntityFilerCategory">Non-accelerated filer</ix:nonNumeric></span> <span style="font-family: Times New Roman, Times, Serif">&#9746;</span></td>
    <td>Smaller reporting company <span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90B_edei--EntitySmallBusiness_c20220101__20221231_zUy8cm09KT02"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" format="ixt:booleantrue" name="dei:EntitySmallBusiness">&#9746;</ix:nonNumeric></span></span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>Emerging growth company <span style="font-family: Times New Roman, Times, Serif"><span id="xdx_909_edei--EntityEmergingGrowthCompany_c20220101__20221231_z1L7ip5bLQoi"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" format="ixt:booleanfalse" name="dei:EntityEmergingGrowthCompany">&#9744;</ix:nonNumeric></span></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">If an emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant
to Section 13(a) of the Exchange Act. <span style="font-family: Times New Roman, Times, Serif">&#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Indicate by check mark whether the registrant has filed a report on and
attestation to its management&#8217;s assessment of the effectiveness of its internal control over financial reporting under Section 404(b)
of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. <span style="font-family: Times New Roman, Times, Serif">&#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">If securities are registered pursuant to Section 12(b) of the Act, indicate
by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously
issued financial statements. <span style="font-family: Times New Roman, Times, Serif">&#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Indicate by check mark whether any of those error corrections are restatements
that required a recovery analysis of incentive-based compensation received by any of the registrant&#8217;s executive officers during
the relevant recovery period pursuant to &#167;240.10D-1(b). <span style="font-family: Times New Roman, Times, Serif">&#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Indicate by check mark whether the registrant is a shell company (as defined
in Rule 12b-2 of the Act). Yes&#160;<span style="font-family: Times New Roman, Times, Serif">&#9744;</span>&#160;&#160;<span id="xdx_90E_edei--EntityShellCompany_c20220101__20221231_zUzsLhqejxnk"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" format="ixt:booleanfalse" name="dei:EntityShellCompany">No</ix:nonNumeric></span>&#160;<span style="font-family: Times New Roman, Times, Serif">&#9746;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Based on the closing sales price of June 30, 2022, the aggregate market
value of the voting and nonvoting common equity held by non-affiliates of the registrant was $<span id="xdx_906_edei--EntityPublicFloat_iI_c20220630_zaCygB32mAZb"><ix:nonFraction name="dei:EntityPublicFloat" contextRef="AsOf2022-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">71,872,771</ix:nonFraction></span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">As of March 8, 2023, <span id="xdx_902_edei--EntityCommonStockSharesOutstanding_iI_pid_uShares_c20230308_zAtowaBcbqMa"><ix:nonFraction name="dei:EntityCommonStockSharesOutstanding" contextRef="AsOf2023-03-08" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">45,519,164</ix:nonFraction></span> shares of common stock, $0.01 par value
per share, were outstanding, which excludes <span id="xdx_90C_eus-gaap--TreasuryStockCommonShares_iI_pid_uShares_c20230308_zC0lHcHy6MK9"><ix:nonFraction name="us-gaap:TreasuryStockCommonShares" contextRef="AsOf2023-03-08" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,420,502</ix:nonFraction></span> shares of Treasury Stock.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">DOCUMENTS INCORPORATED BY REFERENCE</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Portions of the registrant&#8217;s proxy statement for the 2023 Annual
Meeting of Shareholders are incorporated herein by reference in Part III of this Annual Report on Form 10-K to the extent stated herein.
Such proxy statement will be filed with the Securities and Exchange Commission within 120 days of the registrant&#8217;s fiscal year ended
December 31, 2022.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<hr style="border-width: 0; color: Gray; background-color: Gray; height: 2px; width: 100%" /><p style="break-before: always"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="toc"></span>&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>INDEX TO FORM 10-K</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif">
  <tr>
    <td style="vertical-align: top; width: 0.7in">&#160;</td>
    <td style="vertical-align: top; width: 6.3in">&#160;</td>
    <td style="border-bottom: Black 1pt solid; vertical-align: bottom; width: 0.5in; text-align: center">Page</td></tr>
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="text-align: center; vertical-align: bottom">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #E6E6E6">
    <td>PART I</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #E6E6E6">
    <td><a href="#a_001">Item 1.</a></td>
    <td>Business</td>
    <td style="text-align: center">1</td></tr>
  <tr style="vertical-align: top; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #E6E6E6">
    <td><a href="#a_002">Item 1A.</a></td>
    <td>Risk Factors</td>
    <td style="text-align: center">8</td></tr>
  <tr style="vertical-align: top; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #E6E6E6">
    <td><a href="#a_003">Item 1B.</a></td>
    <td>Unresolved Staff Comments</td>
    <td style="text-align: center">24</td></tr>
  <tr style="vertical-align: top; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #E6E6E6">
    <td><a href="#a_004">Item 2.</a></td>
    <td>Properties</td>
    <td style="text-align: center">24</td></tr>
  <tr style="vertical-align: top; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #E6E6E6">
    <td><a href="#a_005">Item 3.</a></td>
    <td>Legal Proceedings</td>
    <td style="text-align: center">24</td></tr>
  <tr style="vertical-align: top; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #E6E6E6">
    <td><a href="#a_006">Item 4.</a></td>
    <td>Mine Safety Disclosures</td>
    <td style="text-align: center">24</td></tr>
  <tr style="vertical-align: top; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #E6E6E6">
    <td>PART II</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #E6E6E6">
    <td><a href="#a_007">Item 5.</a></td>
    <td>Market for the Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities </td>
    <td style="text-align: center">24</td></tr>
  <tr style="vertical-align: top; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #E6E6E6">
    <td><a href="#a_008">Item 6.</a></td>
    <td>Selected Financial Data</td>
    <td style="text-align: center">24</td></tr>
  <tr style="vertical-align: top; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #E6E6E6">
    <td><a href="#a_009">Item 7.</a></td>
    <td>Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</td>
    <td style="text-align: center">24</td></tr>
  <tr style="vertical-align: top; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #E6E6E6">
    <td><a href="#a_010">Item 7A.</a></td>
    <td>Quantitative and Qualitative Disclosures about Market Risk</td>
    <td style="text-align: center">29</td></tr>
  <tr style="vertical-align: top; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #E6E6E6">
    <td><a href="#a_011">Item 8.</a></td>
    <td>Financial Statements and Supplementary Data</td>
    <td style="text-align: center">29</td></tr>
  <tr style="vertical-align: top; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #E6E6E6">
    <td><a href="#a_012">Item 9.</a></td>
    <td>Changes in and Disagreements with Accountants on Accounting and Financial Disclosures</td>
    <td style="text-align: center">47</td></tr>
  <tr style="vertical-align: top; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #E6E6E6">
    <td><a href="#a_013">Item 9A.</a></td>
    <td>Controls and Procedures</td>
    <td style="text-align: center">47</td></tr>
  <tr style="vertical-align: top; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #E6E6E6">
    <td><a href="#a_014">Item 9B.</a></td>
    <td>Other Information</td>
    <td style="text-align: center">47</td></tr>
  <tr style="vertical-align: top; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #E6E6E6">
    <td><a href="#a_015">Item 9C.</a></td>
    <td>Disclosure Regarding Foreign Jurisdictions that Prevent Inspections</td>
    <td style="text-align: center">47</td></tr>
  <tr style="vertical-align: top; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #E6E6E6">
    <td>PART III</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #E6E6E6">
    <td><a href="#a_016">Item 10.</a></td>
    <td>Directors, Executive Officers, and Corporate Governance</td>
    <td style="text-align: center">48</td></tr>
  <tr style="vertical-align: top; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #E6E6E6">
    <td><a href="#a_017">Item 11.</a></td>
    <td>Executive Compensation</td>
    <td style="text-align: center">48</td></tr>
  <tr style="vertical-align: top; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #E6E6E6">
    <td><a href="#a_018">Item 12.</a></td>
    <td>Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</td>
    <td style="text-align: center">48</td></tr>
  <tr style="vertical-align: top; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #E6E6E6">
    <td><a href="#a_019">Item 13.</a></td>
    <td>Certain Relationships and Related Transactions, and Director Independence</td>
    <td style="text-align: center">48</td></tr>
  <tr style="vertical-align: top; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #E6E6E6">
    <td><a href="#a_020">Item 14.</a></td>
    <td>Principal Accountant Fees and Services</td>
    <td style="text-align: center">48</td></tr>
  <tr style="vertical-align: top; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #E6E6E6">
    <td>PART IV</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #E6E6E6">
    <td><a href="#a_021">Item 15.</a></td>
    <td>Exhibits and Financial Statement Schedules</td>
    <td style="text-align: center">48</td></tr>
  <tr style="vertical-align: top; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #E6E6E6">
    <td><a href="#a_022">Item 16.</a></td>
    <td>Form 10-K Summary</td>
    <td style="text-align: center">50</td></tr>
  <tr style="vertical-align: top; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #E6E6E6">
    <td><a href="#a_023">Signatures</a></td>
    <td>&#160;</td>
    <td style="text-align: center">51</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>


<p style="font: 10pt TIMES NEW ROMAN, TIMES, SERIF; margin: 0; text-align: center">- ii -</p>


<hr style="border-width: 0; color: Gray; background-color: Gray; height: 2px; width: 100%" /><p style="break-before: always"></p>


<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; color: blue"><i><a href="#toc">Table of Contents</a></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>PART I</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Throughout this report, the &#8220;Company,&#8221; &#8220;KORU Medical,&#8221;
&#8220;KORU,&#8221; &#8220;we,&#8221; &#8220;us&#8221; or &#8220;our&#8221; refer to KORU Medical Systems, Inc.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>FORWARD LOOKING STATEMENTS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">This Annual Report on Form 10-K contains &#8220;forward-looking
statements&#8221; within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities
Exchange Act of 1934, as amended. &#160;Forward-looking statements can be identified by words such as: &#8220;believe,&#8221;
&#8220;plan,&#8221; &#8220;goal,&#8221; &#8220;intend,&#8221; &#8220;seek,&#8221; &#8220;expect,&#8221; &#8220;will,&#8221; and
similar references to future periods. Examples of forward-looking statements include, among others, statements we make under
&#8220;Our Strategy&#8221; in Business under Item 1 of this Form 10-K and &#8220;Liquidity and Capital Resources&#8221; in
Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations under Item 7 of this Form 10-K, and
statements regarding completion of our move to the newly leased facility including continuity of product supply, compliance with EU
MDR, transition of our outsourced manufacturing, 2023 expenses, needs for additional capital, capital investments, inventory levels,
plans for expansion of our share position and products, and increase in patient SCIg prescriptions. Forward-looking statements are
neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations,
and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the
economy and other future conditions. &#160;Because forward-looking statements relate to the future, they are subject to inherent
uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control.
&#160;Our actual results and financial condition may differ materially from those indicated in the forward-looking statements.
Therefore, readers should not rely on any of these forward-looking statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Important factors that could cause our actual results and financial condition
to differ materially from those indicated in the forward-looking statements include, among others, those discussed in this Annual Report
on Form 10-K, and in particular, the risks discussed under the caption &#8220;Risk Factors&#8221; in Item 1A, and those discussed in other
documents we file with the Securities and Exchange Commission (&#8220;SEC&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Any forward-looking statement made by us in this Annual Report on Form
10-K is based only on information currently available to us and speaks only as of the date on which it is made. &#160;We undertake no
obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a
result of new information, future developments or otherwise.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="a_001"></span>&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>ITEM 1. BUSINESS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>OUR BUSINESS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">KORU Medical develops, manufactures and markets proprietary portable
and innovative medical devices primarily for the subcutaneous drug delivery market as governed by the United States Food and Drug Administration
(the &#8220;FDA&#8221;) quality and regulatory system and international standards for quality system management. Our focus is primarily
concentrated on our mechanical infusion products, the FREEDOM Infusion Systems (which we refer to as the &#8220;FREEDOM System&#8221;
when used with one or more accessories), which include the FREEDOM60&#174; Syringe Driver, the FreedomEdge&#174; Syringe Driver, HIgH-Flo
Subcutaneous Safety Needle Sets&#8482; and Precision Flow Rate Tubing&#8482;.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Our revenues are derived from three business sources: (i) domestic
core, (ii) international core, and (iii) novel therapies. &#160;Our core domestic and international revenues consist of sales of
our syringe drivers, tubing and needles (&#8220;Product Revenue&#8221;) for the delivery of subcutaneous drugs that are FDA cleared
for use with the Freedom Infusion Systems, with the primary delivery for immunoglobulin to treat Primary Immunodeficiency Diseases
(&#8220;PIDD&#8221;) and Chronic Inflammatory Demyelinating Polyneuropathy (&#8220;CIDP&#8221;). Novel therapies consist of Product
Revenue for feasibility/clinical trials (pre-clinical studies, Phase I, Phase II, Phase III, ) of biopharmaceutical companies in the
drug development process as well as non-recurring engineering services (&#8220;NRE&#8221;) revenues (including testing and
registration services) received from biopharmaceutical companies to ready or customize the FREEDOM System for clinical and
commercial use.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>OUR MISSION</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Our mission is to improve the quality of life of patients around the world
by delivering innovative, effective, and easy-to-use drug delivery systems that can be used at home or alternate site settings, for patient
self-administration of drug therapy.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>


<p style="font: 10pt TIMES NEW ROMAN, TIMES, SERIF; margin: 0; text-align: center">- 1 -</p>


<hr style="border-width: 0; color: Gray; background-color: Gray; height: 2px; width: 100%" /><p style="break-before: always"></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; color: blue"><i><a href="#toc">Table of Contents</a></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>OUR STRATEGY</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">We plan to become a leading provider of solutions for subcutaneous large-volume
infusions defined as greater than 10ml. We intend to accomplish this objective by increasing penetration of our core subcutaneous immunoglobulin
(&#8220;SCIg&#8221;) market and extending into new subcutaneous drug therapies.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">We have identified multiple factors we believe are driving growth of the
SCIg market. These include:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 7.5in; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: center">&#8226;</td>
    <td style="width: 7in">Increasing diagnoses of Primary Immunodeficiency Diseases (&#8220;PIDD&#8221;), which often require immunoglobulin (&#8220;Ig&#8221;) treatment</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center">&#8226;</td>
    <td>New on-label indications for SCIg drugs such as Chronic Inflammatory Demyelinating Polyneuropathy (&#8220;CIDP&#8221;), Secondary Immunodeficiency Diseases (&#8220;SIDD&#8221;), and others in clinical development.</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center">&#8226;</td>
    <td>Increase in the number of available SCIg medications such as the introduction of Cutaquig&#174; and Xembify&#174; in the United States and Europe, and planned launches of Cuvitru&#174; and HyQvia&#174; in Japan</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center">&#8226;</td>
    <td>Biopharmaceutical investment in SCIg products, such as prefilled syringe formats that make infusion easier for patients, which may make more patients eligible for SCIg therapy</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center">&#8226;</td>
    <td>Increasing supply of donated plasma, which increases the global supply of Ig medications</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center">&#8226;</td>
    <td>Favorable patient preference, side effect profile, and health economics for at-home SCIg compared with intravenous Ig therapy</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">We intend to maintain and extend our leadership position in the SCIg market
through clinical and product innovation and commercial excellence. By improving our products, establishing thought leadership in subcutaneous
therapy, partnering with drug manufacturers, expanding geographically, and executing commercially, we intend to increase our overall global
share position and the number of patients prescribed SCIg over intravenous Ig.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Furthermore, we plan to expand into new therapies outside of SCIg. We estimate
that at least 100 large-volume drugs are in clinical development utilizing subcutaneous infusion. The pipeline is driven by the need to
deliver high therapeutic doses, difficulty in formulating large molecules into small volumes, nursing shortage, pharmaceutical companies
shifting development programs toward at-home subcutaneous therapy, and other factors. Biopharmaceutical manufacturers seek device partners
during the drug development process. We intend to partner with them during clinical development&#8212;generating services revenues to
prepare and customize our products for clinical use and regulatory clearance, as well as, product revenues post commercialization.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">We believe our track record of regulatory clearance and successful patient use, combined with our channel access,
position KORU to both maximize our growth in the core SCIg market and expand into new therapeutic areas.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>OUR PRODUCTS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">KORU&#8217;s infusion devices work together as a system to deliver life-saving
therapies to patients with chronic illnesses, such as PIDD and CIDP. &#160;The FREEDOM System comprises the FREEDOM60 Syringe Driver (standard
60/50ml syringe compatible) and FreedomEdge Syringe Driver (standard 30ml and 20ml syringe and prefilled syringe compatible), HIgH-Flo
Subcutaneous Safety Needle Sets and Precision Flow Rate Tubing. &#160;The systems are portable, easy to operate, maintenance free and
do not require batteries or electricity. The FREEDOM System operates at a lower pressure than an electrical, volumetric pump and maintains
a balance between what a patient&#8217;s subcutaneous tissues can tolerate what the system delivers.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Our FREEDOM System is cleared for the most on-label subcutaneous
indications including specific FDA clearance for: delivery of specific medications through subcutaneous and intravenous routes,
including specific clearance for leading immune globulins Cutaquig &#174;, Cuvitru&#174;, Hizentra&#174;, Xembify, Empaveli&#174;
(branded Aspaveli&#174; outside the United States), Gammagard Liquid&#174;, and a variety of antibiotics. The FREEDOM System is the
only infusion system specifically cleared for SCIg delivery with a prefilled syringe, the Hizentra&#174; 20ml prefilled syringe.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>


<p style="font: 10pt TIMES NEW ROMAN, TIMES, SERIF; margin: 0; text-align: center">- 2 -</p>


<hr style="border-width: 0; color: Gray; background-color: Gray; height: 2px; width: 100%" /><p style="break-before: always"></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; color: blue"><i><a href="#toc">Table of Contents</a></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Ambulatory infusion systems are most prevalent in the home care and alternate
site markets. &#160;The SCIg products delivered by the FREEDOM System are indicated for a variety of conditions, including PIDD and CIDP
in the United States and PIDD, CIDP and Secondary Immunodeficiency Disease (&#8220;SIDD&#8221;) in Europe. Empaveli&#174; is indicated
for Paroxysmal Nocturnal Hemoglobinuria (&#8220;PNH&#8221;). The use of the FREEDOM System for SCIg drug delivery continues to increase,
and it remains the market leading delivery system in the U.S. for these treatments. &#160;In recent years Hizentra&#174; has received an
expanded indication for treatment of CIDP in the United States and multiple SCIg drugs have received indications for CIDP and SID outside
of the United States. It is expected that patient access to SCIg will expand as new drugs are developed, existing drugs are approved and/or
marketed in new countries, and existing drugs receive new indications.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">HIgH-Flo Subcutaneous Safety Needle Sets are an important element of the
FREEDOM System. The needle sets are available in 26- and 24-gauge sizes and feature unique design elements specific to subcutaneous self-administration.
&#160;One such feature includes a back-cut needle designed for more comfort and less tissue damage with flexible wings to minimize patient
discomfort over prior needle set offerings.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Precision Flow Rate Tubing is designed for repeatable flow rates without
allowing unrestricted flow. &#160;The tubing regulates the flow rate and infusion time for various applications when used with the FREEDOM
System. &#160;Each tubing set provides a different level of flow restriction and consistently delivers medication with low residual volume
to minimize drug waste.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>SALES AND DISTRIBUTION</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The FREEDOM System is sold through both direct sales and medical device
distributors to pharmaceutical companies, specialty pharmacy customers and home infusion providers.&#160; Our products are sold principally
through a small number of distributors so our specialty pharmacy customers receive the benefit of remote inventory management and one-stop
shopping.&#160; We sell the majority of our products through three distributors in the U.S. and two distributors outside the U.S. &#160;As
of December 31, 2022, these five distributors comprised approximately 72% of our net revenues with one of our U.S. distributors contributing
approximately 41%.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Specialty pharmacies, home infusion providers, and distributors are our
primary sales contacts, although we provide education and training materials to clinicians, patients and patient advocates both in the
field and online.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>MANUFACTURING AND RAW MATERIALS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">We currently perform product assembly, calibration, pre- and post-assembly
quality control inspection and testing, and final packaging at our Chester, NY facility and have been transitioning those activities to
our leased facility in Mahwah, NJ. We expect to transition all remaining activities to Mahwah, NJ in March 2023. &#160;We have entered
into an agreement with Command Medical Products, Inc. (&#8220;Command&#8221;), to manufacture and supply substantially all of the Company&#8217;s
subassemblies, needle sets and tubing products for supply continuity and cost savings. We expect the transition to Command to be completed
no later than the second quarter of 2023.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Our ability to meet customer demand depends, in part, on our ability to
obtain timely and adequate delivery of components for our products. All of the components that go into the manufacturing of our products
and accessories are sourced from third-party suppliers on a single source basis. The Company uses single-source suppliers in part due
to governmental approval and validation requirements. A change in supplier, or the use of multiple suppliers of the same materials, often
would necessitate additional approvals and validations, which the Company seeks to avoid unless and until the need arises. The Company
does not have any contracts with suppliers that impose material binding obligations on the Company or provide the Company with any material
rights or benefits, other than the agreement with Command.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>RESEARCH AND DEVELOPMENT</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">We recognize the importance of innovation to our long-term success and
are committed to research and new product development activities. &#160;Our product development team along with outside engineering resources
are engaged in continuously improving existing product performance and researching new product opportunities to enhance our product portfolio.
&#160;We spent $5.0 million and $2.5 million on research and development for the years ended December 31, 2022 and 2021, respectively.
&#160;We intend to make additional investments in research and development over the next twelve months to support adding research and
development capability to develop a &#8220;next-generation&#8221; infusion pump and consumable system.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>


<p style="font: 10pt TIMES NEW ROMAN, TIMES, SERIF; margin: 0; text-align: center">- 3 -</p>


<hr style="border-width: 0; color: Gray; background-color: Gray; height: 2px; width: 100%" /><p style="break-before: always"></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; color: blue"><i><a href="#toc">Table of Contents</a></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>REGULATORY</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Our medical devices and technologies, as well as our business activities,
are subject to a complex set of regulations and rigorous enforcement, principally by the FDA, and numerous other federal, state, and non-U.S.
governmental authorities. &#160;To varying degrees, each of these agencies requires us to comply with laws and regulations governing the
development, testing, manufacturing, labeling, marketing and distribution of our products.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The FDA regulates, among other things, the research, development, testing,
manufacturing, approval, labeling, storage, recordkeeping, advertising, promotion, marketing, distribution, post approval monitoring and
reporting, import and export of medical devices in the U.S. to assure the safety and effectiveness of medical products for their intended
use. &#160;Thus, both before and after a product is commercially released, we have ongoing responsibilities under the FDA. For instance,
all medical devices marketed in the U.S. must be manufactured in accordance with the FDA&#8217;s quality system regulations (&#8220;QSRs&#8221;).
&#160;Accordingly, our facility and procedures and those of our applicable suppliers are also subject to periodic inspections by the FDA
to determine compliance with applicable laws and regulations. &#160;The Federal Trade Commission also regulates the advertising of our
products. &#160;Further, we are subject to laws directed at preventing fraud and abuse, which subject our sales and marketing, training
and other practices to government scrutiny.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Our business is also affected by patient privacy laws and government payor
cost containment initiatives, as well as environmental health and safety laws and regulations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><i>U.S. Device Classification and Clearance</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Except where an exemption applies, each new or significantly modified medical
device we seek to commercially distribute in the U.S. will require either a premarket notification to the FDA requesting permission for
commercial distribution under Section&#160;510(k) of the Federal Food, Drug and Cosmetic Act (&#8220;FFDCA&#8221;), also known as a 510(k)
clearance, approval of a pre-market approval (&#8220;PMA&#8221;) application, or as part of a drug-device combination product through
a Biologics License Application (&#8220;BLA&#8221;) or New Drug Application (&#8220;NDA&#8221;). &#160;For example, the use of our FREEDOM
System with therapies not covered by the existing FDA clearance will require additional 510(k) clearance , BLA, NDA or PMA approval.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Under the 510(k) process, applicants must demonstrate to the FDA that a
device is as safe and effective as, or substantially equivalent to, a legally marketed device, known as the &#8220;predicate&#8221; device.
&#160;Applicants must submit performance data to establish substantial equivalence. &#160;In some instances, data from human clinical
trials must also be submitted in support of a 510(k), and this data must be collected in a manner that conforms to the applicable Investigational
Device Exemption (&#8220;IDE&#8221;) regulations. &#160;The FDA must issue a substantial equivalence determination before commercial distribution
can occur. &#160;Changes to cleared devices that will not significantly affect the safety or effectiveness of the device can generally
be made without additional 510(k) submissions. &#160;Changes that will significantly affect the safety or effectiveness of the device
will require a new 510(k) prior to marketing of the modified device. &#160;We cannot predict with any certainty how future reforms to
Federal regulations may impact our business. &#160;See &#8220;ITEM 1A. RISK FACTORS.&#8221;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Under the PMA application process, the applicant must demonstrate that
the device is safe and effective for its intended use. &#160;This approval process applies to most Class III devices, and generally requires
clinical data to support the safety and effectiveness of the device, obtained in conformance with IDE regulations. &#160;The FDA will
approve a PMA application if it finds that there is a reasonable assurance that the device is safe and effective for its intended purpose,
and that the proposed manufacturing is in compliance with the QSRs. &#160;For novel technologies, the FDA will seek input from an advisory
panel of medical experts regarding the safety and effectiveness of, and their benefit-risk analysis for the device. &#160;The PMA process
is generally more detailed, lengthier and more expensive than the 510(k) process, though both processes can be expensive and lengthy,
and requires payment of significant user fees, unless an exemption is available.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Under the NDA and BLA application process, the applicant must demonstrate
that the drug or drug-device combination is safe and effective for its intended use. &#160;Various FDA reviewers will provide written
evaluations in their areas of expertise which are consolidated and provided to FDA senior staff for final evaluation. FDA then provides
the application sponsor approval or a deficiency letter. In the case of a deficiency letter, the sponsor must submit an adequate response
to continue the review process. The NDA and BLA processes involve considerable expense associated with data collection and analysis and
other expenses.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">We are also required to comply with the regulations of every other country
where we commercialize products before we can launch or maintain new products on the market. &#160;Many countries that previously did
not have medical device regulations, or had minimal regulations, are now introducing them.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>


<p style="font: 10pt TIMES NEW ROMAN, TIMES, SERIF; margin: 0; text-align: center">- 4 -</p>


<hr style="border-width: 0; color: Gray; background-color: Gray; height: 2px; width: 100%" /><p style="break-before: always"></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; color: blue"><i><a href="#toc">Table of Contents</a></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">International sales of medical devices manufactured in the U.S. that are
not approved by the FDA for use in the U.S., or that are banned or deviate from lawful performance standards, are subject to FDA export
requirements. &#160;Additionally, exported devices are subject to the regulatory requirements of each country to which the device is exported.
&#160;Some countries do not have medical device regulations, but in most foreign countries, medical devices are regulated. &#160;Frequently,
regulatory approval may first be obtained in a foreign country prior to application in the U.S. due to differing regulatory requirements;
however, other countries require approval in the country of origin first. &#160;Most countries outside of the U.S. require that product
approvals be recertified on a regular basis, generally every five years. &#160;The recertification process requires that we evaluate any
device changes and any new regulations or standards relevant to the device and, where needed, conduct appropriate testing to document
continued compliance. &#160;Where recertification applications are required, they must be approved in order to continue selling our products
in those countries.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><i>Post-Approval Regulation</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Even after a device is cleared or approved by FDA for marketing, numerous
regulatory requirements continue to apply. &#160;The FDA and other worldwide regulatory agencies and competent authorities actively monitor
compliance to local laws and regulations through review and inspection of design and manufacturing practices, record-keeping, reporting
of adverse events, labeling and promotional practices. &#160;The FDA can ban certain medical devices, detain or seize adulterated or misbranded
medical devices, order repair, replacement or refund of these devices and require notification of health professionals and others with
regard to medical devices that present unreasonable risks of substantial harm to the public health. &#160;The FDA may also enjoin and
restrain a company for certain violations of the FFDCA and the Safe Medical Devices Act pertaining to medical devices or initiate action
for criminal prosecution of such violations. &#160;In addition, FDA and other governmental agencies such as the Department of Justice
can take action against a company that promotes &#8220;off-label&#8221; uses. &#160;Regulatory agencies and authorities in the countries
where we do business can halt production in or distribution within their respective country or otherwise take action in accordance with
local laws and regulations. &#160;Any adverse regulatory action, depending on its magnitude, may restrict a company from effectively marketing
and selling its products, may limit a company&#8217;s ability to obtain future premarket clearances or approvals, and could result in
a substantial modification to a company&#8217;s business practices and operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><i>Manufacturing Regulation</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">We must also comply with FDA and foreign agency regulations governing medical
device manufacturing practices.&#160; The FDA and foreign agencies require manufacturers to register their establishments, and they monitor
compliance with device manufacturing requirements through inspections of manufacturing facilities.&#160; If an investigator observes conditions
that might be violative, the manufacturer must correct those conditions or explain them satisfactorily or face potential regulatory action
that might include physical removal of the product from the marketplace. &#160;We are an FDA-registered medical device manufacturer and
must demonstrate that we comply with the FDA&#8217;s QSR and Current Good Manufacturing Practices (&#8220;cGMPs&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">We believe that our products and procedures are in compliance with all
applicable FDA and international regulations.&#160; There is no assurance, however, that other products we are developing or products
that we may develop in the future will be cleared by the FDA and classified as Class II products, or that additional regulations restricting
the sale of our present or proposed products will not be promulgated by the FDA or other foreign agencies.&#160; In addition, changes
in FDA, or other federal or state health, environmental or safety regulations or their applications could adversely affect our business.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><i>Other Healthcare Laws</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">We are subject to additional healthcare regulation and enforcement by the
federal government and by authorities in the states and foreign jurisdictions in which we conduct our business. &#160;These laws include:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 7.5in; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: center">&#8226;</td>
    <td style="width: 7in">the federal Anti-Kickback Statute, which prohibits, among other things, persons from knowingly and willfully soliciting, receiving, offering or paying remuneration, directly or indirectly, in exchange for or to induce either the referral of an individual for, or the purchase, order or recommendation of, any good or service for which payment may be made under federal healthcare programs, such as the Medicare and Medicaid programs. &#160;A person or entity does not need to have actual knowledge of the federal Anti-Kickback Statute or specific intent to violate it to have committed a violation;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center">&#8226;</td>
    <td>federal false claims laws which prohibit, among other things, individuals or entities from knowingly presenting, or causing to be presented, claims for payment from Medicare, Medicaid or other federal third-party payors that are false or fraudulent. &#160;In addition, the government may assert that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the False Claims Act;</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>


<p style="font: 10pt TIMES NEW ROMAN, TIMES, SERIF; margin: 0; text-align: center">- 5 -</p>


<hr style="border-width: 0; color: Gray; background-color: Gray; height: 2px; width: 100%" /><p style="break-before: always"></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; color: blue"><i><a href="#toc">Table of Contents</a></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 7.5in; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: center">&#8226;</td>
    <td style="width: 7in">the federal Civil Monetary Penalties Law, which prohibits, among other things, offering or transferring remuneration to a federal healthcare beneficiary that a person knows or should know is likely to influence the beneficiary&#8217;s decision to order or receive items or services reimbursable by the government from a particular provider or supplier;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center">&#8226;</td>
    <td>federal criminal laws that prohibit executing a scheme to defraud any federal healthcare benefit program or making false statements relating to healthcare matters;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center">&#8226;</td>
    <td>the federal Health Insurance Portability and Accountability Act of 1996 (&#8220;HIPAA&#8221;), as amended by the Health Information Technology for Economic and Clinical Health Act, which governs the conduct of certain electronic healthcare transactions and protects the security and privacy of protected health information;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center">&#8226;</td>
    <td>the federal Physician Payment Sunshine Act, which requires manufacturers of drugs, devices, biologics and medical supplies for which payment is available under Medicare, Medicaid or the Children&#8217;s Health Insurance Program (with certain exceptions) to report annually to the Centers for Medicare &amp; Medicaid Services (&#8220;CMS&#8221;) information related to payments or other &#8220;transfers of value&#8221; made to physicians (defined to include doctors, dentists, optometrists, podiatrists and chiropractors), certain health care professionals beginning in 2022, and teaching hospitals and ownership and investment interests held by the physicians described above and their immediate family members, and payments or other &#8220;transfers of value&#8221; to such physician owners; and</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center">&#8226;</td>
    <td>analogous state and foreign law equivalents of each of the above federal laws, such as anti-kickback and false claims laws which may apply to items or services reimbursed by any third-party payor, including commercial insurers; state laws that require pharmaceutical and device companies to comply with the industry&#8217;s voluntary compliance guidelines and the applicable compliance guidance promulgated by the federal government or otherwise restrict payments that may be made to healthcare providers and other potential referral sources; state laws that require device manufacturers to track and report information related to payments and other &#8220;transfers of value&#8221; to physicians and other healthcare providers or pricing, marketing expenditures and information; and state laws governing the privacy and security of health information in certain circumstances, many of which differ from each other in significant ways and may not have the same effect, thus complicating compliance efforts.</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Violations of any of the laws described above include civil and criminal
penalties, damages, fines, the curtailment or restructuring of an entity&#8217;s operations, the debarment, suspension or exclusion from
federal and state healthcare programs and/or imprisonment.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><i>Coverage and Reimbursement</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Our profitability and operations are subject to changes in legislative,
regulatory and reimbursement policies and decisions as well as changes in private payer reimbursement coverage and payment decisions and
policies. &#160;Our products are purchased by specialty pharmacies and ambulatory service providers or hospitals that typically bill various
third-party payors, such as governmental programs (e.g., Medicare, Medicaid, and comparable non-U.S. programs), private insurance plans
and managed care plans, for the healthcare services and products provided to their patients. &#160;The ability of our customers to obtain
appropriate coverage and reimbursement for our products and the drugs they administer is critical because it affects which products customers
purchase and the price they are willing to pay. &#160;Third-party payors are increasingly reducing coverage and reimbursement for certain
healthcare services and products and challenging prices charged for healthcare services and products.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><i>Environmental Health and Safety Laws</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">We are required to comply with federal, state, and local environmental
laws; however, there is no significant effect of compliance on capital expenditures, earnings, or competitive position. &#160;We do not
use significant amounts of hazardous materials in the assembly of our products.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>COMPETITION AND THE MARKET</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Competition for the FREEDOM System includes electronic (volumetric) pumps,
elastomeric (infuser) pumps, and fully mechanical pumps as well as other types of pumps. &#160;Safety, ease of use, familiarity, cost
effectiveness, and accuracy are the principal driving influencers of pump selection. &#160;Electronic pumps deliver drugs at a programmed
flow rate. &#160;They are more costly and require electricity or batteries, extensive training and maintenance and must be programmed
by a qualified pharmacist or clinician. Elastomeric pumps are one-time-use balloon type devices used for infusion of drugs in intravenous
and surgical wound site applications. &#160;Pharmacies are required to fill them with drugs and deliver them to the patient. &#160;They
are easy to use from the patient point of view but can be more costly and time consuming to fill, are temperature sensitive and have larger
residual volumes than other delivery systems.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>


<p style="font: 10pt TIMES NEW ROMAN, TIMES, SERIF; margin: 0; text-align: center">- 6 -</p>


<hr style="border-width: 0; color: Gray; background-color: Gray; height: 2px; width: 100%" /><p style="break-before: always"></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; color: blue"><i><a href="#toc">Table of Contents</a></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Competition for infusion devices for new drugs includes a variety of technologies
and companies. No single technological approach&#8212;autoinjectors, electronic (volumetric pumps), mechanical pumps, needle-free injectors,
on-body wearable devices, pen injectors, and pre-filled syringes&#8212;will meet the needs of all or even a majority of drugs. For drugs
requiring infusion volumes over 3 ml, the segment most similar to the SCIg drugs currently delivered by the FREEDOM System, the most relevant
approaches include mechanical pumps, on-body wearable devices, and simple electronic pumps. Challenges to their successful commercialization
include high costs per infusion, increased environmental impact, complexity for users, and complex mechanisms with multiple failure modes.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>HUMAN CAPITAL RESOURCES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">As of December 31, 2022, we had 85 full time employees and 1 part time
employee. &#160;As of December 31, 2022, approximately 53% of the Company&#8217;s workforce was female and approximately 43% of the Company&#8217;s
employees in managerial roles were female. &#160;Approximately 41% were minorities (non-White) in the Company workforce as of December
31, 2022. &#160;None of our employees are represented by a collective bargaining agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">To help drive consistent execution of our business strategy, including
our customer focused philosophy, and support their development, we provide training opportunities to our employees that align with their
responsibilities over their career with us. &#160;We maintain a dedicated Internet-based learning platform with a broad portfolio of written,
audio-visual and interactive enterprise-wide and discipline-specific policy and training materials. &#160;This platform includes a library
of self-directed courses and virtual, instructor-led programs for employees at all levels of our organization. &#160;Managers and supervisors
are provided training to help their employees progress in their professional development.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">We believe our employees are key to achieving our business objectives.
&#160;We have COVID-19 prevention protocols in place to minimize the spread of COVID-19 in our workplace.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Our key human capital measures include employee safety, turnover, absenteeism
and production. &#160;We frequently benchmark our compensation practices and benefits programs against those of comparable industries
and in the geographic areas where our facilities are located. &#160;We believe that our compensation and employee benefits are competitive
and allow us to attract and retain skilled and unskilled labor throughout our organization. &#160;Our notable health, welfare and retirement
benefits include:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 7.5in; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: center">&#8226;</td>
    <td style="width: 7in">Company subsidized health insurance</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center">&#8226;</td>
    <td>401(k) Plan with Company matching contributions</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center">&#8226;</td>
    <td style="text-align: justify">Paid time off</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center">&#8226;</td>
    <td>Life and disability insurance</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">We strive to maintain an inclusive environment free from discrimination
of any kind, including sexual or other discriminatory harassment. &#160;Our employees have multiple avenues available through which inappropriate
behavior can be reported, including a confidential hotline. &#160;All reports of inappropriate behavior are promptly investigated with
appropriate action taken to stop such behavior.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>PATENTS AND INTELLECTUAL PROPERTY</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">We have patents and other intellectual property that we believe protect the FREEDOM System, and we continue to file
patent applications in connection with our research and development activities. As of December 31, 2022, we own 14 U.S. Patents and 60
foreign patents. In addition, we have 5 pending U.S. patent applications and 11 foreign patent applications. The fundamental patents protecting
our drug delivery systems extend until 2034 and beyond.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>EXECUTIVE OFFICERS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The following table sets forth certain information with respect to our
executive officers as of March 8, 2023:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 7.5in">
  <tr style="vertical-align: top">
    <td style="border-bottom: black 1pt solid; width: 1.5in"><b>Name</b></td>
    <td style="width: 0.25in">&#160;</td>
    <td style="border-bottom: black 1pt solid; width: 0.5in; text-align: center"><b>Age</b></td>
    <td style="width: 0.25in">&#160;</td>
    <td style="border-bottom: black 1pt solid; width: 5in"><b>Position / Held Since</b></td></tr>
  <tr style="vertical-align: top; background-color: #E6E6E6">
    <td>Linda Tharby</td>
    <td>&#160;</td>
    <td style="text-align: center">54</td>
    <td>&#160;</td>
    <td>Chief Executive Officer and President (since April 2021)</td></tr>
  <tr style="vertical-align: top">
    <td>Tom Adams</td>
    <td>&#160;</td>
    <td style="text-align: center">50</td>
    <td>&#160;</td>
    <td>Interim Chief Financial Officer, Secretary and Treasurer (since July 2022)</td></tr>
  <tr style="vertical-align: top; background-color: #E6E6E6">
    <td>Brian Case</td>
    <td>&#160;</td>
    <td style="text-align: center">50</td>
    <td>&#160;</td>
    <td>Chief Technology Officer (since April 2022)</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Executive officers hold office at the discretion of the Board of Directors.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>


<p style="font: 10pt TIMES NEW ROMAN, TIMES, SERIF; margin: 0; text-align: center">- 7 -</p>


<hr style="border-width: 0; color: Gray; background-color: Gray; height: 2px; width: 100%" /><p style="break-before: always"></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; color: blue"><i><a href="#toc">Table of Contents</a></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Ms. Tharby was appointed as President and CEO in April 2021. Ms. Tharby
has over 25 years of executive leadership experience building and leading strong performing global organizations that develop and commercialize
products and service innovations, while delivering solutions to patients in the home setting. Prior to joining KORU, Ms. Tharby spent
the last 24 years working in various roles of increased responsibility at Becton Dickinson (&#8220;BD&#8221;). Ms. Tharby was a
member of the Executive Leadership team of BD that transformed the company from an $8 billion medical supplies company to an $18 billion
global medical technology company. Ms. Tharby&#8217;s last role was as Chief Customer Experience Officer from July 2018 through
December 2020. Prior to that she served as BD&#8217;s Chief Human Resources Officer, from October 2016 through July 2018. From 1998
to 2016, she held numerous senior global business leadership roles at BD, including Executive Vice President and President of Life Sciences,
Group President of Pre-Analytical Systems and Biosciences, Worldwide President of Diabetes Care, and Vice President/General Manager of
Pharmaceutical Systems. Ms. Tharby has an Honors Bachelor of Business Administration from Wilfrid Laurier University in Waterloo, Ontario
Canada.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Mr. Adams joined KORU Medical Systems in November 2021 as Vice President
of Financial Planning and Analysis and was appointed Interim- Chief Financial Officer in July 2022. Mr. Adams has an extensive background
in financial planning, corporate finance, commercial and supply chain finance, and mergers and acquisitions (M&amp;A). Prior to joining
KORU, Mr. Adams spent 10 years at Integra Life Sciences in various leadership positions in Finance and Accounting Controllership with
most recent position as Senior Director of Finance. In this role, Mr. Adams was the head of finance for Integra&#8217;s Tissue Technology
Business where he served a leading role in supporting a $500 million business unit to high growth and profitability. Previous roles included
Group Controller/Head of FP&amp;A Global Supply and prior to Integra Life Sciences, Mr. Adams served as Director of Finance at Pfizer
Inc serving in many domestic and international roles. Mr. Adams earned his Bachelor of Science in Business Administration-Accounting &amp;
Finance from the Ohio State University.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Mr. Case joined KORU Medical Systems in April 2022 as Chief Technology
Officer. Mr. Case brings over 20 years of research and development experience working with a combination of large and small medical device
companies. For the 16 years prior to joining KORU, Mr. Case was an R&amp;D leader with Fresenius Kabi, a global leader specializing
in lifesaving medicines and technologies for infusion, transfusion, and clinical nutrition. As the Vice President of R&amp;D for
the Transfusion and Cell Technologies business, Mr. Case provided global business and technical leadership to drive the long-term product
vitality of the business and promote entry into new business areas. &#160;During his time at Fresenius, Mr. Case&#8217;s many accomplishments
included bringing new products and technologies to market, leading to new business divisions, multiple international product approvals
and value creation for the company. Mr. Case also led the Project Management office for the company, responsible for the identification
and implementation of best practices and functional excellence. &#160;Prior to Fresenius, Mr. Case was the R&amp;D Manager, Advanced Research
at Cook Medical where he led a cross-functional team that developed and assessed new technologies to create a product portfolio to service
the peripheral disease market. Mr. Case&#8217;s work has been prolific with over 100 patents filed during his career. Mr. Case received
his Master of Science in Engineering Management from Rose-Hulman Institute of Technology, and his Bachelor of Science in Engineering Mechanics,
from University of Illinois.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="a_002"></span>&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>ITEM 1A. RISK FACTORS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>RISK FACTORS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><i>An investment in our common stock involves significant risks. &#160;Before
making an investment in our common stock, you should carefully consider all of the information contained in this Annual Report on Form
10-K and our other filings with the SEC including the material risks and uncertainties that we have identified below. &#160;The risks
and uncertainties identified below are not the only risks and uncertainties we face. &#160;If any of the material risks or uncertainties
that we face were to occur, the trading price of our common stock could decline and you could lose part or all of your investment. &#160;Please
note that additional risks not currently known to us or that we currently deem immaterial also may adversely affect our business, operations,
results of operations, financial condition and prospects.</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Risks Related to Our Business</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>If we are unable to successfully introduce new products or fail to
keep pace with advances in technology, our business, financial condition and results of operations could be adversely affected.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">We need to successfully introduce new products to achieve our strategic
business objectives. &#160;A significant element of our strategy is to increase revenue growth by investing in innovation and new product
development, which will require substantial resources. &#160;Our successful product development will depend on many factors, including
our ability to attract strong talent to lead our research and development efforts, properly anticipate and satisfy customer needs, adapt
to new technologies, obtain regulatory concurrence on a timely basis, demonstrate satisfactory clinical results, manufacture products
in an economical and timely manner, obtain appropriate intellectual property protection for our products, gain and maintain market acceptance
of our products, and differentiate our products from those of our competitors. &#160;In addition, patents attained by others can preclude
or delay our commercialization of a product. There can be no assurance that any products now in development or that we may seek to develop
in the future will achieve technological feasibility, obtain regulatory concurrence or gain market acceptance. &#160;If we cannot successfully
introduce new products or adapt to changing technologies, our products may become obsolete, and our revenue and profitability could suffer.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>


<p style="font: 10pt TIMES NEW ROMAN, TIMES, SERIF; margin: 0; text-align: center">- 8 -</p>


<hr style="border-width: 0; color: Gray; background-color: Gray; height: 2px; width: 100%" /><p style="break-before: always"></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; color: blue"><i><a href="#toc">Table of Contents</a></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>Our business depends on an adequate supply of drugs to be administered
by our products.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Demand for our products depends on the availability of drugs to be administered
by them. &#160;Currently, most of our products require immunoglobulin therapies that rely on blood plasma collection for drugs such as
Hizentra&#174; and Cuvitru&#174;. &#160;Any disruption in the supply of these drugs for any reason, including contamination, could significantly
adversely affect our business. &#160;The change of any drug indication by the FDA or comparable foreign governmental agencies could also
result in decreased demand for our products. &#160;In addition, pharmaceutical companies and other competitors have or are developing
alternative therapies for disease states that are deliverable with devices we do not offer or without a medical device. &#160;The COVID-19
pandemic has negatively impacted the collection of plasma, the source of the active ingredient of SCIg medications, which may limit the
supply of these drugs. If there is not an adequate supply of drugs requiring administration by medical devices such as those provided
by us or alternative therapies are developed, our sales may suffer and/or our products may become obsolete.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>Our compliance with EU MDR regulations by December 2028 will require significant
investment and, if we are not in compliance by that time, we will not be able to sell our products in the EU.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">In the European Union (&#8220;EU&#8221;), we are required to comply with
the new Medical Device Regulation (&#8220;MDR&#8221; or &#8220;EU MDR&#8221;) effective May 2021, which supersedes the prior Medical Device
Directives. Medical devices which have a valid CE certificate to the current Medical Device Directives (issued before May 2021), as do
all of our current products, can continue to be sold until December 2028 or until the CE certificate expires, whichever comes first, providing
there are no significant changes as defined in Article 120 of EU MDR. The MDR was published in May 2017 with a 3-year transition period.
That transition period was extended to May 2021 due to the COVID-19 pandemic. In early 2023, the transition period was further extended
to December 2028 for class IIa products. The CE mark required to sell medical devices in the EU is affixed following conformity assessment
and either approval from an appointed independent notified body or through self-certification by the manufacturer. The selected pathway
to CE marking is based on product risk classification. CE marking indicates conformity to the applicable essential requirements of the
relevant Medical Device Directives and in the future to the general safety and performance requirements for the new MDR. The MDR will
change multiple aspects of the existing regulatory framework for CE marking, such as increased clinical evidence requirements and other
new requirements, including Unique Device Identification (&#8220;UDI&#8221;) as well as many other post-market obligations. MDR also significantly
modifies and increases the compliance requirements for the industry and will require significant investment by us in the near future to
implement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Our products are also subject to approval and regulation by foreign regulatory
and safety agencies. For example, the EU has adopted the EU Medical Device Regulation (the &#8220;EU MDR&#8221;) and the In Vitro Diagnostic
Regulation (the &#8220;EU IVDR&#8221;), each of which impose stricter requirements for the marketing and sale of medical devices, including
in the area of clinical evaluation requirements, quality systems and post-market surveillance. Implementation of the compliance requirements
of these regulations requires us to incur significant expenditures and utilize resources. Failure to continue to meet these requirements
could adversely impact our business in the EU and other regions that tie their product registrations to the EU requirements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">If we are unable to comply with the MDR by December 2028, we will not be able
to sell our products in the EU, which will materially impact our net revenues.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>Interruption of our manufacturing operations, including due to transitioning
to our new facility, could adversely affect our future revenues and operating income.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The FDA and other U. S. and non-U.S. government agencies regulate our manufacturing
operations, which includes product assembly, calibration, pre- and post-assembly quality control inspection and testing, and final packaging
for all of our products. Variations in the manufacturing process may result in production failures which could lead to launch delays,
product shortage, unanticipated costs, lost revenues and damage to our reputation. &#160;A failure to identify and address manufacturing
problems prior to the release of products to our customers may also result in a quality or safety issue that could result in a recall
or other inability to sell our products.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Our products are currently manufactured and stored at our corporate headquarters
and manufacturing facilities. &#160;Loss or damage to our manufacturing and storage sites due to weather, vandalism, terrorism, a natural
disaster, issues in our manufacturing process, equipment failure or other factors, could adversely affect our ability to manufacture sufficient
quantities of products or otherwise deliver products to meet customer demand or contractual requirements which may result in a loss of
revenue and other adverse business consequences, including damage to our relationship with customers. Additionally, Command manufactures
and supplies the Company&#8217;s subassemblies, needle sets and tubing products in Nicaragua. There could be a delay in providing the
products timely due to their climate and international boundaries.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>


<p style="font: 10pt TIMES NEW ROMAN, TIMES, SERIF; margin: 0; text-align: center">- 9 -</p>


<hr style="border-width: 0; color: Gray; background-color: Gray; height: 2px; width: 100%" /><p style="break-before: always"></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; color: blue"><i><a href="#toc">Table of Contents</a></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">We take precautions to safeguard our facilities, including acquiring insurance,
adopting health and safety protocols and utilizing off-site storage of computer data. &#160;Our insurance may not cover our losses in
any particular case. &#160;In addition, regardless of the level of insurance coverage, damage to our facilities may harm our business,
financial condition and operating results.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>Public health crises, such as the COVID-19 pandemic, have had, and
could in the future have, a negative effect on our business.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Pandemics or disease outbreaks, such as the COVID-19 pandemic, have created
and may continue to create significant volatility, uncertainty and economic disruption in the markets we sell our products into and operate
in, primarily the U.S., Europe, and Asia-Pacific and may negatively impact business and healthcare activity globally. In response to the
COVID-19 pandemic, governments around the world have imposed measures designed to reduce the transmission of COVID-19 and individuals
continue to respond to the fear of contracting COVID-19. In particular, elective procedures and exams were delayed or cancelled, there
were significant reductions in physician office visits, and hospitals postponed or canceled capital purchases as well as limited or eliminated
services. While elective procedures and exams and capital purchases have increased from initially depressed levels, the reduction in elective
procedures, exams and capital purchases has had, and we believe may continue to have, a negative impact on the sales of our products .
Additionally, governments and other third-party payors around the world facing tightening budgets could move to further reduce the reimbursement
rates or the scope of coverage offered, which could further adversely affect sales of our products.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The extent to which fear of exposure to or actual effects of COVID-19,
new variants, disease outbreak, epidemic or a similar widespread health concern impacts our business will depend on future developments,
which are highly uncertain and cannot be predicted with confidence, such as the speed and extent of geographic spread of the disease,
the duration of the outbreak, travel restrictions, the efficacy of vaccination and treatment; impact on the U.S. and international healthcare
systems, the U.S. economy and worldwide economy; the timing, scope and effectiveness of U.S. and international governmental response;
and the impact on the health, well-being and productivity of our employees.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>We may be unable to compete successfully in our highly competitive
industry.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">We operate in a single market &#8211; ambulatory infusion &#8211; and are
dependent upon our success in that market. We face competition in our market from a wide range of international and domestic companies,
including those that deliver electronic volumetric pumps, elastomeric infuser pumps, other mechanical devices, novel drug delivery devices
and methodologies, and devices and formulation technologies that allow drugs to be delivered in volumes smaller than the FREEDOM System
is designed to deliver.&#160;These include large medical device companies with multiple product lines, some of which may have greater
financial and marketing resources than we do. &#160;We also face competition from companies that are even more specialized than ours with
respect to particular markets or product lines. &#160;Some of those companies have greater financial and sales and marketing resources
than we do or offer products at a lower price point than ours. &#160;In addition, former employees may develop products that are competitive
with ours or capitalize on customer relationships developed while employed with us, subject to their continuing obligations under confidentiality
agreements and other restrictive covenants that may survive their employment. &#160;We face competition on the basis of product features,
clinical or economic outcomes, product quality, availability, price, services, technological innovation and other factors. &#160;In addition,
we face changing customer preferences and requirements, changes in the ways health care services are delivered, including the transition
of high-acuity care to lower-acuity, and non-acute care settings.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Competition may increase further as additional companies begin to enter
our market or modify their existing products to compete directly with ours. &#160;If we are forced to reduce our prices due to increased
competition, our business could suffer.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The medical technology industry has also experienced a significant amount
of consolidation, resulting in larger companies with greater access to markets. &#160;Pharmaceutical manufacturers, health care systems,
other health care companies and even retail pharmacies are also consolidating, resulting in greater purchasing power for these companies.
&#160;As a result, competition among medical device suppliers to provide goods and services has increased. &#160;Group purchasing organizations
and integrated health delivery networks have also served to concentrate purchasing decisions for some customers, which has led to downward
pricing pressure for medical device suppliers. &#160;Further consolidation in the industry could intensify competition among medical device
suppliers and exert additional pressure on the prices of our products.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Consolidation in the medical industry could have a negative impact with
payor and provider relationships and distributor relationships, as we could lose market share as consolidation occurs.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>


<p style="font: 10pt TIMES NEW ROMAN, TIMES, SERIF; margin: 0; text-align: center">- 10 -</p>


<hr style="border-width: 0; color: Gray; background-color: Gray; height: 2px; width: 100%" /><p style="break-before: always"></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; color: blue"><i><a href="#toc">Table of Contents</a></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>Technological developments by others may disrupt our business and
negatively impact our revenues.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The medical device industry is subject to rapid technological change and
discovery and frequent product introductions. &#160;The development of new or improved products, processes or technologies by other companies
that provide better features, pricing or clinical outcomes or economic value may render our products or proposed products obsolete or
less competitive. &#160;If our competitors respond more quickly to new or emerging technologies and changes in customer requirements or
we do not introduce new versions or upgrades to our product portfolio in response to those requirements, our products may not be marketable.
&#160;If competitors develop more effective or affordable products or achieve earlier patent protection or product commercialization for
new products than we do, our operations will likely be adversely affected.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>We are subject to costly and complex laws and governmental regulations
and any adverse regulatory action may materially adversely affect our financial condition and business operations.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Our medical devices and technologies, as well as our business activities,
are subject to a complex set of regulations and rigorous enforcement, principally by the FDA, numerous other federal, state, and non-U.S.
governmental authorities and equivalent regulatory bodies of other countries. &#160;To varying degrees, each of these agencies requires
us to comply with laws and regulations governing the design, development, and manufacturing; testing, labeling, content and language of
instructions for use and storage; clinical trials; product safety; establishment registration and device listing; marketing, promotion,
and distribution of our products; premarket clearance and approval; record keeping procedures; advertising and promotion; recalls and
field safety corrective actions; post-market surveillance, including reporting of deaths or serious injuries and malfunctions that, if
they were to recur, could lead to death or serious injury; post-market approval studies; and product import and export.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">In the U.S., our device products are subject to clearance or approval by
FDA under the FFDCA. &#160;Before we can market a new medical device, or a new use of, new claim for, or significant modification to,
an existing product, we must first receive either 510(k) clearance or approval of a PMA application from the FDA, unless an exemption
applies. &#160;Under the 510(k) process, the manufacturer must submit to the FDA a premarket notification, demonstrating that the device
is &#8220;substantially equivalent,&#8221; as defined in the statute, to a legally marketed predicate device. &#160;To be &#8220;substantially
equivalent,&#8221; the proposed device must have the same intended use as the predicate device, and either have the same technological
characteristics as the predicate device or have different technological characteristics and not raise different questions of safety or
effectiveness than the predicate device. &#160;If the manufacturer is unable to demonstrate substantial equivalence to FDA&#8217;s satisfaction,
or if there is no available predicate device, then the manufacturer may be required to seek approval through the PMA application process,
which is generally more costly and time consuming than the 510(k) process. &#160;Through the PMA application process, the applicant must
submit data and information demonstrating reasonable assurance of the safety and effectiveness of the device for its intended use. &#160;Accordingly,
a PMA application typically includes, but is not limited to, extensive technical information regarding device design and development,
pre-clinical and clinical trial data, manufacturing information, labeling and financial disclosure information for the clinical investigators
in device studies. In the future our device products may be approved as part of a drug submission under a combination product regulatory
pathway. Under the combination product approval process, our device would typically be submitted as part of a drug application, typically
a BLA or NDA in the United States. The proof required for approval as a combination product is similar to that required for a 510(k),
but may differ in material ways. In addition, the regulatory approval is held by the pharmaceutical manufacturer, not KORU.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">We cannot guarantee that we will be able to obtain or maintain FDA 510(k)
clearance or premarket approval for our new products or enhancements or modifications to existing products (including the use of our FREEDOM
System with therapies not covered by the existing FDA clearance), and the failure to maintain approvals or clearances, or obtain approval
or clearance could have a material adverse effect on our business, results of operations, financial condition and cash flows. Even if
we are able to obtain approval or clearance, it may:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 7.5in">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: center">&#8226;</td>
    <td style="width: 7in">take a significant amount of time</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center">&#8226;</td>
    <td>require the expenditure of substantial resources</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center">&#8226;</td>
    <td>involve stringent clinical and pre-clinical testing, as well as increased post-market surveillance</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center">&#8226;</td>
    <td>involve modifications, repairs, or replacements of our products, and</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center">&#8226;</td>
    <td>limit the proposed uses of our products.</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>


<p style="font: 10pt TIMES NEW ROMAN, TIMES, SERIF; margin: 0; text-align: center">- 11 -</p>


<hr style="border-width: 0; color: Gray; background-color: Gray; height: 2px; width: 100%" /><p style="break-before: always"></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; color: blue"><i><a href="#toc">Table of Contents</a></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Both before and after a product is commercially released, we have ongoing
responsibilities under the FDA and other applicable non-U.S. government agency laws and regulations. &#160;The FDA and other worldwide
regulatory agencies actively monitor compliance with local laws and regulations through review and inspection of design and manufacturing
practices, recordkeeping, reporting of adverse events, labeling and promotional practices. &#160;The results of these inspections can
include inspectional observations on the FDA&#8217;s Form 483, warning letters, or other forms of enforcement. &#160;If the FDA or any
state or foreign regulatory authorities were to conclude that we are not in compliance with any applicable laws or regulations, or that
any of our medical products are ineffective or pose an unreasonable health risk, they could deem our products adulterated or misbranded,
and take enforcement action against us. &#160;FDA and state and foreign regulatory authorities have broad enforcement powers. &#160;Possible
enforcement actions include, but are not limited to: &#160;temporarily or permanently suspending the sale and/or distribution of such
medical products; detaining or seizing all adulterated or misbranded medical products; ordering recall, repair, replacement, or refund
of such products; refusing to grant pending pre-market approval or 510(k) clearance applications; and/or requiring us to notify health
professionals and others that the devices present unreasonable risks of substantial harm to the public health. &#160;In addition, the
FDA prohibits device manufacturers from promoting their products for uses and indications other than those set forth in the approved product
labeling, and failure to comply with this prohibition could subject us to significant civil or criminal exposure, administrative obligations
and costs, and/or other potential penalties from, and/or agreements with, the federal government. &#160;The FDA and other non-U.S. government
agencies may also assess civil or criminal penalties against us, our officers or employees and impose operating restrictions on a company-wide
basis. &#160;The FDA may also recommend prosecution to the U.S. Department of Justice. &#160;Any adverse regulatory action, depending
on its magnitude, may restrict us from effectively marketing and selling our products and limit our ability to obtain future pre-market
clearances or approvals, and could result in a substantial modification to our business practices and operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Regulations regarding the development, manufacture and sale of medical
devices are evolving and subject to future change and have tended to become more stringent over time. &#160;Regulatory changes could result
in restrictions on our ability to continue or expand our operations, higher than anticipated costs, or lower than anticipated sales. We
cannot predict what impact, if any, those changes might have on our business; however, failure to comply with applicable regulatory requirements
could have a material adverse effect on our business, financial condition, and results of operations. &#160;Later discovery of previously
unknown problems with a product or manufacturer could result in fines, delays or suspensions of regulatory clearances or approvals, seizures
or recalls of products, physician advisories or other field actions, operating restrictions and/or criminal prosecution. &#160;We may
also initiate field actions as a result of a failure to strictly comply with our internal quality policies. &#160;The failure to receive
product approval clearance on a timely basis, suspensions of regulatory clearances, seizures or recalls of products, physician advisories
or other field actions, or the withdrawal of product approval by the FDA or by comparable agencies in foreign countries could have a material
adverse effect on our business, financial condition or results of operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Governmental regulations outside the U.S. have also, and may continue to,
become increasingly stringent and common. &#160;Penalties for regulatory non-compliance could be severe, including fines and revocation
or suspension of a company&#8217;s EU device approval, ability to distribute products and criminal sanctions. &#160;Future foreign governmental
laws and regulations may have a material adverse effect on us.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">In addition, exported devices are subject to the regulatory requirements
of each country to which the device is exported. &#160;Some countries do not have medical device regulations, but in most foreign countries,
medical devices are regulated. &#160;Frequently, regulatory approval may first be obtained in a foreign country prior to application in
the U.S. due to differing regulatory requirements; however, other countries, such as China for example, require approval in the country
of origin or legal manufacturer first. &#160;Most countries outside of the U.S. require that product approvals be renewed or recertified
on a regular basis, generally every four to five years. &#160;The renewal or recertification process requires that we evaluate any device
changes and any new regulations or standards relevant to the device and conduct appropriate testing to document continued compliance.
&#160;Where renewal or recertification applications are required, they may need to be renewed and/or approved in order to continue selling
our products in those countries. &#160;There can be no assurance that we will receive the required approvals for new products or modifications
to existing products on a timely basis or that any approval will not be subsequently withdrawn or conditioned upon extensive post market
study requirements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Our global regulatory environment is becoming increasingly stringent and
unpredictable, which could increase the time, cost and complexity of obtaining regulatory approvals for our products, as well as the clinical
and regulatory costs of supporting those approvals. &#160;Several countries that did not have regulatory requirements for medical devices
have established such requirements in recent years and other countries have expanded on existing regulations. &#160;Certain regulators
are exhibiting less flexibility and are requiring local preclinical and clinical data in addition to global data. &#160;While harmonization
of global regulations has been pursued, requirements continue to differ significantly among countries. &#160;In the United Kingdom, for
example, the Medicines and Healthcare products Regulatory Agency (MHRA) is responsible for regulating the UK medical device market. &#160;With
recent changes in the United Kingdom&#8217;s membership with the European Union, the MHRA has and will continue to impose new regulatory
obligations becoming effective in 2021 through 2023, for medical device manufacturers. &#160;We expect this global regulatory environment
will continue to evolve, which could impact our ability to obtain future approvals for our products or could increase the cost and time
to obtain such approvals in the future.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>


<p style="font: 10pt TIMES NEW ROMAN, TIMES, SERIF; margin: 0; text-align: center">- 12 -</p>


<hr style="border-width: 0; color: Gray; background-color: Gray; height: 2px; width: 100%" /><p style="break-before: always"></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; color: blue"><i><a href="#toc">Table of Contents</a></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>Our business and financial results may be materially adversely affected
if our facility is not ready for manufacturing when the lease on our current facility expires on March 31, 2023.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The lease on our current corporate headquarters and manufacturing facility
expires on March 31, 2023. We have entered into a lease for a new facility for our operations, and we expect to complete our move into
that facility in the first quarter of 2023. If we are unable to establish continuous manufacturing operations in our new facility before
our existing lease expires, our revenues will suffer. We may not be able to establish such operations before our existing lease expires
due to a number of factors, including delays in construction caused by raw materials, labor shortages and unforeseen complications; delays
in receiving necessary regulatory approvals from U.S. and international authorities; unexpected manufacturing quality issues; inability
to hire or retain necessary personnel; and other unforeseen circumstances. We have begun building our product inventory and expect to
continue to do so through the first quarter of 2023, in order to ensure we can continue to service our customers in the event we are unable
to maintain continuous manufacturing operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>Health care policy changes and industry cost-containment measures
could result in downward pricing pressure for our products and limit our sales.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Most of our customers, and those to whom our customers supply medical devices,
rely on third-party payers, including government programs and private health insurance plans, to reimburse some or all the cost of the
medical devices we manufacture. &#160;The continuing efforts of governmental authorities, insurance companies and other payers of health
care costs to contain or reduce these costs and, more generally, to reform the health care system, could limit the prices we are able
to charge for our products or the amounts of reimbursement available for our products or the drugs that they administer, which would put
pressure on us to reduce our prices for our products and/or limit our sales. &#160;The adoption of some or all of these proposals could
have a material adverse effect on our business, results of operations, financial condition and cash flows.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>Issues with product quality could have an adverse effect upon our
business, subject us to regulatory actions, cause a loss of customer confidence in us or our products, among other negative consequences.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Quality management plays an essential role in determining and meeting customer
requirements, preventing defects, improving our products and services, and assuring the safety and efficacy of our products. &#160;Our
future success depends on our ability to maintain and continuously improve our quality management program. &#160;While we have a quality
system that covers the lifecycle of our products, quality and safety issues may occur with respect to any of our products. &#160;A quality
or safety issue may result in adverse inspection reports, voluntary or official action indicated, warning letters, import bans, product
recalls (either voluntary or required by the FDA or</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">similar governmental authorities in other countries) or seizures, monetary
sanctions, injunctions to halt manufacture and distribution of products, civil or criminal sanctions, costly litigation, refusal of a
government to grant approvals and licenses, restrictions on operations or withdrawal of existing approvals and licenses. &#160;An inability
to address a quality or safety issue in an effective and timely manner may also cause negative publicity, a loss of customer confidence
in us or our current or future products, which may result in the loss of sales and difficulty in successfully launching new products.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>Defects or quality issues associated with our products could adversely
affect the results of our operations.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The design, manufacture and marketing of medical devices involve certain
inherent risks. &#160;Manufacturing or design defects, component failures, unapproved or improper use of our products, or inadequate disclosure
of risks or other information relating to the use of our products can lead to injury or other serious adverse events. &#160;We are subject
to the FDA&#8217;s medical device reporting regulations and similar foreign regulations, which require us to report to the FDA when we
receive or become aware of information that reasonably suggests that one or more of our products may have caused or contributed to a death
or serious injury or malfunctioned in a way that, if the malfunction were to recur, it could cause or contribute to a death or serious
injury. &#160;The timing of our obligation to report is triggered by the date we become aware of the adverse event as well as the nature
of the event. &#160;If we fail to comply with our reporting obligations, the FDA could take action, including warning letters, untitled
letters, administrative actions, criminal prosecution, imposition of civil monetary penalties, revocation of our device clearances or
approvals, seizure of our products, or delay in clearance or approval of future products.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">These adverse events could also lead to safety alerts relating to our products
or recalls (either voluntary or as required by the FDA or similar governmental authorities in other countries), and could result, in certain
cases, in the removal of a product from the market. &#160;A recall could result in significant costs and lost sales and customers, enforcement
actions and/or investigations by state and federal governments or other enforcement bodies, as well as negative publicity and damage to
our reputation that could reduce future demand for our products. &#160;Any corrective action, whether voluntary or involuntary, as well
as defending ourselves in a lawsuit, will require the dedication of our time and capital, distract management from operating our business
and may harm our reputation and financial results.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>


<p style="font: 10pt TIMES NEW ROMAN, TIMES, SERIF; margin: 0; text-align: center">- 13 -</p>


<hr style="border-width: 0; color: Gray; background-color: Gray; height: 2px; width: 100%" /><p style="break-before: always"></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; color: blue"><i><a href="#toc">Table of Contents</a></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Personal injuries relating to the use of our products can also result in
significant product liability claims being brought against us. &#160;A product liability claim, regardless of its merit or outcome, could
not only result in significant legal defense costs, but also have a material adverse effect on our business and reputation and ability
to attract and retain customers for our products. &#160;In some circumstances, adverse events could also cause delays in regulatory approval
of new products or the imposition of post-market approval requirements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>We are subject to lawsuits.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">We have been and may be party to lawsuits, settlement discussions, mediations,
arbitrations and other disputes, including patent and product liability claims, whether brought by companies, individuals or governmental
authorities. &#160;These matters may result in a loss of patent protection, reduced revenue, incurrence of significant liabilities and
diversion of our management&#8217;s time, attention and resources. Our insurance coverage may not provide adequate protection against
actual losses. &#160;In addition, we are subject to the risk that one or more of our insurers may become insolvent and become unable to
pay claims that may be made in the future. &#160;Even if we maintain adequate insurance, claims could have a material adverse effect on
our financial condition, liquidity and results of operations and on our ability to obtain suitable, adequate or cost-effective insurance
in the future. &#160;Litigation and other disputes, including any adverse outcomes, may have an adverse impact on our business, operations
or financial condition. &#160;Even claims without merit could subject us to adverse publicity and require us to incur significant legal
fees.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>If we are unable to protect our patents or other proprietary rights,
or if we infringe the patents or other proprietary rights of others, our competitiveness and business prospects may be materially damaged.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Patent and other proprietary rights are essential to our business. &#160;We
own patents, trade secrets, trademarks and/or other intellectual property rights related to many of our products. &#160;Our success depends
to a significant degree on our ability to obtain and enforce patents, both in the U.S. and in other countries. &#160;We can lose the protection
afforded by these intellectual property assets through patent expirations, legal challenges or governmental action. &#160;Additionally,
our intellectual property rights may be challenged or infringed upon by third parties, particularly in countries where property rights
are not highly developed or protected, or we may be unable to enter into license agreements with third-party owners of intellectual property
on reasonable terms. &#160;Unauthorized use of our intellectual property rights or inability to preserve existing intellectual property
rights could adversely impact our competitive position and results of operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The patent position of a medical device company is often uncertain and
involves complex legal and factual questions. &#160;Significant litigation concerning patents and products is pervasive in our industry.
&#160;Patent claims include challenges to the coverage and validity of our patents on products or processes as well as allegations that
our products infringe patents held by competitors or other third parties. &#160;A loss in any of these types of cases could result in
a loss of patent protection or the ability to market products, which could lead to a significant loss of sales, or otherwise materially
affect future results of operations. &#160;We also rely on trademarks, trade secrets and know-how to develop, maintain and strengthen
our competitive positions. &#160;Third parties may know, discover or independently develop equivalent proprietary information or techniques,
or they may gain access to our trade secrets or disclose our trade secrets to the public.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Although our employees, consultants, parties to collaboration agreements
and other business partners are generally subject to confidentiality or similar agreements to protect our confidential and proprietary
information, these agreements may be breached, and we may not have adequate remedies in the event of a breach of confidence. &#160;To
the extent that our employees, consultants, parties to collaboration agreements and other business partners use intellectual property
owned by others in their work for us, disputes may arise as to the rights in related or resulting know-how and inventions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Furthermore, our intellectual property, other proprietary technology and
other sensitive company data is potentially vulnerable to loss, damage or misappropriation from system malfunction, computer viruses,
unauthorized access to our data or misappropriation or misuse thereof by those with permitted access and other events. &#160;While we
have invested to protect our intellectual property, confidential information and other data, and continue to work diligently in this area,
there can be no assurance that our precautionary measures will prevent breakdowns, breaches, cyber incidents or other events. Such events
could have a material adverse effect on our reputation, business, financial condition or results of operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Misappropriation or other loss of our intellectual property from any of
the foregoing would have an adverse effect on our competitive position and may cause us to incur substantial litigation costs.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>


<p style="font: 10pt TIMES NEW ROMAN, TIMES, SERIF; margin: 0; text-align: center">- 14 -</p>


<hr style="border-width: 0; color: Gray; background-color: Gray; height: 2px; width: 100%" /><p style="break-before: always"></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; color: blue"><i><a href="#toc">Table of Contents</a></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>We need to attract and retain key employees to be competitive.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Our ability to compete effectively depends upon our ability to attract
and retain executives and other key employees, including people in technical, marketing, sales, research and development, quality assurance
and regulatory compliance positions. &#160;We depend on key management personnel and attracting and retaining other qualified personnel,
and our business could be harmed if we lose key management personnel or cannot attract and retain other qualified personnel. &#160;We
do not maintain any &#8220;key man&#8221; insurance policies on the lives of any of our employees.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The failure to attract, integrate, motivate, and retain additional skilled
and qualified personnel could have a material adverse effect on our business. &#160;We compete for such personnel against numerous companies,
including larger, more established companies with significantly greater financial resources than we possess. &#160;Our ability to recruit
such talent will depend on a number of factors, including compensation and benefits, work location and work environment. &#160;There can
be no assurance that we will be successful in attracting or retaining such personnel and the failure to do so could have a material adverse
effect on our business, financial condition and results of operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>We sell a majority of our products through only a few distributors
on whom we depend, and our financial results depend on their purchasing patterns.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Most of our customers prefer to purchase our products through distributors,
rather than directly from us, because of &#8220;one-stop shopping&#8221; convenience and their ability to ship directly to patients. &#160;We
sell most of our products through a small number of distributors, three in the U.S. and two outside the U.S. &#160;As of December 31,
2022, these five distributors comprised approximately 72% of our net revenues with one U.S. distributor contributing 41%. &#160;Purchasing
patterns by these distributors cannot always be predicted and fluctuate from quarter to quarter and year to year based on, among other
things, their expectations of customer demand. &#160;Any decline in business with the distributors outside the U.S. could have an adverse
impact on our business. &#160;If we were unable to sell through the distributors outside the U.S., we would have to find other distributors
or broaden our customer base and expand direct relationships with customers. &#160;Other distributors may not be available or may not
agree to arrangements that are commercially reasonable. &#160;In the U.S. we could transition to direct customer purchase; however, customers
may not want to purchase directly from us and may decide to purchase competitors&#8217; products through their distributors. &#160;Moreover,
a transition from distributors to direct customer purchase would be time consuming and costly.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>We and the biopharmaceutical companies with whom we do novel therapies
business (&#8220;our biopharma customers&#8221;) are subject to extensive regulation by governments around the world, and if these regulations
are not complied with, existing and future operations may be curtailed, and we could be subject to liability.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Our devices and our biopharma customers&#8217; products that may utilize
our device are subject to extensive regulation by governmental authorities in the United States, Europe and other countries, including
the FDA. &#160;Not only do these regulations present challenges during the regulatory approval process, but after our devices or our biopharma
customers&#8217; products that may utilize our device are approved for new indications and placed in the market, numerous regulatory requirements
will apply. &#160;These include, but are not limited to QSR, labeling regulations and FDA prohibitions against the promotion of products
for uncleared, unapproved or &#8220;off label&#8221; uses, medical device reporting regulations and post-market surveillance regulations,
and laws and regulations that govern the development, testing, manufacturing, advertising, marketing and distribution of medical devices,
including our devices and our biopharma customers&#8217; products that may utilize our device. &#160;The FDA has broad post-market and
regulatory enforcement powers.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">In the European Union (&#8220;EU&#8221;), we are required to comply with
the new Medical Device Regulation (&#8220;MDR&#8221; or &#8220;EU MDR&#8221;) effective May 2021, which will supersedes the prior Medical
Device Directives. &#160;Class IIa medical devices which have a valid CE certificate to the current Medical Device Directives can continue
to be sold until December 2028 or until the CE certificate expires, whichever comes first, providing there are no significant changes
as defined in Article 120 of EU MDR. &#160;The MDR was published in May 2017 with a 3-year transition period. &#160;That transition period
was extended to May 2021 due to the COVID-19 pandemic. &#160;In 2023, the transition period was extended further to December 2028 for
Class IIa products. The CE mark required to sell medical devices in the EU is affixed following conformity assessment and either approval
from an appointed independent notified body or through self-certification by the manufacturer. &#160;The selected pathway to CE marking
is based on product risk classification. &#160;CE marking indicates conformity to the applicable essential requirements of the relevant
Medical Device Directives and in the future to the general safety and performance requirements for the new MDR. &#160;The MDR will change
multiple aspects of the existing regulatory framework for CE marking, such as increased clinical evidence requirements and other new requirements,
including Unique Device Identification (&#8220;UDI&#8221;) as well as many other post-market obligations. &#160;MDR also significantly
modifies and increases the compliance requirements for the industry and will require significant investment in the near future to implement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>


<p style="font: 10pt TIMES NEW ROMAN, TIMES, SERIF; margin: 0; text-align: center">- 15 -</p>


<hr style="border-width: 0; color: Gray; background-color: Gray; height: 2px; width: 100%" /><p style="break-before: always"></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; color: blue"><i><a href="#toc">Table of Contents</a></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">If our devices are commercialized as part of a drug-delivery combination
product we, as the manufacturer of the device component of that combination product, we are subject to unannounced and preapproval inspections
by the FDA of our manufacturing facility to determine our compliance with QSR and cGMP.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 9.5pt Times New Roman, Times, Serif; margin: 0">Failure to comply with applicable regulatory requirements can result in
an enforcement action by the FDA or other regulatory authority, which may include any or all of the following sanctions: fines, injunctions,
consent decrees and civil penalties, recall or seizure of our products or our biopharma customers&#8217; products, operating restrictions,
partial suspensions or total shutdown of production, refusing our biopharma customers&#8217; requests for regulatory approvals of their
drug-device combination products or new intended uses, as applicable, refusing our requests for regulatory approval of our devices, withdrawing
our biopharma customers&#8217; or our regulatory approvals that may be granted and criminal prosecution.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>The therapeutic efficacy of certain of our biopharma customers&#8217;
products that may utilize our device are either unproven in humans or has only been proven in limited circumstances, and we may not be
able to successfully develop and sell our products in combination with our biopharma customers&#8217; products.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">While some of our biopharma customers use our products with established,
approved drugs, in certain instances, the benefits of those drugs as injectable therapies are either unproven or have only been proven
in limited circumstances. &#160;Our ability to generate revenue from our products will depend heavily on the successful development, commercialization
and sales of our biopharma customers&#8217; products, which is subject to many potential risks. &#160;For example, data developed in clinical
trials or following the commercialization of our biopharma customers&#8217; products may show that such therapies do not prove to be effective
treatments for the targets they are being designed to act against (or as effective as other treatments available). In clinical trials
or following commercialization, it may be shown that those drugs interact with human biological systems in unforeseen, ineffective or
harmful ways. &#160;If those drugs are associated with undesirable side effects or have characteristics that are unexpected, the pharmaceutical
companies that make those drugs may need to abandon clinical development or discontinue commercial sales or limit clinical development
or sales to certain uses or subpopulations in which the undesirable side effects or other characteristics are less prevalent, less severe
or more acceptable from a risk-benefit perspective. &#160;As a result of these and other risks described herein that are inherent in the
development and sale of therapeutic agents, pharmaceutical companies may never successfully develop or successfully commercialize their
drugs, or the commercialization of their drugs may be abandoned or severely limited, which may limit our profitability with respect to
biopharma customers with drugs or drug-device combination products including those drugs and our device, and we may not be successful
in achieving commercial scale production and sales of our injectable drug delivery systems in combination with certain drugs.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>Certain of the injectable therapies being targeted for use with our
products are not approved but are in various phases of clinical development. These injectable therapies may be independently terminated
by their makers prior to submission of a regulatory filing or even after regulatory approval and pharmaceutical developers may cease their
efforts with us, resulting in the cessation of any revenue associated with that contract or program.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">We work with pharmaceutical and biotechnology companies who are targeting
the use of our products with a variety of injectable therapies. &#160;When we collaborate with pharmaceutical developers, they may engage
us in a variety of ways, including <i>in vitro </i>feasibility testing, product customization and validation (&#8220;development&#8221;),
non-interventional user testing of our devices, animal or human clinical research using our devices, regulatory submissions, manufacturing
development, and commercialization. Certain of those injectable therapies are not FDA approved and are in various phases of clinical development.
&#160;The clinical development of these pipeline therapies can be terminated by their developers at any stage. &#160;Our biopharma customers
may choose to continue their drug program without use of our devices. Use in one stage of work does not guarantee use in a future development
stage or in commercialization. Furthermore, these pharmaceutical companies could obtain regulatory approval for their injectable therapies
and decide for business reasons not to require or encourage utilization of our device. &#160;Prior investments we have made in manufacturing
capacity or research and development will then not result in the generation of revenue that would have previously been anticipated.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>Our commercial success depends upon the attainment of significant
market acceptance of drug product candidates to be included in our biopharma customers&#8217; products that may utilize our device, if
approved, among physicians, patients, healthcare payers or the medical community.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Even if biopharmaceutical companies obtain regulatory approval for their
drug product candidates, their product candidates may not gain sufficient levels of market acceptance among physicians, healthcare payers,
patients or the medical community to make them commercially feasible. Market acceptance of our biopharma customers&#8217; product candidates,
if they receive approval, depends on a number of factors, including the:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>


<p style="font: 10pt TIMES NEW ROMAN, TIMES, SERIF; margin: 0; text-align: center">- 16 -</p>


<hr style="border-width: 0; color: Gray; background-color: Gray; height: 2px; width: 100%" /><p style="break-before: always"></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; color: blue"><i><a href="#toc">Table of Contents</a></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 7.5in; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: center">&#8226;</td>
    <td style="width: 7in">efficacy and safety of the product candidates;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center">&#8226;</td>
    <td>clinical indications for which the product candidates are approved;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center">&#8226;</td>
    <td>acceptance by physicians, patients and the medical community of the product candidates as a safe and effective treatment;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center">&#8226;</td>
    <td>potential and perceived advantages of the product candidates over alternative treatments;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center">&#8226;</td>
    <td>safety of the product candidates seen in a broader patient group;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center">&#8226;</td>
    <td>prevalence and severity of any side effects;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center">&#8226;</td>
    <td>product labeling or product insert requirements of the FDA or other regulatory authorities;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center">&#8226;</td>
    <td>timing of market introduction of the product candidates as well as competitive products;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center">&#8226;</td>
    <td>cost of treatment in relation to alternative treatments;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center">&#8226;</td>
    <td>availability of coverage and adequate reimbursement and pricing by third party payers and government authorities;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center">&#8226;</td>
    <td>relative convenience and ease of administration; and</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center">&#8226;</td>
    <td>effectiveness of the pharmaceutical companies&#8217; sales and marketing efforts.</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">If pharmaceutical companies&#8217; candidates are approved but fail to
achieve market acceptance among physicians, patients or healthcare payers, we may not be able to generate anticipated revenue. &#160;This
may limit our ability to generate anticipated revenue from our prior investments. &#160;Moreover, even if we achieve commercial scale
production and sales of our injectable drug delivery systems in combination with certain injectable therapies, the makers of such therapies
may face indirect competition from companies who develop and market other brand name, biosimilar or generic injectable therapies as well
as alternative treatments and delivery methods that compete with our biopharma customers&#8217; products that may utilize our device,
which may have a material adverse effect on our results of operations, our financial condition and/or cash flows.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>Most brand name injectable therapies will face future competition
from generic or biosimilar therapies, which could significantly reduce their commercial viability.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Brand name injectable therapies will usually become exposed to competition
from generic or biosimilar rivals at some time after their regulatory approval and commercial launch. &#160;The average selling price
and market share of brand name injectable therapies can be significantly diminished following the introduction of generic or biosimilar
competition. &#160;These factors may result in our biopharma customers using our products with their brand name injectable therapies seeking
to withdraw such injectable therapy from the market or change market tactics in a way that makes the use of our products cost prohibitive.
&#160;This may result in reduction of revenues due to lower demand, termination of supply contracts, and other factors.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>Most of our components and raw materials are sourced from single
suppliers. If we are unable to obtain sufficient components or raw materials on a timely basis or for a cost-effective price, or if we
experience other supply difficulties, our business and results of operations may be adversely affected.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Our ability to meet customer demand depends, in part, on our ability to
obtain timely and adequate delivery of raw materials and components for our products. &#160;A majority of the materials and components
that go into the manufacturing of our products are single-sourced from third-party suppliers.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The price and supply of materials and components for our products may be
impacted or disrupted for reasons beyond our control. While we work with suppliers to ensure continuity of supply, no assurance can be
given that these efforts will be successful. &#160;Although we do carry strategic inventory and maintain insurance to help mitigate the
potential risk related to any supply disruption, there can be no assurance that such measures will be sufficient or effective. &#160;The
termination, reduction or interruption in supply of raw materials and components and an inability to quickly develop acceptable alternative
sources for such supply, could adversely impact our ability to manufacture and sell our products in a timely or cost-effective manner.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">We do not have long-term agreements in place with any of our suppliers,
with the exception of a long-term agreement with our needle and tubing set subassembly supplier which we entered in 2020. Due to regulatory
requirements relating to the qualification of suppliers, we are not likely to be able to establish additional or replacement sources on
a timely basis or without excessive cost. &#160;We are in the process of establishing alternative sources of supply for our raw materials
and components, but there can be no assurance we will be able to do so.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Additionally, volatility in our cost of energy, raw materials, components,
subassemblies, transportation/freight, and manufacturing and distribution could adversely affect our results of operations. &#160;Climate
change (including laws or regulations passed in response to it) could increase our costs, in particular our costs of supply, energy and
transportation/freight. &#160;Material or sustained increases in the price of oil and natural gas could have an adverse impact on the
cost of many of the plastic materials we use to make and package our products, as well as our transportation/freight costs. &#160;These
outcomes may in turn result in customers transitioning to available competitive products, loss of market share, negative publicity, reputational
damage, loss of customer confidence or other negative consequences (including a decline in stock price).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>


<p style="font: 10pt TIMES NEW ROMAN, TIMES, SERIF; margin: 0; text-align: center">- 17 -</p>


<hr style="border-width: 0; color: Gray; background-color: Gray; height: 2px; width: 100%" /><p style="break-before: always"></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; color: blue"><i><a href="#toc">Table of Contents</a></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>Our failure to comply with laws and regulations relating to reimbursement
of health care products may subject us to penalties and adversely impact our reputation, business, results of operations, financial condition
and cash flows.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Our devices are purchased principally by specialty pharmacies and
ambulatory service providers or hospitals that typically bill various third-party payers, such as governmental programs (e.g.,
Medicare, Medicaid and comparable non-U.S. programs), private insurance plans and managed care plans, for the healthcare services
provided to their patients. &#160;The ability of those customers to obtain appropriate reimbursement from third-party payers for our
products and the drugs they administer is critical because it affects which products customers purchase and the prices they are
willing to pay. &#160;As a result, our devices are subject to regulation regarding quality and cost by U.S. governmental agencies,
including the Centers for Medicare &amp; Medicaid Services (&#8220;CMS&#8221;), as well as comparable state and non-U.S. agencies
responsible for reimbursement and regulation of health care goods and services, including laws and regulations related to kickbacks,
false claims, self-referrals and health care fraud. &#160;Many states have similar laws that apply to reimbursement by state
Medicaid and other funded programs, and in some cases to all payers. &#160;In certain circumstances, insurance companies can attempt
to bring a private cause of action against a manufacturer for causing a false claim to be filed under the Federal Racketeer
Influenced and Corrupt Organizations Act. In addition, as a manufacturer of FDA-approved devices reimbursable by federal healthcare
programs, we are subject to the Physician Payments Sunshine Act, which requires us to annually report certain payments and other
transfers of value we make to U.S.-licensed physicians or U.S. teaching hospitals. &#160;Any failure to comply with these laws and
regulations could subject us or our officers and employees to criminal and civil financial penalties. &#160;Similar reporting requirements applicable to medical device manufacturers have also been implemented by some states. Failure to comply with these state
requirements could result in civil monetary penalties being assessed against us.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">These laws and regulations, among other things, constrain our business,
marketing and other promotional activities by limiting the kinds of financial arrangements, including sales programs, we may have with
hospitals, physicians or other potential purchasers of our products. Due to the breadth of these laws, the narrowness of statutory exceptions
and regulatory safe harbors available, and the range of interpretations to which they are subject, it is possible that some of our current
or future practices might be challenged under one or more of these laws.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">To enforce compliance with the healthcare regulatory laws, certain enforcement
bodies have recently increased their scrutiny of interactions between healthcare companies and healthcare providers, which has led to
a number of investigations, prosecutions, convictions and settlements in the healthcare industry. Responding to investigations can be
time-and resource-consuming and can divert management&#8217;s attention from the business. Additionally, as a result of these investigations,
healthcare providers and entities may have to agree to additional compliance and reporting requirements as part of a consent decree or
corporate integrity agreement. Any such investigation or settlement could increase our costs or otherwise have an adverse effect on our
business. &#160;Even an unsuccessful challenge or investigation into our practices could cause adverse publicity and be costly to respond
to. &#160;If our operations are found to be in violation of any of the healthcare laws or regulations described above or any other healthcare
regulations that apply to us, we may be subject to penalties, including administrative, civil and criminal penalties, damages, fines,
exclusion from participation in government healthcare programs, such as Medicare and Medicaid, imprisonment, contractual damages, reputational
harm, disgorgement and the curtailment or restructuring of our operations. &#160;In addition, we are subject to the U.S. Foreign Corrupt
Practices Act and similar anti-corruption laws outside the U.S. Actual or alleged violation of these laws by our employees, consultants,
sales agents or distributors could subject us to investigations by the U.S. or foreign governments, significant criminal or civil sanctions
and other liabilities, and damage our reputation.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>We may need additional funding in the future, and if we are unable
to raise capital when needed, we may be forced to delay, reduce or eliminate our product development, commercial efforts, or sales efforts.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Producing and marketing our developed products is costly. &#160;Although
we believe we currently have adequate capital to fulfill our near-term funding needs, we may need to raise additional capital in the future
in order to execute our business plan and help us fund the development and commercialization of new products.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">We may finance future cash needs through public or private equity offerings
and may also use debt financings or strategic collaboration and licensing arrangements. &#160;We may seek to access the public or private
equity markets whenever conditions are favorable, even if we do not have an immediate need for additional capital. &#160;To the extent
that we raise additional funds by issuing equity securities, our shareholders may experience additional dilution; any debt financing,
if available, may involve restrictive covenants and could result in high interest expense. &#160;If we raise additional funds through
collaboration and licensing arrangements, it may require us to relinquish certain enumerated rights to our product candidates, processes,
technologies, or development projects, or to enter into licenses on terms that are not favorable to us. &#160;We cannot be certain that
additional funding will be available on acceptable terms, or at all. &#160;If adequate funds are not available from the foregoing sources,
we may consider additional strategic financing options, or we may be required to delay, reduce the scope of, or eliminate our research
or development and/or some of our commercialization efforts.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>


<p style="font: 10pt TIMES NEW ROMAN, TIMES, SERIF; margin: 0; text-align: center">- 18 -</p>


<hr style="border-width: 0; color: Gray; background-color: Gray; height: 2px; width: 100%" /><p style="break-before: always"></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; color: blue"><i><a href="#toc">Table of Contents</a></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>We may experience difficulties resulting from our relatively new
and evolving management structure and executive team.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">We have made a number of changes to our management structure throughout
the organization in recent years and have filled a number of these positions while we are actively recruiting to fill others. &#160;Although,
we believe the persons who currently and will serve in these positions are and will be qualified to do so, they may take time to integrate
into the organization and with each other, if at all. &#160;Many of these persons have or will have had little to no experience with our
company prior to joining us, which may result in delays in our ability to implement our business plans. &#160;If we are unable to integrate,
motivate and retain the services of our new executives and other managers, or if integration takes longer than we expect, it may have
an adverse effect on our business and financial condition.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>Changes in tax or labor laws or exposure to additional income tax
liabilities could increase our costs and reduce our margins.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Changes to the tax and labor laws in the U.S. or other countries in which
we operate could have an adverse effect on our operating results. &#160;Certain changes in tax rates, deductibility of interest, deductibility
of executive compensation expense, expensing of capital expenditures, the ability to use certain tax credits, taxation on earnings from
international business operations, and the system of taxation (from worldwide to territorial) could adversely affect our financial condition
and results of operations. &#160;Taxing authorities may audit us from time to time and disagree with certain positions we have taken in
respect of our tax liabilities. &#160;We regularly assess the likely outcomes of these audits in order to determine the appropriateness
of our tax provision. &#160;However, we may not accurately predict the outcome of these audits, and as a result the actual outcome of
these audits may have an adverse impact on our financial results.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Our manufacturing operations depend on low-cost labor. &#160;Recent increases
in U.S. minimum wage requirements, as well as those imposed by the state of New York and New Jersey will increase our costs for employees
to support those operations, reduce our margins and negatively impact our profit.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>A downturn in global economic conditions could adversely affect our
operations.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Deterioration in the global economic environment, particularly in countries
with government-sponsored healthcare systems, may cause decreased demand for our products and increased competition, which could result
in lower sales volume and downward pressure on the prices for our products, longer sales cycles, and slower adoption of new technologies.
&#160;A weakening of economic conditions in the U.S. and/or abroad may also adversely affect our suppliers, which could result in interruptions
in supply.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>We are subject to foreign currency exchange risk.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">A portion of our revenues is currently, and we expect in the future to
be, derived from international operations. &#160;Our revenues from sales outside the U.S. may be adversely affected by fluctuations in
foreign currency exchange rates. &#160;We cannot predict with any certainty changes in foreign currency exchange rates or our ability
to mitigate these risks. &#160;We may experience additional volatility as a result of inflationary pressures and other macroeconomic factors.
&#160;If we cannot adequately mitigate foreign currency exchange rates, our revenues and profit may suffer.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>Our distribution network and other operations outside the U.S. subject
us to certain risks.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Approximately 15% of our net revenues in the year ended December 31, 2022,
came from our operations outside the U.S., and we intend to continue to pursue growth opportunities in foreign markets. &#160;Our foreign
operations subject us to certain risks, including, among others, the effects of fluctuations in foreign currency exchange, uncertainties
with respect to local economic and political conditions, competition from local companies, trade protectionism and restrictions on the
transfer of goods across borders, U.S. diplomatic and trade relations with the governments of the foreign countries in which we operate,
foreign regulatory requirements or changes in such requirements, local product preferences and product requirements, longer payment terms
for accounts receivable than we experience in the U.S., difficulty in establishing, staffing and managing foreign operations, changes
to international trade agreements and treaties, changes in tax laws, weakening or loss of the protection of intellectual property rights
in some countries, and import or export licensing requirements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>


<p style="font: 10pt TIMES NEW ROMAN, TIMES, SERIF; margin: 0; text-align: center">- 19 -</p>


<hr style="border-width: 0; color: Gray; background-color: Gray; height: 2px; width: 100%" /><p style="break-before: always"></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; color: blue"><i><a href="#toc">Table of Contents</a></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>We are dependent on information technology systems and subject to
privacy and security laws, and our systems and infrastructure face certain risks, including from cyber security breaches and data leakage.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Despite the implementation of security measures, our internal computer
systems, and those of third parties on which we rely, are vulnerable to damage from computer viruses, malware, natural disasters, terrorism,
war, telecommunication and electrical failures, cyber-attacks or cyber-intrusions over the Internet, attachments to emails, persons inside
our organization, or persons with access to systems inside our organization. &#160;While we do not believe that we have experienced any
such system failure, accident, or security breach to date, if such an event were to occur and cause interruptions in our systems, it could
result in a material disruption of our operations. &#160;To the extent that any disruption or security breach results in a loss of or
damage to our data or applications or other data</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">applications relating to our technology, or inappropriate disclosure of
confidential or proprietary information, we could incur liabilities, damage to our reputation, and the further development of our product
candidates could be delayed. &#160;Additionally, such disruptions and security breaches, when there is a risk of patient harm, may require
devices changes to fix vulnerabilities and strengthen cybersecurity. &#160;Such changes could, in some cases, require reporting to and
approval by the FDA prior to implementation, which could cause a delay in the continued marketing of the underlying product that will
result in a loss of revenues to us. Furthermore, failure to adhere to good cybersecurity practices with regards to medical devices could
result in enforcement action by the FDA including warning letters or other forms of enforcement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>We cannot guarantee that any of our strategic acquisitions, investments
or alliances will be successful.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">We may seek to supplement our internal growth through strategic acquisitions,
investments and alliances. &#160;Such transactions are inherently risky, and the integration of any newly acquired business requires significant
effort and management attention. &#160;The success of any acquisition, investment or alliance may be affected by a number of factors,
including our ability to properly assess and value the potential business opportunity or to successfully integrate any business we may
acquire into our existing business. &#160;There can be no assurance that any past or future transaction will be successful.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>Our operating results and financial condition may fluctuate.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Our operating results and financial condition may fluctuate from quarter
to quarter and year to year for a number of reasons. &#160;Events such as a delay in product development, increases in litigation expenses,
changes to our expectations or strategy or even a relatively small revenue shortfall may cause financial results for a period to be below
our expectations or projections. &#160;As a result, we believe that period-to-period comparisons of our results of operations should not
be relied upon as an indication of future performance. &#160;Our operating results and financial condition are also subject to fluctuation
from all of the risks described throughout this section. &#160;These fluctuations may adversely affect our results of operations and financial
conditions and our stock price.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>Future material impairments in the value of our long-lived assets
could negatively affect our operating results.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">We review our long-lived assets, including identifiable intangible assets
and property, plant and equipment, for impairment. &#160;Long-lived assets are reviewed when there is an indication or triggering event
that impairment may have occurred. &#160;Changes in market conditions or other changes in the future outlook of value may lead to impairment
charges in the future. &#160;In addition, we may from time to time sell assets that we determine are not critical to our strategy. &#160;Future
events or decisions may lead to asset impairments and/or related charges. Certain non-cash impairments may result from a change in our
strategic goals, business direction or other factors relating to the overall business environment. &#160;Material impairment charges could
negatively affect our results of operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>Actions of activist stockholders could have an adverse effect on
our business.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">From time to time, we may be subject to proposals by stockholders urging
us to take certain corporate actions. &#160;If activist stockholder activities ensue, our business could be adversely affected because
responding to proxy contests and reacting to other actions by activist stockholders can be costly and time-consuming, disrupt our operations
and divert the attention of management and our employees. For example, we may be required to retain the services of various professionals
to advise us on activist stockholder matters, including legal, financial and communications advisors, the costs of which may negatively
impact our future financial results. &#160;In addition, perceived uncertainties as to our future direction, strategy or leadership created
as a consequence of activist stockholder initiatives may result in the loss of potential business opportunities, harm our ability to attract
new investors, customers, employees, and joint venture partners, and cause our stock price to experience periods of volatility or stagnation.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>


<p style="font: 10pt TIMES NEW ROMAN, TIMES, SERIF; margin: 0; text-align: center">- 20 -</p>


<hr style="border-width: 0; color: Gray; background-color: Gray; height: 2px; width: 100%" /><p style="break-before: always"></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; color: blue"><i><a href="#toc">Table of Contents</a></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>Natural disasters, war and other events could adversely affect our
suppliers and customers.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Natural disasters (including pandemics), war, terrorism, labor disruptions
and international conflicts, and actions taken by the U.S. and other governments or by our customers or suppliers in response to such
events, could cause significant economic disruption and political and social instability in the U.S. and areas outside of the U.S. in
which we operate. &#160;Most of our products are assembled and packaged in Nicaragua, where there is currently civil unrest whose outcome
cannot be predicted. &#160;This and similar events could increase the costs for or cause interruptions in the supply of materials, result
in decreased demand for our products or adversely affect our manufacturing and distribution capabilities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>Our insurance coverage may be inadequate to cover all the liabilities
we may incur.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">We face the risk of exposure to liability claims if any product that we
develop causes injury. &#160;Although we carry insurance at levels customary for companies in our industry, such coverage may become unavailable
or be inadequate to cover all liabilities we may incur. &#160;There can be no assurance that we will be able to continue to maintain such
insurance, or obtain comparable insurance at a reasonable cost, if at all. &#160;If we are unable to obtain sufficient insurance coverage
at an acceptable cost or otherwise, or if the amount of any claim against us exceeds the coverage under our policies, we may face significant
expenses.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>Rising inflation increases economic uncertainty and may require us
to need to raise prices in order to maintain our operating margins.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">For much of the past two years, inflation rates have risen or held steady
at rates not seen in a generation or more. Higher level of inflation not only reduces the real value of the profits we generate from our
business (and in turn our returns to investors), but it also increases the costs of goods and services that we need to run our business.
Should such trends continue, it would not only have a destabilizing macroeconomic effect on the broader U.S. and global economy, but it
may also require us to increase the price of our products in order to maintain sufficient operations margins. Any increase in the prices
we charge our customers could reduce the demand for our products, perhaps significantly. We will continue to monitor inflation trends
and will make adjustments to our business as necessary.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>Brexit may impact our business in the United Kingdom.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">One of our two most significant international distributors is located in
the United Kingdom (&#8220;UK&#8221;), and the other is in Finland, a member of the European Union (&#8220;EU&#8221;). &#160;The June
2016 referendum result in the UK to exit the EU (commonly known as &#8220;Brexit&#8221;), and the subsequent commencement of the official
withdrawal process by the UK government in March 2017, has created uncertainties affecting business operations in the UK and the EU. &#160;On
January 31, 2020, the UK withdrew from the EU. Under the withdrawal agreement agreed between the UK and the EU, the UK was subject to
a transition period until December 31, 2020 (the &#8220;Transition Period&#8221;) during which EU rules continued to apply. &#160;During
the Transition Period, negotiations between the UK and the EU continued in relation to the future customs and trading relationship between
the UK and the EU following the expiration of the Transition Period. Due to the current COVID-19 global pandemic, negotiations between
the UK and the EU scheduled have either been postponed or occurred in a reduced forum via video conference. &#160;However, on December
24, 2020, the negotiators from the EU and UK reached an agreement on a new partnership. &#160;This agreement sets out the rules that apply
between the EU and the UK as of January 1, 2021. &#160;New regulations require medical device registration with the Medicines and Healthcare
Products Regulatory Agency (&#8220;MHRA&#34;) before being placed on the Great Britain market (England, Wales, and Scotland). Additionally,
all medical devices will require a UK Conformity Assessment mark (&#8220;UKCA&#8221;) by July 1, 2024. CE marks issued by Notified Bodies
will remain valid until this time. Therefore, we must be compliant with applicable legislation in order to identify our devices with the
UKCA mark and continue to market and sell our devices in Great Britain beyond July 1, 2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>We could be adversely affected, directly or indirectly, by the effects
of an increased focus on environmental, social and governance issues.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Recently, shareholders generally have increased their focus on environmental,
social and governance (&#34;ESG&#34;) issues, specifically regarding how companies are addressing climate change, diversity, and human
rights, among other ESG-related issues. Our failure to comply with shareholder expectations and standards regarding ESG issues, which
are still evolving and can vary considerably, or the perception that we have not responded appropriately to ESG-related issues, could
result in reputational harm, and could have an adverse effect on our business, results of operations and financial condition.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>


<p style="font: 10pt TIMES NEW ROMAN, TIMES, SERIF; margin: 0; text-align: center">- 21 -</p>


<hr style="border-width: 0; color: Gray; background-color: Gray; height: 2px; width: 100%" /><p style="break-before: always"></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; color: blue"><i><a href="#toc">Table of Contents</a></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Climate change could present immediate and long-term risks to our industry
and our customers. The potential for increased severe weather events could have a material adverse effect on our operations and infrastructure
or the operations and infrastructure of our suppliers. In addition, the effects of climate change could include long-term changes in temperature
levels and water availability, increased energy costs, and increased supply costs impacted by those increasing energy costs. The cost
of mitigating or responding to ESG issues could be significant; however, these costs are too uncertain to predict. In addition, the approaches
taken by the U.S. or foreign governments to regulate ESG issues, which may include legislative or regulatory changes, could adversely
impact our business, results of operations, financial condition, and prospects, and are too uncertain to predict.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>Risks Related to Ownership of Our Common Stock</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>There may be circumstances in which the interests of our significant
stockholders could be in conflict with your interests as a stockholder.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Three stockholders, together with their respective affiliates, beneficially
own approximately 23%, 14%, and 6% of our outstanding common stock, respectively. &#160;An affiliate of Horton Freedom, L.P. currently
serves on our Board of Directors. &#160;Circumstances may arise in which these stockholders may have an interest in exerting influence
to pursue or prevent acquisitions, divestitures or other transactions, including the issuance of additional shares or debt, that, in their
judgment, could enhance their investment in us or another company in which they invest. &#160;Such transactions might adversely affect
us or other holders of our common stock. Furthermore, our significant concentration of share ownership may adversely affect the trading
price of our common stock because investors may perceive disadvantages in owning shares in companies with significant stockholders.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>We do not currently intend to pay dividends on our common stock.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">We have never paid dividends on our common stock, and we do not intend
to pay any dividends to holders of our common stock for the foreseeable future. &#160;We currently intend to invest our future earnings,
if any, to fund our growth. &#160;Therefore, you are not likely to receive any dividends on your common stock for the foreseeable future.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>Future sales and issuances of shares of our common stock or rights
to purchase our common stock, including pursuant to our equity compensation plans, could result in additional dilution of the percentage
ownership of our stockholders.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">We may need additional capital in the future to continue our planned operations.
&#160;To the extent we raise additional capital by issuing equity and/or convertible securities, our stockholders may experience substantial
dilution. &#160;We may sell our common stock, convertible securities or other equity securities in one or more transactions at prices
and in a manner, we determine from time to time. If we sell our common stock, convertible securities or other equity securities, investors
may be materially diluted. &#160;These sales may also result in material dilution to our existing stockholders, and new investors could
gain rights superior to our existing stockholders.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">We provide and intend to continue to provide additional equity-based compensation
to our employees, directors and consultants under our three equity compensation plans. We may issue equity-based compensation outside
of our equity compensation plans as inducement for new employees. &#160;If our Board elects to issue additional stock options or other
equity-based compensation, our stockholders may experience additional dilution, which could cause our stock price to decline. &#160;Because
stock options granted under our equity compensation plans will generally only be exercised when the exercise price for such option is
below the then market value of the common stock, the exercise of such options or the issuance of shares will cause dilution to the book
value per share of our common stock and to existing and new investors.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>There has been volatility in the price of shares of our common stock.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Since our common stock was listed on the Nasdaq Capital Market on October
17, 2019, it has traded between $1.82 per share to $12.84 per share. &#160;Our stock price is subject to wide fluctuations in response
to a variety of factors, including:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 7.5in; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: center">&#8226;</td>
    <td style="width: 7in">quarterly variations in operating results;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center">&#8226;</td>
    <td>announcement of new products or customers by our competitors;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center">&#8226;</td>
    <td>changes in financial estimates by securities analysts;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center">&#8226;</td>
    <td>trading volume on the Nasdaq Capital Market;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center">&#8226;</td>
    <td>announcements related to litigation;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center">&#8226;</td>
    <td>general economic conditions; or</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center">&#8226;</td>
    <td>other events or factors that are beyond our control.</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>


<p style="font: 10pt TIMES NEW ROMAN, TIMES, SERIF; margin: 0; text-align: center">- 22 -</p>


<hr style="border-width: 0; color: Gray; background-color: Gray; height: 2px; width: 100%" /><p style="break-before: always"></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; color: blue"><i><a href="#toc">Table of Contents</a></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">In addition, the stock market has experienced significant price and volume
fluctuations that have particularly affected the trading prices of equity securities of many biotechnology companies. &#160;These fluctuations
have often been unrelated or disproportionate to the operating performance of these companies. &#160;Any negative change in the public&#8217;s
perception of the prospects of medical device companies could further depress our stock price regardless of our results. &#160;Sales of
substantial amounts of our common stock, particularly by our two most significant stockholders, or the perception that such sales might
occur, could adversely affect prevailing market prices of our common stock and our stock price may decline substantially in a short time
and our stockholders could suffer losses or be unable to liquidate their holdings.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>If we do not maintain compliance with the listing standards of the
Nasdaq Capital Market, Nasdaq may delist our common stock from trading on its exchange</i></b>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The Nasdaq Capital Market on which our common stock trades has continued
listing standards that we must maintain on an ongoing basis in order to continue the listing of our common stock. &#160;If we fail to
meet these continued listing requirements, our common stock may be subject to delisting. &#160;If our common stock is delisted and we
are not able to list our common stock on another national securities exchange, we expect our securities would be quoted on an over-the-counter
market. &#160;If this were to occur, our stockholders could face significant material adverse consequences, including limited availability
of market quotations for our common stock and reduced liquidity for the trading of our common stock. &#160;In addition, we could experience
a decreased ability to issue additional securities and obtain additional financing in the future, if or when needed.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>We are a smaller reporting company and non-accelerated filer, and
we cannot be certain if the reduced disclosure requirements applicable to us will make our common stock less attractive to investors.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">We are currently a &#8220;smaller reporting company&#8221; and a &#8220;non-accelerated
filer&#8221;, as those terms are defined in the Securities Act. &#160;Accordingly, we take advantage of certain exemptions from various
reporting requirements that are applicable to other public companies that are not &#8220;smaller reporting companies&#8221; and &#8220;non-accelerated
filers,&#8221; including, but not limited to, reduced disclosure obligations regarding executive compensation in our periodic reports
and proxy statements and exemptions from the provisions of Section&#160;404(b) of the Sarbanes-Oxley Act of 2002 requiring that independent
registered public accounting firms provide an attestation report on the effectiveness of internal control over financial reporting. &#160;Decreased
disclosures in our SEC filings due to our status as a &#8220;smaller reporting company&#8221; and &#8220;non-accelerated filer&#8221;
may make it harder for investors to analyze our results of operations and financial prospects.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">We cannot predict if investors will find our common stock less attractive
if we rely on these exemptions. &#160;If some investors find our common stock less attractive as a result, there may be a less active
trading market for our common stock and our share price may be more volatile.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>The price of our common stock may be adversely affected by the future
issuance and sale of shares of our common stock or other equity securities.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">We cannot predict the size of future issuances or sales of our common stock
or other equity securities future acquisitions or capital raising activities, or the effect, if any, that such issuances or sales may
have on the market price of our common stock. The issuance and sale of substantial amounts of common stock or other equity securities
or announcement that such issuances and sales may occur, could adversely affect the market price of our common stock. Any decline in the
price of our common stock may encourage short sales, which could place further downward pressure on the price of our common stock and
may impair our ability to raise additional capital through the sale of equity securities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>You may find it difficult to sell our common stock.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Only recently has there been any active trading market in our common stock.
&#160;We cannot assure you that such an active trading market for our common stock will be sustained. &#160;Regardless of whether an active
and liquid public market exists, negative fluctuations in our actual or anticipated operating results will likely cause the market price
of our common stock to fall, making it more difficult for you to sell our common stock at a favorable price, or at all.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>


<p style="font: 10pt TIMES NEW ROMAN, TIMES, SERIF; margin: 0; text-align: center">- 23 -</p>


<hr style="border-width: 0; color: Gray; background-color: Gray; height: 2px; width: 100%" /><p style="break-before: always"></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; color: blue"><i><a href="#toc">Table of Contents</a></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="a_003"></span>&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>ITEM 1B. UNRESOLVED STAFF COMMENTS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Not applicable.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="a_004"></span>&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>ITEM 2. PROPERTIES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">We currently rent 43,975 square feet of a building located at 100 Corporate
Drive, Mahwah, New Jersey with the lease having commenced on March 1, 2022 and expiring August 31, 2032. This facility is used as our
headquarters and for our manufacturing operations. The Company&#8217;s existing lease at 24 Carpenter Road, Chester New York, from which
the Company is transitioning manufacturing operations to Mahwah, NJ, expires March 31, 2023.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="a_005"></span>&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>ITEM 3. LEGAL PROCEEDINGS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">None.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="a_006"></span>&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>ITEM 4. MINE SAFETY DISCLOSURES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Not applicable.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>PART II</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="a_007"></span>&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>ITEM 5. MARKET FOR THE REGISTRANT&#8217;S COMMON EQUITY, RELATED STOCKHOLDER
MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Market Information</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Our common stock is traded on the Nasdaq Capital Market under the symbol
&#8220;KRMD.&#8221; &#160;We have not paid any cash dividends on our common stock and do not plan to pay any such dividends in the foreseeable
future. &#160;We currently intend to use all available funds for our business operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">We are authorized to issue 77,000,000 shares of capital stock, of
which 75,000,000 are designated common stock, $0.01 par value per share, and 2,000,000 are designated preferred stock. &#160;As of
March 8, 2023, 45,519,164 shares of our common stock were issued and outstanding held by approximately 516 stockholders of record.
&#160;There were no shares of preferred stock issued and outstanding.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="a_008"></span>&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>ITEM 6. SELECTED FINANCIAL DATA</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Not applicable.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="a_009"></span>&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>ITEM 7. MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION
AND RESULTS OF OPERATIONS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><i>The following discussion and analysis of our financial condition and
results of operations should be read together with our consolidated financial statements and related notes included under ITEM 8 of this
Annual Report on Form 10-K. &#160;This discussion contains forward-looking statements about our business and operations. &#160;Our actual
results may differ materially from those we currently anticipate as a result of many factors, including those described under Part I &#8211;
FORWARD LOOKING STATEMENTS and elsewhere in this Annual Report.</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>OVERVIEW</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The Company develops, manufactures and markets proprietary portable and
innovative medical devices primarily for the subcutaneous drug delivery market as governed by the United States Food and Drug Administration
(the &#8220;FDA&#8221;) quality and regulatory system and international standards for quality system management.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Our revenues derive from three business sources: (i) domestic core, (ii)
international core, and (iii) novel therapies.&#160; Our domestic core and international core revenues consist of sales of our products
for the delivery of subcutaneous drugs that are FDA cleared for use with the Freedom Infusion System, with the primary use being for the
delivery for immunoglobulin to treat Primary Immunodeficiency Diseases (&#8220;PIDD&#8221;) and Chronic Inflammatory Demyelinating Polyneuropathy
(&#8220;CIDP&#8221;). Novel therapies consist of product revenues from our infusion system (syringe drivers, tubing and needles) for feasibility/clinical
trials (pre-clinical studies, Phase I, Phase II, Phase III) of biopharmaceutical companies in the drug development process as well as
non-recurring engineering services revenues (&#8220;NRE&#8221;) received from biopharmaceutical companies to ready or customize the FREEDOM
System for clinical and commercial use.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>


<p style="font: 10pt TIMES NEW ROMAN, TIMES, SERIF; margin: 0; text-align: center">- 24 -</p>


<hr style="border-width: 0; color: Gray; background-color: Gray; height: 2px; width: 100%" /><p style="break-before: always"></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; color: blue"><i><a href="#toc">Table of Contents</a></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The Company continued its transition of substantially all finished goods
manufacturing of its needle and tubing sets to Command Medical Products, a third-party contract manufacturing organization, which began
in 2021, and expects to complete the transition no later than the second quarter of 2023.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The Company entered into a lease commencing March 1, 2022 for a new corporate
headquarters and manufacturing facility located in Mahwah, NJ. During the quarter ended June 30, 2022, the Company completed the first
phase of the move, the headquarters and office staff to the new location, and expects to complete the move of manufacturing before the
end of the first quarter 2023.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The Company ended the 2022 fiscal year with $27.9 million in net revenues,
a 18.8% increase compared with $23.5 million in the same period last year driven by growth in all three of our business sources.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Gross profit, for the year ended December 31, 2022, was $15.4 million,
an increase of 11.6% from the same period last year, and stated as a percentage of net revenues was 55.1%, a decline from 58.6% in the prior
year period.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Operating expenses for the year ended December 31, 2022, were $26.2 million,
up from $20.8 million for the same period last year, driven primarily by research and development, and selling, general and administrative
for new hires to support commercialization, business development, quality, and regulatory capabilities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>RESULTS OF OPERATIONS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Year Ended December 31, 2022 compared to Year Ended December 31, 2021</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>Net Revenues</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The following table summarizes our net revenues for the years ended December
31, 2022 and 2021:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 7.5in; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="5" style="border-bottom: black 1pt solid; text-align: center"><b>Years Ended December 31,</b></td>
    <td>&#160;</td>
    <td colspan="4" style="border-bottom: black 1pt solid; text-align: center"><b>Change from Prior Year</b></td>
    <td>&#160;</td>
    <td colspan="3" style="border-bottom: black 1pt solid; text-align: center"><b>% of Net Revenues</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>2022</b></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>2021</b></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>$</b></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: center"><b>%</b></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: center"><b>2022</b></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: center"><b>2021</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="width: 105.75pt"><b>Net Revenues</b></td>
    <td style="width: 15.7pt">&#160;</td>
    <td style="width: 8.1pt">&#160;</td>
    <td style="width: 64.55pt">&#160;</td>
    <td style="width: 15pt">&#160;</td>
    <td style="width: 9pt">&#160;</td>
    <td style="width: 65pt">&#160;</td>
    <td style="width: 15pt">&#160;</td>
    <td style="width: 9pt">&#160;</td>
    <td style="width: 51.75pt">&#160;</td>
    <td style="width: 15.65pt">&#160;</td>
    <td style="width: 45.2pt">&#160;</td>
    <td style="width: 15.65pt">&#160;</td>
    <td style="width: 40.1pt">&#160;</td>
    <td style="width: 15.65pt">&#160;</td>
    <td style="width: 40.7pt">&#160;</td>
    <td style="width: 8pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="padding-left: 10.7pt">Domestic Core</td>
    <td>&#160;</td>
    <td>$</td>
    <td style="text-align: right">21,205,204</td>
    <td>&#160;</td>
    <td>$</td>
    <td style="text-align: right">19,045,512</td>
    <td>&#160;</td>
    <td>$</td>
    <td style="text-align: right">2,159,692</td>
    <td>&#160;</td>
    <td style="text-align: right">11.3%</td>
    <td>&#160;</td>
    <td style="text-align: right">76.0%</td>
    <td>&#160;</td>
    <td style="text-align: right">81.1%</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 10.7pt">International Core</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">4,164,714</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">3,856,972</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">307,742</td>
    <td>&#160;</td>
    <td style="text-align: right">8.0%</td>
    <td>&#160;</td>
    <td style="text-align: right">14.9%</td>
    <td>&#160;</td>
    <td style="text-align: right">16.4%</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="padding-left: 10.7pt">Novel Therapies</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right">2,526,119</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right">587,691</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right">1,938,428</td>
    <td>&#160;</td>
    <td style="text-align: right">329.8%</td>
    <td>&#160;</td>
    <td style="text-align: right">9.1%</td>
    <td>&#160;</td>
    <td style="text-align: right">2.5%</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td><b>Total</b></td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right">27,896,037</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right">23,490,175</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right">4,405,862</td>
    <td style="border-bottom: white 1.5pt double">&#160;</td>
    <td style="text-align: right">18.8%</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Total net revenues increased $4.4 million, or 18.8%, for the year
ended December 31, 2022, as compared with the same period last year. Double digit sales growth was achieved in our domestic core and
novel therapies businesses. Domestic core growth was primarily driven by increased volume attributed to SCIg market growth and new
label indications including prefill syringes and increases in average selling prices. Novel therapies sales grew by 329.8% for the
year ended 2022 related to services performed on an NRE innovation development agreement for a pharmaceutical customer and increases
in clinical trial product sales for several pharmaceutical customers. Sales growth in our international core business was driven by
volume growth in several EU markets compared with prior year.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>Gross Profit</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Our gross profit for the years ended December 31, 2022, and 2021 is as
follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 7.5in; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="5" style="border-bottom: black 1pt solid; text-align: center"><b>Years Ended December 31,</b></td>
    <td>&#160;</td>
    <td colspan="4" style="border-bottom: black 1pt solid; text-align: center"><b>Change from Prior Year</b></td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>2022</b></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>2021</b></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>$</b></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: center"><b>%</b></td></tr>
  <tr style="background-color: #E6E6E6">
    <td style="width: 206.4pt">Gross Profit</td>
    <td style="vertical-align: bottom; width: 8.95pt">&#160;</td>
    <td style="vertical-align: bottom; width: 9pt">$</td>
    <td style="vertical-align: bottom; width: 64.3pt; text-align: right">15,368,986</td>
    <td style="vertical-align: bottom; width: 20.95pt">&#160;</td>
    <td style="vertical-align: bottom; width: 9pt">$</td>
    <td style="vertical-align: bottom; width: 65.8pt; text-align: right">13,769,578</td>
    <td style="vertical-align: bottom; width: 20.95pt">&#160;</td>
    <td style="vertical-align: bottom; width: 9pt">$</td>
    <td style="vertical-align: bottom; width: 0.8in; text-align: right">1,599,408</td>
    <td style="vertical-align: bottom; width: 20.95pt">&#160;</td>
    <td style="vertical-align: bottom; width: 47.1pt; text-align: right">11.6%</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 11.9pt">Stated as a Percentage of Net Revenues</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">55.1%</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">58.6%</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Gross profit increased $1.6 million or 11.6% for the year ended December
31, 2022, compared to the same period in 2021. This increase was driven by increased volume and an increased average selling price in
net revenues of $4.4 million as described above. Gross profit as a percent of sales decreased to 55.1% compared to 58.6% from the prior year.
&#160;The decline in the gross profit percent was primarily caused by higher manufacturing costs associated with labor and materials,
production rework, and scrap related to our manufacturing transition. Product mix had a negative impact in our domestic core business
and NRE service revenue mix contributed to a lower gross profit percent. Partially offsetting these declines was an increase in average
selling prices.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>


<p style="font: 10pt TIMES NEW ROMAN, TIMES, SERIF; margin: 0; text-align: center">- 25 -</p>


<hr style="border-width: 0; color: Gray; background-color: Gray; height: 2px; width: 100%" /><p style="break-before: always"></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; color: blue"><i><a href="#toc">Table of Contents</a></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>Selling, general and administrative and Research and development</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Our selling, general and administrative and research and development costs
for the years ended December 31, 2022, and 2021 are as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 7.5in; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="5" style="border-bottom: black 1pt solid; text-align: center"><b>Years Ended December 31,</b></td>
    <td>&#160;</td>
    <td colspan="4" style="border-bottom: black 1pt solid; text-align: center"><b>Change from Prior Year</b></td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>2022</b></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>2021</b></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>$</b></td>
    <td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: center"><b>%</b></td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="width: 208.3pt">Selling, general and administrative</td>
    <td style="width: 7.1pt">&#160;</td>
    <td style="width: 0.1in">$</td>
    <td style="width: 68.45pt; text-align: right">20,606,507</td>
    <td style="width: 20.9pt">&#160;</td>
    <td style="width: 8.25pt">$</td>
    <td style="width: 65.15pt; text-align: right">17,862,314</td>
    <td style="width: 19.65pt">&#160;</td>
    <td style="width: 9.5pt">$</td>
    <td style="width: 57.45pt; text-align: right">2,744,193</td>
    <td style="width: 20.9pt">&#160;</td>
    <td style="width: 47.15pt; text-align: right">15.4%</td></tr>
  <tr style="vertical-align: bottom">
    <td>Research and development</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right">4,956,215</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right">2,473,669</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right">2,482,546</td>
    <td>&#160;</td>
    <td style="text-align: right">100.4%</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right">25,562,722</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right">20,335,983</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right">5,226,739</td>
    <td>&#160;</td>
    <td style="text-align: right">25.7%</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 11.7pt">Stated as a Percentage of Net Revenues</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">91.6%</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">86.6%</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Selling, general and administrative expenses increased $2.7 million,
or 15.4%, during the year ended December 31, 2022 compared to the same period last year, primarily due to $2.5 million in
compensation and benefits related mostly to new hires in sales, quality and regulatory to support our strategic growth initiatives,
$0.8 million in executive severance, $0.4 million in building related expense, $0.3 million in travel related costs and $0.2 million
in stock compensation, which was partially offset by lower restructuring costs of $1.2 million, marketing research of $0.3 million,
and recruiting costs of $0.2 million.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Research and development expenses increased $2.5 million, or 100.4%, during
the year ended December 31, 2022 compared with the same period last year primarily due to $1.4 million in consulting spend primarily related
to new product development, $1.1 million in compensation and benefits for new hires to support product development for novel therapies
and $0.2 million in stock compensation, which was partially offset by $0.2 million in testing material expense.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>Depreciation and amortization</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">For the year ended December 31, 2022, depreciation and amortization expense
increased $0.1 million, or 26.8%, compared with the same period last year due to investment in our new corporate office and manufacturing
site.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>Net Loss</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 7.5in; border-collapse: collapse">
  <tr>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td colspan="5" style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: center"><b>Years Ended December 31,</b></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td colspan="4" style="border-bottom: black 1pt solid; vertical-align: top; text-align: center"><b>Change from Prior Year</b></td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>2022</b></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>2021</b></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>$</b></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: center"><b>%</b></td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="width: 195.65pt">Net Loss</td>
    <td style="width: 0.1in">&#160;</td>
    <td style="width: 7.5pt">$</td>
    <td style="width: 63.75pt; text-align: right">(8,661,142</td>
    <td style="width: 19.55pt">)</td>
    <td style="width: 7.5pt">$</td>
    <td style="width: 63.75pt; text-align: right">(4,562,823</td>
    <td style="width: 18.8pt">)</td>
    <td style="width: 7.5pt">$</td>
    <td style="width: 63.75pt; text-align: right">(4,098,319</td>
    <td style="width: 23.35pt">)</td>
    <td style="width: 60.95pt; text-align: right">(89.8%)</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 11.7pt">Stated as a Percentage of Net Revenues</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">(31.0%</td>
    <td>)</td>
    <td>&#160;</td>
    <td style="text-align: right">(19.4%</td>
    <td>)</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Our net loss for the year ended December 31, 2022 was $8.7 million compared
to net loss of $4.6 million for the same period last year driven by higher selling, general and administrative and research and development
expenses. The current year loss includes an income tax benefit of approximately $2.0 million.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>LIQUIDITY AND CAPITAL RESOURCES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Our principal source of liquidity is our cash on hand of $17.4 million
as of December 31, 2022. &#160;Our principal source of operating cash inflows is from sales of our products and NRE services to customers.
Our principal cash outflows relate to the purchase and production of inventory, funding of research and development, and selling, general
and administrative expenses. To develop new products, support future growth, achieve operating efficiencies, and maintain product quality,
we are continuing to invest in research and development, manufacturing technologies, facilities and equipment. Operating expenses for
the 2022 fiscal year were $26.1 million.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Our 2022 capital investments for manufacturing and leasehold improvements
for our new facility in Mahwah, NJ were $2.0 million, net of pre-approved financing arrangements and leasehold improvement credits totaling
$0.5 million and $0.2 million, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Our inventory position was $6.4 million at December 31, 2022, which reflected
an increase of $0.3 million from December 31, 2021. We expect to reduce our inventory position in 2023 following completion of the transition
of substantially all our manufacturing operations to Command, which we expect to be completed no later than the second quarter of 2023.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>


<p style="font: 10pt TIMES NEW ROMAN, TIMES, SERIF; margin: 0; text-align: center">- 26 -</p>


<hr style="border-width: 0; color: Gray; background-color: Gray; height: 2px; width: 100%" /><p style="break-before: always"></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; color: blue"><i><a href="#toc">Table of Contents</a></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">On March 27, 2020, the Coronavirus Aid, Relief, and Economic Security Act
(the &#8220;CARES Act&#8221;) was signed into law. The CARES Act contains a provision known as the Employee Retention Credit (&#8220;ERC&#8221;),
a refundable payroll tax credit for qualified wages paid to retained full-time employees between March 13, 2020, and December 31, 2020.
The Consolidations Appropriations Act (CAA), signed into law on December 27, 2020, significantly modified and expanded the provisions
of the ERC to include wages paid in 2021. For 2021, the ERC provides employers a refundable federal tax credit equal to 70% of the first
$10,000 of qualified wages and benefits paid to retained employees between January 1, 2021, and December 31, 2021. Credits may be claimed
immediately by reducing payroll taxes sent to the Internal Revenue Service. To the extent that the credit exceeds employment withholdings,
the employer may request a refund of prior taxes paid. The Company determined that it qualified for this credit and anticipated utilizing
benefits under this act to aid its liquidity position and as a result recorded a receivable of $0.7 million as of December 31, 2021. As
of December 31, 2022, the credit has not been received.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">We expect that our cash on hand, cash flows from operations and available
financing sources will be sufficient to meet our requirements at least through December 31, 2023. Continued execution on our longer-term
strategic plan may require the Company to take on additional debt or raise capital through issuance of equity, or a combination of both.
Our future capital requirements may vary from those currently planned and will depend on many factors, including our rate of sales growth,
the timing and extent of spending on various strategic initiatives including research and development, our international expansion, the
timing of new product introductions, market acceptance of our solutions, and overall economic conditions including inflation and the potential
impact of global supply imbalances on the global financial markets. To the extent that current and anticipated future sources of liquidity
are or are expected to be insufficient to fund our future business activities and requirements, we may be required to seek additional
equity or debt financing sooner. There can be no assurance the Company will be able to obtain the financing or raise the capital required
to fund its operations or planned expansion.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>Cash Flows</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The following table summarizes our cash flows:</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 7.5in; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>Year Ended<br />
December 31, 2022</b></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>Year Ended<br />
December 31, 2021</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="width: 277.8pt">Net cash used in operating activities</td>
    <td style="width: 9.55pt">&#160;</td>
    <td style="width: 9.55pt">$</td>
    <td style="width: 99.85pt; text-align: right">(5,404,549</td>
    <td style="width: 24.3pt">)</td>
    <td style="width: 9.55pt">$</td>
    <td style="width: 99.85pt; text-align: right">(4,319,510</td>
    <td style="width: 9.55pt">)</td></tr>
  <tr style="vertical-align: bottom">
    <td>Net cash used in investing activities</td>
    <td>&#160;</td>
    <td>$</td>
    <td style="text-align: right">(2,801,568</td>
    <td>)</td>
    <td>$</td>
    <td style="text-align: right">(366,169</td>
    <td>)</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Net cash provided by financing activities</td>
    <td>&#160;</td>
    <td>$</td>
    <td style="text-align: right">279,485</td>
    <td>&#160;</td>
    <td>$</td>
    <td style="text-align: right">2,705,282</td>
    <td>&#160;</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>Operating Activities</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Net cash used in operating activities of $5.4 million for the year ended
December 31, 2022 was primarily due to the net loss of $8.7 million, working capital changes which included an increase in inventory of
$0.3 million, an increase in accrued expenses of $0.2 million, an increase in accrued payroll of $0.4 million and an increase in accounts
payable and other liabilities of $1.3 million. &#160;Further contributing were deferred tax assets of $2.0 million increased for book
to tax differences related to stock option expense. &#160;Offsetting these were primarily non-cash charges for stock-based compensation
of $3.1 million, and depreciation and amortization of $0.6 million.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Operating cash outflows were $4.3 million for the year ended December 31,
2021 and were mostly attributable to net loss adjusted for non-cash charges of $3.2 million, an increase in accounts receivable of $1.0
million due to higher sales in the fourth quarter of 2022 compared with prior year, an increase in other receivables of $0.7 million for
the ERC refund and an increase in prepaids of $0.8 million related to raw materials in transit, all partially offset by a decrease in
inventory of $0.7 million and an increase in accounts payable of $0.6 million.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>Investing Activities</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Net cash used in investing activities of $2.8 million for the year ending
December 31, 2022, was for capital expenditures for manufacturing and office equipment for our corporate office and manufacturing facilities
move.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Our net cash used in investing activities of $0.4 million for the year
ended December 31, 2021, was primarily for capital expenditures for manufacturing equipment and computers for new hires and replacement
of retired computers.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>Financing Activities</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The $0.3 million provided by financing activities for the year ended December
31, 2022, is from $0.4 million in option exercises offset by $0.08 million in net borrowings on our indebtedness for a note payable for
insurance premium financing and $0.05 million in net equipment financing.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>


<p style="font: 10pt TIMES NEW ROMAN, TIMES, SERIF; margin: 0; text-align: center">- 27 -</p>


<hr style="border-width: 0; color: Gray; background-color: Gray; height: 2px; width: 100%" /><p style="break-before: always"></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; color: blue"><i><a href="#toc">Table of Contents</a></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The $2.7 million provided by financing activities for the year ended December
31, 2021 is attributed to cash received for options exercised of $1.3 million, the issuance of common stock as settlement for litigation
of $0.9 million, and $0.5 million on borrowings from indebtedness.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">We expect that our cash on hand, cash flows from operations, and our fully
available credit facility will be sufficient to meet our requirements at least through the next 12 months</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">See &#8220;NOTE 10 &#8212; DEBT OBLIGATIONS&#8221; for further detail regarding
the promissory note and loan agreement in the accompanying &#8220;Notes to Financial Statements&#8221; appearing in this Annual Report
on Form 10-K.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>Debt and Borrowing Capacity</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Refer to &#8220;NOTE 10 &#8212; DEBT OBLIGATIONS&#8221; in the accompanying
&#8220;Notes to Financial Statements&#8221; appearing in this Annual Report on Form 10-K for further details regarding debt.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>COMMITMENTS AND CONTRACTUAL OBLIGATIONS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>Lease Commitments</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">We have finance and operating leases for our corporate office and certain
office and computer equipment. &#160;Our two operating leases have remaining lease terms of 9.7 years and 3 months, respectively. On September
29, 2022, we extended our existing lease at 24 Carpenter Road, in Chester NY, through March 31, 2023 with the same payment terms. We moved
our administrative offices in June 2022 from this building into 43,975 square feet of a building located at 100 Corporate Drive, Mahwah,
New Jersey. The new lease commenced on March 1, 2022 and expires August 31, 2032. Our two finance leases, one commenced in June and the
other in October, have remaining lease terms of 4.4 and 4.8 years, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Refer to &#8220;NOTE 5 &#8211; LEASES&#8221; in the accompanying &#8220;Notes
to Financial Statements&#8221; appearing in this Annual Report on Form 10-K for further details regarding our operating and finance leases.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>SIGNIFICANT ACCOUNTING POLICIES AND CRITICAL ACCOUNTING ESTIMATES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The preparation of financial statements in conformity with generally accepted
accounting principles of the United States (&#8220;GAAP&#8221;) requires estimates and assumptions that affect the reported amounts of
assets and liabilities, revenues and expenses, and related disclosures of contingent liabilities in the financial statements and accompanying
notes. &#160;The SEC has defined a company&#8217;s critical accounting policies as the ones that are most important to the portrayal of
the company&#8217;s financial condition and results of operations, and which require the company to make its most difficult and subjective
judgments, often as a result of the need to make estimates of matters that are inherently uncertain. &#160;Based on this definition, we
have identified some of our more critical accounting estimates below. &#160;We also have other key accounting policies, which involve
the use of estimates, judgments, and assumptions that are significant to understanding our results. &#160;For additional information,
see &#8220;NOTE 1 &#8212; NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES&#8221; in the accompanying &#8220;Notes
to Financial Statements&#8221; appearing in this Annual Report on Form 10-K. &#160;Although we believe that our estimates, assumptions,
and judgments are reasonable, they are based upon information presently available. &#160;Actual results may differ significantly from
these estimates under different assumptions, judgments, or conditions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>Revenue Recognition</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Our revenues are derived from three business sources: (i) domestic core,
(ii) international core, and (iii) novel therapies. &#160;Our core domestic and international revenues consist of sales of our syringe
drivers, tubing and needles (&#8220;Product Revenue&#8221;) for the delivery of subcutaneous drugs that are FDA cleared for use with the
FREEDOM Infusion System, with the primary delivery for immunoglobulin to treat PIDD and CIDP. Novel therapies consist of Product Revenue
for feasibility/clinical trials (pre-clinical studies, Phase I, Phase II, Phase III) of biopharmaceutical companies in the drug development
process as well as non-recurring engineering services (&#8220;NRE&#8221;) revenues (including testing and registration services) received
from biopharmaceutical companies to ready or customize the FREEDOM System for clinical and commercial use.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">For Product Revenues, we recognize revenues when shipment occurs, and at
which point the customer obtains control and ownership of the goods. &#160;Shipping costs generally are billed to customers and are included
in sales.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The Company generally does not accept return of goods shipped unless it
is a Company error. &#160;The only credits provided to customers are for defective merchandise. &#160;The Company warrants the syringe
driver from defects in materials and workmanship under normal use and the warranty does not include a performance obligation. &#160;The
costs under the warranty are expensed as incurred.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>


<p style="font: 10pt TIMES NEW ROMAN, TIMES, SERIF; margin: 0; text-align: center">- 28 -</p>


<hr style="border-width: 0; color: Gray; background-color: Gray; height: 2px; width: 100%" /><p style="break-before: always"></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; color: blue"><i><a href="#toc">Table of Contents</a></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Rebates are provided to distributors for the difference in selling price
to distributor and pricing specified to select customers. &#160;In addition, rebates are provided to customers for meeting growth targets.
&#160;Provisions for both distributor pricing and customer growth rebates are variable consideration and are recorded as a reduction of
revenue in the same period the related sales are recorded or when it is probable the growth target will be achieved.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Our novel therapies revenues can fluctuate and may not be consistent from
period to period. Engineering work performed on our product may be specialized and tailored to the specific needs of each independent
clinical trial and not uniform in nature. The clinical trial size and scope of protocols may also range greatly from customer to customer,
and there is no expectation of repeat customers on a consistent basis compared to our core business. We recognize NRE revenue under an
input method, which recognizes revenue on the basis of our efforts or inputs (for example, resources consumed, labor hours expended, costs
incurred, or time elapsed) to the satisfaction of a performance obligation relative to the total expected inputs to the satisfaction of
that performance obligation (ie completion milestone). The input method that we use is based on costs incurred.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>Inventory</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Inventories of raw materials are stated at the lower of standard cost,
which approximates average cost, or market value including allocable overhead. &#160;Work-in-process and finished goods are stated at
the lower of standard cost or market value and include direct labor and allocable overhead.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">We maintain reserves for excess and obsolete inventory resulting from the
potential inability to sell certain products at prices in excess of current carrying costs. We make estimates regarding the future recoverability
of the costs of these products and record provisions based on historical experience, expiration of sterilization dates and expected future
trends. If actual product life cycles, product demand or acceptance of new product introductions are less favorable than projected by
management, additional inventory write downs may be required, which could unfavorably affect future operating results.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>ACCOUNTING PRONOUNCEMENTS RECENTLY ADOPTED</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Refer to &#8220;NOTE 1 &#8212; NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT
ACCOUNTING POLICIES&#8221; in the accompanying &#8220;Notes to Financial Statements&#8221; appearing in this Annual Report on Form 10-K.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>ACCOUNTING PRONOUNCEMENTS NOT YET ADOPTED</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Refer to &#8220;NOTE 1 &#8212; NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT
ACCOUNTING POLICIES&#8221; in the accompanying &#8220;Notes to Financial Statements&#8221; appearing in this Annual Report on Form 10-K.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="a_010"></span>&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>ITEM 7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Not applicable.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="a_011"></span>&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="index_to_fs"></span>&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>KORU MEDICAL SYSTEMS, INC.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>INDEX TO FINANCIAL STATEMENTS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 7.5in">
  <tr style="vertical-align: bottom">
    <td style="width: 7in">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 0.5in; text-align: center">Page</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td><a href="#audit_report">Report of Independent Registered Public Accounting Firm</a> (PCAOB ID&#160;<span id="xdx_906_edei--AuditorFirmId_c20220101__20221231_zhF5VhN1MMLg" title="Auditor Firm ID"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="dei:AuditorFirmId">256</ix:nonNumeric></span>)</td>
    <td style="text-align: center">30</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Financial Statements</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td><a href="#balance_sheets">Balance Sheets as of December 31, 2022 and 2021</a></td>
    <td style="text-align: center">31</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td><a href="#statements_of_operations">Statements of Operations for the years ended December 31, 2022 and 2021</a></td>
    <td style="text-align: center">32</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td><a href="#stockholders_equity">Statements of Stockholders&#8217; Equity as of December 31, 2022 and 2021</a></td>
    <td style="text-align: center">33</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td><a href="#cashflows">Statements of Cash Flows for the years ended December 31, 2022 and 2021</a></td>
    <td style="text-align: center">34</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td><a href="#notes_to_financials">Notes to Financial Statements</a></td>
    <td style="text-align: center">35</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>


<p style="font: 10pt TIMES NEW ROMAN, TIMES, SERIF; margin: 0; text-align: center">- 29 -</p>


<hr style="border-width: 0; color: Gray; background-color: Gray; height: 2px; width: 100%" /><p style="break-before: always"></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; color: blue"><i><a href="#index_to_fs">Index to Financial Statements</a></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="audit_report"></span>&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Report of Independent Registered Public Accounting
Firm</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">To the Shareholders and the Board of Directors of
KORU Medical Systems, Inc.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Mahwah, New Jersey</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Opinion on the Financial Statements</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We have audited the accompanying balance sheets of
KORU Medical Systems, Inc. (the Company) as of December 31, 2022 and 2021, the related statements of operations, stockholders&#8217; equity
and cash flows for the years then ended, and the related notes to the financial statements (collectively, the financial statements). In
our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31,
2022 and 2021, and the results of its operations and its cash flows for the years then ended, in conformity with accounting principles
generally accepted in the United States of America.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Basis for Opinion</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">These financial statements are the responsibility
of the Company&#8217;s management. Our responsibility is to express an opinion on the Company&#8217;s financial statements based on our
audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are
required to be independent with respect to the Company in accordance with U.S. federal securities laws and the applicable rules and regulations
of the Securities and Exchange Commission and the PCAOB.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We conducted our audits in accordance with the standards
of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements
are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform,
an audit of its internal control over financial reporting. As part of our audits we are required to obtain an understanding of internal
control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company&#8217;s internal
control over financial reporting. Accordingly, we express no such opinion.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our audits included performing procedures to assess
the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond
to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements.
Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating
the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Critical Audit Matters</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The critical audit matters communicated below are
matters arising from the current period audit of the financial statements that were communicated or required to be communicated to the
audit committee and that: (1) relate to accounts or disclosures that are material to the financial statements and (2) involved our especially
challenging, subjective or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the
financial statements, taken as a whole, and we are not, by communicating the critical audit matters below, providing separate opinions
on the critical audit matters or on the accounts or disclosures to which they relate.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><i>Grant of Stock Options</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Description of the Matter:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As discussed in Note 4 to the financial statements,
the Company granted 920,000 options to purchase shares of its common stock with 10-year terms and a grant-date fair value of $1,826,643
to employees and consultants during the year ended December 31, 2022. Management is required to analyze the fair value of each option
granted and amortize it over its vesting period.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We identified the grant of the stock options as a
critical audit matter. Management&#8217;s estimates regarding the fair value of options result in the application of a high degree of
auditor judgment.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">How We Addressed the Matter in Our Audit:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We obtained an understanding of the Company&#8217;s
processes and controls in place for determining the fair value of each granted option. We evaluated the option price model management
selected to determine the fair value, and analyzed the underlying data used to estimate the fair value of the awards. We also recalculated
the fair value of each option granted during the year.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">/s/ <span id="xdx_901_edei--AuditorName_c20220101__20221231_zGHG3pnwFYyc"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="dei:AuditorName">McGrail Merkel Quinn &amp; Associates, P.C.</ix:nonNumeric></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We have served as the Company's auditor since 2014.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span id="xdx_907_edei--AuditorLocation_c20220101__20221231_zZBOrwmmQ9l9" title="Auditor Location"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="dei:AuditorLocation">Scranton, Pennsylvania</ix:nonNumeric></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">March 8, 2023</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>


<p style="font: 10pt TIMES NEW ROMAN, TIMES, SERIF; margin: 0; text-align: center">- 30 -</p>


<hr style="border-width: 0; color: Gray; background-color: Gray; height: 2px; width: 100%" /><p style="break-before: always"></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; color: blue"><i><a href="#index_to_fs">Index to Financial Statements</a></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="balance_sheets"></span>&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>KORU MEDICAL SYSTEMS, INC.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>BALANCE SHEETS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" id="xdx_30A_111_zm0lwgStp2Kj" summary="xdx: Statement - BALANCE SHEETS" style="font: 10pt Times New Roman, Times, Serif; width: 7.5in; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="width: 352.35pt">&#160;</td>
    <td style="width: 7.65pt">&#160;</td>
    <td style="width: 9.3pt">&#160;</td>
    <td id="xdx_499_20221231_zrnRl63DzKzh" style="width: 64.7pt; text-align: right">&#160;</td>
    <td style="width: 22.75pt">&#160;</td>
    <td style="width: 7.7pt">&#160;</td>
    <td id="xdx_496_20211231_zolcbRtxgIra" style="width: 65.05pt; text-align: right">&#160;</td>
    <td style="width: 10.3pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center"><b>December 31,</b></td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center"><b>December 31,</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>2022</b></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>2021</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--AssetsAbstract_iB_zlOrP5bFBBKl" style="vertical-align: bottom; background-color: #E6E6E6">
    <td><b>ASSETS</b></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--AssetsCurrentAbstract_i01B_zkYLUjFExhja" style="vertical-align: bottom; background-color: #E6E6E6">
    <td>CURRENT ASSETS</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--CashAndCashEquivalentsAtCarryingValue_i02I_maACzpIL_zJqVL33bm7H8" style="vertical-align: bottom">
    <td style="padding-left: 24.7pt; text-indent: -8.25pt">Cash and cash equivalents</td>
    <td>&#160;</td>
    <td>$</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">17,408,257</ix:nonFraction></td>
    <td>&#160;</td>
    <td>$</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">25,334,889</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--AccountsReceivableNetCurrent_i02I_maACzpIL_zNEYrH8HBXCd" style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="padding-left: 24.7pt; text-indent: -8.25pt">Accounts receivable less allowance for doubtful accounts of $<span id="xdx_90C_eus-gaap--AllowanceForDoubtfulAccountsReceivableCurrent_iI_c20221231_z1oHBU8TsCGa" title="Accounts receivable, allowance for credit loss, current"><ix:nonFraction name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">21,459</ix:nonFraction></span> and $<span id="xdx_906_eus-gaap--AllowanceForDoubtfulAccountsReceivableCurrent_iI_c20211231_z2vSJKSQG1Yl" title="Accounts receivable, allowance for credit loss, current"><ix:nonFraction name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">24,271</ix:nonFraction></span> for December 31, 2022, and December 31, 2021, respectively</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:AccountsReceivableNetCurrent" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,558,884</ix:nonFraction></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:AccountsReceivableNetCurrent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,592,886</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--InventoryNet_i02I_maACzpIL_zk9iGcKfiiAb" style="vertical-align: bottom">
    <td style="padding-left: 24.7pt; text-indent: -8.25pt">Inventory</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:InventoryNet" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,404,867</ix:nonFraction></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:InventoryNet" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,106,338</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--OtherReceivables_i02I_maACzpIL_za85Nb1sQcU8" style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="padding-left: 24.7pt; text-indent: -8.25pt">Other receivables</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:OtherReceivables" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">972,396</ix:nonFraction></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:OtherReceivables" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">718,220</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--PrepaidExpenseCurrent_i02I_maACzpIL_ztXYvQ0Heqz7" style="vertical-align: bottom">
    <td style="padding-left: 24.7pt; text-indent: -8.25pt">Prepaid expenses and other</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:PrepaidExpenseCurrent" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,457,232</ix:nonFraction></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:PrepaidExpenseCurrent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,568,821</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--AssetsCurrent_i02TI_mtACzpIL_maAzLoa_z0RiUguehgo1" style="vertical-align: bottom; background-color: #E6E6E6">
    <td>TOTAL CURRENT ASSETS</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">29,801,636</ix:nonFraction></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">37,321,154</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--PropertyPlantAndEquipmentNet_i01I_maAzLoa_zPhJPxwocnjh" style="vertical-align: bottom">
    <td>Property and equipment, net</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,886,975</ix:nonFraction></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,106,445</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--FiniteLivedIntangibleAssetsNet_i01I_maAzLoa_zXeGztv9Xsck" style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="padding-left: 8.25pt; text-indent: -8.25pt">Intangible assets, net of accumulated amortization of $<span id="xdx_903_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20221231_zWXQbAVmIcJd" title="Finite-lived intangible assets, accumulated amortization"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">325,872</ix:nonFraction></span> and $<span id="xdx_901_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20211231_zBwqCTjXRVl7" title="Finite-lived intangible assets, accumulated amortization"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">263,729</ix:nonFraction></span> at December 31, 2022 and December 31, 2021, respectively</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">787,182</ix:nonFraction></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">808,813</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--OperatingLeaseRightOfUseAsset_i01I_maAzLoa_z9x5n1Akyod6" style="vertical-align: bottom">
    <td style="padding-left: 45.5pt; text-indent: -45.5pt">Operating lease right-of-use assets</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,786,545</ix:nonFraction></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">95,553</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--DeferredIncomeTaxAssetsNet_i01I_maAzLoa_zB30OLmH7tgk" style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="padding-left: 45.5pt; text-indent: -45.5pt">Deferred income tax assets, net</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredIncomeTaxAssetsNet" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,967,480</ix:nonFraction></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredIncomeTaxAssetsNet" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,941,254</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--OtherAssetsNoncurrent_i01I_maAzLoa_zHEY0auHprA6" style="vertical-align: bottom">
    <td style="padding-left: 45.5pt; text-indent: -45.5pt">Other assets</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:OtherAssetsNoncurrent" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">102,625</ix:nonFraction></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:OtherAssetsNoncurrent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">19,812</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--Assets_i01TI_mtAzLoa_zSLr3MGBucB1" style="vertical-align: bottom; background-color: #E6E6E6">
    <td>TOTAL ASSETS</td>
    <td>&#160;</td>
    <td style="border-top: black 1pt solid; border-bottom: black 2.25pt double">$</td>
    <td style="border-top: black 1pt solid; border-bottom: black 2.25pt double; text-align: right"><ix:nonFraction name="us-gaap:Assets" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">42,332,443</ix:nonFraction></td>
    <td>&#160;</td>
    <td style="border-top: black 1pt solid; border-bottom: black 2.25pt double">$</td>
    <td style="border-top: black 1pt solid; border-bottom: black 2.25pt double; text-align: right"><ix:nonFraction name="us-gaap:Assets" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">41,293,031</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--LiabilitiesAndStockholdersEquityAbstract_iB_zignfGwgP3n" style="vertical-align: bottom; background-color: #E6E6E6">
    <td><b>LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</b></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--LiabilitiesCurrentAbstract_i01B_zyqve8sH9oJ2" style="vertical-align: bottom; background-color: #E6E6E6">
    <td>CURRENT LIABILITIES</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--AccountsPayableCurrent_i02I_maLCzFyo_zYnJdbFFExEl" style="vertical-align: bottom">
    <td style="padding-left: 24.7pt; text-indent: -8.25pt">Accounts payable</td>
    <td>&#160;</td>
    <td>$</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:AccountsPayableCurrent" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,391,799</ix:nonFraction></td>
    <td>&#160;</td>
    <td>$</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:AccountsPayableCurrent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,227,533</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--AccruedLiabilitiesCurrent_i02I_maLCzFyo_zvc5iIiGY9Wf" style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="padding-left: 24.7pt; text-indent: -8.25pt">Accrued expenses</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,889,941</ix:nonFraction></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,709,704</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--NotesPayableCurrent_i02I_maLCzFyo_z1QvnYbcY6t1" style="vertical-align: bottom">
    <td style="padding-left: 24.7pt; text-indent: -8.25pt">Note Payable</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:NotesPayableCurrent" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">433,295</ix:nonFraction></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:NotesPayableCurrent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">508,583</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--OtherLiabilitiesCurrent_i02I_maLCzFyo_zq82EeOyvXEe" style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="padding-left: 24.7pt; text-indent: -8.25pt">Other liabilities</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:OtherLiabilitiesCurrent" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">257,337</ix:nonFraction></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:OtherLiabilitiesCurrent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">90,000</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--EmployeeRelatedLiabilitiesCurrent_i02I_maLCzFyo_ziyIvghIPOw4" style="vertical-align: bottom">
    <td style="padding-left: 24.7pt; text-indent: -8.25pt">Accrued payroll and related taxes</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:EmployeeRelatedLiabilitiesCurrent" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">542,399</ix:nonFraction></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:EmployeeRelatedLiabilitiesCurrent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">160,603</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--FinanceLeaseLiabilityCurrent_i02I_maLCzFyo_zFeB7em8RjJ9" style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="padding-left: 24.7pt; text-indent: -8.25pt">Finance lease liability &#8211; current</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:FinanceLeaseLiabilityCurrent" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">98,335</ix:nonFraction></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0120">&#8212;</span></td>
    <td>&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--OperatingLeaseLiabilityCurrent_i02I_maLCzFyo_zOAxW7sgPNA" style="vertical-align: bottom">
    <td style="padding-left: 24.7pt; text-indent: -8.25pt">Operating lease liability &#8211; current</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">345,834</ix:nonFraction></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">95,553</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--LiabilitiesCurrent_i02TI_mtLCzFyo_maLzYsD_zMjfAOutIOW" style="vertical-align: bottom; background-color: #E6E6E6">
    <td>TOTAL CURRENT LIABILITIES</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,958,940</ix:nonFraction></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,791,976</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--FinanceLeaseLiabilityNoncurrent_i02I_maLzYsD_zpIGSm9ulGsg" style="vertical-align: bottom">
    <td>Finance lease liability, net current portion</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:FinanceLeaseLiabilityNoncurrent" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">394,283</ix:nonFraction></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0129">&#8212;</span></td>
    <td>&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--OperatingLeaseLiabilityNoncurrent_i01I_maLzYsD_zlwbQ4TQevg7" style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="padding-left: 45.5pt; text-indent: -45.5pt">Operating lease liability, net of current portion</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,653,257</ix:nonFraction></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0132">&#8212;</span></td>
    <td>&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--Liabilities_i01TI_mtLzYsD_maLASEzPjK_zy4tWuHPpO45" style="vertical-align: bottom">
    <td>TOTAL LIABILITIES</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:Liabilities" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">11,006,480</ix:nonFraction></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:Liabilities" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,791,976</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Commitments and contingencies (Refer to Note 8)</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--StockholdersEquityAbstract_i01B_zFL9BPlL6Ju" style="vertical-align: bottom">
    <td>STOCKHOLDERS&#8217; EQUITY</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--CommonStockValue_i02I_maSEzxLf_zlxmzYcq6pig" style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="padding-left: 24.7pt; text-indent: -8.25pt">Common stock, $<span id="xdx_908_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_uUSDPShares_c20221231_zCAAuPi5zoG2" title="Common stock, par or stated value per share"><span id="xdx_900_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_uUSDPShares_c20211231_zVWAQEQXT7dg" title="Common stock, par or stated value per share"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.01</ix:nonFraction></ix:nonFraction></span></span> par value, <span id="xdx_903_eus-gaap--CommonStockSharesAuthorized_iI_pid_uShares_c20221231_zHHvIRf3m9F6" title="Common stock, shares authorized"><span id="xdx_902_eus-gaap--CommonStockSharesAuthorized_iI_pid_uShares_c20211231_zfiAqBvf9dtd" title="Common stock, shares authorized"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">75,000,000</ix:nonFraction></ix:nonFraction></span></span> shares authorized, <span id="xdx_90B_eus-gaap--CommonStockSharesIssued_iI_pid_uShares_c20221231_z5WsW0baPIy2" title="Common stock, shares, issued"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">48,861,891</ix:nonFraction></span> and <span id="xdx_90F_eus-gaap--CommonStockSharesIssued_iI_pid_uShares_c20211231_zE7aIsK973Nb" title="Common stock, shares, issued"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">48,044,162</ix:nonFraction></span> shares issued; <span id="xdx_909_eus-gaap--CommonStockSharesOutstanding_iI_pid_uShares_c20221231_zvyS3FPGDL4e" title="Common stock, shares, outstanding"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">45,441,389</ix:nonFraction></span> and <span id="xdx_903_eus-gaap--CommonStockSharesOutstanding_iI_pid_uShares_c20211231_z3tM5T0qsIc4" title="Common stock, shares, outstanding"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">44,623,660</ix:nonFraction></span> shares outstanding at December 31, 2022, and December 31, 2021, respectively</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">488,619</ix:nonFraction></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">480,441</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--AdditionalPaidInCapitalCommonStock_i02I_maSEzxLf_zbxXVJpIwylg" style="vertical-align: bottom">
    <td style="padding-left: 24.7pt; text-indent: -8.25pt">Additional paid-in capital</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:AdditionalPaidInCapitalCommonStock" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">44,252,117</ix:nonFraction></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:AdditionalPaidInCapitalCommonStock" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">40,774,245</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--TreasuryStockValue_i02NI_di_msSEzxLf_zuCvXHT3joXc" style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="padding-left: 24.7pt; text-indent: -8.25pt">Treasury stock, <span id="xdx_90E_eus-gaap--TreasuryStockShares_iI_pid_uShares_c20221231_zqdceDkIj1qa" title="Treasury stock, shares"><span id="xdx_909_eus-gaap--TreasuryStockShares_iI_pid_uShares_c20211231_z03SkRYfONhk" title="Treasury stock, shares"><ix:nonFraction name="us-gaap:TreasuryStockShares" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:TreasuryStockShares" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,420,502</ix:nonFraction></ix:nonFraction></span></span> shares at December 31, 2022 and December 31, 2021, at cost</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">(<ix:nonFraction name="us-gaap:TreasuryStockValue" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,843,562</ix:nonFraction></td>
    <td>)</td>
    <td>&#160;</td>
    <td style="text-align: right">(<ix:nonFraction name="us-gaap:TreasuryStockValue" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,843,562</ix:nonFraction></td>
    <td>)</td></tr>
  <tr id="xdx_401_eus-gaap--RetainedEarningsAccumulatedDeficit_i02I_maSEzxLf_z6CJBsqLvfCk" style="vertical-align: bottom">
    <td style="padding-left: 24.7pt; text-indent: -8.25pt">Retained Deficit</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">9,571,211</ix:nonFraction></td>
    <td>)</td>
    <td style="border-bottom: Black 1pt solid">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">910,069</ix:nonFraction></td>
    <td>)</td></tr>
  <tr id="xdx_409_eus-gaap--StockholdersEquity_i02TI_mtSEzxLf_maLASEzPjK_zMtMeYvcL6x7" style="vertical-align: bottom; background-color: #E6E6E6">
    <td>TOTAL STOCKHOLDERS&#8217; EQUITY</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">31,325,963</ix:nonFraction></td>
    <td>&#160;</td>
    <td style="border-bottom: Black 1pt solid">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">36,501,055</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--LiabilitiesAndStockholdersEquity_i01TI_mtLASEzPjK_zCCyHac0xBEi" style="vertical-align: bottom">
    <td>TOTAL LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">42,332,443</ix:nonFraction></td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">41,293,031</ix:nonFraction></td>
    <td>&#160;</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">See accompanying Notes to Financial Statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>


<p style="font: 10pt TIMES NEW ROMAN, TIMES, SERIF; margin: 0; text-align: center">- 31 -</p>


<hr style="border-width: 0; color: Gray; background-color: Gray; height: 2px; width: 100%" /><p style="break-before: always"></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; color: blue"><i><a href="#index_to_fs">Index to Financial Statements</a></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="statements_of_operations"></span>&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>KORU MEDICAL SYSTEMS, INC.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>STATEMENTS OF OPERATIONS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" id="xdx_305_113_ztgrpMR9zeIg" summary="xdx: Statement - STATEMENTS OF OPERATIONS" style="font: 10pt Times New Roman, Times, Serif; width: 7.5in; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="width: 344.25pt">&#160;</td>
    <td style="width: 7.65pt">&#160;</td>
    <td style="width: 7.3pt">&#160;</td>
    <td id="xdx_49A_20220101__20221231_zBjg1RmJsoe9" style="width: 72.9pt; text-align: right">&#160;</td>
    <td style="width: 20.15pt">&#160;</td>
    <td style="width: 7.3pt">&#160;</td>
    <td id="xdx_49C_20210101__20211231_zjmrNXUpJz5h" style="width: 72.9pt; text-align: right">&#160;</td>
    <td style="width: 7.65pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="5" style="border-bottom: Black 1pt solid; text-align: center"><b>For the Years Ended<br />
December 31,</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>2022</b></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>2021</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--Revenues_maGPz3vf_zMJkT5P1gli" style="vertical-align: bottom; background-color: #E6E6E6">
    <td>NET REVENUES</td>
    <td>&#160;</td>
    <td>$</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">27,896,037</ix:nonFraction></td>
    <td>&#160;</td>
    <td>$</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">23,490,175</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--CostOfGoodsAndServicesSold_msGPz3vf_zeLcnVlauWt7" style="vertical-align: bottom; background-color: white">
    <td style="padding-left: 24.7pt; text-indent: -8.25pt">Cost of goods sold</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:CostOfGoodsAndServicesSold" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">12,527,051</ix:nonFraction></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:CostOfGoodsAndServicesSold" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9,720,597</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--GrossProfit_iT_mtGPz3vf_maOILzg04_zBMsB1kHgrQk" style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Gross Profit</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:GrossProfit" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">15,368,986</ix:nonFraction></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:GrossProfit" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">13,769,578</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--OperatingExpensesAbstract_iB_zw9CtkipWwc4" style="vertical-align: bottom">
    <td>OPERATING EXPENSES</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--SellingGeneralAndAdministrativeExpense_i01_maOEzwCb_zhKLUEHTtuj2" style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="padding-left: 24.7pt; text-indent: -8.25pt">Selling, general and administrative</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:SellingGeneralAndAdministrativeExpense" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">20,606,507</ix:nonFraction></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:SellingGeneralAndAdministrativeExpense" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">17,862,314</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--ResearchAndDevelopmentExpense_i01_maOEzwCb_zivRcPqWVFK3" style="vertical-align: bottom">
    <td style="padding-left: 24.7pt; text-indent: -8.25pt">Research and development</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,956,215</ix:nonFraction></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,473,669</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--DepreciationDepletionAndAmortization_i01_maOEzwCb_zhZW2K6Pw9pf" style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="padding-left: 24.7pt; text-indent: -8.25pt">Depreciation and amortization</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:DepreciationDepletionAndAmortization" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">587,137</ix:nonFraction></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:DepreciationDepletionAndAmortization" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">463,130</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--OperatingExpenses_i01T_mtOEzwCb_msOILzg04_zTNKI1SjoNM9" style="vertical-align: bottom">
    <td>Total Operating Expenses</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">26,149,859</ix:nonFraction></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">20,799,113</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--OperatingIncomeLoss_iT_mtOILzg04_maILFCOzgqq_zmquTnDqqfng" style="vertical-align: bottom">
    <td>Net Operating Loss</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">10,780,873</ix:nonFraction></td>
    <td>)</td>
    <td>&#160;</td>
    <td style="text-align: right">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">7,029,535</ix:nonFraction></td>
    <td>)</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--NonoperatingIncomeExpenseAbstract_iB_zyt5H6kyyAJa" style="vertical-align: bottom">
    <td>Non-Operating Income</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--ForeignCurrencyTransactionGainLossBeforeTax_i01_maNIEz5on_zLGhqZxbeiXj" style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="padding-left: 24.7pt; text-indent: -8.25pt">Loss on foreign currency exchange</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">(<ix:nonFraction name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">39,874</ix:nonFraction>)</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">(<ix:nonFraction name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">28,905</ix:nonFraction></td>
    <td>)</td></tr>
  <tr id="xdx_407_eus-gaap--GainLossOnSaleOfPropertyPlantEquipment_i01_maNIEz5on_zBdhxqX1cZYj" style="vertical-align: bottom">
    <td style="padding-left: 24.7pt; text-indent: -8.25pt">Gain on disposal of fixed assets</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0211">&#8212;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,009</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--OtherIncome_i01_maNIEz5on_zZbAJah2CDr7" style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="padding-left: 24.7pt; text-indent: -8.25pt">Other Income</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0214">&#8212;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:OtherIncome" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">679,907</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--OtherNonoperatingIncomeExpense_i01_maNIEz5on_zqjWSD3ADwwk" style="vertical-align: bottom">
    <td style="padding-left: 24.7pt; text-indent: -8.25pt">Interest income, net</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">145,587</ix:nonFraction></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">13,083</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--NonoperatingIncomeExpense_i01T_mtNIEz5on_maILFCOzgqq_zzpkXs7WLnjh" style="vertical-align: bottom; background-color: #E6E6E6">
    <td>TOTAL OTHER INCOME</td>
    <td>&#160;</td>
    <td style="border-top: black 1pt solid; border-bottom: black 1pt solid">&#160;</td>
    <td style="border-top: black 1pt solid; border-bottom: black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">105,713</ix:nonFraction></td>
    <td>&#160;</td>
    <td style="border-top: black 1pt solid; border-bottom: black 1pt solid">&#160;</td>
    <td style="border-top: black 1pt solid; border-bottom: black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">665,094</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_iT_mtILFCOzgqq_maNILzHPI_z5bBbyUduByj" style="vertical-align: bottom; background-color: #E6E6E6">
    <td>LOSS BEFORE TAXES</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">10,675,160</ix:nonFraction></td>
    <td>)</td>
    <td>&#160;</td>
    <td style="text-align: right">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">6,364,441</ix:nonFraction></td>
    <td>)</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--IncomeTaxExpenseBenefit_iN_di_msNILzHPI_zIJoF0mhMr49" style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="padding-left: 24.7pt; text-indent: -8.25pt">Income tax benefit</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,014,018</ix:nonFraction></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,801,618</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--NetIncomeLoss_iT_mtNILzHPI_zjKjlInEOUB1" style="vertical-align: bottom; background-color: #E6E6E6">
    <td>NET LOSS</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">8,661,142</ix:nonFraction></td>
    <td style="border-bottom: white 2.25pt double">)</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">4,562,823</ix:nonFraction></td>
    <td style="border-bottom: white 2.25pt double">)</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--EarningsPerShareAbstract_iB_zqAv3bmOECIe" style="vertical-align: bottom; background-color: #E6E6E6">
    <td>NET LOSS PER SHARE</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--EarningsPerShareBasic_i01_zrFjkmpRHNXk" style="vertical-align: bottom">
    <td style="padding-left: 24.7pt; text-indent: -8.25pt">Basic</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">0.19</ix:nonFraction></td>
    <td style="border-bottom: white 2.25pt double">)</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">0.10</ix:nonFraction></td>
    <td style="border-bottom: white 2.25pt double">)</td></tr>
  <tr id="xdx_403_eus-gaap--EarningsPerShareDiluted_i01_zMZ2QmebTkW2" style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="padding-left: 24.7pt; text-indent: -8.25pt">Diluted</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right">(<ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">0.19</ix:nonFraction></td>
    <td style="border-bottom: white 2.25pt double">)</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right">(<ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">0.10</ix:nonFraction></td>
    <td style="border-bottom: white 2.25pt double">)</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--WeightedAverageNumberOfSharesOutstandingAbstract_iB_zEcWzBwEHwFk" style="vertical-align: bottom; background-color: #E6E6E6">
    <td>WEIGHTED AVERAGE COMMON SHARES OUTSTANDING</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_i01_uShares_zGkLhrcu0fX5" style="vertical-align: bottom">
    <td style="padding-left: 24.7pt; text-indent: -8.25pt">Basic</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">45,002,074</ix:nonFraction></td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">44,385,032</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_i01_uShares_zcAufcdjGebi" style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="padding-left: 24.7pt; text-indent: -8.25pt">Diluted</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">45,002,074</ix:nonFraction></td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">44,385,032</ix:nonFraction></td>
    <td>&#160;</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">See accompanying Notes to Financial Statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>


<p style="font: 10pt TIMES NEW ROMAN, TIMES, SERIF; margin: 0; text-align: center">- 32 -</p>


<hr style="border-width: 0; color: Gray; background-color: Gray; height: 2px; width: 100%" /><p style="break-before: always"></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; color: blue"><i><a href="#index_to_fs">Index to Financial Statements</a></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="stockholders_equity"></span>&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>KORU MEDICAL SYSTEMS, INC.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>STATEMENTS OF STOCKHOLDERS&#8217; EQUITY</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" id="xdx_305_114_zpqSD6PgfnYd" summary="xdx: Statement - STATEMENTS OF STOCKHOLDERS&apos; EQUITY" style="font: 10pt Times New Roman, Times, Serif; width: 7.5in; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="width: 174.9pt">&#160;</td>
    <td style="width: 6.5pt">&#160;</td>
    <td style="width: 47.45pt">&#160;</td>
    <td style="width: 6.55pt">&#160;</td>
    <td style="width: 6.85pt">&#160;</td>
    <td id="xdx_4BB_us-gaap--StatementEquityComponentsAxis_us-gaap--CommonStockMember_zkbXNTpbLW4a" style="width: 40.75pt">&#160;</td>
    <td style="width: 6.55pt">&#160;</td>
    <td style="width: 6.85pt">&#160;</td>
    <td id="xdx_4BF_us-gaap--StatementEquityComponentsAxis_us-gaap--AdditionalPaidInCapitalMember_zkyw4sr1mwtf" style="width: 48.3pt">&#160;</td>
    <td style="width: 6.55pt">&#160;</td>
    <td style="width: 6.85pt">&#160;</td>
    <td id="xdx_4BB_us-gaap--StatementEquityComponentsAxis_us-gaap--RetainedEarningsMember_zugXHrIHmH4h" style="width: 47.65pt">&#160;</td>
    <td style="width: 6.65pt">&#160;</td>
    <td style="width: 6.85pt">&#160;</td>
    <td id="xdx_4B7_us-gaap--StatementEquityComponentsAxis_us-gaap--TreasuryStockMember_znMl4OmPgFre" style="width: 47.65pt">&#160;</td>
    <td style="width: 6.65pt">&#160;</td>
    <td style="width: 7.1pt">&#160;</td>
    <td id="xdx_4B2_ztdihxyOBORd" style="width: 52.7pt">&#160;</td>
    <td style="width: 6.65pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="4">&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center"><b>Additional</b></td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center"><b>Retained</b></td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center"><b>Total</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="4" style="border-bottom: black 1pt solid; text-align: center"><b>Common Stock</b></td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center"><b>Paid-in</b></td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center"><b>Earnings</b></td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center"><b>Treasury</b></td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center"><b>Stockholders&#8217;</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: center"><b>Shares</b></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>Amount</b></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>Capital</b></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>/(Deficit)</b></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>Stock</b></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>Equity</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_436_c20210101__20211231_eus-gaap--StockholdersEquity_iS_zXVe2NeqNhG8" style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="padding-left: 0.1in; text-indent: -0.1in">BALANCE, DECEMBER 31, 2020</td>
    <td>&#160;</td>
    <td id="xdx_98D_eus-gaap--SharesOutstanding_iS_pid_uShares_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zq5MhEx6jCk9" title="Balance beginning (in shares)" style="text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2020-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">46,680,119</ix:nonFraction></td>
    <td>&#160;</td>
    <td>$</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">466,801</ix:nonFraction></td>
    <td>&#160;</td>
    <td>$</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">35,880,986</ix:nonFraction></td>
    <td>&#160;</td>
    <td>$</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-12-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,652,754</ix:nonFraction></td>
    <td>&#160;</td>
    <td>$</td>
    <td style="text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-12-31_us-gaap_TreasuryStockMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">3,843,562</ix:nonFraction></td>
    <td>)</td>
    <td>$</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">36,156,979</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.1in; text-indent: -0.1in">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_430_c20210101__20211231_eus-gaap--StockIssuedDuringPeriodValueShareBasedCompensation_zssWUwaCHNE5" style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="padding-left: 0.1in; text-indent: -0.1in">Issuance of stock-based compensation</td>
    <td>&#160;</td>
    <td id="xdx_987_eus-gaap--StockIssuedDuringPeriodSharesShareBasedCompensation_pid_uShares_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z1849FvdX2zi" title="Issuance of stock-based compensation (in shares)" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">95,725</ix:nonFraction></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">958</ix:nonFraction></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2021-01-012021-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">432,696</ix:nonFraction></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0260">&#8212;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0261">&#8212;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">433,654</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr id="xdx_43E_c20210101__20211231_eus-gaap--AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_zTyoNDqPxnf2" style="vertical-align: bottom">
    <td style="padding-left: 0.1in; text-indent: -0.1in">Compensation expense related to stock options</td>
    <td>&#160;</td>
    <td style="text-align: right">&#8212;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0266">&#8212;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="From2021-01-012021-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,049,041</ix:nonFraction></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0268">&#8212;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0269">&#8212;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,049,041</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_z67V41F0K7zh" style="vertical-align: bottom; background-color: #E7E6E6">
    <td style="padding-left: 0.1in; text-indent: -0.1in">Issuance of Restricted Stock</td>
    <td>&#160;</td>
    <td style="text-align: right">&#8212;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0272">&#8212;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" contextRef="From2021-01-012021-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">224,859</ix:nonFraction></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0274">&#8212;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0275">&#8212;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">224,859</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr id="xdx_40D_ecustom--NewIssuanceLitigationSettlementAmountIssuance_z9vQUPg5VZV" style="vertical-align: bottom">
    <td style="padding-left: 0.1in; text-indent: -0.1in">Litigation settlement share issuance</td>
    <td>&#160;</td>
    <td id="xdx_98F_ecustom--NewIssuanceLitigationSettlementShareIssuance_pid_uShares_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zsOwa4ZjJWq" title="Litigation settlement share issuance (in shares)" style="text-align: right"><ix:nonFraction name="krmd:NewIssuanceLitigationSettlementShareIssuance" contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">95,238</ix:nonFraction></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="krmd:NewIssuanceLitigationSettlementAmountIssuance" contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">952</ix:nonFraction></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="krmd:NewIssuanceLitigationSettlementAmountIssuance" contextRef="From2021-01-012021-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">937,142</ix:nonFraction></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0280">&#8212;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0281">&#8212;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="krmd:NewIssuanceLitigationSettlementAmountIssuance" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">938,094</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr id="xdx_433_c20210101__20211231_eus-gaap--StockIssuedDuringPeriodValueStockOptionsExercised_zslwA8nC42hb" style="vertical-align: bottom; background-color: #E7E6E6">
    <td style="padding-left: 0.1in; text-indent: -0.1in">Issuance upon options exercised</td>
    <td>&#160;</td>
    <td id="xdx_984_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pid_uShares_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zLvvVDwUBJlj" title="Issuance upon options exercised (in shares)" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,173,080</ix:nonFraction></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">11,730</ix:nonFraction></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2021-01-012021-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,249,521</ix:nonFraction></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0288">&#8212;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0289">&#8212;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,261,251</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr id="xdx_43A_c20210101__20211231_eus-gaap--NetIncomeLoss_zZKh0uoJNxWf" style="vertical-align: bottom">
    <td style="padding-left: 0.1in; text-indent: -0.1in">Net loss</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right">&#8212;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0294">&#8212;</span></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0295">&#8212;</span></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-01-012021-12-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">4,562,823</ix:nonFraction></td>
    <td>)</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0297">&#8212;</span></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">4,562,823</ix:nonFraction></td>
    <td>)</td></tr>
  <tr id="xdx_43A_c20220101__20221231_eus-gaap--StockholdersEquity_iS_zrx92ou8luGi" style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="padding-left: 0.1in; text-indent: -0.1in">BALANCE, DECEMBER 31, 2021</td>
    <td>&#160;</td>
    <td id="xdx_98C_eus-gaap--SharesOutstanding_iS_pid_uShares_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zjE6Yx3X6Gal" title="Balance beginning (in shares)" style="border-bottom: black 2.25pt double; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2021-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">48,044,162</ix:nonFraction></td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">480,441</ix:nonFraction></td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">40,774,245</ix:nonFraction></td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">910,069</ix:nonFraction></td>
    <td style="border-bottom: white 1.5pt double">)</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31_us-gaap_TreasuryStockMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">3,843,562</ix:nonFraction></td>
    <td style="border-bottom: white 2.25pt double">)</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">36,501,055</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.1in; text-indent: -0.1in">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_430_c20220101__20221231_eus-gaap--StockIssuedDuringPeriodValueShareBasedCompensation_z1Z1b5swMpY3" style="vertical-align: bottom">
    <td style="padding-left: 0.1in; text-indent: -0.1in">Issuance of stock-based compensation</td>
    <td>&#160;</td>
    <td id="xdx_98B_eus-gaap--StockIssuedDuringPeriodSharesShareBasedCompensation_pid_uShares_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_ztvqInKZ3u6k" title="Issuance of stock-based compensation (in shares)" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">206,570</ix:nonFraction></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,066</ix:nonFraction></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">511,016</ix:nonFraction></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0310">&#8212;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0311">&#8212;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">513,082</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr id="xdx_430_c20220101__20221231_eus-gaap--AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_zoMs303aA8kb" style="vertical-align: bottom; background-color: #E7E6E6">
    <td style="padding-left: 0.1in; text-indent: -0.1in">Compensation expense related to stock options</td>
    <td>&#160;</td>
    <td style="text-align: right">&#8212;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0316">&#8212;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,083,396</ix:nonFraction></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0318">&#8212;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0319">&#8212;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,083,396</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_zkvDCx6GDxV2" style="vertical-align: bottom">
    <td style="padding-left: 0.1in; text-indent: -0.1in">Compensation expense related to restricted stock awards</td>
    <td>&#160;</td>
    <td id="xdx_982_ecustom--Compensationexpenserelatedtorestrictedstockawards_pid_uShares_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zI9oZaZlO3T6" title="Compensation expense related to restricted stock awards (in shares)" style="text-align: right"><ix:nonFraction name="krmd:Compensationexpenserelatedtorestrictedstockawards" contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">50,000</ix:nonFraction></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">500</ix:nonFraction></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">482,449</ix:nonFraction></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0324">&#8212;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0325">&#8212;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">482,949</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr id="xdx_438_c20220101__20221231_eus-gaap--StockIssuedDuringPeriodValueStockOptionsExercised_zb9zpUs7qQE9" style="vertical-align: bottom; background-color: #E7E6E6">
    <td style="padding-left: 0.1in; text-indent: -0.1in">Issuance upon options exercised</td>
    <td>&#160;</td>
    <td id="xdx_985_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pid_uShares_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zs8InCrRE2P8" title="Issuance upon options exercised (in shares)" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">561,159</ix:nonFraction></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,612</ix:nonFraction></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">401,011</ix:nonFraction></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0332">&#8212;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0333">&#8212;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">406,623</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr id="xdx_43D_c20220101__20221231_eus-gaap--NetIncomeLoss_zbI81U5HnAK3" style="vertical-align: bottom">
    <td style="padding-left: 0.1in; text-indent: -0.1in">Net loss</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right">&#8212;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0338">&#8212;</span></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0339">&#8212;</span></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">8,661,142</ix:nonFraction></td>
    <td>)</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0341">&#8212;</span></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">8,661,142</ix:nonFraction></td>
    <td>)</td></tr>
  <tr id="xdx_430_c20220101__20221231_eus-gaap--StockholdersEquity_iE_z3ghx2asb3j5" style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="padding-left: 0.1in; text-indent: -0.1in">BALANCE, DECEMBER 31, 2022</td>
    <td>&#160;</td>
    <td id="xdx_982_eus-gaap--SharesOutstanding_iE_pid_uShares_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zxhSF9LvjsOa" title="Balance ending (in shares)" style="border-bottom: black 2.25pt double; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2022-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">48,861,891</ix:nonFraction></td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">488,619</ix:nonFraction></td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">44,252,117</ix:nonFraction></td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">9,571,211</ix:nonFraction></td>
    <td style="border-bottom: white 1.5pt double">)</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_us-gaap_TreasuryStockMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">3,843,562</ix:nonFraction></td>
    <td style="border-bottom: white 2.25pt double">)</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">31,325,963</ix:nonFraction></td>
    <td>&#160;</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">See accompanying Notes to Financial Statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>


<p style="font: 10pt TIMES NEW ROMAN, TIMES, SERIF; margin: 0; text-align: center">- 33 -</p>


<hr style="border-width: 0; color: Gray; background-color: Gray; height: 2px; width: 100%" /><p style="break-before: always"></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; color: blue"><i><a href="#index_to_fs">Index to Financial Statements</a></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="cashflows"></span>&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>KORU MEDICAL SYSTEMS, INC.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>STATEMENTS OF CASH FLOWS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" id="xdx_30D_112_zbfe6HLhDWbk" summary="xdx: Statement - STATEMENTS OF CASH FLOWS" style="font: 10pt Times New Roman, Times, Serif; width: 7.5in; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="width: 333.45pt">&#160;</td>
    <td style="width: 12.55pt">&#160;</td>
    <td style="width: 10pt">&#160;</td>
    <td id="xdx_491_20220101__20221231_zPqpJYYllPpi" style="width: 74.8pt">&#160;</td>
    <td style="width: 20.2pt">&#160;</td>
    <td style="width: 10pt">&#160;</td>
    <td id="xdx_494_20210101__20211231_zcBWzx8kHN4g" style="width: 71.5pt">&#160;</td>
    <td style="width: 7.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="5" style="border-bottom: black 1pt solid; text-align: center"><b>For the Years Ended<br />
December 31,</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>2022</b></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>2021</b></td>
    <td>&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--NetCashProvidedByUsedInOperatingActivitiesAbstract_iB_zhykxras80ig" style="vertical-align: bottom; background-color: #E6E6E6">
    <td>CASH FLOWS FROM OPERATING ACTIVITIES</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--NetIncomeLoss_i01_maCz4Pm_maNCPBUzRiH_za71RMieowxf" style="vertical-align: bottom">
    <td style="padding-left: 24.7pt; text-indent: -8.25pt">Net Loss</td>
    <td>&#160;</td>
    <td>$</td>
    <td style="text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">8,661,142</ix:nonFraction></td>
    <td>)</td>
    <td>$</td>
    <td style="text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">4,562,823</ix:nonFraction></td>
    <td>)</td></tr>
  <tr id="xdx_40A_eus-gaap--AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_i01B_zL3osW9sF652" style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="padding-left: 24.7pt; text-indent: -8.25pt">Adjustments to reconcile net loss to net cash used in operating activities:</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--ShareBasedCompensation_i02_maCz4Pm_maNCPBUzRiH_zbumSXa9YxL9" style="vertical-align: bottom">
    <td style="padding-left: 41.15pt; text-indent: -8.25pt">Stock-based compensation expense</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,079,427</ix:nonFraction></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,707,554</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--DepreciationDepletionAndAmortization_i02_maCz4Pm_maNCPBUzRiH_zyn7h57QOAq2" style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="padding-left: 41.15pt; text-indent: -8.25pt">Depreciation and amortization</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:DepreciationDepletionAndAmortization" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">587,137</ix:nonFraction></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:DepreciationDepletionAndAmortization" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">463,130</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--GainLossOnSaleOfOtherAssets_i02N_di_msCz4Pm_msNCPBUzRiH_z6iGZzOuG5Pi">
    <td style="vertical-align: bottom; padding-left: 41.15pt; text-indent: -8.25pt">Loss on disposal of fixed assets</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0367">&#8212;</span></td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right">(<ix:nonFraction name="us-gaap:GainLossOnSaleOfOtherAssets" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,009</ix:nonFraction></td>
    <td style="vertical-align: bottom">)</td></tr>
  <tr id="xdx_406_eus-gaap--DeferredIncomeTaxesAndTaxCredits_i02_maNCPBUzRiH_zcHUNHyhgXVi" style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="padding-left: 41.15pt; text-indent: -8.25pt">Deferred income taxes</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">(<ix:nonFraction name="us-gaap:DeferredIncomeTaxesAndTaxCredits" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,026,226</ix:nonFraction></td>
    <td>)</td>
    <td>&#160;</td>
    <td style="text-align: right">(<ix:nonFraction name="us-gaap:DeferredIncomeTaxesAndTaxCredits" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,815,980</ix:nonFraction></td>
    <td>)</td></tr>
  <tr id="xdx_406_ecustom--RouLandlordCredit_i02_maNCPBUzRiH_z5qwYLoG7Sfb" style="vertical-align: bottom">
    <td style="padding-left: 41.15pt; text-indent: -8.25pt">ROU landlord credit</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="krmd:RouLandlordCredit" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">212,546</ix:nonFraction></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--IncreaseDecreaseInOperatingCapitalAbstract_i01B_z2lVWSxyHYQc" style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="padding-left: 41.15pt; text-indent: -8.25pt">Changes in operating assets and liabilities:</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--IncreaseDecreaseInAccountsReceivable_i02N_di_msNCPBUzRiH_z8xPwfMlVs3" style="vertical-align: bottom">
    <td style="padding-left: 0.8in; text-indent: -8.25pt">Decrease/(Increase)&#160;in accounts receivable</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsReceivable" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">34,002</ix:nonFraction></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsReceivable" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,019,932</ix:nonFraction></td>
    <td>)</td></tr>
  <tr id="xdx_40A_eus-gaap--IncreaseDecreaseInInventories_i02N_di_msNCPBUzRiH_zgVP7J4FdHsi" style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="padding-left: 0.8in; text-indent: -8.25pt">(Increase)/Decrease in inventory</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInInventories" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">298,529</ix:nonFraction></td>
    <td>)</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInInventories" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">723,434</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--IncreaseDecreaseInOtherReceivables_i02N_di_msNCPBUzRiH_zFTUnXgHN0Ci" style="vertical-align: bottom">
    <td style="padding-left: 0.8in; text-indent: -8.25pt">Increase in other receivables</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInOtherReceivables" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">254,176</ix:nonFraction>)</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInOtherReceivables" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">718,220</ix:nonFraction></td>
    <td>)</td></tr>
  <tr id="xdx_405_eus-gaap--IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_i02N_di_msNCPBUzRiH_zoAQVeoCSXZk" style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="padding-left: 0.8in; text-indent: -8.25pt">Decrease/(Increase) in prepaid expenses and other assets</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">28,776</ix:nonFraction></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">761,041</ix:nonFraction></td>
    <td>)</td></tr>
  <tr id="xdx_404_eus-gaap--IncreaseDecreaseInAccountsPayable_i02_maNCPBUzRiH_zB4BZ21hAF9c" style="vertical-align: bottom">
    <td style="padding-left: 0.8in; text-indent: -8.25pt">Increase in accounts payable</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayable" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,164,266</ix:nonFraction></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayable" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">602,613</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--IncreaseDecreaseInEmployeeRelatedLiabilities_i02_maNCPBUzRiH_zo8ZT9wCGK3" style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="padding-left: 0.8in; text-indent: -8.25pt">Increase/(Decrease) in accrued payroll and related taxes</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">381,796</ix:nonFraction></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">126,527</ix:nonFraction></td>
    <td>)</td></tr>
  <tr id="xdx_40D_eus-gaap--IncreaseDecreaseInOtherCurrentLiabilities_i02_maNCPBUzRiH_zxXHEsSV3Hje" style="vertical-align: bottom">
    <td style="padding-left: 0.8in; text-indent: -8.25pt">Increase in other liabilities</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInOtherCurrentLiabilities" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">167,337</ix:nonFraction></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInOtherCurrentLiabilities" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">90,000</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_i02_maNCPBUzRiH_zOp5MFsPGZw6" style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="padding-left: 0.8in; text-indent: -8.25pt">Increase in accrued expenses</td>
    <td>&#160;</td>
    <td style="border-bottom: Black 1pt solid">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">180,237</ix:nonFraction></td>
    <td>&#160;</td>
    <td style="border-bottom: Black 1pt solid">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">99,291</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--NetCashProvidedByUsedInOperatingActivities_i01T_mtNCPBUzRiH_maCCERCzITP_z3IPDWAtf63b" style="vertical-align: bottom">
    <td>NET CASH USED IN OPERATING ACTIVITIES</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">5,404,549</ix:nonFraction></td>
    <td>)</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">4,319,510</ix:nonFraction></td>
    <td>)</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--NetCashProvidedByUsedInInvestingActivitiesAbstract_iB_z1bvPglaZz01" style="vertical-align: bottom">
    <td>CASH FLOWS FROM INVESTING ACTIVITIES</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--PaymentsToAcquireProductiveAssets_i01N_di_msNCPBUz18p_zT83GDsssfv7" style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="padding-left: 41.15pt; text-indent: -8.25pt">Purchases of property and equipment</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">(<ix:nonFraction name="us-gaap:PaymentsToAcquireProductiveAssets" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,761,056</ix:nonFraction></td>
    <td>)</td>
    <td>&#160;</td>
    <td style="text-align: right">(<ix:nonFraction name="us-gaap:PaymentsToAcquireProductiveAssets" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">346,178</ix:nonFraction></td>
    <td>)</td></tr>
  <tr id="xdx_40C_eus-gaap--PaymentsToAcquireIntangibleAssets_i01N_di_msNCPBUz18p_z2k9123L4gR8" style="vertical-align: bottom">
    <td style="padding-left: 41.15pt; text-indent: -8.25pt">Purchases of intangible assets</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">(<ix:nonFraction name="us-gaap:PaymentsToAcquireIntangibleAssets" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">40,512</ix:nonFraction></td>
    <td>)</td>
    <td>&#160;</td>
    <td style="text-align: right">(<ix:nonFraction name="us-gaap:PaymentsToAcquireIntangibleAssets" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">29,056</ix:nonFraction></td>
    <td>)</td></tr>
  <tr id="xdx_40C_eus-gaap--ProceedsFromSaleOfProductiveAssets_i01_maNCPBUz18p_zGHEgHrEGnN3" style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="padding-left: 41.15pt; text-indent: -8.25pt">Proceeds from disposal of property and equipment</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0415">&#8212;</span></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromSaleOfProductiveAssets" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9,065</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--NetCashProvidedByUsedInInvestingActivities_i01T_mtNCPBUz18p_maCCERCzITP_z4e35Jy3Tw5b" style="vertical-align: bottom">
    <td>NET CASH USED IN INVESTING ACTIVITIES</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,801,568</ix:nonFraction></td>
    <td>)</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">366,169</ix:nonFraction></td>
    <td>)</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--NetCashProvidedByUsedInFinancingActivitiesAbstract_iB_zOoBls5gsmPc" style="vertical-align: bottom">
    <td>CASH FLOWS FROM FINANCING ACTIVITIES</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--ProceedsFromIssuanceOfCommonStock_i01_maNCPBUzvre_zLlzAeX5m9Ed" style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="padding-left: 41.15pt; text-indent: -8.25pt">Proceeds from issuance of equity</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">406,623</ix:nonFraction></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,261,251</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr id="xdx_40E_ecustom--CommonStockIssuanceAsSettlementForLitigation_i01_maNCPBUzvre_zTGHlXzogTCb" style="vertical-align: bottom">
    <td style="padding-left: 41.15pt; text-indent: -8.25pt">Common stock issuance settlement of litigation</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0427">&#8212;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="krmd:CommonStockIssuanceAsSettlementForLitigation" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">938,094</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr id="xdx_40A_ecustom--BorrowingsFromIndebtedness_i01_maNCPBUzvre_z8vGGli4p2kk" style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="padding-left: 41.15pt; text-indent: -8.25pt">Borrowings from indebtedness</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="krmd:BorrowingsFromIndebtedness" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">783,799</ix:nonFraction></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="krmd:BorrowingsFromIndebtedness" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">924,389</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr id="xdx_407_ecustom--PaymentsOnIndebtedness_i01N_di_msNCPBUzvre_zl47jpJHuAt6" style="vertical-align: bottom">
    <td style="padding-left: 41.15pt; text-indent: -8.25pt">Payments on indebtedness</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">(<ix:nonFraction name="krmd:PaymentsOnIndebtedness" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">859,087</ix:nonFraction></td>
    <td>)</td>
    <td>&#160;</td>
    <td style="text-align: right">(<ix:nonFraction name="krmd:PaymentsOnIndebtedness" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">415,806</ix:nonFraction></td>
    <td>)</td></tr>
  <tr id="xdx_40B_eus-gaap--FinanceLeasePrincipalPayments_i01N_di_msNCPBUzvre_ztNJMzpVbK93" style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="padding-left: 41.15pt; text-indent: -8.25pt">Payments on finance lease liability</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:FinanceLeasePrincipalPayments" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">51,850</ix:nonFraction></td>
    <td>)</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:FinanceLeasePrincipalPayments" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,646</ix:nonFraction></td>
    <td>)</td></tr>
  <tr id="xdx_401_eus-gaap--NetCashProvidedByUsedInFinancingActivities_i01T_mtNCPBUzvre_maCCERCzITP_z630tJPM7lGh" style="vertical-align: bottom">
    <td>NET CASH PROVIDED BY FINANCING ACTIVITIES</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">279,485</ix:nonFraction></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,705,282</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_iT_mtCCERCzITP_z4BmBox9Q0ra" style="vertical-align: bottom">
    <td>NET DECREASE IN CASH AND CASH EQUIVALENTS</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">(<ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">7,926,632</ix:nonFraction></td>
    <td>)</td>
    <td>&#160;</td>
    <td style="text-align: right">(<ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,980,397</ix:nonFraction></td>
    <td>)</td></tr>
  <tr id="xdx_409_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iS_zpvYaSJBTDG5" style="vertical-align: bottom; background-color: #E6E6E6">
    <td>CASH AND CASH EQUIVALENTS, BEGINNING OF YEAR</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">25,334,889</ix:nonFraction></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">27,315,286</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iE_z5CZabl1zsUc" style="vertical-align: bottom">
    <td>CASH AND CASH EQUIVALENTS, END OF YEAR</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">17,408,257</ix:nonFraction></td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">25,334,889</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--SupplementalCashFlowInformationAbstract_iB_ztDejZCJE4Ob" style="vertical-align: bottom">
    <td>Supplemental Information</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_400_ecustom--CashPaidDuringPeriodsForAbstract_iB_zOeAuGQTbaYi" style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="padding-left: 24.7pt; text-indent: -8.25pt">Cash paid during the years for:</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--InterestPaidNet_i01_z3BXaVUEshOi" style="vertical-align: bottom">
    <td style="padding-left: 41.15pt; text-indent: -8.25pt">Interest</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><ix:nonFraction name="us-gaap:InterestPaidNet" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">28,490</ix:nonFraction></td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><ix:nonFraction name="us-gaap:InterestPaidNet" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">13,241</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--IncomeTaxesPaidNet_i01_zDnqH4fnpXF9" style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="padding-left: 41.15pt; text-indent: -8.25pt">Income taxes</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0460">&#8212;</span></td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><ix:nonFraction name="us-gaap:IncomeTaxesPaidNet" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,903</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_iB_z4Slsm1YnJfd" style="vertical-align: bottom">
    <td>Schedule of Non-Cash Operating, Investing and Financing Activities:</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_40C_ecustom--IssuanceOfCommonStockCompensation_zeP1FU9ODhFh" style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="padding-left: 24.7pt; text-indent: -8.25pt">Issuance of common stock as compensation</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><ix:nonFraction name="krmd:IssuanceOfCommonStockCompensation" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">513,082</ix:nonFraction></td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><ix:nonFraction name="krmd:IssuanceOfCommonStockCompensation" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">433,654</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--StockIssued1_zALYC1PXnJtd" style="vertical-align: bottom">
    <td style="padding-left: 24.7pt; text-indent: -8.25pt">Issuance of common stock as settlement for litigation</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0469">&#8212;</span></td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><ix:nonFraction name="us-gaap:StockIssued1" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">938,094</ix:nonFraction></td>
    <td>&#160;</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">See accompanying Notes to Financial Statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>


<p style="font: 10pt TIMES NEW ROMAN, TIMES, SERIF; margin: 0; text-align: center">- 34 -</p>


<hr style="border-width: 0; color: Gray; background-color: Gray; height: 2px; width: 100%" /><p style="break-before: always"></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; color: blue"><i><a href="#index_to_fs">Index to Financial Statements</a></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="notes_to_financials"></span>&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>KORU MEDICAL SYSTEMS, INC.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>NOTES TO FINANCIAL STATEMENTS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock"><p id="xdx_803_eus-gaap--OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock_zGNfMJCk2tF6" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><span>NOTE 1 &#8212; <span id="xdx_820_z74Qsx9zc2m7">NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING
POLICIES</span></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:NatureOfOperations"><p id="xdx_84C_eus-gaap--NatureOfOperations_zdnVGPzndT5i" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_86B_z8TcbrjdtGD7">NATURE OF OPERATIONS</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">KORU MEDICAL SYSTEMS, INC. (the &#8220;Company,&#8221; &#8220;KORU Medical,&#8221;
&#8220;KORU,&#8221; &#8220;we,&#8221; &#8220;us&#8221; or &#8220;our&#8221;) develops, manufactures and markets proprietary portable and
innovative medical devices primarily for the ambulatory infusion market as governed by the United States Food and Drug Administration
(the &#8220;FDA&#8221;) quality and regulatory system and international standards for quality system management. &#160;The Company operates
as <span id="xdx_907_eus-gaap--NumberOfReportableSegments_dxH_uN_c20220101__20221231_zp0YK2i0Lpfd" title="Number of segments::XDX::1">one</span> segment.</p>

</ix:nonNumeric><p id="xdx_85C_zTv1vbyJcMOa" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock"><p id="xdx_842_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zS9HDKwxKkD4" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_862_za4Wlr4TVcUi">BASIS OF PRESENTATION</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We prepare our financial statements and accompanying
notes in accordance with accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;). &#160;Certain
prior year amounts have been reclassified to conform to the current year presentation in our Financial Statements.</p>

</ix:nonNumeric><p id="xdx_85F_zecxaotkjRZj" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock"><p id="xdx_844_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zohP6xbtb9c3" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_868_zilxnUanv4tl">CASH AND CASH EQUIVALENTS</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">For purposes of the statement of cash flows, the Company considers all
short-term investments with an original maturity of three months or less to be cash equivalents. &#160;The Company holds cash in excess
of $<span id="xdx_902_eus-gaap--CashUninsuredAmount_iI_c20221231_zRZKlxgJI0Ih" title="FDIC cash uninsured amount"><ix:nonFraction name="us-gaap:CashUninsuredAmount" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">250,000</ix:nonFraction></span> at its depository, which exceeds the FDIC insurance limits and is, therefore, uninsured.</p>

</ix:nonNumeric><p id="xdx_85A_zCLiQhLKJEA1" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:InventoryPolicyTextBlock"><p id="xdx_840_eus-gaap--InventoryPolicyTextBlock_zxzLjs6dGw8k" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_86A_zvP96g8ATew6">INVENTORY</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Inventories of raw materials are stated at the lower of standard cost,
which approximates average cost, or market value including allocable overhead. &#160;Work-in-process and finished goods are stated at
the lower of standard cost or market value and include direct labor and allocable overhead.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">We maintain reserves for excess and obsolete inventory resulting from the
potential inability to sell certain products at prices in excess of current carrying costs. &#160;We make estimates regarding the future
recoverability of the costs of these products and record provisions based on historical experience, expiration of sterilization dates
and expected future trends. &#160;If actual product life cycles, product demand or acceptance of new product introductions are less favorable
than projected by management, additional inventory write downs may be required, which could unfavorably affect future operating results.</p>

</ix:nonNumeric><p id="xdx_851_zCJPGSQM6xEj" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:IntangibleAssetsFiniteLivedPolicy"><p id="xdx_841_eus-gaap--IntangibleAssetsFiniteLivedPolicy_zFAchVM8szJb" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_867_zJ95rXxkf8S2">INTANGIBLE ASSETS</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Certain of our identifiable intangible assets, including patents and trademarks,
are amortized using the straight-line method over their estimated useful lives which range from <span id="xdx_905_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dxL_c20220101__20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentsAndTrademarksMember__srt--RangeAxis__srt--MinimumMember_zMgMbxBk72M1" title="Estimated useful lives::XDX::P6Y"><span style="-sec-ix-hidden: xdx2ixbrl0488">6</span></span> to <span id="xdx_906_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dxL_c20220101__20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentsAndTrademarksMember__srt--RangeAxis__srt--MaximumMember_zsMBX7xYZM4" title="Estimated useful lives::XDX::P20Y"><span style="-sec-ix-hidden: xdx2ixbrl0490">20</span></span> years. &#160;All of our intangible
assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be
recoverable. &#160;Our management is responsible for determining if impairment exists and considers various factors when making these
determinations. &#160;Amortization expense related to intangible assets for the years ended December 31, 2022 and 2021 was $<span id="xdx_90A_ecustom--AmortizationOfIntangibleAssets1_c20220101__20221231_zdaQyFTk8Rnc" title="AmortizationOfIntangibleAssets1"><ix:nonFraction name="krmd:AmortizationOfIntangibleAssets1" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">62,143</ix:nonFraction></span> and
$<span id="xdx_907_ecustom--AmortizationOfIntangibleAssets1_c20210101__20211231_zleXm3JB0R5c" title="AmortizationOfIntangibleAssets1"><ix:nonFraction name="krmd:AmortizationOfIntangibleAssets1" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">63,830</ix:nonFraction></span>, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock"><p id="xdx_898_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock_zgEH8iPnMqul" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The estimated amortization expense for the succeeding
years for the intangible assets is approximately:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span><span id="xdx_8B1_zMmeOzpV9qQa" style="display: none; visibility: hidden">Schedule of amortization expense</span></span>&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 3in; border-collapse: collapse">
  <tr style="background-color: white">
    <td style="border-bottom: black 1pt solid; vertical-align: bottom"><b>Year Ending December 31,</b></td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td id="xdx_49C_20221231_zZxBsRzkCe58" style="vertical-align: bottom">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_iI_zkTn0Qh4EZ05" style="background-color: #E6E6E6">
    <td style="vertical-align: bottom; width: 150pt">2023</td>
    <td style="vertical-align: top; width: 10.4pt">&#160;</td>
    <td style="vertical-align: bottom; width: 10pt">$</td>
    <td style="vertical-align: bottom; width: 56.65pt; text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">62,982</ix:nonFraction></td></tr>
  <tr id="xdx_408_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_iI_zq1eV71T9gLc" style="vertical-align: bottom">
    <td>2024</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">62,982</ix:nonFraction></td></tr>
  <tr id="xdx_40F_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_iI_zHCqqdyxmXMa" style="background-color: #E6E6E6">
    <td style="vertical-align: bottom">2025</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">62,842</ix:nonFraction></td></tr>
  <tr id="xdx_40B_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_iI_zj8WKS3ZyaX8" style="background-color: white">
    <td style="vertical-align: bottom">2026</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">61,787</ix:nonFraction></td></tr>
  <tr id="xdx_407_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_iI_zw0Gtw4DlTPe" style="background-color: #E6E6E6">
    <td style="vertical-align: bottom">2027</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">61,356</ix:nonFraction></td></tr>
  <tr id="xdx_401_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_iI_zCI3c5sQsljc" style="background-color: white">
    <td style="vertical-align: bottom">Thereafter</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="border-bottom: black 1pt solid; vertical-align: bottom">&#160;</td>
    <td style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">475,233</ix:nonFraction></td></tr>
  <tr id="xdx_406_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_zCRJMlJKZMk6" style="background-color: #E6E6E6">
    <td style="vertical-align: bottom">Total amortization expense</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="border-bottom: black 2.25pt double; vertical-align: bottom">$</td>
    <td style="border-bottom: black 2.25pt double; vertical-align: bottom; text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">787,182</ix:nonFraction></td></tr>
  </table>
</ix:nonNumeric><p id="xdx_8AC_zS8cA14RTjLd" style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

</ix:nonNumeric><p id="xdx_856_zUAUDDQnci0k" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<ix:exclude><div id="xdx_23E_z1gJGFUUm2Ei">
<p style="font: 10pt TIMES NEW ROMAN, TIMES, SERIF; margin: 0; text-align: center">- 35 -</p>


<hr style="border-width: 0; color: Gray; background-color: Gray; height: 2px; width: 100%" /><p style="break-before: always"></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; color: blue"><i><a href="#index_to_fs">Index to Financial Statements</a></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p></div></ix:exclude>

<ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:IncomeTaxPolicyTextBlock"><p id="xdx_840_eus-gaap--IncomeTaxPolicyTextBlock_zPneQ0ZgQzgh" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_86A_zurAya66UGVf">INCOME TAXES</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Deferred income taxes are provided using the liability method whereby deferred
tax assets are recognized for deductible temporary differences and operating loss and tax credit carry forwards and deferred tax liabilities
are recognized for taxable temporary differences.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The Company believes that it has no uncertain tax positions requiring disclosure
or adjustment.</p>

</ix:nonNumeric><p id="xdx_85D_zUiO08rNX3Rk" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock"><p id="xdx_841_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zOBbEIpyGmd6" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_862_zPYpLF37xpxc">PROPERTY AND EQUIPMENT</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Property and equipment are stated at original acquisition cost less accumulated
depreciation. &#160;Additions and improvements are capitalized which increase the value or extend the life of an asset, while maintenance
and repair costs are expensed as incurred. &#160;When assets are retired or otherwise disposed, the cost and related accumulated depreciation
or amortization is removed from the respective accounts and any resulting gain or loss is included in income. &#160;Depreciation and amortization
are calculated on the straight-line basis over the estimated useful lives of the assets which generally range from <span id="xdx_904_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dxL_c20220101__20221231__srt--RangeAxis__srt--MinimumMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--FurnitureAndOfficeEquipmentMember_zzKLaTSM3CF7" title="Estimated useful lives of property and equipment::XDX::P3Y"><span style="-sec-ix-hidden: xdx2ixbrl0517">3</span></span>-<span id="xdx_905_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dxL_c20220101__20221231__srt--RangeAxis__srt--MaximumMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--FurnitureAndOfficeEquipmentMember_zR5ZBROcRTS8" title="::XDX::P10Y0M0D"><span style="-sec-ix-hidden: xdx2ixbrl0518">10</span></span> years for furniture
and office equipment, <span id="xdx_902_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dxL_c20220101__20221231__srt--RangeAxis__srt--MinimumMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--EquipmentAndToolingMember_zp39ZMDYg8O5" title="::XDX::P3Y"><span style="-sec-ix-hidden: xdx2ixbrl0519">3</span></span>-<span id="xdx_90E_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dxL_c20220101__20221231__srt--RangeAxis__srt--MaximumMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--EquipmentAndToolingMember_z00VDHNAeUH6" title="::XDX::P12Y"><span style="-sec-ix-hidden: xdx2ixbrl0520">12</span></span> years for manufacturing equipment and tooling and shorter of the lease term or their estimated useful lives
for leasehold improvements. Depreciation and amortization expense related to property and equipment for the years ended December 31, 2022
and 2021 was $<span id="xdx_905_eus-gaap--DepreciationDepletionAndAmortization_c20220101__20221231__us-gaap--FairValueByAssetClassAxis__us-gaap--PropertyPlantAndEquipmentMember_zRMvqTTkVI79" title="Depreciation and amortization"><ix:nonFraction name="us-gaap:DepreciationDepletionAndAmortization" contextRef="From2022-01-012022-12-31_us-gaap_PropertyPlantAndEquipmentMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">524,994</ix:nonFraction></span> and $<span id="xdx_908_eus-gaap--DepreciationDepletionAndAmortization_c20210101__20211231__us-gaap--FairValueByAssetClassAxis__us-gaap--PropertyPlantAndEquipmentMember_zK3zQHuOPHwj" title="Depreciation and amortization"><ix:nonFraction name="us-gaap:DepreciationDepletionAndAmortization" contextRef="From2021-01-012021-12-31_us-gaap_PropertyPlantAndEquipmentMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">399,300</ix:nonFraction></span>, respectively.</p>

</ix:nonNumeric><p id="xdx_859_z5gLhjvKiRff" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy"><p id="xdx_84A_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_z4r5Vzf2AITb" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_863_zR62l6wfRBAe">STOCK-BASED COMPENSATION</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The Company maintains a stock option plan and omnibus equity incentive
plan under which it grants stock options to certain executives, key employees and consultants. The fair value of each option grant is
estimated on the date of the grant using the Black-Scholes option-pricing model. &#160;All options are charged against income at their
fair value. &#160;The entire compensation expense of the award is recognized over the vesting period.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Shares of stock granted for director fees under the non-employee director
compensation plan are recorded at the fair value of the shares at the grant date.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The Company has also issued shares of stock for director fees under its
omnibus equity incentive plan. Those shares of stock granted are recorded at the fair value of the shares at the grant date.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The Company issues restricted stock awards. Restricted stock awards are
equity classified and measured at the fair market value of the underlying stock at the grant date. The fair value of restricted stock
awards vesting at certain market capitalization thresholds were estimated on the date of grant using the Brownian Motion Monte Carlo lattice
model. The fair value of restricted stock awards with time-based vesting were estimated on the date of grant at the current stock price.
We recognize restricted stock expense using the straight-line attribution method over the requisite service period and account for forfeitures
as they occur.</p>

</ix:nonNumeric><p id="xdx_85F_zC9odunTWveb" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:EarningsPerSharePolicyTextBlock"><p id="xdx_845_eus-gaap--EarningsPerSharePolicyTextBlock_zZYuIlFBcHfk" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_86C_zhho2Pw2uBn1">NET LOSS PER COMMON SHARE</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"><p id="xdx_89E_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_zMG1jKvSqsWe" style="font: 10pt Times New Roman, Times, Serif; margin: 0">Basic earnings per share are computed on the weighted average of common
shares outstanding during each year. &#160;Diluted earnings per share includes only an increase in the weighted average shares by the
common shares issuable upon exercise of stock options. &#160;See &#8220;NOTE 4 &#8212; STOCK-BASED COMPENSATION&#8221; for further detail.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span><span id="xdx_8BC_zlnjQ0R1CBk9" style="display: none; visibility: hidden">Schedule of net income per common share</span></span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 5.5in; border-collapse: collapse">
  <tr>
    <td style="vertical-align: bottom; width: 167.8pt">&#160;</td>
    <td style="vertical-align: bottom; width: 6.95pt">&#160;</td>
    <td style="vertical-align: top; width: 7.1pt; text-align: center">&#160;</td>
    <td id="xdx_493_20220101__20221231_zzvMb6BBNmGj" style="vertical-align: top; width: 85.9pt; text-align: center">&#160;</td>
    <td style="vertical-align: top; width: 14.1pt; text-align: center">&#160;</td>
    <td style="vertical-align: top; width: 9.35pt; text-align: center">&#160;</td>
    <td style="vertical-align: top; width: 7.1pt; text-align: center">&#160;</td>
    <td id="xdx_496_20210101__20211231_zL1n95ZSVts2" style="vertical-align: top; width: 82.5pt; text-align: center">&#160;</td>
    <td style="vertical-align: bottom; width: 15.1pt">&#160;</td></tr>
  <tr>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td colspan="6" style="border-bottom: black 1pt solid; vertical-align: top; text-align: center"><b>Years Ended</b></td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: center"><b>December 31, 2022</b></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: center"><b>December 31, 2021</b></td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--NetIncomeLoss_zY35B8ztZ5e8" style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Net loss</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">$</td>
    <td style="border-bottom: black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">8,661,142</ix:nonFraction></td>
    <td>)</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">$</td>
    <td style="border-bottom: black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">4,562,823</ix:nonFraction></td>
    <td>)</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasicAbstract_iB_zJKQih5XQNV7" style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Weighted Average Outstanding Shares:</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pid_hus-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zIQ1UMkP0mOc" style="vertical-align: bottom">
    <td style="padding-left: 21.8pt">Outstanding shares</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">45,002,074</ix:nonFraction></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">44,385,032</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--IncrementalCommonSharesAttributableToCallOptionsAndWarrants_pid_zm8oNBHXFS0c" style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="padding-left: 21.8pt">Option shares includable</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0541">&#8212;</span></td>
    <td id="xdx_F51_zXnO0VQ3fCd8">(a)</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0542">&#8212;</span></td>
    <td id="xdx_F56_z8suocOMxah">(a)</td></tr>
  <tr id="xdx_40E_ecustom--IncrementalCommonSharesAttributableToRestrictedStock_pid_ztoKP1mn4Bw" style="vertical-align: bottom">
    <td style="padding-left: 21.8pt">Restricted stock includable</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0544">&#8212;</span></td>
    <td id="xdx_F52_zmpyjNDtJ7Ea">(b)</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0545">&#8212;</span></td>
    <td id="xdx_F5F_z4nwfjQAj7la">(b)</td></tr>
  <tr id="xdx_407_ecustom--WeightedAverageNumberOfSharesOutstanding_zjf5cgBKhkY3" style="vertical-align: bottom">
    <td><p style="margin-top: 0; margin-bottom: 0"><b style="display: none; visibility: hidden">&#160;Total</b></p>
        <p style="margin-top: 0; margin-bottom: 0"></p></td>
    <td></td>
    <td style="border-bottom: black 2.25pt double">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><ix:nonFraction name="krmd:WeightedAverageNumberOfSharesOutstanding" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">45,002,074</ix:nonFraction></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><ix:nonFraction name="krmd:WeightedAverageNumberOfSharesOutstanding" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">44,385,032</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--EarningsPerShareAbstract_iB_zGOHyByYtat1" style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Net loss per share</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--EarningsPerShareBasic_pid_uUSDPShares_zk4hYMtkkq2j" style="vertical-align: bottom">
    <td style="padding-left: 21.8pt">Basic</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">0.19</ix:nonFraction></td>
    <td style="border-bottom: white 2.25pt double">)</td>
    <td style="border-bottom: black 2.25pt double">&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">0.10</ix:nonFraction></td>
    <td style="border-bottom: white 2.25pt double">)</td></tr>
  <tr id="xdx_404_eus-gaap--EarningsPerShareDiluted_pid_uUSDPShares_zoNdyVgzpB1k" style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="padding-left: 21.8pt">Diluted</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right">(<ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">0.19</ix:nonFraction></td>
    <td style="border-bottom: white 2.25pt double">)</td>
    <td style="border-bottom: black 2.25pt double">&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right">(<ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">0.10</ix:nonFraction></td>
    <td style="border-bottom: white 2.25pt double">)</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">__________</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td id="xdx_F07_zpjRlU1tokg5" style="width: 0.5in">(a)</td>
    <td id="xdx_F13_zJ7k0c2TJW51" style="width: 7in"><ix:footnote id="Footnote000558" xml:lang="en-US">Option shares of <span id="xdx_90B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_dxL_uShares_c20220101__20221231__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--EmployeeStockMember_zJscHJ6nJh08" title="Option shares excluded::XDX::0"><span style="-sec-ix-hidden: xdx2ixbrl0560">zero</span></span> and <span id="xdx_906_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_uShares_c20210101__20211231__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--EmployeeStockMember_zOXokNhUvBRh" title="Option shares excluded"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2021-01-012021-12-31_us-gaap_EmployeeStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">273,110</ix:nonFraction></span> for 2022 and 2021, respectively were not included as the impact is anti-dilutive.</ix:footnote></td></tr>
  <tr style="vertical-align: top">
    <td id="xdx_F05_zQfISkekUjdj" style="width: 0.5in">(b)</td>
    <td id="xdx_F12_zj23i9XZITAh" style="width: 7in"><ix:footnote id="Footnote000563" xml:lang="en-US">Linda Tharby's Restricted Stock award shares of <span id="xdx_90D_ecustom--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount1_pid_uShares_c20220101__20221231__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--EmployeeStockMember_zQe25yGQAtl2" title="Restricted stock shares excluded"><ix:nonFraction name="krmd:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount1" contextRef="From2022-01-012022-12-31_us-gaap_EmployeeStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">950,000</ix:nonFraction></span> and <span id="xdx_900_ecustom--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount1_pid_uShares_c20210101__20211231__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--EmployeeStockMember_zQeAAvWnACzb" title="Restricted stock shares excluded"><ix:nonFraction name="krmd:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount1" contextRef="From2021-01-012021-12-31_us-gaap_EmployeeStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,000,000</ix:nonFraction></span> that are unvested for 2022 and 2021, respectively were not included as the impact is anti-dilutive.</ix:footnote></td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AD_z74ojCDpPbsk" style="margin-top: 0; margin-bottom: 0">&#160;</p>
</ix:nonNumeric><p id="xdx_855_zDA565EElgn3" style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<ix:exclude><div id="xdx_23B_zQF0td9OL892">
<p style="font: 10pt TIMES NEW ROMAN, TIMES, SERIF; margin: 0; text-align: center">- 36 -</p>


<hr style="border-width: 0; color: Gray; background-color: Gray; height: 2px; width: 100%" /><p style="break-before: always"></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; color: blue"><i><a href="#index_to_fs">Index to Financial Statements</a></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p></div></ix:exclude>

<ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:UseOfEstimates"><p id="xdx_844_eus-gaap--UseOfEstimates_z6LaBImte0K4" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_869_z4A7A2mqJ7X9">USE OF ESTIMATES IN THE FINANCIAL STATEMENTS</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The preparation of financial statements in conformity with GAAP requires
management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. &#160;Actual
results could differ from those estimates. &#160;Important estimates include but are not limited to asset lives, valuation allowances,
inventory valuation, and accruals.</p>

</ix:nonNumeric><p id="xdx_850_zNIRuhMWrZQ6" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock"><p id="xdx_84F_eus-gaap--RevenueFromContractWithCustomerPolicyTextBlock_zpLpzc1GZBG4" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_860_zt5Gey8twc2c">REVENUE RECOGNITION</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting
Standards Update (&#8220;ASU&#8221;) No. 2014-09, <i>Revenue from Contracts with Customers</i>, which provides a single comprehensive
model for entities to use in accounting for revenue arising from contracts with customers.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The Company&#8217;s revenues result from the sale of assembled products.
&#160;We recognize revenues when shipment occurs, and at which point the customer obtains control and ownership of the goods. &#160;Shipping
costs generally are billed to customers and are included in sales.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The Company generally does not accept return of goods shipped unless it
is a Company error. &#160;The only credits provided to customers are for defective merchandise. &#160;The Company warrants the syringe
driver from defects in materials and workmanship under normal use and the warranty does not include a performance obligation. &#160;The
costs under the warranty are expensed as incurred.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Provisions for distributor pricing and annual customer growth rebates are
variable consideration and are recorded as a reduction of revenue in the same period the related sales are recorded or when it is probable
the annual growth target will be achieved. &#160;Rebates are provided to distributors for the difference in selling price to distributor
and pricing specified to select customers.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The Company established an allowance for charging off uncollectible trade
accounts receivable that have both of the following characteristics: (a) They have a contractual maturity of one year or less, (b) They
arose from the sale of goods or services.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="krmd:ScheduleOfNetRevenuesByGeography"><p id="xdx_89E_ecustom--ScheduleOfNetRevenuesByGeography_z3BIpuyfVG4d" style="font: 10pt Times New Roman, Times, Serif; margin: 0">The following table summarizes net revenues by geography for the years ended
December 31, 2022 and 2021:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_8BD_z3C9ZxreeIk3" style="display: none; visibility: hidden">Schedule of net revenues by geography</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 3.5in; border-collapse: collapse">
  <tr style="background-color: white">
    <td style="vertical-align: bottom; width: 93.35pt">&#160;</td>
    <td style="vertical-align: bottom; width: 8.3pt">&#160;</td>
    <td style="vertical-align: bottom; width: 8.25pt">&#160;</td>
    <td style="vertical-align: bottom; width: 53.4pt">&#160;</td>
    <td style="vertical-align: bottom; width: 18.05pt">&#160;</td>
    <td style="vertical-align: bottom; width: 8.25pt">&#160;</td>
    <td style="vertical-align: bottom; width: 54.15pt">&#160;</td>
    <td style="vertical-align: top; width: 8.25pt">&#160;</td></tr>
  <tr style="background-color: white">
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td colspan="5" style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: center"><b>Years Ended December 31,</b></td>
    <td style="vertical-align: top">&#160;</td></tr>
  <tr style="background-color: white">
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: center"><b>2022</b></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: center"><b>2021</b></td>
    <td style="vertical-align: top">&#160;</td></tr>
  <tr style="background-color: white">
    <td style="vertical-align: bottom"><b>Net Revenues</b></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top">&#160;</td></tr>
  <tr style="background-color: #E6E6E6">
    <td style="vertical-align: bottom; padding-left: 9.45pt">Domestic</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td>$</td>
    <td id="xdx_98D_eus-gaap--Revenues_c20220101__20221231__srt--StatementGeographicalAxis__country--US_zZ4uQjTcgfJc" title="Net Revenue" style="text-align: right"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2022-01-012022-12-31_country_US" format="ixt:numdotdecimal" decimals="0" unitRef="USD">23,586,254</ix:nonFraction></td>
    <td style="vertical-align: top">&#160;</td>
    <td>$</td>
    <td id="xdx_98C_eus-gaap--Revenues_c20210101__20211231__srt--StatementGeographicalAxis__country--US_zmQIeI78tUyl" title="Net Revenue" style="text-align: right"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2021-01-012021-12-31_country_US" format="ixt:numdotdecimal" decimals="0" unitRef="USD">19,488,685</ix:nonFraction></td>
    <td style="vertical-align: top">&#160;</td></tr>
  <tr style="background-color: white">
    <td style="vertical-align: bottom; padding-left: 9.45pt">International</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td id="xdx_987_eus-gaap--Revenues_c20220101__20221231__srt--StatementGeographicalAxis__us-gaap--NonUsMember_zfGG2aByPLz" title="Net Revenues" style="border-bottom: black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2022-01-012022-12-31_us-gaap_NonUsMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,309,783</ix:nonFraction></td>
    <td style="vertical-align: top">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td id="xdx_981_eus-gaap--Revenues_c20210101__20211231__srt--StatementGeographicalAxis__us-gaap--NonUsMember_zRtFKssVTgme" title="Net Revenues" style="border-bottom: black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2021-01-012021-12-31_us-gaap_NonUsMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,001,490</ix:nonFraction></td>
    <td style="vertical-align: top">&#160;</td></tr>
  <tr style="background-color: #E6E6E6">
    <td style="vertical-align: bottom"><b>Total</b></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td id="xdx_988_eus-gaap--Revenues_c20220101__20221231_zbAfS3LpNBGe" title="Revenues" style="border-bottom: black 2.25pt double; text-align: right"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">27,896,037</ix:nonFraction></td>
    <td style="border-bottom: white 2.25pt double; vertical-align: top">&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td id="xdx_980_eus-gaap--Revenues_c20210101__20211231_zn8OKcUznKZg" title="Revenues" style="border-bottom: black 2.25pt double; text-align: right"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">23,490,175</ix:nonFraction></td>
    <td style="vertical-align: top">&#160;</td></tr>
  </table>
</ix:nonNumeric><p id="xdx_8A4_zRN68oI0ioGe" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

</ix:nonNumeric><p id="xdx_85B_zjcwB7y4KIdf" style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:LesseeLeasesPolicyTextBlock"><p id="xdx_846_eus-gaap--LesseeLeasesPolicyTextBlock_zipKrI5L2i54" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_863_zGMa0N0Ww7ef">LEASES</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">In February 2016, the FASB issued a standard related to leases to increase
transparency and comparability among organizations by requiring the recognition of right-of-use (&#8220;ROU&#8221;) assets and lease liabilities
on the balance sheet. &#160;Most prominent among the changes in the standard is the recognition of ROU assets and lease liabilities by
the Company for those leases classified as operating leases under current GAAP, while our accounting for capital leases remains substantially
unchanged. &#160;Under the standard, disclosures are required to meet the objective of enabling users of financial statements to assess
the amount, timing, and uncertainty of cash flows arising from leases. &#160;The standard became effective for us on January 1, 2019.
&#160;The standard had a material impact on our balance sheets but did not have a material impact on our statements of operations. &#160;See
&#8220;NOTE 5 <b>&#8212; </b>LEASES&#8221; for further detail.</p>

</ix:nonNumeric><p id="xdx_859_zEKH0xo3rpFk" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock"><p id="xdx_844_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zyR5yhkl0mx3" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_86D_zfWO34kCXJPi">ACCOUNTING PRONOUNCEMENTS RECENTLY ADOPTED</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">In December 2019, the FASB issued ASU No. 2019-12, <i>Income Taxes (Topic
740): Simplifying the Accounting for Income Taxes</i>. The amendments in this ASU simplify the accounting for income taxes by removing
several exceptions including the exception to the general methodology for calculating income taxes in an interim period when a year-to-date
loss exceeds the anticipated loss for the year. &#160;The amendments also improve consistent application of and simplify GAAP for other
areas of Topic 740 by clarifying and amending existing guidance. &#160;The amendments in this ASU are effective for fiscal years, and
interim periods within those fiscal years, beginning after December 15, 2020. &#160;The Company adopted this standard on January 1, 2021,
and it had no impact on our financial statement disclosures.</p>

</ix:nonNumeric><p id="xdx_853_zmuLohV68dSk" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<ix:exclude><div id="xdx_237_z7JPEzPZHcBh">
<p style="font: 10pt TIMES NEW ROMAN, TIMES, SERIF; margin: 0; text-align: center">- 37 -</p>


<hr style="border-width: 0; color: Gray; background-color: Gray; height: 2px; width: 100%" /><p style="break-before: always"></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; color: blue"><i><a href="#index_to_fs">Index to Financial Statements</a></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p></div></ix:exclude>

<ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="krmd:AccountingPronouncementsNotYetAdopted"><p id="xdx_846_ecustom--AccountingPronouncementsNotYetAdopted_zMJECMpJBn7j" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_865_z8maNI0cLQ6c">ACCOUNTING PRONOUNCEMENTS NOT YET ADOPTED</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">In June 2016, the FASB issued ASU No. 2016-13, <i>Financial Instruments
&#8211; Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments</i>, which amends guidance on reporting credit
losses for assets held at amortized cost basis and available for sale debt securities. &#160;For assets held at amortized cost basis,
Topic 326 eliminates the probable initial recognition threshold in current GAAP and, instead, requires an entity to reflect its current
estimate of all expected credit losses. &#160;The allowance for credit losses is a valuation account that is deducted from the amortized
cost basis of the financial assets to present the net amount expected to be collected. &#160;For available for sale debt securities, credit
losses should be measured in a manner similar to current GAAP, however Topic 326 will require that credit losses be presented as an allowance
rather than as a write-down. &#160;This ASU affects entities holding financial assets and net investment in leases that are not accounted
for at fair value through net income. &#160;The amendments affect loans, debt securities, trade receivables, net investments in leases,
off balance sheet credit exposures, reinsurance receivables, and any other financial assets not excluded from the scope that have the
contractual right to receive cash. &#160;The amendments in this update are effective for fiscal years beginning after December 15, 2022,
including interim periods within those fiscal years. &#160;The Company is assessing the impact of the adoption of the ASU on its financial
statements, disclosure requirements and methods of adoption.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The Company considers the applicability and impact of all recently issued
accounting pronouncements. &#160;Recent accounting pronouncements not specifically identified in our disclosures are either not applicable
to the Company or are not expected to have a material effect on our financial condition or results of operations.</p>

</ix:nonNumeric><p id="xdx_854_z7Zkuvx9a9Pl" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock"><p id="xdx_844_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_zB3qn80oaFa5" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_866_z5Y75OK0JD5g">FAIR VALUE MEASUREMENTS</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Fair value is the exit price that would be received to sell an asset or
paid to transfer a liability. &#160;Fair value is a market-based measurement that should be determined using assumptions that market participants
would use in pricing an asset or liability. Valuation techniques used to measure fair value should maximize the use of observable inputs
and minimize the use of unobservable inputs. &#160;To measure fair value, the Company uses the following fair value hierarchy based on
three levels of inputs, of which the first two are considered observable and the last unobservable:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 7.5in; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: center">&#8226;</td>
    <td style="width: 7in">Level 1 &#8211; Quoted prices in active markets for identical assets or liabilities.</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center">&#8226;</td>
    <td>Level 2 &#8211; Inputs other than Level 1 that are observable for the asset or liability, either directly or indirectly, such as quoted prices for similar assets and liabilities in active markets; quoted prices for identical or similar assets or liabilities in markets that are not active; or other inputs that are observable or can be corroborated by observable market data by correlation or other means.</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center">&#8226;</td>
    <td>Level 3 &#8211; Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. &#160;Value is determined using pricing models, discounted cash flow methodologies, or similar techniques and includes instruments for which the determination of fair value requires significant judgment or estimation.</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The carrying amounts of cash and cash equivalents, accounts receivable,
prepaid expenses, accounts payable and accrued expenses are considered to be representative of their fair values because of the short-term
nature of those instruments. &#160;There were no transfers between levels in the fair value hierarchy during the year ended December 31,
2022.</p>

</ix:nonNumeric><p id="xdx_85B_zAUJFESrAdS1" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"><p id="xdx_849_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_zQZbDx9rQ7We" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_86D_zRmizrHnN8ef">IMPAIRMENT OF LONG-LIVED ASSETS</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The Company reviews long-lived assets for impairment whenever events or
changes in circumstances indicate that the carrying amount of the assets may not be fully recoverable. &#160;An impairment loss would
be recognized when estimated undiscounted future cash flows expected to result from the use of the asset and its eventual disposition
are less than the carrying amount. &#160;The impairment loss, if recognized, would be based on the excess of the carrying value of the
impaired asset over its respective fair value. &#160;No impairment losses have been recorded through December 31, 2022.</p>

</ix:nonNumeric><p id="xdx_85E_zyBIgsY1g1i8" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

</ix:nonNumeric><p id="xdx_812_zAc2X5wPHXni" style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:InventoryDisclosureTextBlock"><p id="xdx_80D_eus-gaap--InventoryDisclosureTextBlock_zBZWP51yiEx8" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>NOTE 2 &#8212; <span id="xdx_82C_zIfPFE30WoU5">INVENTORY</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:ScheduleOfInventoryCurrentTableTextBlock"><p id="xdx_892_eus-gaap--ScheduleOfInventoryCurrentTableTextBlock_zSfOlZuewx4c" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_8B5_zEiwQCi3QSQc">Inventory consists of:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 5.75in; border-collapse: collapse">
  <tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>December 31, 2022</b></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>December 31, 2021</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="width: 208.35pt">&#160;</td>
    <td style="width: 0.1in">&#160;</td>
    <td style="width: 8.25pt">&#160;</td>
    <td style="width: 79.7pt">&#160;</td>
    <td style="width: 14.3pt">&#160;</td>
    <td style="width: 7.5pt">&#160;</td>
    <td style="width: 80.45pt">&#160;</td>
    <td style="width: 8.25pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Raw materials and work-in-process</td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_98A_eus-gaap--InventoryWorkInProcessAndRawMaterials_iI_c20221231_zQs9SGHLFSIl" title="Raw materials and work-in-process" style="text-align: right"><ix:nonFraction name="us-gaap:InventoryWorkInProcessAndRawMaterials" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,853,034</ix:nonFraction></td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_98F_eus-gaap--InventoryWorkInProcessAndRawMaterials_iI_c20211231_zwPKqJbgVxHb" title="Raw materials and work-in-process" style="text-align: right"><ix:nonFraction name="us-gaap:InventoryWorkInProcessAndRawMaterials" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,997,807</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td>Finished goods</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td id="xdx_981_eus-gaap--InventoryFinishedGoods_iI_c20221231_zCjgaLgmr7nf" title="Finished goods" style="border-bottom: black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:InventoryFinishedGoods" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,611,951</ix:nonFraction></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td id="xdx_98B_eus-gaap--InventoryFinishedGoods_iI_c20211231_z4OyKjNY8Aod" title="Finished goods" style="border-bottom: black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:InventoryFinishedGoods" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,176,836</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td>&#160;&#160;&#160;Total</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_988_eus-gaap--InventoryGross_iI_c20221231_zNa94DcM4pi" title="Inventory, Gross" style="text-align: right"><ix:nonFraction name="us-gaap:InventoryGross" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,464,985</ix:nonFraction></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_98B_eus-gaap--InventoryGross_iI_c20211231_zOtHtSUoLgv8" title="Inventory, Gross" style="text-align: right"><ix:nonFraction name="us-gaap:InventoryGross" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,174,643</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td>Less: reserve for obsolete inventory</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td id="xdx_98A_eus-gaap--InventoryValuationReserves_iNI_di_c20221231_zw26NTqXKrF8" title="Less: reserve for obsolete inventory" style="border-bottom: black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:InventoryValuationReserves" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">60,118</ix:nonFraction></td>
    <td>)</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td id="xdx_985_eus-gaap--InventoryValuationReserves_iNI_di_c20211231_z65Ll2xB7sj7" style="border-bottom: black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:InventoryValuationReserves" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">68,305</ix:nonFraction></td>
    <td>)</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Inventory, net</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td id="xdx_983_eus-gaap--InventoryNet_iI_c20221231_zTtndi3ifpb8" title="Inventory" style="border-bottom: black 2.25pt double; text-align: right"><ix:nonFraction name="us-gaap:InventoryNet" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,404,867</ix:nonFraction></td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td id="xdx_98A_eus-gaap--InventoryNet_iI_c20211231_zgsk9QWKuCD" title="Inventory" style="border-bottom: black 2.25pt double; text-align: right"><ix:nonFraction name="us-gaap:InventoryNet" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,106,338</ix:nonFraction></td>
    <td>&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A0_zysOCcAhhAX5" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

</ix:nonNumeric><p id="xdx_81F_zDoMRmHi5361" style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>


<p style="font: 10pt TIMES NEW ROMAN, TIMES, SERIF; margin: 0; text-align: center">- 38 -</p>


<hr style="border-width: 0; color: Gray; background-color: Gray; height: 2px; width: 100%" /><p style="break-before: always"></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; color: blue"><i><a href="#index_to_fs">Index to Financial Statements</a></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock"><p id="xdx_80A_eus-gaap--PropertyPlantAndEquipmentDisclosureTextBlock_zdR6NODU7928" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>NOTE 3 &#8212; <span id="xdx_828_zjpD9hEUjx1">PROPERTY AND EQUIPMENT</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:PropertyPlantAndEquipmentTextBlock"><p id="xdx_895_eus-gaap--PropertyPlantAndEquipmentTextBlock_zaoyxblUiHw7" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span>Property and equipment consists of the following at:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_8BD_zWKiA8IJzf19" style="display: none; visibility: hidden">Schedule of property and equipment</span>&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 5.75in; border-collapse: collapse">
  <tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>December 31, 2022</b></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>December 31, 2021</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td style="width: 203.85pt">&#160;</td>
    <td style="width: 0.1in">&#160;</td>
    <td style="width: 8.25pt">&#160;</td>
    <td style="width: 79.7pt">&#160;</td>
    <td style="width: 14.3pt">&#160;</td>
    <td style="width: 8.25pt">&#160;</td>
    <td style="width: 79.7pt">&#160;</td>
    <td style="width: 8.25pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Furniture and office equipment</td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_98A_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--FurnitureAndOfficeEquipmentMember_zWHnBNx3xFe5" style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2022-12-31_custom_FurnitureAndOfficeEquipmentMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,456,745</ix:nonFraction></td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_987_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20211231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--FurnitureAndOfficeEquipmentMember_zECbEcrxcYZa" style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2021-12-31_custom_FurnitureAndOfficeEquipmentMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">818,897</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Leasehold improvements</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_984_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zW5Uhbm2OpUg" style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2022-12-31_us-gaap_LeaseholdImprovementsMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,413,820</ix:nonFraction></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_984_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20211231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zUBg8Aip0597" style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2021-12-31_us-gaap_LeaseholdImprovementsMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">556,907</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Manufacturing equipment and tooling</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td id="xdx_98C_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ManufacturingEquipmentAndToolingMember_zT0quWrrXv3" style="border-bottom: black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2022-12-31_custom_ManufacturingEquipmentAndToolingMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,810,813</ix:nonFraction></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td id="xdx_988_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20211231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ManufacturingEquipmentAndToolingMember_zNTYU2zCQITe" style="border-bottom: black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2021-12-31_custom_ManufacturingEquipmentAndToolingMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,042,675</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;&#160;&#160;Total property and equipment</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_98C_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20221231_zZxEzqn5ixH1" title="Total property and equipment" style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,681,378</ix:nonFraction></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_983_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20211231_zR6JnYT1Bkpa" title="Total property and equipment" style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,418,479</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Less: accumulated depreciation and amortization</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td id="xdx_989_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_di_c20221231_zELaZxCyfw6b" title="Less: accumulated depreciation and amortization" style="border-bottom: black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,794,403</ix:nonFraction></td>
    <td>)</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td id="xdx_98B_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_di_c20211231_zfIeWTTvng2a" title="Less: accumulated depreciation and amortization" style="border-bottom: black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,312,034</ix:nonFraction></td>
    <td>)</td></tr>
  <tr style="vertical-align: bottom">
    <td>Property and equipment, net</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td id="xdx_985_eus-gaap--PropertyPlantAndEquipmentNet_iI_dxL_c20221231_zTlhecAMheBg" title="Property and equipment, net::XDX::3886975" style="border-bottom: black 2.25pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0640">3,886,975</span></td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td id="xdx_989_eus-gaap--PropertyPlantAndEquipmentNet_iI_c20211231_zsbI0O4sKC4e" title="Property and equipment, net" style="border-bottom: black 2.25pt double; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,106,445</ix:nonFraction></td>
    <td>&#160;</td></tr>
  </table>
</ix:nonNumeric><p id="xdx_8AA_z9ktPti7bLjc" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

</ix:nonNumeric><p id="xdx_81F_zI6e6kcx0O8l" style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>


<ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"><p id="xdx_80D_eus-gaap--DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_z4k1HyoJ39Lj" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>NOTE 4 &#8212; <span id="xdx_82F_z6Rf2R9VgmR9">STOCK-BASED COMPENSATION</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The Company has three equity incentive plans: the 2015 Stock Option Plan,
as amended (the &#8220;2015 Plan&#8221;), the 2021 Omnibus Equity Incentive Plan (the &#8220;2021 Plan&#8221;), and the Non-Employee Director
Compensation Plan. The Company has also issued restricted stock as employment inducement awards to its Chief Executive Officer.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">As of December 31, 2022, there were options to purchase <span id="xdx_907_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pid_uShares_c20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__srt--TitleOfIndividualAxis__custom--ExecutiveskeyEmployeesAndConsultantsMember_zbccPmTX67T6" title="Common stock, shares, outstanding"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" contextRef="AsOf2022-12-31_custom_StockOptionPlan2015Member_custom_ExecutiveskeyEmployeesAndConsultantsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,560,000</ix:nonFraction></span> shares
of the Company&#8217;s common stock outstanding to certain executives, key employees and consultants under the 2015 Plan, of which <span id="xdx_903_ecustom--StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan2015_pid_uShares_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__srt--TitleOfIndividualAxis__custom--ExecutiveskeyEmployeesAndConsultantsMember_zvBJcDgeisBj" title="Stock issued during period"><ix:nonFraction name="krmd:StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan2015" contextRef="From2022-01-012022-12-31_custom_StockOptionPlan2015Member_custom_ExecutiveskeyEmployeesAndConsultantsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">445,000</ix:nonFraction></span>
were issued during the twelve months ended December 31, 2022. Additional options may be issued under the 2015 Plan as outstanding options
are forfeited, subject to a maximum <span id="xdx_901_eus-gaap--StockIssuedDuringPeriodSharesShareBasedCompensation_pid_uShares_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zYVVvbGfdUUj" title="Available for issuance"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" contextRef="From2022-01-012022-12-31_custom_StockOptionPlan2015Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">6,000,000</ix:nonFraction></span> available for issuance under the 2015 Plan.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The 2021 Plan provides for the grant of up to <span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodSharesShareBasedCompensation_pid_uShares_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zL3V1K5nBYe3" title="Available for issuance"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" contextRef="From2022-01-012022-12-31_custom_StockOptionPlan2021Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,000,000</ix:nonFraction></span> incentive stock
options, nonqualified stock options, stock awards, restricted stock awards, restricted stock units and/or stock appreciation rights to
employees, consultants and directors. During the twelve months ended December 31, 2022, there were issued <span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan_pid_uShares_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member__srt--TitleOfIndividualAxis__srt--DirectorMember_zkklXmZ8w7si" title="Stock issued during period"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan" contextRef="From2022-01-012022-12-31_custom_StockOptionPlan2021Member_srt_DirectorMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">97,100</ix:nonFraction></span> shares of common stock, as director compensation and <span id="xdx_904_eus-gaap--StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan_pid_uShares_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member__srt--TitleOfIndividualAxis__custom--ExecutiveMember_zmwBFQCY0xb6" title="Stock issued during period"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan" contextRef="From2022-01-012022-12-31_custom_StockOptionPlan2021Member_custom_ExecutiveMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">475,000</ix:nonFraction></span> options to purchase shares of common stock as executive compensation under the 2021 Plan.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Effective January 1, 2021, each non-employee director of the Company (other
than the Chairman of the Board) and Board advisor were eligible to receive of $<span id="xdx_900_ecustom--NonemployeeServicesTransactionCost_pid_uShares_c20201230__20210102__srt--TitleOfIndividualAxis__custom--NonEmployeeDirectorAndBoardAdvisorMember_zIkhJX6VVOoa" title="Nonemployee services transaction cost"><ix:nonFraction name="krmd:NonemployeeServicesTransactionCost" contextRef="From2020-12-302021-01-02_custom_NonEmployeeDirectorAndBoardAdvisorMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">75,000</ix:nonFraction></span> annually, <span id="xdx_902_eus-gaap--ShareBasedGoodsAndNonemployeeServicesTransaction_c20201230__20210102__srt--TitleOfIndividualAxis__custom--NonEmployeeDirectorAndBoardAdvisorMember_zBE02q8YweT2" title="Share-based goods and nonemployee services transaction"><ix:nonNumeric contextRef="From2020-12-302021-01-02_custom_NonEmployeeDirectorAndBoardAdvisorMember" name="us-gaap:ShareBasedGoodsAndNonemployeeServicesTransaction">to be paid quarterly $12,500 in cash and
$6,250 in common stock</ix:nonNumeric></span>. &#160;The Chairman of the Board is eligible to receive $<span id="xdx_900_ecustom--NonemployeeServicesTransactionCost_pid_uShares_c20201230__20210102__srt--TitleOfIndividualAxis__srt--BoardOfDirectorsChairmanMember_z6PgXGpsFKYb" title="Non-employee director compensation"><ix:nonFraction name="krmd:NonemployeeServicesTransactionCost" contextRef="From2020-12-302021-01-02_srt_BoardOfDirectorsChairmanMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">100,000</ix:nonFraction></span> annually, <span id="xdx_908_eus-gaap--ShareBasedGoodsAndNonemployeeServicesTransaction_c20201230__20210102__srt--TitleOfIndividualAxis__srt--BoardOfDirectorsChairmanMember_zULEuO57yx1a" title="Share-based goods and nonemployee services transaction"><ix:nonNumeric contextRef="From2020-12-302021-01-02_srt_BoardOfDirectorsChairmanMember" name="us-gaap:ShareBasedGoodsAndNonemployeeServicesTransaction">to be paid quarterly $12,500 in cash
and $12,500 in common stock</ix:nonNumeric></span>. Effective May 18, 2021, each non-employee director of the Company (other than the Chairman of the Board)
and Board advisor are eligible to receive of $<span id="xdx_90B_ecustom--NonemployeeServicesTransactionCost_pid_uShares_c20210516__20210518__srt--TitleOfIndividualAxis__custom--NonEmployeeDirectorAndBoardAdvisorMember_zep2nfzAEid" title="Nonemployee services transaction cost"><ix:nonFraction name="krmd:NonemployeeServicesTransactionCost" contextRef="From2021-05-162021-05-18_custom_NonEmployeeDirectorAndBoardAdvisorMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">110,000</ix:nonFraction></span> annually, <span id="xdx_90C_eus-gaap--ShareBasedGoodsAndNonemployeeServicesTransaction_c20210516__20210518__srt--TitleOfIndividualAxis__custom--NonEmployeeDirectorAndBoardAdvisorMember_zxq0BxHtClyc" title="Share-based goods and nonemployee services transaction"><ix:nonNumeric contextRef="From2021-05-162021-05-18_custom_NonEmployeeDirectorAndBoardAdvisorMember" name="us-gaap:ShareBasedGoodsAndNonemployeeServicesTransaction">to be paid quarterly $12,500 in cash and $15,000 in common stock</ix:nonNumeric></span>. &#160;The
Chairman of the Board is eligible to receive $<span id="xdx_90F_ecustom--NonemployeeServicesTransactionCost_pid_uShares_c20210516__20210518__srt--TitleOfIndividualAxis__srt--BoardOfDirectorsChairmanMember_z0I2jjkpupL5"><ix:nonFraction name="krmd:NonemployeeServicesTransactionCost" contextRef="From2021-05-162021-05-18_srt_BoardOfDirectorsChairmanMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">140,000</ix:nonFraction></span> annually, <span id="xdx_90F_eus-gaap--ShareBasedGoodsAndNonemployeeServicesTransaction_c20210516__20210518__srt--TitleOfIndividualAxis__srt--BoardOfDirectorsChairmanMember_zoxWQpIP97N1" title="Share-based goods and nonemployee services transaction"><ix:nonNumeric contextRef="From2021-05-162021-05-18_srt_BoardOfDirectorsChairmanMember" name="us-gaap:ShareBasedGoodsAndNonemployeeServicesTransaction">to be paid quarterly $12,500 in cash and $22,500 in common stock</ix:nonNumeric></span>. From
May 18, 2021 to May 6, 2022, non-employee director compensation was paid pursuant to the 2021 Plan. Since May 6, 2022, non-employee director
compensation has been paid pursuant to the Non-Employee Director Compensation Plan. All payments were and are pro-rated for partial service.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">On April 12, 2021, pursuant to an employment agreement entered into on
March 15, 2021, with Linda Tharby, the Company&#8217;s President and Chief Executive Officer, the Company issued three restricted stock
awards for an aggregate <span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan_pid_uShares_c20210411__20210412__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ChiefExecutiveOfficerLindaTharbyMember_zKxuJPWmyrXe" title="Common stock issued, shares"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan" contextRef="From2021-04-112021-04-12_custom_ChiefExecutiveOfficerLindaTharbyMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,000,000</ix:nonFraction></span> shares of common stock for an aggregate stock price of $<span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan_c20210411__20210412__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ChiefExecutiveOfficerLindaTharbyMember_zTls4M7CGjLf" title="Aggregate stock price"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan" contextRef="From2021-04-112021-04-12_custom_ChiefExecutiveOfficerLindaTharbyMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,310,000</ix:nonFraction></span> and each vesting subject to employment
on the respective vesting date. These awards were issued as an inducement employment.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>2015 STOCK OPTION PLAN, as amended</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Time-Based Stock Options</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The per share weighted average fair value of stock options granted during
the years ended December 31, 2022, and December 31, 2021 was $<span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_pid_uUSDPShares_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zbbDGR8bAfyg" title="Stock options granted"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" contextRef="From2022-01-012022-12-31_custom_StockOptionPlan2015Member" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.98</ix:nonFraction></span> and $<span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_pid_uUSDPShares_c20210101__20211231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zvwWSiUkZFM2"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" contextRef="From2021-01-012021-12-31_custom_StockOptionPlan2015Member" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.85</ix:nonFraction></span>, respectively. &#160;The fair value of each award is estimated
on the grant date using the Black-Scholes option pricing model with the following weighted average assumptions used for grants in the
years ended December 31, 2022, and December 31, 2021. &#160;Historical information was the primary basis for the selection of the expected
volatility, expected dividend yield and the expected lives of the options. &#160;The risk-free interest rate was selected based upon yields
of the U.S. Treasury issues with a term equal to the expected life of the option being valued. &#160;The following table summarizes the
assumptions used in determining fair value. These assumptions are subjective and generally require significant analysis and judgment to
develop. We have recognized tax benefits associated with stock-based compensation of $<span id="xdx_900_eus-gaap--IncomeTaxExpenseBenefit_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zRVLB861j9Cl" title="Tax benefit"><ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="From2022-01-012022-12-31_custom_StockOptionPlan2015Member" format="ixt:numdotdecimal" decimals="0" unitRef="USD">198,258</ix:nonFraction></span> and $<span id="xdx_90B_eus-gaap--IncomeTaxExpenseBenefit_c20210101__20211231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zw662DENIShk" title="Tax benefit"><ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="From2021-01-012021-12-31_custom_StockOptionPlan2015Member" format="ixt:numdotdecimal" decimals="0" unitRef="USD">175,257</ix:nonFraction></span> for the years ended December
31, 2022 and 2021, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<ix:exclude><div id="xdx_236_zQApW3cIcnWc">
<p style="font: 10pt TIMES NEW ROMAN, TIMES, SERIF; margin: 0; text-align: center">- 39 -</p>


<hr style="border-width: 0; color: Gray; background-color: Gray; height: 2px; width: 100%" /><p style="break-before: always"></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; color: blue"><i><a href="#index_to_fs">Index to Financial Statements</a></i></p></div></ix:exclude>

<ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"><p id="xdx_898_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zMJTgRo09HFf" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_8B3_zNIQLyoNSWk4" style="display: none; visibility: hidden">Schedule of time based stock options</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 5.25in; border-collapse: collapse">
  <tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>December 31, 2022</b></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>December 31, 2021</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td style="width: 161.1pt">&#160;</td>
    <td style="width: 9.75pt">&#160;</td>
    <td style="width: 7.25pt">&#160;</td>
    <td style="width: 89.15pt">&#160;</td>
    <td style="width: 10.55pt">&#160;</td>
    <td style="width: 9.05pt">&#160;</td>
    <td style="width: 82.85pt">&#160;</td>
    <td style="width: 8.3pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Dividend yield</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_z9I9JarWYZVl" title="Dividend yield"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="From2022-01-012022-12-31_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0.00</ix:nonFraction></span>%</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20210101__20211231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zwjPMQzkzhQc" title="Dividend yield"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="From2021-01-012021-12-31_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0.00</ix:nonFraction></span>%</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td>Expected volatility</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember__srt--RangeAxis__srt--MinimumMember_z6mvehlaByMj"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="From2022-01-012022-12-31_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember_srt_MinimumMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">65.29</ix:nonFraction></span>% &#8211; <span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember__srt--RangeAxis__srt--MaximumMember_zGJbo5iW8TI1"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="From2022-01-012022-12-31_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember_srt_MaximumMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">77.5</ix:nonFraction></span>%</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20210101__20211231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember__srt--RangeAxis__srt--MinimumMember_zfzDfqq1wrRf"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="From2021-01-012021-12-31_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember_srt_MinimumMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">74.01</ix:nonFraction></span> &#8211; <span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20210101__20211231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember__srt--RangeAxis__srt--MaximumMember_zKyuNYz9KZ8h"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="From2021-01-012021-12-31_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember_srt_MaximumMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">77.91</ix:nonFraction></span>%</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Weighted-average volatility</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_pid_dp0_uPure_c20220101__20221231_zlXJAsd0BLe" title="Weighted-average volatility"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" contextRef="From2022-01-01to2022-12-31" format="ixt:zerodash" decimals="INF" scale="-2" unitRef="Pure">&#8212;</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_pid_dp_uPure_c20210101__20211231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zFG8DozU7zW4" title="Weighted-average volatility"><span style="-sec-ix-hidden: xdx2ixbrl0697">&#8212;</span></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td>Expected dividends</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments_d0_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zs1BAQmLx361" title="Expected dividends"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments" contextRef="From2022-01-012022-12-31_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember" format="ixt:zerodash" decimals="0" unitRef="USD">&#8212;</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments_d0_c20210101__20211231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zAH1DVyaDcb6" title="Expected dividends"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments" contextRef="From2021-01-012021-12-31_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember" format="ixt:zerodash" decimals="0" unitRef="USD">&#8212;</ix:nonFraction></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Expected term (in years)</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dxL_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_ztG1LJY5HuX" title="Expected term (in years)::XDX::P10Y"><span style="-sec-ix-hidden: xdx2ixbrl0703">10</span></span> Years</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dxL_c20210101__20211231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zn7GgykVhqw7" title="Expected term (in years)::XDX::P10Y"><span style="-sec-ix-hidden: xdx2ixbrl0705">10</span></span> Years</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td>Risk-free rate</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember__srt--RangeAxis__srt--MinimumMember_zhBrKaFMEtph" title="Risk-free rate"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="From2022-01-012022-12-31_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember_srt_MinimumMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">1.81</ix:nonFraction></span> &#8211; <span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember__srt--RangeAxis__srt--MaximumMember_zc1gVFzsSI62" title="Risk-free rate"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="From2022-01-012022-12-31_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember_srt_MaximumMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">4.02</ix:nonFraction></span>%</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20210101__20211231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember__srt--RangeAxis__srt--MinimumMember_zCY0GYklx5Sl" title="Risk-free rate"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="From2021-01-012021-12-31_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember_srt_MinimumMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">1.20</ix:nonFraction></span> &#8211; <span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20210101__20211231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember__srt--RangeAxis__srt--MaximumMember_zZufVf0If4Ui" title="Risk-free rate"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="From2021-01-012021-12-31_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember_srt_MaximumMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">1.62</ix:nonFraction></span>%</td>
    <td>&#160;</td></tr>
  </table>
</ix:nonNumeric><p id="xdx_8A5_zQNZNQ0vEXaa" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"><p id="xdx_899_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_z1TmxFWsn1u9" style="font: 10pt Times New Roman, Times, Serif; margin: 0">The following table summarizes the status of the Company&#8217;s stock
option plan:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_8B4_z3SmpQTP4fk1" style="display: none; visibility: hidden">Schedule of status of time based stock options</span>&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 7.5in; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="5" style="border-bottom: black 1pt solid; text-align: center"><b>December 31, 2022</b></td>
    <td>&#160;</td>
    <td colspan="5" style="border-bottom: black 1pt solid; text-align: center"><b>December 31, 2021</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>Shares</b></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>Weighted<br />
Average<br />
Exercise<br />
Price</b></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>Shares</b></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>Weighted<br />
Average<br />
Exercise<br />
Price</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="width: 273.25pt">Outstanding at January 1</td>
    <td style="width: 0.1in">&#160;</td>
    <td style="width: 0.1in">&#160;</td>
    <td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_uShares_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zO2vPnRHQxz" title="Outstanding at beginning" style="width: 49.5pt; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2021-12-31_custom_StockOptionPlan2015Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,672,500</ix:nonFraction></td>
    <td style="width: 11.3pt">&#160;</td>
    <td style="width: 9.75pt">$</td>
    <td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_uUSDPShares_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zG4oARPUgMA1" title="Outstanding at beginning" style="width: 43.8pt; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2021-12-31_custom_StockOptionPlan2015Member" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.42</ix:nonFraction></td>
    <td style="width: 11.3pt">&#160;</td>
    <td style="width: 0.1in">&#160;</td>
    <td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_uShares_c20210101__20211231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zlSM4Nm3iOT6" style="width: 48.75pt; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2020-12-31_custom_StockOptionPlan2015Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,922,494</ix:nonFraction></td>
    <td style="width: 11.3pt">&#160;</td>
    <td style="width: 7.5pt">$</td>
    <td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_uUSDPShares_c20210101__20211231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zACFEiklGXXj" title="Outstanding at beginning" style="width: 43.8pt; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2020-12-31_custom_StockOptionPlan2015Member" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.46</ix:nonFraction></td>
    <td style="width: 7.25pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Granted</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_uShares_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_z2exdIa3IfIg" title="Granted" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2022-01-012022-12-31_custom_StockOptionPlan2015Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">445,000</ix:nonFraction></td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_uUSDPShares_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zM61B6j8h4rd" title="Granted" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="From2022-01-012022-12-31_custom_StockOptionPlan2015Member" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.57</ix:nonFraction></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_uShares_c20210101__20211231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zAtBDtQDZi9f" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2021-01-012021-12-31_custom_StockOptionPlan2015Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,000,000</ix:nonFraction></td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_uUSDPShares_c20210101__20211231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zaDavxuGXPuj" title="Granted" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="From2021-01-012021-12-31_custom_StockOptionPlan2015Member" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.64</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Exercised</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_98C_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pid_uShares_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zRSnnZVL4Ky" title="Exercised" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="From2022-01-012022-12-31_custom_StockOptionPlan2015Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,031,250</ix:nonFraction></td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_uUSDPShares_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zw3P2KzfQM26" title="Exercised" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" contextRef="From2022-01-012022-12-31_custom_StockOptionPlan2015Member" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.57</ix:nonFraction></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_989_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pid_uShares_c20210101__20211231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zy56Oc1yEai" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="From2021-01-012021-12-31_custom_StockOptionPlan2015Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,062,500</ix:nonFraction></td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_uUSDPShares_c20210101__20211231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zGPwU22jiHA2" title="Exercised" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" contextRef="From2021-01-012021-12-31_custom_StockOptionPlan2015Member" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.19</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Forfeited</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_pid_uShares_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zZUUVkZxAPQ1" title="Forfeited" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" contextRef="From2022-01-012022-12-31_custom_StockOptionPlan2015Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">526,250</ix:nonFraction></td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_uUSDPShares_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zBhDcTK1lSae" title="Forfeited" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" contextRef="From2022-01-012022-12-31_custom_StockOptionPlan2015Member" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.73</ix:nonFraction></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_pid_uShares_c20210101__20211231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zyrwK7iZFf47" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" contextRef="From2021-01-012021-12-31_custom_StockOptionPlan2015Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">187,494</ix:nonFraction></td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_uUSDPShares_c20210101__20211231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zM5BVIvfBCm1" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" contextRef="From2021-01-012021-12-31_custom_StockOptionPlan2015Member" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.36</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Outstanding at year end</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_uShares_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zSQ0QcHFXhTi" title="Outstanding at ending" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2022-12-31_custom_StockOptionPlan2015Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,560,000</ix:nonFraction></td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_uUSDPShares_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zdvsy8XZx6q8" title="Outstanding at ending" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2022-12-31_custom_StockOptionPlan2015Member" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">4.15</ix:nonFraction></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_uShares_c20210101__20211231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zIHVknGiXgH6" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2021-12-31_custom_StockOptionPlan2015Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,672,500</ix:nonFraction></td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_uUSDPShares_c20210101__20211231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zFOcStvlapl5" title="Outstanding at ending" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2021-12-31_custom_StockOptionPlan2015Member" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.42</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Options exercisable</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pid_uShares_c20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zOhbICZVlq04" title="Options exercisable" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="AsOf2022-12-31_custom_StockOptionPlan2015Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">737,500</ix:nonFraction></td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_pid_uUSDPShares_c20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zUJmsNslmS74" title="Options exercisable" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" contextRef="AsOf2022-12-31_custom_StockOptionPlan2015Member" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">4.93</ix:nonFraction></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pid_uShares_c20211231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zyPqqxDV8A6k" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="AsOf2021-12-31_custom_StockOptionPlan2015Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">983,750</ix:nonFraction></td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_pid_uUSDPShares_c20211231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zqxiXWdfvja3" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" contextRef="AsOf2021-12-31_custom_StockOptionPlan2015Member" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.73</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="padding-left: 19.05pt; text-indent: -19.05pt">Weighted average fair value of options granted during the period</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#8212;</td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_uUSDPShares_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zjy3QMIiTGn2" title="Weighted average fair value of options granted during the period" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="From2022-01-012022-12-31_custom_StockOptionPlan2015Member" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.98</ix:nonFraction></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#8212;</td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_uUSDPShares_c20210101__20211231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zJ7nUsbGN3G5" title="Weighted average fair value of options granted during the period" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="From2021-01-012021-12-31_custom_StockOptionPlan2015Member" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.85</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Stock-based compensation expense</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#8212;</td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_980_eus-gaap--AllocatedShareBasedCompensationExpense_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zfLR5zcx3wL6" title="Stock-based compensation expense" style="text-align: right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2022-01-012022-12-31_custom_StockOptionPlan2015Member" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,925,861</ix:nonFraction></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#8212;</td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_982_eus-gaap--AllocatedShareBasedCompensationExpense_c20210101__20211231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zrV2bdvx9Ojb" title="Stock-based compensation expense" style="text-align: right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2021-01-012021-12-31_custom_StockOptionPlan2015Member" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,457,788</ix:nonFraction></td>
    <td>&#160;</td></tr>
  </table>
</ix:nonNumeric><p id="xdx_8A6_zuEGKYhqlmKd" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Total stock-based compensation expense, net of forfeitures, for stock
option awards totaled $<span id="xdx_902_eus-gaap--StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zoEgBwBSX584"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" contextRef="From2022-01-012022-12-31_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,925,861</ix:nonFraction></span>
and $<span id="xdx_907_eus-gaap--StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_c20210101__20211231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zK3zxZX4H1xd"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" contextRef="From2021-01-012021-12-31_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,457,788</ix:nonFraction></span>
for the years ended December 31, 2022, and 2021, respectively. &#160;Net cash received from option exercises for the years ended
December 31, 2022, and 2021 was $<span id="xdx_909_eus-gaap--ProceedsFromStockOptionsExercised_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zVHfzAS0Osof"><ix:nonFraction name="us-gaap:ProceedsFromStockOptionsExercised" contextRef="From2022-01-012022-12-31_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">406,623</ix:nonFraction></span>
and $<span id="xdx_90C_eus-gaap--ProceedsFromStockOptionsExercised_pp0p0_c20210101__20211231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_z6b29HqngqGf"><ix:nonFraction name="us-gaap:ProceedsFromStockOptionsExercised" contextRef="From2021-01-012021-12-31_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,261,251</ix:nonFraction></span>,
respectively. We have recognized tax benefits associated with options exercised of <span id="xdx_90F_eus-gaap--IncomeTaxExpenseBenefit_pp0p0_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zSRtStmfjh8k"><ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="From2022-01-012022-12-31_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">103,319</ix:nonFraction></span>
and $<span id="xdx_908_eus-gaap--IncomeTaxExpenseBenefit_pp0p0_c20210101__20211231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_z19jgYcVFgEk"><ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="From2021-01-012021-12-31_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">665,700</ix:nonFraction></span>
for the years ended December 31, 2022 and 2021, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The weighted-average grant-date fair value of options granted during the
years ended December 31, 2022, and 2021, was $<span id="xdx_908_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriodWeightedAverageGrantDateFairValue_uShares_c20220101__20221231__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zS4bMBfKMhif" title="Weighted-average grant-date fair value options granted"><ix:nonFraction name="krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="From2022-01-012022-12-31_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">881,428</ix:nonFraction></span> and $<span id="xdx_903_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriodWeightedAverageGrantDateFairValue_uShares_c20210101__20211231__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_z4r7pCd3Liuf" title="Weighted-average grant-date fair value options granted"><ix:nonFraction name="krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="From2021-01-012021-12-31_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">5,699,986</ix:nonFraction></span>, respectively. &#160;The total intrinsic value of options exercised
during the years ended December 31, 2022, and 2021, was $<span id="xdx_909_ecustom--StockIssuedDuringPeriodSharesStockOptionsExercised1_pid_uShares_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zSHIr6N3f1D1" title="Options exercised"><ix:nonFraction name="krmd:StockIssuedDuringPeriodSharesStockOptionsExercised1" contextRef="From2022-01-012022-12-31_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,150,203</ix:nonFraction></span> and $<span id="xdx_90D_ecustom--StockIssuedDuringPeriodSharesStockOptionsExercised1_pid_uShares_c20210101__20211231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zumE46frju5"><ix:nonFraction name="krmd:StockIssuedDuringPeriodSharesStockOptionsExercised1" contextRef="From2021-01-012021-12-31_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">697,920</ix:nonFraction></span>, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="krmd:ScheduleOfShareBasedCompensationStockOptionsActivityAmendedTableTextBlock"><p id="xdx_89D_ecustom--ScheduleOfShareBasedCompensationStockOptionsActivityAmendedTableTextBlock_zz8RJ2Ki4uS8" style="font: 10pt Times New Roman, Times, Serif; margin: 0">The following table presents information pertaining to options outstanding
as of December 31, 2022:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_8B3_zdHY4FCcHVjd" style="display: none; visibility: hidden">Schedule of information pertaining to options outstanding</span>&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 7.5in; border-collapse: collapse">
  <tr style="vertical-align: bottom; background-color: white">
    <td style="border-bottom: black 1pt solid"><b>Range of Exercise Price</b></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: center"><b>Number<br />
Outstanding</b></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: center"><b>Weighted<br />
Average<br />
Remaining<br />
Contractual<br />
Life</b></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>Weighted<br />
Average<br />
Exercise<br />
Price</b></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: center"><b>Number<br />
Exercisable</b></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>Weighted<br />
Average<br />
Exercise<br />
Price</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td style="width: 131.2pt">&#160;</td>
    <td style="width: 8.25pt">&#160;</td>
    <td style="width: 64.85pt">&#160;</td>
    <td style="width: 14.35pt">&#160;</td>
    <td style="width: 64.85pt">&#160;</td>
    <td style="width: 13.6pt">&#160;</td>
    <td style="width: 7.5pt">&#160;</td>
    <td style="width: 63pt">&#160;</td>
    <td style="width: 13.6pt">&#160;</td>
    <td style="width: 64.85pt">&#160;</td>
    <td style="width: 14.35pt">&#160;</td>
    <td style="width: 8.25pt">&#160;</td>
    <td style="width: 63pt">&#160;</td>
    <td style="width: 7.55pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td>$2.25 - $9.49</td>
    <td>&#160;</td>
    <td id="xdx_985_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pid_uShares_c20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice1Member_zE9AiaUVP7N1" title="Number outstanding" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" contextRef="AsOf2022-12-31_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember_custom_ExercisePrice1Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,560,000</ix:nonFraction></td>
    <td>&#160;</td>
    <td style="text-align: center"><span id="xdx_906_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dxL_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice1Member_zm6fxm2yXdlj" title="Weighted average remaining contractual life::XDX::P8Y9M18D"><span style="-sec-ix-hidden: xdx2ixbrl0782">8.8</span></span> years</td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_988_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pid_uUSDPShares_c20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice1Member_ze4YPaf8jUGe" title="Weighted average exercise price" style="text-align: right"><ix:nonFraction name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" contextRef="AsOf2022-12-31_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember_custom_ExercisePrice1Member" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">4.15</ix:nonFraction></td>
    <td>&#160;</td>
    <td id="xdx_98A_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_uShares_c20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice1Member_zVzOB3aHfG61" title="Number exercisable" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" contextRef="AsOf2022-12-31_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember_custom_ExercisePrice1Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">737,500</ix:nonFraction></td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_98F_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_pid_uUSDPShares_c20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice1Member_z1agaJApbVVc" title="Weighted average exercise price" style="text-align: right"><ix:nonFraction name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" contextRef="AsOf2022-12-31_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember_custom_ExercisePrice1Member" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">4.93</ix:nonFraction></td>
    <td>&#160;</td></tr>
  </table>
</ix:nonNumeric><p id="xdx_8A2_zcTIeuFTe1Ed" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">As of December 31, 2022, there was $<span id="xdx_90C_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_iI_c20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_z63JWR8opn1" title="Total unrecognized compensation cost"><ix:nonFraction name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" contextRef="AsOf2022-12-31_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,299,070</ix:nonFraction></span> of total unrecognized compensation
cost related to non-vested share-based compensation arrangements granted under the 2015 Plan. &#160;That cost is expected to be recognized
over a weighted-average period of <span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dxL_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_z7aL5B4O0RVk" title="Weighted-average period::XDX::P45M"><span style="-sec-ix-hidden: xdx2ixbrl0792">45</span></span> months. &#160;The total fair value of shares vested was $<span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_iI_c20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zj9RxtkaEKf7" title="Fair value of shares"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" contextRef="AsOf2022-12-31_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,703,002</ix:nonFraction></span> and $<span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_iI_c20211231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_z2d9sp2yP0pk"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" contextRef="AsOf2021-12-31_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,923,179</ix:nonFraction></span> at December 31,
2022, and December 31, 2021, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<ix:exclude><div id="xdx_23F_z0Ne5DrGODIe">
<p style="font: 10pt TIMES NEW ROMAN, TIMES, SERIF; margin: 0; text-align: center">- 40 -</p>


<hr style="border-width: 0; color: Gray; background-color: Gray; height: 2px; width: 100%" /><p style="break-before: always"></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; color: blue"><i><a href="#index_to_fs">Index to Financial Statements</a></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p></div></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>2021 STOCK OPTION PLAN, as amended</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Time Based Stock Options</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The per share weighted average fair value of stock options granted during
the years ended December 31, 2022 and December 31, 2021 was $<span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_pid_uUSDPShares_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_z6QrnwW63uv4" title="Stock options granted"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" contextRef="From2022-01-012022-12-31_custom_StockOptionPlan2021Member" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.99</ix:nonFraction></span> and $<span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_pid_uUSDPShares_c20210101__20211231__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zUZ1vKVeb5hg" title="Stock options granted"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" contextRef="From2021-01-012021-12-31_custom_StockOptionPlan2021Member" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0</ix:nonFraction></span> respectively. &#160;The fair value of each award is estimated
on the grant date using the Black-Scholes option pricing model with the following weighted average assumptions used for grants in the
years ended December 31, 2022 and December 31, 2021. Historical information was the primary basis for the selection of the expected volatility,
expected dividend yield and the expected lives of the options. &#160;The risk-free interest rate was selected based upon yields of the
U.S. Treasury issues with a term equal to the expected life of the option being valued. We have recognized tax benefits associated with
stock-based compensation of $<span id="xdx_900_eus-gaap--IncomeTaxExpenseBenefit_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zbekZFstSbci" title="Tax benefit"><ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="From2022-01-012022-12-31_custom_StockOptionPlan2021Member" format="ixt:numdotdecimal" decimals="0" unitRef="USD">33,083</ix:nonFraction></span> and $<span id="xdx_908_eus-gaap--IncomeTaxExpenseBenefit_c20210101__20211231__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zi6mxkU83IU2" title="Tax benefit"><ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="From2021-01-012021-12-31_custom_StockOptionPlan2021Member" format="ixt:numdotdecimal" decimals="0" unitRef="USD">0</ix:nonFraction></span> for the years ended December 31, 2022 and 2021, respectively.</p>

<ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock"><p id="xdx_893_eus-gaap--ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_z1c7sldhvJtd" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span><span id="xdx_8B8_zmgyVB3Zl42e" style="display: none; visibility: hidden">Schedule of time based stock options</span>&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 4.5in; border-collapse: collapse">
  <tr>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="5" style="border-bottom: black 1pt solid; text-align: center"><b>December 31,</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>2022</b></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>2021</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="width: 136.7pt">&#160;</td>
    <td style="width: 0.1in">&#160;</td>
    <td style="width: 0.1in">&#160;</td>
    <td style="width: 71.6pt">&#160;</td>
    <td style="width: 14.25pt">&#160;</td>
    <td style="width: 0.1in">&#160;</td>
    <td style="width: 72.35pt">&#160;</td>
    <td style="width: 7.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Dividend yield</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zJwoESfRyAab" title="Dividend yield"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="From2022-01-012022-12-31_custom_StockOptionPlan2021Member_custom_TimeBasedSharesOptionsMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0.00</ix:nonFraction></span>%</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zhWeaToWIlj8" title="Dividend yield"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="From2022-01-012022-12-31_custom_StockOptionPlan2021Member_custom_TimeBasedSharesOptionsMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0.00</ix:nonFraction></span>%</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Expected Volatility</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zlzsSWsvcP8k" title="Expected volatility"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="From2022-01-012022-12-31_custom_StockOptionPlan2021Member_custom_TimeBasedSharesOptionsMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">65.9</ix:nonFraction></span>%</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20210101__20211231__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember__srt--RangeAxis__srt--MinimumMember_zUmPwsUZYfZd"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="From2021-01-012021-12-31_custom_StockOptionPlan2021Member_custom_TimeBasedSharesOptionsMember_srt_MinimumMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0</ix:nonFraction></span>% &#8211; <span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember__srt--RangeAxis__srt--MaximumMember_zTwmV5AIzBm2" title="Expected volatility"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="From2022-01-012022-12-31_custom_StockOptionPlan2021Member_custom_TimeBasedSharesOptionsMember_srt_MaximumMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0</ix:nonFraction></span>%</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Weighted-average volatility</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_pid_dp_uPure_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zbPtw0LX5FZ7" title="Weighted-average volatility"><span style="-sec-ix-hidden: xdx2ixbrl0817">&#8212;</span></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_pid_dp_uPure_c20210101__20211231__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zdGMNi9skWj6" title="Weighted-average volatility"><span style="-sec-ix-hidden: xdx2ixbrl0819">&#8212;</span></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Expected dividends</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments_d0_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_z50YwJiVy8o3" title="Expected dividends"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments" contextRef="From2022-01-012022-12-31_custom_StockOptionPlan2021Member_custom_TimeBasedSharesOptionsMember" format="ixt:zerodash" decimals="0" unitRef="USD">&#8212;</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments_c20210101__20211231__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_z28VpsVDQRCc" title="Expected dividends"><span style="-sec-ix-hidden: xdx2ixbrl0823">&#8212;</span></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Expected term (in years)</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dxL_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_ziwAuYv74Xbh" title="Expected term (in years)::XDX::P10Y"><span style="-sec-ix-hidden: xdx2ixbrl0825">10</span></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dxL_c20210101__20211231__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zLo14Du90Qd" title="Expected term (in years)::XDX::P0Y"><span style="-sec-ix-hidden: xdx2ixbrl0827">0</span></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Risk-free rate</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zVSeOdzf4oMf" title="Risk-free rate"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="From2022-01-012022-12-31_custom_StockOptionPlan2021Member_custom_TimeBasedSharesOptionsMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">2.99</ix:nonFraction></span>%</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20210101__20211231__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember__srt--RangeAxis__srt--MinimumMember_zaFr9qzZvIm9" title="Risk-free rate"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="From2021-01-012021-12-31_custom_StockOptionPlan2021Member_custom_TimeBasedSharesOptionsMember_srt_MinimumMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0</ix:nonFraction></span>% &#8211; <span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20210101__20211231__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember__srt--RangeAxis__srt--MinimumMember_zB2vYAeILLq4" title="Risk-free rate"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="From2021-01-012021-12-31_custom_StockOptionPlan2021Member_custom_TimeBasedSharesOptionsMember_srt_MinimumMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0</ix:nonFraction></span>%</td>
    <td>&#160;</td></tr>
  </table>
</ix:nonNumeric><p id="xdx_8A1_zDsLo233sWhe" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:ScheduleOfOtherShareBasedCompensationActivityTableTextBlock"><p id="xdx_890_eus-gaap--ScheduleOfOtherShareBasedCompensationActivityTableTextBlock_zgKL1plP0rec" style="font: 10pt Times New Roman, Times, Serif; margin: 0">The following table summarizes the status of the 2021 Plan with respect
to time based stock options:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_8BA_zduzcPjGX2fi" style="display: none; visibility: hidden">Schedule of status of time based stock options</span>&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 7.5in; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="10" style="border-bottom: black 1pt solid; text-align: center"><b>Year Ended December 31,</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="4" style="border-bottom: black 1pt solid; text-align: center"><b>2022</b></td>
    <td>&#160;</td>
    <td colspan="5" style="border-bottom: black 1pt solid; text-align: center"><b>2021</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: center"><b>Shares</b></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>Weighted<br />
Average<br />
Exercise<br />
Price</b></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>Shares</b></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>Weighted<br />
Average<br />
Exercise<br />
Price</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="width: 264.6pt">Outstanding at January 1</td>
    <td style="width: 0.1in">&#160;</td>
    <td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber2_iS_pid_uShares_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zJn084UMm3Hb" title="Outstanding at beginning" style="width: 49.2pt; text-align: right"><ix:nonFraction name="krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber2" contextRef="AsOf2021-12-31_custom_StockOptionPlan2021Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">0</ix:nonFraction></td>
    <td style="width: 0.2in">&#160;</td>
    <td style="width: 0.1in">$</td>
    <td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice2_iS_pid_uUSDPShares_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zdyPJ6msQb84" title="Outstanding at beginning" style="width: 49.15pt; text-align: right"><ix:nonFraction name="krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice2" contextRef="AsOf2021-12-31_custom_StockOptionPlan2021Member" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0</ix:nonFraction></td>
    <td style="width: 14.7pt">&#160;</td>
    <td style="width: 0.1in">&#160;</td>
    <td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber2_iS_pid_uShares_c20210101__20211231__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zBv9XV56t6of" style="width: 48.85pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0840">&#8212;</span></td>
    <td style="width: 14.55pt">&#160;</td>
    <td style="width: 0.1in">$</td>
    <td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice2_iS_pid_uUSDPShares_c20210101__20211231__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zw2MZhDPuTi2" style="width: 48.55pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0841">&#8212;</span></td>
    <td style="width: 0.1in">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Granted</td>
    <td>&#160;</td>
    <td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross2_pid_uShares_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zUhpTJ7MfqGa" title="Granted" style="text-align: right"><ix:nonFraction name="krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross2" contextRef="From2022-01-012022-12-31_custom_StockOptionPlan2021Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">475,000</ix:nonFraction></td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_984_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice2_pid_uUSDPShares_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_z4finuiR92Wl" title="Granted" style="text-align: right"><ix:nonFraction name="krmd:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice2" contextRef="From2022-01-012022-12-31_custom_StockOptionPlan2021Member" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.67</ix:nonFraction></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross2_pid_uShares_c20210101__20211231__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zXjFEbRNUM6g" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0846">&#8212;</span></td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_98E_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice2_pid_uUSDPShares_c20210101__20211231__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_ztMaUpOvkv6g" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0847">&#8212;</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Exercised</td>
    <td>&#160;</td>
    <td id="xdx_989_ecustom--StockIssuedDuringPeriodSharesStockOptionsExercised2_pid_uShares_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zQLVCQI05zL1" title="Exercised" style="text-align: right"><ix:nonFraction name="krmd:StockIssuedDuringPeriodSharesStockOptionsExercised2" contextRef="From2022-01-012022-12-31_custom_StockOptionPlan2021Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">0</ix:nonFraction></td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_980_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice2_pid_uUSDPShares_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zpglE3WdXyxa" title="Exercised" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0851">&#8212;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_980_ecustom--StockIssuedDuringPeriodSharesStockOptionsExercised2_pid_uShares_c20210101__20211231__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zzU0EQfxTLNb" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0852">&#8212;</span></td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_985_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice2_pid_uUSDPShares_c20210101__20211231__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zfke8nRT0Ql6" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0853">&#8212;</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Forfeited</td>
    <td>&#160;</td>
    <td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod2_pid_uShares_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zud5mcwUwd5f" title="Forfeited" style="text-align: right"><ix:nonFraction name="krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod2" contextRef="From2022-01-012022-12-31_custom_StockOptionPlan2021Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">0</ix:nonFraction></td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_981_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice2_pid_uUSDPShares_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zFTArLr4LvO" title="Forfeited" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0857">&#8212;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod2_pid_uShares_c20210101__20211231__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_ztP0z42eq7g6" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0858">&#8212;</span></td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_98C_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice2_pid_uUSDPShares_c20210101__20211231__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zJtGJk5gjWid" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0859">&#8212;</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Outstanding at year end</td>
    <td>&#160;</td>
    <td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber2_iE_pid_uShares_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zzSNeNun6ka7" title="Outstanding at ending" style="text-align: right"><ix:nonFraction name="krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber2" contextRef="AsOf2022-12-31_custom_StockOptionPlan2021Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">475,000</ix:nonFraction></td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice2_iE_pid_uUSDPShares_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_z9U1aKMLdD7k" title="Outstanding at ending" style="text-align: right"><ix:nonFraction name="krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice2" contextRef="AsOf2022-12-31_custom_StockOptionPlan2021Member" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.67</ix:nonFraction></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber2_iE_pid_d0_uShares_c20210101__20211231__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_z3TSrOrdfbhd" style="text-align: right"><ix:nonFraction name="krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber2" contextRef="AsOf2021-12-31_custom_StockOptionPlan2021Member" format="ixt:zerodash" decimals="INF" unitRef="Shares">&#8212;</ix:nonFraction></td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice2_iE_pid_d0_uUSDPShares_c20210101__20211231__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_z25ZkGVljTM7" style="text-align: right"><ix:nonFraction name="krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice2" contextRef="AsOf2021-12-31_custom_StockOptionPlan2021Member" format="ixt:zerodash" decimals="INF" unitRef="USDPShares">&#8212;</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Options exercisable</td>
    <td>&#160;</td>
    <td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pid_uShares_c20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zEmdFXL5jX8k" title="Options exercisable at ending" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="AsOf2022-12-31_custom_StockOptionPlan2021Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">0</ix:nonFraction></td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_984_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice2_iI_pid_uUSDPShares_c20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zPUtOEBvfuQk" title="Options exercisable at ending" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0869">&#8212;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pid_uShares_c20211231__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zurkgefKQTu8" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0870">&#8212;</span></td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_982_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice2_iI_pid_uUSDPShares_c20211231__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zkcGJynuGkA" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0871">&#8212;</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="padding-left: 0.1in; text-indent: -0.1in">Weighted average fair value of options granted during the period</td>
    <td>&#160;</td>
    <td style="text-align: right">&#8212;</td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue2_pid_uUSDPShares_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zPiZtEGtaR89" title="Weighted average fair value of options granted during the period" style="text-align: right"><ix:nonFraction name="krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue2" contextRef="From2022-01-012022-12-31_custom_StockOptionPlan2021Member" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.99</ix:nonFraction></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#8212;</td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue2_pid_uUSDPShares_c20210101__20211231__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zg2K9XA8FE8k" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0874">&#8212;</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Stock-based compensation expense</td>
    <td>&#160;</td>
    <td style="text-align: right">&#8212;</td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_98C_eus-gaap--ShareBasedCompensation_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zMR0a556MYe4" title="Stock-based compensation expense" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2022-01-012022-12-31_custom_StockOptionPlan2021Member" format="ixt:numdotdecimal" decimals="0" unitRef="USD">157,536</ix:nonFraction></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#8212;</td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_98B_eus-gaap--ShareBasedCompensation_c20210101__20211231__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zhI0JtDcVzbl" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0877">&#8212;</span></td>
    <td>&#160;</td></tr>
  </table>
</ix:nonNumeric><p id="xdx_8AA_zqOtN3bblshd" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Total stock-based compensation expense was $<span id="xdx_906_eus-gaap--ShareBasedCompensation_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zZJxsmXDlR32" title="Stock-based compensation expense"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2022-01-012022-12-31_custom_StockOptionPlan2021Member" format="ixt:numdotdecimal" decimals="0" unitRef="USD">157,536</ix:nonFraction></span> and $<span id="xdx_905_eus-gaap--ShareBasedCompensation_dxL_c20210101__20211231__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zP5H5JfGBqG1" title="Stock-based compensation expense::XDX::-"><span style="-sec-ix-hidden: xdx2ixbrl0881">0</span></span> for the years
ended December 31, 2022, and 2021, respectively. There were no options exercised during the years ended December 31, 2022 and December
31, 2021.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The weighted-average grant-date fair value of options granted during the
years ended December 31, 2022, and 2021 was $<span id="xdx_90B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriodWeightedAverageGrantDateFairValue_uShares_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zVFu5SIxjIKh" title="Weighted-average grant-date fair value options granted"><ix:nonFraction name="krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="From2022-01-012022-12-31_custom_StockOptionPlan2021Member_custom_TimeBasedSharesOptionsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">945,215</ix:nonFraction></span> and $<span id="xdx_90E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriodWeightedAverageGrantDateFairValue_uShares_c20210101__20211231__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zBXjZmNM2RF8" title="Weighted-average grant-date fair value options granted"><ix:nonFraction name="krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="From2021-01-012021-12-31_custom_StockOptionPlan2021Member_custom_TimeBasedSharesOptionsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">0</ix:nonFraction></span>, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="krmd:ScheduleOfShareBasedCompensationtaxBenefitsAssociatedWithRestrictedStockAwardCompensationTableTextBlock"><p id="xdx_893_ecustom--ScheduleOfShareBasedCompensationtaxBenefitsAssociatedWithRestrictedStockAwardCompensationTableTextBlock_zPKPQIQxyncf" style="font: 10pt Times New Roman, Times, Serif; margin: 0">The following table presents information pertaining to options outstanding
at December 31, 2022:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_8B1_zPPZmpjvZHPa" style="display: none; visibility: hidden">Schedule of information pertaining to options outstanding</span>&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 7.5in; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: black 1pt solid"><b>Range of Exercise Price</b></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: center"><b>Number<br />
Outstanding</b></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: center"><b>Weighted<br />
Average<br />
Remaining<br />
Contractual<br />
Life</b></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>Weighted<br />
Average<br />
Exercise<br />
Price</b></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: center"><b>Number<br />
Exercisable</b></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>Weighted<br />
Average<br />
Exercise<br />
Price</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="width: 131.2pt">&#160;</td>
    <td style="width: 8.25pt">&#160;</td>
    <td style="width: 64.85pt">&#160;</td>
    <td style="width: 14.35pt">&#160;</td>
    <td style="width: 64.85pt">&#160;</td>
    <td style="width: 13.6pt">&#160;</td>
    <td style="width: 7.55pt">&#160;</td>
    <td style="width: 63.35pt">&#160;</td>
    <td style="width: 13.6pt">&#160;</td>
    <td style="width: 64.85pt">&#160;</td>
    <td style="width: 14.35pt">&#160;</td>
    <td style="width: 8.3pt">&#160;</td>
    <td style="width: 55.8pt">&#160;</td>
    <td style="width: 15.1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td>$2.67</td>
    <td>&#160;</td>
    <td id="xdx_98B_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pid_uShares_c20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice1Member_zsRCclyBqdal" title="Number outstanding" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" contextRef="AsOf2022-12-31_custom_StockOptionPlan2021Member_custom_TimeBasedSharesOptionsMember_custom_ExercisePrice1Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">475,000</ix:nonFraction></td>
    <td>&#160;</td>
    <td style="text-align: center"><span id="xdx_90A_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dxL_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice1Member_zXOIgQYORYWa" title="Weighted average remaining contractual life::XDX::P9Y3M19D"><span style="-sec-ix-hidden: xdx2ixbrl0891">9.3</span></span> years</td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_98F_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_c20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice1Member_zpulwXJjCC2j" title="Weighted average exercise price" style="text-align: center"><ix:nonFraction name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" contextRef="AsOf2022-12-31_custom_StockOptionPlan2021Member_custom_TimeBasedSharesOptionsMember_custom_ExercisePrice1Member" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.67</ix:nonFraction></td>
    <td>&#160;</td>
    <td id="xdx_984_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_uShares_c20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice1Member_zWpe3SyNSA6a" title="Number exercisable" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" contextRef="AsOf2022-12-31_custom_StockOptionPlan2021Member_custom_TimeBasedSharesOptionsMember_custom_ExercisePrice1Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">0</ix:nonFraction></td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_982_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_pid_uUSDPShares_c20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice1Member_z3h6UfDDpwme" title="Weighted average exercise price" style="text-align: right"><ix:nonFraction name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" contextRef="AsOf2022-12-31_custom_StockOptionPlan2021Member_custom_TimeBasedSharesOptionsMember_custom_ExercisePrice1Member" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0</ix:nonFraction></td>
    <td>&#160;</td></tr>
  </table>
</ix:nonNumeric><p id="xdx_8AE_zMK3ItcFGRXd" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">As of December 31, 2022, there was $<span id="xdx_908_ecustom--CompensationCost_iI_c20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zqickrqe2Qyd" title="Unrecognized compensation cost"><ix:nonFraction name="krmd:CompensationCost" contextRef="AsOf2022-12-31_custom_StockOptionPlan2021Member_custom_TimeBasedSharesOptionsMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">787,679</ix:nonFraction></span> of total unrecognized compensation
cost related to non-vested share-based compensation arrangements granted under the 2021 Plan. &#160;That cost is expected to be recognized
over a weighted-average period of <span id="xdx_90B_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm3_dxL_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zHRqLGthcSqk" title="Weighted-average period::XDX::P48M"><span style="-sec-ix-hidden: xdx2ixbrl0901">48</span></span> months. &#160;The total fair value of shares vested as of December 31, 2022, and December 31, 2021,
was <span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_iI_dxL_c20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zS2FHeIBBrlg" title="Fair value of shares::XDX::0"><span style="-sec-ix-hidden: xdx2ixbrl0903">zero</span></span> and <span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_iI_dxL_c20211231__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zsLWGRmOKFSb" title="Fair value of shares::XDX::0"><span style="-sec-ix-hidden: xdx2ixbrl0905">zero</span></span>, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<ix:exclude><div id="xdx_236_z9CKInb2ugpe">
<p style="font: 10pt TIMES NEW ROMAN, TIMES, SERIF; margin: 0; text-align: center">- 41 -</p>


<hr style="border-width: 0; color: Gray; background-color: Gray; height: 2px; width: 100%" /><p style="break-before: always"></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; color: blue"><i><a href="#index_to_fs">Index to Financial Statements</a></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p></div></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Performance-Based Stock Options</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">There were no performance-based stock options granted during the twelve
months ended December 31, 2022, and 2021.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:ShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock"><p id="xdx_89A_eus-gaap--ShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock_ziaATDPStcpg" style="font: 10pt Times New Roman, Times, Serif; margin: 0">The following table summarizes the status of the 2015 Plan with respect
to performance-based stock options as of December 31, 2022 and 2021:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_8B0_zFmIDLEsG1N" style="display: none; visibility: hidden">Schedule of performance base options outstanding</span>&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 7.5in; border-collapse: collapse">
  <tr style="background-color: white">
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td colspan="4" style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: center"><b>December 31, 2022</b></td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td colspan="5" style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: center"><b>December 31, 2021</b></td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr style="background-color: white">
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: center"><b>Shares</b></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: center"><b>Weighted<br />
Average<br />
Exercise<br />
Price</b></td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: center"><b>Shares</b></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: center"><b>Weighted<br />
Average<br />
Exercise<br />
Price</b></td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr style="background-color: white">
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr style="background-color: #E6E6E6">
    <td style="vertical-align: bottom; width: 257.75pt">Outstanding at January 1</td>
    <td style="vertical-align: bottom; width: 7.15pt">&#160;</td>
    <td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber1_iS_pid_dxL_uShares_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_z0M2W59pO8fk" title="Outstanding at beginning::XDX::1000000" style="vertical-align: bottom; width: 47.8pt; text-align: right"><b style="display: none; visibility: hidden"><span style="-sec-ix-hidden: xdx2ixbrl0910">&#8212;</span></b></td>
    <td style="vertical-align: bottom; width: 15.15pt">&#160;</td>
    <td style="vertical-align: bottom; width: 0.1in">$</td>
    <td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice1_iS_pid_dxL_uUSDPShares_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zz6GEJl9i7X2" title="Outstanding at beginning::XDX::1.70" style="vertical-align: bottom; width: 48.5pt; text-align: right"><b style="display: none; visibility: hidden"><span style="-sec-ix-hidden: xdx2ixbrl0912">&#8212;</span></b></td>
    <td style="vertical-align: top; width: 12.9pt">&#160;</td>
    <td style="vertical-align: bottom; width: 12.95pt">&#160;</td>
    <td style="vertical-align: bottom; width: 0.1in">&#160;</td>
    <td id="xdx_982_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber1_iS_pid_uShares_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zNrjDxCN5cw6" title="Outstanding at beginning" style="vertical-align: bottom; width: 48pt; text-align: right"><ix:nonFraction name="krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber1" contextRef="AsOf2020-12-31_us-gaap_PerformanceSharesMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,000,000</ix:nonFraction></td>
    <td style="vertical-align: bottom; width: 11.55pt">&#160;</td>
    <td style="vertical-align: bottom; width: 0.1in">$</td>
    <td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice1_iS_pid_uUSDPShares_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zv9YzAaCKyV2" style="vertical-align: bottom; width: 49.95pt; text-align: right"><ix:nonFraction name="krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice1" contextRef="AsOf2020-12-31_us-gaap_PerformanceSharesMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.70</ix:nonFraction></td>
    <td style="vertical-align: bottom; width: 7.15pt">&#160;</td></tr>
  <tr style="background-color: white">
    <td style="vertical-align: bottom">Granted</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross1_pid_d0_uShares_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_znMigeF3Cy4c" title="Granted" style="vertical-align: bottom; text-align: right"><ix:nonFraction name="krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross1" contextRef="From2022-01-012022-12-31_us-gaap_PerformanceSharesMember" format="ixt:zerodash" decimals="INF" unitRef="Shares">&#8212;</ix:nonFraction></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">$</td>
    <td id="xdx_980_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice1_pid_d0_uUSDPShares_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zw1sSZzmgc77" title="Granted" style="vertical-align: bottom; text-align: right"><ix:nonFraction name="krmd:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice1" contextRef="From2022-01-012022-12-31_us-gaap_PerformanceSharesMember" format="ixt:zerodash" decimals="INF" unitRef="USDPShares">&#8212;</ix:nonFraction></td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross1_pid_d0_uShares_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zajKijFVkUp7" style="vertical-align: bottom; text-align: right"><ix:nonFraction name="krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross1" contextRef="From2021-01-012021-12-31_us-gaap_PerformanceSharesMember" format="ixt:zerodash" decimals="INF" unitRef="Shares">&#8212;</ix:nonFraction></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top">$</td>
    <td id="xdx_98B_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice1_pid_d0_uUSDPShares_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zQMolxBiscE7" style="vertical-align: bottom; text-align: right"><ix:nonFraction name="krmd:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice1" contextRef="From2021-01-012021-12-31_us-gaap_PerformanceSharesMember" format="ixt:zerodash" decimals="INF" unitRef="USDPShares">&#8212;</ix:nonFraction></td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr style="background-color: #E6E6E6">
    <td style="vertical-align: bottom">Exercised</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td id="xdx_989_ecustom--StockIssuedDuringPeriodSharesStockOptionsExercised1_pid_d0_uShares_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_z8CXWSE0Ujvh" title="Exercised" style="vertical-align: bottom; text-align: right"><ix:nonFraction name="krmd:StockIssuedDuringPeriodSharesStockOptionsExercised1" contextRef="From2022-01-012022-12-31_us-gaap_PerformanceSharesMember" format="ixt:zerodash" decimals="INF" unitRef="Shares">&#8212;</ix:nonFraction></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">$</td>
    <td id="xdx_98B_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice1_pid_d0_uUSDPShares_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zKoVOB1QkUB5" title="Exercised" style="vertical-align: bottom; text-align: right"><ix:nonFraction name="krmd:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice1" contextRef="From2022-01-012022-12-31_us-gaap_PerformanceSharesMember" format="ixt:zerodash" decimals="INF" unitRef="USDPShares">&#8212;</ix:nonFraction></td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td id="xdx_980_ecustom--StockIssuedDuringPeriodSharesStockOptionsExercised1_pid_d0_uShares_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zFYgOcOG6Jl" style="vertical-align: bottom; text-align: right"><ix:nonFraction name="krmd:StockIssuedDuringPeriodSharesStockOptionsExercised1" contextRef="From2021-01-012021-12-31_us-gaap_PerformanceSharesMember" format="ixt:zerodash" decimals="INF" unitRef="Shares">&#8212;</ix:nonFraction></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top">$</td>
    <td id="xdx_98E_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice1_pid_d0_uUSDPShares_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zNZK1HJv0i7" style="vertical-align: bottom; text-align: right"><ix:nonFraction name="krmd:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice1" contextRef="From2021-01-012021-12-31_us-gaap_PerformanceSharesMember" format="ixt:zerodash" decimals="INF" unitRef="USDPShares">&#8212;</ix:nonFraction></td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr style="background-color: white">
    <td style="vertical-align: bottom">Forfeited</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod1_pid_d0_uShares_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zsEACKSpxZni" title="Forfeited" style="vertical-align: bottom; text-align: right"><ix:nonFraction name="krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod1" contextRef="From2022-01-012022-12-31_us-gaap_PerformanceSharesMember" format="ixt:zerodash" decimals="INF" unitRef="Shares">&#8212;</ix:nonFraction></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">$</td>
    <td id="xdx_982_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice1_pid_d0_uUSDPShares_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zpMOG22IlwOk" title="Forfeited" style="vertical-align: bottom; text-align: right"><ix:nonFraction name="krmd:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice1" contextRef="From2022-01-012022-12-31_us-gaap_PerformanceSharesMember" format="ixt:zerodash" decimals="INF" unitRef="USDPShares">&#8212;</ix:nonFraction></td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td id="xdx_984_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod1_pid_d0_uShares_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zD9qTNpJmza" style="vertical-align: bottom; text-align: right"><ix:nonFraction name="krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod1" contextRef="From2021-01-012021-12-31_us-gaap_PerformanceSharesMember" format="ixt:zerodash" decimals="INF" unitRef="Shares">&#8212;</ix:nonFraction></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top">$</td>
    <td id="xdx_988_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice1_pid_d0_uUSDPShares_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zMbPSxP2Exd" style="vertical-align: bottom; text-align: right"><ix:nonFraction name="krmd:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice1" contextRef="From2021-01-012021-12-31_us-gaap_PerformanceSharesMember" format="ixt:zerodash" decimals="INF" unitRef="USDPShares">&#8212;</ix:nonFraction></td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr style="background-color: #E6E6E6">
    <td style="vertical-align: bottom">Outstanding at year end</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_d0_uShares_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zyKbhzgvNtke" title="Outstanding at ending" style="vertical-align: bottom; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2022-12-31_us-gaap_PerformanceSharesMember" format="ixt:zerodash" decimals="INF" unitRef="Shares">&#8212;</ix:nonFraction></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">$</td>
    <td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_d0_uUSDPShares_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zfZBqFlaW2Oc" title="Outstanding at ending" style="vertical-align: bottom; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2022-12-31_us-gaap_PerformanceSharesMember" format="ixt:zerodash" decimals="INF" unitRef="USDPShares">&#8212;</ix:nonFraction></td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_uShares_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zgDB6RDXRAB5" style="vertical-align: bottom; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2021-12-31_us-gaap_PerformanceSharesMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,000,000</ix:nonFraction></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">$</td>
    <td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_uUSDPShares_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zm1JZlstwHTg" style="vertical-align: bottom; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2021-12-31_us-gaap_PerformanceSharesMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.70</ix:nonFraction></td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr style="background-color: white">
    <td style="vertical-align: bottom">Options exercisable</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross1_pid_d0_uShares_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zjmL7oDnQJf" title="Options exercisable at ending" style="vertical-align: bottom; text-align: right"><ix:nonFraction name="krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross1" contextRef="From2022-01-012022-12-31_us-gaap_PerformanceSharesMember" format="ixt:zerodash" decimals="INF" unitRef="Shares">&#8212;</ix:nonFraction></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">$</td>
    <td id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice1_iI_pid_d0_uUSDPShares_c20221231__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zhqy6DeuJT83" title="Options exercisable at ending" style="vertical-align: bottom; text-align: right"><ix:nonFraction name="krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice1" contextRef="AsOf2022-12-31_us-gaap_PerformanceSharesMember" format="ixt:zerodash" decimals="INF" unitRef="USDPShares">&#8212;</ix:nonFraction></td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross1_pid_d0_uShares_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zOE2NUXibFT7" style="vertical-align: bottom; text-align: right"><ix:nonFraction name="krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross1" contextRef="From2021-01-012021-12-31_us-gaap_PerformanceSharesMember" format="ixt:zerodash" decimals="INF" unitRef="Shares">&#8212;</ix:nonFraction></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">$</td>
    <td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice1_iI_pid_d0_uUSDPShares_c20211231__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zQkYAvK8aRva" style="vertical-align: bottom; text-align: right"><ix:nonFraction name="krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice1" contextRef="AsOf2021-12-31_us-gaap_PerformanceSharesMember" format="ixt:zerodash" decimals="INF" unitRef="USDPShares">&#8212;</ix:nonFraction></td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr style="background-color: #E6E6E6">
    <td style="vertical-align: bottom; padding-left: 7.4pt; text-indent: -7.4pt">Weighted average fair value of options granted during the period</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_d0_uShares_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zcmhAcGr65Dg" title="Weighted average fair value of options granted during the period" style="vertical-align: bottom; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2022-01-012022-12-31_us-gaap_PerformanceSharesMember" format="ixt:zerodash" decimals="INF" unitRef="Shares">&#8212;</ix:nonFraction></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">$</td>
    <td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue1_pid_d0_uUSDPShares_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zLfM1tdYCCYj" title="Weighted average fair value of options granted during the period" style="vertical-align: bottom; text-align: right"><ix:nonFraction name="krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue1" contextRef="From2022-01-012022-12-31_us-gaap_PerformanceSharesMember" format="ixt:zerodash" decimals="INF" unitRef="USDPShares">&#8212;</ix:nonFraction></td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_d0_uShares_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zTRtxzr0EcSj" style="vertical-align: bottom; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2021-01-012021-12-31_us-gaap_PerformanceSharesMember" format="ixt:zerodash" decimals="INF" unitRef="Shares">&#8212;</ix:nonFraction></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">$</td>
    <td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue1_pid_d0_uUSDPShares_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zkU8GGqbg8be" style="vertical-align: bottom; text-align: right"><ix:nonFraction name="krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue1" contextRef="From2021-01-012021-12-31_us-gaap_PerformanceSharesMember" format="ixt:zerodash" decimals="INF" unitRef="USDPShares">&#8212;</ix:nonFraction></td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr style="background-color: white">
    <td style="vertical-align: bottom">Stock-based compensation expense</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right">&#8212;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">$</td>
    <td id="xdx_98F_ecustom--AllocatedShareBasedCompensationExpense1_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zqjwJjn6fyn5" title="Stock-based compensation expense" style="vertical-align: bottom; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0953">&#8212;</span></td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right">&#8212;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">$</td>
    <td id="xdx_98E_ecustom--AllocatedShareBasedCompensationExpense1_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_z665Xj26ZrH" title="Stock-based compensation expense" style="vertical-align: bottom; text-align: right">(<ix:nonFraction name="krmd:AllocatedShareBasedCompensationExpense1" contextRef="From2021-01-012021-12-31_us-gaap_PerformanceSharesMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">408,747</ix:nonFraction></td>
    <td style="vertical-align: bottom">)</td></tr>
  </table>
</ix:nonNumeric><p id="xdx_8AC_zfrYdCNQQwNl" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Total performance stock-based compensation expense totaled <span id="xdx_90F_eus-gaap--ShareBasedCompensation_dxL_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member__us-gaap--FinancialInstrumentAxis__us-gaap--StockOptionMember_zDfz9QbPcIt1" title="Stock-based compensation expense::XDX::-"><span style="-sec-ix-hidden: xdx2ixbrl0957">zero</span></span> and $<span id="xdx_907_eus-gaap--ShareBasedCompensation_c20210101__20211231__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member__us-gaap--FinancialInstrumentAxis__us-gaap--StockOptionMember_zgrTu7lmcx0h" title="Stock-based compensation expense">(<ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2021-01-012021-12-31_custom_StockOptionPlan2021Member_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">408,747</ix:nonFraction>)</span>
for the years ended December 2022 and 2021, respectively. All performance-based stock options were forfeited as of December 31, 2021,
and there was no unrecognized compensation cost remaining.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>RESTRICTED STOCK AWARDS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">On April 12, 2021, pursuant to an employment agreement entered into on
March 15, 2021, with Linda Tharby, the Company&#8217;s President and Chief Executive Officer and as an inducement to her employment, the
Company issued three restricted stock awards for an aggregate <span id="xdx_909_eus-gaap--CommonStockSharesIssued_iI_pid_uShares_c20210412__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_zsVr6wmj1a2l" title="Common stock issued, shares"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2021-04-12_custom_EmploymentAgreementMember_srt_ChiefExecutiveOfficerMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,000,000</ix:nonFraction></span> shares of common stock for an aggregate stock price of $<span id="xdx_906_eus-gaap--CommonStockValue_iI_c20210412__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_z8fSaic3WZ23" title="Aggregate stock price"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="AsOf2021-04-12_custom_EmploymentAgreementMember_srt_ChiefExecutiveOfficerMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,310,000</ix:nonFraction></span>
and each vesting subject to employment on the respective vesting date.&#160;The following table summarizes the activities for our unvested
restricted stock awards for the twelve months ended December 31, 2022, and 2021.</p>

<ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock"><p id="xdx_890_eus-gaap--ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock_zpEioGXC9xR6" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_8B5_zCprAPbF5XI5" style="display: none; visibility: hidden">The following table summarizes the activities for our unvested
restricted stock awards for the twelve months ended December 31, 2022, and 2021.</span>&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 7.5in; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="9" style="border-bottom: black 1pt solid; text-align: center"><b>Twelve Months Ended December 31,</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="4" style="border-bottom: black 1pt solid; text-align: center"><b>2022</b></td>
    <td>&#160;</td>
    <td colspan="4" style="border-bottom: black 1pt solid; text-align: center"><b>2021</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: center"><b>Shares</b></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>Weighted<br />
Average<br />
Grant-Date Fair Value</b></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: center"><b>Shares</b></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>Weighted<br />
Average<br />
Grant-Date Fair Value</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="width: 201.15pt">Unvested at January 1</td>
    <td style="width: 9.65pt">&#160;</td>
    <td id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberUnvested_iS_pid_uShares_c20220101__20221231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zhacb022pAR" title="Outstanding at beginning" style="width: 53.1pt; text-align: right"><ix:nonFraction name="krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberUnvested" contextRef="AsOf2021-12-31_custom_RestrictedStockAwardsMember_custom_StockOptionPlan2021Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,000,000</ix:nonFraction></td>
    <td style="width: 11pt">&#160;</td>
    <td style="width: 17.4pt">$</td>
    <td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceUnvested_iS_pid_uUSDPShares_c20220101__20221231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zKfcDQ74lxb8" title="Outstanding at beginning" style="width: 72.75pt; text-align: right"><ix:nonFraction name="krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceUnvested" contextRef="AsOf2021-12-31_custom_RestrictedStockAwardsMember_custom_StockOptionPlan2021Member" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.01</ix:nonFraction></td>
    <td style="width: 11pt">&#160;</td>
    <td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberUnvested_iS_pid_uShares_c20210101__20211231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zMTMI0RJsFsg" style="width: 54.75pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0970">&#8212;</span></td>
    <td style="width: 11.35pt">&#160;</td>
    <td style="width: 16.9pt">$</td>
    <td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceUnvested_iS_pid_uUSDPShares_c20210101__20211231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_z8pULxd4p7f9" style="width: 73.25pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0971">&#8212;</span></td>
    <td style="width: 8pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Granted</td>
    <td>&#160;</td>
    <td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrossUnvested_pid_uShares_c20220101__20221231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_ztlm5zGVoigh" title="Granted" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0973">&#8212;</span></td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_982_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePriceUnvested_pid_uUSDPShares_c20220101__20221231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_z3Ak3vyzIfta" title="Granted" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0975">&#8212;</span></td>
    <td>&#160;</td>
    <td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrossUnvested_pid_uShares_c20210101__20211231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zWfQXlJPCfea" style="text-align: right"><ix:nonFraction name="krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrossUnvested" contextRef="From2021-01-012021-12-31_custom_RestrictedStockAwardsMember_custom_StockOptionPlan2021Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,000,000</ix:nonFraction></td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_98C_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePriceUnvested_pid_uUSDPShares_c20210101__20211231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zQmCl6uVkqmf" style="text-align: right"><ix:nonFraction name="krmd:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePriceUnvested" contextRef="From2021-01-012021-12-31_custom_RestrictedStockAwardsMember_custom_StockOptionPlan2021Member" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.01</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Vested</td>
    <td>&#160;</td>
    <td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodGross_pid_uShares_c20220101__20221231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zu2SxkYyxad1" title="Vested" style="text-align: right"><ix:nonFraction name="krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodGross" contextRef="From2022-01-012022-12-31_custom_StockOptionPlan2021Member_custom_RestrictedStockAwardsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">50,000</ix:nonFraction></td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_984_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice_pid_uUSDPShares_c20220101__20221231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_z6jQd1eofYIj" title="Vested" style="text-align: right"><ix:nonFraction name="krmd:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice" contextRef="From2022-01-012022-12-31_custom_StockOptionPlan2021Member_custom_RestrictedStockAwardsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.31</ix:nonFraction></td>
    <td>&#160;</td>
    <td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodGross_pid_uShares_c20210101__20211231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_z31UL0x5WW0l" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0982">&#8212;</span></td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_98C_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice_pid_uUSDPShares_c20210101__20211231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zBgpDsQZkXHl" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0983">&#8212;</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Forfeited/canceled</td>
    <td>&#160;</td>
    <td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodUnvested_pid_uShares_c20220101__20221231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zAeoBmoI2qF" title="Forfeited/canceled" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0985">&#8212;</span></td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_980_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePriceUnvested_pid_uUSDPShares_c20220101__20221231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zXhpyyJIFlC4" title="Forfeited/canceled" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0987">&#8212;</span></td>
    <td>&#160;</td>
    <td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodUnvested_pid_uShares_c20210101__20211231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zAq3e72xb4f6" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0988">&#8212;</span></td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_98C_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePriceUnvested_pid_uUSDPShares_c20210101__20211231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zQ9q8QPPkiJ9" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0989">&#8212;</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Unvested at December 31</td>
    <td>&#160;</td>
    <td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberUnvested_iE_pid_uShares_c20220101__20221231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zrVougvelbUa" title="Outstanding at ending" style="text-align: right"><ix:nonFraction name="krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberUnvested" contextRef="AsOf2022-12-31_custom_RestrictedStockAwardsMember_custom_StockOptionPlan2021Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">950,000</ix:nonFraction></td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceUnvested_iE_pid_uUSDPShares_c20220101__20221231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zMh3yFi4kWh8" title="Outstanding at ending" style="text-align: right"><ix:nonFraction name="krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceUnvested" contextRef="AsOf2022-12-31_custom_RestrictedStockAwardsMember_custom_StockOptionPlan2021Member" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.04</ix:nonFraction></td>
    <td>&#160;</td>
    <td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberUnvested_iE_pid_uShares_c20210101__20211231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zmbmg5YV0JTe" style="text-align: right"><ix:nonFraction name="krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberUnvested" contextRef="AsOf2021-12-31_custom_RestrictedStockAwardsMember_custom_StockOptionPlan2021Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,000,000</ix:nonFraction></td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceUnvested_iE_pid_uUSDPShares_c20210101__20211231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zFQfz3vv3JR5" style="text-align: right"><ix:nonFraction name="krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceUnvested" contextRef="AsOf2021-12-31_custom_RestrictedStockAwardsMember_custom_StockOptionPlan2021Member" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.01</ix:nonFraction></td>
    <td>&#160;</td></tr>
  </table>
</ix:nonNumeric><p id="xdx_8AC_zNaCS3qlyOHg" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">As of December 31, 2022, there was $<span id="xdx_904_ecustom--UnrecognizedCompensationCost_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember_zZusQLPMoQN7" title="Unrecognized compensation cost"><ix:nonFraction name="krmd:UnrecognizedCompensationCost" contextRef="From2022-01-012022-12-31_custom_StockOptionPlan2021Member_custom_RestrictedStockAwardsMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,618,177</ix:nonFraction></span> of unrecognized compensation
cost related to unvested employee restricted shares. This amount is expected to be recognized over a weighted-average period of <span id="xdx_905_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm4_dxL_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember_zSeTpzd1QTA8" title="Weighted-average period::XDX::P21M"><span style="-sec-ix-hidden: xdx2ixbrl0999">21</span></span> months.
We have recognized tax benefits associated with restricted stock award compensation of $<span id="xdx_903_eus-gaap--IncomeTaxExpenseBenefit_c20220101__20221231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zASlgyxk8Cj4"><ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="From2022-01-012022-12-31_custom_StockOptionPlan2021Member_custom_RestrictedStockAwardsMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">101,419</ix:nonFraction></span> and $<span id="xdx_902_eus-gaap--IncomeTaxExpenseBenefit_c20210101__20211231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zv7gaoOBESw7"><ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="From2021-01-012021-12-31_custom_RestrictedStockAwardsMember_custom_StockOptionPlan2021Member" format="ixt:numdotdecimal" decimals="0" unitRef="USD">47,220</ix:nonFraction></span> for the twelve months ended
December 31, 2022 and 2021, respectively.</p>

</ix:nonNumeric><p id="xdx_810_zrdvrLnjoqBc" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>


<p id="xdx_23B_zEcUgy8jR0d8" style="font: 10pt TIMES NEW ROMAN, TIMES, SERIF; margin: 0; text-align: center">- 42 -</p>


<hr style="border-width: 0; color: Gray; background-color: Gray; height: 2px; width: 100%" /><p id="xdx_23A_zBX97FKX6d6c" style="break-before: always"></p>

<p id="xdx_235_zBTxUJi1E0gj" style="font: 8pt Times New Roman, Times, Serif; margin: 0; color: blue"><i><a href="#toc">Table of Contents</a></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:LeasesOfLesseeDisclosureTextBlock"><p id="xdx_80A_eus-gaap--LeasesOfLesseeDisclosureTextBlock_zktF80J4F7ih" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>NOTE 5 &#8212; <span id="xdx_82F_zRVinPaaV2Y3">LEASES</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">We have finance and operating leases for our corporate office and certain
office and computer equipment. &#160;<span id="xdx_900_ecustom--DescriptionOfLessorOperatingLeaseTerm_c20220101__20221231_z0WCfOOTFkO4" title="Description of lease term"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="krmd:DescriptionOfLessorOperatingLeaseTerm">Our leases have remaining lease terms of 10, 5 years, and 3 months.</ix:nonNumeric></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">At contract inception, we evaluate whether an arrangement is or contains
a lease for which we are the lessee (that is, arrangements which provide us with the right to control a physical asset for a period of
time). &#160;Operating leases are accounted for on the balance sheets with ROU assets being recognized in &#8220;Operating lease right-of-use
assets&#8221; and lease liabilities recognized in &#8220;Operating lease liability &#8211; current&#8221; and &#8220;Operating lease liability,
net of current portion.&#8221; Finance leases are accounted for on the balance sheets recognized in &#8220;Property and equipment, net&#8221;
and lease liabilities recognized in &#8220;Finance lease liability &#8211; current&#8221; and &#8220;Finance lease liability, net of current
portion.&#8221;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Operating lease expenses are recognized on a straight-line basis over the
lease term. &#160;With respect to finance leases, amortization of the ROU asset is presented separately from interest expense related
to the finance lease liability.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">We have elected to combine lease and non-lease components for all lease
contracts where we are the lessee. &#160;Additionally, for arrangements with lease terms of 12 months or less, we do not recognize ROU
assets and lease liabilities and lease payments are recognized on a straight-line basis over the lease term with variable lease payments
recognized in the period in which the obligation is incurred. &#160;ROU assets are measured for impairment when a triggering event occurs.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:LeaseCostTableTextBlock"><p id="xdx_890_eus-gaap--LeaseCostTableTextBlock_z1LTQGqoqzE1" style="font: 10pt Times New Roman, Times, Serif; margin: 0">The components of lease expense were as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_8BF_zHnufYvIrM98" style="display: none; visibility: hidden">Schedule of components of lease expense</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 4.75in; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="width: 187.95pt">&#160;</td>
    <td style="width: 7.15pt">&#160;</td>
    <td style="width: 0.1in; text-align: center">&#160;</td>
    <td id="xdx_494_20220101__20221231_z2p5lB62SXuh" style="width: 56.8pt; text-align: center">&#160;</td>
    <td style="width: 11.15pt; text-align: center">&#160;</td>
    <td style="width: 0.1in; text-align: center">&#160;</td>
    <td id="xdx_49B_20210101__20211231_zjrgEIxHcU5c" style="width: 57.4pt; text-align: center">&#160;</td>
    <td style="width: 7.15pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="5" style="text-align: center"><b>Years Ended</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="5" style="border-bottom: black 1pt solid; text-align: center"><b>December 31,</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>2022</b></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>2021</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--OperatingLeaseCost_maLCzGTc_zUsXlNVmwuB6" style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Operating lease cost</td>
    <td>&#160;</td>
    <td>$</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseCost" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">514,294</ix:nonFraction></td>
    <td>&#160;</td>
    <td>$</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseCost" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">149,476</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--ShortTermLeaseCost_maLCzGTc_zSAnfqySRBt5" style="vertical-align: bottom">
    <td>Short-term lease cost</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:ShortTermLeaseCost" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">131,490</ix:nonFraction></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:ShortTermLeaseCost" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">146,604</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--LeaseCost_zvUJoX9MAcG7" style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Total lease cost</td>
    <td>&#160;</td>
    <td style="border-top: black 1pt solid; border-bottom: black 2.25pt double">$</td>
    <td style="border-top: black 1pt solid; border-bottom: black 2.25pt double; text-align: right"><ix:nonFraction name="us-gaap:LeaseCost" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">645,784</ix:nonFraction></td>
    <td>&#160;</td>
    <td style="border-top: black 1pt solid; border-bottom: black 2.25pt double">$</td>
    <td style="border-top: black 1pt solid; border-bottom: black 2.25pt double; text-align: right"><ix:nonFraction name="us-gaap:LeaseCost" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">296,080</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_40F_ecustom--FinanceLeaseCost1Abstract_iB_zWFaUUVzptO8" style="vertical-align: bottom">
    <td style="padding-left: 9.1pt; text-indent: -9.1pt">Finance lease cost:</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--FinanceLeaseRightOfUseAssetAmortization_i01_maFLCzAT2_zftg6rMSJ8Qg" style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="padding-left: 27.5pt; text-indent: -9.1pt">Amortization of right-of-use assets</td>
    <td>&#160;</td>
    <td>$</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">50,895</ix:nonFraction></td>
    <td>&#160;</td>
    <td>$</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,586</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--FinanceLeaseInterestExpense_i01_maFLCzAT2_zDR8tEDw9AQ5" style="vertical-align: bottom">
    <td style="padding-left: 27.5pt; text-indent: -9.1pt">Interest on lease liabilities</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:FinanceLeaseInterestExpense" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,393</ix:nonFraction></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:FinanceLeaseInterestExpense" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">60</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr id="xdx_40A_ecustom--FinanceLeaseCost_i01_zD2FyidY27S9" style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Total finance lease cost</td>
    <td>&#160;</td>
    <td style="border-top: black 1pt solid; border-bottom: black 2.25pt double">$</td>
    <td style="border-top: black 1pt solid; border-bottom: black 2.25pt double; text-align: right"><ix:nonFraction name="krmd:FinanceLeaseCost" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">56,288</ix:nonFraction></td>
    <td>&#160;</td>
    <td style="border-top: black 1pt solid; border-bottom: black 2.25pt double">$</td>
    <td style="border-top: black 1pt solid; border-bottom: black 2.25pt double; text-align: right"><ix:nonFraction name="krmd:FinanceLeaseCost" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,646</ix:nonFraction></td>
    <td>&#160;</td></tr>
  </table>
</ix:nonNumeric><p id="xdx_8A9_zcHQw6kJMYhl" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:OperatingLeaseLeaseIncomeTableTextBlock"><p id="xdx_899_eus-gaap--OperatingLeaseLeaseIncomeTableTextBlock_zEHge4wXvGc" style="font: 10pt Times New Roman, Times, Serif; margin: 0">Supplemental cash flow information related to leases was as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_8BB_zz98rsQUoiYj" style="display: none; visibility: hidden">Schedule of cash flow information related to leases</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 4.75in; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="width: 190pt">&#160;</td>
    <td style="width: 6.8pt">&#160;</td>
    <td style="width: 7.1pt; text-align: center">&#160;</td>
    <td id="xdx_49D_20220101__20221231_zvEQSh5ueQsi" style="width: 56.1pt; text-align: center">&#160;</td>
    <td style="width: 12pt; text-align: center">&#160;</td>
    <td style="width: 7.1pt; text-align: center">&#160;</td>
    <td id="xdx_491_20210101__20211231_zqBJ41jFceVb" style="width: 55.9pt; text-align: center">&#160;</td>
    <td style="width: 6.8pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="5" style="text-align: center"><b>Years Ended</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="5" style="border-bottom: black 1pt solid; text-align: center"><b>December 31,</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>2022</b></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>2021</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--CashFlowOperatingActivitiesLesseeAbstract_iB" style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="padding-left: 9.45pt; text-indent: -9.45pt">Cash paid for amounts included in the measurement of lease liabilities:</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--OperatingLeasePayments_i01_z2KIYtKYcSo1" style="vertical-align: bottom">
    <td>Operating cash flows from operating leases</td>
    <td>&#160;</td>
    <td>$</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeasePayments" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">247,504</ix:nonFraction></td>
    <td>&#160;</td>
    <td>$</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeasePayments" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">141,293</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--FinanceLeaseInterestPaymentOnLiability_i01_zqOSMHTnsu29" style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Financing cash flows from finance leases</td>
    <td>&#160;</td>
    <td>$</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:FinanceLeaseInterestPaymentOnLiability" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">57,243</ix:nonFraction></td>
    <td>&#160;</td>
    <td>$</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:FinanceLeaseInterestPaymentOnLiability" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,646</ix:nonFraction></td>
    <td>&#160;</td></tr>
  </table>
</ix:nonNumeric><p id="xdx_8A8_zPqTb9StI1w3" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<ix:exclude><div id="xdx_23C_zraabMWgCosl">
<p style="font: 10pt TIMES NEW ROMAN, TIMES, SERIF; margin: 0; text-align: center">- 43 -</p>


<hr style="border-width: 0; color: Gray; background-color: Gray; height: 2px; width: 100%" /><p style="break-before: always"></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; color: blue"><i><a href="#index_to_fs">Index to Financial Statements</a></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p></div></ix:exclude>

<ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:OperatingLeasesOfLesseeDisclosureTextBlock"><p id="xdx_899_eus-gaap--OperatingLeasesOfLesseeDisclosureTextBlock_zBDoScivKUk9" style="font: 10pt Times New Roman, Times, Serif; margin: 0">Supplemental balance sheet information related to leases was as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_8B9_zhDohtT1ePmd" style="display: none; visibility: hidden">Schdeule of balance sheet information related to leases</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 5.5in; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" id="xdx_49B_20221231_z8ahI5LaIsN6" style="border-bottom: black 1pt solid; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td colspan="2" id="xdx_498_20211231_zerdUjqQqiPc" style="border-bottom: black 1pt solid; text-align: center">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>December 31,<br />
2022</b></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>December 31,<br />
2021</b></td>
    <td>&#160;</td></tr>
  <tr id="xdx_402_ecustom--AssetsAndLiabilitiesOperatingLesseeAbstract_iB_zY2BfEyxuXfl" style="vertical-align: bottom">
    <td style="width: 217.3pt; padding-left: 9.1pt; text-indent: -9.1pt"><b>Operating Leases</b></td>
    <td style="width: 9.8pt">&#160;</td>
    <td style="width: 11.25pt">&#160;</td>
    <td style="width: 63pt">&#160;</td>
    <td style="width: 12.8pt">&#160;</td>
    <td style="width: 9.75pt">&#160;</td>
    <td style="width: 64.5pt">&#160;</td>
    <td style="width: 0.1in">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--OperatingLeaseRightOfUseAsset_i01I_zf5monxP8L92" style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="padding-left: 28.25pt; text-indent: -9.45pt">Operating lease right-of-use assets</td>
    <td>&#160;</td>
    <td>$</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,786,545</ix:nonFraction></td>
    <td>&#160;</td>
    <td>$</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">95,553</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 28.25pt; text-indent: -9.45pt">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--OperatingLeaseLiabilityCurrent_i01I_zQ08LsJOEJi5" style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="padding-left: 28.25pt; text-indent: -9.45pt">Operating lease liability &#8211; current</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">345,834</ix:nonFraction></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">95,553</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--OperatingLeaseLiabilityNoncurrent_i01I_zfJUy2reio28" style="vertical-align: bottom">
    <td style="padding-left: 28.25pt; text-indent: -9.45pt">Operating lease liability, net of current portion</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,653,257</ix:nonFraction></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1057">&#8212;</span></td>
    <td>&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--OperatingLeaseLiability_i01I_ziKLJsgAbEh5" style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="padding-left: 9.1pt; text-indent: -9.1pt">Total operating lease liabilities</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiability" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,999,091</ix:nonFraction></td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiability" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">95,553</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 9.1pt; text-indent: -9.1pt">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_40F_ecustom--AssetsAndLiabilitiesLesseeFinanceAbstract_iB_z86pRnOO118" style="vertical-align: bottom">
    <td style="padding-left: 9.1pt; text-indent: -9.1pt"><b>Finance Leases</b></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--PropertyPlantAndEquipmentOther_i01I_zkshvzRWwsV7" style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="padding-left: 28.25pt; text-indent: -9.45pt">Property and equipment, at cost</td>
    <td>&#160;</td>
    <td>$</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentOther" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">544,468</ix:nonFraction></td>
    <td>&#160;</td>
    <td>$</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentOther" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">12,725</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--PropertyPlantAndEquipmentOtherAccumulatedDepreciation_i01NI_di_zgPCpK3uctT4" style="vertical-align: bottom">
    <td style="padding-left: 28.25pt; text-indent: -9.45pt">Accumulated depreciation</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentOtherAccumulatedDepreciation" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">50,895</ix:nonFraction></td>
    <td>)</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentOtherAccumulatedDepreciation" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">12,725</ix:nonFraction></td>
    <td>)</td></tr>
  <tr id="xdx_407_eus-gaap--PropertyPlantAndEquipmentOtherNet_i01I_zow00fF4O8Z" style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="padding-left: 28.25pt; text-indent: -9.45pt">Property and equipment, net</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentOtherNet" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">493,573</ix:nonFraction></td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1072">&#8212;</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--FinanceLeaseLiabilityCurrent_iI_ztoM1PT0aWsc" style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="padding-left: 28.25pt; text-indent: -9.45pt">Finance lease liability &#8211; current</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:FinanceLeaseLiabilityCurrent" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">98,335</ix:nonFraction></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1075">&#8212;</span></td>
    <td>&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--FinanceLeaseLiabilityNoncurrent_iI_z0GlI9AHfFLh" style="vertical-align: bottom">
    <td style="padding-left: 28.25pt; text-indent: -9.45pt">Finance lease liability, net of current portion</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:FinanceLeaseLiabilityNoncurrent" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">394,283</ix:nonFraction></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1078">&#8212;</span></td>
    <td>&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--FinanceLeaseLiability_iI_zlJaUSV2xXHj" style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="padding-left: 9.1pt; text-indent: -9.1pt">Total finance lease liabilities</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><ix:nonFraction name="us-gaap:FinanceLeaseLiability" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">492,618</ix:nonFraction></td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1081">&#8212;</span></td>
    <td>&#160;</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 5.5in; border-collapse: collapse">
  <tr style="background-color: white">
    <td style="vertical-align: bottom; width: 218.25pt">&#160;</td>
    <td style="vertical-align: bottom; width: 9.75pt">&#160;</td>
    <td style="border-bottom: black 1pt solid; vertical-align: bottom; width: 74.25pt; text-align: center"><b>December 31,<br />
2022</b></td>
    <td style="vertical-align: bottom; width: 11.25pt">&#160;</td>
    <td style="border-bottom: black 1pt solid; vertical-align: top; width: 74.25pt; text-align: center"><b>December 31,<br />
2021</b></td>
    <td style="vertical-align: top; width: 0.1in">&#160;</td></tr>
  <tr>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top">&#160;</td></tr>
  <tr style="background-color: #E6E6E6">
    <td style="vertical-align: bottom"><b>Weighted Average Remaining Lease Term</b></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top">&#160;</td></tr>
  <tr style="background-color: white">
    <td style="vertical-align: bottom; padding-left: 28.25pt; text-indent: -9.45pt">Operating leases</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="text-align: right"><span id="xdx_908_eus-gaap--LesseeOperatingLeaseRenewalTerm_iI_dxL_c20221231_zArCYc8v9ij" title="Operating leases::XDX::P9Y8M12D"><span style="-sec-ix-hidden: xdx2ixbrl1083">9.7</span></span> Years</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: right"><span id="xdx_90F_eus-gaap--LesseeOperatingLeaseRenewalTerm_iI_dxL_c20211231_zTyjDwcAZdKf" title="Operating leases::XDX::P0Y7M6D"><span style="-sec-ix-hidden: xdx2ixbrl1085">0.6</span></span> Years</td>
    <td style="vertical-align: top">&#160;</td></tr>
  <tr style="background-color: #E6E6E6">
    <td style="vertical-align: bottom; padding-left: 28.25pt; text-indent: -9.45pt">Finance leases</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="text-align: right"><span id="xdx_90D_eus-gaap--LesseeFinanceLeaseRenewalTerm1_iI_dxL_c20221231_zGKlAStG3FY" title="Finance leases::XDX::P4Y0M22D"><span style="-sec-ix-hidden: xdx2ixbrl1087">4.6</span></span> Years</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: right"><span id="xdx_90A_eus-gaap--LesseeFinanceLeaseRenewalTerm1_iI_dxL_c20211231_zrQaTiaSzknd" title="Finance leases::XDX::P0Y0M0D"><span style="-sec-ix-hidden: xdx2ixbrl1089">0</span></span> Years</td>
    <td style="vertical-align: top">&#160;</td></tr>
  <tr style="background-color: white">
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top">&#160;</td></tr>
  <tr style="background-color: #E6E6E6">
    <td style="vertical-align: bottom"><b>Weighted Average Discount Rate</b></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top">&#160;</td></tr>
  <tr style="background-color: white">
    <td style="vertical-align: bottom; padding-left: 28.25pt; text-indent: -9.45pt">Operating leases</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span id="xdx_90C_eus-gaap--LesseeOperatingLeaseDiscountRate_iI_pid_dp_uPure_c20221231_zg4uFdZV446l" title="Operating leases"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseDiscountRate" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">4.00</ix:nonFraction></span>%</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: right"><span id="xdx_90C_eus-gaap--LesseeOperatingLeaseDiscountRate_iI_pid_dp_uPure_c20211231_zJtJWBxHewic" title="Operating leases"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseDiscountRate" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">4.75</ix:nonFraction></span>%</td>
    <td style="vertical-align: top">&#160;</td></tr>
  <tr style="background-color: #E6E6E6">
    <td style="vertical-align: bottom; padding-left: 28.25pt; text-indent: -9.45pt">Finance leases</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span id="xdx_90A_eus-gaap--LesseeFinanceLeaseDiscountRate_iI_pid_dp_uPure_c20221231_zwKlu2rO5mQl" title="Finance leases"><ix:nonFraction name="us-gaap:LesseeFinanceLeaseDiscountRate" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">4.25</ix:nonFraction></span>%</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: right"><span id="xdx_90F_eus-gaap--LesseeFinanceLeaseDiscountRate_iI_pid_dp_uPure_c20211231_z89nbAXUapO4" title="Finance leases"><ix:nonFraction name="us-gaap:LesseeFinanceLeaseDiscountRate" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">4.75</ix:nonFraction></span>%</td>
    <td style="vertical-align: top">&#160;</td></tr>
  </table>
</ix:nonNumeric><p id="xdx_8A8_zJsGcKQZ7H0b" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock"><p id="xdx_894_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_zJzeWiAT4h1l" style="font: 10pt Times New Roman, Times, Serif; margin: 0">Maturities of lease liabilities are as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_8B0_zPfztqAP7W4f" style="display: none; visibility: hidden">Schedule of maturities of lease liabilities</span>&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 5.5in; border-collapse: collapse">
  <tr>
    <td style="border-bottom: black 1pt solid; vertical-align: bottom"><b>Year Ending December 31,</b></td>
    <td style="vertical-align: top">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: center"><b>Operating Leases</b></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: center"><b>Finance Leases</b></td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="width: 210.7pt">2023</td>
    <td style="width: 7pt">&#160;</td>
    <td style="width: 13.95pt">&#160;</td>
    <td id="xdx_98C_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_c20221231_zbdREWlyjfga" title="2023" style="width: 67.6pt; text-align: right"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">499,503</ix:nonFraction></td>
    <td style="width: 10.2pt">&#160;</td>
    <td style="width: 7pt">&#160;</td>
    <td id="xdx_98E_eus-gaap--FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_iI_c20221231_zDBrss7U5qb" title="2023" style="width: 62.05pt; text-align: right"><ix:nonFraction name="us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">123,200</ix:nonFraction></td>
    <td style="width: 8.75pt">&#160;</td></tr>
  <tr>
    <td style="vertical-align: bottom">2024</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td id="xdx_984_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_c20221231_zfrLp93TJoi7" title="2024" style="vertical-align: bottom; text-align: right"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">499,503</ix:nonFraction></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td id="xdx_98D_eus-gaap--FinanceLeaseLiabilityPaymentsDueYearTwo_iI_c20221231_zqwZr9c5qS4c" title="2024" style="vertical-align: bottom; text-align: right"><ix:nonFraction name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">123,200</ix:nonFraction></td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr style="background-color: #E6E6E6">
    <td style="vertical-align: bottom">2025</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td id="xdx_98F_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_c20221231_z6e6Jx5PulYk" title="2025" style="vertical-align: bottom; text-align: right"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">499,503</ix:nonFraction></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td id="xdx_988_eus-gaap--FinanceLeaseLiabilityPaymentsDueYearThree_iI_c20221231_zfR57toQFVqh" title="2025" style="vertical-align: bottom; text-align: right"><ix:nonFraction name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearThree" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">123,200</ix:nonFraction></td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr>
    <td style="vertical-align: bottom">2026</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td id="xdx_985_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFour_iI_c20221231_znlIyIwgCNF8" title="2026" style="vertical-align: bottom; text-align: right"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">499,503</ix:nonFraction></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td id="xdx_98E_eus-gaap--FinanceLeaseLiabilityPaymentsDueYearFour_iI_c20221231_zDrWXBFtwpB7" title="2026" style="vertical-align: bottom; text-align: right"><ix:nonFraction name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearFour" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">123,200</ix:nonFraction></td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr style="background-color: #E6E6E6">
    <td style="vertical-align: bottom">2027</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td id="xdx_98F_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFive_iI_c20221231_zW6ywYksJDz3" title="2027" style="vertical-align: bottom; text-align: right"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">499,503</ix:nonFraction></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td id="xdx_983_eus-gaap--FinanceLeaseLiabilityPaymentsDueYearFive_iI_c20221231_zFhCRsXANDZ4" title="2027" style="vertical-align: bottom; text-align: right"><ix:nonFraction name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearFive" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">65,957</ix:nonFraction></td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr>
    <td style="vertical-align: bottom">Thereafter</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="border-bottom: black 1pt solid; vertical-align: bottom">&#160;</td>
    <td id="xdx_987_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_iI_c20221231_zbg3rVA8sdA3" title="Thereafter" style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: right"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,331,015</ix:nonFraction></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="border-bottom: black 1pt solid; vertical-align: bottom">&#160;</td>
    <td id="xdx_98B_eus-gaap--FinanceLeaseLiabilityPaymentsDueAfterYearFive_iI_c20221231_zQFXPu2ksYAf" title="Thereafter" style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1123">&#8212;</span></td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr style="background-color: #E6E6E6">
    <td style="vertical-align: bottom">Total undiscounted lease payments</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td id="xdx_980_ecustom--LesseeOperatingLeaseLiabilityPaymentsDueTotal_iI_c20221231_zLPcSKlSzTzc" title="Total undiscounted lease payments" style="vertical-align: bottom; text-align: right"><ix:nonFraction name="krmd:LesseeOperatingLeaseLiabilityPaymentsDueTotal" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,828,530</ix:nonFraction></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td id="xdx_98B_ecustom--LesseeFinancingLeaseLeaseLiabilityPaymentsDueTotal_iI_c20221231_z5kCzifwgWPj" title="Total undiscounted lease payments" style="vertical-align: bottom; text-align: right"><ix:nonFraction name="krmd:LesseeFinancingLeaseLeaseLiabilityPaymentsDueTotal" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">558,757</ix:nonFraction></td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr>
    <td style="vertical-align: bottom; padding-left: 18.8pt">Less: imputed interest</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="border-bottom: black 1pt solid; vertical-align: bottom">&#160;</td>
    <td id="xdx_98B_ecustom--LesseeOperatingLeaseImputedInterest_iNI_di_c20221231_zODxEvreSjwd" title="Less: imputed interest" style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: right">(<ix:nonFraction name="krmd:LesseeOperatingLeaseImputedInterest" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">829,439</ix:nonFraction></td>
    <td style="vertical-align: bottom">)</td>
    <td style="border-bottom: black 1pt solid; vertical-align: bottom">&#160;</td>
    <td id="xdx_985_ecustom--LesseeFinancingLeaseImputedInterest_iNI_di_c20221231_zAhvBU1ADOQc" title="Less: imputed interest" style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: right">(<ix:nonFraction name="krmd:LesseeFinancingLeaseImputedInterest" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">66,139</ix:nonFraction></td>
    <td style="vertical-align: bottom">)</td></tr>
  <tr style="background-color: #E6E6E6">
    <td style="vertical-align: bottom">Total lease liabilities</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="border-bottom: black 2.25pt double; vertical-align: bottom">$</td>
    <td id="xdx_98C_eus-gaap--OperatingLeaseLiability_iI_c20221231_zbVRBidywo6k" title="Total lease liabilities" style="border-bottom: black 2.25pt double; vertical-align: bottom; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiability" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,999,091</ix:nonFraction></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="border-bottom: black 2.25pt double; vertical-align: bottom">$</td>
    <td id="xdx_981_eus-gaap--FinanceLeaseLiability_iI_c20221231_zHnd4FjVhccl" title="Total lease liabilities" style="border-bottom: black 2.25pt double; vertical-align: bottom; text-align: right"><ix:nonFraction name="us-gaap:FinanceLeaseLiability" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">492,618</ix:nonFraction></td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  </table>
</ix:nonNumeric><p id="xdx_8A8_zkXgyaoYOY7h" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:IncomeTaxDisclosureTextBlock"><p id="xdx_801_eus-gaap--IncomeTaxDisclosureTextBlock_zlWt42gbfGN2" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>NOTE 6 &#8212; <span id="xdx_822_zaj4n2rmGLn4">FEDERAL AND STATE INCOME TAXES</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"><p id="xdx_899_eus-gaap--ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_zglEySmcueM1" style="font: 10pt Times New Roman, Times, Serif; margin: 0">Income tax expense consisted of the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_8BE_zsMQiuMp5bRh" style="display: none; visibility: hidden">Schedule of provision for income taxes</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 4.5in; border-collapse: collapse">
  <tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" id="xdx_496_20220101__20221231_zuCjSxBaV0T6" style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td colspan="2" id="xdx_49E_20210101__20211231_z9VxYzvHVC4f" style="text-align: center">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>Year Ended<br />
December 31,<br />
2022</b></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>Year Ended<br />
December 31,<br />
2021</b></td>
    <td>&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--StateAndLocalIncomeTaxExpenseBenefitContinuingOperationsAbstract_iB_zpVHNQEH2yh8" style="vertical-align: bottom; background-color: white">
    <td>State income tax:</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--CurrentStateAndLocalTaxExpenseBenefit_zuRz3QqK79eg" style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="width: 145.15pt; padding-left: 21.8pt">Current, net of refund</td>
    <td style="width: 8.25pt">&#160;</td>
    <td style="width: 8.25pt">$</td>
    <td style="width: 63.75pt; text-align: right"><ix:nonFraction name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">0</ix:nonFraction></td>
    <td style="width: 17.3pt">&#160;</td>
    <td style="width: 8.25pt">$</td>
    <td style="width: 64.5pt; text-align: right">(<ix:nonFraction name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">12,800</ix:nonFraction></td>
    <td style="width: 8.25pt">)</td></tr>
  <tr id="xdx_409_eus-gaap--FederalIncomeTaxExpenseBenefitContinuingOperationsAbstract_iB_zgNMkE8zBaDc" style="vertical-align: bottom; background-color: white">
    <td>Federal income tax:</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--DeferredFederalIncomeTaxExpenseBenefit_zuGwJOXBnkO" style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="padding-left: 21.8pt">Deferred</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,014,018</ix:nonFraction></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,814,418</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--CurrentFederalTaxExpenseBenefit_zR3uewbkPO6l" style="vertical-align: bottom; background-color: white">
    <td style="padding-left: 21.8pt">Current</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1153">&#8212;</span></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1154">&#8212;</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Income tax benefit/(expense)</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td id="xdx_987_eus-gaap--IncomeTaxExpenseBenefit_iN_dixL_c20220101__20221231_z0H20cITsBPk" title="Income tax benefit/(expense)::XDX::2014018" style="border-bottom: black 2.25pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1156">2,014,018</span></td>
    <td style="border-bottom: white 2.25pt double">&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td id="xdx_98E_eus-gaap--IncomeTaxExpenseBenefit_iN_di_c20210101__20211231_zwg8wpJI77sk" title="Income tax benefit/(expense)" style="border-bottom: black 2.25pt double; text-align: right"><ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,801,618</ix:nonFraction></td>
    <td style="border-bottom: white 2.25pt double">&#160;</td></tr>
  </table>
</ix:nonNumeric><p id="xdx_8A4_z9Z1GHVHUYtg" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<ix:exclude><div id="xdx_238_zxaVVU8pRkIc">
<p style="font: 10pt TIMES NEW ROMAN, TIMES, SERIF; margin: 0; text-align: center">- 44 -</p>


<hr style="border-width: 0; color: Gray; background-color: Gray; height: 2px; width: 100%" /><p style="break-before: always"></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; color: blue"><i><a href="#index_to_fs">Index to Financial Statements</a></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p></div></ix:exclude>

<ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"><p id="xdx_898_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zUMt6iPfMcs4" style="font: 10pt Times New Roman, Times, Serif; margin: 0">The reconciliation of income taxes shown in the financial statements and
amounts computed by applying the Federal expected tax rate of 21% for year 2022 and 2021 is as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_8BF_zfXXktFPaDB4" style="display: none; visibility: hidden">Schedule of reconciliation of income taxes</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 5.5in; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" id="xdx_497_20220101__20221231_zZfBG566rN03" style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td colspan="2" id="xdx_49D_20210101__20211231_zbbvnlqEnBN7" style="text-align: center">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>Year Ended<br />
December 31,<br />
2022</b></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>Year Ended<br />
December 31,<br />
2021</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_zkkH8IRj2kNg" style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="width: 217.2pt">Loss before taxes</td>
    <td style="width: 8.3pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double; width: 8.25pt">$</td>
    <td style="border-bottom: black 2.25pt double; width: 65.25pt; text-align: right">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">10,675,160</ix:nonFraction></td>
    <td style="border-bottom: white 2.25pt double; width: 17.3pt">)</td>
    <td style="border-bottom: black 2.25pt double; width: 7.5pt">$</td>
    <td style="border-bottom: black 2.25pt double; width: 63.75pt; text-align: right">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">6,364,441</ix:nonFraction></td>
    <td style="border-bottom: white 2.25pt double; width: 8.25pt">)</td></tr>
  <tr id="xdx_407_eus-gaap--IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_zFpk8I5fX0u3" style="vertical-align: bottom">
    <td>Income taxes computed at the federal statutory rate</td>
    <td>&#160;</td>
    <td>$</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,241,784</ix:nonFraction></td>
    <td>&#160;</td>
    <td>$</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,336,533</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--IncomeTaxReconciliationStateAndLocalIncomeTaxes_zYOmqgxXiNCd" style="vertical-align: bottom; background-color: #E6E6E6">
    <td>State income and franchise tax</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">(<ix:nonFraction name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">0</ix:nonFraction></td>
    <td>)</td>
    <td>&#160;</td>
    <td style="text-align: right">(<ix:nonFraction name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">12,800</ix:nonFraction></td>
    <td>)</td></tr>
  <tr id="xdx_400_eus-gaap--IncomeTaxReconciliationOtherAdjustments_znIbNnOLWCgd" style="vertical-align: bottom">
    <td>Permanent differences and other</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:IncomeTaxReconciliationOtherAdjustments" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">227,766</ix:nonFraction></td>
    <td>)</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:IncomeTaxReconciliationOtherAdjustments" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">477,885</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Income tax benefit/(expense)</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td id="xdx_987_eus-gaap--IncomeTaxExpenseBenefit_iN_dixL_c20220101__20221231_zX2yburYThGc" title="Income tax benefit/(expense)::XDX::2014018" style="border-bottom: black 2.25pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1175">2,014,018</span></td>
    <td style="border-bottom: white 1.5pt double">&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td id="xdx_980_eus-gaap--IncomeTaxExpenseBenefit_iN_di_c20210101__20211231_zvntdnqNBLhj" title="Income tax benefit/(expense)" style="border-bottom: black 2.25pt double; text-align: right"><ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,801,618</ix:nonFraction></td>
    <td style="border-bottom: white 1.5pt double">&#160;</td></tr>
  </table>
</ix:nonNumeric><p id="xdx_8AF_zMjx34GGqG33" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"><p id="xdx_894_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zlffzBYaydZ" style="font: 10pt Times New Roman, Times, Serif; margin: 0">The significant components of deferred income tax assets, net are as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_8B0_za0gIlKRnn84" style="display: none; visibility: hidden">Schedule of components of deferred tax assets</span>&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 5.5in; border-collapse: collapse">
  <tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" id="xdx_493_20221231_z7Xum9LAfpOi" style="border-bottom: black 1pt solid; text-align: center"><b>December 31,<br />
2022</b></td>
    <td>&#160;</td>
    <td colspan="2" id="xdx_49E_20211231_z1A44rbmRDqc" style="border-bottom: black 1pt solid; text-align: center"><b>December 31,<br />
2021</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--DeferredCompensationPlanAssets_iI_zt6hAbjnyePh" style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="width: 207.9pt">Deferred compensation cost</td>
    <td style="width: 0.1in">&#160;</td>
    <td style="width: 7.35pt">$</td>
    <td style="width: 80pt; text-align: right"><ix:nonFraction name="us-gaap:DeferredCompensationPlanAssets" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">557,931</ix:nonFraction></td>
    <td style="width: 17.15pt">&#160;</td>
    <td style="width: 8.05pt">$</td>
    <td style="width: 61.1pt; text-align: right"><ix:nonFraction name="us-gaap:DeferredCompensationPlanAssets" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">389,981</ix:nonFraction></td>
    <td style="width: 7.25pt">&#160;</td></tr>
  <tr id="xdx_40F_ecustom--DepreciationDepletionAndAmortization1_iI_zhEmxRj9hFYd" style="vertical-align: bottom; background-color: white">
    <td>Depreciation and amortization</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">(<ix:nonFraction name="krmd:DepreciationDepletionAndAmortization1" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">624,184</ix:nonFraction></td>
    <td>)</td>
    <td>&#160;</td>
    <td style="text-align: right">(<ix:nonFraction name="krmd:DepreciationDepletionAndAmortization1" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">116,911</ix:nonFraction></td>
    <td>)</td></tr>
  <tr id="xdx_403_ecustom--RdCredit_zgXcDJvczNKj" style="vertical-align: bottom; background-color: #E6E6E6">
    <td>R&amp;D credit</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="krmd:RdCredit" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">142,030</ix:nonFraction></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="krmd:RdCredit" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">142,538</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr id="xdx_40D_ecustom--Nol_zhcYeQUIMA8" style="vertical-align: bottom; background-color: white">
    <td>NOL</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="krmd:Nol" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,956,685</ix:nonFraction></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="krmd:Nol" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,507,982</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr id="xdx_40D_ecustom--AllowanceForDoubtfulOtherReceivables1Current_zuvcrVoDDgo4" style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Allowance for bad debts and other</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><ix:nonFraction name="krmd:AllowanceForDoubtfulOtherReceivables1Current" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">935,018</ix:nonFraction></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><ix:nonFraction name="krmd:AllowanceForDoubtfulOtherReceivables1Current" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">17,664</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--DeferredTaxAssetsNet_iI_zNZ0sJT5k5o5" style="vertical-align: bottom; background-color: white">
    <td>Deferred income tax assets, net</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsNet" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,967,480</ix:nonFraction></td>
    <td style="border-bottom: white 2.25pt double">&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsNet" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,941,254</ix:nonFraction></td>
    <td style="border-bottom: white 2.25pt double">&#160;</td></tr>
  </table>
</ix:nonNumeric><p id="xdx_8AF_zunDjj9Fxttg" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Our U.S. federal and state income tax returns remain open to examination
for the tax years 2019 through 2021.</p>

</ix:nonNumeric><p id="xdx_815_zy8crliQ4gjf" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:ConcentrationRiskDisclosureTextBlock"><p id="xdx_807_eus-gaap--ConcentrationRiskDisclosureTextBlock_zp9zL7iFsihl" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>NOTE 7 &#8212; <span id="xdx_823_zAAZm5feetge">MAJOR CUSTOMERS</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">For the years ended December 31, 2022 and December 31, 2021,
approximately <span id="xdx_902_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20221231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerOneMember_zQguANDOkgv8" title="Concentration risk, percentage"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2022-01-012022-12-31_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerOneMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">64</ix:nonFraction></span>%
and <span id="xdx_90C_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20210101__20211231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerOneMember_zmwq5IkLWFw9"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2021-01-012021-12-31_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerOneMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">64</ix:nonFraction></span>%,
respectively, of the Company&#8217;s net product revenues were derived from three major customers that are distributors. &#160;As of
December 31, 2022 and December 31, 2021, accounts receivable due from the three major customers was $2.2 million and $2.1 million,
respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The largest customer in both years is a domestic medical products and supplies
distributor. &#160;Although, a number of larger infusion customers have elected to consolidate their purchases through one or more distributors
in recent years, we continue to maintain strong direct relationships with them. &#160;We do not believe that their continued purchase
of FREEDOM System products and related supplies is contingent upon the distributor.</p>

</ix:nonNumeric><p id="xdx_817_zypHgOJhMug1" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock"><p id="xdx_80A_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_zwUo59jiRuq5" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>NOTE 8 &#8212; <span id="xdx_827_zDSZ7RSQs8rb">COMMITMENTS AND CONTINGENCIES</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>LEGAL PROCEEDINGS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The Company has been and may again become involved in legal proceedings,
claims and litigation arising in the ordinary course of business. &#160;KORU Medical is not presently a party to any litigation or other
legal proceeding that is believed to be material to its financial condition.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>OTHER</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">On November 11, 2020, the Company entered into a Manufacturing and Supply
Agreement with Command Medical Products, Inc. (&#8220;Command&#8221;), pursuant to which Command has agreed to manufacture and supply
the Company&#8217;s subassemblies, needle sets and tubing products pursuant to the Company&#8217;s specifications and purchase orders.
&#160;The first binding purchase order pursuant to the Manufacturing and Supply Agreement was made on November 17, 2020 (the &#8220;Effective
Date&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The Manufacturing and Supply Agreement provides for a term of five years
from the Effective Date. &#160;Either party may terminate the Manufacturing and Supply Agreement upon a material breach by the other Party
that has not been cured within 90 days, upon the bankruptcy or insolvency of the other Party or as expressly set forth elsewhere in the
Agreement. &#160;If the Company terminates the Manufacturing and Supply Agreement other than for those reasons within the first three
years from the Effective Date, the Company is obligated to pay an early termination fee to Command.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<ix:exclude><div id="xdx_237_za18NSWHa08i">
<p style="font: 10pt TIMES NEW ROMAN, TIMES, SERIF; margin: 0; text-align: center">- 45 -</p>


<hr style="border-width: 0; color: Gray; background-color: Gray; height: 2px; width: 100%" /><p style="break-before: always"></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; color: blue"><i><a href="#index_to_fs">Index to Financial Statements</a></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p></div></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The Manufacturing and Supply Agreement also includes customary provisions
relating to, among other things, delivery, inspection procedures, warranties, quality management, business continuity plans, handling
and transport, intellectual property, confidentiality and indemnification.</p>

</ix:nonNumeric><p id="xdx_817_zMPTpmWRA10c" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock"><p id="xdx_803_eus-gaap--PensionAndOtherPostretirementBenefitsDisclosureTextBlock_z9c2bq4t4VWh" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>NOTE 9 &#8212;<span id="xdx_82E_z9PnJ8HC491j"> EMPLOYEE BENEFITS</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">We provide a safe harbor 401(k) plan for our employees that allows for
employee elective contributions, Company matching contributions and discretionary profit-sharing contributions. &#160;Employee elective
contributions are funded through voluntary payroll deductions. &#160;<span id="xdx_90D_ecustom--DescriptionOfMatchingContribution_c20220101__20221231_ziktIA9RrVP2" title="Description of matching contribution"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="krmd:DescriptionOfMatchingContribution">The Company makes safe harbor matching contributions in an amount
equal to 100% of the employee&#8217;s contribution, not to exceed 3% of employee&#8217;s compensation plus 50% of employee&#8217;s pay
contributed between 3% and 5% of employee&#8217;s compensation</ix:nonNumeric></span>. &#160;Company matching expense for the years ended December 31, 2022 and
December 31, 2021 was $<span id="xdx_904_eus-gaap--DefinedContributionPlanEmployerDiscretionaryContributionAmount_c20220101__20221231_zx16SqhdblOc" title="Matching expense"><ix:nonFraction name="us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">214,931</ix:nonFraction></span> and $<span id="xdx_901_eus-gaap--DefinedContributionPlanEmployerDiscretionaryContributionAmount_c20210101__20211231_zV7fv98IDyha" title="Matching expense"><ix:nonFraction name="us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">166,014</ix:nonFraction></span>, respectively. &#160;The Company has not provided for a discretionary profit-sharing contribution.</p>

</ix:nonNumeric><p id="xdx_81E_zsaMBzb5OyJc" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:DebtDisclosureTextBlock"><p id="xdx_80C_eus-gaap--DebtDisclosureTextBlock_zWXV1QzCJny8" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>NOTE 10 &#8212; <span id="xdx_827_zNtvDGCyZBni">DEBT OBLIGATIONS</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">On June 29, 2022, the Company entered into a Loan Modification Extension
Agreement (the &#8220;Modification Agreement&#8221;) with Keybank National Association (&#8220;Lender&#8221;) to modify its revolving
line of credit with Lender in the amount of $3,500,000 (the &#8220;Loan&#8221;) that was originally made available on April 14, 2020 and
renewed on June 24, 2021. Among other things, the Modification Agreement: (i) extends the maturity date of the Loan from June 1, 2022
to June 1, 2023; (ii) changes the interest rate applicable to the Loan from Prime &#8211; 1.50% to Prime + 0%; (iii) releases the Company
from its obligations under a certain security agreement dated June 24, 2021 pursuant to which the Company had previously granted the Lender
a first priority security interest in all equipment, inventory, accounts, instruments, chattel paper and general intangibles of the Company
(the &#8220;Security Agreement&#8221;); and (iv) replaces the Security Agreement with a new pledge security agreement dated June 29, 2022
by and between the Company and Lender (the &#8220;Pledge Agreement&#8221;), which Pledge Agreement grants Lender a first priority security
interest in certain of the Company&#8217;s bank accounts as collateral security for the Loan. The Company had zero outstanding against
the line of credit as of December 31, 2022.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">On August 5, 2022, the Company entered into a commercial insurance premium
finance and security agreement with AON Premium Finance, LLC in the aggregate principal amount of $<span id="xdx_909_eus-gaap--NotesPayable_iI_dm_c20220805__dei--LegalEntityAxis__custom--AONPremiumFinanceLLCMember__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember_z0Knt7TLj9Wd" title="Notes payable"><ix:nonFraction name="us-gaap:NotesPayable" contextRef="AsOf2022-08-05_custom_AONPremiumFinanceLLCMember_custom_PromissoryNoteMember" format="ixt:numdotdecimal" decimals="0" scale="6" unitRef="USD">0.8</ix:nonFraction> million</span> bearing an annual percentage
rate of <span id="xdx_903_ecustom--NotePayableTerms_pid_dp_uPure_c20220803__20220805__dei--LegalEntityAxis__custom--AONPremiumFinanceLLCMember__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember__us-gaap--CreditFacilityAxis__us-gaap--LineOfCreditMember_zjnelyJAHTq6" title="Note payable terms"><ix:nonFraction name="krmd:NotePayableTerms" contextRef="From2022-08-032022-08-05_custom_AONPremiumFinanceLLCMember_custom_PromissoryNoteMember_us-gaap_LineOfCreditMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">6.5</ix:nonFraction></span>%, to finance its insurance premiums. Monthly payments are due on the first of each month beginning August 1, 2022 through
June 1, 2023.</p>

</ix:nonNumeric><p id="xdx_81C_zoChHJriYjIg" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>


<p style="font: 10pt TIMES NEW ROMAN, TIMES, SERIF; margin: 0; text-align: center">- 46 -</p>


<hr style="border-width: 0; color: Gray; background-color: Gray; height: 2px; width: 100%" /><p style="break-before: always"></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; color: blue"><i><a href="#toc">Table of Contents</a></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="a_012"></span>&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>ITEM 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING
AND FINANCIAL DISCLOSURE</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">None.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="a_013"></span>&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>ITEM 9A. CONTROLS AND PROCEDURES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">EVALUATION OF DISCLOSURE CONTROLS AND PROCEDURES</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">An evaluation was performed under the supervision and with the participation
of our management, including our principal executive officer or CEO, and principal financial officer or CFO, of the effectiveness of our
disclosure controls and procedures (as defined in Rule 13a-15(e) under the Securities Exchange Act of 1934, as amended (the &#8220;Exchange
Act&#8221;)) as of December 31, 2022. &#160;Based on that evaluation, our management, including our CEO and CFO, concluded that as of
December 31, 2022, our disclosure controls and procedures are effective to ensure that information required to be disclosed by us in reports
that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the
SEC&#8217;s rules and forms, and is accumulated and communicated to our management, including our CEO and CFO, to allow timely decisions
regarding required disclosure.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">MANAGEMENT&#8217;S REPORT ON INTERNAL CONTROL OVER FINANCIAL REPORTING</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Management of the Company is responsible for establishing and maintaining
adequate internal control over financial reporting. &#160;The Company&#8217;s internal control over financial reporting is a process designed
under the supervision of the Company&#8217;s principal executive officer and principal financial officer, and implemented in conjunction
with management and other personnel, to provide reasonable assurance regarding the reliability of financial reporting and the preparation
of the Company&#8217;s financial statements for external purposes in accordance with generally accepted accounting principles.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">There are inherent limitations in the effectiveness of any internal control,
including the possibility of human error and the circumvention or overriding of controls. &#160;Accordingly, even effective internal control
can provide only reasonable assurance with respect to financial statement preparation. Further, because of changes in conditions, the
effectiveness of internal control may vary over time.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Management assessed the effectiveness of the Company&#8217;s internal control
over financial reporting as of December 31, 2022. &#160;This assessment was based on criteria for effective internal control over financial
reporting described in &#8220;Internal Control - Integrated Framework,&#8221; issued by the Committee of Sponsoring Organizations of the
Treadway Commission (COSO). &#160;Based on this assessment, management determined that, as of December 31, 2022, the Company maintained
effective internal control over financial reporting.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">CHANGES IN INTERNAL CONTROL OVER FINANCIAL REPORTING</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">There has been no change in our internal control over financial reporting
(as defined in Rule 13a-15(f) under the Exchange Act) during the year ended December 31, 2022, that has materially affected, or that is
reasonably likely to materially affect, our internal control over financial reporting.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="a_014"></span>&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>ITEM 9B. OTHER INFORMATION</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">None.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span id="a_015"></span>&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>ITEM 9C. DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Not applicable.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>


<p style="font: 10pt TIMES NEW ROMAN, TIMES, SERIF; margin: 0; text-align: center">- 47 -</p>


<hr style="border-width: 0; color: Gray; background-color: Gray; height: 2px; width: 100%" /><p style="break-before: always"></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; color: blue"><i><a href="#toc">Table of Contents</a></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>PART III</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="a_016"></span>&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>ITEM 10. DIRECTORS, EXECUTIVE OFFICERS, AND CORPORATE GOVERNANCE</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Information regarding our executive officers required by Item 10 of Part
III is set forth in Item 1 of Part I &#8220;Business &#8212; Executive Officers.&#8221; &#160;Information required by Item 10 of Part
III regarding our directors and any material changes to the process by which security holders may recommend nominees to the Board of Directors
is included in our Proxy Statement relating to our 2023 Annual Meeting of Shareholders, and is incorporated herein by reference. &#160;Information
relating to our Code of Ethics and to compliance with Section 16(a) of the 1934 Act is set forth in our Proxy Statement relating to our
2023 Annual Meeting of Shareholders and is incorporated herein by reference. &#160;We intend to disclose amendments to our Code of Ethics,
as well as waivers of the provisions thereof, on our website under the heading &#8220;Investors - Governance&#8221; at www.korumedical.com.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="a_017"></span>&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>ITEM 11. EXECUTIVE COMPENSATION</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Information required by Item 11 of Part III is included in our Proxy Statement
relating to our 2023 Annual Meeting of Shareholders and is incorporated herein by reference.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="a_018"></span>&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>ITEM 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT
AND RELATED STOCKHOLDER MATTERS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Information required by Item 12 of Part III is included in our Proxy Statement
relating to our 2023 Annual Meeting of Shareholders and is incorporated herein by reference.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="a_019"></span>&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>ITEM 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR
INDEPENDENCE</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Information required by Item 13 of Part III is included in our Proxy Statement
relating to our 2023 Annual Meeting of Shareholders and is incorporated herein by reference.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="a_020"></span>&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>ITEM 14. PRINCIPAL ACCOUNTANT FEES AND SERVICES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Information required by Item 14 of Part III is included in our Proxy Statement
relating to our 2023 Annual Meeting of Shareholders and is incorporated herein by reference.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>PART IV</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="a_021"></span>&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>ITEM 15. EXHIBITS AND FINANCIAL STATEMENT SCHEDULES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">All financial statement schedules have been omitted because they are not
required, not applicable, not present in amounts sufficient to require submission of the schedule, or the required information is otherwise
included.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>


<p style="font: 10pt TIMES NEW ROMAN, TIMES, SERIF; margin: 0; text-align: center">- 48 -</p>


<hr style="border-width: 0; color: Gray; background-color: Gray; height: 2px; width: 100%" /><p style="break-before: always"></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; color: blue"><i><a href="#toc">Table of Contents</a></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The following exhibits are filed herewith or incorporated by reference
as part of this Annual Report.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 7.5in">
  <tr style="vertical-align: top; background-color: white">
    <td style="border-bottom: black 1pt solid; width: 0.8in"><b>Exhibit&#160;No.</b></td>
    <td style="width: 0.2in">&#160;</td>
    <td style="border-bottom: black 1pt solid; width: 6.5in"><b>Description</b></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #E6E6E6">
    <td>3.1(i)</td>
    <td>&#160;</td>
    <td><a href="http://www.sec.gov/Archives/edgar/data/704440/000116169719000090/ex_3-i.htm">Restated Certificate of Incorporation effective March 1, 2019</a> (incorporated by reference to our Form 10-K filed with the SEC on March 5, 2019).</td></tr>
  <tr style="vertical-align: top; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #E6E6E6">
    <td>3.1(ii)</td>
    <td>&#160;</td>
    <td><a href="http://www.sec.gov/Archives/edgar/data/704440/000116169718000565/ex_3iii.htm">Amended and Restated By-Laws dated December 5, 2018</a> (incorporated by reference to our Form 8-K filed with the SEC on December 7, 2018).</td></tr>
  <tr style="vertical-align: top; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #E6E6E6">
    <td>4.1</td>
    <td>&#160;</td>
    <td><a href="http://www.sec.gov/Archives/edgar/data/704440/000116169721000169/ex_4-1.htm">Description of Securities</a> (incorporated by reference to the Company&#8217;s Form 10-K filed with the SEC on March 23, 2021).</td></tr>
  <tr style="vertical-align: top; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #E6E6E6">
    <td>10.1</td>
    <td>&#160;</td>
    <td><a href="http://www.sec.gov/Archives/edgar/data/704440/000116169722000133/ex_10-3.htm">Lease Extension Agreement dated February 16, 2022</a> (incorporated by reference to the Company&#8217;s Form 10-K filed with the SEC on March 2, 2022).</td></tr>
  <tr style="vertical-align: top; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #E6E6E6">
    <td>10.2</td>
    <td>&#160;</td>
    <td><a href="http://www.sec.gov/Archives/edgar/data/704440/000116169716001008/schedule_14a.htm">2015 Stock Option Plan, as amended</a> (incorporated by reference to the Company&#8217;s Proxy Statement on Schedule 14A filed with the SEC on July 28, 2016).</td></tr>
  <tr style="vertical-align: top; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #E6E6E6">
    <td>10.3</td>
    <td>&#160;</td>
    <td><a href="http://www.sec.gov/Archives/edgar/data/704440/000116169721000196/schedule_14a.htm#Koru2021OmnibusEquityIncentivePlan">2021 Omnibus Equity Incentive Plan</a> (incorporated by reference to the Company&#8217;s Proxy Statement on Schedule 14A filed with the SEC on April 5, 2021).</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #E6E6E6">
    <td>10.4</td>
    <td>&#160;</td>
    <td><a href="http://www.sec.gov/Archives/edgar/data/704440/000116169721000169/ex_10-5.htm">Form of Non-Qualified Stock Option</a> (incorporated by reference to the Company&#8217;s Form 10-K filed with the SEC on March 23, 2021).</td></tr>
  <tr style="vertical-align: top; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #E6E6E6">
    <td>10.5</td>
    <td>&#160;</td>
    <td><a href="http://www.sec.gov/Archives/edgar/data/704440/000116169721000169/ex_10-6.htm">Form of Incentive Stock Option</a> (incorporated by reference to the Company&#8217;s Form 10-K filed with the SEC on March 23, 2021).</td></tr>
  <tr style="vertical-align: top; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #E6E6E6">
    <td>10.6</td>
    <td>&#160;</td>
    <td><a href="http://www.sec.gov/Archives/edgar/data/704440/000116169722000140/schedule_14a.htm#a_021">Non-Employee Director Compensation Plan</a> (incorporated by reference to the Company&#8217;s Proxy Statement on Schedule 14A filed with the SEC on March 18, 2022).</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #E6E6E6">
    <td>10.7</td>
    <td>&#160;</td>
    <td><a href="http://www.sec.gov/Archives/edgar/data/704440/000116169720000481/ex_10-1.htm">Manufacturing and Supply Agreement dated as of November 11, 2020 between KORU Medical Systems, Inc. and Command Medical Products</a> (incorporated by reference to the Company&#8217;s Form 10-Q filed with the SEC on November 12, 2020). &#160;Certain information has been excluded from this exhibit because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</td></tr>
  <tr style="vertical-align: top; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #E6E6E6">
    <td>10.8</td>
    <td>&#160;</td>
    <td><a href="http://www.sec.gov/Archives/edgar/data/704440/000116169720000170/ex_10-1.htm">Promissory Note in the aggregate principal amount of $3.5 million dated April 14, 2020 issued by the Company to KeyBank National Association</a> (incorporated by reference to the Company&#8217;s Form 8-K filed with the SEC on April 30, 2020).</td></tr>
  <tr style="vertical-align: top; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #E6E6E6">
    <td>10.9</td>
    <td>&#160;</td>
    <td><a href="http://www.sec.gov/Archives/edgar/data/704440/000116169720000170/ex_10-2.htm">Commercial Security Agreement dated April 14, 2020 between the Company and KeyBank National Association</a> (incorporated by reference to the Company&#8217;s Form 8-K filed with the SEC on April 30, 2020).</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #E6E6E6">
    <td>10.10</td>
    <td>&#160;</td>
    <td><a href="http://www.sec.gov/Archives/edgar/data/704440/000116169720000170/ex_10-3.htm">Loan Agreement dated April 20, 2020 between the Company and KeyBank National Association</a> (incorporated by reference to the Company&#8217;s Form 8-K filed with the SEC on April 30, 2020).</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #E6E6E6">
    <td>10.11</td>
    <td>&#160;</td>
    <td><a href="http://www.sec.gov/Archives/edgar/data/704440/000116169722000345/ex_10-1.htm">Loan Modification Extension and Addendum Agreement dated June 29, 2022 between the Company and KeyBank National Association</a> (incorporated by reference to the Company&#8217;s Form 8-K filed with the SEC on July 6, 2022).</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #E6E6E6">
    <td>10.12</td>
    <td>&#160;</td>
    <td><a href="http://www.sec.gov/Archives/edgar/data/704440/000116169720000170/ex_10-4.htm">Progress Payment Loan and Security Agreement dated as of April 20, 2020 between the Company and Key Equipment Finance, a Division of KeyBank National Association</a> (incorporated by reference to the Company&#8217;s Form 8-K filed with the SEC on April 30, 2020).</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #E7E6E6">
    <td>10.13</td>
    <td>&#160;</td>
    <td><a href="http://www.sec.gov/Archives/edgar/data/704440/000116169722000345/ex_10-2.htm">Pledge Agreement dated as of June 29, 2022 between the Company and KeyBank National Association</a> (incorporated by reference to the Company&#8217;s Form 8-K filed with the SEC on July 6, 2022).</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><i>continued</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>


<p style="font: 10pt TIMES NEW ROMAN, TIMES, SERIF; margin: 0; text-align: center">- 49 -</p>


<hr style="border-width: 0; color: Gray; background-color: Gray; height: 2px; width: 100%" /><p style="break-before: always"></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; color: blue"><i><a href="#toc">Table of Contents</a></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 7.5in">
  <tr style="vertical-align: top; background-color: white">
    <td style="border-bottom: black 1pt solid; width: 0.8in"><b>Exhibit&#160;No.</b></td>
    <td style="width: 0.2in">&#160;</td>
    <td style="border-bottom: black 1pt solid; width: 6.5in"><b>Description</b></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #E7E6E6">
    <td>10.14</td>
    <td>&#160;</td>
    <td><a href="http://www.sec.gov/Archives/edgar/data/704440/000116169721000169/ex_10-15.htm">Employment Agreement effective as of March 15, 2021 between KORU Medical Systems, Inc. and Linda Tharby</a> (incorporated by reference to the Company&#8217;s Form 10-K filed with the SEC on March 23, 2021).* &#8224;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #E7E6E6">
    <td>10.15</td>
    <td>&#160;</td>
    <td><a href="ex_10-15.htm">Employment Agreement effective as of March 18, 2022 between KORU Medical Systems, Inc. and Brian Case</a> (filed herewith).*</td></tr>
  <tr style="vertical-align: top; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #E7E6E6">
    <td>10.16</td>
    <td>&#160;</td>
    <td><a href="http://www.sec.gov/Archives/edgar/data/704440/000116169722000377/ex_10-1.htm">Employment Agreement effective as of October 20, 2021 between KORU Medical Systems, Inc. and Thomas Adams</a> (incorporated by reference to the Company&#8217;s Form 10-Q filed with the SEC on August 3, 2022).</td></tr>
  <tr style="vertical-align: top; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #E7E6E6">
    <td>10.17</td>
    <td>&#160;</td>
    <td><a href="http://www.sec.gov/Archives/edgar/data/704440/000116169722000133/ex_10-16.htm">Lease dated as of January 21, 2022 between the Company and Breit Industrial Canyon NJ1W05 LLC</a> (incorporated by reference to the Company&#8217;s Form 10-K filed with the SEC on March 2, 2022).</td></tr>
  <tr style="vertical-align: top; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #E7E6E6">
    <td>23.1</td>
    <td>&#160;</td>
    <td><a href="ex_23-1.htm">Consent of Independent Auditors</a> (filed herewith).</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #E7E6E6">
    <td>31.1</td>
    <td>&#160;</td>
    <td><a href="ex_31-1.htm">Certification of the Principal Executive Officer of registrant required under Section 302 of the Sarbanes-Oxley Act of 2002</a> (filed herewith).</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #E7E6E6">
    <td>31.2</td>
    <td>&#160;</td>
    <td><a href="ex_31-2.htm">Certification of the Principal Financial Officer of registrant required under Section 302 of the Sarbanes-Oxley Act of 2002</a> (filed herewith).</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #E7E6E6">
    <td>32.1</td>
    <td>&#160;</td>
    <td><a href="ex_32-1.htm">Certification of the Principal Executive Officer of registrant required under Section 906 of the Sarbanes-Oxley Act of 2002</a> (filed herewith).</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #E7E6E6">
    <td>32.2</td>
    <td>&#160;</td>
    <td><a href="ex_32-2.htm">Certification of the Principal Financial Officer of registrant required under Section 906 of the Sarbanes-Oxley Act of 2002</a> (filed herewith).</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #E7E6E6">
    <td>101.INS</td>
    <td>&#160;</td>
    <td>Inline XBRL Instance Document - the XBRL Instance Document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #E7E6E6">
    <td>101.SCH</td>
    <td>&#160;</td>
    <td>Inline XBRL Taxonomy Extension Schema Document.</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #E7E6E6">
    <td>101.CAL</td>
    <td>&#160;</td>
    <td>Inline XBRL Taxonomy Extension Calculation Linkbase Document.</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #E7E6E6">
    <td>101.DEF</td>
    <td>&#160;</td>
    <td>Inline XBRL Taxonomy Definition Linkbase Document.</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #E7E6E6">
    <td>101.LAB</td>
    <td>&#160;</td>
    <td>Inline XBRL Taxonomy Extension Label Linkbase Document.</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #E7E6E6">
    <td>101.PRE</td>
    <td>&#160;</td>
    <td>Inline XBRL Taxonomy Extension Presentation Linkbase Document.</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #E7E6E6">
    <td>104</td>
    <td>&#160;</td>
    <td>Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">__________</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 7.5in; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.2in">+</td>
    <td style="width: 7.3in">Certain schedules, appendices and/or exhibits to this agreement have been omitted in accordance with Item 601 of Regulation S-K. A copy of any omitted schedule and/or exhibit will be furnished supplementally to the Securities and Exchange Commission staff upon request.</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>*</td>
    <td>Denotes management compensatory agreement or arrangement.</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#8224;</td>
    <td>Certain information has been omitted from this exhibit because it is not material and would be competitively harmful if publicly disclosed.</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="a_022"></span>&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>ITEM 16. FORM 10-K SUMMARY</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">None.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>


<p style="font: 10pt TIMES NEW ROMAN, TIMES, SERIF; margin: 0; text-align: center">- 50 -</p>


<hr style="border-width: 0; color: Gray; background-color: Gray; height: 2px; width: 100%" /><p style="break-before: always"></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; color: blue"><i><a href="#toc">Table of Contents</a></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="a_023"></span>&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>SIGNATURES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange
Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized on March
8, 2023.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">KORU MEDICAL SYSTEMS, INC.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="text-decoration: underline">/s/ Linda Tharby</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Linda Tharby, President and Chief Executive Officer</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="text-decoration: underline">/s/ Thomas Adams</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Tom Adams, Interim- Chief Financial Officer and Treasurer</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Pursuant to the requirements of the Securities Exchange Act of 1934, this
report has been signed below by the following persons on behalf of the Registrant and in the capacities indicated on March 8, 2023.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="text-decoration: underline">/s/ R. John Fletcher</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">R. John Fletcher, Chairman of the Board</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="text-decoration: underline">/s/ James M. Beck</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">James M. Beck, Director</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="text-decoration: underline">/s/ Robert A. Casella</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Robert A. Casella, Director</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="text-decoration: underline">/s/ Joseph M. Manko, Jr.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Joseph M. Manko, Jr., Director</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="text-decoration: underline">/s/ Shahriar Matin</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Shahriar Matin, Director</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="text-decoration: underline">/s/ Donna French</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Donna French, Director</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="text-decoration: underline">/s/ Linda Tharby</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Linda Tharby, Director</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt TIMES NEW ROMAN, TIMES, SERIF; margin: 0; text-align: center">- 51 -</p>

<hr style="border-width: 0; color: Gray; background-color: Gray; height: 2px; width: 100%" />
</div>
</body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10
<SEQUENCE>2
<FILENAME>ex_10-15.htm
<DESCRIPTION>EMPLOYMENT AGREEMENT MARCH 18, 2022 - BRIAN CASE
<TEXT>
<HTML>
<HEAD>
<TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<DIV STYLE="width: 6.5in">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Exhibit 10.15</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>EMPLOYMENT AGREEMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">THIS EMPLOYMENT AGREEMENT (this
&ldquo;<U>Agreement</U>&rdquo;) effective as of March 18, 2022, is made by and between Repro Med Systems, Inc. d/b/a KORU Medical Systems,
a New York corporation, having its principal place of business at 24 Carpenter Road, Chester, NY 10918 (the &ldquo;<U>Company</U>&rdquo;),
and Brian Case<U>,</U> an individual having a domicile at [address] (&ldquo;<U>Employee</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">WHEREAS, the Company desires to
employ Employee, and Employee desires to be employed by the Company, upon terms and conditions set forth herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">NOW, THEREFORE, in consideration
of the mutual promises set forth herein, and for other good and valuable consideration, the receipt and sufficiency of which is hereby
acknowledged, intending to be legally bound hereby, the parties hereto agree as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Employment.</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Position.</U>
The Company hereby employs Employee as Chief Technology Officer of the Company. Employee shall report directly to the President/Chief
Employee Officer of the Company (the &ldquo;CEO&rdquo;) and shall have the duties, authority and responsibilities customarily held by
a person holding the position Chief Technology Officer in companies engaged in business similar to the Company&rsquo;s business and of
similar size to the Company. Employee shall render such other services as may be reasonably assigned to them from time to time by the
CEO. Employee shall be a full-time, exempt employee. Employee&rsquo;s employment under this Agreement is expected to commence on April
18, 2022.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Duties.</U>
Employee hereby agrees to be employed as Chief Technology Officer. Employee agrees that he shall: (i) faithfully and to the best of their
ability perform all of the duties that may be required of their pursuant to the terms of this Agreement; (ii) devote substantially all
of their business time and attention to the performance of Employee&rsquo;s duties hereunder ; and (iii) not engage in any other business,
profession or occupation for compensation or otherwise which would conflict or interfere with the performance of such services either
directly or indirectly without the prior written consent of the CEO.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Place
of Performance.</U> The principal place of Employee&rsquo;s employment shall be at Employee&rsquo;s domicile, provided that Employee shall
spend, on average, three weeks each calendar month, for the first year, at the Company&rsquo;s principal place of business and/or other
sites for customer meetings, conferences or other activities requisite to perform his duties. Employee will be required to travel routinely
on Company business. The Company shall reimburse the Employee for all reasonable, necessary, and documented travel expenses incurred by
Employee in performing duties set forth in Section 1(c).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>At-Will
Employment</U>. The Company and Employee agree that Employee&rsquo;s employment with the Company is &ldquo;at-will,&rdquo; meaning that
Employee may terminate their employment at any time for any reason or no reason, and that Company may terminate Employee&rsquo;s employment
at any time for any reason or no reason, subject to the terms, conditions, and obligations set forth in Section 4 of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Compensation
and Related Matters.</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Base
Salary.</U> The Company shall pay to Employee an annual base salary of $350,000 (the &ldquo;Base Salary&rdquo;), less such deductions
as are required by law or that Employee may elect in accordance with Company policy and procedure, payable in equal periodic installments
in accordance with the Company&rsquo;s customary payroll practices, but no less frequently than monthly. The Base Salary shall be prorated
for any partial year of employment on the basis of a 365-day year. The Base Salary shall be reviewed at least annually by the Company&rsquo;s
Board of Directors (the &ldquo;Board&rdquo;) and may increase (but not decrease) at the Board&rsquo;s sole and absolute discretion.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Annual
Bonus.</U> For each complete calendar year, Employee shall be eligible to earn an annual bonus (the &ldquo;<U>Annual Bonus</U>&rdquo;)
of up to 45% of the Base Salary in accordance with Company policy and procedure for granting of a management specified employee bonus,
based on achievement of Company and individual performance targets that will be set by the Company as part of the annual budget process
and within the Company&rsquo;s</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>


<HR ALIGN="CENTER" NOSHADE SIZE="2" STYLE="WIDTH: 100%"><P STYLE="BREAK-BEFORE: ALWAYS"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">sole discretion. The determination as to whether applicable
targets have been achieved, and whether and to what extent any Annual Bonus is to be paid with respect to such targets, shall be made
in the sole and absolute discretion of the Company. Any Annual Bonus so determined shall be paid in the month of March following the applicable
bonus year, no later than March 31, less such deductions as are required by law or that Employee may elect in accordance with Company
policy and procedure. Employee must be fully and actively employed as of the payment date and must not have provided notice of termination
for any reason prior to the payment date to be entitled to the Annual Bonus. The Annual Bonus shall be reviewed at least annually by the
Company&rsquo;s Board of Directors (the &ldquo;Board&rdquo;) and may increase (but not decrease) at the Board&rsquo;s sole and absolute
discretion.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Stock
Options.</U> Subject to the approval and sole discretion of the Board, Employee shall be granted a non-qualified option (the &ldquo;Option&rdquo;)
to acquire 475,000 shares of common stock (the &ldquo;Shares&rdquo;), which shall be subject to the terms of the Company&rsquo;s 2015
Stock Option Plan or 2021 Omnibus Equity Compensation Plan, as each may be amended from time to time, and any associated equity and/or
grant agreement required to be entered into by Employee and the Company. The Shares will be subject to a four (4) year vesting schedule.
Twenty-five percent of the Shares shall vest on the one (1) year anniversary of the date of grant (the &ldquo;Vesting Commencement Date&rdquo;),
and the remaining Shares shall vest as follows: 25% of the Shares at the end of each successive twelve (12) month period following the
Vesting Commencement Date, provided that the Employee is still employed by the Company pursuant to this Agreement on each respective Vesting
Date. The exercise price of the Shares shall be determined on May 2, 2022.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">(i) Upon a Change of Control Termination,
the Shares underlying the Option shall automatically vest in full.&nbsp; &ldquo;<B><I>Change of Control Termination</I></B>&rdquo; as
used herein means Employee&rsquo;s employment being terminated by the Company (or its successor) without Cause or by the Employee for
Good Reason (as defined below) within three (3) months before or twelve (12) months after any of the following occur: (A) the acquisition
by any person or group, other than the Company, of 50% or more of the voting stock of the Company; (B) within any two year period the
individuals who constituted the Board at the beginning of the period shall cease for any reason to constitute a majority of the Board,
provided that the election of each subsequent member who was approved in advance by two-thirds of the members of the Board in office at
the beginning of such two year period or whose election or nomination for election was previously so approved, shall be considered as
though such individual was a member of the Board at the beginning of the period; (C) the consummation of a merger, consolidation or reorganization,
the result of which is that the shareholders of the Company immediately prior to the merger, consolidation or reorganization do not own
and control immediately after the merger, consolidation or reorganization at least 50% of the value of the outstanding equity and combined
voting power of the then outstanding voting securities of the Company entitled to vote generally in the election of directors of the Board;
or (D) a sale, exclusive license or other disposition (in one transaction or a series of related transactions) of all or substantially
all of the Company&rsquo;s assets.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Business
Expenses.</U> Employee shall receive reimbursement from the Company for all reasonable and documented out-of-pocket expenses incurred
by Employee in performing services hereunder; provided that, in each case, that such expenses are accounted for in accordance with the
standard policies and procedures established by the Company for reimbursement of expenses.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Paid
Vacation; Sick Time; Personal Days; and Holidays.</U> Employee shall be entitled to four (4) weeks of paid vacation time off per calendar
year (pro-rated according to the Company&rsquo;s standard policies and procedures related to accrual of paid vacation time off), to be
taken at such times and for such periods as shall not interfere with the duties required to be rendered by Employee hereunder. Employee
shall also accrue a total of seven (7) paid sick days and two (2) paid personal days per calendar year in accordance with current Company
policy, which may be revised from time. In addition to the foregoing, Employee shall be entitled to paid holidays in accordance with the
Company&rsquo;s policies and procedures. Employee shall not be paid for accrued but unused vacation paid time off, paid sick time, or
paid personal days upon termination of Employee&rsquo;s employment for any reason, unless otherwise required by law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(f)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Other
Benefits</U>. Employee shall be entitled to participate in such life insurance, medical, dental disability, pension and retirement plans
and other programs as may be approved from time to time by the Company</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>


<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">- 2 -</P>


<HR ALIGN="CENTER" NOSHADE SIZE="2" STYLE="WIDTH: 100%"><P STYLE="BREAK-BEFORE: ALWAYS"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">for the benefit of its employees, except any such
plan or program with respect to which Employee voluntarily executes a legally effective waiver. Nothing herein shall affect the Company&rsquo;s
right to amend, modify or terminate any retirement or other benefit plan at any time for any reason.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Termination
of Employment.</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Termination
by Company</U>. The Company may terminate Employee&rsquo;s employment with the Company at any time effective immediately: (i) without
Cause (as defined below); or (ii) with Cause (as defined below). For purposes of this Agreement, &ldquo;<U>Cause</U>&rdquo; shall mean
Employee&rsquo;s: (A) gross negligence or willful misconduct with respect to the Company, including, without limitation, engagement in
dishonesty with respect to the Company&rsquo;s business, or conduct that is injurious to the Company, its business or its reputation;
(B) embezzlement, theft or fraud; (C) conviction of or plea of guilty or no contest to any felony, or any lesser crime of dishonesty;
(D) personal conduct in furtherance of a hostile work environment or personal engagement in discrimination in violation of any state or
federal anti-harassment or discrimination statute; (E) breach of any material obligation under this Agreement or any other written agreement
between Employee and the Company; (F) Employee&rsquo;s failure to perform Employee&rsquo;s duties (other than any such failure resulting
from incapacity due to physical or mental illness); or (G) violation of the Company&rsquo;s written policies, including but not limited
to its Code of Ethics and/or Code of Conduct.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Termination
by Employee.</U> Employee may terminate their employment with the Company by giving Company not less than sixty (60) days&rsquo; prior
written notice, provided that the Company may waive all or any part of the sixty (60) day notice period for no consideration by giving
written notice to the Employee and, for all purposes of this Agreement, the Employee&rsquo;s effective date of termination shall be the
date determined by the Company in such notice.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">(i) <U>For Good Reason By Employee</U>.
Employee may terminate their employment under this Agreement for Good Reason. &ldquo;Good Reason&rdquo; shall mean, in each case to the
extent not consented by Employee: (i) a breach by the Company of any material provision of this Agreement or any other written agreement
between Employee and the Company; (ii) material reduction of the Employee&rsquo;s authority, duties, or responsibilities; (iii) a reduction
of the Employee&rsquo;s then-current Base Salary or Annual Bonus Target; (iv) the Company&rsquo;s failure to obtain an agreement from
any successor to the Company to assume and agree to perform this Agreement in the same manner and to the same extent that the Company
would be required to perform if no succession had taken place, except where such assumption occurs by operation of law; (v) the Company&rsquo;s
Common Stock no longer being publicly traded;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Death.</U>
Employee&rsquo;s employment hereunder shall terminate effective immediately upon their death.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Disability.</U>
The Company may terminate Employee&rsquo;s employment hereunder if: (i) as a result of Employee&rsquo;s incapacity due to physical or
mental illness, Employee shall have been absent from their duties hereunder for a period of 120 consecutive days or a total of 180 days
during any 365-day period and is unable to perform the essential duties of the job with or without a reasonable accommodation; and (ii)
if within ten (10) days after written notice of termination is given by the Company to Employee (which may occur at or after the end of
such period), Employee shall not have returned to the performance of their duties hereunder on a full-time basis. During any period that
Employee fails to perform their duties hereunder as a result of incapacity due to physical or mental illness (the &ldquo;Disability Period&rdquo;),
Employee shall continue to receive their Base Salary as set forth in Section 3(a) of this Agreement until their employment is terminated
pursuant to this Section 4(d), provided that payments so made to Employee during the Disability Period shall be reduced by the sum of
the amounts, if any, payable to Employee under disability benefit plans of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Compensation
upon Termination of Employment.</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Accrued
and Unpaid Compensation</U>. If Employee&rsquo;s employment is terminated for any reason, the Company shall pay Employee their full Base
Salary through the effective date of the termination of Employee&rsquo;s employment (&ldquo;<U>Termination Date</U>&rdquo;), plus all
accrued and unpaid benefits (including all health and welfare benefits in which Employee was a participant in accordance with their terms),
and the Company shall have no further</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>


<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">- 3 -</P>


<HR ALIGN="CENTER" NOSHADE SIZE="2" STYLE="WIDTH: 100%"><P STYLE="BREAK-BEFORE: ALWAYS"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">obligations whatsoever to Employee under this Agreement
except as expressly provided otherwise in this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Severance.</U>
If Employee&rsquo;s employment is terminated either by the Company without Cause (as defined above) (and not for death or Disability),
or by Employee pursuant to Section 4(c) above, then, subject to their execution and non-revocation of a reasonable and customary general
release of claims in favor of the Company and its affiliates, Employee shall be entitled to receive the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">(i) if the Termination Date is less
than twelve (12) months after Employee&rsquo;s commencement of employment with the Company, an amount equal to six (6) months of their
Base Salary in effect as of the Termination Date, paid in accordance with the Company&rsquo;s normal payroll cycle over the six (6) month
period following the Termination Date; or if the Termination Date is twelve (12) months or more after Employee&rsquo;s commencement of
employment with the Company, an amount equal to twelve (12) months of their Base Salary in effect as of the Termination Date, paid in
accordance with the Company&rsquo;s normal payroll cycle over the twelve (12) month period following the Termination Date; provided that
such payments shall automatically cease upon Employee&rsquo;s employment or engagement as a consultant, contractor, or service provider
by any person or entity other than the Company within the applicable payment period; and provided that such amounts shall be paid in accordance
with the Company&rsquo;s customary payroll practices, and less such deductions as are required by law or that Employee may elect in accordance
with Company policy and procedure; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">(ii) for the same six (6) or twelve
(12) month period after the Termination Date, as applicable under Section 5(b)(i) above, and subject to applicable law, the Company will
also pay its share of premiums for Employee&rsquo;s health insurance as currently enrolled on the Termination Date; provided that such
payments shall automatically cease upon Employee&rsquo;s employment or engagement as a consultant, contractor, or service provider by
any person or entity other than the Company within the applicable payment period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Representations
and Warranties of Employee.</U> Employee represents and warrants to the Company that he is free to accept employment hereunder and that
he has no prior or other obligations or commitments of any kind that would in any way hinder or interfere with their acceptance of, or
the full performance of, such employment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">7.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Confidentiality.</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;During
Employee&rsquo;s employment and at all times thereafter, Employee shall keep Confidential Information (as defined below) strictly confidential.
Employee shall not at any time, directly or indirectly, disclose or divulge any Confidential Information, except (i) if required by law,
regulation or legal or regulatory process, but only in accordance with Section 7(b) below, or (ii) to their affiliates and their and their
respective directors, officers, employees, managing members, general partners, agents and consultants (including attorneys, financial
advisors and accountants) (&ldquo;<U>Representatives</U>&rdquo;), as applicable, to the extent necessary to permit such Representatives
to assist Employee in any Permitted Use (as defined below); <U>provided</U> that Employee shall require each such Representative to be
bound by the terms of this Section 7 to the same extent as if they were parties hereto and Employee shall be responsible for any breach
of this Section 7 by any of its Representatives.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
Employee or any of their Representatives is required, in the written opinion of Employee&rsquo;s counsel, to disclose any Confidential
Information, by law, regulation or legal or regulatory process, Employee shall: (i) take all reasonable steps to preserve the privileged
nature and confidentiality of the Confidential Information, including requesting that the Confidential Information not be disclosed to
non-parties or the public; (ii) give the Company prompt prior written notice of such request or requirement so that the Company may seek,
at its sole cost and expense, an appropriate protective order or other remedy; and (iii) cooperate with the Company, at the Company&rsquo;s
sole cost and expense, to obtain such protective order. In the event that such protective order or other remedy is not obtained, Employee
(or such other persons to whom such request is directed) will furnish only that portion of the Confidential Information which, on the
advice of such person&rsquo;s counsel, is legally required to be disclosed and, upon the Company&rsquo;s request, use its reasonable best
efforts to obtain assurances that confidential treatment will be accorded to such information.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>


<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">- 4 -</P>


<HR ALIGN="CENTER" NOSHADE SIZE="2" STYLE="WIDTH: 100%"><P STYLE="BREAK-BEFORE: ALWAYS"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;For
the purposes hereof, &ldquo;<U>Confidential Information</U>&rdquo; shall mean all trade secrets, information, data, documents, agreements,
files and other materials, whether disclosed orally or disclosed or stored in written, electronic or other form or media, which is obtained
from or disclosed by the Company or its Representatives before or after the date hereof regarding the Company or its clients, including,
without limitation, all analyses, compilations, reports, forecasts, studies, samples and other documents which contain or otherwise reflect
or are generated from such information, data, documents, agreements, files or other materials. The term &ldquo;Confidential Information&rdquo;
as used herein does not include information that at the time of disclosure or thereafter is generally available to and known by the public
(other than as a result of its disclosure directly or indirectly by Employee or any of their Representatives in violation of this Agreement).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Employee
shall make no use whatsoever, directly or indirectly, of any Confidential Information, except for: (i) the purposes of performing Employee&rsquo;s
duties and obligations to the Company; (ii) evaluating Employee&rsquo;s ownership interest in the Company; and (iii) use for the benefit
of the Company as part of the solicitation of existing or prospective customers of the Company (the &ldquo;<U>Permitted Uses</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Upon
the termination of. Employee&rsquo;s employment or upon the Company&rsquo;s request at any time and for any reason, Employee shall immediately
deliver to the Company all materials (including all soft and hard copies) in Employee&rsquo;s possession which contain or relate to Confidential
Information, as well as all information necessary to access such confidential information.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(f)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Notwithstanding
the foregoing confidentiality obligations, pursuant to 18 USC &sect; 1833(b), Employee will not be held criminally or civilly liable under
any federal or state trade secret law for disclosing a trade secret if such disclosure is made: (i) in confidence to a federal, state
or local government official, either directly or indirectly, or to an attorney, and solely for the purpose of reporting or investigating
a suspected violation of law; or (ii) in a complaint or other document filed in a lawsuit or other proceeding, if such filing is made
under seal. Additionally, if Employee files a lawsuit claiming retaliation by Company based on the reporting of a suspected violation
of law, Employee may disclose a trade secret to Employee&rsquo;s attorney and use the trade secret information in the court proceeding,
so long as any document containing the trade secret is filed under seal and Employee does not disclose the trade secret except pursuant
to court order.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">8.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Assignment
of Developments.</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;All
inventions, modifications, discoveries, designs, developments, improvements , processes, works of authorship, documentation, formulae,
data, techniques, know-how, secrets or intellectual property rights or any interest therein made by Employee, either alone or in conjunction
with others, at any place or at any time during the Term, whether or not reduced to writing or practice during such period , which result
, in whole or in part, from (i) any services performed directly or indirectly for the Company by Employee or (ii) Employee&rsquo;s use
of the Company&rsquo;s time, equipment, supplies, facilities or information (collectively, the &ldquo;<U>Company Developments</U>&rdquo;)
shall be and hereby is the exclusive property of the Company without any further compensation to Employee. In addition, without limiting
the generality of the foregoing, all Company Developments which are copyrightable work by Employee are intended to be &ldquo;work made
for hire&rdquo; as defined in Section 81 of the Copyright Act of 1976, as amended, and shall be and hereby are the property of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Employee
shall promptly disclose any Company Developments to the Company. If any Company Development is not the property of the Company by operation
of law, this Agreement or otherwise, Employee will, and hereby does, without further consideration, assign to the Company all right, title
and interest in such Company Development and will reasonably assist the Company and its nominees in every way, at the Company&rsquo;s
expense, to secure, maintain and defend the Company&rsquo;s rights in such Company Development. Employee shall sign all instruments necessary
for the filing and prosecution of any applications for, or extension or renewals of, letters patent (or other intellectual property registrations
or filings) of the United States or any foreign country which the Company desires to file. Employee hereby irrevocably designates and
appoints the Company and its duly authorized officers and agents as Employee&rsquo;s agent and attorney-in-fact (which designation and
appointment shall be deemed coupled with an interest and shall survive Employee&rsquo;s death or incapacity), to act for and in Employee&rsquo;s
behalf to execute and file any such applications, extensions or renewals and to do all other lawfully permitted acts to further</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>


<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">- 5 -</P>


<HR ALIGN="CENTER" NOSHADE SIZE="2" STYLE="WIDTH: 100%"><P STYLE="BREAK-BEFORE: ALWAYS"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">the prosecution and issuance of such letters patent
or other intellectual property registrations or filings, or such other similar documents, with the same legal force and effect as if executed
by Employee.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">9.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Non-Competition;
Non-Solicitation; Non-Disparagement.</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;During
Employee&rsquo;s employment and for the Restricted Period (as defined below), Employee shall not engage in any Prohibited Activity anywhere
in the world. For the purposes of this Agreement, (i) &ldquo;<U>Restricted Period</U>&rdquo; shall mean the later of (A) the period during
which Employee is entitled to receive any payment pursuant to Section 5(b) of this Agreement, or (B) twelve (12) months following termination
of this Agreement; and (ii) <U>&ldquo;Prohibited Activity</U>&rdquo; shall mean the design, development, marketing, sale, re-sale, manufacture
or distribution of home infusion products, or other similar activities, or the engagement in any other business in which the Company is
actively engaged immediately prior to the commencement of the Restricted Period, in each case on Employee&rsquo;s behalf or on behalf
of another (including as a shareholder, member, employee, employer, owner, operator, manager, advisor, consultant, agent, partner, joint
venturer or investor of another person or entity). Prohibited Activity also includes activity that may require or inevitably require disclosure
of trade secrets, proprietary information or other Confidential Information of the Company except as otherwise permitted hereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;During
the Restricted Period, Employee shall not, directly or indirectly: (i) solicit, hire, recruit, attempt to hire or recruit, or induce the
termination of employment of any employee of the Company; (ii) solicit, contact (including but not limited to e-mail, regular mail, express
mail, telephone, fax, and instant message), attempt to contact or meet with any (x) existing or prospective customer of the Company for
purposes of offering or accepting goods or services similar to or competitive with those offered by the Company, or (y) competitor of
the Company for any purpose related to the business or services of the competitor or the Company; or (iii) induce, influence or encourage
any existing or prospective customer, supplier or other business partner of the Company for purposes of diverting their business or services
from the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Employee
shall not, during their employment or thereafter, make, publish or communicate to any person or in any public forum any comments or statements
(whether written or oral) that denigrate or disparage the reputation or stature of the Company, its affiliates or any of their respective
officers, directors, managers or employees (acting in their capacity as officers, directors, managers or employees of the Company or its
affiliates). Notwithstanding the foregoing, nothing in this Section 9(c) is intended to, nor shall it, interfere with Employee&rsquo;s
protected rights under applicable labor laws to engage in protected concerted activity, or to file a charge or complaint with, or participate
in an investigation or proceeding pursuant to, the statutes administered by the Equal Employment Opportunity Commission or equivalent
state agency, or any federal, state or local government agency.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Employee
acknowledges that the restrictions contained in this Section 9 are reasonable and necessary to protect the legitimate interests of the
Company and constitute a material inducement to the Company to enter into this Agreement and offer employment to Employee under this Agreement.
In the event that any covenant contained in this Section 9 should ever be adjudicated to exceed the time, geographic, product or service,
or other limitations permitted by applicable law in any jurisdiction, then any court is expressly empowered to reform such covenant, and
such covenant shall be deemed reformed, in such jurisdiction to the maximum time, geographic, product or service, or other limitations
permitted by applicable law. The covenants contained in this Section 9 and each provision hereof are severable and distinct covenants
and provisions. The invalidity or unenforceability of any such covenant or provision as written shall not invalidate or render unenforceable
the remaining covenants or provisions hereof, and any such invalidity or unenforceability in any jurisdiction shall not invalidate or
render unenforceable such covenant or provision in any other jurisdiction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">10.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Amendment;
Waiver.</U> This Agreement may be amended, and the observance of any term of this Agreement may be waived (either generally or in a particular
instance and either retroactively or prospectively), only by an instrument in writing signed by the parties hereto. Waiver of any term
or condition of this Agreement will not be construed as a waiver of any subsequent breach or waiver of the same term or condition, or
a waiver of any other term or condition of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>


<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">- 6 -</P>


<HR ALIGN="CENTER" NOSHADE SIZE="2" STYLE="WIDTH: 100%"><P STYLE="BREAK-BEFORE: ALWAYS"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">11.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Applicable
Law; Severability</U>. This Agreement shall be governed by and construed under the laws of the State of New York, exclusive of the body
of law known as conflicts of law. Should a court or other body of competent jurisdiction determine that any term or provision of this
Agreement is excessive in scope or duration or is illegal, invalid or unenforceable, then the parties agree that such term or provision
shall not be voided or made unenforceable , but rather shall be modified so as to be valid, legal and enforceable to the maximum extent
possible, under the purposes stated in the preceding sentence and with applicable law, and all other terms and provisions of this Agreement
shall remain valid and fully enforceable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">12.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Submission
to Jurisdiction; Waiver of Jury Trial.</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="text-transform: uppercase">If
a dispute arises between the Parties concerning the subject matter of this Agreement, the Parties consent to the sole and exclusive jurisdiction
of the state courts situated in CHESTER County, New York and the federal United States District Court for the Southern District of New
York.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;EACH
PARTY ACKNOWLEDGES AND AGREES THAT ANY CONTROVERSY WHICH MAY ARISE UNDER THIS AGREEMENT IS LIKELY TO INVOLVE COMPLICATED AND DIFFICULT
ISSUES AND, THEREFORE, EACH SUCH PARTY IRREVOCABLY AND UNCONDITIONALLY WAIVES ANY RIGHT IT MAY HAVE TO A TRIAL BY JURY IN RESPECT OF ANY
LEGAL ACTION ARISING OUT OF OR RELATING TO THIS AGREEMENT OR THE TRANSACTIONS CONTEMPLATED HEREBY OR THEREBY.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">13.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Equitable
Relief.</U> In the event of a breach or threatened breach by Employee of Sections 7 through 9, Employee hereby consents and agrees that
the Company shall be entitled to seek, in addition to other available remedies, a temporary or permanent injunction or other equitable
relief against such breach or threatened breach from any court of competent jurisdiction, without the necessity of showing any actual
damages or that monetary damages would not afford an adequate remedy, and without the necessity of posting any bond or other security.
The aforementioned equitable relief shall be in addition to, not in lieu of, legal remedies, monetary damages or other available forms
of relief.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">14.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Further
Assurances</U>. The Company and Employee shall each take all actions as may be reasonably necessary or appropriate in furtherance of their
respective obligations and covenants set forth in this Agreement, including, without limitation, executing and delivering such additional
agreements, certificates, instruments and other documents as may be deemed necessary or appropriate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">15.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Assignability;
Third-Party Beneficiary.</U> This Agreement will be binding upon, enforceable by and inure solely to the benefit of, the parties and their
respective permitted successors and assigns. Except as otherwise expressly provided in this Agreement, this Agreement shall not be assigned
by any party hereto without the prior written consent of the non- assigning parties. Except as otherwise expressly provided in this Agreement,
nothing in this Agreement is intended to or will confer upon any person, other than the parties to this Agreement and their respective
heirs, successors and assigns, any right, benefit or remedy of any nature whatsoever under or by reason of this Agreement. Notwithstanding
anything to the contrary herein, nothing in this Agreement shall preclude the Company from consolidating or merging into or with, transferring
all or substantially all of its equity or assets to, or otherwise assigning this Agreement by operation of law to another person or entity
without the consent of Employee; provided that, in each case, such other person or entity shall assume this Agreement and all obligations
of the Company hereunder. Upon such consolidation, merger, transfer of equity or assets, or assignment by operation of law, and such assumption,
the term the &ldquo;Company&rdquo; as used herein, shall mean such other person or entity and this Agreement shall continue in full force
and effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">16.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Notices.</U>
All notices and other communications under this Agreement must be in writing and will be deemed given if delivered personally, faxed,
sent by internationally recognized overnight courier, mailed by registered or certified mail (return receipt requested), postage prepaid,
or sent by electronic mail (without a failed transmission response) to the parties at the following addresses (or at such other address
for a party as such party specifies by like notice):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>


<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">- 7 -</P>


<HR ALIGN="CENTER" NOSHADE SIZE="2" STYLE="WIDTH: 100%"><P STYLE="BREAK-BEFORE: ALWAYS"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 11pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 3.5in; text-underline-color: black"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If to the Company:</FONT></TD>
    <TD STYLE="width: 3in; text-underline-color: black"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Email: ltharby@korumedical.com</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-underline-color: black"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Repro Med Systems, Inc. d/b/a </FONT></TD>
    <TD STYLE="text-underline-color: black">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-underline-color: black"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">KORU Medical Systems</FONT></TD>
    <TD STYLE="text-underline-color: black">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-underline-color: black"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">24 Carpenter Road</FONT></TD>
    <TD STYLE="text-underline-color: black"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If to the Employee:</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-underline-color: black"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chester, NY 10918</FONT></TD>
    <TD STYLE="text-underline-color: black"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Brian Case</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-underline-color: black"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Attention: Linda Tharby</FONT></TD>
    <TD STYLE="text-underline-color: black"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[address, email, phone]</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-underline-color: black"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Telephone: 845-610-5561</FONT></TD>
    <TD STYLE="text-underline-color: black">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">All such notices, consents, requests, demands, waivers
and other communications so delivered, mailed or sent shall be deemed to have been received (i) if by personal delivery, on the day delivered,
(ii) if by certified or registered mail, on the earlier of the date of receipt or the third business day after the mailing thereof , (iii)
if by next-day or overnight mail or delivery service such as Federal Express or UPS, on the day delivered or (iv) if by fax or electronic
mail, on the day on which such fax or electronic mail was sent, provided that a copy is also sent by certified or registered mail or by
next-day or overnight mail or delivery service such as Federal Express or UPS.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">17.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Termination
of Agreement; Survival.</U> This Agreement shall terminate upon termination of Employee&rsquo;s employment as provided herein; provided,
however, that the provisions of Sections 7, 8, 9, 11, 12, 13 and this Section 17 shall survive termination of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">18.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Section
409A.</U> Notwithstanding any provision to the contrary in this Agreement, no payment shall be made and no election shall be permitted
that would violate the requirements of or cause taxation under Section 409A of the Internal Revenue Code and the Treasury regulations
promulgated thereunder. Further, all provisions in this Agreement shall be interpreted in a manner consistent with Section 409A and guidance
related thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">19.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Counterparts.</U>
This Agreement may be executed in one or more counterparts, and by the different parties hereto in separate counterparts, each of which
when executed shall be deemed to be an original but all of which taken together shall constitute one and the same agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">20.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Electronic
Execution and Delivery.</U> The parties may execute and deliver this Agreement by facsimile, electronic mail of a .PDF or other electronic
means under which the signature of or on behalf of such party can be seen, and such execution and delivery will be considered valid, binding
and effective for all purposes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">21.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Entire
Agreement:</U> This Agreement, constitutes the entire agreement and supersedes all prior agreements and understandings, both written and
oral, among or between any of the parties with respect to the subject matter hereof and thereof, excluding any separate confidentiality
and/or assignment of inventions agreement Employee may have previously signed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">[signature page follows]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">- 8 -</P>


<HR ALIGN="CENTER" NOSHADE SIZE="2" STYLE="WIDTH: 100%"><P STYLE="BREAK-BEFORE: ALWAYS"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">IN WITNESS WHEREOF, the parties
and/or their authorized representatives have executed this Employment Agreement as of the date first set forth above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 2.5in">COMPANY:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 2.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 2.5in">REPRO MED SYSTEMS, INC. d/b/a KORU MEDICAL SYSTEMS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 2.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 2.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 2.5in">By: <U>/s/ Linda Tharby</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 2.5in">Name: Linda Tharby</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 2.5in">Title: President and Chief Employee Officer</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 2.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 2.5in">Dated: __________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 2.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 2.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 2.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 2.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 2.5in">Employee:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 2.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 2.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 2.5in"><U>/s/ Brian Case</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 2.5in">Brian Case</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 2.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 2.5in">Dated: ____________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">- 9 -</P>

<HR ALIGN="CENTER" NOSHADE SIZE="2" STYLE="WIDTH: 100%">

</DIV>
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23
<SEQUENCE>3
<FILENAME>ex_23-1.htm
<DESCRIPTION>CONSENT OF INDEPENDENT AUDITORS
<TEXT>
<HTML>
<HEAD>
<TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<DIV STYLE="width: 7.5in">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">EXHIBIT 23.1</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Consent of Independent Registered Public Accounting
Firm</B></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">We consent to the incorporation by reference in the Registration Statement
on Form S-3 (No. 333-229498), Registration Statement on Form S-3 (No. 333-238242), Registration Statement on Form S-8 (No. 333-262054),
and related Prospectuses of KORU Medical Systems, Inc. of our reports dated March 8, 2023, with respect to the financial statements of
KORU Medical Systems, Inc. appearing in this Annual Report on Form 10-K for the year ended December 31, 2022.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0"><U>/s/ McGrail Merkel Quinn &amp; Associates, P.C.</U></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">Scranton, Pennsylvania</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">March 8, 2023</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<HR NOSHADE ALIGN="CENTER" WIDTH="100%" SIZE="2">

</DIV>
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31
<SEQUENCE>4
<FILENAME>ex_31-1.htm
<DESCRIPTION>CERTIFICATION OF THE PRINCIPAL EXECUTIVE OFFICER
<TEXT>
<HTML>
<HEAD>
<TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<DIV STYLE="width: 7.5in">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">EXHIBIT 31.1</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">RULE 13A-14(A) / 15D-14(A) CERTIFICATION OF</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">PRINCIPAL EXECUTIVE OFFICER</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">I, Linda Tharby, Principal Executive Officer, certify that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 7.5in; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD>1)</TD>
    <TD COLSPAN="2">I have reviewed this Annual Report on Form 10-K of KORU MEDICAL SYSTEMS, INC.;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>2)</TD>
    <TD COLSPAN="2">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>3)</TD>
    <TD COLSPAN="2">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations, and cash flows of the registrant as of, and for, the periods presented in this report;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>4)</TD>
    <TD COLSPAN="2">The registrant&rsquo;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in">(a)</TD>
    <TD STYLE="width: 7in">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>(b)</TD>
    <TD>Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>(c)</TD>
    <TD>Evaluated the effectiveness of the registrant&rsquo;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>(d)</TD>
    <TD>Disclosed in this report any change in the registrant&rsquo;s internal control over financial reporting that occurred during the registrant&rsquo;s most recent fiscal quarter (the registrant&rsquo;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&rsquo;s internal control over financial reporting; and</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>5)</TD>
    <TD COLSPAN="2">The registrant&rsquo;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&rsquo;s auditors and the audit committee of the registrant&rsquo;s board of directors:</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>(a)</TD>
    <TD>All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&rsquo;s ability to record, process, summarize and report financial information; and</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>(b)</TD>
    <TD>Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&rsquo;s internal control over financial reporting.</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><U>/s/ Linda Tharby</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Linda Tharby</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">President and Chief Executive Officer</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Date: March 8, 2023</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<HR ALIGN="CENTER" NOSHADE SIZE="2" STYLE="WIDTH: 100%">

</DIV>
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31
<SEQUENCE>5
<FILENAME>ex_31-2.htm
<DESCRIPTION>CERTIFICATION OF THE PRINCIPAL FINANCIAL OFFICER
<TEXT>
<HTML>
<HEAD>
<TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<DIV STYLE="width: 7.5in">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">EXHIBIT 31.2</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">RULE 13A-14(A) / 15D-14(A) CERTIFICATION OF</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">PRINCIPAL FINANCIAL OFFICER</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">I, Thomas Adams, Principal Financial Officer, certify that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 7.5in; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD>1)</TD>
    <TD COLSPAN="2">I have reviewed this Annual Report on Form 10-K of KORU MEDICAL SYSTEMS, INC.;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>2)</TD>
    <TD COLSPAN="2">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>3)</TD>
    <TD COLSPAN="2">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations, and cash flows of the registrant as of, and for, the periods presented in this report;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>4)</TD>
    <TD COLSPAN="2">The registrant&rsquo;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in">(a)</TD>
    <TD STYLE="width: 7in">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>(b)</TD>
    <TD>Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>(c)</TD>
    <TD>Evaluated the effectiveness of the registrant&rsquo;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>(d)</TD>
    <TD>Disclosed in this report any change in the registrant&rsquo;s internal control over financial reporting that occurred during the registrant&rsquo;s most recent fiscal quarter (the registrant&rsquo;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&rsquo;s internal control over financial reporting; and</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>5)</TD>
    <TD COLSPAN="2">The registrant&rsquo;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&rsquo;s auditors and the audit committee of the registrant&rsquo;s board of directors:</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>(a)</TD>
    <TD>All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&rsquo;s ability to record, process, summarize and report financial information; and</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>(b)</TD>
    <TD>Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&rsquo;s internal control over financial reporting.</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><U>/s/ Thomas Adams</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Thomas Adams</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Interim- Chief Financial Officer and Treasurer</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Date: March 8, 2023</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<HR ALIGN="CENTER" NOSHADE SIZE="2" STYLE="WIDTH: 100%">

</DIV>
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32
<SEQUENCE>6
<FILENAME>ex_32-1.htm
<DESCRIPTION>CERTIFICATION OF THE PRINCIPAL EXECUTIVE OFFICER
<TEXT>
<HTML>
<HEAD>
<TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<DIV STYLE="width: 7.5in">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">EXHIBIT 32.1</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">AS ADDED BY SECTION 906 OF THE SARBANES-OXLEY ACT OF
2002</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">In connection with the Annual Report of KORU MEDICAL SYSTEMS, INC. (the
&ldquo;Company&rdquo;) on Form 10-K for the year ended December 31, 2022 as filed with the Securities and Exchange Commission (the &ldquo;Report&rdquo;),
I, Linda Tharby, Principal Executive Officer, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley
Act of 2002, that, to the best of my knowledge:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 7.5in; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">(1)</TD>
    <TD STYLE="width: 7in">the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>(2)</TD>
    <TD>the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company as of the dates and for the periods expressed in the Report.</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><U>/s/ Linda Tharby</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Linda Tharby</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Chief Executive Officer and President</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Date: March 8, 2023</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<HR ALIGN="CENTER" NOSHADE SIZE="2" STYLE="WIDTH: 100%">

</DIV>
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32
<SEQUENCE>7
<FILENAME>ex_32-2.htm
<DESCRIPTION>CERTIFICATION OF THE PRINCIPAL FINANCIAL OFFICER
<TEXT>
<HTML>
<HEAD>
<TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<DIV STYLE="width: 7.5in">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">EXHIBIT 32.2</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">AS ADDED BY SECTION 906 OF THE SARBANES-OXLEY ACT OF
2002</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">In connection with the Annual Report of KORU MEDICAL SYSTEMS, INC. (the
&ldquo;Company&rdquo;) on Form 10-K for the year ended December 31, 2022 as filed with the Securities and Exchange Commission (the &ldquo;Report&rdquo;),
I, Thomas Adams, Principal Financial Officer and Treasurer, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section
906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 7.5in; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">(1)</TD>
    <TD STYLE="width: 7in">the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>(2)</TD>
    <TD>the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company as of the dates and for the periods expressed in the Report.</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><U>/s/ Thomas Adams</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Thomas Adams</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Interim- Chief Financial Officer and Treasurer</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Date: March 8, 2023</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<HR ALIGN="CENTER" NOSHADE SIZE="2" STYLE="WIDTH: 100%">

</DIV>
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>8
<FILENAME>krmd-20221231.xsd
<DESCRIPTION>INLINE XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.17b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: /6I5w7xRiXgen8uPa3csWayN+aPtzJZymekxvmxyHWna/yAnQTvjdy7R+zhWkYME -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:us-gaap="http://fasb.org/srt-sup/2022q3" xmlns:srt="http://fasb.org/srt/2022" xmlns:srt-types="http://fasb.org/srt-types/2022" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:krmd="http://korumedical.com/20221231" elementFormDefault="qualified" targetNamespace="http://korumedical.com/20221231">
    <annotation>
      <appinfo>
	<link:roleType roleURI="http://korumedical.com/role/Cover" id="Cover">
	  <link:definition>00000001 - Document - Cover</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://korumedical.com/role/BalanceSheets" id="BalanceSheets">
	  <link:definition>00000002 - Statement - BALANCE SHEETS</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://korumedical.com/role/BalanceSheetsParenthetical" id="BalanceSheetsParenthetical">
	  <link:definition>00000003 - Statement - BALANCE SHEETS (Parenthetical)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://korumedical.com/role/StatementsOfOperations" id="StatementsOfOperations">
	  <link:definition>00000004 - Statement - STATEMENTS OF OPERATIONS</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://korumedical.com/role/StatementsOfStockholdersEquity" id="StatementsOfStockholdersEquity">
	  <link:definition>00000005 - Statement - STATEMENTS OF STOCKHOLDERS' EQUITY</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://korumedical.com/role/StatementsOfCashFlows" id="StatementsOfCashFlows">
	  <link:definition>00000006 - Statement - STATEMENTS OF CASH FLOWS</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://korumedical.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPolicies" id="NatureOfOperationsAndSummaryOfSignificantAccountingPolicies">
	  <link:definition>00000007 - Disclosure - NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://korumedical.com/role/Inventory" id="Inventory">
	  <link:definition>00000008 - Disclosure - INVENTORY</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://korumedical.com/role/PropertyAndEquipment" id="PropertyAndEquipment">
	  <link:definition>00000009 - Disclosure - PROPERTY AND EQUIPMENT</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://korumedical.com/role/Stock-basedCompensation" id="Stock-basedCompensation">
	  <link:definition>00000010 - Disclosure - STOCK-BASED COMPENSATION</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://korumedical.com/role/Leases" id="Leases">
	  <link:definition>00000011 - Disclosure - LEASES</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://korumedical.com/role/FederalAndStateIncomeTaxes" id="FederalAndStateIncomeTaxes">
	  <link:definition>00000012 - Disclosure - FEDERAL AND STATE INCOME TAXES</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://korumedical.com/role/MajorCustomers" id="MajorCustomers">
	  <link:definition>00000013 - Disclosure - MAJOR CUSTOMERS</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://korumedical.com/role/CommitmentsAndContingencies" id="CommitmentsAndContingencies">
	  <link:definition>00000014 - Disclosure - COMMITMENTS AND CONTINGENCIES</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://korumedical.com/role/EmployeeBenefits" id="EmployeeBenefits">
	  <link:definition>00000015 - Disclosure - EMPLOYEE BENEFITS</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://korumedical.com/role/DebtObligations" id="DebtObligations">
	  <link:definition>00000016 - Disclosure - DEBT OBLIGATIONS</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://korumedical.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies" id="NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies">
	  <link:definition>00000017 - Disclosure - NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://korumedical.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesTables" id="NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesTables">
	  <link:definition>00000018 - Disclosure - NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://korumedical.com/role/InventoryTables" id="InventoryTables">
	  <link:definition>00000019 - Disclosure - INVENTORY (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://korumedical.com/role/PropertyAndEquipmentTables" id="PropertyAndEquipmentTables">
	  <link:definition>00000020 - Disclosure - PROPERTY AND EQUIPMENT (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://korumedical.com/role/Stock-basedCompensationTables" id="Stock-basedCompensationTables">
	  <link:definition>00000021 - Disclosure - STOCK-BASED COMPENSATION (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://korumedical.com/role/LeasesTables" id="LeasesTables">
	  <link:definition>00000022 - Disclosure - LEASES (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://korumedical.com/role/FederalAndStateIncomeTaxesTables" id="FederalAndStateIncomeTaxesTables">
	  <link:definition>00000023 - Disclosure - FEDERAL AND STATE INCOME TAXES (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://korumedical.com/role/ScheduleOfAmortizationExpenseDetails" id="ScheduleOfAmortizationExpenseDetails">
	  <link:definition>00000024 - Disclosure - Schedule of amortization expense (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://korumedical.com/role/ScheduleOfNetIncomePerCommonShareDetails" id="ScheduleOfNetIncomePerCommonShareDetails">
	  <link:definition>00000025 - Disclosure - Schedule of net income per common share (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://korumedical.com/role/ScheduleOfNetRevenuesByGeographyDetails" id="ScheduleOfNetRevenuesByGeographyDetails">
	  <link:definition>00000026 - Disclosure - Schedule of net revenues by geography (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://korumedical.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" id="NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesDetailsNarrative">
	  <link:definition>00000027 - Disclosure - NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://korumedical.com/role/InventoryConsistsOfDetails" id="InventoryConsistsOfDetails">
	  <link:definition>00000028 - Disclosure - Inventory consists of: (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://korumedical.com/role/ScheduleOfPropertyAndEquipmentDetails" id="ScheduleOfPropertyAndEquipmentDetails">
	  <link:definition>00000029 - Disclosure - Schedule of property and equipment (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://korumedical.com/role/ScheduleOfTimeBasedStockOptionsDetails" id="ScheduleOfTimeBasedStockOptionsDetails">
	  <link:definition>00000030 - Disclosure - Schedule of time based stock options (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://korumedical.com/role/ScheduleOfStatusOfTimeBasedStockOptionsDetails" id="ScheduleOfStatusOfTimeBasedStockOptionsDetails">
	  <link:definition>00000031 - Disclosure - Schedule of status of time based stock options (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://korumedical.com/role/ScheduleOfInformationPertainingToOptionsOutstandingDetails" id="ScheduleOfInformationPertainingToOptionsOutstandingDetails">
	  <link:definition>00000032 - Disclosure - Schedule of information pertaining to options outstanding (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://korumedical.com/role/ScheduleOfPerformanceBaseOptionsOutstandingDetails" id="ScheduleOfPerformanceBaseOptionsOutstandingDetails">
	  <link:definition>00000033 - Disclosure - Schedule of performance base options outstanding (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://korumedical.com/role/FollowingTableSummarizesActivitiesForOurUnvestedRestrictedStockAwardsForTwelveMonthsEndedDecember312022And2021.Details" id="FollowingTableSummarizesActivitiesForOurUnvestedRestrictedStockAwardsForTwelveMonthsEndedDecember312022And2021.Details">
	  <link:definition>00000034 - Disclosure - The following table summarizes the activities for our unvested restricted stock awards for the twelve months ended December 31, 2022, and 2021. (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://korumedical.com/role/Stock-basedCompensationDetailsNarrative" id="Stock-basedCompensationDetailsNarrative">
	  <link:definition>00000035 - Disclosure - STOCK-BASED COMPENSATION (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://korumedical.com/role/ScheduleOfComponentsOfLeaseExpenseDetails" id="ScheduleOfComponentsOfLeaseExpenseDetails">
	  <link:definition>00000036 - Disclosure - Schedule of components of lease expense (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://korumedical.com/role/ScheduleOfCashFlowInformationRelatedToLeasesDetails" id="ScheduleOfCashFlowInformationRelatedToLeasesDetails">
	  <link:definition>00000037 - Disclosure - Schedule of cash flow information related to leases (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://korumedical.com/role/SchdeuleOfBalanceSheetInformationRelatedToLeasesDetails" id="SchdeuleOfBalanceSheetInformationRelatedToLeasesDetails">
	  <link:definition>00000038 - Disclosure - Schdeule of balance sheet information related to leases (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://korumedical.com/role/ScheduleOfMaturitiesOfLeaseLiabilitiesDetails" id="ScheduleOfMaturitiesOfLeaseLiabilitiesDetails">
	  <link:definition>00000039 - Disclosure - Schedule of maturities of lease liabilities (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://korumedical.com/role/LeasesDetailsNarrative" id="LeasesDetailsNarrative">
	  <link:definition>00000040 - Disclosure - LEASES (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://korumedical.com/role/ScheduleOfProvisionForIncomeTaxesDetails" id="ScheduleOfProvisionForIncomeTaxesDetails">
	  <link:definition>00000041 - Disclosure - Schedule of provision for income taxes (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://korumedical.com/role/ScheduleOfReconciliationOfIncomeTaxesDetails" id="ScheduleOfReconciliationOfIncomeTaxesDetails">
	  <link:definition>00000042 - Disclosure - Schedule of reconciliation of income taxes (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://korumedical.com/role/ScheduleOfComponentsOfDeferredTaxAssetsDetails" id="ScheduleOfComponentsOfDeferredTaxAssetsDetails">
	  <link:definition>00000043 - Disclosure - Schedule of components of deferred tax assets (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://korumedical.com/role/MajorCustomersDetailsNarrative" id="MajorCustomersDetailsNarrative">
	  <link:definition>00000044 - Disclosure - MAJOR CUSTOMERS (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://korumedical.com/role/EmployeeBenefitsDetailsNarrative" id="EmployeeBenefitsDetailsNarrative">
	  <link:definition>00000045 - Disclosure - EMPLOYEE BENEFITS (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://korumedical.com/role/DebtObligationsDetailsNarrative" id="DebtObligationsDetailsNarrative">
	  <link:definition>00000046 - Disclosure - DEBT OBLIGATIONS (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:linkbaseRef xlink:type="simple" xlink:href="krmd-20221231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="krmd-20221231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="krmd-20221231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Calculation Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="krmd-20221231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Definition Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2022" schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd" />
    <import namespace="http://fasb.org/us-gaap/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd" />
    <import namespace="http://fasb.org/us-gaap-sup/2022q3" schemaLocation="https://xbrl.fasb.org/us-gaap/2022q3/us-gaap-sup-2022q3.xsd" />
    <import namespace="http://fasb.org/srt-sup/2022q3" schemaLocation="https://xbrl.fasb.org/srt/2022q3/srt-sup-2022q3.xsd" />
    <import namespace="http://fasb.org/us-types/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2022" schemaLocation="https://xbrl.sec.gov/country/2022/country-2022.xsd" />
    <import namespace="http://fasb.org/srt/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd" />
    <import namespace="http://fasb.org/srt-types/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd" />
    <element id="krmd_PatentsAndTrademarksMember" name="PatentsAndTrademarksMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_FurnitureAndOfficeEquipmentMember" name="FurnitureAndOfficeEquipmentMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_EquipmentAndToolingMember" name="EquipmentAndToolingMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_ManufacturingEquipmentAndToolingMember" name="ManufacturingEquipmentAndToolingMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_StockOptionPlan2015Member" name="StockOptionPlan2015Member" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_ExecutiveskeyEmployeesAndConsultantsMember" name="ExecutiveskeyEmployeesAndConsultantsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_StockOptionPlan2021Member" name="StockOptionPlan2021Member" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_ExecutiveMember" name="ExecutiveMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_NonEmployeeDirectorAndBoardAdvisorMember" name="NonEmployeeDirectorAndBoardAdvisorMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_ChiefExecutiveOfficerLindaTharbyMember" name="ChiefExecutiveOfficerLindaTharbyMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_TimeBasedSharesOptionsMember" name="TimeBasedSharesOptionsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_EmploymentAgreementMember" name="EmploymentAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_RestrictedStockAwardsMember" name="RestrictedStockAwardsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_ExercisePrice1Member" name="ExercisePrice1Member" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_CustomerOneMember" name="CustomerOneMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_AONPremiumFinanceLLCMember" name="AONPremiumFinanceLLCMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_PromissoryNoteMember" name="PromissoryNoteMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_NewIssuanceLitigationSettlementAmountIssuance" name="NewIssuanceLitigationSettlementAmountIssuance" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_NewIssuanceLitigationSettlementShareIssuance" name="NewIssuanceLitigationSettlementShareIssuance" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_Compensationexpenserelatedtorestrictedstockawards" name="Compensationexpenserelatedtorestrictedstockawards" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_RouLandlordCredit" name="RouLandlordCredit" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_CommonStockIssuanceAsSettlementForLitigation" name="CommonStockIssuanceAsSettlementForLitigation" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_BorrowingsFromIndebtedness" name="BorrowingsFromIndebtedness" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_PaymentsOnIndebtedness" name="PaymentsOnIndebtedness" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_CashPaidDuringPeriodsForAbstract" name="CashPaidDuringPeriodsForAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_IssuanceOfCommonStockCompensation" name="IssuanceOfCommonStockCompensation" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_AccountingPronouncementsNotYetAdopted" name="AccountingPronouncementsNotYetAdopted" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_ScheduleOfNetRevenuesByGeography" name="ScheduleOfNetRevenuesByGeography" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_ScheduleOfShareBasedCompensationStockOptionsActivityAmendedTableTextBlock" name="ScheduleOfShareBasedCompensationStockOptionsActivityAmendedTableTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_ScheduleOfShareBasedCompensationtaxBenefitsAssociatedWithRestrictedStockAwardCompensationTableTextBlock" name="ScheduleOfShareBasedCompensationtaxBenefitsAssociatedWithRestrictedStockAwardCompensationTableTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_IncrementalCommonSharesAttributableToRestrictedStock" name="IncrementalCommonSharesAttributableToRestrictedStock" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_WeightedAverageNumberOfSharesOutstanding" name="WeightedAverageNumberOfSharesOutstanding" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount1" name="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount1" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_AmortizationOfIntangibleAssets1" name="AmortizationOfIntangibleAssets1" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber2" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber2" nillable="true" xbrli:periodType="instant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice2" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice2" nillable="true" xbrli:periodType="instant" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross2" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross2" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice2" name="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice2" nillable="true" xbrli:periodType="duration" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_StockIssuedDuringPeriodSharesStockOptionsExercised2" name="StockIssuedDuringPeriodSharesStockOptionsExercised2" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice2" name="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice2" nillable="true" xbrli:periodType="duration" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod2" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod2" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice2" name="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice2" nillable="true" xbrli:periodType="duration" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice2" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice2" nillable="true" xbrli:periodType="instant" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue2" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue2" nillable="true" xbrli:periodType="duration" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber1" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber1" nillable="true" xbrli:periodType="instant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice1" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice1" nillable="true" xbrli:periodType="instant" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross1" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross1" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice1" name="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice1" nillable="true" xbrli:periodType="duration" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_StockIssuedDuringPeriodSharesStockOptionsExercised1" name="StockIssuedDuringPeriodSharesStockOptionsExercised1" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice1" name="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice1" nillable="true" xbrli:periodType="duration" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod1" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod1" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice1" name="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice1" nillable="true" xbrli:periodType="duration" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice1" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice1" nillable="true" xbrli:periodType="instant" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue1" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue1" nillable="true" xbrli:periodType="duration" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_AllocatedShareBasedCompensationExpense1" name="AllocatedShareBasedCompensationExpense1" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberUnvested" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberUnvested" nillable="true" xbrli:periodType="instant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceUnvested" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceUnvested" nillable="true" xbrli:periodType="instant" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrossUnvested" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrossUnvested" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePriceUnvested" name="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePriceUnvested" nillable="true" xbrli:periodType="duration" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodGross" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodGross" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice" name="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice" nillable="true" xbrli:periodType="duration" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodUnvested" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodUnvested" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePriceUnvested" name="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePriceUnvested" nillable="true" xbrli:periodType="duration" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan2015" name="StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan2015" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_NonemployeeServicesTransactionCost" name="NonemployeeServicesTransactionCost" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriodWeightedAverageGrantDateFairValue" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriodWeightedAverageGrantDateFairValue" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_CompensationCost" name="CompensationCost" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm3" name="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm3" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_UnrecognizedCompensationCost" name="UnrecognizedCompensationCost" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm4" name="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm4" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_FinanceLeaseCost1Abstract" name="FinanceLeaseCost1Abstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_FinanceLeaseCost" name="FinanceLeaseCost" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_AssetsAndLiabilitiesOperatingLesseeAbstract" name="AssetsAndLiabilitiesOperatingLesseeAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_AssetsAndLiabilitiesLesseeFinanceAbstract" name="AssetsAndLiabilitiesLesseeFinanceAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_LesseeOperatingLeaseLiabilityPaymentsDueTotal" name="LesseeOperatingLeaseLiabilityPaymentsDueTotal" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_LesseeFinancingLeaseLeaseLiabilityPaymentsDueTotal" name="LesseeFinancingLeaseLeaseLiabilityPaymentsDueTotal" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_LesseeOperatingLeaseImputedInterest" name="LesseeOperatingLeaseImputedInterest" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_LesseeFinancingLeaseImputedInterest" name="LesseeFinancingLeaseImputedInterest" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_DescriptionOfLessorOperatingLeaseTerm" name="DescriptionOfLessorOperatingLeaseTerm" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_DepreciationDepletionAndAmortization1" name="DepreciationDepletionAndAmortization1" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_RdCredit" name="RdCredit" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_Nol" name="Nol" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_AllowanceForDoubtfulOtherReceivables1Current" name="AllowanceForDoubtfulOtherReceivables1Current" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_DescriptionOfMatchingContribution" name="DescriptionOfMatchingContribution" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_NotePayableTerms" name="NotePayableTerms" nillable="true" xbrli:periodType="duration" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_ScheduleOfNetSalesByGeography" name="ScheduleOfNetSalesByGeography" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_CompensationExpenseRrelatedToRestrictedStockAwards" name="CompensationExpenseRrelatedToRestrictedStockAwards" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_FinanceLeaseRightOfUseAssetAmortization1" name="FinanceLeaseRightOfUseAssetAmortization1" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate1" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate1" nillable="true" xbrli:periodType="duration" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_AllocatedShareBasedCompensationExpense2" name="AllocatedShareBasedCompensationExpense2" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm" name="SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance" name="SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance" nillable="true" xbrli:periodType="instant" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_LesseeFinancingLeaseLeaseLiabilityPaymentsDue" name="LesseeFinancingLeaseLeaseLiabilityPaymentsDue" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_KeyEquipmentFinanceMember" name="KeyEquipmentFinanceMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_ProgressPaymentLoanAndSecurityAgreementMember" name="ProgressPaymentLoanAndSecurityAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_NotePayableTermsAxis" name="NotePayableTermsAxis" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrldt:dimensionItem" />
    <element id="krmd_FinanceLeaseLiabilityPaymentsDueYearSix" name="FinanceLeaseLiabilityPaymentsDueYearSix" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_StockIssued" name="StockIssued" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_LessorOperatingLeaseOptionToTerminate1" name="LessorOperatingLeaseOptionToTerminate1" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_WeightedAverageNumberOfCommonSharesOutstanding" name="WeightedAverageNumberOfCommonSharesOutstanding" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_TimeBasedSharesOptionsOneMember" name="TimeBasedSharesOptionsOneMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_ProceedsFromStockOptionsExercisedCashless" name="ProceedsFromStockOptionsExercisedCashless" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>9
<FILENAME>krmd-20221231_cal.xml
<DESCRIPTION>INLINE XBRL CALCULATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.17b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://korumedical.com/role/Cover" xlink:href="krmd-20221231.xsd#Cover" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/BalanceSheets" xlink:href="krmd-20221231.xsd#BalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/BalanceSheetsParenthetical" xlink:href="krmd-20221231.xsd#BalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/StatementsOfOperations" xlink:href="krmd-20221231.xsd#StatementsOfOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/StatementsOfStockholdersEquity" xlink:href="krmd-20221231.xsd#StatementsOfStockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/StatementsOfCashFlows" xlink:href="krmd-20221231.xsd#StatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPolicies" xlink:href="krmd-20221231.xsd#NatureOfOperationsAndSummaryOfSignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/Inventory" xlink:href="krmd-20221231.xsd#Inventory" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/PropertyAndEquipment" xlink:href="krmd-20221231.xsd#PropertyAndEquipment" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/Stock-basedCompensation" xlink:href="krmd-20221231.xsd#Stock-basedCompensation" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/Leases" xlink:href="krmd-20221231.xsd#Leases" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/FederalAndStateIncomeTaxes" xlink:href="krmd-20221231.xsd#FederalAndStateIncomeTaxes" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/MajorCustomers" xlink:href="krmd-20221231.xsd#MajorCustomers" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/CommitmentsAndContingencies" xlink:href="krmd-20221231.xsd#CommitmentsAndContingencies" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/EmployeeBenefits" xlink:href="krmd-20221231.xsd#EmployeeBenefits" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/DebtObligations" xlink:href="krmd-20221231.xsd#DebtObligations" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:href="krmd-20221231.xsd#NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesTables" xlink:href="krmd-20221231.xsd#NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/InventoryTables" xlink:href="krmd-20221231.xsd#InventoryTables" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/PropertyAndEquipmentTables" xlink:href="krmd-20221231.xsd#PropertyAndEquipmentTables" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/Stock-basedCompensationTables" xlink:href="krmd-20221231.xsd#Stock-basedCompensationTables" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/LeasesTables" xlink:href="krmd-20221231.xsd#LeasesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/FederalAndStateIncomeTaxesTables" xlink:href="krmd-20221231.xsd#FederalAndStateIncomeTaxesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/ScheduleOfAmortizationExpenseDetails" xlink:href="krmd-20221231.xsd#ScheduleOfAmortizationExpenseDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/ScheduleOfNetIncomePerCommonShareDetails" xlink:href="krmd-20221231.xsd#ScheduleOfNetIncomePerCommonShareDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/ScheduleOfNetRevenuesByGeographyDetails" xlink:href="krmd-20221231.xsd#ScheduleOfNetRevenuesByGeographyDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:href="krmd-20221231.xsd#NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/InventoryConsistsOfDetails" xlink:href="krmd-20221231.xsd#InventoryConsistsOfDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/ScheduleOfPropertyAndEquipmentDetails" xlink:href="krmd-20221231.xsd#ScheduleOfPropertyAndEquipmentDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/ScheduleOfTimeBasedStockOptionsDetails" xlink:href="krmd-20221231.xsd#ScheduleOfTimeBasedStockOptionsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/ScheduleOfStatusOfTimeBasedStockOptionsDetails" xlink:href="krmd-20221231.xsd#ScheduleOfStatusOfTimeBasedStockOptionsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/ScheduleOfInformationPertainingToOptionsOutstandingDetails" xlink:href="krmd-20221231.xsd#ScheduleOfInformationPertainingToOptionsOutstandingDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/ScheduleOfPerformanceBaseOptionsOutstandingDetails" xlink:href="krmd-20221231.xsd#ScheduleOfPerformanceBaseOptionsOutstandingDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/FollowingTableSummarizesActivitiesForOurUnvestedRestrictedStockAwardsForTwelveMonthsEndedDecember312022And2021.Details" xlink:href="krmd-20221231.xsd#FollowingTableSummarizesActivitiesForOurUnvestedRestrictedStockAwardsForTwelveMonthsEndedDecember312022And2021.Details" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/Stock-basedCompensationDetailsNarrative" xlink:href="krmd-20221231.xsd#Stock-basedCompensationDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/ScheduleOfComponentsOfLeaseExpenseDetails" xlink:href="krmd-20221231.xsd#ScheduleOfComponentsOfLeaseExpenseDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/ScheduleOfCashFlowInformationRelatedToLeasesDetails" xlink:href="krmd-20221231.xsd#ScheduleOfCashFlowInformationRelatedToLeasesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/SchdeuleOfBalanceSheetInformationRelatedToLeasesDetails" xlink:href="krmd-20221231.xsd#SchdeuleOfBalanceSheetInformationRelatedToLeasesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/ScheduleOfMaturitiesOfLeaseLiabilitiesDetails" xlink:href="krmd-20221231.xsd#ScheduleOfMaturitiesOfLeaseLiabilitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/LeasesDetailsNarrative" xlink:href="krmd-20221231.xsd#LeasesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/ScheduleOfProvisionForIncomeTaxesDetails" xlink:href="krmd-20221231.xsd#ScheduleOfProvisionForIncomeTaxesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/ScheduleOfReconciliationOfIncomeTaxesDetails" xlink:href="krmd-20221231.xsd#ScheduleOfReconciliationOfIncomeTaxesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/ScheduleOfComponentsOfDeferredTaxAssetsDetails" xlink:href="krmd-20221231.xsd#ScheduleOfComponentsOfDeferredTaxAssetsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/MajorCustomersDetailsNarrative" xlink:href="krmd-20221231.xsd#MajorCustomersDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/EmployeeBenefitsDetailsNarrative" xlink:href="krmd-20221231.xsd#EmployeeBenefitsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/DebtObligationsDetailsNarrative" xlink:href="krmd-20221231.xsd#DebtObligationsDetailsNarrative" xlink:type="simple" />
    <link:calculationLink xlink:type="extended" xlink:role="http://korumedical.com/role/Cover" xlink:title="00000001 - Document - Cover" />
    <link:calculationLink xlink:type="extended" xlink:role="http://korumedical.com/role/BalanceSheets" xlink:title="00000002 - Statement - BALANCE SHEETS">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaapAccountsReceivableNetCurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapAccountsReceivableNetCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaapInventoryNet" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapInventoryNet" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherReceivables" xlink:label="loc_us-gaapOtherReceivables" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapOtherReceivables" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaapPrepaidExpenseCurrent" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapPrepaidExpenseCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapAssetsCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsNet" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsNet" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxAssetsNet" xlink:label="loc_us-gaapDeferredIncomeTaxAssetsNet" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapDeferredIncomeTaxAssetsNet" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaapOtherAssetsNoncurrent" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapOtherAssetsNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapAccountsPayableCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccruedLiabilitiesCurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapAccruedLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesPayableCurrent" xlink:label="loc_us-gaapNotesPayableCurrent" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapNotesPayableCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaapOtherLiabilitiesCurrent" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapOtherLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="loc_us-gaapEmployeeRelatedLiabilitiesCurrent" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapEmployeeRelatedLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityCurrent" xlink:label="loc_us-gaapFinanceLeaseLiabilityCurrent" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapFinanceLeaseLiabilityCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityCurrent" />
      <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapOperatingLeaseLiabilityCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapFinanceLeaseLiabilityNoncurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapFinanceLeaseLiabilityNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityNoncurrent" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapOperatingLeaseLiabilityNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaapAdditionalPaidInCapitalCommonStock" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapAdditionalPaidInCapitalCommonStock" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockValue" xlink:label="loc_us-gaapTreasuryStockValue" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapTreasuryStockValue" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapLiabilities" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://korumedical.com/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - BALANCE SHEETS (Parenthetical)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://korumedical.com/role/StatementsOfOperations" xlink:title="00000004 - Statement - STATEMENTS OF OPERATIONS">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GrossProfit" xlink:label="loc_us-gaapGrossProfit" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues" xlink:label="loc_us-gaapRevenues" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapGrossProfit" xlink:to="loc_us-gaapRevenues" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="loc_us-gaapCostOfGoodsAndServicesSold" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapGrossProfit" xlink:to="loc_us-gaapCostOfGoodsAndServicesSold" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaapOperatingExpenses" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_us-gaapSellingGeneralAndAdministrativeExpense" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapSellingGeneralAndAdministrativeExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaapDepreciationDepletionAndAmortization" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapDepreciationDepletionAndAmortization" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingIncomeLoss" xlink:to="loc_us-gaapGrossProfit" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingIncomeLoss" xlink:to="loc_us-gaapOperatingExpenses" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaapNonoperatingIncomeExpense" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="loc_us-gaapForeignCurrencyTransactionGainLossBeforeTax" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapForeignCurrencyTransactionGainLossBeforeTax" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="loc_us-gaapGainLossOnSaleOfPropertyPlantEquipment" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapGainLossOnSaleOfPropertyPlantEquipment" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherIncome" xlink:label="loc_us-gaapOtherIncome" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapOtherIncome" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaapOtherNonoperatingIncomeExpense" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapOtherNonoperatingIncomeExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:to="loc_us-gaapNonoperatingIncomeExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaapIncomeTaxExpenseBenefit" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapIncomeTaxExpenseBenefit" xlink:type="arc" weight="-1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://korumedical.com/role/StatementsOfStockholdersEquity" xlink:title="00000005 - Statement - STATEMENTS OF STOCKHOLDERS&apos; EQUITY" />
    <link:calculationLink xlink:type="extended" xlink:role="http://korumedical.com/role/StatementsOfCashFlows" xlink:title="00000006 - Statement - STATEMENTS OF CASH FLOWS">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaapDepreciationDepletionAndAmortization" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapDepreciationDepletionAndAmortization" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnSaleOfOtherAssets" xlink:label="loc_us-gaapGainLossOnSaleOfOtherAssets" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapGainLossOnSaleOfOtherAssets" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxesAndTaxCredits" xlink:label="loc_us-gaapDeferredIncomeTaxesAndTaxCredits" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapDeferredIncomeTaxesAndTaxCredits" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="krmd-20221231.xsd#krmd_RouLandlordCredit" xlink:label="loc_krmdRouLandlordCredit" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_krmdRouLandlordCredit" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsReceivable" />
      <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsReceivable" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_us-gaapIncreaseDecreaseInInventories" />
      <link:calculationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInInventories" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherReceivables" xlink:label="loc_us-gaapIncreaseDecreaseInOtherReceivables" />
      <link:calculationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInOtherReceivables" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaapIncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
      <link:calculationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayable" />
      <link:calculationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayable" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInEmployeeRelatedLiabilities" />
      <link:calculationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInEmployeeRelatedLiabilities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInOtherCurrentLiabilities" />
      <link:calculationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInOtherCurrentLiabilities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" />
      <link:calculationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireProductiveAssets" xlink:label="loc_us-gaapPaymentsToAcquireProductiveAssets" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaapPaymentsToAcquireProductiveAssets" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="loc_us-gaapPaymentsToAcquireIntangibleAssets" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaapPaymentsToAcquireIntangibleAssets" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfProductiveAssets" xlink:label="loc_us-gaapProceedsFromSaleOfProductiveAssets" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaapProceedsFromSaleOfProductiveAssets" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="krmd-20221231.xsd#krmd_CommonStockIssuanceAsSettlementForLitigation" xlink:label="loc_krmdCommonStockIssuanceAsSettlementForLitigation" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_krmdCommonStockIssuanceAsSettlementForLitigation" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="krmd-20221231.xsd#krmd_BorrowingsFromIndebtedness" xlink:label="loc_krmdBorrowingsFromIndebtedness" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_krmdBorrowingsFromIndebtedness" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="krmd-20221231.xsd#krmd_PaymentsOnIndebtedness" xlink:label="loc_krmdPaymentsOnIndebtedness" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_krmdPaymentsOnIndebtedness" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeasePrincipalPayments" xlink:label="loc_us-gaapFinanceLeasePrincipalPayments" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapFinanceLeasePrincipalPayments" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:type="arc" weight="1" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://korumedical.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPolicies" xlink:title="00000007 - Disclosure - NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES" />
    <link:calculationLink xlink:type="extended" xlink:role="http://korumedical.com/role/Inventory" xlink:title="00000008 - Disclosure - INVENTORY" />
    <link:calculationLink xlink:type="extended" xlink:role="http://korumedical.com/role/PropertyAndEquipment" xlink:title="00000009 - Disclosure - PROPERTY AND EQUIPMENT" />
    <link:calculationLink xlink:type="extended" xlink:role="http://korumedical.com/role/Stock-basedCompensation" xlink:title="00000010 - Disclosure - STOCK-BASED COMPENSATION" />
    <link:calculationLink xlink:type="extended" xlink:role="http://korumedical.com/role/Leases" xlink:title="00000011 - Disclosure - LEASES" />
    <link:calculationLink xlink:type="extended" xlink:role="http://korumedical.com/role/FederalAndStateIncomeTaxes" xlink:title="00000012 - Disclosure - FEDERAL AND STATE INCOME TAXES" />
    <link:calculationLink xlink:type="extended" xlink:role="http://korumedical.com/role/MajorCustomers" xlink:title="00000013 - Disclosure - MAJOR CUSTOMERS" />
    <link:calculationLink xlink:type="extended" xlink:role="http://korumedical.com/role/CommitmentsAndContingencies" xlink:title="00000014 - Disclosure - COMMITMENTS AND CONTINGENCIES" />
    <link:calculationLink xlink:type="extended" xlink:role="http://korumedical.com/role/EmployeeBenefits" xlink:title="00000015 - Disclosure - EMPLOYEE BENEFITS" />
    <link:calculationLink xlink:type="extended" xlink:role="http://korumedical.com/role/DebtObligations" xlink:title="00000016 - Disclosure - DEBT OBLIGATIONS" />
    <link:calculationLink xlink:type="extended" xlink:role="http://korumedical.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:title="00000017 - Disclosure - NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://korumedical.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesTables" xlink:title="00000018 - Disclosure - NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://korumedical.com/role/InventoryTables" xlink:title="00000019 - Disclosure - INVENTORY (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://korumedical.com/role/PropertyAndEquipmentTables" xlink:title="00000020 - Disclosure - PROPERTY AND EQUIPMENT (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://korumedical.com/role/Stock-basedCompensationTables" xlink:title="00000021 - Disclosure - STOCK-BASED COMPENSATION (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://korumedical.com/role/LeasesTables" xlink:title="00000022 - Disclosure - LEASES (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://korumedical.com/role/FederalAndStateIncomeTaxesTables" xlink:title="00000023 - Disclosure - FEDERAL AND STATE INCOME TAXES (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://korumedical.com/role/ScheduleOfAmortizationExpenseDetails" xlink:title="00000024 - Disclosure - Schedule of amortization expense (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://korumedical.com/role/ScheduleOfNetIncomePerCommonShareDetails" xlink:title="00000025 - Disclosure - Schedule of net income per common share (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://korumedical.com/role/ScheduleOfNetRevenuesByGeographyDetails" xlink:title="00000026 - Disclosure - Schedule of net revenues by geography (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://korumedical.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:title="00000027 - Disclosure - NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://korumedical.com/role/InventoryConsistsOfDetails" xlink:title="00000028 - Disclosure - Inventory consists of: (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://korumedical.com/role/ScheduleOfPropertyAndEquipmentDetails" xlink:title="00000029 - Disclosure - Schedule of property and equipment (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://korumedical.com/role/ScheduleOfTimeBasedStockOptionsDetails" xlink:title="00000030 - Disclosure - Schedule of time based stock options (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://korumedical.com/role/ScheduleOfStatusOfTimeBasedStockOptionsDetails" xlink:title="00000031 - Disclosure - Schedule of status of time based stock options (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://korumedical.com/role/ScheduleOfInformationPertainingToOptionsOutstandingDetails" xlink:title="00000032 - Disclosure - Schedule of information pertaining to options outstanding (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://korumedical.com/role/ScheduleOfPerformanceBaseOptionsOutstandingDetails" xlink:title="00000033 - Disclosure - Schedule of performance base options outstanding (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://korumedical.com/role/FollowingTableSummarizesActivitiesForOurUnvestedRestrictedStockAwardsForTwelveMonthsEndedDecember312022And2021.Details" xlink:title="00000034 - Disclosure - The following table summarizes the activities for our unvested restricted stock awards for the twelve months ended December 31, 2022, and 2021. (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://korumedical.com/role/Stock-basedCompensationDetailsNarrative" xlink:title="00000035 - Disclosure - STOCK-BASED COMPENSATION (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://korumedical.com/role/ScheduleOfComponentsOfLeaseExpenseDetails" xlink:title="00000036 - Disclosure - Schedule of components of lease expense (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://korumedical.com/role/ScheduleOfCashFlowInformationRelatedToLeasesDetails" xlink:title="00000037 - Disclosure - Schedule of cash flow information related to leases (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://korumedical.com/role/SchdeuleOfBalanceSheetInformationRelatedToLeasesDetails" xlink:title="00000038 - Disclosure - Schdeule of balance sheet information related to leases (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://korumedical.com/role/ScheduleOfMaturitiesOfLeaseLiabilitiesDetails" xlink:title="00000039 - Disclosure - Schedule of maturities of lease liabilities (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://korumedical.com/role/LeasesDetailsNarrative" xlink:title="00000040 - Disclosure - LEASES (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://korumedical.com/role/ScheduleOfProvisionForIncomeTaxesDetails" xlink:title="00000041 - Disclosure - Schedule of provision for income taxes (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://korumedical.com/role/ScheduleOfReconciliationOfIncomeTaxesDetails" xlink:title="00000042 - Disclosure - Schedule of reconciliation of income taxes (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://korumedical.com/role/ScheduleOfComponentsOfDeferredTaxAssetsDetails" xlink:title="00000043 - Disclosure - Schedule of components of deferred tax assets (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://korumedical.com/role/MajorCustomersDetailsNarrative" xlink:title="00000044 - Disclosure - MAJOR CUSTOMERS (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://korumedical.com/role/EmployeeBenefitsDetailsNarrative" xlink:title="00000045 - Disclosure - EMPLOYEE BENEFITS (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://korumedical.com/role/DebtObligationsDetailsNarrative" xlink:title="00000046 - Disclosure - DEBT OBLIGATIONS (Details Narrative)" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>10
<FILENAME>krmd-20221231_def.xml
<DESCRIPTION>INLINE XBRL DEFINITION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.17b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://korumedical.com/role/Cover" xlink:href="krmd-20221231.xsd#Cover" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/BalanceSheets" xlink:href="krmd-20221231.xsd#BalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/BalanceSheetsParenthetical" xlink:href="krmd-20221231.xsd#BalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/StatementsOfOperations" xlink:href="krmd-20221231.xsd#StatementsOfOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/StatementsOfStockholdersEquity" xlink:href="krmd-20221231.xsd#StatementsOfStockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/StatementsOfCashFlows" xlink:href="krmd-20221231.xsd#StatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPolicies" xlink:href="krmd-20221231.xsd#NatureOfOperationsAndSummaryOfSignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/Inventory" xlink:href="krmd-20221231.xsd#Inventory" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/PropertyAndEquipment" xlink:href="krmd-20221231.xsd#PropertyAndEquipment" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/Stock-basedCompensation" xlink:href="krmd-20221231.xsd#Stock-basedCompensation" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/Leases" xlink:href="krmd-20221231.xsd#Leases" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/FederalAndStateIncomeTaxes" xlink:href="krmd-20221231.xsd#FederalAndStateIncomeTaxes" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/MajorCustomers" xlink:href="krmd-20221231.xsd#MajorCustomers" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/CommitmentsAndContingencies" xlink:href="krmd-20221231.xsd#CommitmentsAndContingencies" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/EmployeeBenefits" xlink:href="krmd-20221231.xsd#EmployeeBenefits" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/DebtObligations" xlink:href="krmd-20221231.xsd#DebtObligations" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:href="krmd-20221231.xsd#NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesTables" xlink:href="krmd-20221231.xsd#NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/InventoryTables" xlink:href="krmd-20221231.xsd#InventoryTables" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/PropertyAndEquipmentTables" xlink:href="krmd-20221231.xsd#PropertyAndEquipmentTables" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/Stock-basedCompensationTables" xlink:href="krmd-20221231.xsd#Stock-basedCompensationTables" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/LeasesTables" xlink:href="krmd-20221231.xsd#LeasesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/FederalAndStateIncomeTaxesTables" xlink:href="krmd-20221231.xsd#FederalAndStateIncomeTaxesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/ScheduleOfAmortizationExpenseDetails" xlink:href="krmd-20221231.xsd#ScheduleOfAmortizationExpenseDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/ScheduleOfNetIncomePerCommonShareDetails" xlink:href="krmd-20221231.xsd#ScheduleOfNetIncomePerCommonShareDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/ScheduleOfNetRevenuesByGeographyDetails" xlink:href="krmd-20221231.xsd#ScheduleOfNetRevenuesByGeographyDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:href="krmd-20221231.xsd#NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/InventoryConsistsOfDetails" xlink:href="krmd-20221231.xsd#InventoryConsistsOfDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/ScheduleOfPropertyAndEquipmentDetails" xlink:href="krmd-20221231.xsd#ScheduleOfPropertyAndEquipmentDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/ScheduleOfTimeBasedStockOptionsDetails" xlink:href="krmd-20221231.xsd#ScheduleOfTimeBasedStockOptionsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/ScheduleOfStatusOfTimeBasedStockOptionsDetails" xlink:href="krmd-20221231.xsd#ScheduleOfStatusOfTimeBasedStockOptionsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/ScheduleOfInformationPertainingToOptionsOutstandingDetails" xlink:href="krmd-20221231.xsd#ScheduleOfInformationPertainingToOptionsOutstandingDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/ScheduleOfPerformanceBaseOptionsOutstandingDetails" xlink:href="krmd-20221231.xsd#ScheduleOfPerformanceBaseOptionsOutstandingDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/FollowingTableSummarizesActivitiesForOurUnvestedRestrictedStockAwardsForTwelveMonthsEndedDecember312022And2021.Details" xlink:href="krmd-20221231.xsd#FollowingTableSummarizesActivitiesForOurUnvestedRestrictedStockAwardsForTwelveMonthsEndedDecember312022And2021.Details" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/Stock-basedCompensationDetailsNarrative" xlink:href="krmd-20221231.xsd#Stock-basedCompensationDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/ScheduleOfComponentsOfLeaseExpenseDetails" xlink:href="krmd-20221231.xsd#ScheduleOfComponentsOfLeaseExpenseDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/ScheduleOfCashFlowInformationRelatedToLeasesDetails" xlink:href="krmd-20221231.xsd#ScheduleOfCashFlowInformationRelatedToLeasesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/SchdeuleOfBalanceSheetInformationRelatedToLeasesDetails" xlink:href="krmd-20221231.xsd#SchdeuleOfBalanceSheetInformationRelatedToLeasesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/ScheduleOfMaturitiesOfLeaseLiabilitiesDetails" xlink:href="krmd-20221231.xsd#ScheduleOfMaturitiesOfLeaseLiabilitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/LeasesDetailsNarrative" xlink:href="krmd-20221231.xsd#LeasesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/ScheduleOfProvisionForIncomeTaxesDetails" xlink:href="krmd-20221231.xsd#ScheduleOfProvisionForIncomeTaxesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/ScheduleOfReconciliationOfIncomeTaxesDetails" xlink:href="krmd-20221231.xsd#ScheduleOfReconciliationOfIncomeTaxesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/ScheduleOfComponentsOfDeferredTaxAssetsDetails" xlink:href="krmd-20221231.xsd#ScheduleOfComponentsOfDeferredTaxAssetsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/MajorCustomersDetailsNarrative" xlink:href="krmd-20221231.xsd#MajorCustomersDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/EmployeeBenefitsDetailsNarrative" xlink:href="krmd-20221231.xsd#EmployeeBenefitsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/DebtObligationsDetailsNarrative" xlink:href="krmd-20221231.xsd#DebtObligationsDetailsNarrative" xlink:type="simple" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll" arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" />
    <link:definitionLink xlink:type="extended" xlink:role="http://korumedical.com/role/Cover" xlink:title="00000001 - Document - Cover" />
    <link:definitionLink xlink:type="extended" xlink:role="http://korumedical.com/role/BalanceSheets" xlink:title="00000002 - Statement - BALANCE SHEETS" />
    <link:definitionLink xlink:type="extended" xlink:role="http://korumedical.com/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - BALANCE SHEETS (Parenthetical)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://korumedical.com/role/StatementsOfOperations" xlink:title="00000004 - Statement - STATEMENTS OF OPERATIONS" />
    <link:definitionLink xlink:type="extended" xlink:role="http://korumedical.com/role/StatementsOfStockholdersEquity" xlink:title="00000005 - Statement - STATEMENTS OF STOCKHOLDERS&apos; EQUITY">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapRetainedEarningsMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockMember" xlink:label="loc_us-gaapTreasuryStockMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapTreasuryStockMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity_60" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding_60" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueShareBasedCompensation_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueShareBasedCompensation_60" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesShareBasedCompensation_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesShareBasedCompensation_60" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_60" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_60" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="krmd-20221231.xsd#krmd_NewIssuanceLitigationSettlementAmountIssuance" xlink:label="loc_krmdNewIssuanceLitigationSettlementAmountIssuance_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_krmdNewIssuanceLitigationSettlementAmountIssuance_60" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="krmd-20221231.xsd#krmd_NewIssuanceLitigationSettlementShareIssuance" xlink:label="loc_krmdNewIssuanceLitigationSettlementShareIssuance_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_krmdNewIssuanceLitigationSettlementShareIssuance_60" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueStockOptionsExercised_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueStockOptionsExercised_60" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_60" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLoss_60" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="krmd-20221231.xsd#krmd_Compensationexpenserelatedtorestrictedstockawards" xlink:label="loc_krmdCompensationexpenserelatedtorestrictedstockawards_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_krmdCompensationexpenserelatedtorestrictedstockawards_60" xlink:type="arc" order="12" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://korumedical.com/role/StatementsOfCashFlows" xlink:title="00000006 - Statement - STATEMENTS OF CASH FLOWS" />
    <link:definitionLink xlink:type="extended" xlink:role="http://korumedical.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPolicies" xlink:title="00000007 - Disclosure - NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES" />
    <link:definitionLink xlink:type="extended" xlink:role="http://korumedical.com/role/Inventory" xlink:title="00000008 - Disclosure - INVENTORY" />
    <link:definitionLink xlink:type="extended" xlink:role="http://korumedical.com/role/PropertyAndEquipment" xlink:title="00000009 - Disclosure - PROPERTY AND EQUIPMENT" />
    <link:definitionLink xlink:type="extended" xlink:role="http://korumedical.com/role/Stock-basedCompensation" xlink:title="00000010 - Disclosure - STOCK-BASED COMPENSATION" />
    <link:definitionLink xlink:type="extended" xlink:role="http://korumedical.com/role/Leases" xlink:title="00000011 - Disclosure - LEASES" />
    <link:definitionLink xlink:type="extended" xlink:role="http://korumedical.com/role/FederalAndStateIncomeTaxes" xlink:title="00000012 - Disclosure - FEDERAL AND STATE INCOME TAXES" />
    <link:definitionLink xlink:type="extended" xlink:role="http://korumedical.com/role/MajorCustomers" xlink:title="00000013 - Disclosure - MAJOR CUSTOMERS" />
    <link:definitionLink xlink:type="extended" xlink:role="http://korumedical.com/role/CommitmentsAndContingencies" xlink:title="00000014 - Disclosure - COMMITMENTS AND CONTINGENCIES" />
    <link:definitionLink xlink:type="extended" xlink:role="http://korumedical.com/role/EmployeeBenefits" xlink:title="00000015 - Disclosure - EMPLOYEE BENEFITS" />
    <link:definitionLink xlink:type="extended" xlink:role="http://korumedical.com/role/DebtObligations" xlink:title="00000016 - Disclosure - DEBT OBLIGATIONS" />
    <link:definitionLink xlink:type="extended" xlink:role="http://korumedical.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:title="00000017 - Disclosure - NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://korumedical.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesTables" xlink:title="00000018 - Disclosure - NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://korumedical.com/role/InventoryTables" xlink:title="00000019 - Disclosure - INVENTORY (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://korumedical.com/role/PropertyAndEquipmentTables" xlink:title="00000020 - Disclosure - PROPERTY AND EQUIPMENT (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://korumedical.com/role/Stock-basedCompensationTables" xlink:title="00000021 - Disclosure - STOCK-BASED COMPENSATION (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://korumedical.com/role/LeasesTables" xlink:title="00000022 - Disclosure - LEASES (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://korumedical.com/role/FederalAndStateIncomeTaxesTables" xlink:title="00000023 - Disclosure - FEDERAL AND STATE INCOME TAXES (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://korumedical.com/role/ScheduleOfAmortizationExpenseDetails" xlink:title="00000024 - Disclosure - Schedule of amortization expense (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://korumedical.com/role/ScheduleOfNetIncomePerCommonShareDetails" xlink:title="00000025 - Disclosure - Schedule of net income per common share (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaapSubsidiarySaleOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockMember" xlink:label="loc_us-gaapEmployeeStockMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_us-gaapEmployeeStockMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLoss_70" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract" xlink:label="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasicAbstract_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasicAbstract_70" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaapWeightedAverageNumberOfDilutedSharesOutstanding_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapWeightedAverageNumberOfDilutedSharesOutstanding_70" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants" xlink:label="loc_us-gaapIncrementalCommonSharesAttributableToCallOptionsAndWarrants_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapIncrementalCommonSharesAttributableToCallOptionsAndWarrants_70" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="krmd-20221231.xsd#krmd_IncrementalCommonSharesAttributableToRestrictedStock" xlink:label="loc_krmdIncrementalCommonSharesAttributableToRestrictedStock_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_krmdIncrementalCommonSharesAttributableToRestrictedStock_70" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="krmd-20221231.xsd#krmd_WeightedAverageNumberOfSharesOutstanding" xlink:label="loc_krmdWeightedAverageNumberOfSharesOutstanding_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_krmdWeightedAverageNumberOfSharesOutstanding_70" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaapEarningsPerShareAbstract_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapEarningsPerShareAbstract_70" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaapEarningsPerShareBasic_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapEarningsPerShareBasic_70" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaapEarningsPerShareDiluted_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapEarningsPerShareDiluted_70" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_70" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="krmd-20221231.xsd#krmd_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount1" xlink:label="loc_krmdAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount1_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_krmdAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount1_70" xlink:type="arc" order="10" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://korumedical.com/role/ScheduleOfNetRevenuesByGeographyDetails" xlink:title="00000026 - Disclosure - Schedule of net revenues by geography (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srtStatementGeographicalAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtStatementGeographicalAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srtSegmentGeographicalDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtStatementGeographicalAxis" xlink:to="loc_srtSegmentGeographicalDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srtSegmentGeographicalDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtStatementGeographicalAxis" xlink:to="loc_srtSegmentGeographicalDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US" xlink:label="loc_countryUS_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_countryUS_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonUsMember" xlink:label="loc_us-gaapNonUsMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_us-gaapNonUsMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues" xlink:label="loc_us-gaapRevenues_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapRevenues_70" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://korumedical.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:title="00000027 - Disclosure - NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaapPropertyPlantAndEquipmentLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="krmd-20221231.xsd#krmd_PatentsAndTrademarksMember" xlink:label="loc_krmdPatentsAndTrademarksMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_krmdPatentsAndTrademarksMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember_20" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_30" xlink:type="arc" order="32" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="krmd-20221231.xsd#krmd_FurnitureAndOfficeEquipmentMember" xlink:label="loc_krmdFurnitureAndOfficeEquipmentMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_krmdFurnitureAndOfficeEquipmentMember_50" xlink:type="arc" order="52" />
      <link:loc xlink:type="locator" xlink:href="krmd-20221231.xsd#krmd_EquipmentAndToolingMember" xlink:label="loc_krmdEquipmentAndToolingMember_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_krmdEquipmentAndToolingMember_70" xlink:type="arc" order="72" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="loc_us-gaapFairValueByAssetClassAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapFairValueByAssetClassAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="loc_us-gaapFairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapFairValueByAssetClassAxis" xlink:to="loc_us-gaapFairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="loc_us-gaapFairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFairValueByAssetClassAxis" xlink:to="loc_us-gaapFairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentMember" xlink:label="loc_us-gaapPropertyPlantAndEquipmentMember_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="loc_us-gaapPropertyPlantAndEquipmentMember_90" xlink:type="arc" order="91" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfReportableSegments" xlink:label="loc_us-gaapNumberOfReportableSegments_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapNumberOfReportableSegments_120" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashUninsuredAmount" xlink:label="loc_us-gaapCashUninsuredAmount_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapCashUninsuredAmount_120" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetUsefulLife_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetUsefulLife_120" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="krmd-20221231.xsd#krmd_AmortizationOfIntangibleAssets1" xlink:label="loc_krmdAmortizationOfIntangibleAssets1_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_krmdAmortizationOfIntangibleAssets1_120" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaapPropertyPlantAndEquipmentUsefulLife_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentUsefulLife_120" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaapDepreciationDepletionAndAmortization_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapDepreciationDepletionAndAmortization_120" xlink:type="arc" order="5" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://korumedical.com/role/InventoryConsistsOfDetails" xlink:title="00000028 - Disclosure - Inventory consists of: (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://korumedical.com/role/ScheduleOfPropertyAndEquipmentDetails" xlink:title="00000029 - Disclosure - Schedule of property and equipment (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaapPropertyPlantAndEquipmentLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="krmd-20221231.xsd#krmd_FurnitureAndOfficeEquipmentMember" xlink:label="loc_krmdFurnitureAndOfficeEquipmentMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_krmdFurnitureAndOfficeEquipmentMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaapLeaseholdImprovementsMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapLeaseholdImprovementsMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="krmd-20221231.xsd#krmd_ManufacturingEquipmentAndToolingMember" xlink:label="loc_krmdManufacturingEquipmentAndToolingMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_krmdManufacturingEquipmentAndToolingMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaapPropertyPlantAndEquipmentGross_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentGross_90" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_90" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet_90" xlink:type="arc" order="2" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://korumedical.com/role/ScheduleOfTimeBasedStockOptionsDetails" xlink:title="00000030 - Disclosure - Schedule of time based stock options (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapPlanNameAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="krmd-20221231.xsd#krmd_StockOptionPlan2015Member" xlink:label="loc_krmdStockOptionPlan2015Member_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_krmdStockOptionPlan2015Member_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="krmd-20221231.xsd#krmd_StockOptionPlan2021Member" xlink:label="loc_krmdStockOptionPlan2021Member_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_krmdStockOptionPlan2021Member_70" xlink:type="arc" order="71" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="krmd-20221231.xsd#krmd_TimeBasedSharesOptionsMember" xlink:label="loc_krmdTimeBasedSharesOptionsMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_krmdTimeBasedSharesOptionsMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember_20" xlink:type="arc" order="23" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_30" xlink:type="arc" order="33" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_120" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_120" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_120" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments_120" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_120" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_120" xlink:type="arc" order="5" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://korumedical.com/role/ScheduleOfStatusOfTimeBasedStockOptionsDetails" xlink:title="00000031 - Disclosure - Schedule of status of time based stock options (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapPlanNameAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="krmd-20221231.xsd#krmd_StockOptionPlan2015Member" xlink:label="loc_krmdStockOptionPlan2015Member_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_krmdStockOptionPlan2015Member_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="krmd-20221231.xsd#krmd_StockOptionPlan2021Member" xlink:label="loc_krmdStockOptionPlan2021Member_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_krmdStockOptionPlan2021Member_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_110" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_110" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_110" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_110" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_110" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_110" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_110" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_110" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_110" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_110" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_110" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaapAllocatedShareBasedCompensationExpense_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapAllocatedShareBasedCompensationExpense_110" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="krmd-20221231.xsd#krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber2" xlink:label="loc_krmdShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber2_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_krmdShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber2_110" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="krmd-20221231.xsd#krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice2" xlink:label="loc_krmdShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice2_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_krmdShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice2_110" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="krmd-20221231.xsd#krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross2" xlink:label="loc_krmdShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross2_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_krmdShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross2_110" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="krmd-20221231.xsd#krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice2" xlink:label="loc_krmdShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice2_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_krmdShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice2_110" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="krmd-20221231.xsd#krmd_StockIssuedDuringPeriodSharesStockOptionsExercised2" xlink:label="loc_krmdStockIssuedDuringPeriodSharesStockOptionsExercised2_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_krmdStockIssuedDuringPeriodSharesStockOptionsExercised2_110" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="krmd-20221231.xsd#krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice2" xlink:label="loc_krmdShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice2_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_krmdShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice2_110" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="krmd-20221231.xsd#krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod2" xlink:label="loc_krmdShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod2_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_krmdShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod2_110" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="krmd-20221231.xsd#krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice2" xlink:label="loc_krmdShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice2_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_krmdShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice2_110" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="krmd-20221231.xsd#krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice2" xlink:label="loc_krmdShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice2_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_krmdShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice2_110" xlink:type="arc" order="24" />
      <link:loc xlink:type="locator" xlink:href="krmd-20221231.xsd#krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue2" xlink:label="loc_krmdShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue2_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_krmdShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue2_110" xlink:type="arc" order="25" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensation_110" xlink:type="arc" order="26" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://korumedical.com/role/ScheduleOfInformationPertainingToOptionsOutstandingDetails" xlink:title="00000032 - Disclosure - Schedule of information pertaining to options outstanding (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapPlanNameAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="krmd-20221231.xsd#krmd_StockOptionPlan2015Member" xlink:label="loc_krmdStockOptionPlan2015Member_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_krmdStockOptionPlan2015Member_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="krmd-20221231.xsd#krmd_StockOptionPlan2021Member" xlink:label="loc_krmdStockOptionPlan2021Member_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_krmdStockOptionPlan2021Member_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="krmd-20221231.xsd#krmd_TimeBasedSharesOptionsMember" xlink:label="loc_krmdTimeBasedSharesOptionsMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_krmdTimeBasedSharesOptionsMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="krmd-20221231.xsd#krmd_ExercisePrice1Member" xlink:label="loc_krmdExercisePrice1Member_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_krmdExercisePrice1Member_0" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_50" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaapSharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_50" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:label="loc_us-gaapSharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_50" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_50" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:label="loc_us-gaapSharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_50" xlink:type="arc" order="4" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://korumedical.com/role/ScheduleOfPerformanceBaseOptionsOutstandingDetails" xlink:title="00000033 - Disclosure - Schedule of performance base options outstanding (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PerformanceSharesMember" xlink:label="loc_us-gaapPerformanceSharesMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapPerformanceSharesMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="krmd-20221231.xsd#krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber1" xlink:label="loc_krmdShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber1_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_krmdShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber1_60" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="krmd-20221231.xsd#krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice1" xlink:label="loc_krmdShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice1_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_krmdShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice1_60" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="krmd-20221231.xsd#krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross1" xlink:label="loc_krmdShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross1_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_krmdShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross1_60" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="krmd-20221231.xsd#krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice1" xlink:label="loc_krmdShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice1_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_krmdShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice1_60" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="krmd-20221231.xsd#krmd_StockIssuedDuringPeriodSharesStockOptionsExercised1" xlink:label="loc_krmdStockIssuedDuringPeriodSharesStockOptionsExercised1_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_krmdStockIssuedDuringPeriodSharesStockOptionsExercised1_60" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="krmd-20221231.xsd#krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice1" xlink:label="loc_krmdShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice1_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_krmdShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice1_60" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="krmd-20221231.xsd#krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod1" xlink:label="loc_krmdShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod1_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_krmdShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod1_60" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="krmd-20221231.xsd#krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice1" xlink:label="loc_krmdShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice1_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_krmdShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice1_60" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_60" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_60" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="krmd-20221231.xsd#krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice1" xlink:label="loc_krmdShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice1_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_krmdShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice1_60" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_60" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="krmd-20221231.xsd#krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue1" xlink:label="loc_krmdShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue1_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_krmdShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue1_60" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="krmd-20221231.xsd#krmd_AllocatedShareBasedCompensationExpense1" xlink:label="loc_krmdAllocatedShareBasedCompensationExpense1_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_krmdAllocatedShareBasedCompensationExpense1_60" xlink:type="arc" order="13" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://korumedical.com/role/FollowingTableSummarizesActivitiesForOurUnvestedRestrictedStockAwardsForTwelveMonthsEndedDecember312022And2021.Details" xlink:title="00000034 - Disclosure - The following table summarizes the activities for our unvested restricted stock awards for the twelve months ended December 31, 2022, and 2021. (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="krmd-20221231.xsd#krmd_RestrictedStockAwardsMember" xlink:label="loc_krmdRestrictedStockAwardsMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_krmdRestrictedStockAwardsMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapPlanNameAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="krmd-20221231.xsd#krmd_StockOptionPlan2021Member" xlink:label="loc_krmdStockOptionPlan2021Member_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_krmdStockOptionPlan2021Member_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="krmd-20221231.xsd#krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberUnvested" xlink:label="loc_krmdShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberUnvested_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_krmdShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberUnvested_60" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="krmd-20221231.xsd#krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceUnvested" xlink:label="loc_krmdShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceUnvested_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_krmdShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceUnvested_60" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="krmd-20221231.xsd#krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrossUnvested" xlink:label="loc_krmdShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrossUnvested_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_krmdShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrossUnvested_60" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="krmd-20221231.xsd#krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePriceUnvested" xlink:label="loc_krmdShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePriceUnvested_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_krmdShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePriceUnvested_60" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="krmd-20221231.xsd#krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodGross" xlink:label="loc_krmdShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodGross_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_krmdShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodGross_60" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="krmd-20221231.xsd#krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice" xlink:label="loc_krmdShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_krmdShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice_60" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="krmd-20221231.xsd#krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodUnvested" xlink:label="loc_krmdShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodUnvested_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_krmdShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodUnvested_60" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="krmd-20221231.xsd#krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePriceUnvested" xlink:label="loc_krmdShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePriceUnvested_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_krmdShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePriceUnvested_60" xlink:type="arc" order="7" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://korumedical.com/role/Stock-basedCompensationDetailsNarrative" xlink:title="00000035 - Disclosure - STOCK-BASED COMPENSATION (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapPlanNameAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="krmd-20221231.xsd#krmd_StockOptionPlan2015Member" xlink:label="loc_krmdStockOptionPlan2015Member_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_krmdStockOptionPlan2015Member_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="krmd-20221231.xsd#krmd_StockOptionPlan2021Member" xlink:label="loc_krmdStockOptionPlan2021Member_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_krmdStockOptionPlan2021Member_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_srtTitleOfIndividualAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="krmd-20221231.xsd#krmd_ExecutiveskeyEmployeesAndConsultantsMember" xlink:label="loc_krmdExecutiveskeyEmployeesAndConsultantsMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_krmdExecutiveskeyEmployeesAndConsultantsMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_DirectorMember" xlink:label="loc_srtDirectorMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_srtDirectorMember_40" xlink:type="arc" order="42" />
      <link:loc xlink:type="locator" xlink:href="krmd-20221231.xsd#krmd_ExecutiveMember" xlink:label="loc_krmdExecutiveMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_krmdExecutiveMember_50" xlink:type="arc" order="52" />
      <link:loc xlink:type="locator" xlink:href="krmd-20221231.xsd#krmd_NonEmployeeDirectorAndBoardAdvisorMember" xlink:label="loc_krmdNonEmployeeDirectorAndBoardAdvisorMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_krmdNonEmployeeDirectorAndBoardAdvisorMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_BoardOfDirectorsChairmanMember" xlink:label="loc_srtBoardOfDirectorsChairmanMember_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_srtBoardOfDirectorsChairmanMember_70" xlink:type="arc" order="71" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ChiefExecutiveOfficerMember" xlink:label="loc_srtChiefExecutiveOfficerMember_240" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_srtChiefExecutiveOfficerMember_240" xlink:type="arc" order="242" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="krmd-20221231.xsd#krmd_ChiefExecutiveOfficerLindaTharbyMember" xlink:label="loc_krmdChiefExecutiveOfficerLindaTharbyMember_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_krmdChiefExecutiveOfficerLindaTharbyMember_100" xlink:type="arc" order="101" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="krmd-20221231.xsd#krmd_TimeBasedSharesOptionsMember" xlink:label="loc_krmdTimeBasedSharesOptionsMember_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_krmdTimeBasedSharesOptionsMember_120" xlink:type="arc" order="122" />
      <link:loc xlink:type="locator" xlink:href="krmd-20221231.xsd#krmd_RestrictedStockAwardsMember" xlink:label="loc_krmdRestrictedStockAwardsMember_250" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_krmdRestrictedStockAwardsMember_250" xlink:type="arc" order="252" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaapFinancialInstrumentAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapFinancialInstrumentAxis" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapFinancialInstrumentAxis" xlink:to="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFinancialInstrumentAxis" xlink:to="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockOptionMember" xlink:label="loc_us-gaapStockOptionMember_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="loc_us-gaapStockOptionMember_220" xlink:type="arc" order="222" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="krmd-20221231.xsd#krmd_EmploymentAgreementMember" xlink:label="loc_krmdEmploymentAgreementMember_240" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_krmdEmploymentAgreementMember_240" xlink:type="arc" order="241" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_280" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_280" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="krmd-20221231.xsd#krmd_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan2015" xlink:label="loc_krmdStockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan2015_280" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_krmdStockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan2015_280" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesShareBasedCompensation_280" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesShareBasedCompensation_280" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan_280" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan_280" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="krmd-20221231.xsd#krmd_NonemployeeServicesTransactionCost" xlink:label="loc_krmdNonemployeeServicesTransactionCost_280" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_krmdNonemployeeServicesTransactionCost_280" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransaction" xlink:label="loc_us-gaapShareBasedGoodsAndNonemployeeServicesTransaction_280" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedGoodsAndNonemployeeServicesTransaction_280" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueEmployeeStockOwnershipPlan_280" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueEmployeeStockOwnershipPlan_280" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_280" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_280" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaapIncomeTaxExpenseBenefit_280" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapIncomeTaxExpenseBenefit_280" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_280" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_280" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaapProceedsFromStockOptionsExercised_280" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapProceedsFromStockOptionsExercised_280" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="krmd-20221231.xsd#krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_krmdShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriodWeightedAverageGrantDateFairValue_280" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_krmdShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriodWeightedAverageGrantDateFairValue_280" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="krmd-20221231.xsd#krmd_StockIssuedDuringPeriodSharesStockOptionsExercised1" xlink:label="loc_krmdStockIssuedDuringPeriodSharesStockOptionsExercised1_280" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_krmdStockIssuedDuringPeriodSharesStockOptionsExercised1_280" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_280" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_280" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_280" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_280" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_280" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_280" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation_280" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensation_280" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="krmd-20221231.xsd#krmd_CompensationCost" xlink:label="loc_krmdCompensationCost_280" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_krmdCompensationCost_280" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="krmd-20221231.xsd#krmd_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm3" xlink:label="loc_krmdSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm3_280" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_krmdSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm3_280" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued_280" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapCommonStockSharesIssued_280" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue_280" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapCommonStockValue_280" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="krmd-20221231.xsd#krmd_UnrecognizedCompensationCost" xlink:label="loc_krmdUnrecognizedCompensationCost_280" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_krmdUnrecognizedCompensationCost_280" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="krmd-20221231.xsd#krmd_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm4" xlink:label="loc_krmdSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm4_280" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_krmdSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm4_280" xlink:type="arc" order="22" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://korumedical.com/role/ScheduleOfComponentsOfLeaseExpenseDetails" xlink:title="00000036 - Disclosure - Schedule of components of lease expense (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://korumedical.com/role/ScheduleOfCashFlowInformationRelatedToLeasesDetails" xlink:title="00000037 - Disclosure - Schedule of cash flow information related to leases (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://korumedical.com/role/SchdeuleOfBalanceSheetInformationRelatedToLeasesDetails" xlink:title="00000038 - Disclosure - Schdeule of balance sheet information related to leases (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://korumedical.com/role/ScheduleOfMaturitiesOfLeaseLiabilitiesDetails" xlink:title="00000039 - Disclosure - Schedule of maturities of lease liabilities (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://korumedical.com/role/LeasesDetailsNarrative" xlink:title="00000040 - Disclosure - LEASES (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://korumedical.com/role/ScheduleOfProvisionForIncomeTaxesDetails" xlink:title="00000041 - Disclosure - Schedule of provision for income taxes (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://korumedical.com/role/ScheduleOfReconciliationOfIncomeTaxesDetails" xlink:title="00000042 - Disclosure - Schedule of reconciliation of income taxes (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://korumedical.com/role/ScheduleOfComponentsOfDeferredTaxAssetsDetails" xlink:title="00000043 - Disclosure - Schedule of components of deferred tax assets (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://korumedical.com/role/MajorCustomersDetailsNarrative" xlink:title="00000044 - Disclosure - MAJOR CUSTOMERS (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskLineItems" xlink:label="loc_us-gaapConcentrationRiskLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTable" xlink:label="loc_us-gaapConcentrationRiskTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapConcentrationRiskLineItems" xlink:to="loc_us-gaapConcentrationRiskTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="loc_us-gaapConcentrationRiskByBenchmarkAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapConcentrationRiskTable" xlink:to="loc_us-gaapConcentrationRiskByBenchmarkAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaapConcentrationRiskBenchmarkDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapConcentrationRiskByBenchmarkAxis" xlink:to="loc_us-gaapConcentrationRiskBenchmarkDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaapConcentrationRiskBenchmarkDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapConcentrationRiskByBenchmarkAxis" xlink:to="loc_us-gaapConcentrationRiskBenchmarkDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesRevenueNetMember" xlink:label="loc_us-gaapSalesRevenueNetMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapConcentrationRiskBenchmarkDomain" xlink:to="loc_us-gaapSalesRevenueNetMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="loc_us-gaapConcentrationRiskByTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapConcentrationRiskTable" xlink:to="loc_us-gaapConcentrationRiskByTypeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaapConcentrationRiskTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapConcentrationRiskByTypeAxis" xlink:to="loc_us-gaapConcentrationRiskTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaapConcentrationRiskTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapConcentrationRiskByTypeAxis" xlink:to="loc_us-gaapConcentrationRiskTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="loc_us-gaapCustomerConcentrationRiskMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapConcentrationRiskTypeDomain" xlink:to="loc_us-gaapCustomerConcentrationRiskMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MajorCustomersAxis" xlink:label="loc_srtMajorCustomersAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapConcentrationRiskTable" xlink:to="loc_srtMajorCustomersAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srtNameOfMajorCustomerDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtMajorCustomersAxis" xlink:to="loc_srtNameOfMajorCustomerDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srtNameOfMajorCustomerDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtMajorCustomersAxis" xlink:to="loc_srtNameOfMajorCustomerDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="krmd-20221231.xsd#krmd_CustomerOneMember" xlink:label="loc_krmdCustomerOneMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtNameOfMajorCustomerDomain" xlink:to="loc_krmdCustomerOneMember_0" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="loc_us-gaapConcentrationRiskPercentage1_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapConcentrationRiskLineItems" xlink:to="loc_us-gaapConcentrationRiskPercentage1_30" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://korumedical.com/role/EmployeeBenefitsDetailsNarrative" xlink:title="00000045 - Disclosure - EMPLOYEE BENEFITS (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://korumedical.com/role/DebtObligationsDetailsNarrative" xlink:title="00000046 - Disclosure - DEBT OBLIGATIONS (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtLineItems" xlink:label="loc_us-gaapShortTermDebtLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShortTermDebtTable" xlink:label="loc_us-gaapScheduleOfShortTermDebtTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapScheduleOfShortTermDebtTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_deiLegalEntityAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="krmd-20221231.xsd#krmd_AONPremiumFinanceLLCMember" xlink:label="loc_krmdAONPremiumFinanceLLCMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_krmdAONPremiumFinanceLLCMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaapDebtInstrumentAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_us-gaapDebtInstrumentAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaapDebtInstrumentNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapDebtInstrumentAxis" xlink:to="loc_us-gaapDebtInstrumentNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaapDebtInstrumentNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapDebtInstrumentAxis" xlink:to="loc_us-gaapDebtInstrumentNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="krmd-20221231.xsd#krmd_PromissoryNoteMember" xlink:label="loc_krmdPromissoryNoteMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_krmdPromissoryNoteMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityAxis" xlink:label="loc_us-gaapCreditFacilityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_us-gaapCreditFacilityAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain" xlink:label="loc_us-gaapCreditFacilityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapCreditFacilityAxis" xlink:to="loc_us-gaapCreditFacilityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain" xlink:label="loc_us-gaapCreditFacilityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapCreditFacilityAxis" xlink:to="loc_us-gaapCreditFacilityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditMember" xlink:label="loc_us-gaapLineOfCreditMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCreditFacilityDomain" xlink:to="loc_us-gaapLineOfCreditMember_10" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesPayable" xlink:label="loc_us-gaapNotesPayable_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapNotesPayable_30" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="krmd-20221231.xsd#krmd_NotePayableTerms" xlink:label="loc_krmdNotePayableTerms_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_krmdNotePayableTerms_30" xlink:type="arc" order="1" />
    </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>11
<FILENAME>krmd-20221231_lab.xml
<DESCRIPTION>INLINE XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.17b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US">Equity Components [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US">Common Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US">Retained Earnings [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockMember" xlink:label="us-gaap_TreasuryStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TreasuryStockMember" xlink:to="us-gaap_TreasuryStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TreasuryStockMember_lbl" xml:lang="en-US">Treasury Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20221231.xsd#krmd_PatentsAndTrademarksMember" xlink:label="krmd_PatentsAndTrademarksMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_PatentsAndTrademarksMember" xlink:to="krmd_PatentsAndTrademarksMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="krmd_PatentsAndTrademarksMember_lbl" xml:lang="en-US">Patents And Trademarks [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeAxis_lbl" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MinimumMember_lbl" xml:lang="en-US">Minimum [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MaximumMember_lbl" xml:lang="en-US">Maximum [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20221231.xsd#krmd_FurnitureAndOfficeEquipmentMember" xlink:label="krmd_FurnitureAndOfficeEquipmentMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_FurnitureAndOfficeEquipmentMember" xlink:to="krmd_FurnitureAndOfficeEquipmentMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="krmd_FurnitureAndOfficeEquipmentMember_lbl" xml:lang="en-US">Furniture And Office Equipment [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20221231.xsd#krmd_EquipmentAndToolingMember" xlink:label="krmd_EquipmentAndToolingMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_EquipmentAndToolingMember" xlink:to="krmd_EquipmentAndToolingMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="krmd_EquipmentAndToolingMember_lbl" xml:lang="en-US">Equipment and tooling [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="us-gaap_FairValueByAssetClassAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueByAssetClassAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByAssetClassAxis_lbl" xml:lang="en-US">Asset Class [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentMember" xlink:label="us-gaap_PropertyPlantAndEquipmentMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentMember" xlink:to="us-gaap_PropertyPlantAndEquipmentMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentMember_lbl" xml:lang="en-US">Property, Plant and Equipment [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xml:lang="en-US">Sale of Stock [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockMember" xlink:label="us-gaap_EmployeeStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockMember" xlink:to="us-gaap_EmployeeStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeStockMember_lbl" xml:lang="en-US">Employee Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_StatementGeographicalAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_StatementGeographicalAxis_lbl" xml:lang="en-US">Geographical [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US" xlink:label="country_US" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_US" xlink:to="country_US_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="country_US_lbl" xml:lang="en-US">UNITED STATES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonUsMember" xlink:label="us-gaap_NonUsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonUsMember" xlink:to="us-gaap_NonUsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonUsMember_lbl" xml:lang="en-US">Non-US [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdImprovementsMember" xlink:to="us-gaap_LeaseholdImprovementsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xml:lang="en-US">Leasehold Improvements [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20221231.xsd#krmd_ManufacturingEquipmentAndToolingMember" xlink:label="krmd_ManufacturingEquipmentAndToolingMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_ManufacturingEquipmentAndToolingMember" xlink:to="krmd_ManufacturingEquipmentAndToolingMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="krmd_ManufacturingEquipmentAndToolingMember_lbl" xml:lang="en-US">Manufacturing Equipment And Tooling [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameAxis_lbl" xml:lang="en-US">Plan Name [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20221231.xsd#krmd_StockOptionPlan2015Member" xlink:label="krmd_StockOptionPlan2015Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_StockOptionPlan2015Member" xlink:to="krmd_StockOptionPlan2015Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="krmd_StockOptionPlan2015Member_lbl" xml:lang="en-US">Stock Option Plan 2015 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_TitleOfIndividualAxis_lbl" xml:lang="en-US">Title of Individual [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20221231.xsd#krmd_ExecutiveskeyEmployeesAndConsultantsMember" xlink:label="krmd_ExecutiveskeyEmployeesAndConsultantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_ExecutiveskeyEmployeesAndConsultantsMember" xlink:to="krmd_ExecutiveskeyEmployeesAndConsultantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="krmd_ExecutiveskeyEmployeesAndConsultantsMember_lbl" xml:lang="en-US">Executiveskey Employees And Consultants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20221231.xsd#krmd_StockOptionPlan2021Member" xlink:label="krmd_StockOptionPlan2021Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_StockOptionPlan2021Member" xlink:to="krmd_StockOptionPlan2021Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="krmd_StockOptionPlan2021Member_lbl" xml:lang="en-US">Stock Option Plan 2021 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_DirectorMember" xlink:label="srt_DirectorMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_DirectorMember" xlink:to="srt_DirectorMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_DirectorMember_lbl" xml:lang="en-US">Director [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20221231.xsd#krmd_ExecutiveMember" xlink:label="krmd_ExecutiveMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_ExecutiveMember" xlink:to="krmd_ExecutiveMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="krmd_ExecutiveMember_lbl" xml:lang="en-US">Executive [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20221231.xsd#krmd_NonEmployeeDirectorAndBoardAdvisorMember" xlink:label="krmd_NonEmployeeDirectorAndBoardAdvisorMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_NonEmployeeDirectorAndBoardAdvisorMember" xlink:to="krmd_NonEmployeeDirectorAndBoardAdvisorMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="krmd_NonEmployeeDirectorAndBoardAdvisorMember_lbl" xml:lang="en-US">Non Employee Director And Board Advisor [Member[</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_BoardOfDirectorsChairmanMember" xlink:label="srt_BoardOfDirectorsChairmanMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_BoardOfDirectorsChairmanMember" xlink:to="srt_BoardOfDirectorsChairmanMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_BoardOfDirectorsChairmanMember_lbl" xml:lang="en-US">Board of Directors Chairman [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xml:lang="en-US">Related Party [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20221231.xsd#krmd_ChiefExecutiveOfficerLindaTharbyMember" xlink:label="krmd_ChiefExecutiveOfficerLindaTharbyMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_ChiefExecutiveOfficerLindaTharbyMember" xlink:to="krmd_ChiefExecutiveOfficerLindaTharbyMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="krmd_ChiefExecutiveOfficerLindaTharbyMember_lbl" xml:lang="en-US">Chief Executive Officer Linda Tharby [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AwardTypeAxis_lbl" xml:lang="en-US">Award Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20221231.xsd#krmd_TimeBasedSharesOptionsMember" xlink:label="krmd_TimeBasedSharesOptionsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_TimeBasedSharesOptionsMember" xlink:to="krmd_TimeBasedSharesOptionsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="krmd_TimeBasedSharesOptionsMember_lbl" xml:lang="en-US">Time Based Shares Options [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_FinancialInstrumentAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinancialInstrumentAxis_lbl" xml:lang="en-US">Financial Instrument [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockOptionMember" xlink:label="us-gaap_StockOptionMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockOptionMember" xlink:to="us-gaap_StockOptionMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockOptionMember_lbl" xml:lang="en-US">Equity Option [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20221231.xsd#krmd_EmploymentAgreementMember" xlink:label="krmd_EmploymentAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_EmploymentAgreementMember" xlink:to="krmd_EmploymentAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="krmd_EmploymentAgreementMember_lbl" xml:lang="en-US">Employment Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ChiefExecutiveOfficerMember" xlink:label="srt_ChiefExecutiveOfficerMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ChiefExecutiveOfficerMember" xlink:to="srt_ChiefExecutiveOfficerMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ChiefExecutiveOfficerMember_lbl" xml:lang="en-US">Chief Executive Officer [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20221231.xsd#krmd_RestrictedStockAwardsMember" xlink:label="krmd_RestrictedStockAwardsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_RestrictedStockAwardsMember" xlink:to="krmd_RestrictedStockAwardsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="krmd_RestrictedStockAwardsMember_lbl" xml:lang="en-US">Restricted Stock Awards [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_lbl" xml:lang="en-US">Exercise Price Range [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20221231.xsd#krmd_ExercisePrice1Member" xlink:label="krmd_ExercisePrice1Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_ExercisePrice1Member" xlink:to="krmd_ExercisePrice1Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="krmd_ExercisePrice1Member_lbl" xml:lang="en-US">Exercise Price1 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PerformanceSharesMember" xlink:label="us-gaap_PerformanceSharesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PerformanceSharesMember" xlink:to="us-gaap_PerformanceSharesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PerformanceSharesMember_lbl" xml:lang="en-US">Performance Shares [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis_lbl" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesRevenueNetMember" xlink:label="us-gaap_SalesRevenueNetMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SalesRevenueNetMember" xlink:to="us-gaap_SalesRevenueNetMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SalesRevenueNetMember_lbl" xml:lang="en-US">Revenue Benchmark [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="us-gaap_ConcentrationRiskByTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskByTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskByTypeAxis_lbl" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="us-gaap_CustomerConcentrationRiskMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CustomerConcentrationRiskMember" xlink:to="us-gaap_CustomerConcentrationRiskMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CustomerConcentrationRiskMember_lbl" xml:lang="en-US">Customer Concentration Risk [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MajorCustomersAxis" xlink:label="srt_MajorCustomersAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MajorCustomersAxis" xlink:to="srt_MajorCustomersAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MajorCustomersAxis_lbl" xml:lang="en-US">Customer [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20221231.xsd#krmd_CustomerOneMember" xlink:label="krmd_CustomerOneMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_CustomerOneMember" xlink:to="krmd_CustomerOneMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="krmd_CustomerOneMember_lbl" xml:lang="en-US">Customer One [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LegalEntityAxis" xlink:to="dei_LegalEntityAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LegalEntityAxis_lbl" xml:lang="en-US">Legal Entity [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20221231.xsd#krmd_AONPremiumFinanceLLCMember" xlink:label="krmd_AONPremiumFinanceLLCMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_AONPremiumFinanceLLCMember" xlink:to="krmd_AONPremiumFinanceLLCMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="krmd_AONPremiumFinanceLLCMember_lbl" xml:lang="en-US">A O N Premium Finance L L C [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentAxis_lbl" xml:lang="en-US">Debt Instrument [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20221231.xsd#krmd_PromissoryNoteMember" xlink:label="krmd_PromissoryNoteMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_PromissoryNoteMember" xlink:to="krmd_PromissoryNoteMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="krmd_PromissoryNoteMember_lbl" xml:lang="en-US">Promissory Note [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityAxis" xlink:label="us-gaap_CreditFacilityAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CreditFacilityAxis_lbl" xml:lang="en-US">Credit Facility [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditMember" xlink:label="us-gaap_LineOfCreditMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditMember" xlink:to="us-gaap_LineOfCreditMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LineOfCreditMember_lbl" xml:lang="en-US">Line of Credit [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Cover [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockCommonShares" xlink:label="us-gaap_TreasuryStockCommonShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TreasuryStockCommonShares" xlink:to="us-gaap_TreasuryStockCommonShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TreasuryStockCommonShares_lbl" xml:lang="en-US">Treasury Stock, Common, Shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorFirmId" xlink:to="dei_AuditorFirmId_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorFirmId_lbl" xml:lang="en-US">Auditor Firm ID</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorName" xlink:label="dei_AuditorName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorName" xlink:to="dei_AuditorName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorName_lbl" xml:lang="en-US">Auditor Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorLocation" xlink:to="dei_AuditorLocation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorLocation_lbl" xml:lang="en-US">Auditor Location</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US">ASSETS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">CURRENT ASSETS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash and cash equivalents</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNetCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xml:lang="en-US">Accounts receivable less allowance for doubtful accounts of $21,459 and $24,271 for December 31, 2022, and December 31, 2021, respectively</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryNet_lbl" xml:lang="en-US">Inventory</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherReceivables" xlink:label="us-gaap_OtherReceivables" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherReceivables" xlink:to="us-gaap_OtherReceivables_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherReceivables_lbl" xml:lang="en-US">Other receivables</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="us-gaap_PrepaidExpenseCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseCurrent" xlink:to="us-gaap_PrepaidExpenseCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseCurrent_lbl" xml:lang="en-US">Prepaid expenses and other</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">TOTAL CURRENT ASSETS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US">Property and equipment, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xml:lang="en-US">Intangible assets, net of accumulated amortization of $325,872 and $263,729 at December 31, 2022 and December 31, 2021, respectively</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US">Operating lease right-of-use assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxAssetsNet" xlink:label="us-gaap_DeferredIncomeTaxAssetsNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxAssetsNet" xlink:to="us-gaap_DeferredIncomeTaxAssetsNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredIncomeTaxAssetsNet_lbl" xml:lang="en-US">Deferred income tax assets, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xml:lang="en-US">Other assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">TOTAL ASSETS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">CURRENT LIABILITIES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US">Accounts payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Accrued expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesPayableCurrent" xlink:label="us-gaap_NotesPayableCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesPayableCurrent" xlink:to="us-gaap_NotesPayableCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NotesPayableCurrent_lbl" xml:lang="en-US">Note Payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesCurrent" xlink:to="us-gaap_OtherLiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherLiabilitiesCurrent_lbl" xml:lang="en-US">Other liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xml:lang="en-US">Accrued payroll and related taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityCurrent" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityCurrent" xlink:to="us-gaap_FinanceLeaseLiabilityCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent_lbl" xml:lang="en-US">Finance lease liability &#8211; current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xml:lang="en-US">Operating lease liability &#8211; current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">TOTAL CURRENT LIABILITIES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:to="us-gaap_FinanceLeaseLiabilityNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent_lbl" xml:lang="en-US">Finance lease liability, net current portion</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xml:lang="en-US">Operating lease liability, net of current portion</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US">TOTAL LIABILITIES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US">STOCKHOLDERS&#8217; EQUITY</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US">Common stock, $0.01 par value, 75,000,000 shares authorized, 48,861,891 and 48,044,162 shares issued; 45,441,389 and 44,623,660 shares outstanding at December 31, 2022, and December 31, 2021, respectively</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xml:lang="en-US">Additional paid-in capital</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockValue" xlink:label="us-gaap_TreasuryStockValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TreasuryStockValue" xlink:to="us-gaap_TreasuryStockValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_TreasuryStockValue_lbl" xml:lang="en-US">Treasury stock, 3,420,502 shares at December 31, 2022 and December 31, 2021, at cost</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US">Retained Deficit</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">TOTAL STOCKHOLDERS&#8217; EQUITY</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">TOTAL LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:to="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_lbl" xml:lang="en-US">Accounts receivable, allowance for credit loss, current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl" xml:lang="en-US">Finite-lived intangible assets, accumulated amortization</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Common stock, par or stated value per share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US">Common stock, shares authorized</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US">Common stock, shares, issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US">Common stock, shares, outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockShares" xlink:label="us-gaap_TreasuryStockShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TreasuryStockShares" xlink:to="us-gaap_TreasuryStockShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TreasuryStockShares_lbl" xml:lang="en-US">Treasury stock, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US">Income Statement [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_Revenues_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Revenues_lbl" xml:lang="en-US">NET REVENUES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="us-gaap_CostOfGoodsAndServicesSold" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfGoodsAndServicesSold" xlink:to="us-gaap_CostOfGoodsAndServicesSold_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostOfGoodsAndServicesSold_lbl" xml:lang="en-US">Cost of goods sold</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GrossProfit" xlink:label="us-gaap_GrossProfit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GrossProfit" xlink:to="us-gaap_GrossProfit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_GrossProfit_lbl" xml:lang="en-US">Gross Profit</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US">OPERATING EXPENSES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense_lbl" xml:lang="en-US">Selling, general and administrative</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Research and development</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationDepletionAndAmortization" xlink:to="us-gaap_DepreciationDepletionAndAmortization_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xml:lang="en-US">Depreciation and amortization</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US">Total Operating Expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US">Net Operating Loss</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xml:lang="en-US">Non-Operating Income</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_lbl" xml:lang="en-US">Loss on foreign currency exchange</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_lbl" xml:lang="en-US">Gain on disposal of fixed assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherIncome" xlink:label="us-gaap_OtherIncome" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherIncome" xlink:to="us-gaap_OtherIncome_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherIncome_lbl" xml:lang="en-US">Other Income</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xml:lang="en-US">Interest income, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xml:lang="en-US">TOTAL OTHER INCOME</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_lbl" xml:lang="en-US">LOSS BEFORE TAXES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Income tax benefit</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">NET LOSS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xml:lang="en-US">NET LOSS PER SHARE</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US">Basic</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US">Diluted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl" xml:lang="en-US">WEIGHTED AVERAGE COMMON SHARES OUTSTANDING</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US">Basic</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US">Diluted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US">Statement [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US">Statement [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquity_2_lbl" xml:lang="en-US">Beginning balance, value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US">Balance beginning (in shares)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_lbl" xml:lang="en-US">Issuance of stock-based compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:to="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_lbl" xml:lang="en-US">Issuance of stock-based compensation (in shares)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_lbl" xml:lang="en-US">Compensation expense related to stock options</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_lbl" xml:lang="en-US">Compensation expense related to restricted stock awards</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20221231.xsd#krmd_NewIssuanceLitigationSettlementAmountIssuance" xlink:label="krmd_NewIssuanceLitigationSettlementAmountIssuance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_NewIssuanceLitigationSettlementAmountIssuance" xlink:to="krmd_NewIssuanceLitigationSettlementAmountIssuance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="krmd_NewIssuanceLitigationSettlementAmountIssuance_lbl" xml:lang="en-US">Litigation settlement share issuance</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20221231.xsd#krmd_NewIssuanceLitigationSettlementShareIssuance" xlink:label="krmd_NewIssuanceLitigationSettlementShareIssuance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_NewIssuanceLitigationSettlementShareIssuance" xlink:to="krmd_NewIssuanceLitigationSettlementShareIssuance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="krmd_NewIssuanceLitigationSettlementShareIssuance_lbl" xml:lang="en-US">Litigation settlement share issuance (in shares)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xml:lang="en-US">Issuance upon options exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US">Issuance upon options exercised (in shares)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_2_lbl" xml:lang="en-US">Net loss</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20221231.xsd#krmd_Compensationexpenserelatedtorestrictedstockawards" xlink:label="krmd_Compensationexpenserelatedtorestrictedstockawards" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_Compensationexpenserelatedtorestrictedstockawards" xlink:to="krmd_Compensationexpenserelatedtorestrictedstockawards_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="krmd_Compensationexpenserelatedtorestrictedstockawards_lbl" xml:lang="en-US">Compensation expense related to restricted stock awards (in shares)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquity_3_lbl" xml:lang="en-US">Ending balance, value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharesOutstanding_2_lbl" xml:lang="en-US">Balance ending (in shares)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">CASH FLOWS FROM OPERATING ACTIVITIES</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NetIncomeLoss_3_lbl" xml:lang="en-US">Net Loss</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US">Stock-based compensation expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnSaleOfOtherAssets" xlink:label="us-gaap_GainLossOnSaleOfOtherAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnSaleOfOtherAssets" xlink:to="us-gaap_GainLossOnSaleOfOtherAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_GainLossOnSaleOfOtherAssets_lbl" xml:lang="en-US">Loss on disposal of fixed assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxesAndTaxCredits" xlink:label="us-gaap_DeferredIncomeTaxesAndTaxCredits" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxesAndTaxCredits" xlink:to="us-gaap_DeferredIncomeTaxesAndTaxCredits_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredIncomeTaxesAndTaxCredits_lbl" xml:lang="en-US">Deferred income taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20221231.xsd#krmd_RouLandlordCredit" xlink:label="krmd_RouLandlordCredit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_RouLandlordCredit" xlink:to="krmd_RouLandlordCredit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="krmd_RouLandlordCredit_lbl" xml:lang="en-US">ROU landlord credit</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xml:lang="en-US">Decrease/(Increase)&#160;in accounts receivable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="us-gaap_IncreaseDecreaseInInventories" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInInventories" xlink:to="us-gaap_IncreaseDecreaseInInventories_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInInventories_lbl" xml:lang="en-US">(Increase)/Decrease in inventory</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherReceivables" xlink:label="us-gaap_IncreaseDecreaseInOtherReceivables" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherReceivables" xlink:to="us-gaap_IncreaseDecreaseInOtherReceivables_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInOtherReceivables_lbl" xml:lang="en-US">Increase in other receivables</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xml:lang="en-US">Decrease/(Increase) in prepaid expenses and other assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xml:lang="en-US">Increase in accounts payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_lbl" xml:lang="en-US">Increase/(Decrease) in accrued payroll and related taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:to="us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_lbl" xml:lang="en-US">Increase in other liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_lbl" xml:lang="en-US">Increase in accrued expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">NET CASH USED IN OPERATING ACTIVITIES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US">CASH FLOWS FROM INVESTING ACTIVITIES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireProductiveAssets" xlink:label="us-gaap_PaymentsToAcquireProductiveAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireProductiveAssets" xlink:to="us-gaap_PaymentsToAcquireProductiveAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquireProductiveAssets_lbl" xml:lang="en-US">Purchases of property and equipment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireIntangibleAssets" xlink:to="us-gaap_PaymentsToAcquireIntangibleAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets_lbl" xml:lang="en-US">Purchases of intangible assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfProductiveAssets" xlink:label="us-gaap_ProceedsFromSaleOfProductiveAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleOfProductiveAssets" xlink:to="us-gaap_ProceedsFromSaleOfProductiveAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromSaleOfProductiveAssets_lbl" xml:lang="en-US">Proceeds from disposal of property and equipment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US">NET CASH USED IN INVESTING ACTIVITIES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US">CASH FLOWS FROM FINANCING ACTIVITIES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US">Proceeds from issuance of equity</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20221231.xsd#krmd_CommonStockIssuanceAsSettlementForLitigation" xlink:label="krmd_CommonStockIssuanceAsSettlementForLitigation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_CommonStockIssuanceAsSettlementForLitigation" xlink:to="krmd_CommonStockIssuanceAsSettlementForLitigation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="krmd_CommonStockIssuanceAsSettlementForLitigation_lbl" xml:lang="en-US">Common stock issuance settlement of litigation</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20221231.xsd#krmd_BorrowingsFromIndebtedness" xlink:label="krmd_BorrowingsFromIndebtedness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_BorrowingsFromIndebtedness" xlink:to="krmd_BorrowingsFromIndebtedness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="krmd_BorrowingsFromIndebtedness_lbl" xml:lang="en-US">Borrowings from indebtedness</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20221231.xsd#krmd_PaymentsOnIndebtedness" xlink:label="krmd_PaymentsOnIndebtedness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_PaymentsOnIndebtedness" xlink:to="krmd_PaymentsOnIndebtedness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="krmd_PaymentsOnIndebtedness_lbl" xml:lang="en-US">Payments on indebtedness</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeasePrincipalPayments" xlink:label="us-gaap_FinanceLeasePrincipalPayments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeasePrincipalPayments" xlink:to="us-gaap_FinanceLeasePrincipalPayments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_FinanceLeasePrincipalPayments_lbl" xml:lang="en-US">Payments on finance lease liability</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">NET CASH PROVIDED BY FINANCING ACTIVITIES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xml:lang="en-US">NET DECREASE IN CASH AND CASH EQUIVALENTS</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_2_lbl" xml:lang="en-US">CASH AND CASH EQUIVALENTS, BEGINNING OF YEAR</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_3_lbl" xml:lang="en-US">CASH AND CASH EQUIVALENTS, END OF YEAR</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US">Supplemental Information</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20221231.xsd#krmd_CashPaidDuringPeriodsForAbstract" xlink:label="krmd_CashPaidDuringPeriodsForAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_CashPaidDuringPeriodsForAbstract" xlink:to="krmd_CashPaidDuringPeriodsForAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="krmd_CashPaidDuringPeriodsForAbstract_lbl" xml:lang="en-US">Cash paid during the years for:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaidNet" xlink:to="us-gaap_InterestPaidNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestPaidNet_lbl" xml:lang="en-US">Interest</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxesPaidNet" xlink:label="us-gaap_IncomeTaxesPaidNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxesPaidNet" xlink:to="us-gaap_IncomeTaxesPaidNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxesPaidNet_lbl" xml:lang="en-US">Income taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xml:lang="en-US">Schedule of Non-Cash Operating, Investing and Financing Activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20221231.xsd#krmd_IssuanceOfCommonStockCompensation" xlink:label="krmd_IssuanceOfCommonStockCompensation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_IssuanceOfCommonStockCompensation" xlink:to="krmd_IssuanceOfCommonStockCompensation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="krmd_IssuanceOfCommonStockCompensation_lbl" xml:lang="en-US">Issuance of common stock as compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssued1" xlink:label="us-gaap_StockIssued1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssued1" xlink:to="us-gaap_StockIssued1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssued1_lbl" xml:lang="en-US">Issuance of common stock as settlement for litigation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" xlink:label="us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" xlink:to="us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock_lbl" xml:lang="en-US">NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="us-gaap_InventoryDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryDisclosureAbstract" xlink:to="us-gaap_InventoryDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryDisclosureAbstract_lbl" xml:lang="en-US">Inventory Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureTextBlock" xlink:label="us-gaap_InventoryDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryDisclosureTextBlock" xlink:to="us-gaap_InventoryDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryDisclosureTextBlock_lbl" xml:lang="en-US">INVENTORY</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xml:lang="en-US">PROPERTY AND EQUIPMENT</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xml:lang="en-US">Share-Based Payment Arrangement [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xml:lang="en-US">STOCK-BASED COMPENSATION</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LeasesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeasesAbstract_lbl" xml:lang="en-US">Leases [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesOfLesseeDisclosureTextBlock" xlink:label="us-gaap_LeasesOfLesseeDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeasesOfLesseeDisclosureTextBlock" xlink:to="us-gaap_LeasesOfLesseeDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeasesOfLesseeDisclosureTextBlock_lbl" xml:lang="en-US">LEASES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US">FEDERAL AND STATE INCOME TAXES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RisksAndUncertaintiesAbstract" xlink:label="us-gaap_RisksAndUncertaintiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RisksAndUncertaintiesAbstract" xlink:to="us-gaap_RisksAndUncertaintiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RisksAndUncertaintiesAbstract_lbl" xml:lang="en-US">Risks and Uncertainties [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskDisclosureTextBlock" xlink:label="us-gaap_ConcentrationRiskDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskDisclosureTextBlock" xlink:to="us-gaap_ConcentrationRiskDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskDisclosureTextBlock_lbl" xml:lang="en-US">MAJOR CUSTOMERS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US">COMMITMENTS AND CONTINGENCIES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_CompensationAndRetirementDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract_lbl" xml:lang="en-US">Retirement Benefits [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:to="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_lbl" xml:lang="en-US">EMPLOYEE BENEFITS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtDisclosureAbstract_lbl" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="us-gaap_DebtDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureTextBlock" xlink:to="us-gaap_DebtDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl" xml:lang="en-US">DEBT OBLIGATIONS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NatureOfOperations" xlink:label="us-gaap_NatureOfOperations" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NatureOfOperations" xlink:to="us-gaap_NatureOfOperations_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NatureOfOperations_lbl" xml:lang="en-US">NATURE OF OPERATIONS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xml:lang="en-US">BASIS OF PRESENTATION</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xml:lang="en-US">CASH AND CASH EQUIVALENTS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryPolicyTextBlock" xlink:label="us-gaap_InventoryPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryPolicyTextBlock" xlink:to="us-gaap_InventoryPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_InventoryPolicyTextBlock_lbl" xml:lang="en-US">INVENTORY</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:label="us-gaap_IntangibleAssetsFiniteLivedPolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:to="us-gaap_IntangibleAssetsFiniteLivedPolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IntangibleAssetsFiniteLivedPolicy_lbl" xml:lang="en-US">INTANGIBLE ASSETS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xml:lang="en-US">INCOME TAXES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xml:lang="en-US">PROPERTY AND EQUIPMENT</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xml:lang="en-US">STOCK-BASED COMPENSATION</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US">NET LOSS PER COMMON SHARE</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US">USE OF ESTIMATES IN THE FINANCIAL STATEMENTS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:to="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_lbl" xml:lang="en-US">REVENUE RECOGNITION</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xml:lang="en-US">LEASES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US">ACCOUNTING PRONOUNCEMENTS RECENTLY ADOPTED</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20221231.xsd#krmd_AccountingPronouncementsNotYetAdopted" xlink:label="krmd_AccountingPronouncementsNotYetAdopted" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_AccountingPronouncementsNotYetAdopted" xlink:to="krmd_AccountingPronouncementsNotYetAdopted_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="krmd_AccountingPronouncementsNotYetAdopted_lbl" xml:lang="en-US">ACCOUNTING PRONOUNCEMENTS NOT YET ADOPTED</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xml:lang="en-US">FAIR VALUE MEASUREMENTS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xml:lang="en-US">IMPAIRMENT OF LONG-LIVED ASSETS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock_lbl" xml:lang="en-US">Schedule of amortization expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xml:lang="en-US">Schedule of net income per common share</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20221231.xsd#krmd_ScheduleOfNetRevenuesByGeography" xlink:label="krmd_ScheduleOfNetRevenuesByGeography" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_ScheduleOfNetRevenuesByGeography" xlink:to="krmd_ScheduleOfNetRevenuesByGeography_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="krmd_ScheduleOfNetRevenuesByGeography_lbl" xml:lang="en-US">Schedule of net revenues by geography</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_lbl" xml:lang="en-US">Inventory consists of:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xml:lang="en-US">Schedule of property and equipment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US">Schedule of time based stock options</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US">Schedule of status of time based stock options</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20221231.xsd#krmd_ScheduleOfShareBasedCompensationStockOptionsActivityAmendedTableTextBlock" xlink:label="krmd_ScheduleOfShareBasedCompensationStockOptionsActivityAmendedTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_ScheduleOfShareBasedCompensationStockOptionsActivityAmendedTableTextBlock" xlink:to="krmd_ScheduleOfShareBasedCompensationStockOptionsActivityAmendedTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="krmd_ScheduleOfShareBasedCompensationStockOptionsActivityAmendedTableTextBlock_lbl" xml:lang="en-US">Schedule of information pertaining to options outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_lbl" xml:lang="en-US">Schedule of time based stock options</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfOtherShareBasedCompensationActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfOtherShareBasedCompensationActivityTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfOtherShareBasedCompensationActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfOtherShareBasedCompensationActivityTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ScheduleOfOtherShareBasedCompensationActivityTableTextBlock_lbl" xml:lang="en-US">Schedule of status of time based stock options</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20221231.xsd#krmd_ScheduleOfShareBasedCompensationtaxBenefitsAssociatedWithRestrictedStockAwardCompensationTableTextBlock" xlink:label="krmd_ScheduleOfShareBasedCompensationtaxBenefitsAssociatedWithRestrictedStockAwardCompensationTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_ScheduleOfShareBasedCompensationtaxBenefitsAssociatedWithRestrictedStockAwardCompensationTableTextBlock" xlink:to="krmd_ScheduleOfShareBasedCompensationtaxBenefitsAssociatedWithRestrictedStockAwardCompensationTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="krmd_ScheduleOfShareBasedCompensationtaxBenefitsAssociatedWithRestrictedStockAwardCompensationTableTextBlock_lbl" xml:lang="en-US">Schedule of information pertaining to options outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock" xlink:label="us-gaap_ShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock" xlink:to="us-gaap_ShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock_lbl" xml:lang="en-US">Schedule of performance base options outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock" xlink:label="us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock" xlink:to="us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock_lbl" xml:lang="en-US">The following table summarizes the activities for our unvested restricted stock awards for the twelve months ended December 31, 2022, and 2021.</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="us-gaap_LeaseCostTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCostTableTextBlock" xlink:to="us-gaap_LeaseCostTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseCostTableTextBlock_lbl" xml:lang="en-US">Schedule of components of lease expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLeaseIncomeTableTextBlock" xlink:label="us-gaap_OperatingLeaseLeaseIncomeTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLeaseIncomeTableTextBlock" xlink:to="us-gaap_OperatingLeaseLeaseIncomeTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLeaseIncomeTableTextBlock_lbl" xml:lang="en-US">Schedule of cash flow information related to leases</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock" xlink:label="us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock" xlink:to="us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock_lbl" xml:lang="en-US">Schdeule of balance sheet information related to leases</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xml:lang="en-US">Schedule of maturities of lease liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:to="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" xml:lang="en-US">Schedule of provision for income taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xml:lang="en-US">Schedule of reconciliation of income taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xml:lang="en-US">Schedule of components of deferred tax assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_lbl" xml:lang="en-US">2023</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_lbl" xml:lang="en-US">2024</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_lbl" xml:lang="en-US">2025</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_lbl" xml:lang="en-US">2026</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_lbl" xml:lang="en-US">2027</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_lbl" xml:lang="en-US">Thereafter</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_2_lbl" xml:lang="en-US">Total amortization expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_lbl" xml:lang="en-US">Weighted Average Outstanding Shares:</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_2_lbl" xml:lang="en-US">Outstanding shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants" xlink:label="us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants" xlink:to="us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants_lbl" xml:lang="en-US">Option shares includable</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20221231.xsd#krmd_IncrementalCommonSharesAttributableToRestrictedStock" xlink:label="krmd_IncrementalCommonSharesAttributableToRestrictedStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_IncrementalCommonSharesAttributableToRestrictedStock" xlink:to="krmd_IncrementalCommonSharesAttributableToRestrictedStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="krmd_IncrementalCommonSharesAttributableToRestrictedStock_lbl" xml:lang="en-US">Restricted stock includable</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20221231.xsd#krmd_WeightedAverageNumberOfSharesOutstanding" xlink:label="krmd_WeightedAverageNumberOfSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_WeightedAverageNumberOfSharesOutstanding" xlink:to="krmd_WeightedAverageNumberOfSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="krmd_WeightedAverageNumberOfSharesOutstanding_lbl" xml:lang="en-US">&#160;Total</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EarningsPerShareAbstract_2_lbl" xml:lang="en-US">Net loss per share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US">Option shares excluded</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20221231.xsd#krmd_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount1" xlink:label="krmd_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount1" xlink:to="krmd_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="krmd_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount1_lbl" xml:lang="en-US">Restricted stock shares excluded</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_Revenues_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_Revenues_2_lbl" xml:lang="en-US">Revenues</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfReportableSegments" xlink:label="us-gaap_NumberOfReportableSegments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfReportableSegments" xlink:to="us-gaap_NumberOfReportableSegments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NumberOfReportableSegments_lbl" xml:lang="en-US">Number of segments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashUninsuredAmount" xlink:label="us-gaap_CashUninsuredAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashUninsuredAmount" xlink:to="us-gaap_CashUninsuredAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashUninsuredAmount_lbl" xml:lang="en-US">FDIC cash uninsured amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:to="us-gaap_FiniteLivedIntangibleAssetUsefulLife_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife_lbl" xml:lang="en-US">Estimated useful lives</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20221231.xsd#krmd_AmortizationOfIntangibleAssets1" xlink:label="krmd_AmortizationOfIntangibleAssets1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_AmortizationOfIntangibleAssets1" xlink:to="krmd_AmortizationOfIntangibleAssets1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="krmd_AmortizationOfIntangibleAssets1_lbl" xml:lang="en-US">AmortizationOfIntangibleAssets1</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xml:lang="en-US">Estimated useful lives of property and equipment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryWorkInProcessAndRawMaterials" xlink:label="us-gaap_InventoryWorkInProcessAndRawMaterials" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryWorkInProcessAndRawMaterials" xlink:to="us-gaap_InventoryWorkInProcessAndRawMaterials_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryWorkInProcessAndRawMaterials_lbl" xml:lang="en-US">Raw materials and work-in-process</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryFinishedGoods" xlink:label="us-gaap_InventoryFinishedGoods" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryFinishedGoods" xlink:to="us-gaap_InventoryFinishedGoods_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryFinishedGoods_lbl" xml:lang="en-US">Finished goods</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryGross" xlink:label="us-gaap_InventoryGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryGross" xlink:to="us-gaap_InventoryGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryGross_lbl" xml:lang="en-US">Inventory, Gross</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryValuationReserves" xlink:label="us-gaap_InventoryValuationReserves" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryValuationReserves" xlink:to="us-gaap_InventoryValuationReserves_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_InventoryValuationReserves_lbl" xml:lang="en-US">Less: reserve for obsolete inventory</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xml:lang="en-US">Total property and equipment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xml:lang="en-US">Less: accumulated depreciation and amortization</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US">Dividend yield</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xml:lang="en-US">Expected volatility</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_lbl" xml:lang="en-US">Weighted-average volatility</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments_lbl" xml:lang="en-US">Expected dividends</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US">Expected term (in years)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xml:lang="en-US">Risk-free rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US">Outstanding at beginning</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Outstanding at beginning</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US">Granted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Granted</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_2_lbl" xml:lang="en-US">Exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xml:lang="en-US">Forfeited</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Forfeited</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2_lbl" xml:lang="en-US">Outstanding at ending</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Outstanding at ending</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xml:lang="en-US">Options exercisable at ending</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US">Options exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted average fair value of options granted during the period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US">Stock-based compensation expense</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20221231.xsd#krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber2" xlink:label="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber2" xlink:to="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber2_lbl" xml:lang="en-US">Outstanding at beginning</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20221231.xsd#krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice2" xlink:label="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice2" xlink:to="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice2_lbl" xml:lang="en-US">Outstanding at beginning</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20221231.xsd#krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross2" xlink:label="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross2" xlink:to="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross2_lbl" xml:lang="en-US">Granted</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20221231.xsd#krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice2" xlink:label="krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice2" xlink:to="krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice2_lbl" xml:lang="en-US">Granted</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20221231.xsd#krmd_StockIssuedDuringPeriodSharesStockOptionsExercised2" xlink:label="krmd_StockIssuedDuringPeriodSharesStockOptionsExercised2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_StockIssuedDuringPeriodSharesStockOptionsExercised2" xlink:to="krmd_StockIssuedDuringPeriodSharesStockOptionsExercised2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="krmd_StockIssuedDuringPeriodSharesStockOptionsExercised2_lbl" xml:lang="en-US">Exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20221231.xsd#krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice2" xlink:label="krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice2" xlink:to="krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice2_lbl" xml:lang="en-US">Exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20221231.xsd#krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod2" xlink:label="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod2" xlink:to="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod2_lbl" xml:lang="en-US">Forfeited</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20221231.xsd#krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice2" xlink:label="krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice2" xlink:to="krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice2_lbl" xml:lang="en-US">Forfeited</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber2" xlink:to="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber2_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber2_2_lbl" xml:lang="en-US">Outstanding at ending</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice2" xlink:to="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice2_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice2_2_lbl" xml:lang="en-US">Outstanding at ending</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20221231.xsd#krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice2" xlink:label="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice2" xlink:to="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice2_lbl" xml:lang="en-US">Options exercisable at ending</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20221231.xsd#krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue2" xlink:label="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue2" xlink:to="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue2_lbl" xml:lang="en-US">Weighted average fair value of options granted during the period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_lbl" xml:lang="en-US">Number outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US">Weighted average remaining contractual life</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_lbl" xml:lang="en-US">Weighted average exercise price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_lbl" xml:lang="en-US">Number exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_lbl" xml:lang="en-US">Weighted average exercise price</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20221231.xsd#krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber1" xlink:label="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber1" xlink:to="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber1_lbl" xml:lang="en-US">Outstanding at beginning</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20221231.xsd#krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice1" xlink:label="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice1" xlink:to="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice1_lbl" xml:lang="en-US">Outstanding at beginning</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20221231.xsd#krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross1" xlink:label="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross1" xlink:to="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross1_lbl" xml:lang="en-US">Options exercisable at ending</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20221231.xsd#krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice1" xlink:label="krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice1" xlink:to="krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice1_lbl" xml:lang="en-US">Granted</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20221231.xsd#krmd_StockIssuedDuringPeriodSharesStockOptionsExercised1" xlink:label="krmd_StockIssuedDuringPeriodSharesStockOptionsExercised1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_StockIssuedDuringPeriodSharesStockOptionsExercised1" xlink:to="krmd_StockIssuedDuringPeriodSharesStockOptionsExercised1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="krmd_StockIssuedDuringPeriodSharesStockOptionsExercised1_lbl" xml:lang="en-US">Exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20221231.xsd#krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice1" xlink:label="krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice1" xlink:to="krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice1_lbl" xml:lang="en-US">Exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20221231.xsd#krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod1" xlink:label="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod1" xlink:to="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod1_lbl" xml:lang="en-US">Forfeited</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20221231.xsd#krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice1" xlink:label="krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice1" xlink:to="krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice1_lbl" xml:lang="en-US">Forfeited</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20221231.xsd#krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice1" xlink:label="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice1" xlink:to="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice1_lbl" xml:lang="en-US">Options exercisable at ending</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_2_lbl" xml:lang="en-US">Weighted average fair value of options granted during the period</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20221231.xsd#krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue1" xlink:label="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue1" xlink:to="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue1_lbl" xml:lang="en-US">Weighted average fair value of options granted during the period</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20221231.xsd#krmd_AllocatedShareBasedCompensationExpense1" xlink:label="krmd_AllocatedShareBasedCompensationExpense1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_AllocatedShareBasedCompensationExpense1" xlink:to="krmd_AllocatedShareBasedCompensationExpense1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="krmd_AllocatedShareBasedCompensationExpense1_lbl" xml:lang="en-US">Stock-based compensation expense</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20221231.xsd#krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberUnvested" xlink:label="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberUnvested" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberUnvested" xlink:to="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberUnvested_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberUnvested_lbl" xml:lang="en-US">Outstanding at beginning</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20221231.xsd#krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceUnvested" xlink:label="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceUnvested" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceUnvested" xlink:to="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceUnvested_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceUnvested_lbl" xml:lang="en-US">Outstanding at beginning</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20221231.xsd#krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrossUnvested" xlink:label="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrossUnvested" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrossUnvested" xlink:to="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrossUnvested_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrossUnvested_lbl" xml:lang="en-US">Granted</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20221231.xsd#krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePriceUnvested" xlink:label="krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePriceUnvested" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePriceUnvested" xlink:to="krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePriceUnvested_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePriceUnvested_lbl" xml:lang="en-US">Granted</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20221231.xsd#krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodGross" xlink:label="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodGross" xlink:to="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodGross_lbl" xml:lang="en-US">Vested</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20221231.xsd#krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice" xlink:label="krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice" xlink:to="krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Vested</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20221231.xsd#krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodUnvested" xlink:label="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodUnvested" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodUnvested" xlink:to="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodUnvested_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodUnvested_lbl" xml:lang="en-US">Forfeited/canceled</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20221231.xsd#krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePriceUnvested" xlink:label="krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePriceUnvested" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePriceUnvested" xlink:to="krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePriceUnvested_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePriceUnvested_lbl" xml:lang="en-US">Forfeited/canceled</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberUnvested" xlink:to="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberUnvested_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberUnvested_2_lbl" xml:lang="en-US">Outstanding at ending</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceUnvested" xlink:to="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceUnvested_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceUnvested_2_lbl" xml:lang="en-US">Outstanding at ending</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_2_lbl" xml:lang="en-US">Common stock, shares, outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20221231.xsd#krmd_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan2015" xlink:label="krmd_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan2015" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan2015" xlink:to="krmd_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan2015_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="krmd_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan2015_lbl" xml:lang="en-US">Stock issued during period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:to="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_2_lbl" xml:lang="en-US">Available for issuance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan_lbl" xml:lang="en-US">Common stock issued, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20221231.xsd#krmd_NonemployeeServicesTransactionCost" xlink:label="krmd_NonemployeeServicesTransactionCost" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_NonemployeeServicesTransactionCost" xlink:to="krmd_NonemployeeServicesTransactionCost_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="krmd_NonemployeeServicesTransactionCost_lbl" xml:lang="en-US">Nonemployee services transaction cost</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransaction" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransaction" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransaction" xlink:to="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransaction_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransaction_lbl" xml:lang="en-US">Share-based goods and nonemployee services transaction</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan_lbl" xml:lang="en-US">Aggregate stock price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Stock options granted</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxExpenseBenefit_2_lbl" xml:lang="en-US">Tax benefit</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_lbl" xml:lang="en-US">Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xml:lang="en-US">Proceeds from Stock Options Exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20221231.xsd#krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriodWeightedAverageGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted-average grant-date fair value options granted</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_StockIssuedDuringPeriodSharesStockOptionsExercised1" xlink:to="krmd_StockIssuedDuringPeriodSharesStockOptionsExercised1_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="krmd_StockIssuedDuringPeriodSharesStockOptionsExercised1_2_lbl" xml:lang="en-US">Options exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xml:lang="en-US">Total unrecognized compensation cost</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US">Weighted-average period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_lbl" xml:lang="en-US">Fair value of shares</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20221231.xsd#krmd_CompensationCost" xlink:label="krmd_CompensationCost" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_CompensationCost" xlink:to="krmd_CompensationCost_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="krmd_CompensationCost_lbl" xml:lang="en-US">Unrecognized compensation cost</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20221231.xsd#krmd_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm3" xlink:label="krmd_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm3" xlink:to="krmd_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="krmd_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm3_lbl" xml:lang="en-US">Weighted-average period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockSharesIssued_2_lbl" xml:lang="en-US">Common stock issued, shares</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockValue_2_lbl" xml:lang="en-US">Aggregate stock price</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20221231.xsd#krmd_UnrecognizedCompensationCost" xlink:label="krmd_UnrecognizedCompensationCost" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_UnrecognizedCompensationCost" xlink:to="krmd_UnrecognizedCompensationCost_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="krmd_UnrecognizedCompensationCost_lbl" xml:lang="en-US">Unrecognized compensation cost</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20221231.xsd#krmd_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm4" xlink:label="krmd_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm4" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm4" xlink:to="krmd_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="krmd_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm4_lbl" xml:lang="en-US">Weighted-average period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseCost" xlink:to="us-gaap_OperatingLeaseCost_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseCost_lbl" xml:lang="en-US">Operating lease cost</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermLeaseCost" xlink:label="us-gaap_ShortTermLeaseCost" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermLeaseCost" xlink:to="us-gaap_ShortTermLeaseCost_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermLeaseCost_lbl" xml:lang="en-US">Short-term lease cost</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCost" xlink:label="us-gaap_LeaseCost" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_LeaseCost_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseCost_lbl" xml:lang="en-US">Total lease cost</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20221231.xsd#krmd_FinanceLeaseCost1Abstract" xlink:label="krmd_FinanceLeaseCost1Abstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_FinanceLeaseCost1Abstract" xlink:to="krmd_FinanceLeaseCost1Abstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="krmd_FinanceLeaseCost1Abstract_lbl" xml:lang="en-US">Finance lease cost:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetAmortization" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:to="us-gaap_FinanceLeaseRightOfUseAssetAmortization_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetAmortization_lbl" xml:lang="en-US">Amortization of right-of-use assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseInterestExpense" xlink:label="us-gaap_FinanceLeaseInterestExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseInterestExpense" xlink:to="us-gaap_FinanceLeaseInterestExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseInterestExpense_lbl" xml:lang="en-US">Interest on lease liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20221231.xsd#krmd_FinanceLeaseCost" xlink:label="krmd_FinanceLeaseCost" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_FinanceLeaseCost" xlink:to="krmd_FinanceLeaseCost_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="krmd_FinanceLeaseCost_lbl" xml:lang="en-US">Total finance lease cost</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFlowOperatingActivitiesLesseeAbstract" xlink:label="us-gaap_CashFlowOperatingActivitiesLesseeAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFlowOperatingActivitiesLesseeAbstract" xlink:to="us-gaap_CashFlowOperatingActivitiesLesseeAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashFlowOperatingActivitiesLesseeAbstract_lbl" xml:lang="en-US">Cash paid for amounts included in the measurement of lease liabilities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasePayments" xlink:to="us-gaap_OperatingLeasePayments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasePayments_lbl" xml:lang="en-US">Operating cash flows from operating leases</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:label="us-gaap_FinanceLeaseInterestPaymentOnLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:to="us-gaap_FinanceLeaseInterestPaymentOnLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseInterestPaymentOnLiability_lbl" xml:lang="en-US">Financing cash flows from finance leases</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20221231.xsd#krmd_AssetsAndLiabilitiesOperatingLesseeAbstract" xlink:label="krmd_AssetsAndLiabilitiesOperatingLesseeAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_AssetsAndLiabilitiesOperatingLesseeAbstract" xlink:to="krmd_AssetsAndLiabilitiesOperatingLesseeAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="krmd_AssetsAndLiabilitiesOperatingLesseeAbstract_lbl" xml:lang="en-US">Operating Leases</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xml:lang="en-US">Total operating lease liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20221231.xsd#krmd_AssetsAndLiabilitiesLesseeFinanceAbstract" xlink:label="krmd_AssetsAndLiabilitiesLesseeFinanceAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_AssetsAndLiabilitiesLesseeFinanceAbstract" xlink:to="krmd_AssetsAndLiabilitiesLesseeFinanceAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="krmd_AssetsAndLiabilitiesLesseeFinanceAbstract_lbl" xml:lang="en-US">Finance Leases</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentOther" xlink:label="us-gaap_PropertyPlantAndEquipmentOther" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentOther" xlink:to="us-gaap_PropertyPlantAndEquipmentOther_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentOther_lbl" xml:lang="en-US">Property and equipment, at cost</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentOtherAccumulatedDepreciation" xlink:label="us-gaap_PropertyPlantAndEquipmentOtherAccumulatedDepreciation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentOtherAccumulatedDepreciation" xlink:to="us-gaap_PropertyPlantAndEquipmentOtherAccumulatedDepreciation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentOtherAccumulatedDepreciation_lbl" xml:lang="en-US">Accumulated depreciation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentOtherNet" xlink:label="us-gaap_PropertyPlantAndEquipmentOtherNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentOtherNet" xlink:to="us-gaap_PropertyPlantAndEquipmentOtherNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentOtherNet_lbl" xml:lang="en-US">Property and equipment, net</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:to="us-gaap_FinanceLeaseLiabilityNoncurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent_2_lbl" xml:lang="en-US">Finance lease liability, net of current portion</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiability" xlink:label="us-gaap_FinanceLeaseLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiability" xlink:to="us-gaap_FinanceLeaseLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiability_lbl" xml:lang="en-US">Total finance lease liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl" xml:lang="en-US">Operating leases</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeFinanceLeaseRenewalTerm1" xlink:label="us-gaap_LesseeFinanceLeaseRenewalTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeFinanceLeaseRenewalTerm1" xlink:to="us-gaap_LesseeFinanceLeaseRenewalTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeFinanceLeaseRenewalTerm1_lbl" xml:lang="en-US">Finance leases</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseDiscountRate" xlink:label="us-gaap_LesseeOperatingLeaseDiscountRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseDiscountRate" xlink:to="us-gaap_LesseeOperatingLeaseDiscountRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LesseeOperatingLeaseDiscountRate_lbl" xml:lang="en-US">Operating leases</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeFinanceLeaseDiscountRate" xlink:label="us-gaap_LesseeFinanceLeaseDiscountRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeFinanceLeaseDiscountRate" xlink:to="us-gaap_LesseeFinanceLeaseDiscountRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LesseeFinanceLeaseDiscountRate_lbl" xml:lang="en-US">Finance leases</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xml:lang="en-US">2023</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xml:lang="en-US">2023</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xml:lang="en-US">2024</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_lbl" xml:lang="en-US">2024</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xml:lang="en-US">2025</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_lbl" xml:lang="en-US">2025</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xml:lang="en-US">2026</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_lbl" xml:lang="en-US">2026</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl" xml:lang="en-US">2027</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive_lbl" xml:lang="en-US">2027</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl" xml:lang="en-US">Thereafter</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive_lbl" xml:lang="en-US">Thereafter</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20221231.xsd#krmd_LesseeOperatingLeaseLiabilityPaymentsDueTotal" xlink:label="krmd_LesseeOperatingLeaseLiabilityPaymentsDueTotal" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_LesseeOperatingLeaseLiabilityPaymentsDueTotal" xlink:to="krmd_LesseeOperatingLeaseLiabilityPaymentsDueTotal_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="krmd_LesseeOperatingLeaseLiabilityPaymentsDueTotal_lbl" xml:lang="en-US">Total undiscounted lease payments</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20221231.xsd#krmd_LesseeFinancingLeaseLeaseLiabilityPaymentsDueTotal" xlink:label="krmd_LesseeFinancingLeaseLeaseLiabilityPaymentsDueTotal" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_LesseeFinancingLeaseLeaseLiabilityPaymentsDueTotal" xlink:to="krmd_LesseeFinancingLeaseLeaseLiabilityPaymentsDueTotal_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="krmd_LesseeFinancingLeaseLeaseLiabilityPaymentsDueTotal_lbl" xml:lang="en-US">Total undiscounted lease payments</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20221231.xsd#krmd_LesseeOperatingLeaseImputedInterest" xlink:label="krmd_LesseeOperatingLeaseImputedInterest" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_LesseeOperatingLeaseImputedInterest" xlink:to="krmd_LesseeOperatingLeaseImputedInterest_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="krmd_LesseeOperatingLeaseImputedInterest_lbl" xml:lang="en-US">Less: imputed interest</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20221231.xsd#krmd_LesseeFinancingLeaseImputedInterest" xlink:label="krmd_LesseeFinancingLeaseImputedInterest" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_LesseeFinancingLeaseImputedInterest" xlink:to="krmd_LesseeFinancingLeaseImputedInterest_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="krmd_LesseeFinancingLeaseImputedInterest_lbl" xml:lang="en-US">Less: imputed interest</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseLiability_2_lbl" xml:lang="en-US">Total lease liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiability" xlink:to="us-gaap_FinanceLeaseLiability_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FinanceLeaseLiability_2_lbl" xml:lang="en-US">Total lease liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20221231.xsd#krmd_DescriptionOfLessorOperatingLeaseTerm" xlink:label="krmd_DescriptionOfLessorOperatingLeaseTerm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_DescriptionOfLessorOperatingLeaseTerm" xlink:to="krmd_DescriptionOfLessorOperatingLeaseTerm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="krmd_DescriptionOfLessorOperatingLeaseTerm_lbl" xml:lang="en-US">Description of lease term</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperationsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl" xml:lang="en-US">State income tax:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:to="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_lbl" xml:lang="en-US">Current, net of refund</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperationsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl" xml:lang="en-US">Federal income tax:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Deferred</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentFederalTaxExpenseBenefit" xlink:to="us-gaap_CurrentFederalTaxExpenseBenefit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit_lbl" xml:lang="en-US">Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="us-gaap_IncomeTaxExpenseBenefit_3_lbl" xml:lang="en-US">Income tax benefit/(expense)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_2_lbl" xml:lang="en-US">Loss before taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US">Income taxes computed at the federal statutory rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_lbl" xml:lang="en-US">State income and franchise tax</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:to="us-gaap_IncomeTaxReconciliationOtherAdjustments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments_lbl" xml:lang="en-US">Permanent differences and other</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCompensationPlanAssets" xlink:label="us-gaap_DeferredCompensationPlanAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCompensationPlanAssets" xlink:to="us-gaap_DeferredCompensationPlanAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredCompensationPlanAssets_lbl" xml:lang="en-US">Deferred compensation cost</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20221231.xsd#krmd_DepreciationDepletionAndAmortization1" xlink:label="krmd_DepreciationDepletionAndAmortization1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_DepreciationDepletionAndAmortization1" xlink:to="krmd_DepreciationDepletionAndAmortization1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="krmd_DepreciationDepletionAndAmortization1_lbl" xml:lang="en-US">Depreciation and amortization</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20221231.xsd#krmd_RdCredit" xlink:label="krmd_RdCredit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_RdCredit" xlink:to="krmd_RdCredit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="krmd_RdCredit_lbl" xml:lang="en-US">R&amp;D credit</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20221231.xsd#krmd_Nol" xlink:label="krmd_Nol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_Nol" xlink:to="krmd_Nol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="krmd_Nol_lbl" xml:lang="en-US">NOL</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20221231.xsd#krmd_AllowanceForDoubtfulOtherReceivables1Current" xlink:label="krmd_AllowanceForDoubtfulOtherReceivables1Current" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_AllowanceForDoubtfulOtherReceivables1Current" xlink:to="krmd_AllowanceForDoubtfulOtherReceivables1Current_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="krmd_AllowanceForDoubtfulOtherReceivables1Current_lbl" xml:lang="en-US">Allowance for bad debts and other</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xml:lang="en-US">Deferred income tax assets, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTable" xlink:label="us-gaap_ConcentrationRiskTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskTable" xlink:to="us-gaap_ConcentrationRiskTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskTable_lbl" xml:lang="en-US">Concentration Risk [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskLineItems" xlink:label="us-gaap_ConcentrationRiskLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskLineItems" xlink:to="us-gaap_ConcentrationRiskLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskLineItems_lbl" xml:lang="en-US">Concentration Risk [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="us-gaap_ConcentrationRiskPercentage1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskPercentage1" xlink:to="us-gaap_ConcentrationRiskPercentage1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskPercentage1_lbl" xml:lang="en-US">Concentration risk, percentage</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20221231.xsd#krmd_DescriptionOfMatchingContribution" xlink:label="krmd_DescriptionOfMatchingContribution" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_DescriptionOfMatchingContribution" xlink:to="krmd_DescriptionOfMatchingContribution_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="krmd_DescriptionOfMatchingContribution_lbl" xml:lang="en-US">Description of matching contribution</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:to="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_lbl" xml:lang="en-US">Matching expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShortTermDebtTable" xlink:label="us-gaap_ScheduleOfShortTermDebtTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShortTermDebtTable" xlink:to="us-gaap_ScheduleOfShortTermDebtTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShortTermDebtTable_lbl" xml:lang="en-US">Schedule of Short-Term Debt [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtLineItems" xlink:label="us-gaap_ShortTermDebtLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermDebtLineItems" xlink:to="us-gaap_ShortTermDebtLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermDebtLineItems_lbl" xml:lang="en-US">Short-Term Debt [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesPayable" xlink:label="us-gaap_NotesPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesPayable" xlink:to="us-gaap_NotesPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NotesPayable_lbl" xml:lang="en-US">Notes payable</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20221231.xsd#krmd_NotePayableTerms" xlink:label="krmd_NotePayableTerms" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_NotePayableTerms" xlink:to="krmd_NotePayableTerms_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="krmd_NotePayableTerms_lbl" xml:lang="en-US">Note payable terms</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_WeightedAverageNumberOfSharesOutstanding" xlink:to="krmd_WeightedAverageNumberOfSharesOutstanding_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_WeightedAverageNumberOfSharesOutstanding_doc" xml:lang="en-US">The element represents weighted average number of shares outstanding.</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20221231.xsd#krmd_ScheduleOfNetSalesByGeography" xlink:label="krmd_ScheduleOfNetSalesByGeography" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_ScheduleOfNetSalesByGeography" xlink:to="krmd_ScheduleOfNetSalesByGeography_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_ScheduleOfNetSalesByGeography_doc" xml:lang="en-US">The element represents schedule of net sales by geography.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_AccountingPronouncementsNotYetAdopted" xlink:to="krmd_AccountingPronouncementsNotYetAdopted_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_AccountingPronouncementsNotYetAdopted_doc" xml:lang="en-US">The element represents accounting pronouncements not yet adopted.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_FurnitureAndOfficeEquipmentMember" xlink:to="krmd_FurnitureAndOfficeEquipmentMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_FurnitureAndOfficeEquipmentMember_doc" xml:lang="en-US">The element represents furniture and office equipment member.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_ManufacturingEquipmentAndToolingMember" xlink:to="krmd_ManufacturingEquipmentAndToolingMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_ManufacturingEquipmentAndToolingMember_doc" xml:lang="en-US">The element represents manufacturing equipment and tooling member.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_PaymentsOnIndebtedness" xlink:to="krmd_PaymentsOnIndebtedness_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_PaymentsOnIndebtedness_doc" xml:lang="en-US">The element represents payments on indebtedness.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_CommonStockIssuanceAsSettlementForLitigation" xlink:to="krmd_CommonStockIssuanceAsSettlementForLitigation_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_CommonStockIssuanceAsSettlementForLitigation_doc" xml:lang="en-US">The element represents common stock issuance as settlement for litigation.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_IssuanceOfCommonStockCompensation" xlink:to="krmd_IssuanceOfCommonStockCompensation_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_IssuanceOfCommonStockCompensation_doc" xml:lang="en-US">The element represents issuance of common stock compensation.</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20221231.xsd#krmd_CompensationExpenseRrelatedToRestrictedStockAwards" xlink:label="krmd_CompensationExpenseRrelatedToRestrictedStockAwards" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_CompensationExpenseRrelatedToRestrictedStockAwards" xlink:to="krmd_CompensationExpenseRrelatedToRestrictedStockAwards_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_CompensationExpenseRrelatedToRestrictedStockAwards_doc" xml:lang="en-US">The element represents compensation expense rrelated to restricted stock awards.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_NewIssuanceLitigationSettlementAmountIssuance" xlink:to="krmd_NewIssuanceLitigationSettlementAmountIssuance_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_NewIssuanceLitigationSettlementAmountIssuance_doc" xml:lang="en-US">The element represents new issuance litigation settlement amount issuance.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_NewIssuanceLitigationSettlementShareIssuance" xlink:to="krmd_NewIssuanceLitigationSettlementShareIssuance_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_NewIssuanceLitigationSettlementShareIssuance_doc" xml:lang="en-US">The element represents new issuance litigation settlement share issuance.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_ScheduleOfShareBasedCompensationtaxBenefitsAssociatedWithRestrictedStockAwardCompensationTableTextBlock" xlink:to="krmd_ScheduleOfShareBasedCompensationtaxBenefitsAssociatedWithRestrictedStockAwardCompensationTableTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_ScheduleOfShareBasedCompensationtaxBenefitsAssociatedWithRestrictedStockAwardCompensationTableTextBlock_doc" xml:lang="en-US">The element represents schedule of share based compensationtax benefits associated with restricted stock award compensation table text block.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_StockOptionPlan2015Member" xlink:to="krmd_StockOptionPlan2015Member_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_StockOptionPlan2015Member_doc" xml:lang="en-US">The element represents stock option plan2015 member.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_StockOptionPlan2021Member" xlink:to="krmd_StockOptionPlan2021Member_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_StockOptionPlan2021Member_doc" xml:lang="en-US">The element represents stock option plan2021 member.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_NonEmployeeDirectorAndBoardAdvisorMember" xlink:to="krmd_NonEmployeeDirectorAndBoardAdvisorMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_NonEmployeeDirectorAndBoardAdvisorMember_doc" xml:lang="en-US">The element represents non employee director and board advisor member.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_NonemployeeServicesTransactionCost" xlink:to="krmd_NonemployeeServicesTransactionCost_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_NonemployeeServicesTransactionCost_doc" xml:lang="en-US">The element represents nonemployee services transaction cost.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_ChiefExecutiveOfficerLindaTharbyMember" xlink:to="krmd_ChiefExecutiveOfficerLindaTharbyMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_ChiefExecutiveOfficerLindaTharbyMember_doc" xml:lang="en-US">The element represents chief executive officer linda tharby member.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_TimeBasedSharesOptionsMember" xlink:to="krmd_TimeBasedSharesOptionsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_TimeBasedSharesOptionsMember_doc" xml:lang="en-US">The element represents time based shares options member.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriodWeightedAverageGrantDateFairValue_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriodWeightedAverageGrantDateFairValue_doc" xml:lang="en-US">The element represents share based compensation arrangement by share based payment award grants in period weighted average grant date fair value.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_StockIssuedDuringPeriodSharesStockOptionsExercised1" xlink:to="krmd_StockIssuedDuringPeriodSharesStockOptionsExercised1_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_StockIssuedDuringPeriodSharesStockOptionsExercised1_doc" xml:lang="en-US">The element represents stock issued during period shares stock options exercised1.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_ExercisePrice1Member" xlink:to="krmd_ExercisePrice1Member_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_ExercisePrice1Member_doc" xml:lang="en-US">The element represents exercise price1 member.</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20221231.xsd#krmd_FinanceLeaseRightOfUseAssetAmortization1" xlink:label="krmd_FinanceLeaseRightOfUseAssetAmortization1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_FinanceLeaseRightOfUseAssetAmortization1" xlink:to="krmd_FinanceLeaseRightOfUseAssetAmortization1_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_FinanceLeaseRightOfUseAssetAmortization1_doc" xml:lang="en-US">The element represents finance lease right of use asset amortization1.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber1" xlink:to="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber1_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber1_doc" xml:lang="en-US">The element represents share based compensation arrangement by share based payment award options outstanding number1.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross1" xlink:to="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross1_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross1_doc" xml:lang="en-US">The element represents share based compensation arrangement by share based payment award options grants in period gross1.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod1" xlink:to="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod1_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod1_doc" xml:lang="en-US">The element represents share based compensation arrangement by share based payment award options forfeitures in period1.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice1" xlink:to="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice1_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice1_doc" xml:lang="en-US">The element represents share based compensation arrangement by share based payment award options outstanding weighted average exercise price1.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice1" xlink:to="krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice1_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice1_doc" xml:lang="en-US">The element represents share based compensation arrangements by share based payment award options grants in period weighted average exercise price1..</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice1" xlink:to="krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice1_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice1_doc" xml:lang="en-US">The element represents share based compensation arrangements by share based payment award options exercises in period weighted average exercise price1.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice1" xlink:to="krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice1_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice1_doc" xml:lang="en-US">The element represents share based compensation arrangements by share based payment award options forfeitures in period weighted average exercise price1.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice1" xlink:to="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice1_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice1_doc" xml:lang="en-US">The element represents share based compensation arrangement by share based payment award options exercisable weighted average exercise price1.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue1" xlink:to="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue1_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue1_doc" xml:lang="en-US">The element represents share based compensation arrangement by share based payment award options grants in period weighted average grant date fair value1.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_AllocatedShareBasedCompensationExpense1" xlink:to="krmd_AllocatedShareBasedCompensationExpense1_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_AllocatedShareBasedCompensationExpense1_doc" xml:lang="en-US">The element represents allocated share based compensation expense1.</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20221231.xsd#krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate1" xlink:label="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate1" xlink:to="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate1_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate1_doc" xml:lang="en-US">The element represents share based compensation arrangement by share based payment award fair value assumptions expected dividend rate1.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_CashPaidDuringPeriodsForAbstract" xlink:to="krmd_CashPaidDuringPeriodsForAbstract_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_CashPaidDuringPeriodsForAbstract_doc" xml:lang="en-US">The element represents cash paid during periods for abstract.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber2" xlink:to="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber2_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber2_doc" xml:lang="en-US">The element represents share based compensation arrangement by share based payment award options outstanding number2.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross2" xlink:to="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross2_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross2_doc" xml:lang="en-US">The element represents share based compensation arrangement by share based payment award options grants in period gross2.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_StockIssuedDuringPeriodSharesStockOptionsExercised2" xlink:to="krmd_StockIssuedDuringPeriodSharesStockOptionsExercised2_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_StockIssuedDuringPeriodSharesStockOptionsExercised2_doc" xml:lang="en-US">The element represents stock issued during period shares stock options exercised2.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod2" xlink:to="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod2_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod2_doc" xml:lang="en-US">The element represents share based compensation arrangement by share based payment award options forfeitures in period2.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice2" xlink:to="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice2_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice2_doc" xml:lang="en-US">The element represents share based compensation arrangement by share based payment award options outstanding weighted average exercise price2.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice2" xlink:to="krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice2_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice2_doc" xml:lang="en-US">The element represents share based compensation arrangements by share based payment award options grants in period weighted average exercise price2.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice2" xlink:to="krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice2_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice2_doc" xml:lang="en-US">The element represents share based compensation arrangements by share based payment award options exercises in period weighted average exercise price2.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice2" xlink:to="krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice2_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice2_doc" xml:lang="en-US">The element represents share based compensation arrangements by share based payment award options forfeitures in period weighted average exercise price2.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice2" xlink:to="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice2_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice2_doc" xml:lang="en-US">The element represents share based compensation arrangement by share based payment award options exercisable weighted average exercise price2.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue2" xlink:to="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue2_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue2_doc" xml:lang="en-US">The element represents share based compensation arrangement by share based payment award options grants in period weighted average grant date fair value2.</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20221231.xsd#krmd_AllocatedShareBasedCompensationExpense2" xlink:label="krmd_AllocatedShareBasedCompensationExpense2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_AllocatedShareBasedCompensationExpense2" xlink:to="krmd_AllocatedShareBasedCompensationExpense2_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_AllocatedShareBasedCompensationExpense2_doc" xml:lang="en-US">The element represents allocated share based compensation expense2.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberUnvested" xlink:to="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberUnvested_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberUnvested_doc" xml:lang="en-US">The element represents share based compensation arrangement by share based payment award options outstanding number unvested.</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20221231.xsd#krmd_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm" xlink:label="krmd_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm" xlink:to="krmd_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm_doc" xml:lang="en-US">The element represents sharebased compensation shares authorized under stock option plans exercise price range outstanding options weighted average remaining contractual term.</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20221231.xsd#krmd_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance" xlink:label="krmd_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance" xlink:to="krmd_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance_doc" xml:lang="en-US">The element represents sharebased compensation shares authorized under stock option plans exercise price range outstanding options weighted average exercise price beginning balance.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_RestrictedStockAwardsMember" xlink:to="krmd_RestrictedStockAwardsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_RestrictedStockAwardsMember_doc" xml:lang="en-US">The element represents restricted stock awards member.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrossUnvested" xlink:to="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrossUnvested_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrossUnvested_doc" xml:lang="en-US">The element represents share based compensation arrangement by share based payment award options grants in period gross unvested.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodGross" xlink:to="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodGross_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodGross_doc" xml:lang="en-US">The element represents share based compensation arrangement by share based payment award options vested in period gross.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodUnvested" xlink:to="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodUnvested_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodUnvested_doc" xml:lang="en-US">The element represents share based compensation arrangement by share based payment award options forfeitures in period unvested.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceUnvested" xlink:to="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceUnvested_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceUnvested_doc" xml:lang="en-US">The element represents share based compensation arrangement by share based payment award options outstanding weighted average exercise price unvested.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePriceUnvested" xlink:to="krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePriceUnvested_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePriceUnvested_doc" xml:lang="en-US">The element represents share based compensation arrangements by share based payment award options grants in period weighted average exercise price unvested.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice" xlink:to="krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice_doc" xml:lang="en-US">The element represents share based compensation arrangements by share based payment award options vested in period weighted average exercise price.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePriceUnvested" xlink:to="krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePriceUnvested_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePriceUnvested_doc" xml:lang="en-US">The element represents share based compensation arrangements by share based payment award options forfeitures in period weighted average exercise price unvested.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_FinanceLeaseCost1Abstract" xlink:to="krmd_FinanceLeaseCost1Abstract_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_FinanceLeaseCost1Abstract_doc" xml:lang="en-US">The element represents finance lease cost1 abstract.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_FinanceLeaseCost" xlink:to="krmd_FinanceLeaseCost_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_FinanceLeaseCost_doc" xml:lang="en-US">The element represents finance lease cost.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_AssetsAndLiabilitiesOperatingLesseeAbstract" xlink:to="krmd_AssetsAndLiabilitiesOperatingLesseeAbstract_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_AssetsAndLiabilitiesOperatingLesseeAbstract_doc" xml:lang="en-US">The element represents assets and liabilities operating lessee abstract.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_AssetsAndLiabilitiesLesseeFinanceAbstract" xlink:to="krmd_AssetsAndLiabilitiesLesseeFinanceAbstract_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_AssetsAndLiabilitiesLesseeFinanceAbstract_doc" xml:lang="en-US">The element represents assets and liabilities lessee finance abstract.</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20221231.xsd#krmd_LesseeFinancingLeaseLeaseLiabilityPaymentsDue" xlink:label="krmd_LesseeFinancingLeaseLeaseLiabilityPaymentsDue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_LesseeFinancingLeaseLeaseLiabilityPaymentsDue" xlink:to="krmd_LesseeFinancingLeaseLeaseLiabilityPaymentsDue_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_LesseeFinancingLeaseLeaseLiabilityPaymentsDue_doc" xml:lang="en-US">The element represents lessee financing lease lease liability payments due.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_LesseeOperatingLeaseImputedInterest" xlink:to="krmd_LesseeOperatingLeaseImputedInterest_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_LesseeOperatingLeaseImputedInterest_doc" xml:lang="en-US">The element represents lessee operating lease imputed interest.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_LesseeFinancingLeaseImputedInterest" xlink:to="krmd_LesseeFinancingLeaseImputedInterest_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_LesseeFinancingLeaseImputedInterest_doc" xml:lang="en-US">The element represents lessee financing lease imputed interest.</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20221231.xsd#krmd_KeyEquipmentFinanceMember" xlink:label="krmd_KeyEquipmentFinanceMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_KeyEquipmentFinanceMember" xlink:to="krmd_KeyEquipmentFinanceMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_KeyEquipmentFinanceMember_doc" xml:lang="en-US">The element represents key equipment finance member.</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20221231.xsd#krmd_ProgressPaymentLoanAndSecurityAgreementMember" xlink:label="krmd_ProgressPaymentLoanAndSecurityAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_ProgressPaymentLoanAndSecurityAgreementMember" xlink:to="krmd_ProgressPaymentLoanAndSecurityAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_ProgressPaymentLoanAndSecurityAgreementMember_doc" xml:lang="en-US">The element represents progress payment loan and security agreement member.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_AONPremiumFinanceLLCMember" xlink:to="krmd_AONPremiumFinanceLLCMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_AONPremiumFinanceLLCMember_doc" xml:lang="en-US">The element represents a o n premium finance l l c member.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_PromissoryNoteMember" xlink:to="krmd_PromissoryNoteMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_PromissoryNoteMember_doc" xml:lang="en-US">The element represents promissory note member.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_NotePayableTerms" xlink:to="krmd_NotePayableTerms_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_NotePayableTerms_doc" xml:lang="en-US">The element represents note payable terms.</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20221231.xsd#krmd_NotePayableTermsAxis" xlink:label="krmd_NotePayableTermsAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_NotePayableTermsAxis" xlink:to="krmd_NotePayableTermsAxis_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_NotePayableTermsAxis_doc" xml:lang="en-US">The element represents note payable terms axis.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_LesseeFinancingLeaseLeaseLiabilityPaymentsDueTotal" xlink:to="krmd_LesseeFinancingLeaseLeaseLiabilityPaymentsDueTotal_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_LesseeFinancingLeaseLeaseLiabilityPaymentsDueTotal_doc" xml:lang="en-US">The element represents lessee financing lease lease liability payments due total.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_LesseeOperatingLeaseLiabilityPaymentsDueTotal" xlink:to="krmd_LesseeOperatingLeaseLiabilityPaymentsDueTotal_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_LesseeOperatingLeaseLiabilityPaymentsDueTotal_doc" xml:lang="en-US">The element represents lessee operating lease liability payments due total.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_ScheduleOfShareBasedCompensationStockOptionsActivityAmendedTableTextBlock" xlink:to="krmd_ScheduleOfShareBasedCompensationStockOptionsActivityAmendedTableTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_ScheduleOfShareBasedCompensationStockOptionsActivityAmendedTableTextBlock_doc" xml:lang="en-US">The element represents schedule of share based compensation stock options activity amended table text block.</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20221231.xsd#krmd_FinanceLeaseLiabilityPaymentsDueYearSix" xlink:label="krmd_FinanceLeaseLiabilityPaymentsDueYearSix" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_FinanceLeaseLiabilityPaymentsDueYearSix" xlink:to="krmd_FinanceLeaseLiabilityPaymentsDueYearSix_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_FinanceLeaseLiabilityPaymentsDueYearSix_doc" xml:lang="en-US">The element represents finance lease liability payments due year six.</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20221231.xsd#krmd_StockIssued" xlink:label="krmd_StockIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_StockIssued" xlink:to="krmd_StockIssued_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_StockIssued_doc" xml:lang="en-US">The element represents stock issued.</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20221231.xsd#krmd_LessorOperatingLeaseOptionToTerminate1" xlink:label="krmd_LessorOperatingLeaseOptionToTerminate1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_LessorOperatingLeaseOptionToTerminate1" xlink:to="krmd_LessorOperatingLeaseOptionToTerminate1_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_LessorOperatingLeaseOptionToTerminate1_doc" xml:lang="en-US">The element represents lessor operating lease option to terminate1.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_Compensationexpenserelatedtorestrictedstockawards" xlink:to="krmd_Compensationexpenserelatedtorestrictedstockawards_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_Compensationexpenserelatedtorestrictedstockawards_doc" xml:lang="en-US">The element represents compensationexpenserelatedtorestrictedstockawards.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_ExecutiveskeyEmployeesAndConsultantsMember" xlink:to="krmd_ExecutiveskeyEmployeesAndConsultantsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_ExecutiveskeyEmployeesAndConsultantsMember_doc" xml:lang="en-US">The element represents executiveskey employees and consultants member.</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20221231.xsd#krmd_WeightedAverageNumberOfCommonSharesOutstanding" xlink:label="krmd_WeightedAverageNumberOfCommonSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_WeightedAverageNumberOfCommonSharesOutstanding" xlink:to="krmd_WeightedAverageNumberOfCommonSharesOutstanding_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_WeightedAverageNumberOfCommonSharesOutstanding_doc" xml:lang="en-US">The element represents weighted average number of common shares outstanding</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_RouLandlordCredit" xlink:to="krmd_RouLandlordCredit_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_RouLandlordCredit_doc" xml:lang="en-US">The element represents rou landlord credit.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_BorrowingsFromIndebtedness" xlink:to="krmd_BorrowingsFromIndebtedness_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_BorrowingsFromIndebtedness_doc" xml:lang="en-US">The element represents borrowings from indebtedness.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan2015" xlink:to="krmd_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan2015_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan2015_doc" xml:lang="en-US">The element represents stock issued during period shares employee stock ownership plan2015.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_AmortizationOfIntangibleAssets1" xlink:to="krmd_AmortizationOfIntangibleAssets1_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_AmortizationOfIntangibleAssets1_doc" xml:lang="en-US">The element represents amortization of intangible assets1.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_CompensationCost" xlink:to="krmd_CompensationCost_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_CompensationCost_doc" xml:lang="en-US">The element represents compensation cost.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_DepreciationDepletionAndAmortization1" xlink:to="krmd_DepreciationDepletionAndAmortization1_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_DepreciationDepletionAndAmortization1_doc" xml:lang="en-US">The element represents depreciation depletion and amortization1.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_RdCredit" xlink:to="krmd_RdCredit_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_RdCredit_doc" xml:lang="en-US">The element represents rd credit.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_Nol" xlink:to="krmd_Nol_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_Nol_doc" xml:lang="en-US">The element represents nol.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_AllowanceForDoubtfulOtherReceivables1Current" xlink:to="krmd_AllowanceForDoubtfulOtherReceivables1Current_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_AllowanceForDoubtfulOtherReceivables1Current_doc" xml:lang="en-US">The element represents allowance for doubtful other receivables1 current.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_DescriptionOfMatchingContribution" xlink:to="krmd_DescriptionOfMatchingContribution_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_DescriptionOfMatchingContribution_doc" xml:lang="en-US">The element represents description of matching contribution.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_DescriptionOfLessorOperatingLeaseTerm" xlink:to="krmd_DescriptionOfLessorOperatingLeaseTerm_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_DescriptionOfLessorOperatingLeaseTerm_doc" xml:lang="en-US">The element represents description of lessor operating lease term.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_EquipmentAndToolingMember" xlink:to="krmd_EquipmentAndToolingMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_EquipmentAndToolingMember_doc" xml:lang="en-US">The element represents equipment and tooling member.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_UnrecognizedCompensationCost" xlink:to="krmd_UnrecognizedCompensationCost_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_UnrecognizedCompensationCost_doc" xml:lang="en-US">The element represents unrecognized compensation cost.</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20221231.xsd#krmd_TimeBasedSharesOptionsOneMember" xlink:label="krmd_TimeBasedSharesOptionsOneMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_TimeBasedSharesOptionsOneMember" xlink:to="krmd_TimeBasedSharesOptionsOneMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_TimeBasedSharesOptionsOneMember_doc" xml:lang="en-US">The element represents time based shares options one member.</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20221231.xsd#krmd_ProceedsFromStockOptionsExercisedCashless" xlink:label="krmd_ProceedsFromStockOptionsExercisedCashless" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_ProceedsFromStockOptionsExercisedCashless" xlink:to="krmd_ProceedsFromStockOptionsExercisedCashless_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_ProceedsFromStockOptionsExercisedCashless_doc" xml:lang="en-US">The element represents proceeds from stock options exercised cashless.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_EmploymentAgreementMember" xlink:to="krmd_EmploymentAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_EmploymentAgreementMember_doc" xml:lang="en-US">The element represents employment agreement member.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_2_lbl" xml:lang="en-US">Assets, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_2_lbl" xml:lang="en-US">Assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_2_lbl" xml:lang="en-US">Liabilities, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_2_lbl" xml:lang="en-US">Liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TreasuryStockValue" xlink:to="us-gaap_TreasuryStockValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TreasuryStockValue_2_lbl" xml:lang="en-US">Treasury Stock, Value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_4_lbl" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_2_lbl" xml:lang="en-US">Liabilities and Equity</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GrossProfit" xlink:to="us-gaap_GrossProfit_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GrossProfit_2_lbl" xml:lang="en-US">Gross Profit</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpenses_2_lbl" xml:lang="en-US">Operating Expenses</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_2_lbl" xml:lang="en-US">Operating Income (Loss)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpense_2_lbl" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_2_lbl" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesOutstanding_3_lbl" xml:lang="en-US">Shares, Outstanding</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnSaleOfOtherAssets" xlink:to="us-gaap_GainLossOnSaleOfOtherAssets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GainLossOnSaleOfOtherAssets_2_lbl" xml:lang="en-US">Gain (Loss) on Disposition of Other Assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_2_lbl" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInInventories" xlink:to="us-gaap_IncreaseDecreaseInInventories_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInInventories_2_lbl" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherReceivables" xlink:to="us-gaap_IncreaseDecreaseInOtherReceivables_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOtherReceivables_2_lbl" xml:lang="en-US">Increase (Decrease) in Other Receivables</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_2_lbl" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireProductiveAssets" xlink:to="us-gaap_PaymentsToAcquireProductiveAssets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquireProductiveAssets_2_lbl" xml:lang="en-US">Payments to Acquire Productive Assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireIntangibleAssets" xlink:to="us-gaap_PaymentsToAcquireIntangibleAssets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets_2_lbl" xml:lang="en-US">Payments to Acquire Intangible Assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_PaymentsOnIndebtedness" xlink:to="krmd_PaymentsOnIndebtedness_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="krmd_PaymentsOnIndebtedness_3_lbl" xml:lang="en-US">Payments On Indebtedness</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeasePrincipalPayments" xlink:to="us-gaap_FinanceLeasePrincipalPayments_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeasePrincipalPayments_2_lbl" xml:lang="en-US">Finance Lease, Principal Payments</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_2_lbl" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryPolicyTextBlock" xlink:to="us-gaap_InventoryPolicyTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryPolicyTextBlock_2_lbl" xml:lang="en-US">Inventory, Policy [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_2_lbl" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_2_lbl" xml:lang="en-US">Share-Based Payment Arrangement [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_2_lbl" xml:lang="en-US">Lessee, Leases [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_2_lbl" xml:lang="en-US">Share-Based Payment Arrangement, Option, Exercise Price Range [Table Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfOtherShareBasedCompensationActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfOtherShareBasedCompensationActivityTableTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfOtherShareBasedCompensationActivityTableTextBlock_2_lbl" xml:lang="en-US">Share-Based Payment Arrangement, Outstanding Award, Activity, Excluding Option [Table Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_ScheduleOfShareBasedCompensationtaxBenefitsAssociatedWithRestrictedStockAwardCompensationTableTextBlock" xlink:to="krmd_ScheduleOfShareBasedCompensationtaxBenefitsAssociatedWithRestrictedStockAwardCompensationTableTextBlock_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="krmd_ScheduleOfShareBasedCompensationtaxBenefitsAssociatedWithRestrictedStockAwardCompensationTableTextBlock_3_lbl" xml:lang="en-US">Schedule Of Share Based Compensationtax Benefits Associated With Restricted Stock Award Compensation Table Text Block</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryValuationReserves" xlink:to="us-gaap_InventoryValuationReserves_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryValuationReserves_2_lbl" xml:lang="en-US">Inventory Valuation Reserves</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_2_lbl" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_2_lbl" xml:lang="en-US">Share-Based Payment Arrangement, Expense</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber2" xlink:to="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber2_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber2_4_lbl" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number2</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice2" xlink:to="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice2_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice2_4_lbl" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price2</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross2" xlink:to="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross2_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross2_3_lbl" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross2</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice2" xlink:to="krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice2_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice2_3_lbl" xml:lang="en-US">ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice2</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_StockIssuedDuringPeriodSharesStockOptionsExercised2" xlink:to="krmd_StockIssuedDuringPeriodSharesStockOptionsExercised2_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="krmd_StockIssuedDuringPeriodSharesStockOptionsExercised2_3_lbl" xml:lang="en-US">Stock Issued During Period Shares Stock Options Exercised2</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice2" xlink:to="krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice2_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice2_3_lbl" xml:lang="en-US">Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price2</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod2" xlink:to="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod2_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod2_3_lbl" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period2</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice2" xlink:to="krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice2_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice2_3_lbl" xml:lang="en-US">Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price2</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice2" xlink:to="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice2_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice2_3_lbl" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price2</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue2" xlink:to="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue2_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue2_3_lbl" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value2</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_2_lbl" xml:lang="en-US">Share-Based Payment Arrangement, Option, Exercise Price Range, Exercisable, Weighted Average Exercise Price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber1" xlink:to="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber1_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber1_3_lbl" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number1</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice1" xlink:to="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice1_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice1_3_lbl" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price1</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross1" xlink:to="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross1_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross1_3_lbl" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Option Grants In Period Gross1</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice1" xlink:to="krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice1_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice1_3_lbl" xml:lang="en-US">Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price1</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice1" xlink:to="krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice1_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice1_3_lbl" xml:lang="en-US">Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price1</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod1" xlink:to="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod1_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod1_3_lbl" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period 1</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice1" xlink:to="krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice1_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice1_3_lbl" xml:lang="en-US">ShareBased Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price1</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice1" xlink:to="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice1_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice1_3_lbl" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price1</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue1" xlink:to="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue1_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue1_3_lbl" xml:lang="en-US">ShareBasedCompensationArrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value1</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_AllocatedShareBasedCompensationExpense1" xlink:to="krmd_AllocatedShareBasedCompensationExpense1_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="krmd_AllocatedShareBasedCompensationExpense1_3_lbl" xml:lang="en-US">Allocated Share Based Compensation Expense1</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberUnvested" xlink:to="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberUnvested_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberUnvested_4_lbl" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number Unvested</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceUnvested" xlink:to="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceUnvested_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceUnvested_4_lbl" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price Unvested</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrossUnvested" xlink:to="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrossUnvested_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrossUnvested_3_lbl" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross Unvested</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePriceUnvested" xlink:to="krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePriceUnvested_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePriceUnvested_3_lbl" xml:lang="en-US">Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price Unvested</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice" xlink:to="krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice_3_lbl" xml:lang="en-US">Share Based Compensation Arrangements By Share Based Payment Award Options Vested In Period Weighted Average Exercise Price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePriceUnvested" xlink:to="krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePriceUnvested_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePriceUnvested_3_lbl" xml:lang="en-US">Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price Unvested</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm3" xlink:to="krmd_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm3_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="krmd_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm3_2_lbl" xml:lang="en-US">SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm3</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_UnrecognizedCompensationCost" xlink:to="krmd_UnrecognizedCompensationCost_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="krmd_UnrecognizedCompensationCost_3_lbl" xml:lang="en-US">Unrecognized Compensation Cost</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm4" xlink:to="krmd_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm4_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="krmd_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm4_2_lbl" xml:lang="en-US">SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm4</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentOtherAccumulatedDepreciation" xlink:to="us-gaap_PropertyPlantAndEquipmentOtherAccumulatedDepreciation_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentOtherAccumulatedDepreciation_2_lbl" xml:lang="en-US">Property, Plant and Equipment, Other, Accumulated Depreciation</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentOtherNet" xlink:to="us-gaap_PropertyPlantAndEquipmentOtherNet_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentOtherNet_2_lbl" xml:lang="en-US">Property, Plant and Equipment, Other, Net</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseDiscountRate" xlink:to="us-gaap_LesseeOperatingLeaseDiscountRate_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseDiscountRate_2_lbl" xml:lang="en-US">Lessee, Operating Lease, Discount Rate</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeFinanceLeaseDiscountRate" xlink:to="us-gaap_LesseeFinanceLeaseDiscountRate_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeFinanceLeaseDiscountRate_2_lbl" xml:lang="en-US">Lessee, Finance Lease, Discount Rate</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_2_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_2_lbl" xml:lang="en-US">Finance Lease, Liability, to be Paid, Year One</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_2_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_2_lbl" xml:lang="en-US">Finance Lease, Liability, to be Paid, Year Two</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_2_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_2_lbl" xml:lang="en-US">Finance Lease, Liability, to be Paid, Year Three</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_2_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Four</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_2_lbl" xml:lang="en-US">Finance Lease, Liability, to be Paid, Year Four</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_2_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Five</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive_2_lbl" xml:lang="en-US">Finance Lease, Liability, to be Paid, Year Five</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_2_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, after Year Five</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive_2_lbl" xml:lang="en-US">Finance Lease, Liability, to be Paid, after Year Five</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_LesseeFinancingLeaseLeaseLiabilityPaymentsDueTotal" xlink:to="krmd_LesseeFinancingLeaseLeaseLiabilityPaymentsDueTotal_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="krmd_LesseeFinancingLeaseLeaseLiabilityPaymentsDueTotal_3_lbl" xml:lang="en-US">Lessee Financing Lease Lease Liability Payments Due Total</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_LesseeOperatingLeaseImputedInterest" xlink:to="krmd_LesseeOperatingLeaseImputedInterest_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="krmd_LesseeOperatingLeaseImputedInterest_3_lbl" xml:lang="en-US">Lessee Operating Lease Imputed Interest</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_LesseeFinancingLeaseImputedInterest" xlink:to="krmd_LesseeFinancingLeaseImputedInterest_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="krmd_LesseeFinancingLeaseImputedInterest_3_lbl" xml:lang="en-US">Lessee Financing Lease Imputed Interest</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_DepreciationDepletionAndAmortization1" xlink:to="krmd_DepreciationDepletionAndAmortization1_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="krmd_DepreciationDepletionAndAmortization1_3_lbl" xml:lang="en-US">Depreciation Depletion and Amortization1</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsNet_2_lbl" xml:lang="en-US">Deferred Tax Assets, Net of Valuation Allowance</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>12
<FILENAME>krmd-20221231_pre.xml
<DESCRIPTION>INLINE XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.17b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://korumedical.com/role/Cover" xlink:href="krmd-20221231.xsd#Cover" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/BalanceSheets" xlink:href="krmd-20221231.xsd#BalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/BalanceSheetsParenthetical" xlink:href="krmd-20221231.xsd#BalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/StatementsOfOperations" xlink:href="krmd-20221231.xsd#StatementsOfOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/StatementsOfStockholdersEquity" xlink:href="krmd-20221231.xsd#StatementsOfStockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/StatementsOfCashFlows" xlink:href="krmd-20221231.xsd#StatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPolicies" xlink:href="krmd-20221231.xsd#NatureOfOperationsAndSummaryOfSignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/Inventory" xlink:href="krmd-20221231.xsd#Inventory" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/PropertyAndEquipment" xlink:href="krmd-20221231.xsd#PropertyAndEquipment" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/Stock-basedCompensation" xlink:href="krmd-20221231.xsd#Stock-basedCompensation" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/Leases" xlink:href="krmd-20221231.xsd#Leases" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/FederalAndStateIncomeTaxes" xlink:href="krmd-20221231.xsd#FederalAndStateIncomeTaxes" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/MajorCustomers" xlink:href="krmd-20221231.xsd#MajorCustomers" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/CommitmentsAndContingencies" xlink:href="krmd-20221231.xsd#CommitmentsAndContingencies" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/EmployeeBenefits" xlink:href="krmd-20221231.xsd#EmployeeBenefits" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/DebtObligations" xlink:href="krmd-20221231.xsd#DebtObligations" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:href="krmd-20221231.xsd#NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesTables" xlink:href="krmd-20221231.xsd#NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/InventoryTables" xlink:href="krmd-20221231.xsd#InventoryTables" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/PropertyAndEquipmentTables" xlink:href="krmd-20221231.xsd#PropertyAndEquipmentTables" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/Stock-basedCompensationTables" xlink:href="krmd-20221231.xsd#Stock-basedCompensationTables" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/LeasesTables" xlink:href="krmd-20221231.xsd#LeasesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/FederalAndStateIncomeTaxesTables" xlink:href="krmd-20221231.xsd#FederalAndStateIncomeTaxesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/ScheduleOfAmortizationExpenseDetails" xlink:href="krmd-20221231.xsd#ScheduleOfAmortizationExpenseDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/ScheduleOfNetIncomePerCommonShareDetails" xlink:href="krmd-20221231.xsd#ScheduleOfNetIncomePerCommonShareDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/ScheduleOfNetRevenuesByGeographyDetails" xlink:href="krmd-20221231.xsd#ScheduleOfNetRevenuesByGeographyDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:href="krmd-20221231.xsd#NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/InventoryConsistsOfDetails" xlink:href="krmd-20221231.xsd#InventoryConsistsOfDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/ScheduleOfPropertyAndEquipmentDetails" xlink:href="krmd-20221231.xsd#ScheduleOfPropertyAndEquipmentDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/ScheduleOfTimeBasedStockOptionsDetails" xlink:href="krmd-20221231.xsd#ScheduleOfTimeBasedStockOptionsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/ScheduleOfStatusOfTimeBasedStockOptionsDetails" xlink:href="krmd-20221231.xsd#ScheduleOfStatusOfTimeBasedStockOptionsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/ScheduleOfInformationPertainingToOptionsOutstandingDetails" xlink:href="krmd-20221231.xsd#ScheduleOfInformationPertainingToOptionsOutstandingDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/ScheduleOfPerformanceBaseOptionsOutstandingDetails" xlink:href="krmd-20221231.xsd#ScheduleOfPerformanceBaseOptionsOutstandingDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/FollowingTableSummarizesActivitiesForOurUnvestedRestrictedStockAwardsForTwelveMonthsEndedDecember312022And2021.Details" xlink:href="krmd-20221231.xsd#FollowingTableSummarizesActivitiesForOurUnvestedRestrictedStockAwardsForTwelveMonthsEndedDecember312022And2021.Details" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/Stock-basedCompensationDetailsNarrative" xlink:href="krmd-20221231.xsd#Stock-basedCompensationDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/ScheduleOfComponentsOfLeaseExpenseDetails" xlink:href="krmd-20221231.xsd#ScheduleOfComponentsOfLeaseExpenseDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/ScheduleOfCashFlowInformationRelatedToLeasesDetails" xlink:href="krmd-20221231.xsd#ScheduleOfCashFlowInformationRelatedToLeasesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/SchdeuleOfBalanceSheetInformationRelatedToLeasesDetails" xlink:href="krmd-20221231.xsd#SchdeuleOfBalanceSheetInformationRelatedToLeasesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/ScheduleOfMaturitiesOfLeaseLiabilitiesDetails" xlink:href="krmd-20221231.xsd#ScheduleOfMaturitiesOfLeaseLiabilitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/LeasesDetailsNarrative" xlink:href="krmd-20221231.xsd#LeasesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/ScheduleOfProvisionForIncomeTaxesDetails" xlink:href="krmd-20221231.xsd#ScheduleOfProvisionForIncomeTaxesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/ScheduleOfReconciliationOfIncomeTaxesDetails" xlink:href="krmd-20221231.xsd#ScheduleOfReconciliationOfIncomeTaxesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/ScheduleOfComponentsOfDeferredTaxAssetsDetails" xlink:href="krmd-20221231.xsd#ScheduleOfComponentsOfDeferredTaxAssetsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/MajorCustomersDetailsNarrative" xlink:href="krmd-20221231.xsd#MajorCustomersDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/EmployeeBenefitsDetailsNarrative" xlink:href="krmd-20221231.xsd#EmployeeBenefitsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/DebtObligationsDetailsNarrative" xlink:href="krmd-20221231.xsd#DebtObligationsDetailsNarrative" xlink:type="simple" />
    <link:presentationLink xlink:type="extended" xlink:role="http://korumedical.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockCommonShares" xlink:label="loc_us-gaapTreasuryStockCommonShares" />
      <link:presentationArc order="580" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_us-gaapTreasuryStockCommonShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorFirmId" xlink:label="loc_deiAuditorFirmId" />
      <link:presentationArc order="590" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditorFirmId" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorName" xlink:label="loc_deiAuditorName" />
      <link:presentationArc order="600" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditorName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorLocation" xlink:label="loc_deiAuditorLocation" />
      <link:presentationArc order="610" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditorLocation" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://korumedical.com/role/BalanceSheets" xlink:title="00000002 - Statement - BALANCE SHEETS">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaapAssetsAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapAssetsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaapAssetsCurrentAbstract" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapAssetsCurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaapAccountsReceivableNetCurrent" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapAccountsReceivableNetCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaapInventoryNet" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapInventoryNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherReceivables" xlink:label="loc_us-gaapOtherReceivables" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapOtherReceivables" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaapPrepaidExpenseCurrent" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapPrepaidExpenseCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapAssetsCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsNet" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxAssetsNet" xlink:label="loc_us-gaapDeferredIncomeTaxAssetsNet" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapDeferredIncomeTaxAssetsNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaapOtherAssetsNoncurrent" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapOtherAssetsNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaapLiabilitiesCurrentAbstract" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilitiesCurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapAccountsPayableCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccruedLiabilitiesCurrent" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapAccruedLiabilitiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesPayableCurrent" xlink:label="loc_us-gaapNotesPayableCurrent" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapNotesPayableCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaapOtherLiabilitiesCurrent" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapOtherLiabilitiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="loc_us-gaapEmployeeRelatedLiabilitiesCurrent" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapEmployeeRelatedLiabilitiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityCurrent" xlink:label="loc_us-gaapFinanceLeaseLiabilityCurrent" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapFinanceLeaseLiabilityCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityCurrent" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapOperatingLeaseLiabilityCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapLiabilitiesCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapFinanceLeaseLiabilityNoncurrent" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapFinanceLeaseLiabilityNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityNoncurrent" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapOperatingLeaseLiabilityNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaapStockholdersEquityAbstract" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapStockholdersEquityAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaapAdditionalPaidInCapitalCommonStock" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapAdditionalPaidInCapitalCommonStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockValue" xlink:label="loc_us-gaapTreasuryStockValue" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapTreasuryStockValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://korumedical.com/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - BALANCE SHEETS (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:label="loc_us-gaapAllowanceForDoubtfulAccountsReceivableCurrent" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapAllowanceForDoubtfulAccountsReceivableCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAccumulatedAmortization" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockShares" xlink:label="loc_us-gaapTreasuryStockShares" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapTreasuryStockShares" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://korumedical.com/role/StatementsOfOperations" xlink:title="00000004 - Statement - STATEMENTS OF OPERATIONS">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaapIncomeStatementAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues" xlink:label="loc_us-gaapRevenues" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapRevenues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="loc_us-gaapCostOfGoodsAndServicesSold" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapCostOfGoodsAndServicesSold" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GrossProfit" xlink:label="loc_us-gaapGrossProfit" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapGrossProfit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaapOperatingExpensesAbstract" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapOperatingExpensesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_us-gaapSellingGeneralAndAdministrativeExpense" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapSellingGeneralAndAdministrativeExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaapDepreciationDepletionAndAmortization" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapDepreciationDepletionAndAmortization" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaapOperatingExpenses" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapOperatingExpenses" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaapNonoperatingIncomeExpenseAbstract" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="loc_us-gaapForeignCurrencyTransactionGainLossBeforeTax" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapForeignCurrencyTransactionGainLossBeforeTax" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="loc_us-gaapGainLossOnSaleOfPropertyPlantEquipment" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapGainLossOnSaleOfPropertyPlantEquipment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherIncome" xlink:label="loc_us-gaapOtherIncome" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapOtherIncome" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaapOtherNonoperatingIncomeExpense" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapOtherNonoperatingIncomeExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaapNonoperatingIncomeExpense" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapNonoperatingIncomeExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaapIncomeTaxExpenseBenefit" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapIncomeTaxExpenseBenefit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaapEarningsPerShareAbstract" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapEarningsPerShareAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaapEarningsPerShareBasic" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareAbstract" xlink:to="loc_us-gaapEarningsPerShareBasic" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaapEarningsPerShareDiluted" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareAbstract" xlink:to="loc_us-gaapEarningsPerShareDiluted" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="loc_us-gaapWeightedAverageNumberOfSharesOutstandingAbstract" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapWeightedAverageNumberOfSharesOutstandingAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapWeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaapWeightedAverageNumberOfDilutedSharesOutstanding" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapWeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="loc_us-gaapWeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://korumedical.com/role/StatementsOfStockholdersEquity" xlink:title="00000005 - Statement - STATEMENTS OF STOCKHOLDERS&apos; EQUITY">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaapStatementOfStockholdersEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfStockholdersEquityAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="50" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapRetainedEarningsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockMember" xlink:label="loc_us-gaapTreasuryStockMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapTreasuryStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueShareBasedCompensation" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueShareBasedCompensation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesShareBasedCompensation" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesShareBasedCompensation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="krmd-20221231.xsd#krmd_NewIssuanceLitigationSettlementAmountIssuance" xlink:label="loc_krmdNewIssuanceLitigationSettlementAmountIssuance" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_krmdNewIssuanceLitigationSettlementAmountIssuance" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="krmd-20221231.xsd#krmd_NewIssuanceLitigationSettlementShareIssuance" xlink:label="loc_krmdNewIssuanceLitigationSettlementShareIssuance" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_krmdNewIssuanceLitigationSettlementShareIssuance" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueStockOptionsExercised" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="krmd-20221231.xsd#krmd_Compensationexpenserelatedtorestrictedstockawards" xlink:label="loc_krmdCompensationexpenserelatedtorestrictedstockawards" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_krmdCompensationexpenserelatedtorestrictedstockawards" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_2" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding_2" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://korumedical.com/role/StatementsOfCashFlows" xlink:title="00000006 - Statement - STATEMENTS OF CASH FLOWS">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaapStatementOfCashFlowsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaapAdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapAdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaapDepreciationDepletionAndAmortization" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapDepreciationDepletionAndAmortization" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnSaleOfOtherAssets" xlink:label="loc_us-gaapGainLossOnSaleOfOtherAssets" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapGainLossOnSaleOfOtherAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxesAndTaxCredits" xlink:label="loc_us-gaapDeferredIncomeTaxesAndTaxCredits" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapDeferredIncomeTaxesAndTaxCredits" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="krmd-20221231.xsd#krmd_RouLandlordCredit" xlink:label="loc_krmdRouLandlordCredit" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_krmdRouLandlordCredit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsReceivable" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsReceivable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_us-gaapIncreaseDecreaseInInventories" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInInventories" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherReceivables" xlink:label="loc_us-gaapIncreaseDecreaseInOtherReceivables" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOtherReceivables" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaapIncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayable" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInEmployeeRelatedLiabilities" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInEmployeeRelatedLiabilities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInOtherCurrentLiabilities" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOtherCurrentLiabilities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireProductiveAssets" xlink:label="loc_us-gaapPaymentsToAcquireProductiveAssets" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_us-gaapPaymentsToAcquireProductiveAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="loc_us-gaapPaymentsToAcquireIntangibleAssets" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_us-gaapPaymentsToAcquireIntangibleAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfProductiveAssets" xlink:label="loc_us-gaapProceedsFromSaleOfProductiveAssets" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromSaleOfProductiveAssets" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="krmd-20221231.xsd#krmd_CommonStockIssuanceAsSettlementForLitigation" xlink:label="loc_krmdCommonStockIssuanceAsSettlementForLitigation" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_krmdCommonStockIssuanceAsSettlementForLitigation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="krmd-20221231.xsd#krmd_BorrowingsFromIndebtedness" xlink:label="loc_krmdBorrowingsFromIndebtedness" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_krmdBorrowingsFromIndebtedness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="krmd-20221231.xsd#krmd_PaymentsOnIndebtedness" xlink:label="loc_krmdPaymentsOnIndebtedness" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_krmdPaymentsOnIndebtedness" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeasePrincipalPayments" xlink:label="loc_us-gaapFinanceLeasePrincipalPayments" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapFinanceLeasePrincipalPayments" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue_2" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaapSupplementalCashFlowInformationAbstract" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="krmd-20221231.xsd#krmd_CashPaidDuringPeriodsForAbstract" xlink:label="loc_krmdCashPaidDuringPeriodsForAbstract" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_krmdCashPaidDuringPeriodsForAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPaidNet" xlink:label="loc_us-gaapInterestPaidNet" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_krmdCashPaidDuringPeriodsForAbstract" xlink:to="loc_us-gaapInterestPaidNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxesPaidNet" xlink:label="loc_us-gaapIncomeTaxesPaidNet" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_krmdCashPaidDuringPeriodsForAbstract" xlink:to="loc_us-gaapIncomeTaxesPaidNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="loc_us-gaapCashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="krmd-20221231.xsd#krmd_IssuanceOfCommonStockCompensation" xlink:label="loc_krmdIssuanceOfCommonStockCompensation" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_krmdIssuanceOfCommonStockCompensation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssued1" xlink:label="loc_us-gaapStockIssued1" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapStockIssued1" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://korumedical.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPolicies" xlink:title="00000007 - Disclosure - NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" xlink:label="loc_us-gaapOrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapOrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://korumedical.com/role/Inventory" xlink:title="00000008 - Disclosure - INVENTORY">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaapInventoryDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureTextBlock" xlink:label="loc_us-gaapInventoryDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInventoryDisclosureAbstract" xlink:to="loc_us-gaapInventoryDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://korumedical.com/role/PropertyAndEquipment" xlink:title="00000009 - Disclosure - PROPERTY AND EQUIPMENT">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaapPropertyPlantAndEquipmentAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="loc_us-gaapPropertyPlantAndEquipmentDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://korumedical.com/role/Stock-basedCompensation" xlink:title="00000010 - Disclosure - STOCK-BASED COMPENSATION">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://korumedical.com/role/Leases" xlink:title="00000011 - Disclosure - LEASES">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaapLeasesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesOfLesseeDisclosureTextBlock" xlink:label="loc_us-gaapLeasesOfLesseeDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_us-gaapLeasesOfLesseeDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://korumedical.com/role/FederalAndStateIncomeTaxes" xlink:title="00000012 - Disclosure - FEDERAL AND STATE INCOME TAXES">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaapIncomeTaxDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://korumedical.com/role/MajorCustomers" xlink:title="00000013 - Disclosure - MAJOR CUSTOMERS">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RisksAndUncertaintiesAbstract" xlink:label="loc_us-gaapRisksAndUncertaintiesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskDisclosureTextBlock" xlink:label="loc_us-gaapConcentrationRiskDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRisksAndUncertaintiesAbstract" xlink:to="loc_us-gaapConcentrationRiskDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://korumedical.com/role/CommitmentsAndContingencies" xlink:title="00000014 - Disclosure - COMMITMENTS AND CONTINGENCIES">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapCommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://korumedical.com/role/EmployeeBenefits" xlink:title="00000015 - Disclosure - EMPLOYEE BENEFITS">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="loc_us-gaapCompensationAndRetirementDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:label="loc_us-gaapPensionAndOtherPostretirementBenefitsDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCompensationAndRetirementDisclosureAbstract" xlink:to="loc_us-gaapPensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://korumedical.com/role/DebtObligations" xlink:title="00000016 - Disclosure - DEBT OBLIGATIONS">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaapDebtDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="loc_us-gaapDebtDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapDebtDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://korumedical.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:title="00000017 - Disclosure - NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NatureOfOperations" xlink:label="loc_us-gaapNatureOfOperations" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapNatureOfOperations" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="loc_us-gaapBasisOfAccountingPolicyPolicyTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapBasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="loc_us-gaapCashAndCashEquivalentsPolicyTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryPolicyTextBlock" xlink:label="loc_us-gaapInventoryPolicyTextBlock" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapInventoryPolicyTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:label="loc_us-gaapIntangibleAssetsFiniteLivedPolicy" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapIntangibleAssetsFiniteLivedPolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_us-gaapIncomeTaxPolicyTextBlock" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapIncomeTaxPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="loc_us-gaapPropertyPlantAndEquipmentPolicyTextBlock" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentPolicyTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="loc_us-gaapShareBasedCompensationOptionAndIncentivePlansPolicy" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaapEarningsPerSharePolicyTextBlock" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapEarningsPerSharePolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaapUseOfEstimates" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapUseOfEstimates" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:label="loc_us-gaapRevenueFromContractWithCustomerPolicyTextBlock" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapRevenueFromContractWithCustomerPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="loc_us-gaapLesseeLeasesPolicyTextBlock" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapLesseeLeasesPolicyTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaapNewAccountingPronouncementsPolicyPolicyTextBlock" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapNewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="krmd-20221231.xsd#krmd_AccountingPronouncementsNotYetAdopted" xlink:label="loc_krmdAccountingPronouncementsNotYetAdopted" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_krmdAccountingPronouncementsNotYetAdopted" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="loc_us-gaapFairValueMeasurementPolicyPolicyTextBlock" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapFairValueMeasurementPolicyPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="loc_us-gaapImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://korumedical.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesTables" xlink:title="00000018 - Disclosure - NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="loc_us-gaapScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="krmd-20221231.xsd#krmd_ScheduleOfNetRevenuesByGeography" xlink:label="loc_krmdScheduleOfNetRevenuesByGeography" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_krmdScheduleOfNetRevenuesByGeography" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://korumedical.com/role/InventoryTables" xlink:title="00000019 - Disclosure - INVENTORY (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaapInventoryDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:label="loc_us-gaapScheduleOfInventoryCurrentTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInventoryDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfInventoryCurrentTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://korumedical.com/role/PropertyAndEquipmentTables" xlink:title="00000020 - Disclosure - PROPERTY AND EQUIPMENT (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaapPropertyPlantAndEquipmentAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://korumedical.com/role/Stock-basedCompensationTables" xlink:title="00000021 - Disclosure - STOCK-BASED COMPENSATION (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="krmd-20221231.xsd#krmd_ScheduleOfShareBasedCompensationStockOptionsActivityAmendedTableTextBlock" xlink:label="loc_krmdScheduleOfShareBasedCompensationStockOptionsActivityAmendedTableTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_krmdScheduleOfShareBasedCompensationStockOptionsActivityAmendedTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfOtherShareBasedCompensationActivityTableTextBlock" xlink:label="loc_us-gaapScheduleOfOtherShareBasedCompensationActivityTableTextBlock" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfOtherShareBasedCompensationActivityTableTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="krmd-20221231.xsd#krmd_ScheduleOfShareBasedCompensationtaxBenefitsAssociatedWithRestrictedStockAwardCompensationTableTextBlock" xlink:label="loc_krmdScheduleOfShareBasedCompensationtaxBenefitsAssociatedWithRestrictedStockAwardCompensationTableTextBlock" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_krmdScheduleOfShareBasedCompensationtaxBenefitsAssociatedWithRestrictedStockAwardCompensationTableTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock" xlink:label="loc_us-gaapShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock" xlink:label="loc_us-gaapScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://korumedical.com/role/LeasesTables" xlink:title="00000022 - Disclosure - LEASES (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaapLeasesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="loc_us-gaapLeaseCostTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_us-gaapLeaseCostTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLeaseIncomeTableTextBlock" xlink:label="loc_us-gaapOperatingLeaseLeaseIncomeTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_us-gaapOperatingLeaseLeaseIncomeTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock" xlink:label="loc_us-gaapOperatingLeasesOfLesseeDisclosureTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_us-gaapOperatingLeasesOfLesseeDisclosureTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityMaturityTableTextBlock" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://korumedical.com/role/FederalAndStateIncomeTaxesTables" xlink:title="00000023 - Disclosure - FEDERAL AND STATE INCOME TAXES (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="loc_us-gaapScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="loc_us-gaapScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="loc_us-gaapScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://korumedical.com/role/ScheduleOfAmortizationExpenseDetails" xlink:title="00000024 - Disclosure - Schedule of amortization expense (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearThree" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearFour" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearFive" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsNet" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://korumedical.com/role/ScheduleOfNetIncomePerCommonShareDetails" xlink:title="00000025 - Disclosure - Schedule of net income per common share (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaapSubsidiarySaleOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockMember" xlink:label="loc_us-gaapEmployeeStockMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_us-gaapEmployeeStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract" xlink:label="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasicAbstract" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasicAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaapWeightedAverageNumberOfDilutedSharesOutstanding" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapWeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants" xlink:label="loc_us-gaapIncrementalCommonSharesAttributableToCallOptionsAndWarrants" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapIncrementalCommonSharesAttributableToCallOptionsAndWarrants" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="krmd-20221231.xsd#krmd_IncrementalCommonSharesAttributableToRestrictedStock" xlink:label="loc_krmdIncrementalCommonSharesAttributableToRestrictedStock" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_krmdIncrementalCommonSharesAttributableToRestrictedStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="krmd-20221231.xsd#krmd_WeightedAverageNumberOfSharesOutstanding" xlink:label="loc_krmdWeightedAverageNumberOfSharesOutstanding" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_krmdWeightedAverageNumberOfSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaapEarningsPerShareAbstract" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapEarningsPerShareAbstract" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaapEarningsPerShareBasic" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapEarningsPerShareBasic" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaapEarningsPerShareDiluted" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapEarningsPerShareDiluted" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="krmd-20221231.xsd#krmd_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount1" xlink:label="loc_krmdAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount1" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_krmdAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount1" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://korumedical.com/role/ScheduleOfNetRevenuesByGeographyDetails" xlink:title="00000026 - Disclosure - Schedule of net revenues by geography (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srtStatementGeographicalAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtStatementGeographicalAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srtSegmentGeographicalDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtStatementGeographicalAxis" xlink:to="loc_srtSegmentGeographicalDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US" xlink:label="loc_countryUS" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_countryUS" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonUsMember" xlink:label="loc_us-gaapNonUsMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_us-gaapNonUsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues" xlink:label="loc_us-gaapRevenues" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapRevenues" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://korumedical.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:title="00000027 - Disclosure - NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaapPropertyPlantAndEquipmentLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="krmd-20221231.xsd#krmd_PatentsAndTrademarksMember" xlink:label="loc_krmdPatentsAndTrademarksMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_krmdPatentsAndTrademarksMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_srtRangeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="krmd-20221231.xsd#krmd_FurnitureAndOfficeEquipmentMember" xlink:label="loc_krmdFurnitureAndOfficeEquipmentMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_krmdFurnitureAndOfficeEquipmentMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="krmd-20221231.xsd#krmd_EquipmentAndToolingMember" xlink:label="loc_krmdEquipmentAndToolingMember" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_krmdEquipmentAndToolingMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="loc_us-gaapFairValueByAssetClassAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapFairValueByAssetClassAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="loc_us-gaapFairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueByAssetClassAxis" xlink:to="loc_us-gaapFairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentMember" xlink:label="loc_us-gaapPropertyPlantAndEquipmentMember" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="loc_us-gaapPropertyPlantAndEquipmentMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfReportableSegments" xlink:label="loc_us-gaapNumberOfReportableSegments" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapNumberOfReportableSegments" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashUninsuredAmount" xlink:label="loc_us-gaapCashUninsuredAmount" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapCashUninsuredAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetUsefulLife" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetUsefulLife" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="krmd-20221231.xsd#krmd_AmortizationOfIntangibleAssets1" xlink:label="loc_krmdAmortizationOfIntangibleAssets1" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_krmdAmortizationOfIntangibleAssets1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaapPropertyPlantAndEquipmentUsefulLife" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentUsefulLife" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaapDepreciationDepletionAndAmortization" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapDepreciationDepletionAndAmortization" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://korumedical.com/role/InventoryConsistsOfDetails" xlink:title="00000028 - Disclosure - Inventory consists of: (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaapInventoryDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryWorkInProcessAndRawMaterials" xlink:label="loc_us-gaapInventoryWorkInProcessAndRawMaterials" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInventoryDisclosureAbstract" xlink:to="loc_us-gaapInventoryWorkInProcessAndRawMaterials" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryFinishedGoods" xlink:label="loc_us-gaapInventoryFinishedGoods" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInventoryDisclosureAbstract" xlink:to="loc_us-gaapInventoryFinishedGoods" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryGross" xlink:label="loc_us-gaapInventoryGross" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInventoryDisclosureAbstract" xlink:to="loc_us-gaapInventoryGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryValuationReserves" xlink:label="loc_us-gaapInventoryValuationReserves" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInventoryDisclosureAbstract" xlink:to="loc_us-gaapInventoryValuationReserves" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaapInventoryNet" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInventoryDisclosureAbstract" xlink:to="loc_us-gaapInventoryNet" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://korumedical.com/role/ScheduleOfPropertyAndEquipmentDetails" xlink:title="00000029 - Disclosure - Schedule of property and equipment (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaapPropertyPlantAndEquipmentAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract" xlink:to="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaapPropertyPlantAndEquipmentLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="krmd-20221231.xsd#krmd_FurnitureAndOfficeEquipmentMember" xlink:label="loc_krmdFurnitureAndOfficeEquipmentMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_krmdFurnitureAndOfficeEquipmentMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaapLeaseholdImprovementsMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapLeaseholdImprovementsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="krmd-20221231.xsd#krmd_ManufacturingEquipmentAndToolingMember" xlink:label="loc_krmdManufacturingEquipmentAndToolingMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_krmdManufacturingEquipmentAndToolingMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaapPropertyPlantAndEquipmentGross" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://korumedical.com/role/ScheduleOfTimeBasedStockOptionsDetails" xlink:title="00000030 - Disclosure - Schedule of time based stock options (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapPlanNameAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="krmd-20221231.xsd#krmd_StockOptionPlan2015Member" xlink:label="loc_krmdStockOptionPlan2015Member" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_krmdStockOptionPlan2015Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="krmd-20221231.xsd#krmd_StockOptionPlan2021Member" xlink:label="loc_krmdStockOptionPlan2021Member" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_krmdStockOptionPlan2021Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="krmd-20221231.xsd#krmd_TimeBasedSharesOptionsMember" xlink:label="loc_krmdTimeBasedSharesOptionsMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_krmdTimeBasedSharesOptionsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_srtRangeAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://korumedical.com/role/ScheduleOfStatusOfTimeBasedStockOptionsDetails" xlink:title="00000031 - Disclosure - Schedule of status of time based stock options (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapPlanNameAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="krmd-20221231.xsd#krmd_StockOptionPlan2015Member" xlink:label="loc_krmdStockOptionPlan2015Member" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_krmdStockOptionPlan2015Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="krmd-20221231.xsd#krmd_StockOptionPlan2021Member" xlink:label="loc_krmdStockOptionPlan2021Member" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_krmdStockOptionPlan2021Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaapAllocatedShareBasedCompensationExpense" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapAllocatedShareBasedCompensationExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="krmd-20221231.xsd#krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber2" xlink:label="loc_krmdShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber2" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_krmdShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="krmd-20221231.xsd#krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice2" xlink:label="loc_krmdShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice2" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_krmdShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="krmd-20221231.xsd#krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross2" xlink:label="loc_krmdShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross2" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_krmdShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="krmd-20221231.xsd#krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice2" xlink:label="loc_krmdShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice2" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_krmdShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="krmd-20221231.xsd#krmd_StockIssuedDuringPeriodSharesStockOptionsExercised2" xlink:label="loc_krmdStockIssuedDuringPeriodSharesStockOptionsExercised2" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_krmdStockIssuedDuringPeriodSharesStockOptionsExercised2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="krmd-20221231.xsd#krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice2" xlink:label="loc_krmdShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice2" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_krmdShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="krmd-20221231.xsd#krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod2" xlink:label="loc_krmdShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod2" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_krmdShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="krmd-20221231.xsd#krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice2" xlink:label="loc_krmdShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_krmdShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="krmd-20221231.xsd#krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber2" xlink:label="loc_krmdShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber2_2" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_krmdShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber2_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="krmd-20221231.xsd#krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice2" xlink:label="loc_krmdShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice2_2" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_krmdShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice2_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="krmd-20221231.xsd#krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice2" xlink:label="loc_krmdShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice2" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_krmdShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="krmd-20221231.xsd#krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue2" xlink:label="loc_krmdShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue2" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_krmdShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://korumedical.com/role/ScheduleOfInformationPertainingToOptionsOutstandingDetails" xlink:title="00000032 - Disclosure - Schedule of information pertaining to options outstanding (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapPlanNameAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="krmd-20221231.xsd#krmd_StockOptionPlan2015Member" xlink:label="loc_krmdStockOptionPlan2015Member" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_krmdStockOptionPlan2015Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="krmd-20221231.xsd#krmd_StockOptionPlan2021Member" xlink:label="loc_krmdStockOptionPlan2021Member" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_krmdStockOptionPlan2021Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="krmd-20221231.xsd#krmd_TimeBasedSharesOptionsMember" xlink:label="loc_krmdTimeBasedSharesOptionsMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_krmdTimeBasedSharesOptionsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="krmd-20221231.xsd#krmd_ExercisePrice1Member" xlink:label="loc_krmdExercisePrice1Member" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_krmdExercisePrice1Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaapSharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:label="loc_us-gaapSharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:label="loc_us-gaapSharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://korumedical.com/role/ScheduleOfPerformanceBaseOptionsOutstandingDetails" xlink:title="00000033 - Disclosure - Schedule of performance base options outstanding (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PerformanceSharesMember" xlink:label="loc_us-gaapPerformanceSharesMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapPerformanceSharesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="krmd-20221231.xsd#krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber1" xlink:label="loc_krmdShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber1" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_krmdShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="krmd-20221231.xsd#krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice1" xlink:label="loc_krmdShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice1" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_krmdShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="krmd-20221231.xsd#krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross1" xlink:label="loc_krmdShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross1" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_krmdShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="krmd-20221231.xsd#krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice1" xlink:label="loc_krmdShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice1" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_krmdShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="krmd-20221231.xsd#krmd_StockIssuedDuringPeriodSharesStockOptionsExercised1" xlink:label="loc_krmdStockIssuedDuringPeriodSharesStockOptionsExercised1" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_krmdStockIssuedDuringPeriodSharesStockOptionsExercised1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="krmd-20221231.xsd#krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice1" xlink:label="loc_krmdShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice1" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_krmdShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="krmd-20221231.xsd#krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod1" xlink:label="loc_krmdShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod1" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_krmdShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="krmd-20221231.xsd#krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice1" xlink:label="loc_krmdShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice1" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_krmdShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="krmd-20221231.xsd#krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice1" xlink:label="loc_krmdShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice1" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_krmdShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="krmd-20221231.xsd#krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue1" xlink:label="loc_krmdShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue1" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_krmdShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="krmd-20221231.xsd#krmd_AllocatedShareBasedCompensationExpense1" xlink:label="loc_krmdAllocatedShareBasedCompensationExpense1" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_krmdAllocatedShareBasedCompensationExpense1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://korumedical.com/role/FollowingTableSummarizesActivitiesForOurUnvestedRestrictedStockAwardsForTwelveMonthsEndedDecember312022And2021.Details" xlink:title="00000034 - Disclosure - The following table summarizes the activities for our unvested restricted stock awards for the twelve months ended December 31, 2022, and 2021. (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="krmd-20221231.xsd#krmd_RestrictedStockAwardsMember" xlink:label="loc_krmdRestrictedStockAwardsMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_krmdRestrictedStockAwardsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapPlanNameAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="krmd-20221231.xsd#krmd_StockOptionPlan2021Member" xlink:label="loc_krmdStockOptionPlan2021Member" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_krmdStockOptionPlan2021Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="krmd-20221231.xsd#krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberUnvested" xlink:label="loc_krmdShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberUnvested" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_krmdShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberUnvested" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="krmd-20221231.xsd#krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceUnvested" xlink:label="loc_krmdShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceUnvested" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_krmdShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceUnvested" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="krmd-20221231.xsd#krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrossUnvested" xlink:label="loc_krmdShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrossUnvested" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_krmdShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrossUnvested" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="krmd-20221231.xsd#krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePriceUnvested" xlink:label="loc_krmdShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePriceUnvested" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_krmdShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePriceUnvested" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="krmd-20221231.xsd#krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodGross" xlink:label="loc_krmdShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodGross" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_krmdShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="krmd-20221231.xsd#krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice" xlink:label="loc_krmdShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_krmdShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="krmd-20221231.xsd#krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodUnvested" xlink:label="loc_krmdShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodUnvested" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_krmdShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodUnvested" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="krmd-20221231.xsd#krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePriceUnvested" xlink:label="loc_krmdShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePriceUnvested" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_krmdShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePriceUnvested" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="krmd-20221231.xsd#krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberUnvested" xlink:label="loc_krmdShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberUnvested_2" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_krmdShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberUnvested_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="krmd-20221231.xsd#krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceUnvested" xlink:label="loc_krmdShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceUnvested_2" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_krmdShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceUnvested_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://korumedical.com/role/Stock-basedCompensationDetailsNarrative" xlink:title="00000035 - Disclosure - STOCK-BASED COMPENSATION (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapPlanNameAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="krmd-20221231.xsd#krmd_StockOptionPlan2015Member" xlink:label="loc_krmdStockOptionPlan2015Member" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_krmdStockOptionPlan2015Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="krmd-20221231.xsd#krmd_StockOptionPlan2021Member" xlink:label="loc_krmdStockOptionPlan2021Member" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_krmdStockOptionPlan2021Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_srtTitleOfIndividualAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="krmd-20221231.xsd#krmd_ExecutiveskeyEmployeesAndConsultantsMember" xlink:label="loc_krmdExecutiveskeyEmployeesAndConsultantsMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_krmdExecutiveskeyEmployeesAndConsultantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_DirectorMember" xlink:label="loc_srtDirectorMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_srtDirectorMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="krmd-20221231.xsd#krmd_ExecutiveMember" xlink:label="loc_krmdExecutiveMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_krmdExecutiveMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="krmd-20221231.xsd#krmd_NonEmployeeDirectorAndBoardAdvisorMember" xlink:label="loc_krmdNonEmployeeDirectorAndBoardAdvisorMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_krmdNonEmployeeDirectorAndBoardAdvisorMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_BoardOfDirectorsChairmanMember" xlink:label="loc_srtBoardOfDirectorsChairmanMember" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_srtBoardOfDirectorsChairmanMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ChiefExecutiveOfficerMember" xlink:label="loc_srtChiefExecutiveOfficerMember" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_srtChiefExecutiveOfficerMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="krmd-20221231.xsd#krmd_ChiefExecutiveOfficerLindaTharbyMember" xlink:label="loc_krmdChiefExecutiveOfficerLindaTharbyMember" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_krmdChiefExecutiveOfficerLindaTharbyMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="krmd-20221231.xsd#krmd_TimeBasedSharesOptionsMember" xlink:label="loc_krmdTimeBasedSharesOptionsMember" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_krmdTimeBasedSharesOptionsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="krmd-20221231.xsd#krmd_RestrictedStockAwardsMember" xlink:label="loc_krmdRestrictedStockAwardsMember" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_krmdRestrictedStockAwardsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaapFinancialInstrumentAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapFinancialInstrumentAxis" order="50" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFinancialInstrumentAxis" xlink:to="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockOptionMember" xlink:label="loc_us-gaapStockOptionMember" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="loc_us-gaapStockOptionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="60" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="krmd-20221231.xsd#krmd_EmploymentAgreementMember" xlink:label="loc_krmdEmploymentAgreementMember" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_krmdEmploymentAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="krmd-20221231.xsd#krmd_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan2015" xlink:label="loc_krmdStockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan2015" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_krmdStockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan2015" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesShareBasedCompensation" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesShareBasedCompensation" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="krmd-20221231.xsd#krmd_NonemployeeServicesTransactionCost" xlink:label="loc_krmdNonemployeeServicesTransactionCost" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_krmdNonemployeeServicesTransactionCost" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransaction" xlink:label="loc_us-gaapShareBasedGoodsAndNonemployeeServicesTransaction" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedGoodsAndNonemployeeServicesTransaction" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueEmployeeStockOwnershipPlan" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueEmployeeStockOwnershipPlan" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaapIncomeTaxExpenseBenefit" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapIncomeTaxExpenseBenefit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaapProceedsFromStockOptionsExercised" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapProceedsFromStockOptionsExercised" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="krmd-20221231.xsd#krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_krmdShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriodWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_krmdShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="krmd-20221231.xsd#krmd_StockIssuedDuringPeriodSharesStockOptionsExercised1" xlink:label="loc_krmdStockIssuedDuringPeriodSharesStockOptionsExercised1" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_krmdStockIssuedDuringPeriodSharesStockOptionsExercised1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="krmd-20221231.xsd#krmd_CompensationCost" xlink:label="loc_krmdCompensationCost" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_krmdCompensationCost" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="krmd-20221231.xsd#krmd_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm3" xlink:label="loc_krmdSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm3" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_krmdSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapCommonStockSharesIssued" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="krmd-20221231.xsd#krmd_UnrecognizedCompensationCost" xlink:label="loc_krmdUnrecognizedCompensationCost" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_krmdUnrecognizedCompensationCost" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="krmd-20221231.xsd#krmd_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm4" xlink:label="loc_krmdSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm4" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_krmdSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://korumedical.com/role/ScheduleOfComponentsOfLeaseExpenseDetails" xlink:title="00000036 - Disclosure - Schedule of components of lease expense (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaapLeasesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseCost" xlink:label="loc_us-gaapOperatingLeaseCost" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_us-gaapOperatingLeaseCost" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermLeaseCost" xlink:label="loc_us-gaapShortTermLeaseCost" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_us-gaapShortTermLeaseCost" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCost" xlink:label="loc_us-gaapLeaseCost" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_us-gaapLeaseCost" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="krmd-20221231.xsd#krmd_FinanceLeaseCost1Abstract" xlink:label="loc_krmdFinanceLeaseCost1Abstract" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_krmdFinanceLeaseCost1Abstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:label="loc_us-gaapFinanceLeaseRightOfUseAssetAmortization" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_krmdFinanceLeaseCost1Abstract" xlink:to="loc_us-gaapFinanceLeaseRightOfUseAssetAmortization" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseInterestExpense" xlink:label="loc_us-gaapFinanceLeaseInterestExpense" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_krmdFinanceLeaseCost1Abstract" xlink:to="loc_us-gaapFinanceLeaseInterestExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="krmd-20221231.xsd#krmd_FinanceLeaseCost" xlink:label="loc_krmdFinanceLeaseCost" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_krmdFinanceLeaseCost1Abstract" xlink:to="loc_krmdFinanceLeaseCost" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://korumedical.com/role/ScheduleOfCashFlowInformationRelatedToLeasesDetails" xlink:title="00000037 - Disclosure - Schedule of cash flow information related to leases (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaapLeasesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFlowOperatingActivitiesLesseeAbstract" xlink:label="loc_us-gaapCashFlowOperatingActivitiesLesseeAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_us-gaapCashFlowOperatingActivitiesLesseeAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasePayments" xlink:label="loc_us-gaapOperatingLeasePayments" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCashFlowOperatingActivitiesLesseeAbstract" xlink:to="loc_us-gaapOperatingLeasePayments" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:label="loc_us-gaapFinanceLeaseInterestPaymentOnLiability" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCashFlowOperatingActivitiesLesseeAbstract" xlink:to="loc_us-gaapFinanceLeaseInterestPaymentOnLiability" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://korumedical.com/role/SchdeuleOfBalanceSheetInformationRelatedToLeasesDetails" xlink:title="00000038 - Disclosure - Schdeule of balance sheet information related to leases (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaapLeasesAbstract" />
      <link:loc xlink:type="locator" xlink:href="krmd-20221231.xsd#krmd_AssetsAndLiabilitiesOperatingLesseeAbstract" xlink:label="loc_krmdAssetsAndLiabilitiesOperatingLesseeAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_krmdAssetsAndLiabilitiesOperatingLesseeAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_krmdAssetsAndLiabilitiesOperatingLesseeAbstract" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityCurrent" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_krmdAssetsAndLiabilitiesOperatingLesseeAbstract" xlink:to="loc_us-gaapOperatingLeaseLiabilityCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityNoncurrent" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_krmdAssetsAndLiabilitiesOperatingLesseeAbstract" xlink:to="loc_us-gaapOperatingLeaseLiabilityNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaapOperatingLeaseLiability" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_krmdAssetsAndLiabilitiesOperatingLesseeAbstract" xlink:to="loc_us-gaapOperatingLeaseLiability" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="krmd-20221231.xsd#krmd_AssetsAndLiabilitiesLesseeFinanceAbstract" xlink:label="loc_krmdAssetsAndLiabilitiesLesseeFinanceAbstract" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_krmdAssetsAndLiabilitiesLesseeFinanceAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentOther" xlink:label="loc_us-gaapPropertyPlantAndEquipmentOther" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_krmdAssetsAndLiabilitiesLesseeFinanceAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentOther" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentOtherAccumulatedDepreciation" xlink:label="loc_us-gaapPropertyPlantAndEquipmentOtherAccumulatedDepreciation" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_krmdAssetsAndLiabilitiesLesseeFinanceAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentOtherAccumulatedDepreciation" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentOtherNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentOtherNet" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_krmdAssetsAndLiabilitiesLesseeFinanceAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentOtherNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityCurrent" xlink:label="loc_us-gaapFinanceLeaseLiabilityCurrent" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_us-gaapFinanceLeaseLiabilityCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapFinanceLeaseLiabilityNoncurrent" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_us-gaapFinanceLeaseLiabilityNoncurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiability" xlink:label="loc_us-gaapFinanceLeaseLiability" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_us-gaapFinanceLeaseLiability" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="loc_us-gaapLesseeOperatingLeaseRenewalTerm" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseRenewalTerm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeFinanceLeaseRenewalTerm1" xlink:label="loc_us-gaapLesseeFinanceLeaseRenewalTerm1" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_us-gaapLesseeFinanceLeaseRenewalTerm1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseDiscountRate" xlink:label="loc_us-gaapLesseeOperatingLeaseDiscountRate" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseDiscountRate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeFinanceLeaseDiscountRate" xlink:label="loc_us-gaapLesseeFinanceLeaseDiscountRate" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_us-gaapLesseeFinanceLeaseDiscountRate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://korumedical.com/role/ScheduleOfMaturitiesOfLeaseLiabilitiesDetails" xlink:title="00000039 - Disclosure - Schedule of maturities of lease liabilities (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaapLeasesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="loc_us-gaapFinanceLeaseLiabilityPaymentsDueNextTwelveMonths" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_us-gaapFinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaapFinanceLeaseLiabilityPaymentsDueYearTwo" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_us-gaapFinanceLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearThree" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:label="loc_us-gaapFinanceLeaseLiabilityPaymentsDueYearThree" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_us-gaapFinanceLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearFour" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:label="loc_us-gaapFinanceLeaseLiabilityPaymentsDueYearFour" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_us-gaapFinanceLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearFive" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive" xlink:label="loc_us-gaapFinanceLeaseLiabilityPaymentsDueYearFive" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_us-gaapFinanceLeaseLiabilityPaymentsDueYearFive" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="loc_us-gaapFinanceLeaseLiabilityPaymentsDueAfterYearFive" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_us-gaapFinanceLeaseLiabilityPaymentsDueAfterYearFive" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="krmd-20221231.xsd#krmd_LesseeOperatingLeaseLiabilityPaymentsDueTotal" xlink:label="loc_krmdLesseeOperatingLeaseLiabilityPaymentsDueTotal" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_krmdLesseeOperatingLeaseLiabilityPaymentsDueTotal" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="krmd-20221231.xsd#krmd_LesseeFinancingLeaseLeaseLiabilityPaymentsDueTotal" xlink:label="loc_krmdLesseeFinancingLeaseLeaseLiabilityPaymentsDueTotal" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_krmdLesseeFinancingLeaseLeaseLiabilityPaymentsDueTotal" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="krmd-20221231.xsd#krmd_LesseeOperatingLeaseImputedInterest" xlink:label="loc_krmdLesseeOperatingLeaseImputedInterest" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_krmdLesseeOperatingLeaseImputedInterest" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="krmd-20221231.xsd#krmd_LesseeFinancingLeaseImputedInterest" xlink:label="loc_krmdLesseeFinancingLeaseImputedInterest" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_krmdLesseeFinancingLeaseImputedInterest" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaapOperatingLeaseLiability" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_us-gaapOperatingLeaseLiability" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiability" xlink:label="loc_us-gaapFinanceLeaseLiability" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_us-gaapFinanceLeaseLiability" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://korumedical.com/role/LeasesDetailsNarrative" xlink:title="00000040 - Disclosure - LEASES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaapLeasesAbstract" />
      <link:loc xlink:type="locator" xlink:href="krmd-20221231.xsd#krmd_DescriptionOfLessorOperatingLeaseTerm" xlink:label="loc_krmdDescriptionOfLessorOperatingLeaseTerm" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_krmdDescriptionOfLessorOperatingLeaseTerm" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://korumedical.com/role/ScheduleOfProvisionForIncomeTaxesDetails" xlink:title="00000041 - Disclosure - Schedule of provision for income taxes (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="loc_us-gaapStateAndLocalIncomeTaxExpenseBenefitContinuingOperationsAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapStateAndLocalIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="loc_us-gaapCurrentStateAndLocalTaxExpenseBenefit" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapCurrentStateAndLocalTaxExpenseBenefit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="loc_us-gaapFederalIncomeTaxExpenseBenefitContinuingOperationsAbstract" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapFederalIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:label="loc_us-gaapDeferredFederalIncomeTaxExpenseBenefit" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredFederalIncomeTaxExpenseBenefit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:label="loc_us-gaapCurrentFederalTaxExpenseBenefit" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapCurrentFederalTaxExpenseBenefit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaapIncomeTaxExpenseBenefit" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxExpenseBenefit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://korumedical.com/role/ScheduleOfReconciliationOfIncomeTaxesDetails" xlink:title="00000042 - Disclosure - Schedule of reconciliation of income taxes (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaapIncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaapIncomeTaxReconciliationStateAndLocalIncomeTaxes" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:label="loc_us-gaapIncomeTaxReconciliationOtherAdjustments" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxReconciliationOtherAdjustments" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaapIncomeTaxExpenseBenefit" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxExpenseBenefit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://korumedical.com/role/ScheduleOfComponentsOfDeferredTaxAssetsDetails" xlink:title="00000043 - Disclosure - Schedule of components of deferred tax assets (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCompensationPlanAssets" xlink:label="loc_us-gaapDeferredCompensationPlanAssets" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredCompensationPlanAssets" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="krmd-20221231.xsd#krmd_DepreciationDepletionAndAmortization1" xlink:label="loc_krmdDepreciationDepletionAndAmortization1" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_krmdDepreciationDepletionAndAmortization1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="krmd-20221231.xsd#krmd_RdCredit" xlink:label="loc_krmdRdCredit" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_krmdRdCredit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="krmd-20221231.xsd#krmd_Nol" xlink:label="loc_krmdNol" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_krmdNol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="krmd-20221231.xsd#krmd_AllowanceForDoubtfulOtherReceivables1Current" xlink:label="loc_krmdAllowanceForDoubtfulOtherReceivables1Current" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_krmdAllowanceForDoubtfulOtherReceivables1Current" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="loc_us-gaapDeferredTaxAssetsNet" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://korumedical.com/role/MajorCustomersDetailsNarrative" xlink:title="00000044 - Disclosure - MAJOR CUSTOMERS (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RisksAndUncertaintiesAbstract" xlink:label="loc_us-gaapRisksAndUncertaintiesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTable" xlink:label="loc_us-gaapConcentrationRiskTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRisksAndUncertaintiesAbstract" xlink:to="loc_us-gaapConcentrationRiskTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskLineItems" xlink:label="loc_us-gaapConcentrationRiskLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskTable" xlink:to="loc_us-gaapConcentrationRiskLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="loc_us-gaapConcentrationRiskByBenchmarkAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskTable" xlink:to="loc_us-gaapConcentrationRiskByBenchmarkAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaapConcentrationRiskBenchmarkDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskByBenchmarkAxis" xlink:to="loc_us-gaapConcentrationRiskBenchmarkDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesRevenueNetMember" xlink:label="loc_us-gaapSalesRevenueNetMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskBenchmarkDomain" xlink:to="loc_us-gaapSalesRevenueNetMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="loc_us-gaapConcentrationRiskByTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskTable" xlink:to="loc_us-gaapConcentrationRiskByTypeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaapConcentrationRiskTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskByTypeAxis" xlink:to="loc_us-gaapConcentrationRiskTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="loc_us-gaapCustomerConcentrationRiskMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskTypeDomain" xlink:to="loc_us-gaapCustomerConcentrationRiskMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MajorCustomersAxis" xlink:label="loc_srtMajorCustomersAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskTable" xlink:to="loc_srtMajorCustomersAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srtNameOfMajorCustomerDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtMajorCustomersAxis" xlink:to="loc_srtNameOfMajorCustomerDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="krmd-20221231.xsd#krmd_CustomerOneMember" xlink:label="loc_krmdCustomerOneMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtNameOfMajorCustomerDomain" xlink:to="loc_krmdCustomerOneMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="loc_us-gaapConcentrationRiskPercentage1" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskLineItems" xlink:to="loc_us-gaapConcentrationRiskPercentage1" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://korumedical.com/role/EmployeeBenefitsDetailsNarrative" xlink:title="00000045 - Disclosure - EMPLOYEE BENEFITS (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="loc_us-gaapCompensationAndRetirementDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="krmd-20221231.xsd#krmd_DescriptionOfMatchingContribution" xlink:label="loc_krmdDescriptionOfMatchingContribution" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCompensationAndRetirementDisclosureAbstract" xlink:to="loc_krmdDescriptionOfMatchingContribution" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:label="loc_us-gaapDefinedContributionPlanEmployerDiscretionaryContributionAmount" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCompensationAndRetirementDisclosureAbstract" xlink:to="loc_us-gaapDefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://korumedical.com/role/DebtObligationsDetailsNarrative" xlink:title="00000046 - Disclosure - DEBT OBLIGATIONS (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaapDebtDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShortTermDebtTable" xlink:label="loc_us-gaapScheduleOfShortTermDebtTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfShortTermDebtTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtLineItems" xlink:label="loc_us-gaapShortTermDebtLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_us-gaapShortTermDebtLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_deiLegalEntityAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="krmd-20221231.xsd#krmd_AONPremiumFinanceLLCMember" xlink:label="loc_krmdAONPremiumFinanceLLCMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_krmdAONPremiumFinanceLLCMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaapDebtInstrumentAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_us-gaapDebtInstrumentAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaapDebtInstrumentNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentAxis" xlink:to="loc_us-gaapDebtInstrumentNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="krmd-20221231.xsd#krmd_PromissoryNoteMember" xlink:label="loc_krmdPromissoryNoteMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_krmdPromissoryNoteMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityAxis" xlink:label="loc_us-gaapCreditFacilityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_us-gaapCreditFacilityAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain" xlink:label="loc_us-gaapCreditFacilityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCreditFacilityAxis" xlink:to="loc_us-gaapCreditFacilityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditMember" xlink:label="loc_us-gaapLineOfCreditMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCreditFacilityDomain" xlink:to="loc_us-gaapLineOfCreditMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesPayable" xlink:label="loc_us-gaapNotesPayable" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapNotesPayable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="krmd-20221231.xsd#krmd_NotePayableTerms" xlink:label="loc_krmdNotePayableTerms" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_krmdNotePayableTerms" xlink:type="arc" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139621727753520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Mar. 08, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">0-12305<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">KORU MEDICAL SYSTEMS, INC<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000704440<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">13-3044880<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">NY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">100 Corporate Drive<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Mahwah<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">NJ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">07430<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">845<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">469-2042<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">common stock, $0.01 par value<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">KRMD<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 71,872,771<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45,519,164<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Treasury Stock, Common, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,420,502<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">256<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">McGrail Merkel Quinn & Associates, P.C.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">Scranton, Pennsylvania<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockCommonShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of previously issued common shares repurchased by the issuing entity and held in treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockCommonShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139621726800688">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>BALANCE SHEETS - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>CURRENT ASSETS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 17,408,257<span></span>
</td>
<td class="nump">$ 25,334,889<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable less allowance for doubtful accounts of $21,459 and $24,271 for December 31, 2022, and December 31, 2021, respectively</a></td>
<td class="nump">3,558,884<span></span>
</td>
<td class="nump">3,592,886<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory</a></td>
<td class="nump">6,404,867<span></span>
</td>
<td class="nump">6,106,338<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherReceivables', window );">Other receivables</a></td>
<td class="nump">972,396<span></span>
</td>
<td class="nump">718,220<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrent', window );">Prepaid expenses and other</a></td>
<td class="nump">1,457,232<span></span>
</td>
<td class="nump">1,568,821<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">TOTAL CURRENT ASSETS</a></td>
<td class="nump">29,801,636<span></span>
</td>
<td class="nump">37,321,154<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">3,886,975<span></span>
</td>
<td class="nump">1,106,445<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Intangible assets, net of accumulated amortization of $325,872 and $263,729 at December 31, 2022 and December 31, 2021, respectively</a></td>
<td class="nump">787,182<span></span>
</td>
<td class="nump">808,813<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">3,786,545<span></span>
</td>
<td class="nump">95,553<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxAssetsNet', window );">Deferred income tax assets, net</a></td>
<td class="nump">3,967,480<span></span>
</td>
<td class="nump">1,941,254<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">102,625<span></span>
</td>
<td class="nump">19,812<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">TOTAL ASSETS</a></td>
<td class="nump">42,332,443<span></span>
</td>
<td class="nump">41,293,031<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>CURRENT LIABILITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">2,391,799<span></span>
</td>
<td class="nump">1,227,533<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">2,889,941<span></span>
</td>
<td class="nump">2,709,704<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayableCurrent', window );">Note Payable</a></td>
<td class="nump">433,295<span></span>
</td>
<td class="nump">508,583<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other liabilities</a></td>
<td class="nump">257,337<span></span>
</td>
<td class="nump">90,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Accrued payroll and related taxes</a></td>
<td class="nump">542,399<span></span>
</td>
<td class="nump">160,603<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityCurrent', window );">Finance lease liability &#8211; current</a></td>
<td class="nump">98,335<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liability &#8211; current</a></td>
<td class="nump">345,834<span></span>
</td>
<td class="nump">95,553<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">TOTAL CURRENT LIABILITIES</a></td>
<td class="nump">6,958,940<span></span>
</td>
<td class="nump">4,791,976<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityNoncurrent', window );">Finance lease liability, net current portion</a></td>
<td class="nump">394,283<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liability, net of current portion</a></td>
<td class="nump">3,653,257<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">TOTAL LIABILITIES</a></td>
<td class="nump">11,006,480<span></span>
</td>
<td class="nump">4,791,976<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>STOCKHOLDERS&#8217; EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.01 par value, 75,000,000 shares authorized, 48,861,891 and 48,044,162 shares issued; 45,441,389 and 44,623,660 shares outstanding at December 31, 2022, and December 31, 2021, respectively</a></td>
<td class="nump">488,619<span></span>
</td>
<td class="nump">480,441<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">44,252,117<span></span>
</td>
<td class="nump">40,774,245<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockValue', window );">Treasury stock, 3,420,502 shares at December 31, 2022 and December 31, 2021, at cost</a></td>
<td class="num">(3,843,562)<span></span>
</td>
<td class="num">(3,843,562)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Retained Deficit</a></td>
<td class="num">(9,571,211)<span></span>
</td>
<td class="num">(910,069)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">TOTAL STOCKHOLDERS&#8217; EQUITY</a></td>
<td class="nump">31,325,963<span></span>
</td>
<td class="nump">36,501,055<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">TOTAL LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</a></td>
<td class="nump">$ 42,332,443<span></span>
</td>
<td class="nump">$ 41,293,031<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31917-109318<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6904-107765<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount due from parties in nontrade transactions, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6387103&amp;loc=d3e6435-108320<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126905020&amp;loc=d3e5879-108316<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23315-112656<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29,30)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139621727063472">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>BALANCE SHEETS (Parenthetical) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent', window );">Accounts receivable, allowance for credit loss, current</a></td>
<td class="nump">$ 21,459<span></span>
</td>
<td class="nump">$ 24,271<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Finite-lived intangible assets, accumulated amortization</a></td>
<td class="nump">$ 325,872<span></span>
</td>
<td class="nump">$ 263,729<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par or stated value per share</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">75,000,000<span></span>
</td>
<td class="nump">75,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares, issued</a></td>
<td class="nump">48,861,891<span></span>
</td>
<td class="nump">48,044,162<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares, outstanding</a></td>
<td class="nump">45,441,389<span></span>
</td>
<td class="nump">44,623,660<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockShares', window );">Treasury stock, shares</a></td>
<td class="nump">3,420,502<span></span>
</td>
<td class="nump">3,420,502<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on accounts receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5074-111524<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124255206&amp;loc=SL82895884-210446<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of common and preferred shares that were previously issued and that were repurchased by the issuing entity and held in treasury on the financial statement date. This stock has no voting rights and receives no dividends.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29,30)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139621727782528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STATEMENTS OF OPERATIONS - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">NET REVENUES</a></td>
<td class="nump">$ 27,896,037<span></span>
</td>
<td class="nump">$ 23,490,175<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of goods sold</a></td>
<td class="nump">12,527,051<span></span>
</td>
<td class="nump">9,720,597<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross Profit</a></td>
<td class="nump">15,368,986<span></span>
</td>
<td class="nump">13,769,578<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>OPERATING EXPENSES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="nump">20,606,507<span></span>
</td>
<td class="nump">17,862,314<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">4,956,215<span></span>
</td>
<td class="nump">2,473,669<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">587,137<span></span>
</td>
<td class="nump">463,130<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total Operating Expenses</a></td>
<td class="nump">26,149,859<span></span>
</td>
<td class="nump">20,799,113<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Net Operating Loss</a></td>
<td class="num">(10,780,873)<span></span>
</td>
<td class="num">(7,029,535)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Non-Operating Income</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax', window );">Loss on foreign currency exchange</a></td>
<td class="num">(39,874)<span></span>
</td>
<td class="num">(28,905)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment', window );">Gain on disposal of fixed assets</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">1,009<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherIncome', window );">Other Income</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">679,907<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Interest income, net</a></td>
<td class="nump">145,587<span></span>
</td>
<td class="nump">13,083<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">TOTAL OTHER INCOME</a></td>
<td class="nump">105,713<span></span>
</td>
<td class="nump">665,094<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments', window );">LOSS BEFORE TAXES</a></td>
<td class="num">(10,675,160)<span></span>
</td>
<td class="num">(6,364,441)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax benefit</a></td>
<td class="nump">2,014,018<span></span>
</td>
<td class="nump">1,801,618<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">NET LOSS</a></td>
<td class="num">$ (8,661,142)<span></span>
</td>
<td class="num">$ (4,562,823)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>NET LOSS PER SHARE</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic</a></td>
<td class="num">$ (0.19)<span></span>
</td>
<td class="num">$ (0.10)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted</a></td>
<td class="num">$ (0.19)<span></span>
</td>
<td class="num">$ (0.10)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>WEIGHTED AVERAGE COMMON SHARES OUTSTANDING</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic</a></td>
<td class="nump">45,002,074<span></span>
</td>
<td class="nump">44,385,032<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted</a></td>
<td class="nump">45,002,074<span></span>
</td>
<td class="nump">44,385,032<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=125521441&amp;loc=d3e30690-110894<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 35<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123602790&amp;loc=d3e30226-110892<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=126980362&amp;loc=d3e28228-110885<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124440516&amp;loc=d3e30840-110895<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfPropertyPlantEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrossProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 18: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1,2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrossProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue and income classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139621726836432">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($)<br></strong></div></th>
<th class="th"><div>Common Stock [Member]</div></th>
<th class="th"><div>Additional Paid-in Capital [Member]</div></th>
<th class="th"><div>Retained Earnings [Member]</div></th>
<th class="th"><div>Treasury Stock [Member]</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance, value at Dec. 31, 2020</a></td>
<td class="nump">$ 466,801<span></span>
</td>
<td class="nump">$ 35,880,986<span></span>
</td>
<td class="nump">$ 3,652,754<span></span>
</td>
<td class="num">$ (3,843,562)<span></span>
</td>
<td class="nump">$ 36,156,979<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance beginning (in shares) at Dec. 31, 2020</a></td>
<td class="nump">46,680,119<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Issuance of stock-based compensation</a></td>
<td class="nump">$ 958<span></span>
</td>
<td class="nump">432,696<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">433,654<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Issuance of stock-based compensation (in shares)</a></td>
<td class="nump">95,725<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition', window );">Compensation expense related to stock options</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">2,049,041<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">2,049,041<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts', window );">Compensation expense related to restricted stock awards</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">224,859<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">224,859<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krmd_NewIssuanceLitigationSettlementAmountIssuance', window );">Litigation settlement share issuance</a></td>
<td class="nump">$ 952<span></span>
</td>
<td class="nump">937,142<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">938,094<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krmd_NewIssuanceLitigationSettlementShareIssuance', window );">Litigation settlement share issuance (in shares)</a></td>
<td class="nump">95,238<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance upon options exercised</a></td>
<td class="nump">$ 11,730<span></span>
</td>
<td class="nump">1,249,521<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,261,251<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance upon options exercised (in shares)</a></td>
<td class="nump">1,173,080<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(4,562,823)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(4,562,823)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance, value at Dec. 31, 2021</a></td>
<td class="nump">$ 480,441<span></span>
</td>
<td class="nump">40,774,245<span></span>
</td>
<td class="num">(910,069)<span></span>
</td>
<td class="num">(3,843,562)<span></span>
</td>
<td class="nump">36,501,055<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance ending (in shares) at Dec. 31, 2021</a></td>
<td class="nump">48,044,162<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Issuance of stock-based compensation</a></td>
<td class="nump">$ 2,066<span></span>
</td>
<td class="nump">511,016<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">513,082<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Issuance of stock-based compensation (in shares)</a></td>
<td class="nump">206,570<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition', window );">Compensation expense related to stock options</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">2,083,396<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">2,083,396<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts', window );">Compensation expense related to restricted stock awards</a></td>
<td class="nump">500<span></span>
</td>
<td class="nump">482,449<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">482,949<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance upon options exercised</a></td>
<td class="nump">$ 5,612<span></span>
</td>
<td class="nump">401,011<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">406,623<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance upon options exercised (in shares)</a></td>
<td class="nump">561,159<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(8,661,142)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(8,661,142)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krmd_Compensationexpenserelatedtorestrictedstockawards', window );">Compensation expense related to restricted stock awards (in shares)</a></td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance, value at Dec. 31, 2022</a></td>
<td class="nump">$ 488,619<span></span>
</td>
<td class="nump">$ 44,252,117<span></span>
</td>
<td class="num">$ (9,571,211)<span></span>
</td>
<td class="num">$ (3,843,562)<span></span>
</td>
<td class="nump">$ 31,325,963<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance ending (in shares) at Dec. 31, 2022</a></td>
<td class="nump">48,861,891<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krmd_Compensationexpenserelatedtorestrictedstockawards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The element represents compensationexpenserelatedtorestrictedstockawards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krmd_Compensationexpenserelatedtorestrictedstockawards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krmd_NewIssuanceLitigationSettlementAmountIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The element represents new issuance litigation settlement amount issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krmd_NewIssuanceLitigationSettlementAmountIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krmd_NewIssuanceLitigationSettlementShareIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The element represents new issuance litigation settlement share issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krmd_NewIssuanceLitigationSettlementShareIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139621727775680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STATEMENTS OF CASH FLOWS - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>CASH FLOWS FROM OPERATING ACTIVITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Loss</a></td>
<td class="num">$ (8,661,142)<span></span>
</td>
<td class="num">$ (4,562,823)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">3,079,427<span></span>
</td>
<td class="nump">2,707,554<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">587,137<span></span>
</td>
<td class="nump">463,130<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfOtherAssets', window );">Loss on disposal of fixed assets</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(1,009)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxesAndTaxCredits', window );">Deferred income taxes</a></td>
<td class="num">(2,026,226)<span></span>
</td>
<td class="num">(1,815,980)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krmd_RouLandlordCredit', window );">ROU landlord credit</a></td>
<td class="nump">212,546<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Decrease/(Increase)&#160;in accounts receivable</a></td>
<td class="nump">34,002<span></span>
</td>
<td class="num">(1,019,932)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">(Increase)/Decrease in inventory</a></td>
<td class="num">(298,529)<span></span>
</td>
<td class="nump">723,434<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherReceivables', window );">Increase in other receivables</a></td>
<td class="num">(254,176)<span></span>
</td>
<td class="num">(718,220)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Decrease/(Increase) in prepaid expenses and other assets</a></td>
<td class="nump">28,776<span></span>
</td>
<td class="num">(761,041)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Increase in accounts payable</a></td>
<td class="nump">1,164,266<span></span>
</td>
<td class="nump">602,613<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities', window );">Increase/(Decrease) in accrued payroll and related taxes</a></td>
<td class="nump">381,796<span></span>
</td>
<td class="num">(126,527)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities', window );">Increase in other liabilities</a></td>
<td class="nump">167,337<span></span>
</td>
<td class="nump">90,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities', window );">Increase in accrued expenses</a></td>
<td class="nump">180,237<span></span>
</td>
<td class="nump">99,291<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">NET CASH USED IN OPERATING ACTIVITIES</a></td>
<td class="num">(5,404,549)<span></span>
</td>
<td class="num">(4,319,510)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>CASH FLOWS FROM INVESTING ACTIVITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireProductiveAssets', window );">Purchases of property and equipment</a></td>
<td class="num">(2,761,056)<span></span>
</td>
<td class="num">(346,178)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireIntangibleAssets', window );">Purchases of intangible assets</a></td>
<td class="num">(40,512)<span></span>
</td>
<td class="num">(29,056)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfProductiveAssets', window );">Proceeds from disposal of property and equipment</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">9,065<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">NET CASH USED IN INVESTING ACTIVITIES</a></td>
<td class="num">(2,801,568)<span></span>
</td>
<td class="num">(366,169)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>CASH FLOWS FROM FINANCING ACTIVITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of equity</a></td>
<td class="nump">406,623<span></span>
</td>
<td class="nump">1,261,251<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krmd_CommonStockIssuanceAsSettlementForLitigation', window );">Common stock issuance settlement of litigation</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">938,094<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krmd_BorrowingsFromIndebtedness', window );">Borrowings from indebtedness</a></td>
<td class="nump">783,799<span></span>
</td>
<td class="nump">924,389<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krmd_PaymentsOnIndebtedness', window );">Payments on indebtedness</a></td>
<td class="num">(859,087)<span></span>
</td>
<td class="num">(415,806)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeasePrincipalPayments', window );">Payments on finance lease liability</a></td>
<td class="num">(51,850)<span></span>
</td>
<td class="num">(2,646)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">NET CASH PROVIDED BY FINANCING ACTIVITIES</a></td>
<td class="nump">279,485<span></span>
</td>
<td class="nump">2,705,282<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">NET DECREASE IN CASH AND CASH EQUIVALENTS</a></td>
<td class="num">(7,926,632)<span></span>
</td>
<td class="num">(1,980,397)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">CASH AND CASH EQUIVALENTS, BEGINNING OF YEAR</a></td>
<td class="nump">25,334,889<span></span>
</td>
<td class="nump">27,315,286<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">CASH AND CASH EQUIVALENTS, END OF YEAR</a></td>
<td class="nump">17,408,257<span></span>
</td>
<td class="nump">25,334,889<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krmd_CashPaidDuringPeriodsForAbstract', window );"><strong>Cash paid during the years for:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Interest</a></td>
<td class="nump">28,490<span></span>
</td>
<td class="nump">13,241<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaidNet', window );">Income taxes</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">1,903<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Schedule of Non-Cash Operating, Investing and Financing Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krmd_IssuanceOfCommonStockCompensation', window );">Issuance of common stock as compensation</a></td>
<td class="nump">513,082<span></span>
</td>
<td class="nump">433,654<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssued1', window );">Issuance of common stock as settlement for litigation</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 938,094<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krmd_BorrowingsFromIndebtedness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The element represents borrowings from indebtedness.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krmd_BorrowingsFromIndebtedness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krmd_CashPaidDuringPeriodsForAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The element represents cash paid during periods for abstract.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krmd_CashPaidDuringPeriodsForAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krmd_CommonStockIssuanceAsSettlementForLitigation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The element represents common stock issuance as settlement for litigation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krmd_CommonStockIssuanceAsSettlementForLitigation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krmd_IssuanceOfCommonStockCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The element represents issuance of common stock compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krmd_IssuanceOfCommonStockCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krmd_PaymentsOnIndebtedness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The element represents payments on indebtedness.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krmd_PaymentsOnIndebtedness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krmd_RouLandlordCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The element represents rou landlord credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krmd_RouLandlordCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxesAndTaxCredits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) and income tax credits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxesAndTaxCredits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeasePrincipalPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for principal payment on finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeasePrincipalPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of other assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4297-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in accrued expenses, and obligations classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in current liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in receivables classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireProductiveAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for purchases of and capital improvements on property, plant and equipment (capital expenditures), software, and other intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 30<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126928898&amp;loc=d3e9212-128498<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 30<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126928898&amp;loc=d3e9215-128498<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=127000608&amp;loc=d3e9135-128495<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireProductiveAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfProductiveAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the sale of property, plant and equipment (capital expenditures), software, and other intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfProductiveAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The fair value of stock issued in noncash financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4304-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4332-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4313-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139621731185056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock', window );">NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</a></td>
<td class="text"><p id="xdx_803_eus-gaap--OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock_zGNfMJCk2tF6" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><span>NOTE 1 &#8212; <span id="xdx_820_z74Qsx9zc2m7">NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING
POLICIES</span></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p id="xdx_84C_eus-gaap--NatureOfOperations_zdnVGPzndT5i" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_86B_z8TcbrjdtGD7">NATURE OF OPERATIONS</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">KORU MEDICAL SYSTEMS, INC. (the &#8220;Company,&#8221; &#8220;KORU Medical,&#8221;
&#8220;KORU,&#8221; &#8220;we,&#8221; &#8220;us&#8221; or &#8220;our&#8221;) develops, manufactures and markets proprietary portable and
innovative medical devices primarily for the ambulatory infusion market as governed by the United States Food and Drug Administration
(the &#8220;FDA&#8221;) quality and regulatory system and international standards for quality system management. &#160;The Company operates
as <span id="xdx_907_eus-gaap--NumberOfReportableSegments_dxH_uN_c20220101__20221231_zp0YK2i0Lpfd" title="Number of segments::XDX::1">one</span> segment.</p>

<p id="xdx_85C_zTv1vbyJcMOa" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p id="xdx_842_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zS9HDKwxKkD4" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_862_za4Wlr4TVcUi">BASIS OF PRESENTATION</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We prepare our financial statements and accompanying
notes in accordance with accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;). &#160;Certain
prior year amounts have been reclassified to conform to the current year presentation in our Financial Statements.</p>

<p id="xdx_85F_zecxaotkjRZj" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p id="xdx_844_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zohP6xbtb9c3" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_868_zilxnUanv4tl">CASH AND CASH EQUIVALENTS</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">For purposes of the statement of cash flows, the Company considers all
short-term investments with an original maturity of three months or less to be cash equivalents. &#160;The Company holds cash in excess
of $<span id="xdx_902_eus-gaap--CashUninsuredAmount_iI_c20221231_zRZKlxgJI0Ih" title="FDIC cash uninsured amount">250,000</span> at its depository, which exceeds the FDIC insurance limits and is, therefore, uninsured.</p>

<p id="xdx_85A_zCLiQhLKJEA1" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p id="xdx_840_eus-gaap--InventoryPolicyTextBlock_zxzLjs6dGw8k" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_86A_zvP96g8ATew6">INVENTORY</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Inventories of raw materials are stated at the lower of standard cost,
which approximates average cost, or market value including allocable overhead. &#160;Work-in-process and finished goods are stated at
the lower of standard cost or market value and include direct labor and allocable overhead.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">We maintain reserves for excess and obsolete inventory resulting from the
potential inability to sell certain products at prices in excess of current carrying costs. &#160;We make estimates regarding the future
recoverability of the costs of these products and record provisions based on historical experience, expiration of sterilization dates
and expected future trends. &#160;If actual product life cycles, product demand or acceptance of new product introductions are less favorable
than projected by management, additional inventory write downs may be required, which could unfavorably affect future operating results.</p>

<p id="xdx_851_zCJPGSQM6xEj" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p id="xdx_841_eus-gaap--IntangibleAssetsFiniteLivedPolicy_zFAchVM8szJb" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_867_zJ95rXxkf8S2">INTANGIBLE ASSETS</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Certain of our identifiable intangible assets, including patents and trademarks,
are amortized using the straight-line method over their estimated useful lives which range from <span id="xdx_905_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dxL_c20220101__20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentsAndTrademarksMember__srt--RangeAxis__srt--MinimumMember_zMgMbxBk72M1" title="Estimated useful lives::XDX::P6Y"><span style="-sec-ix-hidden: xdx2ixbrl0488">6</span></span> to <span id="xdx_906_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dxL_c20220101__20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentsAndTrademarksMember__srt--RangeAxis__srt--MaximumMember_zsMBX7xYZM4" title="Estimated useful lives::XDX::P20Y"><span style="-sec-ix-hidden: xdx2ixbrl0490">20</span></span> years. &#160;All of our intangible
assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be
recoverable. &#160;Our management is responsible for determining if impairment exists and considers various factors when making these
determinations. &#160;Amortization expense related to intangible assets for the years ended December 31, 2022 and 2021 was $<span id="xdx_90A_ecustom--AmortizationOfIntangibleAssets1_c20220101__20221231_zdaQyFTk8Rnc" title="AmortizationOfIntangibleAssets1">62,143</span> and
$<span id="xdx_907_ecustom--AmortizationOfIntangibleAssets1_c20210101__20211231_zleXm3JB0R5c" title="AmortizationOfIntangibleAssets1">63,830</span>, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p id="xdx_898_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock_zgEH8iPnMqul" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The estimated amortization expense for the succeeding
years for the intangible assets is approximately:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span><span id="xdx_8B1_zMmeOzpV9qQa" style="display: none; visibility: hidden">Schedule of amortization expense</span></span>&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 3in; border-collapse: collapse">
  <tr style="background-color: white">
    <td style="border-bottom: black 1pt solid; vertical-align: bottom"><b>Year Ending December 31,</b></td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td id="xdx_49C_20221231_zZxBsRzkCe58" style="vertical-align: bottom">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_iI_zkTn0Qh4EZ05" style="background-color: #E6E6E6">
    <td style="vertical-align: bottom; width: 150pt">2023</td>
    <td style="vertical-align: top; width: 10.4pt">&#160;</td>
    <td style="vertical-align: bottom; width: 10pt">$</td>
    <td style="vertical-align: bottom; width: 56.65pt; text-align: right">62,982</td></tr>
  <tr id="xdx_408_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_iI_zq1eV71T9gLc" style="vertical-align: bottom">
    <td>2024</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">62,982</td></tr>
  <tr id="xdx_40F_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_iI_zHCqqdyxmXMa" style="background-color: #E6E6E6">
    <td style="vertical-align: bottom">2025</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right">62,842</td></tr>
  <tr id="xdx_40B_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_iI_zj8WKS3ZyaX8" style="background-color: white">
    <td style="vertical-align: bottom">2026</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right">61,787</td></tr>
  <tr id="xdx_407_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_iI_zw0Gtw4DlTPe" style="background-color: #E6E6E6">
    <td style="vertical-align: bottom">2027</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right">61,356</td></tr>
  <tr id="xdx_401_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_iI_zCI3c5sQsljc" style="background-color: white">
    <td style="vertical-align: bottom">Thereafter</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="border-bottom: black 1pt solid; vertical-align: bottom">&#160;</td>
    <td style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: right">475,233</td></tr>
  <tr id="xdx_406_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_zCRJMlJKZMk6" style="background-color: #E6E6E6">
    <td style="vertical-align: bottom">Total amortization expense</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="border-bottom: black 2.25pt double; vertical-align: bottom">$</td>
    <td style="border-bottom: black 2.25pt double; vertical-align: bottom; text-align: right">787,182</td></tr>
  </table>
<p id="xdx_8AC_zS8cA14RTjLd" style="font: 10pt Times New Roman, Times, Serif; margin: 0"/>

<p id="xdx_856_zUAUDDQnci0k" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>



<p id="xdx_840_eus-gaap--IncomeTaxPolicyTextBlock_zPneQ0ZgQzgh" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_86A_zurAya66UGVf">INCOME TAXES</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Deferred income taxes are provided using the liability method whereby deferred
tax assets are recognized for deductible temporary differences and operating loss and tax credit carry forwards and deferred tax liabilities
are recognized for taxable temporary differences.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The Company believes that it has no uncertain tax positions requiring disclosure
or adjustment.</p>

<p id="xdx_85D_zUiO08rNX3Rk" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p id="xdx_841_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zOBbEIpyGmd6" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_862_zPYpLF37xpxc">PROPERTY AND EQUIPMENT</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Property and equipment are stated at original acquisition cost less accumulated
depreciation. &#160;Additions and improvements are capitalized which increase the value or extend the life of an asset, while maintenance
and repair costs are expensed as incurred. &#160;When assets are retired or otherwise disposed, the cost and related accumulated depreciation
or amortization is removed from the respective accounts and any resulting gain or loss is included in income. &#160;Depreciation and amortization
are calculated on the straight-line basis over the estimated useful lives of the assets which generally range from <span id="xdx_904_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dxL_c20220101__20221231__srt--RangeAxis__srt--MinimumMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--FurnitureAndOfficeEquipmentMember_zzKLaTSM3CF7" title="Estimated useful lives of property and equipment::XDX::P3Y"><span style="-sec-ix-hidden: xdx2ixbrl0517">3</span></span>-<span id="xdx_905_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dxL_c20220101__20221231__srt--RangeAxis__srt--MaximumMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--FurnitureAndOfficeEquipmentMember_zR5ZBROcRTS8" title="::XDX::P10Y0M0D"><span style="-sec-ix-hidden: xdx2ixbrl0518">10</span></span> years for furniture
and office equipment, <span id="xdx_902_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dxL_c20220101__20221231__srt--RangeAxis__srt--MinimumMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--EquipmentAndToolingMember_zp39ZMDYg8O5" title="::XDX::P3Y"><span style="-sec-ix-hidden: xdx2ixbrl0519">3</span></span>-<span id="xdx_90E_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dxL_c20220101__20221231__srt--RangeAxis__srt--MaximumMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--EquipmentAndToolingMember_z00VDHNAeUH6" title="::XDX::P12Y"><span style="-sec-ix-hidden: xdx2ixbrl0520">12</span></span> years for manufacturing equipment and tooling and shorter of the lease term or their estimated useful lives
for leasehold improvements. Depreciation and amortization expense related to property and equipment for the years ended December 31, 2022
and 2021 was $<span id="xdx_905_eus-gaap--DepreciationDepletionAndAmortization_c20220101__20221231__us-gaap--FairValueByAssetClassAxis__us-gaap--PropertyPlantAndEquipmentMember_zRMvqTTkVI79" title="Depreciation and amortization">524,994</span> and $<span id="xdx_908_eus-gaap--DepreciationDepletionAndAmortization_c20210101__20211231__us-gaap--FairValueByAssetClassAxis__us-gaap--PropertyPlantAndEquipmentMember_zK3zQHuOPHwj" title="Depreciation and amortization">399,300</span>, respectively.</p>

<p id="xdx_859_z5gLhjvKiRff" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p id="xdx_84A_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_z4r5Vzf2AITb" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_863_zR62l6wfRBAe">STOCK-BASED COMPENSATION</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The Company maintains a stock option plan and omnibus equity incentive
plan under which it grants stock options to certain executives, key employees and consultants. The fair value of each option grant is
estimated on the date of the grant using the Black-Scholes option-pricing model. &#160;All options are charged against income at their
fair value. &#160;The entire compensation expense of the award is recognized over the vesting period.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Shares of stock granted for director fees under the non-employee director
compensation plan are recorded at the fair value of the shares at the grant date.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The Company has also issued shares of stock for director fees under its
omnibus equity incentive plan. Those shares of stock granted are recorded at the fair value of the shares at the grant date.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The Company issues restricted stock awards. Restricted stock awards are
equity classified and measured at the fair market value of the underlying stock at the grant date. The fair value of restricted stock
awards vesting at certain market capitalization thresholds were estimated on the date of grant using the Brownian Motion Monte Carlo lattice
model. The fair value of restricted stock awards with time-based vesting were estimated on the date of grant at the current stock price.
We recognize restricted stock expense using the straight-line attribution method over the requisite service period and account for forfeitures
as they occur.</p>

<p id="xdx_85F_zC9odunTWveb" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p id="xdx_845_eus-gaap--EarningsPerSharePolicyTextBlock_zZYuIlFBcHfk" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_86C_zhho2Pw2uBn1">NET LOSS PER COMMON SHARE</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p id="xdx_89E_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_zMG1jKvSqsWe" style="font: 10pt Times New Roman, Times, Serif; margin: 0">Basic earnings per share are computed on the weighted average of common
shares outstanding during each year. &#160;Diluted earnings per share includes only an increase in the weighted average shares by the
common shares issuable upon exercise of stock options. &#160;See &#8220;NOTE 4 &#8212; STOCK-BASED COMPENSATION&#8221; for further detail.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span><span id="xdx_8BC_zlnjQ0R1CBk9" style="display: none; visibility: hidden">Schedule of net income per common share</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 5.5in; border-collapse: collapse">
  <tr>
    <td style="vertical-align: bottom; width: 167.8pt">&#160;</td>
    <td style="vertical-align: bottom; width: 6.95pt">&#160;</td>
    <td style="vertical-align: top; width: 7.1pt; text-align: center">&#160;</td>
    <td id="xdx_493_20220101__20221231_zzvMb6BBNmGj" style="vertical-align: top; width: 85.9pt; text-align: center">&#160;</td>
    <td style="vertical-align: top; width: 14.1pt; text-align: center">&#160;</td>
    <td style="vertical-align: top; width: 9.35pt; text-align: center">&#160;</td>
    <td style="vertical-align: top; width: 7.1pt; text-align: center">&#160;</td>
    <td id="xdx_496_20210101__20211231_zL1n95ZSVts2" style="vertical-align: top; width: 82.5pt; text-align: center">&#160;</td>
    <td style="vertical-align: bottom; width: 15.1pt">&#160;</td></tr>
  <tr>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td colspan="6" style="border-bottom: black 1pt solid; vertical-align: top; text-align: center"><b>Years Ended</b></td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: center"><b>December 31, 2022</b></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: center"><b>December 31, 2021</b></td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--NetIncomeLoss_zY35B8ztZ5e8" style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Net loss</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">$</td>
    <td style="border-bottom: black 1pt solid; text-align: right">(8,661,142</td>
    <td>)</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">$</td>
    <td style="border-bottom: black 1pt solid; text-align: right">(4,562,823</td>
    <td>)</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasicAbstract_iB_zJKQih5XQNV7" style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Weighted Average Outstanding Shares:</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pid_hus-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zIQ1UMkP0mOc" style="vertical-align: bottom">
    <td style="padding-left: 21.8pt">Outstanding shares</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">45,002,074</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">44,385,032</td>
    <td>&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--IncrementalCommonSharesAttributableToCallOptionsAndWarrants_pid_zm8oNBHXFS0c" style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="padding-left: 21.8pt">Option shares includable</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0541">&#8212;</span></td>
    <td id="xdx_F51_zXnO0VQ3fCd8">(a)</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0542">&#8212;</span></td>
    <td id="xdx_F56_z8suocOMxah">(a)</td></tr>
  <tr id="xdx_40E_ecustom--IncrementalCommonSharesAttributableToRestrictedStock_pid_ztoKP1mn4Bw" style="vertical-align: bottom">
    <td style="padding-left: 21.8pt">Restricted stock includable</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0544">&#8212;</span></td>
    <td id="xdx_F52_zmpyjNDtJ7Ea">(b)</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0545">&#8212;</span></td>
    <td id="xdx_F5F_z4nwfjQAj7la">(b)</td></tr>
  <tr id="xdx_407_ecustom--WeightedAverageNumberOfSharesOutstanding_zjf5cgBKhkY3" style="vertical-align: bottom">
    <td><p style="margin-top: 0; margin-bottom: 0"><b style="display: none; visibility: hidden">&#160;Total</b></p>
        <p style="margin-top: 0; margin-bottom: 0"/></td>
    <td/>
    <td style="border-bottom: black 2.25pt double">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right">45,002,074</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right">44,385,032</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--EarningsPerShareAbstract_iB_zGOHyByYtat1" style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Net loss per share</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--EarningsPerShareBasic_pid_uUSDPShares_zk4hYMtkkq2j" style="vertical-align: bottom">
    <td style="padding-left: 21.8pt">Basic</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right">(0.19</td>
    <td style="border-bottom: white 2.25pt double">)</td>
    <td style="border-bottom: black 2.25pt double">&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right">(0.10</td>
    <td style="border-bottom: white 2.25pt double">)</td></tr>
  <tr id="xdx_404_eus-gaap--EarningsPerShareDiluted_pid_uUSDPShares_zoNdyVgzpB1k" style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="padding-left: 21.8pt">Diluted</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right">(0.19</td>
    <td style="border-bottom: white 2.25pt double">)</td>
    <td style="border-bottom: black 2.25pt double">&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right">(0.10</td>
    <td style="border-bottom: white 2.25pt double">)</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">__________</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td id="xdx_F07_zpjRlU1tokg5" style="width: 0.5in">(a)</td>
    <td id="xdx_F13_zJ7k0c2TJW51" style="width: 7in">Option shares of <span id="xdx_90B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_dxL_uShares_c20220101__20221231__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--EmployeeStockMember_zJscHJ6nJh08" title="Option shares excluded::XDX::0"><span style="-sec-ix-hidden: xdx2ixbrl0560">zero</span></span> and <span id="xdx_906_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_uShares_c20210101__20211231__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--EmployeeStockMember_zOXokNhUvBRh" title="Option shares excluded">273,110</span> for 2022 and 2021, respectively were not included as the impact is anti-dilutive.</td></tr>
  <tr style="vertical-align: top">
    <td id="xdx_F05_zQfISkekUjdj" style="width: 0.5in">(b)</td>
    <td id="xdx_F12_zj23i9XZITAh" style="width: 7in">Linda Tharby's Restricted Stock award shares of <span id="xdx_90D_ecustom--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount1_pid_uShares_c20220101__20221231__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--EmployeeStockMember_zQe25yGQAtl2" title="Restricted stock shares excluded">950,000</span> and <span id="xdx_900_ecustom--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount1_pid_uShares_c20210101__20211231__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--EmployeeStockMember_zQeAAvWnACzb" title="Restricted stock shares excluded">1,000,000</span> that are unvested for 2022 and 2021, respectively were not included as the impact is anti-dilutive.</td></tr>
  </table>

<p id="xdx_8AD_z74ojCDpPbsk" style="margin-top: 0; margin-bottom: 0">&#160;</p>
<p id="xdx_855_zDA565EElgn3" style="font: 10pt Times New Roman, Times, Serif; margin: 0"/>



<p id="xdx_844_eus-gaap--UseOfEstimates_z6LaBImte0K4" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_869_z4A7A2mqJ7X9">USE OF ESTIMATES IN THE FINANCIAL STATEMENTS</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The preparation of financial statements in conformity with GAAP requires
management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. &#160;Actual
results could differ from those estimates. &#160;Important estimates include but are not limited to asset lives, valuation allowances,
inventory valuation, and accruals.</p>

<p id="xdx_850_zNIRuhMWrZQ6" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p id="xdx_84F_eus-gaap--RevenueFromContractWithCustomerPolicyTextBlock_zpLpzc1GZBG4" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_860_zt5Gey8twc2c">REVENUE RECOGNITION</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting
Standards Update (&#8220;ASU&#8221;) No. 2014-09, <i>Revenue from Contracts with Customers</i>, which provides a single comprehensive
model for entities to use in accounting for revenue arising from contracts with customers.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The Company&#8217;s revenues result from the sale of assembled products.
&#160;We recognize revenues when shipment occurs, and at which point the customer obtains control and ownership of the goods. &#160;Shipping
costs generally are billed to customers and are included in sales.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The Company generally does not accept return of goods shipped unless it
is a Company error. &#160;The only credits provided to customers are for defective merchandise. &#160;The Company warrants the syringe
driver from defects in materials and workmanship under normal use and the warranty does not include a performance obligation. &#160;The
costs under the warranty are expensed as incurred.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Provisions for distributor pricing and annual customer growth rebates are
variable consideration and are recorded as a reduction of revenue in the same period the related sales are recorded or when it is probable
the annual growth target will be achieved. &#160;Rebates are provided to distributors for the difference in selling price to distributor
and pricing specified to select customers.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The Company established an allowance for charging off uncollectible trade
accounts receivable that have both of the following characteristics: (a) They have a contractual maturity of one year or less, (b) They
arose from the sale of goods or services.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p id="xdx_89E_ecustom--ScheduleOfNetRevenuesByGeography_z3BIpuyfVG4d" style="font: 10pt Times New Roman, Times, Serif; margin: 0">The following table summarizes net revenues by geography for the years ended
December 31, 2022 and 2021:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_8BD_z3C9ZxreeIk3" style="display: none; visibility: hidden">Schedule of net revenues by geography</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 3.5in; border-collapse: collapse">
  <tr style="background-color: white">
    <td style="vertical-align: bottom; width: 93.35pt">&#160;</td>
    <td style="vertical-align: bottom; width: 8.3pt">&#160;</td>
    <td style="vertical-align: bottom; width: 8.25pt">&#160;</td>
    <td style="vertical-align: bottom; width: 53.4pt">&#160;</td>
    <td style="vertical-align: bottom; width: 18.05pt">&#160;</td>
    <td style="vertical-align: bottom; width: 8.25pt">&#160;</td>
    <td style="vertical-align: bottom; width: 54.15pt">&#160;</td>
    <td style="vertical-align: top; width: 8.25pt">&#160;</td></tr>
  <tr style="background-color: white">
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td colspan="5" style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: center"><b>Years Ended December 31,</b></td>
    <td style="vertical-align: top">&#160;</td></tr>
  <tr style="background-color: white">
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: center"><b>2022</b></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: center"><b>2021</b></td>
    <td style="vertical-align: top">&#160;</td></tr>
  <tr style="background-color: white">
    <td style="vertical-align: bottom"><b>Net Revenues</b></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top">&#160;</td></tr>
  <tr style="background-color: #E6E6E6">
    <td style="vertical-align: bottom; padding-left: 9.45pt">Domestic</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td>$</td>
    <td id="xdx_98D_eus-gaap--Revenues_c20220101__20221231__srt--StatementGeographicalAxis__country--US_zZ4uQjTcgfJc" style="text-align: right" title="Net Revenue">23,586,254</td>
    <td style="vertical-align: top">&#160;</td>
    <td>$</td>
    <td id="xdx_98C_eus-gaap--Revenues_c20210101__20211231__srt--StatementGeographicalAxis__country--US_zmQIeI78tUyl" style="text-align: right" title="Net Revenue">19,488,685</td>
    <td style="vertical-align: top">&#160;</td></tr>
  <tr style="background-color: white">
    <td style="vertical-align: bottom; padding-left: 9.45pt">International</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td id="xdx_987_eus-gaap--Revenues_c20220101__20221231__srt--StatementGeographicalAxis__us-gaap--NonUsMember_zfGG2aByPLz" style="border-bottom: black 1pt solid; text-align: right" title="Net Revenues">4,309,783</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td id="xdx_981_eus-gaap--Revenues_c20210101__20211231__srt--StatementGeographicalAxis__us-gaap--NonUsMember_zRtFKssVTgme" style="border-bottom: black 1pt solid; text-align: right" title="Net Revenues">4,001,490</td>
    <td style="vertical-align: top">&#160;</td></tr>
  <tr style="background-color: #E6E6E6">
    <td style="vertical-align: bottom"><b>Total</b></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td id="xdx_988_eus-gaap--Revenues_c20220101__20221231_zbAfS3LpNBGe" style="border-bottom: black 2.25pt double; text-align: right" title="Revenues">27,896,037</td>
    <td style="border-bottom: white 2.25pt double; vertical-align: top">&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td id="xdx_980_eus-gaap--Revenues_c20210101__20211231_zn8OKcUznKZg" style="border-bottom: black 2.25pt double; text-align: right" title="Revenues">23,490,175</td>
    <td style="vertical-align: top">&#160;</td></tr>
  </table>
<p id="xdx_8A4_zRN68oI0ioGe" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p id="xdx_85B_zjcwB7y4KIdf" style="font: 10pt Times New Roman, Times, Serif; margin: 0"/>

<p id="xdx_846_eus-gaap--LesseeLeasesPolicyTextBlock_zipKrI5L2i54" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_863_zGMa0N0Ww7ef">LEASES</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">In February 2016, the FASB issued a standard related to leases to increase
transparency and comparability among organizations by requiring the recognition of right-of-use (&#8220;ROU&#8221;) assets and lease liabilities
on the balance sheet. &#160;Most prominent among the changes in the standard is the recognition of ROU assets and lease liabilities by
the Company for those leases classified as operating leases under current GAAP, while our accounting for capital leases remains substantially
unchanged. &#160;Under the standard, disclosures are required to meet the objective of enabling users of financial statements to assess
the amount, timing, and uncertainty of cash flows arising from leases. &#160;The standard became effective for us on January 1, 2019.
&#160;The standard had a material impact on our balance sheets but did not have a material impact on our statements of operations. &#160;See
&#8220;NOTE 5 <b>&#8212; </b>LEASES&#8221; for further detail.</p>

<p id="xdx_859_zEKH0xo3rpFk" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p id="xdx_844_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zyR5yhkl0mx3" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_86D_zfWO34kCXJPi">ACCOUNTING PRONOUNCEMENTS RECENTLY ADOPTED</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">In December 2019, the FASB issued ASU No. 2019-12, <i>Income Taxes (Topic
740): Simplifying the Accounting for Income Taxes</i>. The amendments in this ASU simplify the accounting for income taxes by removing
several exceptions including the exception to the general methodology for calculating income taxes in an interim period when a year-to-date
loss exceeds the anticipated loss for the year. &#160;The amendments also improve consistent application of and simplify GAAP for other
areas of Topic 740 by clarifying and amending existing guidance. &#160;The amendments in this ASU are effective for fiscal years, and
interim periods within those fiscal years, beginning after December 15, 2020. &#160;The Company adopted this standard on January 1, 2021,
and it had no impact on our financial statement disclosures.</p>

<p id="xdx_853_zmuLohV68dSk" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>



<p id="xdx_846_ecustom--AccountingPronouncementsNotYetAdopted_zMJECMpJBn7j" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_865_z8maNI0cLQ6c">ACCOUNTING PRONOUNCEMENTS NOT YET ADOPTED</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">In June 2016, the FASB issued ASU No. 2016-13, <i>Financial Instruments
&#8211; Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments</i>, which amends guidance on reporting credit
losses for assets held at amortized cost basis and available for sale debt securities. &#160;For assets held at amortized cost basis,
Topic 326 eliminates the probable initial recognition threshold in current GAAP and, instead, requires an entity to reflect its current
estimate of all expected credit losses. &#160;The allowance for credit losses is a valuation account that is deducted from the amortized
cost basis of the financial assets to present the net amount expected to be collected. &#160;For available for sale debt securities, credit
losses should be measured in a manner similar to current GAAP, however Topic 326 will require that credit losses be presented as an allowance
rather than as a write-down. &#160;This ASU affects entities holding financial assets and net investment in leases that are not accounted
for at fair value through net income. &#160;The amendments affect loans, debt securities, trade receivables, net investments in leases,
off balance sheet credit exposures, reinsurance receivables, and any other financial assets not excluded from the scope that have the
contractual right to receive cash. &#160;The amendments in this update are effective for fiscal years beginning after December 15, 2022,
including interim periods within those fiscal years. &#160;The Company is assessing the impact of the adoption of the ASU on its financial
statements, disclosure requirements and methods of adoption.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The Company considers the applicability and impact of all recently issued
accounting pronouncements. &#160;Recent accounting pronouncements not specifically identified in our disclosures are either not applicable
to the Company or are not expected to have a material effect on our financial condition or results of operations.</p>

<p id="xdx_854_z7Zkuvx9a9Pl" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p id="xdx_844_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_zB3qn80oaFa5" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_866_z5Y75OK0JD5g">FAIR VALUE MEASUREMENTS</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Fair value is the exit price that would be received to sell an asset or
paid to transfer a liability. &#160;Fair value is a market-based measurement that should be determined using assumptions that market participants
would use in pricing an asset or liability. Valuation techniques used to measure fair value should maximize the use of observable inputs
and minimize the use of unobservable inputs. &#160;To measure fair value, the Company uses the following fair value hierarchy based on
three levels of inputs, of which the first two are considered observable and the last unobservable:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 7.5in; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: center">&#8226;</td>
    <td style="width: 7in">Level 1 &#8211; Quoted prices in active markets for identical assets or liabilities.</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center">&#8226;</td>
    <td>Level 2 &#8211; Inputs other than Level 1 that are observable for the asset or liability, either directly or indirectly, such as quoted prices for similar assets and liabilities in active markets; quoted prices for identical or similar assets or liabilities in markets that are not active; or other inputs that are observable or can be corroborated by observable market data by correlation or other means.</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center">&#8226;</td>
    <td>Level 3 &#8211; Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. &#160;Value is determined using pricing models, discounted cash flow methodologies, or similar techniques and includes instruments for which the determination of fair value requires significant judgment or estimation.</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The carrying amounts of cash and cash equivalents, accounts receivable,
prepaid expenses, accounts payable and accrued expenses are considered to be representative of their fair values because of the short-term
nature of those instruments. &#160;There were no transfers between levels in the fair value hierarchy during the year ended December 31,
2022.</p>

<p id="xdx_85B_zAUJFESrAdS1" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p id="xdx_849_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_zQZbDx9rQ7We" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_86D_zRmizrHnN8ef">IMPAIRMENT OF LONG-LIVED ASSETS</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The Company reviews long-lived assets for impairment whenever events or
changes in circumstances indicate that the carrying amount of the assets may not be fully recoverable. &#160;An impairment loss would
be recognized when estimated undiscounted future cash flows expected to result from the use of the asset and its eventual disposition
are less than the carrying amount. &#160;The impairment loss, if recognized, would be based on the excess of the carrying value of the
impaired asset over its respective fair value. &#160;No impairment losses have been recorded through December 31, 2022.</p>

<p id="xdx_85E_zyBIgsY1g1i8" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the general note to the financial statements for the reporting entity which may include, descriptions of the basis of presentation, business description, significant accounting policies, consolidations, reclassifications, new pronouncements not yet adopted and changes in accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI https://asc.fasb.org/topic&amp;trid=2197479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI https://asc.fasb.org/topic&amp;trid=2134479<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -URI https://asc.fasb.org/topic&amp;trid=2122394<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI https://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139621731612160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INVENTORY<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureTextBlock', window );">INVENTORY</a></td>
<td class="text"><p id="xdx_80D_eus-gaap--InventoryDisclosureTextBlock_zBZWP51yiEx8" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>NOTE 2 &#8212; <span id="xdx_82C_zIfPFE30WoU5">INVENTORY</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p id="xdx_892_eus-gaap--ScheduleOfInventoryCurrentTableTextBlock_zSfOlZuewx4c" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_8B5_zEiwQCi3QSQc">Inventory consists of:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 5.75in; border-collapse: collapse">
  <tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>December 31, 2022</b></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>December 31, 2021</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="width: 208.35pt">&#160;</td>
    <td style="width: 0.1in">&#160;</td>
    <td style="width: 8.25pt">&#160;</td>
    <td style="width: 79.7pt">&#160;</td>
    <td style="width: 14.3pt">&#160;</td>
    <td style="width: 7.5pt">&#160;</td>
    <td style="width: 80.45pt">&#160;</td>
    <td style="width: 8.25pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Raw materials and work-in-process</td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_98A_eus-gaap--InventoryWorkInProcessAndRawMaterials_iI_c20221231_zQs9SGHLFSIl" style="text-align: right" title="Raw materials and work-in-process">3,853,034</td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_98F_eus-gaap--InventoryWorkInProcessAndRawMaterials_iI_c20211231_zwPKqJbgVxHb" style="text-align: right" title="Raw materials and work-in-process">2,997,807</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td>Finished goods</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td id="xdx_981_eus-gaap--InventoryFinishedGoods_iI_c20221231_zCjgaLgmr7nf" style="border-bottom: black 1pt solid; text-align: right" title="Finished goods">2,611,951</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td id="xdx_98B_eus-gaap--InventoryFinishedGoods_iI_c20211231_z4OyKjNY8Aod" style="border-bottom: black 1pt solid; text-align: right" title="Finished goods">3,176,836</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td>&#160;&#160;&#160;Total</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_988_eus-gaap--InventoryGross_iI_c20221231_zNa94DcM4pi" style="text-align: right" title="Inventory, Gross">6,464,985</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_98B_eus-gaap--InventoryGross_iI_c20211231_zOtHtSUoLgv8" style="text-align: right" title="Inventory, Gross">6,174,643</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td>Less: reserve for obsolete inventory</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td id="xdx_98A_eus-gaap--InventoryValuationReserves_iNI_di_c20221231_zw26NTqXKrF8" style="border-bottom: black 1pt solid; text-align: right" title="Less: reserve for obsolete inventory">(60,118</td>
    <td>)</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td id="xdx_985_eus-gaap--InventoryValuationReserves_iNI_di_c20211231_z65Ll2xB7sj7" style="border-bottom: black 1pt solid; text-align: right">(68,305</td>
    <td>)</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Inventory, net</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td id="xdx_983_eus-gaap--InventoryNet_iI_c20221231_zTtndi3ifpb8" style="border-bottom: black 2.25pt double; text-align: right" title="Inventory">6,404,867</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td id="xdx_98A_eus-gaap--InventoryNet_iI_c20211231_zgsk9QWKuCD" style="border-bottom: black 2.25pt double; text-align: right" title="Inventory">6,106,338</td>
    <td>&#160;</td></tr>
  </table>

<p id="xdx_8A0_zysOCcAhhAX5" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI https://asc.fasb.org/topic&amp;trid=2126998<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139621810515616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PROPERTY AND EQUIPMENT<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">PROPERTY AND EQUIPMENT</a></td>
<td class="text"><p id="xdx_80A_eus-gaap--PropertyPlantAndEquipmentDisclosureTextBlock_zdR6NODU7928" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>NOTE 3 &#8212; <span id="xdx_828_zjpD9hEUjx1">PROPERTY AND EQUIPMENT</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p id="xdx_895_eus-gaap--PropertyPlantAndEquipmentTextBlock_zaoyxblUiHw7" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span>Property and equipment consists of the following at:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_8BD_zWKiA8IJzf19" style="display: none; visibility: hidden">Schedule of property and equipment</span>&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 5.75in; border-collapse: collapse">
  <tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>December 31, 2022</b></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>December 31, 2021</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td style="width: 203.85pt">&#160;</td>
    <td style="width: 0.1in">&#160;</td>
    <td style="width: 8.25pt">&#160;</td>
    <td style="width: 79.7pt">&#160;</td>
    <td style="width: 14.3pt">&#160;</td>
    <td style="width: 8.25pt">&#160;</td>
    <td style="width: 79.7pt">&#160;</td>
    <td style="width: 8.25pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Furniture and office equipment</td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_98A_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--FurnitureAndOfficeEquipmentMember_zWHnBNx3xFe5" style="text-align: right">1,456,745</td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_987_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20211231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--FurnitureAndOfficeEquipmentMember_zECbEcrxcYZa" style="text-align: right">818,897</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Leasehold improvements</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_984_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zW5Uhbm2OpUg" style="text-align: right">2,413,820</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_984_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20211231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zUBg8Aip0597" style="text-align: right">556,907</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Manufacturing equipment and tooling</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td id="xdx_98C_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ManufacturingEquipmentAndToolingMember_zT0quWrrXv3" style="border-bottom: black 1pt solid; text-align: right">2,810,813</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td id="xdx_988_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20211231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ManufacturingEquipmentAndToolingMember_zNTYU2zCQITe" style="border-bottom: black 1pt solid; text-align: right">2,042,675</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;&#160;&#160;Total property and equipment</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_98C_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20221231_zZxEzqn5ixH1" style="text-align: right" title="Total property and equipment">6,681,378</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_983_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20211231_zR6JnYT1Bkpa" style="text-align: right" title="Total property and equipment">3,418,479</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Less: accumulated depreciation and amortization</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td id="xdx_989_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_di_c20221231_zELaZxCyfw6b" style="border-bottom: black 1pt solid; text-align: right" title="Less: accumulated depreciation and amortization">(2,794,403</td>
    <td>)</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td id="xdx_98B_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_di_c20211231_zfIeWTTvng2a" style="border-bottom: black 1pt solid; text-align: right" title="Less: accumulated depreciation and amortization">(2,312,034</td>
    <td>)</td></tr>
  <tr style="vertical-align: bottom">
    <td>Property and equipment, net</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td id="xdx_985_eus-gaap--PropertyPlantAndEquipmentNet_iI_dxL_c20221231_zTlhecAMheBg" style="border-bottom: black 2.25pt double; text-align: right" title="Property and equipment, net::XDX::3886975"><span style="-sec-ix-hidden: xdx2ixbrl0640">3,886,975</span></td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td id="xdx_989_eus-gaap--PropertyPlantAndEquipmentNet_iI_c20211231_zsbI0O4sKC4e" style="border-bottom: black 2.25pt double; text-align: right" title="Property and equipment, net">1,106,445</td>
    <td>&#160;</td></tr>
  </table>
<p id="xdx_8AA_z9ktPti7bLjc" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99893-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI https://asc.fasb.org/topic&amp;trid=2155823<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=SL120174063-112916<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99779-112916<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139621731057456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK-BASED COMPENSATION<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">STOCK-BASED COMPENSATION</a></td>
<td class="text"><p id="xdx_80D_eus-gaap--DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_z4k1HyoJ39Lj" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>NOTE 4 &#8212; <span id="xdx_82F_z6Rf2R9VgmR9">STOCK-BASED COMPENSATION</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The Company has three equity incentive plans: the 2015 Stock Option Plan,
as amended (the &#8220;2015 Plan&#8221;), the 2021 Omnibus Equity Incentive Plan (the &#8220;2021 Plan&#8221;), and the Non-Employee Director
Compensation Plan. The Company has also issued restricted stock as employment inducement awards to its Chief Executive Officer.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">As of December 31, 2022, there were options to purchase <span id="xdx_907_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pid_uShares_c20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__srt--TitleOfIndividualAxis__custom--ExecutiveskeyEmployeesAndConsultantsMember_zbccPmTX67T6" title="Common stock, shares, outstanding">2,560,000</span> shares
of the Company&#8217;s common stock outstanding to certain executives, key employees and consultants under the 2015 Plan, of which <span id="xdx_903_ecustom--StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan2015_pid_uShares_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__srt--TitleOfIndividualAxis__custom--ExecutiveskeyEmployeesAndConsultantsMember_zvBJcDgeisBj" title="Stock issued during period">445,000</span>
were issued during the twelve months ended December 31, 2022. Additional options may be issued under the 2015 Plan as outstanding options
are forfeited, subject to a maximum <span id="xdx_901_eus-gaap--StockIssuedDuringPeriodSharesShareBasedCompensation_pid_uShares_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zYVVvbGfdUUj" title="Available for issuance">6,000,000</span> available for issuance under the 2015 Plan.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The 2021 Plan provides for the grant of up to <span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodSharesShareBasedCompensation_pid_uShares_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zL3V1K5nBYe3" title="Available for issuance">1,000,000</span> incentive stock
options, nonqualified stock options, stock awards, restricted stock awards, restricted stock units and/or stock appreciation rights to
employees, consultants and directors. During the twelve months ended December 31, 2022, there were issued <span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan_pid_uShares_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member__srt--TitleOfIndividualAxis__srt--DirectorMember_zkklXmZ8w7si" title="Stock issued during period">97,100</span> shares of common stock, as director compensation and <span id="xdx_904_eus-gaap--StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan_pid_uShares_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member__srt--TitleOfIndividualAxis__custom--ExecutiveMember_zmwBFQCY0xb6" title="Stock issued during period">475,000</span> options to purchase shares of common stock as executive compensation under the 2021 Plan.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Effective January 1, 2021, each non-employee director of the Company (other
than the Chairman of the Board) and Board advisor were eligible to receive of $<span id="xdx_900_ecustom--NonemployeeServicesTransactionCost_pid_uShares_c20201230__20210102__srt--TitleOfIndividualAxis__custom--NonEmployeeDirectorAndBoardAdvisorMember_zIkhJX6VVOoa" title="Nonemployee services transaction cost">75,000</span> annually, <span id="xdx_902_eus-gaap--ShareBasedGoodsAndNonemployeeServicesTransaction_c20201230__20210102__srt--TitleOfIndividualAxis__custom--NonEmployeeDirectorAndBoardAdvisorMember_zBE02q8YweT2" title="Share-based goods and nonemployee services transaction">to be paid quarterly $12,500 in cash and
$6,250 in common stock</span>. &#160;The Chairman of the Board is eligible to receive $<span id="xdx_900_ecustom--NonemployeeServicesTransactionCost_pid_uShares_c20201230__20210102__srt--TitleOfIndividualAxis__srt--BoardOfDirectorsChairmanMember_z6PgXGpsFKYb" title="Non-employee director compensation">100,000</span> annually, <span id="xdx_908_eus-gaap--ShareBasedGoodsAndNonemployeeServicesTransaction_c20201230__20210102__srt--TitleOfIndividualAxis__srt--BoardOfDirectorsChairmanMember_zULEuO57yx1a" title="Share-based goods and nonemployee services transaction">to be paid quarterly $12,500 in cash
and $12,500 in common stock</span>. Effective May 18, 2021, each non-employee director of the Company (other than the Chairman of the Board)
and Board advisor are eligible to receive of $<span id="xdx_90B_ecustom--NonemployeeServicesTransactionCost_pid_uShares_c20210516__20210518__srt--TitleOfIndividualAxis__custom--NonEmployeeDirectorAndBoardAdvisorMember_zep2nfzAEid" title="Nonemployee services transaction cost">110,000</span> annually, <span id="xdx_90C_eus-gaap--ShareBasedGoodsAndNonemployeeServicesTransaction_c20210516__20210518__srt--TitleOfIndividualAxis__custom--NonEmployeeDirectorAndBoardAdvisorMember_zxq0BxHtClyc" title="Share-based goods and nonemployee services transaction">to be paid quarterly $12,500 in cash and $15,000 in common stock</span>. &#160;The
Chairman of the Board is eligible to receive $<span id="xdx_90F_ecustom--NonemployeeServicesTransactionCost_pid_uShares_c20210516__20210518__srt--TitleOfIndividualAxis__srt--BoardOfDirectorsChairmanMember_z0I2jjkpupL5">140,000</span> annually, <span id="xdx_90F_eus-gaap--ShareBasedGoodsAndNonemployeeServicesTransaction_c20210516__20210518__srt--TitleOfIndividualAxis__srt--BoardOfDirectorsChairmanMember_zoxWQpIP97N1" title="Share-based goods and nonemployee services transaction">to be paid quarterly $12,500 in cash and $22,500 in common stock</span>. From
May 18, 2021 to May 6, 2022, non-employee director compensation was paid pursuant to the 2021 Plan. Since May 6, 2022, non-employee director
compensation has been paid pursuant to the Non-Employee Director Compensation Plan. All payments were and are pro-rated for partial service.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">On April 12, 2021, pursuant to an employment agreement entered into on
March 15, 2021, with Linda Tharby, the Company&#8217;s President and Chief Executive Officer, the Company issued three restricted stock
awards for an aggregate <span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan_pid_uShares_c20210411__20210412__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ChiefExecutiveOfficerLindaTharbyMember_zKxuJPWmyrXe" title="Common stock issued, shares">1,000,000</span> shares of common stock for an aggregate stock price of $<span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan_c20210411__20210412__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ChiefExecutiveOfficerLindaTharbyMember_zTls4M7CGjLf" title="Aggregate stock price">3,310,000</span> and each vesting subject to employment
on the respective vesting date. These awards were issued as an inducement employment.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>2015 STOCK OPTION PLAN, as amended</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Time-Based Stock Options</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The per share weighted average fair value of stock options granted during
the years ended December 31, 2022, and December 31, 2021 was $<span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_pid_uUSDPShares_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zbbDGR8bAfyg" title="Stock options granted">1.98</span> and $<span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_pid_uUSDPShares_c20210101__20211231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zvwWSiUkZFM2">2.85</span>, respectively. &#160;The fair value of each award is estimated
on the grant date using the Black-Scholes option pricing model with the following weighted average assumptions used for grants in the
years ended December 31, 2022, and December 31, 2021. &#160;Historical information was the primary basis for the selection of the expected
volatility, expected dividend yield and the expected lives of the options. &#160;The risk-free interest rate was selected based upon yields
of the U.S. Treasury issues with a term equal to the expected life of the option being valued. &#160;The following table summarizes the
assumptions used in determining fair value. These assumptions are subjective and generally require significant analysis and judgment to
develop. We have recognized tax benefits associated with stock-based compensation of $<span id="xdx_900_eus-gaap--IncomeTaxExpenseBenefit_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zRVLB861j9Cl" title="Tax benefit">198,258</span> and $<span id="xdx_90B_eus-gaap--IncomeTaxExpenseBenefit_c20210101__20211231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zw662DENIShk" title="Tax benefit">175,257</span> for the years ended December
31, 2022 and 2021, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>



<p id="xdx_898_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zMJTgRo09HFf" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_8B3_zNIQLyoNSWk4" style="display: none; visibility: hidden">Schedule of time based stock options</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 5.25in; border-collapse: collapse">
  <tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>December 31, 2022</b></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>December 31, 2021</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td style="width: 161.1pt">&#160;</td>
    <td style="width: 9.75pt">&#160;</td>
    <td style="width: 7.25pt">&#160;</td>
    <td style="width: 89.15pt">&#160;</td>
    <td style="width: 10.55pt">&#160;</td>
    <td style="width: 9.05pt">&#160;</td>
    <td style="width: 82.85pt">&#160;</td>
    <td style="width: 8.3pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Dividend yield</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_z9I9JarWYZVl" title="Dividend yield">0.00</span>%</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20210101__20211231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zwjPMQzkzhQc" title="Dividend yield">0.00</span>%</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td>Expected volatility</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember__srt--RangeAxis__srt--MinimumMember_z6mvehlaByMj">65.29</span>% &#8211; <span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember__srt--RangeAxis__srt--MaximumMember_zGJbo5iW8TI1">77.5</span>%</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20210101__20211231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember__srt--RangeAxis__srt--MinimumMember_zfzDfqq1wrRf">74.01</span> &#8211; <span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20210101__20211231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember__srt--RangeAxis__srt--MaximumMember_zKyuNYz9KZ8h">77.91</span>%</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Weighted-average volatility</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_pid_dp0_uPure_c20220101__20221231_zlXJAsd0BLe" title="Weighted-average volatility">&#8212;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_pid_dp_uPure_c20210101__20211231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zFG8DozU7zW4" title="Weighted-average volatility"><span style="-sec-ix-hidden: xdx2ixbrl0697">&#8212;</span></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td>Expected dividends</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments_d0_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zs1BAQmLx361" title="Expected dividends">&#8212;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments_d0_c20210101__20211231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zAH1DVyaDcb6" title="Expected dividends">&#8212;</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Expected term (in years)</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dxL_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_ztG1LJY5HuX" title="Expected term (in years)::XDX::P10Y"><span style="-sec-ix-hidden: xdx2ixbrl0703">10</span></span> Years</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dxL_c20210101__20211231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zn7GgykVhqw7" title="Expected term (in years)::XDX::P10Y"><span style="-sec-ix-hidden: xdx2ixbrl0705">10</span></span> Years</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td>Risk-free rate</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember__srt--RangeAxis__srt--MinimumMember_zhBrKaFMEtph" title="Risk-free rate">1.81</span> &#8211; <span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember__srt--RangeAxis__srt--MaximumMember_zc1gVFzsSI62" title="Risk-free rate">4.02</span>%</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20210101__20211231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember__srt--RangeAxis__srt--MinimumMember_zCY0GYklx5Sl" title="Risk-free rate">1.20</span> &#8211; <span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20210101__20211231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember__srt--RangeAxis__srt--MaximumMember_zZufVf0If4Ui" title="Risk-free rate">1.62</span>%</td>
    <td>&#160;</td></tr>
  </table>
<p id="xdx_8A5_zQNZNQ0vEXaa" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p id="xdx_899_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_z1TmxFWsn1u9" style="font: 10pt Times New Roman, Times, Serif; margin: 0">The following table summarizes the status of the Company&#8217;s stock
option plan:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_8B4_z3SmpQTP4fk1" style="display: none; visibility: hidden">Schedule of status of time based stock options</span>&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 7.5in; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="5" style="border-bottom: black 1pt solid; text-align: center"><b>December 31, 2022</b></td>
    <td>&#160;</td>
    <td colspan="5" style="border-bottom: black 1pt solid; text-align: center"><b>December 31, 2021</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>Shares</b></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>Weighted<br/>
Average<br/>
Exercise<br/>
Price</b></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>Shares</b></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>Weighted<br/>
Average<br/>
Exercise<br/>
Price</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="width: 273.25pt">Outstanding at January 1</td>
    <td style="width: 0.1in">&#160;</td>
    <td style="width: 0.1in">&#160;</td>
    <td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_uShares_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zO2vPnRHQxz" style="width: 49.5pt; text-align: right" title="Outstanding at beginning">3,672,500</td>
    <td style="width: 11.3pt">&#160;</td>
    <td style="width: 9.75pt">$</td>
    <td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_uUSDPShares_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zG4oARPUgMA1" style="width: 43.8pt; text-align: right" title="Outstanding at beginning">3.42</td>
    <td style="width: 11.3pt">&#160;</td>
    <td style="width: 0.1in">&#160;</td>
    <td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_uShares_c20210101__20211231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zlSM4Nm3iOT6" style="width: 48.75pt; text-align: right">2,922,494</td>
    <td style="width: 11.3pt">&#160;</td>
    <td style="width: 7.5pt">$</td>
    <td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_uUSDPShares_c20210101__20211231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zACFEiklGXXj" style="width: 43.8pt; text-align: right" title="Outstanding at beginning">2.46</td>
    <td style="width: 7.25pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Granted</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_uShares_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_z2exdIa3IfIg" style="text-align: right" title="Granted">445,000</td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_uUSDPShares_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zM61B6j8h4rd" style="text-align: right" title="Granted">2.57</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_uShares_c20210101__20211231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zAtBDtQDZi9f" style="text-align: right">2,000,000</td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_uUSDPShares_c20210101__20211231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zaDavxuGXPuj" style="text-align: right" title="Granted">3.64</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Exercised</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_98C_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pid_uShares_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zRSnnZVL4Ky" style="text-align: right" title="Exercised">1,031,250</td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_uUSDPShares_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zw3P2KzfQM26" style="text-align: right" title="Exercised">1.57</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_989_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pid_uShares_c20210101__20211231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zy56Oc1yEai" style="text-align: right">1,062,500</td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_uUSDPShares_c20210101__20211231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zGPwU22jiHA2" style="text-align: right" title="Exercised">1.19</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Forfeited</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_pid_uShares_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zZUUVkZxAPQ1" style="text-align: right" title="Forfeited">526,250</td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_uUSDPShares_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zBhDcTK1lSae" style="text-align: right" title="Forfeited">2.73</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_pid_uShares_c20210101__20211231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zyrwK7iZFf47" style="text-align: right">187,494</td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_uUSDPShares_c20210101__20211231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zM5BVIvfBCm1" style="text-align: right">3.36</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Outstanding at year end</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_uShares_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zSQ0QcHFXhTi" style="text-align: right" title="Outstanding at ending">2,560,000</td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_uUSDPShares_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zdvsy8XZx6q8" style="text-align: right" title="Outstanding at ending">4.15</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_uShares_c20210101__20211231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zIHVknGiXgH6" style="text-align: right">3,672,500</td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_uUSDPShares_c20210101__20211231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zFOcStvlapl5" style="text-align: right" title="Outstanding at ending">3.42</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Options exercisable</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pid_uShares_c20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zOhbICZVlq04" style="text-align: right" title="Options exercisable">737,500</td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_pid_uUSDPShares_c20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zUJmsNslmS74" style="text-align: right" title="Options exercisable">4.93</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pid_uShares_c20211231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zyPqqxDV8A6k" style="text-align: right">983,750</td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_pid_uUSDPShares_c20211231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zqxiXWdfvja3" style="text-align: right">2.73</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="padding-left: 19.05pt; text-indent: -19.05pt">Weighted average fair value of options granted during the period</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#8212;</td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_uUSDPShares_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zjy3QMIiTGn2" style="text-align: right" title="Weighted average fair value of options granted during the period">1.98</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#8212;</td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_uUSDPShares_c20210101__20211231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zJ7nUsbGN3G5" style="text-align: right" title="Weighted average fair value of options granted during the period">2.85</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Stock-based compensation expense</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#8212;</td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_980_eus-gaap--AllocatedShareBasedCompensationExpense_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zfLR5zcx3wL6" style="text-align: right" title="Stock-based compensation expense">1,925,861</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#8212;</td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_982_eus-gaap--AllocatedShareBasedCompensationExpense_c20210101__20211231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zrV2bdvx9Ojb" style="text-align: right" title="Stock-based compensation expense">2,457,788</td>
    <td>&#160;</td></tr>
  </table>
<p id="xdx_8A6_zuEGKYhqlmKd" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Total stock-based compensation expense, net of forfeitures, for stock
option awards totaled $<span id="xdx_902_eus-gaap--StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zoEgBwBSX584">1,925,861</span>
and $<span id="xdx_907_eus-gaap--StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_c20210101__20211231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zK3zxZX4H1xd">2,457,788</span>
for the years ended December 31, 2022, and 2021, respectively. &#160;Net cash received from option exercises for the years ended
December 31, 2022, and 2021 was $<span id="xdx_909_eus-gaap--ProceedsFromStockOptionsExercised_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zVHfzAS0Osof">406,623</span>
and $<span id="xdx_90C_eus-gaap--ProceedsFromStockOptionsExercised_pp0p0_c20210101__20211231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_z6b29HqngqGf">1,261,251</span>,
respectively. We have recognized tax benefits associated with options exercised of <span id="xdx_90F_eus-gaap--IncomeTaxExpenseBenefit_pp0p0_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zSRtStmfjh8k">103,319</span>
and $<span id="xdx_908_eus-gaap--IncomeTaxExpenseBenefit_pp0p0_c20210101__20211231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_z19jgYcVFgEk">665,700</span>
for the years ended December 31, 2022 and 2021, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The weighted-average grant-date fair value of options granted during the
years ended December 31, 2022, and 2021, was $<span id="xdx_908_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriodWeightedAverageGrantDateFairValue_uShares_c20220101__20221231__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zS4bMBfKMhif" title="Weighted-average grant-date fair value options granted">881,428</span> and $<span id="xdx_903_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriodWeightedAverageGrantDateFairValue_uShares_c20210101__20211231__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_z4r7pCd3Liuf" title="Weighted-average grant-date fair value options granted">5,699,986</span>, respectively. &#160;The total intrinsic value of options exercised
during the years ended December 31, 2022, and 2021, was $<span id="xdx_909_ecustom--StockIssuedDuringPeriodSharesStockOptionsExercised1_pid_uShares_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zSHIr6N3f1D1" title="Options exercised">1,150,203</span> and $<span id="xdx_90D_ecustom--StockIssuedDuringPeriodSharesStockOptionsExercised1_pid_uShares_c20210101__20211231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zumE46frju5">697,920</span>, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p id="xdx_89D_ecustom--ScheduleOfShareBasedCompensationStockOptionsActivityAmendedTableTextBlock_zz8RJ2Ki4uS8" style="font: 10pt Times New Roman, Times, Serif; margin: 0">The following table presents information pertaining to options outstanding
as of December 31, 2022:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_8B3_zdHY4FCcHVjd" style="display: none; visibility: hidden">Schedule of information pertaining to options outstanding</span>&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 7.5in; border-collapse: collapse">
  <tr style="vertical-align: bottom; background-color: white">
    <td style="border-bottom: black 1pt solid"><b>Range of Exercise Price</b></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: center"><b>Number<br/>
Outstanding</b></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: center"><b>Weighted<br/>
Average<br/>
Remaining<br/>
Contractual<br/>
Life</b></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>Weighted<br/>
Average<br/>
Exercise<br/>
Price</b></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: center"><b>Number<br/>
Exercisable</b></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>Weighted<br/>
Average<br/>
Exercise<br/>
Price</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td style="width: 131.2pt">&#160;</td>
    <td style="width: 8.25pt">&#160;</td>
    <td style="width: 64.85pt">&#160;</td>
    <td style="width: 14.35pt">&#160;</td>
    <td style="width: 64.85pt">&#160;</td>
    <td style="width: 13.6pt">&#160;</td>
    <td style="width: 7.5pt">&#160;</td>
    <td style="width: 63pt">&#160;</td>
    <td style="width: 13.6pt">&#160;</td>
    <td style="width: 64.85pt">&#160;</td>
    <td style="width: 14.35pt">&#160;</td>
    <td style="width: 8.25pt">&#160;</td>
    <td style="width: 63pt">&#160;</td>
    <td style="width: 7.55pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td>$2.25 - $9.49</td>
    <td>&#160;</td>
    <td id="xdx_985_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pid_uShares_c20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice1Member_zE9AiaUVP7N1" style="text-align: right" title="Number outstanding">2,560,000</td>
    <td>&#160;</td>
    <td style="text-align: center"><span id="xdx_906_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dxL_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice1Member_zm6fxm2yXdlj" title="Weighted average remaining contractual life::XDX::P8Y9M18D"><span style="-sec-ix-hidden: xdx2ixbrl0782">8.8</span></span> years</td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_988_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pid_uUSDPShares_c20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice1Member_ze4YPaf8jUGe" style="text-align: right" title="Weighted average exercise price">4.15</td>
    <td>&#160;</td>
    <td id="xdx_98A_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_uShares_c20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice1Member_zVzOB3aHfG61" style="text-align: right" title="Number exercisable">737,500</td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_98F_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_pid_uUSDPShares_c20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice1Member_z1agaJApbVVc" style="text-align: right" title="Weighted average exercise price">4.93</td>
    <td>&#160;</td></tr>
  </table>
<p id="xdx_8A2_zcTIeuFTe1Ed" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">As of December 31, 2022, there was $<span id="xdx_90C_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_iI_c20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_z63JWR8opn1" title="Total unrecognized compensation cost">4,299,070</span> of total unrecognized compensation
cost related to non-vested share-based compensation arrangements granted under the 2015 Plan. &#160;That cost is expected to be recognized
over a weighted-average period of <span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dxL_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_z7aL5B4O0RVk" title="Weighted-average period::XDX::P45M"><span style="-sec-ix-hidden: xdx2ixbrl0792">45</span></span> months. &#160;The total fair value of shares vested was $<span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_iI_c20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zj9RxtkaEKf7" title="Fair value of shares">2,703,002</span> and $<span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_iI_c20211231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_z2d9sp2yP0pk">1,923,179</span> at December 31,
2022, and December 31, 2021, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>2021 STOCK OPTION PLAN, as amended</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Time Based Stock Options</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The per share weighted average fair value of stock options granted during
the years ended December 31, 2022 and December 31, 2021 was $<span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_pid_uUSDPShares_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_z6QrnwW63uv4" title="Stock options granted">1.99</span> and $<span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_pid_uUSDPShares_c20210101__20211231__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zUZ1vKVeb5hg" title="Stock options granted">0</span> respectively. &#160;The fair value of each award is estimated
on the grant date using the Black-Scholes option pricing model with the following weighted average assumptions used for grants in the
years ended December 31, 2022 and December 31, 2021. Historical information was the primary basis for the selection of the expected volatility,
expected dividend yield and the expected lives of the options. &#160;The risk-free interest rate was selected based upon yields of the
U.S. Treasury issues with a term equal to the expected life of the option being valued. We have recognized tax benefits associated with
stock-based compensation of $<span id="xdx_900_eus-gaap--IncomeTaxExpenseBenefit_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zbekZFstSbci" title="Tax benefit">33,083</span> and $<span id="xdx_908_eus-gaap--IncomeTaxExpenseBenefit_c20210101__20211231__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zi6mxkU83IU2" title="Tax benefit">0</span> for the years ended December 31, 2022 and 2021, respectively.</p>

<p id="xdx_893_eus-gaap--ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_z1c7sldhvJtd" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span><span id="xdx_8B8_zmgyVB3Zl42e" style="display: none; visibility: hidden">Schedule of time based stock options</span>&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 4.5in; border-collapse: collapse">
  <tr>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="5" style="border-bottom: black 1pt solid; text-align: center"><b>December 31,</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>2022</b></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>2021</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="width: 136.7pt">&#160;</td>
    <td style="width: 0.1in">&#160;</td>
    <td style="width: 0.1in">&#160;</td>
    <td style="width: 71.6pt">&#160;</td>
    <td style="width: 14.25pt">&#160;</td>
    <td style="width: 0.1in">&#160;</td>
    <td style="width: 72.35pt">&#160;</td>
    <td style="width: 7.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Dividend yield</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zJwoESfRyAab" title="Dividend yield">0.00</span>%</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zhWeaToWIlj8" title="Dividend yield">0.00</span>%</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Expected Volatility</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zlzsSWsvcP8k" title="Expected volatility">65.9</span>%</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20210101__20211231__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember__srt--RangeAxis__srt--MinimumMember_zUmPwsUZYfZd">0</span>% &#8211; <span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember__srt--RangeAxis__srt--MaximumMember_zTwmV5AIzBm2" title="Expected volatility">0</span>%</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Weighted-average volatility</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_pid_dp_uPure_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zbPtw0LX5FZ7" title="Weighted-average volatility"><span style="-sec-ix-hidden: xdx2ixbrl0817">&#8212;</span></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_pid_dp_uPure_c20210101__20211231__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zdGMNi9skWj6" title="Weighted-average volatility"><span style="-sec-ix-hidden: xdx2ixbrl0819">&#8212;</span></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Expected dividends</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments_d0_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_z50YwJiVy8o3" title="Expected dividends">&#8212;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments_c20210101__20211231__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_z28VpsVDQRCc" title="Expected dividends"><span style="-sec-ix-hidden: xdx2ixbrl0823">&#8212;</span></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Expected term (in years)</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dxL_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_ziwAuYv74Xbh" title="Expected term (in years)::XDX::P10Y"><span style="-sec-ix-hidden: xdx2ixbrl0825">10</span></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dxL_c20210101__20211231__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zLo14Du90Qd" title="Expected term (in years)::XDX::P0Y"><span style="-sec-ix-hidden: xdx2ixbrl0827">0</span></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Risk-free rate</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zVSeOdzf4oMf" title="Risk-free rate">2.99</span>%</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20210101__20211231__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember__srt--RangeAxis__srt--MinimumMember_zaFr9qzZvIm9" title="Risk-free rate">0</span>% &#8211; <span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20210101__20211231__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember__srt--RangeAxis__srt--MinimumMember_zB2vYAeILLq4" title="Risk-free rate">0</span>%</td>
    <td>&#160;</td></tr>
  </table>
<p id="xdx_8A1_zDsLo233sWhe" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p id="xdx_890_eus-gaap--ScheduleOfOtherShareBasedCompensationActivityTableTextBlock_zgKL1plP0rec" style="font: 10pt Times New Roman, Times, Serif; margin: 0">The following table summarizes the status of the 2021 Plan with respect
to time based stock options:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_8BA_zduzcPjGX2fi" style="display: none; visibility: hidden">Schedule of status of time based stock options</span>&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 7.5in; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="10" style="border-bottom: black 1pt solid; text-align: center"><b>Year Ended December 31,</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="4" style="border-bottom: black 1pt solid; text-align: center"><b>2022</b></td>
    <td>&#160;</td>
    <td colspan="5" style="border-bottom: black 1pt solid; text-align: center"><b>2021</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: center"><b>Shares</b></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>Weighted<br/>
Average<br/>
Exercise<br/>
Price</b></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>Shares</b></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>Weighted<br/>
Average<br/>
Exercise<br/>
Price</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="width: 264.6pt">Outstanding at January 1</td>
    <td style="width: 0.1in">&#160;</td>
    <td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber2_iS_pid_uShares_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zJn084UMm3Hb" style="width: 49.2pt; text-align: right" title="Outstanding at beginning">0</td>
    <td style="width: 0.2in">&#160;</td>
    <td style="width: 0.1in">$</td>
    <td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice2_iS_pid_uUSDPShares_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zdyPJ6msQb84" style="width: 49.15pt; text-align: right" title="Outstanding at beginning">0</td>
    <td style="width: 14.7pt">&#160;</td>
    <td style="width: 0.1in">&#160;</td>
    <td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber2_iS_pid_uShares_c20210101__20211231__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zBv9XV56t6of" style="width: 48.85pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0840">&#8212;</span></td>
    <td style="width: 14.55pt">&#160;</td>
    <td style="width: 0.1in">$</td>
    <td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice2_iS_pid_uUSDPShares_c20210101__20211231__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zw2MZhDPuTi2" style="width: 48.55pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0841">&#8212;</span></td>
    <td style="width: 0.1in">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Granted</td>
    <td>&#160;</td>
    <td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross2_pid_uShares_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zUhpTJ7MfqGa" style="text-align: right" title="Granted">475,000</td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_984_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice2_pid_uUSDPShares_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_z4finuiR92Wl" style="text-align: right" title="Granted">2.67</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross2_pid_uShares_c20210101__20211231__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zXjFEbRNUM6g" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0846">&#8212;</span></td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_98E_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice2_pid_uUSDPShares_c20210101__20211231__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_ztMaUpOvkv6g" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0847">&#8212;</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Exercised</td>
    <td>&#160;</td>
    <td id="xdx_989_ecustom--StockIssuedDuringPeriodSharesStockOptionsExercised2_pid_uShares_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zQLVCQI05zL1" style="text-align: right" title="Exercised">0</td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_980_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice2_pid_uUSDPShares_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zpglE3WdXyxa" style="text-align: right" title="Exercised"><span style="-sec-ix-hidden: xdx2ixbrl0851">&#8212;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_980_ecustom--StockIssuedDuringPeriodSharesStockOptionsExercised2_pid_uShares_c20210101__20211231__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zzU0EQfxTLNb" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0852">&#8212;</span></td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_985_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice2_pid_uUSDPShares_c20210101__20211231__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zfke8nRT0Ql6" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0853">&#8212;</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Forfeited</td>
    <td>&#160;</td>
    <td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod2_pid_uShares_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zud5mcwUwd5f" style="text-align: right" title="Forfeited">0</td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_981_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice2_pid_uUSDPShares_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zFTArLr4LvO" style="text-align: right" title="Forfeited"><span style="-sec-ix-hidden: xdx2ixbrl0857">&#8212;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod2_pid_uShares_c20210101__20211231__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_ztP0z42eq7g6" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0858">&#8212;</span></td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_98C_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice2_pid_uUSDPShares_c20210101__20211231__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zJtGJk5gjWid" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0859">&#8212;</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Outstanding at year end</td>
    <td>&#160;</td>
    <td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber2_iE_pid_uShares_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zzSNeNun6ka7" style="text-align: right" title="Outstanding at ending">475,000</td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice2_iE_pid_uUSDPShares_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_z9U1aKMLdD7k" style="text-align: right" title="Outstanding at ending">2.67</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber2_iE_pid_d0_uShares_c20210101__20211231__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_z3TSrOrdfbhd" style="text-align: right">&#8212;</td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice2_iE_pid_d0_uUSDPShares_c20210101__20211231__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_z25ZkGVljTM7" style="text-align: right">&#8212;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Options exercisable</td>
    <td>&#160;</td>
    <td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pid_uShares_c20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zEmdFXL5jX8k" style="text-align: right" title="Options exercisable at ending">0</td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_984_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice2_iI_pid_uUSDPShares_c20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zPUtOEBvfuQk" style="text-align: right" title="Options exercisable at ending"><span style="-sec-ix-hidden: xdx2ixbrl0869">&#8212;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pid_uShares_c20211231__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zurkgefKQTu8" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0870">&#8212;</span></td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_982_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice2_iI_pid_uUSDPShares_c20211231__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zkcGJynuGkA" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0871">&#8212;</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="padding-left: 0.1in; text-indent: -0.1in">Weighted average fair value of options granted during the period</td>
    <td>&#160;</td>
    <td style="text-align: right">&#8212;</td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue2_pid_uUSDPShares_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zPiZtEGtaR89" style="text-align: right" title="Weighted average fair value of options granted during the period">1.99</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#8212;</td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue2_pid_uUSDPShares_c20210101__20211231__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zg2K9XA8FE8k" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0874">&#8212;</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Stock-based compensation expense</td>
    <td>&#160;</td>
    <td style="text-align: right">&#8212;</td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_98C_eus-gaap--ShareBasedCompensation_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zMR0a556MYe4" style="text-align: right" title="Stock-based compensation expense">157,536</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#8212;</td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_98B_eus-gaap--ShareBasedCompensation_c20210101__20211231__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zhI0JtDcVzbl" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0877">&#8212;</span></td>
    <td>&#160;</td></tr>
  </table>
<p id="xdx_8AA_zqOtN3bblshd" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Total stock-based compensation expense was $<span id="xdx_906_eus-gaap--ShareBasedCompensation_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zZJxsmXDlR32" title="Stock-based compensation expense">157,536</span> and $<span id="xdx_905_eus-gaap--ShareBasedCompensation_dxL_c20210101__20211231__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zP5H5JfGBqG1" title="Stock-based compensation expense::XDX::-"><span style="-sec-ix-hidden: xdx2ixbrl0881">0</span></span> for the years
ended December 31, 2022, and 2021, respectively. There were no options exercised during the years ended December 31, 2022 and December
31, 2021.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The weighted-average grant-date fair value of options granted during the
years ended December 31, 2022, and 2021 was $<span id="xdx_90B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriodWeightedAverageGrantDateFairValue_uShares_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zVFu5SIxjIKh" title="Weighted-average grant-date fair value options granted">945,215</span> and $<span id="xdx_90E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriodWeightedAverageGrantDateFairValue_uShares_c20210101__20211231__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zBXjZmNM2RF8" title="Weighted-average grant-date fair value options granted">0</span>, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p id="xdx_893_ecustom--ScheduleOfShareBasedCompensationtaxBenefitsAssociatedWithRestrictedStockAwardCompensationTableTextBlock_zPKPQIQxyncf" style="font: 10pt Times New Roman, Times, Serif; margin: 0">The following table presents information pertaining to options outstanding
at December 31, 2022:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_8B1_zPPZmpjvZHPa" style="display: none; visibility: hidden">Schedule of information pertaining to options outstanding</span>&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 7.5in; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: black 1pt solid"><b>Range of Exercise Price</b></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: center"><b>Number<br/>
Outstanding</b></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: center"><b>Weighted<br/>
Average<br/>
Remaining<br/>
Contractual<br/>
Life</b></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>Weighted<br/>
Average<br/>
Exercise<br/>
Price</b></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: center"><b>Number<br/>
Exercisable</b></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>Weighted<br/>
Average<br/>
Exercise<br/>
Price</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="width: 131.2pt">&#160;</td>
    <td style="width: 8.25pt">&#160;</td>
    <td style="width: 64.85pt">&#160;</td>
    <td style="width: 14.35pt">&#160;</td>
    <td style="width: 64.85pt">&#160;</td>
    <td style="width: 13.6pt">&#160;</td>
    <td style="width: 7.55pt">&#160;</td>
    <td style="width: 63.35pt">&#160;</td>
    <td style="width: 13.6pt">&#160;</td>
    <td style="width: 64.85pt">&#160;</td>
    <td style="width: 14.35pt">&#160;</td>
    <td style="width: 8.3pt">&#160;</td>
    <td style="width: 55.8pt">&#160;</td>
    <td style="width: 15.1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td>$2.67</td>
    <td>&#160;</td>
    <td id="xdx_98B_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pid_uShares_c20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice1Member_zsRCclyBqdal" style="text-align: right" title="Number outstanding">475,000</td>
    <td>&#160;</td>
    <td style="text-align: center"><span id="xdx_90A_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dxL_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice1Member_zXOIgQYORYWa" title="Weighted average remaining contractual life::XDX::P9Y3M19D"><span style="-sec-ix-hidden: xdx2ixbrl0891">9.3</span></span> years</td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_98F_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_c20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice1Member_zpulwXJjCC2j" style="text-align: center" title="Weighted average exercise price">2.67</td>
    <td>&#160;</td>
    <td id="xdx_984_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_uShares_c20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice1Member_zWpe3SyNSA6a" style="text-align: right" title="Number exercisable">0</td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_982_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_pid_uUSDPShares_c20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice1Member_z3h6UfDDpwme" style="text-align: right" title="Weighted average exercise price">0</td>
    <td>&#160;</td></tr>
  </table>
<p id="xdx_8AE_zMK3ItcFGRXd" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">As of December 31, 2022, there was $<span id="xdx_908_ecustom--CompensationCost_iI_c20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zqickrqe2Qyd" title="Unrecognized compensation cost">787,679</span> of total unrecognized compensation
cost related to non-vested share-based compensation arrangements granted under the 2021 Plan. &#160;That cost is expected to be recognized
over a weighted-average period of <span id="xdx_90B_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm3_dxL_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zHRqLGthcSqk" title="Weighted-average period::XDX::P48M"><span style="-sec-ix-hidden: xdx2ixbrl0901">48</span></span> months. &#160;The total fair value of shares vested as of December 31, 2022, and December 31, 2021,
was <span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_iI_dxL_c20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zS2FHeIBBrlg" title="Fair value of shares::XDX::0"><span style="-sec-ix-hidden: xdx2ixbrl0903">zero</span></span> and <span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_iI_dxL_c20211231__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zsLWGRmOKFSb" title="Fair value of shares::XDX::0"><span style="-sec-ix-hidden: xdx2ixbrl0905">zero</span></span>, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Performance-Based Stock Options</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">There were no performance-based stock options granted during the twelve
months ended December 31, 2022, and 2021.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p id="xdx_89A_eus-gaap--ShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock_ziaATDPStcpg" style="font: 10pt Times New Roman, Times, Serif; margin: 0">The following table summarizes the status of the 2015 Plan with respect
to performance-based stock options as of December 31, 2022 and 2021:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_8B0_zFmIDLEsG1N" style="display: none; visibility: hidden">Schedule of performance base options outstanding</span>&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 7.5in; border-collapse: collapse">
  <tr style="background-color: white">
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td colspan="4" style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: center"><b>December 31, 2022</b></td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td colspan="5" style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: center"><b>December 31, 2021</b></td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr style="background-color: white">
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: center"><b>Shares</b></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: center"><b>Weighted<br/>
Average<br/>
Exercise<br/>
Price</b></td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: center"><b>Shares</b></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: center"><b>Weighted<br/>
Average<br/>
Exercise<br/>
Price</b></td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr style="background-color: white">
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr style="background-color: #E6E6E6">
    <td style="vertical-align: bottom; width: 257.75pt">Outstanding at January 1</td>
    <td style="vertical-align: bottom; width: 7.15pt">&#160;</td>
    <td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber1_iS_pid_dxL_uShares_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_z0M2W59pO8fk" style="vertical-align: bottom; width: 47.8pt; text-align: right" title="Outstanding at beginning::XDX::1000000"><b style="display: none; visibility: hidden"><span style="-sec-ix-hidden: xdx2ixbrl0910">&#8212;</span></b></td>
    <td style="vertical-align: bottom; width: 15.15pt">&#160;</td>
    <td style="vertical-align: bottom; width: 0.1in">$</td>
    <td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice1_iS_pid_dxL_uUSDPShares_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zz6GEJl9i7X2" style="vertical-align: bottom; width: 48.5pt; text-align: right" title="Outstanding at beginning::XDX::1.70"><b style="display: none; visibility: hidden"><span style="-sec-ix-hidden: xdx2ixbrl0912">&#8212;</span></b></td>
    <td style="vertical-align: top; width: 12.9pt">&#160;</td>
    <td style="vertical-align: bottom; width: 12.95pt">&#160;</td>
    <td style="vertical-align: bottom; width: 0.1in">&#160;</td>
    <td id="xdx_982_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber1_iS_pid_uShares_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zNrjDxCN5cw6" style="vertical-align: bottom; width: 48pt; text-align: right" title="Outstanding at beginning">1,000,000</td>
    <td style="vertical-align: bottom; width: 11.55pt">&#160;</td>
    <td style="vertical-align: bottom; width: 0.1in">$</td>
    <td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice1_iS_pid_uUSDPShares_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zv9YzAaCKyV2" style="vertical-align: bottom; width: 49.95pt; text-align: right">1.70</td>
    <td style="vertical-align: bottom; width: 7.15pt">&#160;</td></tr>
  <tr style="background-color: white">
    <td style="vertical-align: bottom">Granted</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross1_pid_d0_uShares_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_znMigeF3Cy4c" style="vertical-align: bottom; text-align: right" title="Granted">&#8212;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">$</td>
    <td id="xdx_980_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice1_pid_d0_uUSDPShares_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zw1sSZzmgc77" style="vertical-align: bottom; text-align: right" title="Granted">&#8212;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross1_pid_d0_uShares_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zajKijFVkUp7" style="vertical-align: bottom; text-align: right">&#8212;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top">$</td>
    <td id="xdx_98B_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice1_pid_d0_uUSDPShares_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zQMolxBiscE7" style="vertical-align: bottom; text-align: right">&#8212;</td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr style="background-color: #E6E6E6">
    <td style="vertical-align: bottom">Exercised</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td id="xdx_989_ecustom--StockIssuedDuringPeriodSharesStockOptionsExercised1_pid_d0_uShares_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_z8CXWSE0Ujvh" style="vertical-align: bottom; text-align: right" title="Exercised">&#8212;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">$</td>
    <td id="xdx_98B_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice1_pid_d0_uUSDPShares_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zKoVOB1QkUB5" style="vertical-align: bottom; text-align: right" title="Exercised">&#8212;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td id="xdx_980_ecustom--StockIssuedDuringPeriodSharesStockOptionsExercised1_pid_d0_uShares_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zFYgOcOG6Jl" style="vertical-align: bottom; text-align: right">&#8212;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top">$</td>
    <td id="xdx_98E_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice1_pid_d0_uUSDPShares_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zNZK1HJv0i7" style="vertical-align: bottom; text-align: right">&#8212;</td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr style="background-color: white">
    <td style="vertical-align: bottom">Forfeited</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod1_pid_d0_uShares_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zsEACKSpxZni" style="vertical-align: bottom; text-align: right" title="Forfeited">&#8212;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">$</td>
    <td id="xdx_982_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice1_pid_d0_uUSDPShares_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zpMOG22IlwOk" style="vertical-align: bottom; text-align: right" title="Forfeited">&#8212;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td id="xdx_984_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod1_pid_d0_uShares_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zD9qTNpJmza" style="vertical-align: bottom; text-align: right">&#8212;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top">$</td>
    <td id="xdx_988_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice1_pid_d0_uUSDPShares_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zMbPSxP2Exd" style="vertical-align: bottom; text-align: right">&#8212;</td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr style="background-color: #E6E6E6">
    <td style="vertical-align: bottom">Outstanding at year end</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_d0_uShares_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zyKbhzgvNtke" style="vertical-align: bottom; text-align: right" title="Outstanding at ending">&#8212;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">$</td>
    <td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_d0_uUSDPShares_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zfZBqFlaW2Oc" style="vertical-align: bottom; text-align: right" title="Outstanding at ending">&#8212;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_uShares_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zgDB6RDXRAB5" style="vertical-align: bottom; text-align: right">1,000,000</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">$</td>
    <td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_uUSDPShares_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zm1JZlstwHTg" style="vertical-align: bottom; text-align: right">1.70</td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr style="background-color: white">
    <td style="vertical-align: bottom">Options exercisable</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross1_pid_d0_uShares_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zjmL7oDnQJf" style="vertical-align: bottom; text-align: right" title="Options exercisable at ending">&#8212;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">$</td>
    <td id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice1_iI_pid_d0_uUSDPShares_c20221231__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zhqy6DeuJT83" style="vertical-align: bottom; text-align: right" title="Options exercisable at ending">&#8212;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross1_pid_d0_uShares_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zOE2NUXibFT7" style="vertical-align: bottom; text-align: right">&#8212;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">$</td>
    <td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice1_iI_pid_d0_uUSDPShares_c20211231__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zQkYAvK8aRva" style="vertical-align: bottom; text-align: right">&#8212;</td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr style="background-color: #E6E6E6">
    <td style="vertical-align: bottom; padding-left: 7.4pt; text-indent: -7.4pt">Weighted average fair value of options granted during the period</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_d0_uShares_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zcmhAcGr65Dg" style="vertical-align: bottom; text-align: right" title="Weighted average fair value of options granted during the period">&#8212;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">$</td>
    <td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue1_pid_d0_uUSDPShares_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zLfM1tdYCCYj" style="vertical-align: bottom; text-align: right" title="Weighted average fair value of options granted during the period">&#8212;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_d0_uShares_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zTRtxzr0EcSj" style="vertical-align: bottom; text-align: right">&#8212;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">$</td>
    <td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue1_pid_d0_uUSDPShares_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zkU8GGqbg8be" style="vertical-align: bottom; text-align: right">&#8212;</td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr style="background-color: white">
    <td style="vertical-align: bottom">Stock-based compensation expense</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right">&#8212;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">$</td>
    <td id="xdx_98F_ecustom--AllocatedShareBasedCompensationExpense1_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zqjwJjn6fyn5" style="vertical-align: bottom; text-align: right" title="Stock-based compensation expense"><span style="-sec-ix-hidden: xdx2ixbrl0953">&#8212;</span></td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right">&#8212;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">$</td>
    <td id="xdx_98E_ecustom--AllocatedShareBasedCompensationExpense1_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_z665Xj26ZrH" style="vertical-align: bottom; text-align: right" title="Stock-based compensation expense">(408,747</td>
    <td style="vertical-align: bottom">)</td></tr>
  </table>
<p id="xdx_8AC_zfrYdCNQQwNl" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Total performance stock-based compensation expense totaled <span id="xdx_90F_eus-gaap--ShareBasedCompensation_dxL_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member__us-gaap--FinancialInstrumentAxis__us-gaap--StockOptionMember_zDfz9QbPcIt1" title="Stock-based compensation expense::XDX::-"><span style="-sec-ix-hidden: xdx2ixbrl0957">zero</span></span> and $<span id="xdx_907_eus-gaap--ShareBasedCompensation_c20210101__20211231__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member__us-gaap--FinancialInstrumentAxis__us-gaap--StockOptionMember_zgrTu7lmcx0h" title="Stock-based compensation expense">(408,747)</span>
for the years ended December 2022 and 2021, respectively. All performance-based stock options were forfeited as of December 31, 2021,
and there was no unrecognized compensation cost remaining.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>RESTRICTED STOCK AWARDS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">On April 12, 2021, pursuant to an employment agreement entered into on
March 15, 2021, with Linda Tharby, the Company&#8217;s President and Chief Executive Officer and as an inducement to her employment, the
Company issued three restricted stock awards for an aggregate <span id="xdx_909_eus-gaap--CommonStockSharesIssued_iI_pid_uShares_c20210412__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_zsVr6wmj1a2l" title="Common stock issued, shares">1,000,000</span> shares of common stock for an aggregate stock price of $<span id="xdx_906_eus-gaap--CommonStockValue_iI_c20210412__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_z8fSaic3WZ23" title="Aggregate stock price">3,310,000</span>
and each vesting subject to employment on the respective vesting date.&#160;The following table summarizes the activities for our unvested
restricted stock awards for the twelve months ended December 31, 2022, and 2021.</p>

<p id="xdx_890_eus-gaap--ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock_zpEioGXC9xR6" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_8B5_zCprAPbF5XI5" style="display: none; visibility: hidden">The following table summarizes the activities for our unvested
restricted stock awards for the twelve months ended December 31, 2022, and 2021.</span>&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 7.5in; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="9" style="border-bottom: black 1pt solid; text-align: center"><b>Twelve Months Ended December 31,</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="4" style="border-bottom: black 1pt solid; text-align: center"><b>2022</b></td>
    <td>&#160;</td>
    <td colspan="4" style="border-bottom: black 1pt solid; text-align: center"><b>2021</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: center"><b>Shares</b></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>Weighted<br/>
Average<br/>
Grant-Date Fair Value</b></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: center"><b>Shares</b></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>Weighted<br/>
Average<br/>
Grant-Date Fair Value</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="width: 201.15pt">Unvested at January 1</td>
    <td style="width: 9.65pt">&#160;</td>
    <td id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberUnvested_iS_pid_uShares_c20220101__20221231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zhacb022pAR" style="width: 53.1pt; text-align: right" title="Outstanding at beginning">1,000,000</td>
    <td style="width: 11pt">&#160;</td>
    <td style="width: 17.4pt">$</td>
    <td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceUnvested_iS_pid_uUSDPShares_c20220101__20221231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zKfcDQ74lxb8" style="width: 72.75pt; text-align: right" title="Outstanding at beginning">3.01</td>
    <td style="width: 11pt">&#160;</td>
    <td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberUnvested_iS_pid_uShares_c20210101__20211231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zMTMI0RJsFsg" style="width: 54.75pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0970">&#8212;</span></td>
    <td style="width: 11.35pt">&#160;</td>
    <td style="width: 16.9pt">$</td>
    <td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceUnvested_iS_pid_uUSDPShares_c20210101__20211231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_z8pULxd4p7f9" style="width: 73.25pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0971">&#8212;</span></td>
    <td style="width: 8pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Granted</td>
    <td>&#160;</td>
    <td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrossUnvested_pid_uShares_c20220101__20221231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_ztlm5zGVoigh" style="text-align: right" title="Granted"><span style="-sec-ix-hidden: xdx2ixbrl0973">&#8212;</span></td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_982_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePriceUnvested_pid_uUSDPShares_c20220101__20221231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_z3Ak3vyzIfta" style="text-align: right" title="Granted"><span style="-sec-ix-hidden: xdx2ixbrl0975">&#8212;</span></td>
    <td>&#160;</td>
    <td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrossUnvested_pid_uShares_c20210101__20211231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zWfQXlJPCfea" style="text-align: right">1,000,000</td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_98C_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePriceUnvested_pid_uUSDPShares_c20210101__20211231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zQmCl6uVkqmf" style="text-align: right">3.01</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Vested</td>
    <td>&#160;</td>
    <td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodGross_pid_uShares_c20220101__20221231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zu2SxkYyxad1" style="text-align: right" title="Vested">50,000</td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_984_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice_pid_uUSDPShares_c20220101__20221231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_z6jQd1eofYIj" style="text-align: right" title="Vested">3.31</td>
    <td>&#160;</td>
    <td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodGross_pid_uShares_c20210101__20211231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_z31UL0x5WW0l" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0982">&#8212;</span></td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_98C_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice_pid_uUSDPShares_c20210101__20211231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zBgpDsQZkXHl" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0983">&#8212;</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Forfeited/canceled</td>
    <td>&#160;</td>
    <td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodUnvested_pid_uShares_c20220101__20221231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zAeoBmoI2qF" style="text-align: right" title="Forfeited/canceled"><span style="-sec-ix-hidden: xdx2ixbrl0985">&#8212;</span></td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_980_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePriceUnvested_pid_uUSDPShares_c20220101__20221231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zXhpyyJIFlC4" style="text-align: right" title="Forfeited/canceled"><span style="-sec-ix-hidden: xdx2ixbrl0987">&#8212;</span></td>
    <td>&#160;</td>
    <td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodUnvested_pid_uShares_c20210101__20211231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zAq3e72xb4f6" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0988">&#8212;</span></td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_98C_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePriceUnvested_pid_uUSDPShares_c20210101__20211231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zQ9q8QPPkiJ9" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0989">&#8212;</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Unvested at December 31</td>
    <td>&#160;</td>
    <td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberUnvested_iE_pid_uShares_c20220101__20221231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zrVougvelbUa" style="text-align: right" title="Outstanding at ending">950,000</td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceUnvested_iE_pid_uUSDPShares_c20220101__20221231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zMh3yFi4kWh8" style="text-align: right" title="Outstanding at ending">3.04</td>
    <td>&#160;</td>
    <td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberUnvested_iE_pid_uShares_c20210101__20211231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zmbmg5YV0JTe" style="text-align: right">1,000,000</td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceUnvested_iE_pid_uUSDPShares_c20210101__20211231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zFQfz3vv3JR5" style="text-align: right">3.01</td>
    <td>&#160;</td></tr>
  </table>
<p id="xdx_8AC_zNaCS3qlyOHg" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">As of December 31, 2022, there was $<span id="xdx_904_ecustom--UnrecognizedCompensationCost_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember_zZusQLPMoQN7" title="Unrecognized compensation cost">1,618,177</span> of unrecognized compensation
cost related to unvested employee restricted shares. This amount is expected to be recognized over a weighted-average period of <span id="xdx_905_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm4_dxL_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember_zSeTpzd1QTA8" title="Weighted-average period::XDX::P21M"><span style="-sec-ix-hidden: xdx2ixbrl0999">21</span></span> months.
We have recognized tax benefits associated with restricted stock award compensation of $<span id="xdx_903_eus-gaap--IncomeTaxExpenseBenefit_c20220101__20221231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zASlgyxk8Cj4">101,419</span> and $<span id="xdx_902_eus-gaap--IncomeTaxExpenseBenefit_c20210101__20211231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zv7gaoOBESw7">47,220</span> for the twelve months ended
December 31, 2022 and 2021, respectively.</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI https://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139621730311232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LEASES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesOfLesseeDisclosureTextBlock', window );">LEASES</a></td>
<td class="text"><p id="xdx_80A_eus-gaap--LeasesOfLesseeDisclosureTextBlock_zktF80J4F7ih" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>NOTE 5 &#8212; <span id="xdx_82F_zRVinPaaV2Y3">LEASES</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">We have finance and operating leases for our corporate office and certain
office and computer equipment. &#160;<span id="xdx_900_ecustom--DescriptionOfLessorOperatingLeaseTerm_c20220101__20221231_z0WCfOOTFkO4" title="Description of lease term">Our leases have remaining lease terms of 10, 5 years, and 3 months.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">At contract inception, we evaluate whether an arrangement is or contains
a lease for which we are the lessee (that is, arrangements which provide us with the right to control a physical asset for a period of
time). &#160;Operating leases are accounted for on the balance sheets with ROU assets being recognized in &#8220;Operating lease right-of-use
assets&#8221; and lease liabilities recognized in &#8220;Operating lease liability &#8211; current&#8221; and &#8220;Operating lease liability,
net of current portion.&#8221; Finance leases are accounted for on the balance sheets recognized in &#8220;Property and equipment, net&#8221;
and lease liabilities recognized in &#8220;Finance lease liability &#8211; current&#8221; and &#8220;Finance lease liability, net of current
portion.&#8221;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Operating lease expenses are recognized on a straight-line basis over the
lease term. &#160;With respect to finance leases, amortization of the ROU asset is presented separately from interest expense related
to the finance lease liability.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">We have elected to combine lease and non-lease components for all lease
contracts where we are the lessee. &#160;Additionally, for arrangements with lease terms of 12 months or less, we do not recognize ROU
assets and lease liabilities and lease payments are recognized on a straight-line basis over the lease term with variable lease payments
recognized in the period in which the obligation is incurred. &#160;ROU assets are measured for impairment when a triggering event occurs.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p id="xdx_890_eus-gaap--LeaseCostTableTextBlock_z1LTQGqoqzE1" style="font: 10pt Times New Roman, Times, Serif; margin: 0">The components of lease expense were as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_8BF_zHnufYvIrM98" style="display: none; visibility: hidden">Schedule of components of lease expense</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 4.75in; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="width: 187.95pt">&#160;</td>
    <td style="width: 7.15pt">&#160;</td>
    <td style="width: 0.1in; text-align: center">&#160;</td>
    <td id="xdx_494_20220101__20221231_z2p5lB62SXuh" style="width: 56.8pt; text-align: center">&#160;</td>
    <td style="width: 11.15pt; text-align: center">&#160;</td>
    <td style="width: 0.1in; text-align: center">&#160;</td>
    <td id="xdx_49B_20210101__20211231_zjrgEIxHcU5c" style="width: 57.4pt; text-align: center">&#160;</td>
    <td style="width: 7.15pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="5" style="text-align: center"><b>Years Ended</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="5" style="border-bottom: black 1pt solid; text-align: center"><b>December 31,</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>2022</b></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>2021</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--OperatingLeaseCost_maLCzGTc_zUsXlNVmwuB6" style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Operating lease cost</td>
    <td>&#160;</td>
    <td>$</td>
    <td style="text-align: right">514,294</td>
    <td>&#160;</td>
    <td>$</td>
    <td style="text-align: right">149,476</td>
    <td>&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--ShortTermLeaseCost_maLCzGTc_zSAnfqySRBt5" style="vertical-align: bottom">
    <td>Short-term lease cost</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">131,490</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">146,604</td>
    <td>&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--LeaseCost_zvUJoX9MAcG7" style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Total lease cost</td>
    <td>&#160;</td>
    <td style="border-top: black 1pt solid; border-bottom: black 2.25pt double">$</td>
    <td style="border-top: black 1pt solid; border-bottom: black 2.25pt double; text-align: right">645,784</td>
    <td>&#160;</td>
    <td style="border-top: black 1pt solid; border-bottom: black 2.25pt double">$</td>
    <td style="border-top: black 1pt solid; border-bottom: black 2.25pt double; text-align: right">296,080</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_40F_ecustom--FinanceLeaseCost1Abstract_iB_zWFaUUVzptO8" style="vertical-align: bottom">
    <td style="padding-left: 9.1pt; text-indent: -9.1pt">Finance lease cost:</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--FinanceLeaseRightOfUseAssetAmortization_i01_maFLCzAT2_zftg6rMSJ8Qg" style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="padding-left: 27.5pt; text-indent: -9.1pt">Amortization of right-of-use assets</td>
    <td>&#160;</td>
    <td>$</td>
    <td style="text-align: right">50,895</td>
    <td>&#160;</td>
    <td>$</td>
    <td style="text-align: right">2,586</td>
    <td>&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--FinanceLeaseInterestExpense_i01_maFLCzAT2_zDR8tEDw9AQ5" style="vertical-align: bottom">
    <td style="padding-left: 27.5pt; text-indent: -9.1pt">Interest on lease liabilities</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">5,393</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">60</td>
    <td>&#160;</td></tr>
  <tr id="xdx_40A_ecustom--FinanceLeaseCost_i01_zD2FyidY27S9" style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Total finance lease cost</td>
    <td>&#160;</td>
    <td style="border-top: black 1pt solid; border-bottom: black 2.25pt double">$</td>
    <td style="border-top: black 1pt solid; border-bottom: black 2.25pt double; text-align: right">56,288</td>
    <td>&#160;</td>
    <td style="border-top: black 1pt solid; border-bottom: black 2.25pt double">$</td>
    <td style="border-top: black 1pt solid; border-bottom: black 2.25pt double; text-align: right">2,646</td>
    <td>&#160;</td></tr>
  </table>
<p id="xdx_8A9_zcHQw6kJMYhl" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p id="xdx_899_eus-gaap--OperatingLeaseLeaseIncomeTableTextBlock_zEHge4wXvGc" style="font: 10pt Times New Roman, Times, Serif; margin: 0">Supplemental cash flow information related to leases was as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_8BB_zz98rsQUoiYj" style="display: none; visibility: hidden">Schedule of cash flow information related to leases</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 4.75in; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="width: 190pt">&#160;</td>
    <td style="width: 6.8pt">&#160;</td>
    <td style="width: 7.1pt; text-align: center">&#160;</td>
    <td id="xdx_49D_20220101__20221231_zvEQSh5ueQsi" style="width: 56.1pt; text-align: center">&#160;</td>
    <td style="width: 12pt; text-align: center">&#160;</td>
    <td style="width: 7.1pt; text-align: center">&#160;</td>
    <td id="xdx_491_20210101__20211231_zqBJ41jFceVb" style="width: 55.9pt; text-align: center">&#160;</td>
    <td style="width: 6.8pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="5" style="text-align: center"><b>Years Ended</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="5" style="border-bottom: black 1pt solid; text-align: center"><b>December 31,</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>2022</b></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>2021</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--CashFlowOperatingActivitiesLesseeAbstract_iB" style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="padding-left: 9.45pt; text-indent: -9.45pt">Cash paid for amounts included in the measurement of lease liabilities:</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--OperatingLeasePayments_i01_z2KIYtKYcSo1" style="vertical-align: bottom">
    <td>Operating cash flows from operating leases</td>
    <td>&#160;</td>
    <td>$</td>
    <td style="text-align: right">247,504</td>
    <td>&#160;</td>
    <td>$</td>
    <td style="text-align: right">141,293</td>
    <td>&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--FinanceLeaseInterestPaymentOnLiability_i01_zqOSMHTnsu29" style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Financing cash flows from finance leases</td>
    <td>&#160;</td>
    <td>$</td>
    <td style="text-align: right">57,243</td>
    <td>&#160;</td>
    <td>$</td>
    <td style="text-align: right">2,646</td>
    <td>&#160;</td></tr>
  </table>
<p id="xdx_8A8_zPqTb9StI1w3" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>



<p id="xdx_899_eus-gaap--OperatingLeasesOfLesseeDisclosureTextBlock_zBDoScivKUk9" style="font: 10pt Times New Roman, Times, Serif; margin: 0">Supplemental balance sheet information related to leases was as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_8B9_zhDohtT1ePmd" style="display: none; visibility: hidden">Schdeule of balance sheet information related to leases</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 5.5in; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" id="xdx_49B_20221231_z8ahI5LaIsN6" style="border-bottom: black 1pt solid; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td colspan="2" id="xdx_498_20211231_zerdUjqQqiPc" style="border-bottom: black 1pt solid; text-align: center">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>December 31,<br/>
2022</b></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>December 31,<br/>
2021</b></td>
    <td>&#160;</td></tr>
  <tr id="xdx_402_ecustom--AssetsAndLiabilitiesOperatingLesseeAbstract_iB_zY2BfEyxuXfl" style="vertical-align: bottom">
    <td style="width: 217.3pt; padding-left: 9.1pt; text-indent: -9.1pt"><b>Operating Leases</b></td>
    <td style="width: 9.8pt">&#160;</td>
    <td style="width: 11.25pt">&#160;</td>
    <td style="width: 63pt">&#160;</td>
    <td style="width: 12.8pt">&#160;</td>
    <td style="width: 9.75pt">&#160;</td>
    <td style="width: 64.5pt">&#160;</td>
    <td style="width: 0.1in">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--OperatingLeaseRightOfUseAsset_i01I_zf5monxP8L92" style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="padding-left: 28.25pt; text-indent: -9.45pt">Operating lease right-of-use assets</td>
    <td>&#160;</td>
    <td>$</td>
    <td style="text-align: right">3,786,545</td>
    <td>&#160;</td>
    <td>$</td>
    <td style="text-align: right">95,553</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 28.25pt; text-indent: -9.45pt">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--OperatingLeaseLiabilityCurrent_i01I_zQ08LsJOEJi5" style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="padding-left: 28.25pt; text-indent: -9.45pt">Operating lease liability &#8211; current</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">345,834</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">95,553</td>
    <td>&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--OperatingLeaseLiabilityNoncurrent_i01I_zfJUy2reio28" style="vertical-align: bottom">
    <td style="padding-left: 28.25pt; text-indent: -9.45pt">Operating lease liability, net of current portion</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right">3,653,257</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1057">&#8212;</span></td>
    <td>&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--OperatingLeaseLiability_i01I_ziKLJsgAbEh5" style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="padding-left: 9.1pt; text-indent: -9.1pt">Total operating lease liabilities</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right">3,999,091</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right">95,553</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 9.1pt; text-indent: -9.1pt">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_40F_ecustom--AssetsAndLiabilitiesLesseeFinanceAbstract_iB_z86pRnOO118" style="vertical-align: bottom">
    <td style="padding-left: 9.1pt; text-indent: -9.1pt"><b>Finance Leases</b></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--PropertyPlantAndEquipmentOther_i01I_zkshvzRWwsV7" style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="padding-left: 28.25pt; text-indent: -9.45pt">Property and equipment, at cost</td>
    <td>&#160;</td>
    <td>$</td>
    <td style="text-align: right">544,468</td>
    <td>&#160;</td>
    <td>$</td>
    <td style="text-align: right">12,725</td>
    <td>&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--PropertyPlantAndEquipmentOtherAccumulatedDepreciation_i01NI_di_zgPCpK3uctT4" style="vertical-align: bottom">
    <td style="padding-left: 28.25pt; text-indent: -9.45pt">Accumulated depreciation</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right">(50,895</td>
    <td>)</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right">(12,725</td>
    <td>)</td></tr>
  <tr id="xdx_407_eus-gaap--PropertyPlantAndEquipmentOtherNet_i01I_zow00fF4O8Z" style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="padding-left: 28.25pt; text-indent: -9.45pt">Property and equipment, net</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right">493,573</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1072">&#8212;</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--FinanceLeaseLiabilityCurrent_iI_ztoM1PT0aWsc" style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="padding-left: 28.25pt; text-indent: -9.45pt">Finance lease liability &#8211; current</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">98,335</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1075">&#8212;</span></td>
    <td>&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--FinanceLeaseLiabilityNoncurrent_iI_z0GlI9AHfFLh" style="vertical-align: bottom">
    <td style="padding-left: 28.25pt; text-indent: -9.45pt">Finance lease liability, net of current portion</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right">394,283</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1078">&#8212;</span></td>
    <td>&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--FinanceLeaseLiability_iI_zlJaUSV2xXHj" style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="padding-left: 9.1pt; text-indent: -9.1pt">Total finance lease liabilities</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right">492,618</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1081">&#8212;</span></td>
    <td>&#160;</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 5.5in; border-collapse: collapse">
  <tr style="background-color: white">
    <td style="vertical-align: bottom; width: 218.25pt">&#160;</td>
    <td style="vertical-align: bottom; width: 9.75pt">&#160;</td>
    <td style="border-bottom: black 1pt solid; vertical-align: bottom; width: 74.25pt; text-align: center"><b>December 31,<br/>
2022</b></td>
    <td style="vertical-align: bottom; width: 11.25pt">&#160;</td>
    <td style="border-bottom: black 1pt solid; vertical-align: top; width: 74.25pt; text-align: center"><b>December 31,<br/>
2021</b></td>
    <td style="vertical-align: top; width: 0.1in">&#160;</td></tr>
  <tr>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top">&#160;</td></tr>
  <tr style="background-color: #E6E6E6">
    <td style="vertical-align: bottom"><b>Weighted Average Remaining Lease Term</b></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top">&#160;</td></tr>
  <tr style="background-color: white">
    <td style="vertical-align: bottom; padding-left: 28.25pt; text-indent: -9.45pt">Operating leases</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="text-align: right"><span id="xdx_908_eus-gaap--LesseeOperatingLeaseRenewalTerm_iI_dxL_c20221231_zArCYc8v9ij" title="Operating leases::XDX::P9Y8M12D"><span style="-sec-ix-hidden: xdx2ixbrl1083">9.7</span></span> Years</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: right"><span id="xdx_90F_eus-gaap--LesseeOperatingLeaseRenewalTerm_iI_dxL_c20211231_zTyjDwcAZdKf" title="Operating leases::XDX::P0Y7M6D"><span style="-sec-ix-hidden: xdx2ixbrl1085">0.6</span></span> Years</td>
    <td style="vertical-align: top">&#160;</td></tr>
  <tr style="background-color: #E6E6E6">
    <td style="vertical-align: bottom; padding-left: 28.25pt; text-indent: -9.45pt">Finance leases</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="text-align: right"><span id="xdx_90D_eus-gaap--LesseeFinanceLeaseRenewalTerm1_iI_dxL_c20221231_zGKlAStG3FY" title="Finance leases::XDX::P4Y0M22D"><span style="-sec-ix-hidden: xdx2ixbrl1087">4.6</span></span> Years</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: right"><span id="xdx_90A_eus-gaap--LesseeFinanceLeaseRenewalTerm1_iI_dxL_c20211231_zrQaTiaSzknd" title="Finance leases::XDX::P0Y0M0D"><span style="-sec-ix-hidden: xdx2ixbrl1089">0</span></span> Years</td>
    <td style="vertical-align: top">&#160;</td></tr>
  <tr style="background-color: white">
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top">&#160;</td></tr>
  <tr style="background-color: #E6E6E6">
    <td style="vertical-align: bottom"><b>Weighted Average Discount Rate</b></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top">&#160;</td></tr>
  <tr style="background-color: white">
    <td style="vertical-align: bottom; padding-left: 28.25pt; text-indent: -9.45pt">Operating leases</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span id="xdx_90C_eus-gaap--LesseeOperatingLeaseDiscountRate_iI_pid_dp_uPure_c20221231_zg4uFdZV446l" title="Operating leases">4.00</span>%</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: right"><span id="xdx_90C_eus-gaap--LesseeOperatingLeaseDiscountRate_iI_pid_dp_uPure_c20211231_zJtJWBxHewic" title="Operating leases">4.75</span>%</td>
    <td style="vertical-align: top">&#160;</td></tr>
  <tr style="background-color: #E6E6E6">
    <td style="vertical-align: bottom; padding-left: 28.25pt; text-indent: -9.45pt">Finance leases</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span id="xdx_90A_eus-gaap--LesseeFinanceLeaseDiscountRate_iI_pid_dp_uPure_c20221231_zwKlu2rO5mQl" title="Finance leases">4.25</span>%</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: right"><span id="xdx_90F_eus-gaap--LesseeFinanceLeaseDiscountRate_iI_pid_dp_uPure_c20211231_z89nbAXUapO4" title="Finance leases">4.75</span>%</td>
    <td style="vertical-align: top">&#160;</td></tr>
  </table>
<p id="xdx_8A8_zJsGcKQZ7H0b" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p id="xdx_894_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_zJzeWiAT4h1l" style="font: 10pt Times New Roman, Times, Serif; margin: 0">Maturities of lease liabilities are as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_8B0_zPfztqAP7W4f" style="display: none; visibility: hidden">Schedule of maturities of lease liabilities</span>&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"/>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 5.5in; border-collapse: collapse">
  <tr>
    <td style="border-bottom: black 1pt solid; vertical-align: bottom"><b>Year Ending December 31,</b></td>
    <td style="vertical-align: top">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: center"><b>Operating Leases</b></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: center"><b>Finance Leases</b></td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="width: 210.7pt">2023</td>
    <td style="width: 7pt">&#160;</td>
    <td style="width: 13.95pt">&#160;</td>
    <td id="xdx_98C_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_c20221231_zbdREWlyjfga" style="width: 67.6pt; text-align: right" title="2023">499,503</td>
    <td style="width: 10.2pt">&#160;</td>
    <td style="width: 7pt">&#160;</td>
    <td id="xdx_98E_eus-gaap--FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_iI_c20221231_zDBrss7U5qb" style="width: 62.05pt; text-align: right" title="2023">123,200</td>
    <td style="width: 8.75pt">&#160;</td></tr>
  <tr>
    <td style="vertical-align: bottom">2024</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td id="xdx_984_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_c20221231_zfrLp93TJoi7" style="vertical-align: bottom; text-align: right" title="2024">499,503</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td id="xdx_98D_eus-gaap--FinanceLeaseLiabilityPaymentsDueYearTwo_iI_c20221231_zqwZr9c5qS4c" style="vertical-align: bottom; text-align: right" title="2024">123,200</td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr style="background-color: #E6E6E6">
    <td style="vertical-align: bottom">2025</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td id="xdx_98F_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_c20221231_z6e6Jx5PulYk" style="vertical-align: bottom; text-align: right" title="2025">499,503</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td id="xdx_988_eus-gaap--FinanceLeaseLiabilityPaymentsDueYearThree_iI_c20221231_zfR57toQFVqh" style="vertical-align: bottom; text-align: right" title="2025">123,200</td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr>
    <td style="vertical-align: bottom">2026</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td id="xdx_985_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFour_iI_c20221231_znlIyIwgCNF8" style="vertical-align: bottom; text-align: right" title="2026">499,503</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td id="xdx_98E_eus-gaap--FinanceLeaseLiabilityPaymentsDueYearFour_iI_c20221231_zDrWXBFtwpB7" style="vertical-align: bottom; text-align: right" title="2026">123,200</td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr style="background-color: #E6E6E6">
    <td style="vertical-align: bottom">2027</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td id="xdx_98F_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFive_iI_c20221231_zW6ywYksJDz3" style="vertical-align: bottom; text-align: right" title="2027">499,503</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td id="xdx_983_eus-gaap--FinanceLeaseLiabilityPaymentsDueYearFive_iI_c20221231_zFhCRsXANDZ4" style="vertical-align: bottom; text-align: right" title="2027">65,957</td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr>
    <td style="vertical-align: bottom">Thereafter</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="border-bottom: black 1pt solid; vertical-align: bottom">&#160;</td>
    <td id="xdx_987_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_iI_c20221231_zbg3rVA8sdA3" style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: right" title="Thereafter">2,331,015</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="border-bottom: black 1pt solid; vertical-align: bottom">&#160;</td>
    <td id="xdx_98B_eus-gaap--FinanceLeaseLiabilityPaymentsDueAfterYearFive_iI_c20221231_zQFXPu2ksYAf" style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: right" title="Thereafter"><span style="-sec-ix-hidden: xdx2ixbrl1123">&#8212;</span></td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr style="background-color: #E6E6E6">
    <td style="vertical-align: bottom">Total undiscounted lease payments</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td id="xdx_980_ecustom--LesseeOperatingLeaseLiabilityPaymentsDueTotal_iI_c20221231_zLPcSKlSzTzc" style="vertical-align: bottom; text-align: right" title="Total undiscounted lease payments">4,828,530</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td id="xdx_98B_ecustom--LesseeFinancingLeaseLeaseLiabilityPaymentsDueTotal_iI_c20221231_z5kCzifwgWPj" style="vertical-align: bottom; text-align: right" title="Total undiscounted lease payments">558,757</td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr>
    <td style="vertical-align: bottom; padding-left: 18.8pt">Less: imputed interest</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="border-bottom: black 1pt solid; vertical-align: bottom">&#160;</td>
    <td id="xdx_98B_ecustom--LesseeOperatingLeaseImputedInterest_iNI_di_c20221231_zODxEvreSjwd" style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: right" title="Less: imputed interest">(829,439</td>
    <td style="vertical-align: bottom">)</td>
    <td style="border-bottom: black 1pt solid; vertical-align: bottom">&#160;</td>
    <td id="xdx_985_ecustom--LesseeFinancingLeaseImputedInterest_iNI_di_c20221231_zAhvBU1ADOQc" style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: right" title="Less: imputed interest">(66,139</td>
    <td style="vertical-align: bottom">)</td></tr>
  <tr style="background-color: #E6E6E6">
    <td style="vertical-align: bottom">Total lease liabilities</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="border-bottom: black 2.25pt double; vertical-align: bottom">$</td>
    <td id="xdx_98C_eus-gaap--OperatingLeaseLiability_iI_c20221231_zbVRBidywo6k" style="border-bottom: black 2.25pt double; vertical-align: bottom; text-align: right" title="Total lease liabilities">3,999,091</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="border-bottom: black 2.25pt double; vertical-align: bottom">$</td>
    <td id="xdx_981_eus-gaap--FinanceLeaseLiability_iI_c20221231_zHnd4FjVhccl" style="border-bottom: black 2.25pt double; vertical-align: bottom; text-align: right" title="Total lease liabilities">492,618</td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  </table>
<p id="xdx_8A8_zkXgyaoYOY7h" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesOfLesseeDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for lessee entity's leasing arrangements including, but not limited to, all of the following: (a.) The basis on which contingent rental payments are determined, (b.) The existence and terms of renewal or purchase options and escalation clauses, (c.) Restrictions imposed by lease agreements, such as those concerning dividends, additional debt, and further leasing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -URI https://asc.fasb.org/topic&amp;trid=2208923<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesOfLesseeDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139621731045440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FEDERAL AND STATE INCOME TAXES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">FEDERAL AND STATE INCOME TAXES</a></td>
<td class="text"><p id="xdx_801_eus-gaap--IncomeTaxDisclosureTextBlock_zlWt42gbfGN2" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>NOTE 6 &#8212; <span id="xdx_822_zaj4n2rmGLn4">FEDERAL AND STATE INCOME TAXES</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p id="xdx_899_eus-gaap--ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_zglEySmcueM1" style="font: 10pt Times New Roman, Times, Serif; margin: 0">Income tax expense consisted of the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_8BE_zsMQiuMp5bRh" style="display: none; visibility: hidden">Schedule of provision for income taxes</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 4.5in; border-collapse: collapse">
  <tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" id="xdx_496_20220101__20221231_zuCjSxBaV0T6" style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td colspan="2" id="xdx_49E_20210101__20211231_z9VxYzvHVC4f" style="text-align: center">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>Year Ended<br/>
December 31,<br/>
2022</b></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>Year Ended<br/>
December 31,<br/>
2021</b></td>
    <td>&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--StateAndLocalIncomeTaxExpenseBenefitContinuingOperationsAbstract_iB_zpVHNQEH2yh8" style="vertical-align: bottom; background-color: white">
    <td>State income tax:</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--CurrentStateAndLocalTaxExpenseBenefit_zuRz3QqK79eg" style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="width: 145.15pt; padding-left: 21.8pt">Current, net of refund</td>
    <td style="width: 8.25pt">&#160;</td>
    <td style="width: 8.25pt">$</td>
    <td style="width: 63.75pt; text-align: right">0</td>
    <td style="width: 17.3pt">&#160;</td>
    <td style="width: 8.25pt">$</td>
    <td style="width: 64.5pt; text-align: right">(12,800</td>
    <td style="width: 8.25pt">)</td></tr>
  <tr id="xdx_409_eus-gaap--FederalIncomeTaxExpenseBenefitContinuingOperationsAbstract_iB_zgNMkE8zBaDc" style="vertical-align: bottom; background-color: white">
    <td>Federal income tax:</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--DeferredFederalIncomeTaxExpenseBenefit_zuGwJOXBnkO" style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="padding-left: 21.8pt">Deferred</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">2,014,018</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">1,814,418</td>
    <td>&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--CurrentFederalTaxExpenseBenefit_zR3uewbkPO6l" style="vertical-align: bottom; background-color: white">
    <td style="padding-left: 21.8pt">Current</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1153">&#8212;</span></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1154">&#8212;</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Income tax benefit/(expense)</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td id="xdx_987_eus-gaap--IncomeTaxExpenseBenefit_iN_dixL_c20220101__20221231_z0H20cITsBPk" style="border-bottom: black 2.25pt double; text-align: right" title="Income tax benefit/(expense)::XDX::2014018"><span style="-sec-ix-hidden: xdx2ixbrl1156">2,014,018</span></td>
    <td style="border-bottom: white 2.25pt double">&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td id="xdx_98E_eus-gaap--IncomeTaxExpenseBenefit_iN_di_c20210101__20211231_zwg8wpJI77sk" style="border-bottom: black 2.25pt double; text-align: right" title="Income tax benefit/(expense)">1,801,618</td>
    <td style="border-bottom: white 2.25pt double">&#160;</td></tr>
  </table>
<p id="xdx_8A4_z9Z1GHVHUYtg" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>



<p id="xdx_898_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zUMt6iPfMcs4" style="font: 10pt Times New Roman, Times, Serif; margin: 0">The reconciliation of income taxes shown in the financial statements and
amounts computed by applying the Federal expected tax rate of 21% for year 2022 and 2021 is as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_8BF_zfXXktFPaDB4" style="display: none; visibility: hidden">Schedule of reconciliation of income taxes</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 5.5in; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" id="xdx_497_20220101__20221231_zZfBG566rN03" style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td colspan="2" id="xdx_49D_20210101__20211231_zbbvnlqEnBN7" style="text-align: center">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>Year Ended<br/>
December 31,<br/>
2022</b></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>Year Ended<br/>
December 31,<br/>
2021</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_zkkH8IRj2kNg" style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="width: 217.2pt">Loss before taxes</td>
    <td style="width: 8.3pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double; width: 8.25pt">$</td>
    <td style="border-bottom: black 2.25pt double; width: 65.25pt; text-align: right">(10,675,160</td>
    <td style="border-bottom: white 2.25pt double; width: 17.3pt">)</td>
    <td style="border-bottom: black 2.25pt double; width: 7.5pt">$</td>
    <td style="border-bottom: black 2.25pt double; width: 63.75pt; text-align: right">(6,364,441</td>
    <td style="border-bottom: white 2.25pt double; width: 8.25pt">)</td></tr>
  <tr id="xdx_407_eus-gaap--IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_zFpk8I5fX0u3" style="vertical-align: bottom">
    <td>Income taxes computed at the federal statutory rate</td>
    <td>&#160;</td>
    <td>$</td>
    <td style="text-align: right">2,241,784</td>
    <td>&#160;</td>
    <td>$</td>
    <td style="text-align: right">1,336,533</td>
    <td>&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--IncomeTaxReconciliationStateAndLocalIncomeTaxes_zYOmqgxXiNCd" style="vertical-align: bottom; background-color: #E6E6E6">
    <td>State income and franchise tax</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">(0</td>
    <td>)</td>
    <td>&#160;</td>
    <td style="text-align: right">(12,800</td>
    <td>)</td></tr>
  <tr id="xdx_400_eus-gaap--IncomeTaxReconciliationOtherAdjustments_znIbNnOLWCgd" style="vertical-align: bottom">
    <td>Permanent differences and other</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right">(227,766</td>
    <td>)</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right">477,885</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Income tax benefit/(expense)</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td id="xdx_987_eus-gaap--IncomeTaxExpenseBenefit_iN_dixL_c20220101__20221231_zX2yburYThGc" style="border-bottom: black 2.25pt double; text-align: right" title="Income tax benefit/(expense)::XDX::2014018"><span style="-sec-ix-hidden: xdx2ixbrl1175">2,014,018</span></td>
    <td style="border-bottom: white 1.5pt double">&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td id="xdx_980_eus-gaap--IncomeTaxExpenseBenefit_iN_di_c20210101__20211231_zvntdnqNBLhj" style="border-bottom: black 2.25pt double; text-align: right" title="Income tax benefit/(expense)">1,801,618</td>
    <td style="border-bottom: white 1.5pt double">&#160;</td></tr>
  </table>
<p id="xdx_8AF_zMjx34GGqG33" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p id="xdx_894_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zlffzBYaydZ" style="font: 10pt Times New Roman, Times, Serif; margin: 0">The significant components of deferred income tax assets, net are as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_8B0_za0gIlKRnn84" style="display: none; visibility: hidden">Schedule of components of deferred tax assets</span>&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 5.5in; border-collapse: collapse">
  <tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" id="xdx_493_20221231_z7Xum9LAfpOi" style="border-bottom: black 1pt solid; text-align: center"><b>December 31,<br/>
2022</b></td>
    <td>&#160;</td>
    <td colspan="2" id="xdx_49E_20211231_z1A44rbmRDqc" style="border-bottom: black 1pt solid; text-align: center"><b>December 31,<br/>
2021</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--DeferredCompensationPlanAssets_iI_zt6hAbjnyePh" style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="width: 207.9pt">Deferred compensation cost</td>
    <td style="width: 0.1in">&#160;</td>
    <td style="width: 7.35pt">$</td>
    <td style="width: 80pt; text-align: right">557,931</td>
    <td style="width: 17.15pt">&#160;</td>
    <td style="width: 8.05pt">$</td>
    <td style="width: 61.1pt; text-align: right">389,981</td>
    <td style="width: 7.25pt">&#160;</td></tr>
  <tr id="xdx_40F_ecustom--DepreciationDepletionAndAmortization1_iI_zhEmxRj9hFYd" style="vertical-align: bottom; background-color: white">
    <td>Depreciation and amortization</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">(624,184</td>
    <td>)</td>
    <td>&#160;</td>
    <td style="text-align: right">(116,911</td>
    <td>)</td></tr>
  <tr id="xdx_403_ecustom--RdCredit_zgXcDJvczNKj" style="vertical-align: bottom; background-color: #E6E6E6">
    <td>R&amp;D credit</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">142,030</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">142,538</td>
    <td>&#160;</td></tr>
  <tr id="xdx_40D_ecustom--Nol_zhcYeQUIMA8" style="vertical-align: bottom; background-color: white">
    <td>NOL</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">2,956,685</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">1,507,982</td>
    <td>&#160;</td></tr>
  <tr id="xdx_40D_ecustom--AllowanceForDoubtfulOtherReceivables1Current_zuvcrVoDDgo4" style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Allowance for bad debts and other</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right">935,018</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right">17,664</td>
    <td>&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--DeferredTaxAssetsNet_iI_zNZ0sJT5k5o5" style="vertical-align: bottom; background-color: white">
    <td>Deferred income tax assets, net</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right">3,967,480</td>
    <td style="border-bottom: white 2.25pt double">&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right">1,941,254</td>
    <td style="border-bottom: white 2.25pt double">&#160;</td></tr>
  </table>
<p id="xdx_8AF_zunDjj9Fxttg" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Our U.S. federal and state income tax returns remain open to examination
for the tax years 2019 through 2021.</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI https://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139621731091280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>MAJOR CUSTOMERS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RisksAndUncertaintiesAbstract', window );"><strong>Risks and Uncertainties [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskDisclosureTextBlock', window );">MAJOR CUSTOMERS</a></td>
<td class="text"><p id="xdx_807_eus-gaap--ConcentrationRiskDisclosureTextBlock_zp9zL7iFsihl" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>NOTE 7 &#8212; <span id="xdx_823_zAAZm5feetge">MAJOR CUSTOMERS</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">For the years ended December 31, 2022 and December 31, 2021,
approximately <span id="xdx_902_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20221231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerOneMember_zQguANDOkgv8" title="Concentration risk, percentage">64</span>%
and <span id="xdx_90C_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20210101__20211231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerOneMember_zmwq5IkLWFw9">64</span>%,
respectively, of the Company&#8217;s net product revenues were derived from three major customers that are distributors. &#160;As of
December 31, 2022 and December 31, 2021, accounts receivable due from the three major customers was $2.2 million and $2.1 million,
respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The largest customer in both years is a domestic medical products and supplies
distributor. &#160;Although, a number of larger infusion customers have elected to consolidate their purchases through one or more distributors
in recent years, we continue to maintain strong direct relationships with them. &#160;We do not believe that their continued purchase
of FREEDOM System products and related supplies is contingent upon the distributor.</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for any concentrations existing at the date of the financial statements that make an entity vulnerable to a reasonably possible, near-term, severe impact. This disclosure informs financial statement users about the general nature of the risk associated with the concentration, and may indicate the percentage of concentration risk as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI https://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RisksAndUncertaintiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RisksAndUncertaintiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139621731213232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">COMMITMENTS AND CONTINGENCIES</a></td>
<td class="text"><p id="xdx_80A_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_zwUo59jiRuq5" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>NOTE 8 &#8212; <span id="xdx_827_zDSZ7RSQs8rb">COMMITMENTS AND CONTINGENCIES</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>LEGAL PROCEEDINGS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The Company has been and may again become involved in legal proceedings,
claims and litigation arising in the ordinary course of business. &#160;KORU Medical is not presently a party to any litigation or other
legal proceeding that is believed to be material to its financial condition.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>OTHER</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">On November 11, 2020, the Company entered into a Manufacturing and Supply
Agreement with Command Medical Products, Inc. (&#8220;Command&#8221;), pursuant to which Command has agreed to manufacture and supply
the Company&#8217;s subassemblies, needle sets and tubing products pursuant to the Company&#8217;s specifications and purchase orders.
&#160;The first binding purchase order pursuant to the Manufacturing and Supply Agreement was made on November 17, 2020 (the &#8220;Effective
Date&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The Manufacturing and Supply Agreement provides for a term of five years
from the Effective Date. &#160;Either party may terminate the Manufacturing and Supply Agreement upon a material breach by the other Party
that has not been cured within 90 days, upon the bankruptcy or insolvency of the other Party or as expressly set forth elsewhere in the
Agreement. &#160;If the Company terminates the Manufacturing and Supply Agreement other than for those reasons within the first three
years from the Effective Date, the Company is obligated to pay an early termination fee to Command.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The Manufacturing and Supply Agreement also includes customary provisions
relating to, among other things, delivery, inspection procedures, warranties, quality management, business continuity plans, handling
and transport, intellectual property, confidentiality and indemnification.</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI https://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI https://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139621731103200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EMPLOYEE BENEFITS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock', window );">EMPLOYEE BENEFITS</a></td>
<td class="text"><p id="xdx_803_eus-gaap--PensionAndOtherPostretirementBenefitsDisclosureTextBlock_z9c2bq4t4VWh" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>NOTE 9 &#8212;<span id="xdx_82E_z9PnJ8HC491j"> EMPLOYEE BENEFITS</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">We provide a safe harbor 401(k) plan for our employees that allows for
employee elective contributions, Company matching contributions and discretionary profit-sharing contributions. &#160;Employee elective
contributions are funded through voluntary payroll deductions. &#160;<span id="xdx_90D_ecustom--DescriptionOfMatchingContribution_c20220101__20221231_ziktIA9RrVP2" title="Description of matching contribution">The Company makes safe harbor matching contributions in an amount
equal to 100% of the employee&#8217;s contribution, not to exceed 3% of employee&#8217;s compensation plus 50% of employee&#8217;s pay
contributed between 3% and 5% of employee&#8217;s compensation</span>. &#160;Company matching expense for the years ended December 31, 2022 and
December 31, 2021 was $<span id="xdx_904_eus-gaap--DefinedContributionPlanEmployerDiscretionaryContributionAmount_c20220101__20221231_zx16SqhdblOc" title="Matching expense">214,931</span> and $<span id="xdx_901_eus-gaap--DefinedContributionPlanEmployerDiscretionaryContributionAmount_c20210101__20211231_zV7fv98IDyha" title="Matching expense">166,014</span>, respectively. &#160;The Company has not provided for a discretionary profit-sharing contribution.</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for retirement benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section S99<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=21916913&amp;loc=d3e273930-122802<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (o)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (p)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 70<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=49170846&amp;loc=d3e28014-114942<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -URI https://asc.fasb.org/topic&amp;trid=2235017<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 60<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=6414203&amp;loc=d3e39689-114964<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (q)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (r)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (l)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (r)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139621731111584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DEBT OBLIGATIONS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">DEBT OBLIGATIONS</a></td>
<td class="text"><p id="xdx_80C_eus-gaap--DebtDisclosureTextBlock_zWXV1QzCJny8" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>NOTE 10 &#8212; <span id="xdx_827_zNtvDGCyZBni">DEBT OBLIGATIONS</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">On June 29, 2022, the Company entered into a Loan Modification Extension
Agreement (the &#8220;Modification Agreement&#8221;) with Keybank National Association (&#8220;Lender&#8221;) to modify its revolving
line of credit with Lender in the amount of $3,500,000 (the &#8220;Loan&#8221;) that was originally made available on April 14, 2020 and
renewed on June 24, 2021. Among other things, the Modification Agreement: (i) extends the maturity date of the Loan from June 1, 2022
to June 1, 2023; (ii) changes the interest rate applicable to the Loan from Prime &#8211; 1.50% to Prime + 0%; (iii) releases the Company
from its obligations under a certain security agreement dated June 24, 2021 pursuant to which the Company had previously granted the Lender
a first priority security interest in all equipment, inventory, accounts, instruments, chattel paper and general intangibles of the Company
(the &#8220;Security Agreement&#8221;); and (iv) replaces the Security Agreement with a new pledge security agreement dated June 29, 2022
by and between the Company and Lender (the &#8220;Pledge Agreement&#8221;), which Pledge Agreement grants Lender a first priority security
interest in certain of the Company&#8217;s bank accounts as collateral security for the Loan. The Company had zero outstanding against
the line of credit as of December 31, 2022.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">On August 5, 2022, the Company entered into a commercial insurance premium
finance and security agreement with AON Premium Finance, LLC in the aggregate principal amount of $<span id="xdx_909_eus-gaap--NotesPayable_iI_dm_c20220805__dei--LegalEntityAxis__custom--AONPremiumFinanceLLCMember__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember_z0Knt7TLj9Wd" title="Notes payable">0.8 million</span> bearing an annual percentage
rate of <span id="xdx_903_ecustom--NotePayableTerms_pid_dp_uPure_c20220803__20220805__dei--LegalEntityAxis__custom--AONPremiumFinanceLLCMember__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember__us-gaap--CreditFacilityAxis__us-gaap--LineOfCreditMember_zjnelyJAHTq6" title="Note payable terms">6.5</span>%, to finance its insurance premiums. Monthly payments are due on the first of each month beginning August 1, 2022 through
June 1, 2023.</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI https://asc.fasb.org/topic&amp;trid=2208564<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139621726507888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NatureOfOperations', window );">NATURE OF OPERATIONS</a></td>
<td class="text"><p id="xdx_84C_eus-gaap--NatureOfOperations_zdnVGPzndT5i" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_86B_z8TcbrjdtGD7">NATURE OF OPERATIONS</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">KORU MEDICAL SYSTEMS, INC. (the &#8220;Company,&#8221; &#8220;KORU Medical,&#8221;
&#8220;KORU,&#8221; &#8220;we,&#8221; &#8220;us&#8221; or &#8220;our&#8221;) develops, manufactures and markets proprietary portable and
innovative medical devices primarily for the ambulatory infusion market as governed by the United States Food and Drug Administration
(the &#8220;FDA&#8221;) quality and regulatory system and international standards for quality system management. &#160;The Company operates
as <span id="xdx_907_eus-gaap--NumberOfReportableSegments_dxH_uN_c20220101__20221231_zp0YK2i0Lpfd" title="Number of segments::XDX::1">one</span> segment.</p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">BASIS OF PRESENTATION</a></td>
<td class="text"><p id="xdx_842_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zS9HDKwxKkD4" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_862_za4Wlr4TVcUi">BASIS OF PRESENTATION</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We prepare our financial statements and accompanying
notes in accordance with accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;). &#160;Certain
prior year amounts have been reclassified to conform to the current year presentation in our Financial Statements.</p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">CASH AND CASH EQUIVALENTS</a></td>
<td class="text"><p id="xdx_844_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zohP6xbtb9c3" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_868_zilxnUanv4tl">CASH AND CASH EQUIVALENTS</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">For purposes of the statement of cash flows, the Company considers all
short-term investments with an original maturity of three months or less to be cash equivalents. &#160;The Company holds cash in excess
of $<span id="xdx_902_eus-gaap--CashUninsuredAmount_iI_c20221231_zRZKlxgJI0Ih" title="FDIC cash uninsured amount">250,000</span> at its depository, which exceeds the FDIC insurance limits and is, therefore, uninsured.</p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryPolicyTextBlock', window );">INVENTORY</a></td>
<td class="text"><p id="xdx_840_eus-gaap--InventoryPolicyTextBlock_zxzLjs6dGw8k" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_86A_zvP96g8ATew6">INVENTORY</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Inventories of raw materials are stated at the lower of standard cost,
which approximates average cost, or market value including allocable overhead. &#160;Work-in-process and finished goods are stated at
the lower of standard cost or market value and include direct labor and allocable overhead.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">We maintain reserves for excess and obsolete inventory resulting from the
potential inability to sell certain products at prices in excess of current carrying costs. &#160;We make estimates regarding the future
recoverability of the costs of these products and record provisions based on historical experience, expiration of sterilization dates
and expected future trends. &#160;If actual product life cycles, product demand or acceptance of new product introductions are less favorable
than projected by management, additional inventory write downs may be required, which could unfavorably affect future operating results.</p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsFiniteLivedPolicy', window );">INTANGIBLE ASSETS</a></td>
<td class="text"><p id="xdx_841_eus-gaap--IntangibleAssetsFiniteLivedPolicy_zFAchVM8szJb" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_867_zJ95rXxkf8S2">INTANGIBLE ASSETS</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Certain of our identifiable intangible assets, including patents and trademarks,
are amortized using the straight-line method over their estimated useful lives which range from <span id="xdx_905_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dxL_c20220101__20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentsAndTrademarksMember__srt--RangeAxis__srt--MinimumMember_zMgMbxBk72M1" title="Estimated useful lives::XDX::P6Y"><span style="-sec-ix-hidden: xdx2ixbrl0488">6</span></span> to <span id="xdx_906_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dxL_c20220101__20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentsAndTrademarksMember__srt--RangeAxis__srt--MaximumMember_zsMBX7xYZM4" title="Estimated useful lives::XDX::P20Y"><span style="-sec-ix-hidden: xdx2ixbrl0490">20</span></span> years. &#160;All of our intangible
assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be
recoverable. &#160;Our management is responsible for determining if impairment exists and considers various factors when making these
determinations. &#160;Amortization expense related to intangible assets for the years ended December 31, 2022 and 2021 was $<span id="xdx_90A_ecustom--AmortizationOfIntangibleAssets1_c20220101__20221231_zdaQyFTk8Rnc" title="AmortizationOfIntangibleAssets1">62,143</span> and
$<span id="xdx_907_ecustom--AmortizationOfIntangibleAssets1_c20210101__20211231_zleXm3JB0R5c" title="AmortizationOfIntangibleAssets1">63,830</span>, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p id="xdx_898_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock_zgEH8iPnMqul" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The estimated amortization expense for the succeeding
years for the intangible assets is approximately:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span><span id="xdx_8B1_zMmeOzpV9qQa" style="display: none; visibility: hidden">Schedule of amortization expense</span></span>&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 3in; border-collapse: collapse">
  <tr style="background-color: white">
    <td style="border-bottom: black 1pt solid; vertical-align: bottom"><b>Year Ending December 31,</b></td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td id="xdx_49C_20221231_zZxBsRzkCe58" style="vertical-align: bottom">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_iI_zkTn0Qh4EZ05" style="background-color: #E6E6E6">
    <td style="vertical-align: bottom; width: 150pt">2023</td>
    <td style="vertical-align: top; width: 10.4pt">&#160;</td>
    <td style="vertical-align: bottom; width: 10pt">$</td>
    <td style="vertical-align: bottom; width: 56.65pt; text-align: right">62,982</td></tr>
  <tr id="xdx_408_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_iI_zq1eV71T9gLc" style="vertical-align: bottom">
    <td>2024</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">62,982</td></tr>
  <tr id="xdx_40F_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_iI_zHCqqdyxmXMa" style="background-color: #E6E6E6">
    <td style="vertical-align: bottom">2025</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right">62,842</td></tr>
  <tr id="xdx_40B_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_iI_zj8WKS3ZyaX8" style="background-color: white">
    <td style="vertical-align: bottom">2026</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right">61,787</td></tr>
  <tr id="xdx_407_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_iI_zw0Gtw4DlTPe" style="background-color: #E6E6E6">
    <td style="vertical-align: bottom">2027</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right">61,356</td></tr>
  <tr id="xdx_401_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_iI_zCI3c5sQsljc" style="background-color: white">
    <td style="vertical-align: bottom">Thereafter</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="border-bottom: black 1pt solid; vertical-align: bottom">&#160;</td>
    <td style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: right">475,233</td></tr>
  <tr id="xdx_406_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_zCRJMlJKZMk6" style="background-color: #E6E6E6">
    <td style="vertical-align: bottom">Total amortization expense</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="border-bottom: black 2.25pt double; vertical-align: bottom">$</td>
    <td style="border-bottom: black 2.25pt double; vertical-align: bottom; text-align: right">787,182</td></tr>
  </table>
<p id="xdx_8AC_zS8cA14RTjLd" style="font: 10pt Times New Roman, Times, Serif; margin: 0"/>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">INCOME TAXES</a></td>
<td class="text"><p id="xdx_840_eus-gaap--IncomeTaxPolicyTextBlock_zPneQ0ZgQzgh" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_86A_zurAya66UGVf">INCOME TAXES</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Deferred income taxes are provided using the liability method whereby deferred
tax assets are recognized for deductible temporary differences and operating loss and tax credit carry forwards and deferred tax liabilities
are recognized for taxable temporary differences.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The Company believes that it has no uncertain tax positions requiring disclosure
or adjustment.</p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">PROPERTY AND EQUIPMENT</a></td>
<td class="text"><p id="xdx_841_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zOBbEIpyGmd6" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_862_zPYpLF37xpxc">PROPERTY AND EQUIPMENT</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Property and equipment are stated at original acquisition cost less accumulated
depreciation. &#160;Additions and improvements are capitalized which increase the value or extend the life of an asset, while maintenance
and repair costs are expensed as incurred. &#160;When assets are retired or otherwise disposed, the cost and related accumulated depreciation
or amortization is removed from the respective accounts and any resulting gain or loss is included in income. &#160;Depreciation and amortization
are calculated on the straight-line basis over the estimated useful lives of the assets which generally range from <span id="xdx_904_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dxL_c20220101__20221231__srt--RangeAxis__srt--MinimumMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--FurnitureAndOfficeEquipmentMember_zzKLaTSM3CF7" title="Estimated useful lives of property and equipment::XDX::P3Y"><span style="-sec-ix-hidden: xdx2ixbrl0517">3</span></span>-<span id="xdx_905_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dxL_c20220101__20221231__srt--RangeAxis__srt--MaximumMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--FurnitureAndOfficeEquipmentMember_zR5ZBROcRTS8" title="::XDX::P10Y0M0D"><span style="-sec-ix-hidden: xdx2ixbrl0518">10</span></span> years for furniture
and office equipment, <span id="xdx_902_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dxL_c20220101__20221231__srt--RangeAxis__srt--MinimumMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--EquipmentAndToolingMember_zp39ZMDYg8O5" title="::XDX::P3Y"><span style="-sec-ix-hidden: xdx2ixbrl0519">3</span></span>-<span id="xdx_90E_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dxL_c20220101__20221231__srt--RangeAxis__srt--MaximumMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--EquipmentAndToolingMember_z00VDHNAeUH6" title="::XDX::P12Y"><span style="-sec-ix-hidden: xdx2ixbrl0520">12</span></span> years for manufacturing equipment and tooling and shorter of the lease term or their estimated useful lives
for leasehold improvements. Depreciation and amortization expense related to property and equipment for the years ended December 31, 2022
and 2021 was $<span id="xdx_905_eus-gaap--DepreciationDepletionAndAmortization_c20220101__20221231__us-gaap--FairValueByAssetClassAxis__us-gaap--PropertyPlantAndEquipmentMember_zRMvqTTkVI79" title="Depreciation and amortization">524,994</span> and $<span id="xdx_908_eus-gaap--DepreciationDepletionAndAmortization_c20210101__20211231__us-gaap--FairValueByAssetClassAxis__us-gaap--PropertyPlantAndEquipmentMember_zK3zQHuOPHwj" title="Depreciation and amortization">399,300</span>, respectively.</p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">STOCK-BASED COMPENSATION</a></td>
<td class="text"><p id="xdx_84A_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_z4r5Vzf2AITb" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_863_zR62l6wfRBAe">STOCK-BASED COMPENSATION</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The Company maintains a stock option plan and omnibus equity incentive
plan under which it grants stock options to certain executives, key employees and consultants. The fair value of each option grant is
estimated on the date of the grant using the Black-Scholes option-pricing model. &#160;All options are charged against income at their
fair value. &#160;The entire compensation expense of the award is recognized over the vesting period.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Shares of stock granted for director fees under the non-employee director
compensation plan are recorded at the fair value of the shares at the grant date.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The Company has also issued shares of stock for director fees under its
omnibus equity incentive plan. Those shares of stock granted are recorded at the fair value of the shares at the grant date.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The Company issues restricted stock awards. Restricted stock awards are
equity classified and measured at the fair market value of the underlying stock at the grant date. The fair value of restricted stock
awards vesting at certain market capitalization thresholds were estimated on the date of grant using the Brownian Motion Monte Carlo lattice
model. The fair value of restricted stock awards with time-based vesting were estimated on the date of grant at the current stock price.
We recognize restricted stock expense using the straight-line attribution method over the requisite service period and account for forfeitures
as they occur.</p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">NET LOSS PER COMMON SHARE</a></td>
<td class="text"><p id="xdx_845_eus-gaap--EarningsPerSharePolicyTextBlock_zZYuIlFBcHfk" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_86C_zhho2Pw2uBn1">NET LOSS PER COMMON SHARE</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p id="xdx_89E_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_zMG1jKvSqsWe" style="font: 10pt Times New Roman, Times, Serif; margin: 0">Basic earnings per share are computed on the weighted average of common
shares outstanding during each year. &#160;Diluted earnings per share includes only an increase in the weighted average shares by the
common shares issuable upon exercise of stock options. &#160;See &#8220;NOTE 4 &#8212; STOCK-BASED COMPENSATION&#8221; for further detail.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span><span id="xdx_8BC_zlnjQ0R1CBk9" style="display: none; visibility: hidden">Schedule of net income per common share</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 5.5in; border-collapse: collapse">
  <tr>
    <td style="vertical-align: bottom; width: 167.8pt">&#160;</td>
    <td style="vertical-align: bottom; width: 6.95pt">&#160;</td>
    <td style="vertical-align: top; width: 7.1pt; text-align: center">&#160;</td>
    <td id="xdx_493_20220101__20221231_zzvMb6BBNmGj" style="vertical-align: top; width: 85.9pt; text-align: center">&#160;</td>
    <td style="vertical-align: top; width: 14.1pt; text-align: center">&#160;</td>
    <td style="vertical-align: top; width: 9.35pt; text-align: center">&#160;</td>
    <td style="vertical-align: top; width: 7.1pt; text-align: center">&#160;</td>
    <td id="xdx_496_20210101__20211231_zL1n95ZSVts2" style="vertical-align: top; width: 82.5pt; text-align: center">&#160;</td>
    <td style="vertical-align: bottom; width: 15.1pt">&#160;</td></tr>
  <tr>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td colspan="6" style="border-bottom: black 1pt solid; vertical-align: top; text-align: center"><b>Years Ended</b></td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: center"><b>December 31, 2022</b></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: center"><b>December 31, 2021</b></td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--NetIncomeLoss_zY35B8ztZ5e8" style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Net loss</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">$</td>
    <td style="border-bottom: black 1pt solid; text-align: right">(8,661,142</td>
    <td>)</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">$</td>
    <td style="border-bottom: black 1pt solid; text-align: right">(4,562,823</td>
    <td>)</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasicAbstract_iB_zJKQih5XQNV7" style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Weighted Average Outstanding Shares:</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pid_hus-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zIQ1UMkP0mOc" style="vertical-align: bottom">
    <td style="padding-left: 21.8pt">Outstanding shares</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">45,002,074</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">44,385,032</td>
    <td>&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--IncrementalCommonSharesAttributableToCallOptionsAndWarrants_pid_zm8oNBHXFS0c" style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="padding-left: 21.8pt">Option shares includable</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0541">&#8212;</span></td>
    <td id="xdx_F51_zXnO0VQ3fCd8">(a)</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0542">&#8212;</span></td>
    <td id="xdx_F56_z8suocOMxah">(a)</td></tr>
  <tr id="xdx_40E_ecustom--IncrementalCommonSharesAttributableToRestrictedStock_pid_ztoKP1mn4Bw" style="vertical-align: bottom">
    <td style="padding-left: 21.8pt">Restricted stock includable</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0544">&#8212;</span></td>
    <td id="xdx_F52_zmpyjNDtJ7Ea">(b)</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0545">&#8212;</span></td>
    <td id="xdx_F5F_z4nwfjQAj7la">(b)</td></tr>
  <tr id="xdx_407_ecustom--WeightedAverageNumberOfSharesOutstanding_zjf5cgBKhkY3" style="vertical-align: bottom">
    <td><p style="margin-top: 0; margin-bottom: 0"><b style="display: none; visibility: hidden">&#160;Total</b></p>
        <p style="margin-top: 0; margin-bottom: 0"/></td>
    <td/>
    <td style="border-bottom: black 2.25pt double">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right">45,002,074</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right">44,385,032</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--EarningsPerShareAbstract_iB_zGOHyByYtat1" style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Net loss per share</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--EarningsPerShareBasic_pid_uUSDPShares_zk4hYMtkkq2j" style="vertical-align: bottom">
    <td style="padding-left: 21.8pt">Basic</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right">(0.19</td>
    <td style="border-bottom: white 2.25pt double">)</td>
    <td style="border-bottom: black 2.25pt double">&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right">(0.10</td>
    <td style="border-bottom: white 2.25pt double">)</td></tr>
  <tr id="xdx_404_eus-gaap--EarningsPerShareDiluted_pid_uUSDPShares_zoNdyVgzpB1k" style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="padding-left: 21.8pt">Diluted</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right">(0.19</td>
    <td style="border-bottom: white 2.25pt double">)</td>
    <td style="border-bottom: black 2.25pt double">&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right">(0.10</td>
    <td style="border-bottom: white 2.25pt double">)</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">__________</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td id="xdx_F07_zpjRlU1tokg5" style="width: 0.5in">(a)</td>
    <td id="xdx_F13_zJ7k0c2TJW51" style="width: 7in">Option shares of <span id="xdx_90B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_dxL_uShares_c20220101__20221231__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--EmployeeStockMember_zJscHJ6nJh08" title="Option shares excluded::XDX::0"><span style="-sec-ix-hidden: xdx2ixbrl0560">zero</span></span> and <span id="xdx_906_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_uShares_c20210101__20211231__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--EmployeeStockMember_zOXokNhUvBRh" title="Option shares excluded">273,110</span> for 2022 and 2021, respectively were not included as the impact is anti-dilutive.</td></tr>
  <tr style="vertical-align: top">
    <td id="xdx_F05_zQfISkekUjdj" style="width: 0.5in">(b)</td>
    <td id="xdx_F12_zj23i9XZITAh" style="width: 7in">Linda Tharby's Restricted Stock award shares of <span id="xdx_90D_ecustom--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount1_pid_uShares_c20220101__20221231__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--EmployeeStockMember_zQe25yGQAtl2" title="Restricted stock shares excluded">950,000</span> and <span id="xdx_900_ecustom--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount1_pid_uShares_c20210101__20211231__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--EmployeeStockMember_zQeAAvWnACzb" title="Restricted stock shares excluded">1,000,000</span> that are unvested for 2022 and 2021, respectively were not included as the impact is anti-dilutive.</td></tr>
  </table>

<p id="xdx_8AD_z74ojCDpPbsk" style="margin-top: 0; margin-bottom: 0">&#160;</p>
<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">USE OF ESTIMATES IN THE FINANCIAL STATEMENTS</a></td>
<td class="text"><p id="xdx_844_eus-gaap--UseOfEstimates_z6LaBImte0K4" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_869_z4A7A2mqJ7X9">USE OF ESTIMATES IN THE FINANCIAL STATEMENTS</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The preparation of financial statements in conformity with GAAP requires
management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. &#160;Actual
results could differ from those estimates. &#160;Important estimates include but are not limited to asset lives, valuation allowances,
inventory valuation, and accruals.</p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">REVENUE RECOGNITION</a></td>
<td class="text"><p id="xdx_84F_eus-gaap--RevenueFromContractWithCustomerPolicyTextBlock_zpLpzc1GZBG4" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_860_zt5Gey8twc2c">REVENUE RECOGNITION</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting
Standards Update (&#8220;ASU&#8221;) No. 2014-09, <i>Revenue from Contracts with Customers</i>, which provides a single comprehensive
model for entities to use in accounting for revenue arising from contracts with customers.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The Company&#8217;s revenues result from the sale of assembled products.
&#160;We recognize revenues when shipment occurs, and at which point the customer obtains control and ownership of the goods. &#160;Shipping
costs generally are billed to customers and are included in sales.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The Company generally does not accept return of goods shipped unless it
is a Company error. &#160;The only credits provided to customers are for defective merchandise. &#160;The Company warrants the syringe
driver from defects in materials and workmanship under normal use and the warranty does not include a performance obligation. &#160;The
costs under the warranty are expensed as incurred.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Provisions for distributor pricing and annual customer growth rebates are
variable consideration and are recorded as a reduction of revenue in the same period the related sales are recorded or when it is probable
the annual growth target will be achieved. &#160;Rebates are provided to distributors for the difference in selling price to distributor
and pricing specified to select customers.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The Company established an allowance for charging off uncollectible trade
accounts receivable that have both of the following characteristics: (a) They have a contractual maturity of one year or less, (b) They
arose from the sale of goods or services.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p id="xdx_89E_ecustom--ScheduleOfNetRevenuesByGeography_z3BIpuyfVG4d" style="font: 10pt Times New Roman, Times, Serif; margin: 0">The following table summarizes net revenues by geography for the years ended
December 31, 2022 and 2021:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_8BD_z3C9ZxreeIk3" style="display: none; visibility: hidden">Schedule of net revenues by geography</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 3.5in; border-collapse: collapse">
  <tr style="background-color: white">
    <td style="vertical-align: bottom; width: 93.35pt">&#160;</td>
    <td style="vertical-align: bottom; width: 8.3pt">&#160;</td>
    <td style="vertical-align: bottom; width: 8.25pt">&#160;</td>
    <td style="vertical-align: bottom; width: 53.4pt">&#160;</td>
    <td style="vertical-align: bottom; width: 18.05pt">&#160;</td>
    <td style="vertical-align: bottom; width: 8.25pt">&#160;</td>
    <td style="vertical-align: bottom; width: 54.15pt">&#160;</td>
    <td style="vertical-align: top; width: 8.25pt">&#160;</td></tr>
  <tr style="background-color: white">
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td colspan="5" style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: center"><b>Years Ended December 31,</b></td>
    <td style="vertical-align: top">&#160;</td></tr>
  <tr style="background-color: white">
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: center"><b>2022</b></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: center"><b>2021</b></td>
    <td style="vertical-align: top">&#160;</td></tr>
  <tr style="background-color: white">
    <td style="vertical-align: bottom"><b>Net Revenues</b></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top">&#160;</td></tr>
  <tr style="background-color: #E6E6E6">
    <td style="vertical-align: bottom; padding-left: 9.45pt">Domestic</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td>$</td>
    <td id="xdx_98D_eus-gaap--Revenues_c20220101__20221231__srt--StatementGeographicalAxis__country--US_zZ4uQjTcgfJc" style="text-align: right" title="Net Revenue">23,586,254</td>
    <td style="vertical-align: top">&#160;</td>
    <td>$</td>
    <td id="xdx_98C_eus-gaap--Revenues_c20210101__20211231__srt--StatementGeographicalAxis__country--US_zmQIeI78tUyl" style="text-align: right" title="Net Revenue">19,488,685</td>
    <td style="vertical-align: top">&#160;</td></tr>
  <tr style="background-color: white">
    <td style="vertical-align: bottom; padding-left: 9.45pt">International</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td id="xdx_987_eus-gaap--Revenues_c20220101__20221231__srt--StatementGeographicalAxis__us-gaap--NonUsMember_zfGG2aByPLz" style="border-bottom: black 1pt solid; text-align: right" title="Net Revenues">4,309,783</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td id="xdx_981_eus-gaap--Revenues_c20210101__20211231__srt--StatementGeographicalAxis__us-gaap--NonUsMember_zRtFKssVTgme" style="border-bottom: black 1pt solid; text-align: right" title="Net Revenues">4,001,490</td>
    <td style="vertical-align: top">&#160;</td></tr>
  <tr style="background-color: #E6E6E6">
    <td style="vertical-align: bottom"><b>Total</b></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td id="xdx_988_eus-gaap--Revenues_c20220101__20221231_zbAfS3LpNBGe" style="border-bottom: black 2.25pt double; text-align: right" title="Revenues">27,896,037</td>
    <td style="border-bottom: white 2.25pt double; vertical-align: top">&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td id="xdx_980_eus-gaap--Revenues_c20210101__20211231_zn8OKcUznKZg" style="border-bottom: black 2.25pt double; text-align: right" title="Revenues">23,490,175</td>
    <td style="vertical-align: top">&#160;</td></tr>
  </table>
<p id="xdx_8A4_zRN68oI0ioGe" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">LEASES</a></td>
<td class="text"><p id="xdx_846_eus-gaap--LesseeLeasesPolicyTextBlock_zipKrI5L2i54" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_863_zGMa0N0Ww7ef">LEASES</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">In February 2016, the FASB issued a standard related to leases to increase
transparency and comparability among organizations by requiring the recognition of right-of-use (&#8220;ROU&#8221;) assets and lease liabilities
on the balance sheet. &#160;Most prominent among the changes in the standard is the recognition of ROU assets and lease liabilities by
the Company for those leases classified as operating leases under current GAAP, while our accounting for capital leases remains substantially
unchanged. &#160;Under the standard, disclosures are required to meet the objective of enabling users of financial statements to assess
the amount, timing, and uncertainty of cash flows arising from leases. &#160;The standard became effective for us on January 1, 2019.
&#160;The standard had a material impact on our balance sheets but did not have a material impact on our statements of operations. &#160;See
&#8220;NOTE 5 <b>&#8212; </b>LEASES&#8221; for further detail.</p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">ACCOUNTING PRONOUNCEMENTS RECENTLY ADOPTED</a></td>
<td class="text"><p id="xdx_844_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zyR5yhkl0mx3" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_86D_zfWO34kCXJPi">ACCOUNTING PRONOUNCEMENTS RECENTLY ADOPTED</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">In December 2019, the FASB issued ASU No. 2019-12, <i>Income Taxes (Topic
740): Simplifying the Accounting for Income Taxes</i>. The amendments in this ASU simplify the accounting for income taxes by removing
several exceptions including the exception to the general methodology for calculating income taxes in an interim period when a year-to-date
loss exceeds the anticipated loss for the year. &#160;The amendments also improve consistent application of and simplify GAAP for other
areas of Topic 740 by clarifying and amending existing guidance. &#160;The amendments in this ASU are effective for fiscal years, and
interim periods within those fiscal years, beginning after December 15, 2020. &#160;The Company adopted this standard on January 1, 2021,
and it had no impact on our financial statement disclosures.</p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krmd_AccountingPronouncementsNotYetAdopted', window );">ACCOUNTING PRONOUNCEMENTS NOT YET ADOPTED</a></td>
<td class="text"><p id="xdx_846_ecustom--AccountingPronouncementsNotYetAdopted_zMJECMpJBn7j" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_865_z8maNI0cLQ6c">ACCOUNTING PRONOUNCEMENTS NOT YET ADOPTED</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">In June 2016, the FASB issued ASU No. 2016-13, <i>Financial Instruments
&#8211; Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments</i>, which amends guidance on reporting credit
losses for assets held at amortized cost basis and available for sale debt securities. &#160;For assets held at amortized cost basis,
Topic 326 eliminates the probable initial recognition threshold in current GAAP and, instead, requires an entity to reflect its current
estimate of all expected credit losses. &#160;The allowance for credit losses is a valuation account that is deducted from the amortized
cost basis of the financial assets to present the net amount expected to be collected. &#160;For available for sale debt securities, credit
losses should be measured in a manner similar to current GAAP, however Topic 326 will require that credit losses be presented as an allowance
rather than as a write-down. &#160;This ASU affects entities holding financial assets and net investment in leases that are not accounted
for at fair value through net income. &#160;The amendments affect loans, debt securities, trade receivables, net investments in leases,
off balance sheet credit exposures, reinsurance receivables, and any other financial assets not excluded from the scope that have the
contractual right to receive cash. &#160;The amendments in this update are effective for fiscal years beginning after December 15, 2022,
including interim periods within those fiscal years. &#160;The Company is assessing the impact of the adoption of the ASU on its financial
statements, disclosure requirements and methods of adoption.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The Company considers the applicability and impact of all recently issued
accounting pronouncements. &#160;Recent accounting pronouncements not specifically identified in our disclosures are either not applicable
to the Company or are not expected to have a material effect on our financial condition or results of operations.</p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">FAIR VALUE MEASUREMENTS</a></td>
<td class="text"><p id="xdx_844_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_zB3qn80oaFa5" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_866_z5Y75OK0JD5g">FAIR VALUE MEASUREMENTS</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Fair value is the exit price that would be received to sell an asset or
paid to transfer a liability. &#160;Fair value is a market-based measurement that should be determined using assumptions that market participants
would use in pricing an asset or liability. Valuation techniques used to measure fair value should maximize the use of observable inputs
and minimize the use of unobservable inputs. &#160;To measure fair value, the Company uses the following fair value hierarchy based on
three levels of inputs, of which the first two are considered observable and the last unobservable:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 7.5in; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: center">&#8226;</td>
    <td style="width: 7in">Level 1 &#8211; Quoted prices in active markets for identical assets or liabilities.</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center">&#8226;</td>
    <td>Level 2 &#8211; Inputs other than Level 1 that are observable for the asset or liability, either directly or indirectly, such as quoted prices for similar assets and liabilities in active markets; quoted prices for identical or similar assets or liabilities in markets that are not active; or other inputs that are observable or can be corroborated by observable market data by correlation or other means.</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center">&#8226;</td>
    <td>Level 3 &#8211; Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. &#160;Value is determined using pricing models, discounted cash flow methodologies, or similar techniques and includes instruments for which the determination of fair value requires significant judgment or estimation.</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The carrying amounts of cash and cash equivalents, accounts receivable,
prepaid expenses, accounts payable and accrued expenses are considered to be representative of their fair values because of the short-term
nature of those instruments. &#160;There were no transfers between levels in the fair value hierarchy during the year ended December 31,
2022.</p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">IMPAIRMENT OF LONG-LIVED ASSETS</a></td>
<td class="text"><p id="xdx_849_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_zQZbDx9rQ7We" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_86D_zRmizrHnN8ef">IMPAIRMENT OF LONG-LIVED ASSETS</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The Company reviews long-lived assets for impairment whenever events or
changes in circumstances indicate that the carrying amount of the assets may not be fully recoverable. &#160;An impairment loss would
be recognized when estimated undiscounted future cash flows expected to result from the use of the asset and its eventual disposition
are less than the carrying amount. &#160;The impairment loss, if recognized, would be based on the excess of the carrying value of the
impaired asset over its respective fair value. &#160;No impairment losses have been recorded through December 31, 2022.</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krmd_AccountingPronouncementsNotYetAdopted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The element represents accounting pronouncements not yet adopted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krmd_AccountingPronouncementsNotYetAdopted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4273-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=109226317&amp;loc=d3e202-110218<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -URI https://asc.fasb.org/extlink&amp;oid=27011434&amp;loc=d3e125687-122742<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32247-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32847-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32840-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL116659661-227067<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32280-109318<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsFiniteLivedPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for finite-lived intangible assets. This accounting policy also might address: (1) the amortization method used; (2) the useful lives of such assets; and (3) how the entity assesses and measures impairment of such assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 920<br> -SubTopic 350<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=120155617&amp;loc=SL120155638-234783<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 920<br> -SubTopic 350<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=120155617&amp;loc=SL120155628-234783<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 920<br> -SubTopic 350<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=120155617&amp;loc=SL120155628-234783<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsFiniteLivedPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4556-108314<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI https://asc.fasb.org/topic&amp;trid=2126998<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 330<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6471895&amp;loc=d3e55923-109411<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4492-108314<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126900757&amp;loc=d3e543-108305<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918666-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI https://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99779-112916<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99893-112916<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130561-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130566-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130563-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI https://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130566-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130563-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130566-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130564-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130566-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI https://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -URI https://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139621726683232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock', window );">Schedule of amortization expense</a></td>
<td class="text"><p id="xdx_898_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock_zgEH8iPnMqul" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The estimated amortization expense for the succeeding
years for the intangible assets is approximately:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span><span id="xdx_8B1_zMmeOzpV9qQa" style="display: none; visibility: hidden">Schedule of amortization expense</span></span>&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 3in; border-collapse: collapse">
  <tr style="background-color: white">
    <td style="border-bottom: black 1pt solid; vertical-align: bottom"><b>Year Ending December 31,</b></td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td id="xdx_49C_20221231_zZxBsRzkCe58" style="vertical-align: bottom">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_iI_zkTn0Qh4EZ05" style="background-color: #E6E6E6">
    <td style="vertical-align: bottom; width: 150pt">2023</td>
    <td style="vertical-align: top; width: 10.4pt">&#160;</td>
    <td style="vertical-align: bottom; width: 10pt">$</td>
    <td style="vertical-align: bottom; width: 56.65pt; text-align: right">62,982</td></tr>
  <tr id="xdx_408_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_iI_zq1eV71T9gLc" style="vertical-align: bottom">
    <td>2024</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">62,982</td></tr>
  <tr id="xdx_40F_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_iI_zHCqqdyxmXMa" style="background-color: #E6E6E6">
    <td style="vertical-align: bottom">2025</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right">62,842</td></tr>
  <tr id="xdx_40B_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_iI_zj8WKS3ZyaX8" style="background-color: white">
    <td style="vertical-align: bottom">2026</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right">61,787</td></tr>
  <tr id="xdx_407_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_iI_zw0Gtw4DlTPe" style="background-color: #E6E6E6">
    <td style="vertical-align: bottom">2027</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right">61,356</td></tr>
  <tr id="xdx_401_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_iI_zCI3c5sQsljc" style="background-color: white">
    <td style="vertical-align: bottom">Thereafter</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="border-bottom: black 1pt solid; vertical-align: bottom">&#160;</td>
    <td style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: right">475,233</td></tr>
  <tr id="xdx_406_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_zCRJMlJKZMk6" style="background-color: #E6E6E6">
    <td style="vertical-align: bottom">Total amortization expense</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="border-bottom: black 2.25pt double; vertical-align: bottom">$</td>
    <td style="border-bottom: black 2.25pt double; vertical-align: bottom; text-align: right">787,182</td></tr>
  </table>
<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of net income per common share</a></td>
<td class="text"><p id="xdx_89E_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_zMG1jKvSqsWe" style="font: 10pt Times New Roman, Times, Serif; margin: 0">Basic earnings per share are computed on the weighted average of common
shares outstanding during each year. &#160;Diluted earnings per share includes only an increase in the weighted average shares by the
common shares issuable upon exercise of stock options. &#160;See &#8220;NOTE 4 &#8212; STOCK-BASED COMPENSATION&#8221; for further detail.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span><span id="xdx_8BC_zlnjQ0R1CBk9" style="display: none; visibility: hidden">Schedule of net income per common share</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 5.5in; border-collapse: collapse">
  <tr>
    <td style="vertical-align: bottom; width: 167.8pt">&#160;</td>
    <td style="vertical-align: bottom; width: 6.95pt">&#160;</td>
    <td style="vertical-align: top; width: 7.1pt; text-align: center">&#160;</td>
    <td id="xdx_493_20220101__20221231_zzvMb6BBNmGj" style="vertical-align: top; width: 85.9pt; text-align: center">&#160;</td>
    <td style="vertical-align: top; width: 14.1pt; text-align: center">&#160;</td>
    <td style="vertical-align: top; width: 9.35pt; text-align: center">&#160;</td>
    <td style="vertical-align: top; width: 7.1pt; text-align: center">&#160;</td>
    <td id="xdx_496_20210101__20211231_zL1n95ZSVts2" style="vertical-align: top; width: 82.5pt; text-align: center">&#160;</td>
    <td style="vertical-align: bottom; width: 15.1pt">&#160;</td></tr>
  <tr>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td colspan="6" style="border-bottom: black 1pt solid; vertical-align: top; text-align: center"><b>Years Ended</b></td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: center"><b>December 31, 2022</b></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: center"><b>December 31, 2021</b></td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--NetIncomeLoss_zY35B8ztZ5e8" style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Net loss</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">$</td>
    <td style="border-bottom: black 1pt solid; text-align: right">(8,661,142</td>
    <td>)</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">$</td>
    <td style="border-bottom: black 1pt solid; text-align: right">(4,562,823</td>
    <td>)</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasicAbstract_iB_zJKQih5XQNV7" style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Weighted Average Outstanding Shares:</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pid_hus-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zIQ1UMkP0mOc" style="vertical-align: bottom">
    <td style="padding-left: 21.8pt">Outstanding shares</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">45,002,074</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">44,385,032</td>
    <td>&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--IncrementalCommonSharesAttributableToCallOptionsAndWarrants_pid_zm8oNBHXFS0c" style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="padding-left: 21.8pt">Option shares includable</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0541">&#8212;</span></td>
    <td id="xdx_F51_zXnO0VQ3fCd8">(a)</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0542">&#8212;</span></td>
    <td id="xdx_F56_z8suocOMxah">(a)</td></tr>
  <tr id="xdx_40E_ecustom--IncrementalCommonSharesAttributableToRestrictedStock_pid_ztoKP1mn4Bw" style="vertical-align: bottom">
    <td style="padding-left: 21.8pt">Restricted stock includable</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0544">&#8212;</span></td>
    <td id="xdx_F52_zmpyjNDtJ7Ea">(b)</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0545">&#8212;</span></td>
    <td id="xdx_F5F_z4nwfjQAj7la">(b)</td></tr>
  <tr id="xdx_407_ecustom--WeightedAverageNumberOfSharesOutstanding_zjf5cgBKhkY3" style="vertical-align: bottom">
    <td><p style="margin-top: 0; margin-bottom: 0"><b style="display: none; visibility: hidden">&#160;Total</b></p>
        <p style="margin-top: 0; margin-bottom: 0"/></td>
    <td/>
    <td style="border-bottom: black 2.25pt double">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right">45,002,074</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right">44,385,032</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--EarningsPerShareAbstract_iB_zGOHyByYtat1" style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Net loss per share</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--EarningsPerShareBasic_pid_uUSDPShares_zk4hYMtkkq2j" style="vertical-align: bottom">
    <td style="padding-left: 21.8pt">Basic</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right">(0.19</td>
    <td style="border-bottom: white 2.25pt double">)</td>
    <td style="border-bottom: black 2.25pt double">&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right">(0.10</td>
    <td style="border-bottom: white 2.25pt double">)</td></tr>
  <tr id="xdx_404_eus-gaap--EarningsPerShareDiluted_pid_uUSDPShares_zoNdyVgzpB1k" style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="padding-left: 21.8pt">Diluted</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right">(0.19</td>
    <td style="border-bottom: white 2.25pt double">)</td>
    <td style="border-bottom: black 2.25pt double">&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right">(0.10</td>
    <td style="border-bottom: white 2.25pt double">)</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">__________</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td id="xdx_F07_zpjRlU1tokg5" style="width: 0.5in">(a)</td>
    <td id="xdx_F13_zJ7k0c2TJW51" style="width: 7in">Option shares of <span id="xdx_90B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_dxL_uShares_c20220101__20221231__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--EmployeeStockMember_zJscHJ6nJh08" title="Option shares excluded::XDX::0"><span style="-sec-ix-hidden: xdx2ixbrl0560">zero</span></span> and <span id="xdx_906_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_uShares_c20210101__20211231__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--EmployeeStockMember_zOXokNhUvBRh" title="Option shares excluded">273,110</span> for 2022 and 2021, respectively were not included as the impact is anti-dilutive.</td></tr>
  <tr style="vertical-align: top">
    <td id="xdx_F05_zQfISkekUjdj" style="width: 0.5in">(b)</td>
    <td id="xdx_F12_zj23i9XZITAh" style="width: 7in">Linda Tharby's Restricted Stock award shares of <span id="xdx_90D_ecustom--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount1_pid_uShares_c20220101__20221231__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--EmployeeStockMember_zQe25yGQAtl2" title="Restricted stock shares excluded">950,000</span> and <span id="xdx_900_ecustom--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount1_pid_uShares_c20210101__20211231__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--EmployeeStockMember_zQeAAvWnACzb" title="Restricted stock shares excluded">1,000,000</span> that are unvested for 2022 and 2021, respectively were not included as the impact is anti-dilutive.</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krmd_ScheduleOfNetRevenuesByGeography', window );">Schedule of net revenues by geography</a></td>
<td class="text"><p id="xdx_89E_ecustom--ScheduleOfNetRevenuesByGeography_z3BIpuyfVG4d" style="font: 10pt Times New Roman, Times, Serif; margin: 0">The following table summarizes net revenues by geography for the years ended
December 31, 2022 and 2021:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_8BD_z3C9ZxreeIk3" style="display: none; visibility: hidden">Schedule of net revenues by geography</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 3.5in; border-collapse: collapse">
  <tr style="background-color: white">
    <td style="vertical-align: bottom; width: 93.35pt">&#160;</td>
    <td style="vertical-align: bottom; width: 8.3pt">&#160;</td>
    <td style="vertical-align: bottom; width: 8.25pt">&#160;</td>
    <td style="vertical-align: bottom; width: 53.4pt">&#160;</td>
    <td style="vertical-align: bottom; width: 18.05pt">&#160;</td>
    <td style="vertical-align: bottom; width: 8.25pt">&#160;</td>
    <td style="vertical-align: bottom; width: 54.15pt">&#160;</td>
    <td style="vertical-align: top; width: 8.25pt">&#160;</td></tr>
  <tr style="background-color: white">
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td colspan="5" style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: center"><b>Years Ended December 31,</b></td>
    <td style="vertical-align: top">&#160;</td></tr>
  <tr style="background-color: white">
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: center"><b>2022</b></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: center"><b>2021</b></td>
    <td style="vertical-align: top">&#160;</td></tr>
  <tr style="background-color: white">
    <td style="vertical-align: bottom"><b>Net Revenues</b></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top">&#160;</td></tr>
  <tr style="background-color: #E6E6E6">
    <td style="vertical-align: bottom; padding-left: 9.45pt">Domestic</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td>$</td>
    <td id="xdx_98D_eus-gaap--Revenues_c20220101__20221231__srt--StatementGeographicalAxis__country--US_zZ4uQjTcgfJc" style="text-align: right" title="Net Revenue">23,586,254</td>
    <td style="vertical-align: top">&#160;</td>
    <td>$</td>
    <td id="xdx_98C_eus-gaap--Revenues_c20210101__20211231__srt--StatementGeographicalAxis__country--US_zmQIeI78tUyl" style="text-align: right" title="Net Revenue">19,488,685</td>
    <td style="vertical-align: top">&#160;</td></tr>
  <tr style="background-color: white">
    <td style="vertical-align: bottom; padding-left: 9.45pt">International</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td id="xdx_987_eus-gaap--Revenues_c20220101__20221231__srt--StatementGeographicalAxis__us-gaap--NonUsMember_zfGG2aByPLz" style="border-bottom: black 1pt solid; text-align: right" title="Net Revenues">4,309,783</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td id="xdx_981_eus-gaap--Revenues_c20210101__20211231__srt--StatementGeographicalAxis__us-gaap--NonUsMember_zRtFKssVTgme" style="border-bottom: black 1pt solid; text-align: right" title="Net Revenues">4,001,490</td>
    <td style="vertical-align: top">&#160;</td></tr>
  <tr style="background-color: #E6E6E6">
    <td style="vertical-align: bottom"><b>Total</b></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td id="xdx_988_eus-gaap--Revenues_c20220101__20221231_zbAfS3LpNBGe" style="border-bottom: black 2.25pt double; text-align: right" title="Revenues">27,896,037</td>
    <td style="border-bottom: white 2.25pt double; vertical-align: top">&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td id="xdx_980_eus-gaap--Revenues_c20210101__20211231_zn8OKcUznKZg" style="border-bottom: black 2.25pt double; text-align: right" title="Revenues">23,490,175</td>
    <td style="vertical-align: top">&#160;</td></tr>
  </table>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krmd_ScheduleOfNetRevenuesByGeography">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krmd_ScheduleOfNetRevenuesByGeography</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of amortization expense of assets, excluding financial assets, that lack physical substance, having a limited useful life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139621731132880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INVENTORY (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Inventory consists of:</a></td>
<td class="text"><p id="xdx_892_eus-gaap--ScheduleOfInventoryCurrentTableTextBlock_zSfOlZuewx4c" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_8B5_zEiwQCi3QSQc">Inventory consists of:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 5.75in; border-collapse: collapse">
  <tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>December 31, 2022</b></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>December 31, 2021</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="width: 208.35pt">&#160;</td>
    <td style="width: 0.1in">&#160;</td>
    <td style="width: 8.25pt">&#160;</td>
    <td style="width: 79.7pt">&#160;</td>
    <td style="width: 14.3pt">&#160;</td>
    <td style="width: 7.5pt">&#160;</td>
    <td style="width: 80.45pt">&#160;</td>
    <td style="width: 8.25pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Raw materials and work-in-process</td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_98A_eus-gaap--InventoryWorkInProcessAndRawMaterials_iI_c20221231_zQs9SGHLFSIl" style="text-align: right" title="Raw materials and work-in-process">3,853,034</td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_98F_eus-gaap--InventoryWorkInProcessAndRawMaterials_iI_c20211231_zwPKqJbgVxHb" style="text-align: right" title="Raw materials and work-in-process">2,997,807</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td>Finished goods</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td id="xdx_981_eus-gaap--InventoryFinishedGoods_iI_c20221231_zCjgaLgmr7nf" style="border-bottom: black 1pt solid; text-align: right" title="Finished goods">2,611,951</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td id="xdx_98B_eus-gaap--InventoryFinishedGoods_iI_c20211231_z4OyKjNY8Aod" style="border-bottom: black 1pt solid; text-align: right" title="Finished goods">3,176,836</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td>&#160;&#160;&#160;Total</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_988_eus-gaap--InventoryGross_iI_c20221231_zNa94DcM4pi" style="text-align: right" title="Inventory, Gross">6,464,985</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_98B_eus-gaap--InventoryGross_iI_c20211231_zOtHtSUoLgv8" style="text-align: right" title="Inventory, Gross">6,174,643</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td>Less: reserve for obsolete inventory</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td id="xdx_98A_eus-gaap--InventoryValuationReserves_iNI_di_c20221231_zw26NTqXKrF8" style="border-bottom: black 1pt solid; text-align: right" title="Less: reserve for obsolete inventory">(60,118</td>
    <td>)</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td id="xdx_985_eus-gaap--InventoryValuationReserves_iNI_di_c20211231_z65Ll2xB7sj7" style="border-bottom: black 1pt solid; text-align: right">(68,305</td>
    <td>)</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Inventory, net</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td id="xdx_983_eus-gaap--InventoryNet_iI_c20221231_zTtndi3ifpb8" style="border-bottom: black 2.25pt double; text-align: right" title="Inventory">6,404,867</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td id="xdx_98A_eus-gaap--InventoryNet_iI_c20211231_zgsk9QWKuCD" style="border-bottom: black 2.25pt double; text-align: right" title="Inventory">6,106,338</td>
    <td>&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139621731138480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PROPERTY AND EQUIPMENT (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of property and equipment</a></td>
<td class="text"><p id="xdx_895_eus-gaap--PropertyPlantAndEquipmentTextBlock_zaoyxblUiHw7" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span>Property and equipment consists of the following at:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_8BD_zWKiA8IJzf19" style="display: none; visibility: hidden">Schedule of property and equipment</span>&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 5.75in; border-collapse: collapse">
  <tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>December 31, 2022</b></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>December 31, 2021</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td style="width: 203.85pt">&#160;</td>
    <td style="width: 0.1in">&#160;</td>
    <td style="width: 8.25pt">&#160;</td>
    <td style="width: 79.7pt">&#160;</td>
    <td style="width: 14.3pt">&#160;</td>
    <td style="width: 8.25pt">&#160;</td>
    <td style="width: 79.7pt">&#160;</td>
    <td style="width: 8.25pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Furniture and office equipment</td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_98A_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--FurnitureAndOfficeEquipmentMember_zWHnBNx3xFe5" style="text-align: right">1,456,745</td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_987_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20211231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--FurnitureAndOfficeEquipmentMember_zECbEcrxcYZa" style="text-align: right">818,897</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Leasehold improvements</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_984_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zW5Uhbm2OpUg" style="text-align: right">2,413,820</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_984_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20211231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zUBg8Aip0597" style="text-align: right">556,907</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Manufacturing equipment and tooling</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td id="xdx_98C_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ManufacturingEquipmentAndToolingMember_zT0quWrrXv3" style="border-bottom: black 1pt solid; text-align: right">2,810,813</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td id="xdx_988_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20211231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ManufacturingEquipmentAndToolingMember_zNTYU2zCQITe" style="border-bottom: black 1pt solid; text-align: right">2,042,675</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;&#160;&#160;Total property and equipment</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_98C_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20221231_zZxEzqn5ixH1" style="text-align: right" title="Total property and equipment">6,681,378</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_983_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20211231_zR6JnYT1Bkpa" style="text-align: right" title="Total property and equipment">3,418,479</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Less: accumulated depreciation and amortization</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td id="xdx_989_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_di_c20221231_zELaZxCyfw6b" style="border-bottom: black 1pt solid; text-align: right" title="Less: accumulated depreciation and amortization">(2,794,403</td>
    <td>)</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td id="xdx_98B_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_di_c20211231_zfIeWTTvng2a" style="border-bottom: black 1pt solid; text-align: right" title="Less: accumulated depreciation and amortization">(2,312,034</td>
    <td>)</td></tr>
  <tr style="vertical-align: bottom">
    <td>Property and equipment, net</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td id="xdx_985_eus-gaap--PropertyPlantAndEquipmentNet_iI_dxL_c20221231_zTlhecAMheBg" style="border-bottom: black 2.25pt double; text-align: right" title="Property and equipment, net::XDX::3886975"><span style="-sec-ix-hidden: xdx2ixbrl0640">3,886,975</span></td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td id="xdx_989_eus-gaap--PropertyPlantAndEquipmentNet_iI_c20211231_zsbI0O4sKC4e" style="border-bottom: black 2.25pt double; text-align: right" title="Property and equipment, net">1,106,445</td>
    <td>&#160;</td></tr>
  </table>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139621726734704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK-BASED COMPENSATION (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of time based stock options</a></td>
<td class="text"><p id="xdx_898_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zMJTgRo09HFf" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_8B3_zNIQLyoNSWk4" style="display: none; visibility: hidden">Schedule of time based stock options</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 5.25in; border-collapse: collapse">
  <tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>December 31, 2022</b></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>December 31, 2021</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td style="width: 161.1pt">&#160;</td>
    <td style="width: 9.75pt">&#160;</td>
    <td style="width: 7.25pt">&#160;</td>
    <td style="width: 89.15pt">&#160;</td>
    <td style="width: 10.55pt">&#160;</td>
    <td style="width: 9.05pt">&#160;</td>
    <td style="width: 82.85pt">&#160;</td>
    <td style="width: 8.3pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Dividend yield</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_z9I9JarWYZVl" title="Dividend yield">0.00</span>%</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20210101__20211231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zwjPMQzkzhQc" title="Dividend yield">0.00</span>%</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td>Expected volatility</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember__srt--RangeAxis__srt--MinimumMember_z6mvehlaByMj">65.29</span>% &#8211; <span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember__srt--RangeAxis__srt--MaximumMember_zGJbo5iW8TI1">77.5</span>%</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20210101__20211231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember__srt--RangeAxis__srt--MinimumMember_zfzDfqq1wrRf">74.01</span> &#8211; <span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20210101__20211231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember__srt--RangeAxis__srt--MaximumMember_zKyuNYz9KZ8h">77.91</span>%</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Weighted-average volatility</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_pid_dp0_uPure_c20220101__20221231_zlXJAsd0BLe" title="Weighted-average volatility">&#8212;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_pid_dp_uPure_c20210101__20211231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zFG8DozU7zW4" title="Weighted-average volatility"><span style="-sec-ix-hidden: xdx2ixbrl0697">&#8212;</span></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td>Expected dividends</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments_d0_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zs1BAQmLx361" title="Expected dividends">&#8212;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments_d0_c20210101__20211231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zAH1DVyaDcb6" title="Expected dividends">&#8212;</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Expected term (in years)</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dxL_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_ztG1LJY5HuX" title="Expected term (in years)::XDX::P10Y"><span style="-sec-ix-hidden: xdx2ixbrl0703">10</span></span> Years</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dxL_c20210101__20211231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zn7GgykVhqw7" title="Expected term (in years)::XDX::P10Y"><span style="-sec-ix-hidden: xdx2ixbrl0705">10</span></span> Years</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td>Risk-free rate</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember__srt--RangeAxis__srt--MinimumMember_zhBrKaFMEtph" title="Risk-free rate">1.81</span> &#8211; <span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember__srt--RangeAxis__srt--MaximumMember_zc1gVFzsSI62" title="Risk-free rate">4.02</span>%</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20210101__20211231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember__srt--RangeAxis__srt--MinimumMember_zCY0GYklx5Sl" title="Risk-free rate">1.20</span> &#8211; <span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20210101__20211231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember__srt--RangeAxis__srt--MaximumMember_zZufVf0If4Ui" title="Risk-free rate">1.62</span>%</td>
    <td>&#160;</td></tr>
  </table>
<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of status of time based stock options</a></td>
<td class="text"><p id="xdx_899_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_z1TmxFWsn1u9" style="font: 10pt Times New Roman, Times, Serif; margin: 0">The following table summarizes the status of the Company&#8217;s stock
option plan:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_8B4_z3SmpQTP4fk1" style="display: none; visibility: hidden">Schedule of status of time based stock options</span>&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 7.5in; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="5" style="border-bottom: black 1pt solid; text-align: center"><b>December 31, 2022</b></td>
    <td>&#160;</td>
    <td colspan="5" style="border-bottom: black 1pt solid; text-align: center"><b>December 31, 2021</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>Shares</b></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>Weighted<br/>
Average<br/>
Exercise<br/>
Price</b></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>Shares</b></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>Weighted<br/>
Average<br/>
Exercise<br/>
Price</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="width: 273.25pt">Outstanding at January 1</td>
    <td style="width: 0.1in">&#160;</td>
    <td style="width: 0.1in">&#160;</td>
    <td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_uShares_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zO2vPnRHQxz" style="width: 49.5pt; text-align: right" title="Outstanding at beginning">3,672,500</td>
    <td style="width: 11.3pt">&#160;</td>
    <td style="width: 9.75pt">$</td>
    <td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_uUSDPShares_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zG4oARPUgMA1" style="width: 43.8pt; text-align: right" title="Outstanding at beginning">3.42</td>
    <td style="width: 11.3pt">&#160;</td>
    <td style="width: 0.1in">&#160;</td>
    <td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_uShares_c20210101__20211231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zlSM4Nm3iOT6" style="width: 48.75pt; text-align: right">2,922,494</td>
    <td style="width: 11.3pt">&#160;</td>
    <td style="width: 7.5pt">$</td>
    <td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_uUSDPShares_c20210101__20211231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zACFEiklGXXj" style="width: 43.8pt; text-align: right" title="Outstanding at beginning">2.46</td>
    <td style="width: 7.25pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Granted</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_uShares_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_z2exdIa3IfIg" style="text-align: right" title="Granted">445,000</td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_uUSDPShares_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zM61B6j8h4rd" style="text-align: right" title="Granted">2.57</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_uShares_c20210101__20211231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zAtBDtQDZi9f" style="text-align: right">2,000,000</td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_uUSDPShares_c20210101__20211231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zaDavxuGXPuj" style="text-align: right" title="Granted">3.64</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Exercised</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_98C_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pid_uShares_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zRSnnZVL4Ky" style="text-align: right" title="Exercised">1,031,250</td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_uUSDPShares_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zw3P2KzfQM26" style="text-align: right" title="Exercised">1.57</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_989_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pid_uShares_c20210101__20211231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zy56Oc1yEai" style="text-align: right">1,062,500</td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_uUSDPShares_c20210101__20211231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zGPwU22jiHA2" style="text-align: right" title="Exercised">1.19</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Forfeited</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_pid_uShares_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zZUUVkZxAPQ1" style="text-align: right" title="Forfeited">526,250</td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_uUSDPShares_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zBhDcTK1lSae" style="text-align: right" title="Forfeited">2.73</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_pid_uShares_c20210101__20211231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zyrwK7iZFf47" style="text-align: right">187,494</td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_uUSDPShares_c20210101__20211231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zM5BVIvfBCm1" style="text-align: right">3.36</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Outstanding at year end</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_uShares_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zSQ0QcHFXhTi" style="text-align: right" title="Outstanding at ending">2,560,000</td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_uUSDPShares_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zdvsy8XZx6q8" style="text-align: right" title="Outstanding at ending">4.15</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_uShares_c20210101__20211231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zIHVknGiXgH6" style="text-align: right">3,672,500</td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_uUSDPShares_c20210101__20211231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zFOcStvlapl5" style="text-align: right" title="Outstanding at ending">3.42</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Options exercisable</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pid_uShares_c20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zOhbICZVlq04" style="text-align: right" title="Options exercisable">737,500</td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_pid_uUSDPShares_c20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zUJmsNslmS74" style="text-align: right" title="Options exercisable">4.93</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pid_uShares_c20211231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zyPqqxDV8A6k" style="text-align: right">983,750</td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_pid_uUSDPShares_c20211231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zqxiXWdfvja3" style="text-align: right">2.73</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="padding-left: 19.05pt; text-indent: -19.05pt">Weighted average fair value of options granted during the period</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#8212;</td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_uUSDPShares_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zjy3QMIiTGn2" style="text-align: right" title="Weighted average fair value of options granted during the period">1.98</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#8212;</td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_uUSDPShares_c20210101__20211231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zJ7nUsbGN3G5" style="text-align: right" title="Weighted average fair value of options granted during the period">2.85</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Stock-based compensation expense</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#8212;</td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_980_eus-gaap--AllocatedShareBasedCompensationExpense_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zfLR5zcx3wL6" style="text-align: right" title="Stock-based compensation expense">1,925,861</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#8212;</td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_982_eus-gaap--AllocatedShareBasedCompensationExpense_c20210101__20211231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zrV2bdvx9Ojb" style="text-align: right" title="Stock-based compensation expense">2,457,788</td>
    <td>&#160;</td></tr>
  </table>
<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krmd_ScheduleOfShareBasedCompensationStockOptionsActivityAmendedTableTextBlock', window );">Schedule of information pertaining to options outstanding</a></td>
<td class="text"><p id="xdx_89D_ecustom--ScheduleOfShareBasedCompensationStockOptionsActivityAmendedTableTextBlock_zz8RJ2Ki4uS8" style="font: 10pt Times New Roman, Times, Serif; margin: 0">The following table presents information pertaining to options outstanding
as of December 31, 2022:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_8B3_zdHY4FCcHVjd" style="display: none; visibility: hidden">Schedule of information pertaining to options outstanding</span>&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 7.5in; border-collapse: collapse">
  <tr style="vertical-align: bottom; background-color: white">
    <td style="border-bottom: black 1pt solid"><b>Range of Exercise Price</b></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: center"><b>Number<br/>
Outstanding</b></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: center"><b>Weighted<br/>
Average<br/>
Remaining<br/>
Contractual<br/>
Life</b></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>Weighted<br/>
Average<br/>
Exercise<br/>
Price</b></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: center"><b>Number<br/>
Exercisable</b></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>Weighted<br/>
Average<br/>
Exercise<br/>
Price</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td style="width: 131.2pt">&#160;</td>
    <td style="width: 8.25pt">&#160;</td>
    <td style="width: 64.85pt">&#160;</td>
    <td style="width: 14.35pt">&#160;</td>
    <td style="width: 64.85pt">&#160;</td>
    <td style="width: 13.6pt">&#160;</td>
    <td style="width: 7.5pt">&#160;</td>
    <td style="width: 63pt">&#160;</td>
    <td style="width: 13.6pt">&#160;</td>
    <td style="width: 64.85pt">&#160;</td>
    <td style="width: 14.35pt">&#160;</td>
    <td style="width: 8.25pt">&#160;</td>
    <td style="width: 63pt">&#160;</td>
    <td style="width: 7.55pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td>$2.25 - $9.49</td>
    <td>&#160;</td>
    <td id="xdx_985_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pid_uShares_c20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice1Member_zE9AiaUVP7N1" style="text-align: right" title="Number outstanding">2,560,000</td>
    <td>&#160;</td>
    <td style="text-align: center"><span id="xdx_906_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dxL_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice1Member_zm6fxm2yXdlj" title="Weighted average remaining contractual life::XDX::P8Y9M18D"><span style="-sec-ix-hidden: xdx2ixbrl0782">8.8</span></span> years</td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_988_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pid_uUSDPShares_c20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice1Member_ze4YPaf8jUGe" style="text-align: right" title="Weighted average exercise price">4.15</td>
    <td>&#160;</td>
    <td id="xdx_98A_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_uShares_c20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice1Member_zVzOB3aHfG61" style="text-align: right" title="Number exercisable">737,500</td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_98F_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_pid_uUSDPShares_c20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice1Member_z1agaJApbVVc" style="text-align: right" title="Weighted average exercise price">4.93</td>
    <td>&#160;</td></tr>
  </table>
<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock', window );">Schedule of time based stock options</a></td>
<td class="text"><p id="xdx_893_eus-gaap--ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_z1c7sldhvJtd" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span><span id="xdx_8B8_zmgyVB3Zl42e" style="display: none; visibility: hidden">Schedule of time based stock options</span>&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 4.5in; border-collapse: collapse">
  <tr>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="5" style="border-bottom: black 1pt solid; text-align: center"><b>December 31,</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>2022</b></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>2021</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="width: 136.7pt">&#160;</td>
    <td style="width: 0.1in">&#160;</td>
    <td style="width: 0.1in">&#160;</td>
    <td style="width: 71.6pt">&#160;</td>
    <td style="width: 14.25pt">&#160;</td>
    <td style="width: 0.1in">&#160;</td>
    <td style="width: 72.35pt">&#160;</td>
    <td style="width: 7.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Dividend yield</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zJwoESfRyAab" title="Dividend yield">0.00</span>%</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zhWeaToWIlj8" title="Dividend yield">0.00</span>%</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Expected Volatility</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zlzsSWsvcP8k" title="Expected volatility">65.9</span>%</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20210101__20211231__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember__srt--RangeAxis__srt--MinimumMember_zUmPwsUZYfZd">0</span>% &#8211; <span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember__srt--RangeAxis__srt--MaximumMember_zTwmV5AIzBm2" title="Expected volatility">0</span>%</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Weighted-average volatility</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_pid_dp_uPure_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zbPtw0LX5FZ7" title="Weighted-average volatility"><span style="-sec-ix-hidden: xdx2ixbrl0817">&#8212;</span></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_pid_dp_uPure_c20210101__20211231__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zdGMNi9skWj6" title="Weighted-average volatility"><span style="-sec-ix-hidden: xdx2ixbrl0819">&#8212;</span></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Expected dividends</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments_d0_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_z50YwJiVy8o3" title="Expected dividends">&#8212;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments_c20210101__20211231__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_z28VpsVDQRCc" title="Expected dividends"><span style="-sec-ix-hidden: xdx2ixbrl0823">&#8212;</span></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Expected term (in years)</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dxL_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_ziwAuYv74Xbh" title="Expected term (in years)::XDX::P10Y"><span style="-sec-ix-hidden: xdx2ixbrl0825">10</span></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dxL_c20210101__20211231__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zLo14Du90Qd" title="Expected term (in years)::XDX::P0Y"><span style="-sec-ix-hidden: xdx2ixbrl0827">0</span></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Risk-free rate</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zVSeOdzf4oMf" title="Risk-free rate">2.99</span>%</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20210101__20211231__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember__srt--RangeAxis__srt--MinimumMember_zaFr9qzZvIm9" title="Risk-free rate">0</span>% &#8211; <span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20210101__20211231__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember__srt--RangeAxis__srt--MinimumMember_zB2vYAeILLq4" title="Risk-free rate">0</span>%</td>
    <td>&#160;</td></tr>
  </table>
<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfOtherShareBasedCompensationActivityTableTextBlock', window );">Schedule of status of time based stock options</a></td>
<td class="text"><p id="xdx_890_eus-gaap--ScheduleOfOtherShareBasedCompensationActivityTableTextBlock_zgKL1plP0rec" style="font: 10pt Times New Roman, Times, Serif; margin: 0">The following table summarizes the status of the 2021 Plan with respect
to time based stock options:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_8BA_zduzcPjGX2fi" style="display: none; visibility: hidden">Schedule of status of time based stock options</span>&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 7.5in; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="10" style="border-bottom: black 1pt solid; text-align: center"><b>Year Ended December 31,</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="4" style="border-bottom: black 1pt solid; text-align: center"><b>2022</b></td>
    <td>&#160;</td>
    <td colspan="5" style="border-bottom: black 1pt solid; text-align: center"><b>2021</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: center"><b>Shares</b></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>Weighted<br/>
Average<br/>
Exercise<br/>
Price</b></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>Shares</b></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>Weighted<br/>
Average<br/>
Exercise<br/>
Price</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="width: 264.6pt">Outstanding at January 1</td>
    <td style="width: 0.1in">&#160;</td>
    <td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber2_iS_pid_uShares_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zJn084UMm3Hb" style="width: 49.2pt; text-align: right" title="Outstanding at beginning">0</td>
    <td style="width: 0.2in">&#160;</td>
    <td style="width: 0.1in">$</td>
    <td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice2_iS_pid_uUSDPShares_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zdyPJ6msQb84" style="width: 49.15pt; text-align: right" title="Outstanding at beginning">0</td>
    <td style="width: 14.7pt">&#160;</td>
    <td style="width: 0.1in">&#160;</td>
    <td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber2_iS_pid_uShares_c20210101__20211231__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zBv9XV56t6of" style="width: 48.85pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0840">&#8212;</span></td>
    <td style="width: 14.55pt">&#160;</td>
    <td style="width: 0.1in">$</td>
    <td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice2_iS_pid_uUSDPShares_c20210101__20211231__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zw2MZhDPuTi2" style="width: 48.55pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0841">&#8212;</span></td>
    <td style="width: 0.1in">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Granted</td>
    <td>&#160;</td>
    <td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross2_pid_uShares_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zUhpTJ7MfqGa" style="text-align: right" title="Granted">475,000</td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_984_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice2_pid_uUSDPShares_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_z4finuiR92Wl" style="text-align: right" title="Granted">2.67</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross2_pid_uShares_c20210101__20211231__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zXjFEbRNUM6g" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0846">&#8212;</span></td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_98E_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice2_pid_uUSDPShares_c20210101__20211231__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_ztMaUpOvkv6g" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0847">&#8212;</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Exercised</td>
    <td>&#160;</td>
    <td id="xdx_989_ecustom--StockIssuedDuringPeriodSharesStockOptionsExercised2_pid_uShares_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zQLVCQI05zL1" style="text-align: right" title="Exercised">0</td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_980_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice2_pid_uUSDPShares_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zpglE3WdXyxa" style="text-align: right" title="Exercised"><span style="-sec-ix-hidden: xdx2ixbrl0851">&#8212;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_980_ecustom--StockIssuedDuringPeriodSharesStockOptionsExercised2_pid_uShares_c20210101__20211231__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zzU0EQfxTLNb" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0852">&#8212;</span></td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_985_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice2_pid_uUSDPShares_c20210101__20211231__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zfke8nRT0Ql6" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0853">&#8212;</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Forfeited</td>
    <td>&#160;</td>
    <td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod2_pid_uShares_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zud5mcwUwd5f" style="text-align: right" title="Forfeited">0</td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_981_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice2_pid_uUSDPShares_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zFTArLr4LvO" style="text-align: right" title="Forfeited"><span style="-sec-ix-hidden: xdx2ixbrl0857">&#8212;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod2_pid_uShares_c20210101__20211231__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_ztP0z42eq7g6" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0858">&#8212;</span></td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_98C_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice2_pid_uUSDPShares_c20210101__20211231__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zJtGJk5gjWid" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0859">&#8212;</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Outstanding at year end</td>
    <td>&#160;</td>
    <td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber2_iE_pid_uShares_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zzSNeNun6ka7" style="text-align: right" title="Outstanding at ending">475,000</td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice2_iE_pid_uUSDPShares_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_z9U1aKMLdD7k" style="text-align: right" title="Outstanding at ending">2.67</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber2_iE_pid_d0_uShares_c20210101__20211231__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_z3TSrOrdfbhd" style="text-align: right">&#8212;</td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice2_iE_pid_d0_uUSDPShares_c20210101__20211231__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_z25ZkGVljTM7" style="text-align: right">&#8212;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Options exercisable</td>
    <td>&#160;</td>
    <td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pid_uShares_c20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zEmdFXL5jX8k" style="text-align: right" title="Options exercisable at ending">0</td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_984_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice2_iI_pid_uUSDPShares_c20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zPUtOEBvfuQk" style="text-align: right" title="Options exercisable at ending"><span style="-sec-ix-hidden: xdx2ixbrl0869">&#8212;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pid_uShares_c20211231__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zurkgefKQTu8" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0870">&#8212;</span></td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_982_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice2_iI_pid_uUSDPShares_c20211231__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zkcGJynuGkA" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0871">&#8212;</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="padding-left: 0.1in; text-indent: -0.1in">Weighted average fair value of options granted during the period</td>
    <td>&#160;</td>
    <td style="text-align: right">&#8212;</td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue2_pid_uUSDPShares_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zPiZtEGtaR89" style="text-align: right" title="Weighted average fair value of options granted during the period">1.99</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#8212;</td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue2_pid_uUSDPShares_c20210101__20211231__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zg2K9XA8FE8k" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0874">&#8212;</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Stock-based compensation expense</td>
    <td>&#160;</td>
    <td style="text-align: right">&#8212;</td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_98C_eus-gaap--ShareBasedCompensation_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zMR0a556MYe4" style="text-align: right" title="Stock-based compensation expense">157,536</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#8212;</td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_98B_eus-gaap--ShareBasedCompensation_c20210101__20211231__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zhI0JtDcVzbl" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0877">&#8212;</span></td>
    <td>&#160;</td></tr>
  </table>
<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krmd_ScheduleOfShareBasedCompensationtaxBenefitsAssociatedWithRestrictedStockAwardCompensationTableTextBlock', window );">Schedule of information pertaining to options outstanding</a></td>
<td class="text"><p id="xdx_893_ecustom--ScheduleOfShareBasedCompensationtaxBenefitsAssociatedWithRestrictedStockAwardCompensationTableTextBlock_zPKPQIQxyncf" style="font: 10pt Times New Roman, Times, Serif; margin: 0">The following table presents information pertaining to options outstanding
at December 31, 2022:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_8B1_zPPZmpjvZHPa" style="display: none; visibility: hidden">Schedule of information pertaining to options outstanding</span>&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 7.5in; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: black 1pt solid"><b>Range of Exercise Price</b></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: center"><b>Number<br/>
Outstanding</b></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: center"><b>Weighted<br/>
Average<br/>
Remaining<br/>
Contractual<br/>
Life</b></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>Weighted<br/>
Average<br/>
Exercise<br/>
Price</b></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: center"><b>Number<br/>
Exercisable</b></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>Weighted<br/>
Average<br/>
Exercise<br/>
Price</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="width: 131.2pt">&#160;</td>
    <td style="width: 8.25pt">&#160;</td>
    <td style="width: 64.85pt">&#160;</td>
    <td style="width: 14.35pt">&#160;</td>
    <td style="width: 64.85pt">&#160;</td>
    <td style="width: 13.6pt">&#160;</td>
    <td style="width: 7.55pt">&#160;</td>
    <td style="width: 63.35pt">&#160;</td>
    <td style="width: 13.6pt">&#160;</td>
    <td style="width: 64.85pt">&#160;</td>
    <td style="width: 14.35pt">&#160;</td>
    <td style="width: 8.3pt">&#160;</td>
    <td style="width: 55.8pt">&#160;</td>
    <td style="width: 15.1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td>$2.67</td>
    <td>&#160;</td>
    <td id="xdx_98B_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pid_uShares_c20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice1Member_zsRCclyBqdal" style="text-align: right" title="Number outstanding">475,000</td>
    <td>&#160;</td>
    <td style="text-align: center"><span id="xdx_90A_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dxL_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice1Member_zXOIgQYORYWa" title="Weighted average remaining contractual life::XDX::P9Y3M19D"><span style="-sec-ix-hidden: xdx2ixbrl0891">9.3</span></span> years</td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_98F_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_c20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice1Member_zpulwXJjCC2j" style="text-align: center" title="Weighted average exercise price">2.67</td>
    <td>&#160;</td>
    <td id="xdx_984_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_uShares_c20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice1Member_zWpe3SyNSA6a" style="text-align: right" title="Number exercisable">0</td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_982_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_pid_uUSDPShares_c20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice1Member_z3h6UfDDpwme" style="text-align: right" title="Weighted average exercise price">0</td>
    <td>&#160;</td></tr>
  </table>
<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock', window );">Schedule of performance base options outstanding</a></td>
<td class="text"><p id="xdx_89A_eus-gaap--ShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock_ziaATDPStcpg" style="font: 10pt Times New Roman, Times, Serif; margin: 0">The following table summarizes the status of the 2015 Plan with respect
to performance-based stock options as of December 31, 2022 and 2021:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_8B0_zFmIDLEsG1N" style="display: none; visibility: hidden">Schedule of performance base options outstanding</span>&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 7.5in; border-collapse: collapse">
  <tr style="background-color: white">
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td colspan="4" style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: center"><b>December 31, 2022</b></td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td colspan="5" style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: center"><b>December 31, 2021</b></td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr style="background-color: white">
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: center"><b>Shares</b></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: center"><b>Weighted<br/>
Average<br/>
Exercise<br/>
Price</b></td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: center"><b>Shares</b></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: center"><b>Weighted<br/>
Average<br/>
Exercise<br/>
Price</b></td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr style="background-color: white">
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr style="background-color: #E6E6E6">
    <td style="vertical-align: bottom; width: 257.75pt">Outstanding at January 1</td>
    <td style="vertical-align: bottom; width: 7.15pt">&#160;</td>
    <td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber1_iS_pid_dxL_uShares_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_z0M2W59pO8fk" style="vertical-align: bottom; width: 47.8pt; text-align: right" title="Outstanding at beginning::XDX::1000000"><b style="display: none; visibility: hidden"><span style="-sec-ix-hidden: xdx2ixbrl0910">&#8212;</span></b></td>
    <td style="vertical-align: bottom; width: 15.15pt">&#160;</td>
    <td style="vertical-align: bottom; width: 0.1in">$</td>
    <td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice1_iS_pid_dxL_uUSDPShares_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zz6GEJl9i7X2" style="vertical-align: bottom; width: 48.5pt; text-align: right" title="Outstanding at beginning::XDX::1.70"><b style="display: none; visibility: hidden"><span style="-sec-ix-hidden: xdx2ixbrl0912">&#8212;</span></b></td>
    <td style="vertical-align: top; width: 12.9pt">&#160;</td>
    <td style="vertical-align: bottom; width: 12.95pt">&#160;</td>
    <td style="vertical-align: bottom; width: 0.1in">&#160;</td>
    <td id="xdx_982_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber1_iS_pid_uShares_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zNrjDxCN5cw6" style="vertical-align: bottom; width: 48pt; text-align: right" title="Outstanding at beginning">1,000,000</td>
    <td style="vertical-align: bottom; width: 11.55pt">&#160;</td>
    <td style="vertical-align: bottom; width: 0.1in">$</td>
    <td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice1_iS_pid_uUSDPShares_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zv9YzAaCKyV2" style="vertical-align: bottom; width: 49.95pt; text-align: right">1.70</td>
    <td style="vertical-align: bottom; width: 7.15pt">&#160;</td></tr>
  <tr style="background-color: white">
    <td style="vertical-align: bottom">Granted</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross1_pid_d0_uShares_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_znMigeF3Cy4c" style="vertical-align: bottom; text-align: right" title="Granted">&#8212;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">$</td>
    <td id="xdx_980_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice1_pid_d0_uUSDPShares_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zw1sSZzmgc77" style="vertical-align: bottom; text-align: right" title="Granted">&#8212;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross1_pid_d0_uShares_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zajKijFVkUp7" style="vertical-align: bottom; text-align: right">&#8212;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top">$</td>
    <td id="xdx_98B_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice1_pid_d0_uUSDPShares_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zQMolxBiscE7" style="vertical-align: bottom; text-align: right">&#8212;</td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr style="background-color: #E6E6E6">
    <td style="vertical-align: bottom">Exercised</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td id="xdx_989_ecustom--StockIssuedDuringPeriodSharesStockOptionsExercised1_pid_d0_uShares_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_z8CXWSE0Ujvh" style="vertical-align: bottom; text-align: right" title="Exercised">&#8212;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">$</td>
    <td id="xdx_98B_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice1_pid_d0_uUSDPShares_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zKoVOB1QkUB5" style="vertical-align: bottom; text-align: right" title="Exercised">&#8212;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td id="xdx_980_ecustom--StockIssuedDuringPeriodSharesStockOptionsExercised1_pid_d0_uShares_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zFYgOcOG6Jl" style="vertical-align: bottom; text-align: right">&#8212;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top">$</td>
    <td id="xdx_98E_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice1_pid_d0_uUSDPShares_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zNZK1HJv0i7" style="vertical-align: bottom; text-align: right">&#8212;</td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr style="background-color: white">
    <td style="vertical-align: bottom">Forfeited</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod1_pid_d0_uShares_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zsEACKSpxZni" style="vertical-align: bottom; text-align: right" title="Forfeited">&#8212;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">$</td>
    <td id="xdx_982_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice1_pid_d0_uUSDPShares_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zpMOG22IlwOk" style="vertical-align: bottom; text-align: right" title="Forfeited">&#8212;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td id="xdx_984_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod1_pid_d0_uShares_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zD9qTNpJmza" style="vertical-align: bottom; text-align: right">&#8212;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top">$</td>
    <td id="xdx_988_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice1_pid_d0_uUSDPShares_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zMbPSxP2Exd" style="vertical-align: bottom; text-align: right">&#8212;</td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr style="background-color: #E6E6E6">
    <td style="vertical-align: bottom">Outstanding at year end</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_d0_uShares_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zyKbhzgvNtke" style="vertical-align: bottom; text-align: right" title="Outstanding at ending">&#8212;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">$</td>
    <td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_d0_uUSDPShares_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zfZBqFlaW2Oc" style="vertical-align: bottom; text-align: right" title="Outstanding at ending">&#8212;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_uShares_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zgDB6RDXRAB5" style="vertical-align: bottom; text-align: right">1,000,000</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">$</td>
    <td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_uUSDPShares_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zm1JZlstwHTg" style="vertical-align: bottom; text-align: right">1.70</td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr style="background-color: white">
    <td style="vertical-align: bottom">Options exercisable</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross1_pid_d0_uShares_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zjmL7oDnQJf" style="vertical-align: bottom; text-align: right" title="Options exercisable at ending">&#8212;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">$</td>
    <td id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice1_iI_pid_d0_uUSDPShares_c20221231__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zhqy6DeuJT83" style="vertical-align: bottom; text-align: right" title="Options exercisable at ending">&#8212;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross1_pid_d0_uShares_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zOE2NUXibFT7" style="vertical-align: bottom; text-align: right">&#8212;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">$</td>
    <td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice1_iI_pid_d0_uUSDPShares_c20211231__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zQkYAvK8aRva" style="vertical-align: bottom; text-align: right">&#8212;</td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr style="background-color: #E6E6E6">
    <td style="vertical-align: bottom; padding-left: 7.4pt; text-indent: -7.4pt">Weighted average fair value of options granted during the period</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_d0_uShares_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zcmhAcGr65Dg" style="vertical-align: bottom; text-align: right" title="Weighted average fair value of options granted during the period">&#8212;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">$</td>
    <td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue1_pid_d0_uUSDPShares_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zLfM1tdYCCYj" style="vertical-align: bottom; text-align: right" title="Weighted average fair value of options granted during the period">&#8212;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_d0_uShares_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zTRtxzr0EcSj" style="vertical-align: bottom; text-align: right">&#8212;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">$</td>
    <td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue1_pid_d0_uUSDPShares_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zkU8GGqbg8be" style="vertical-align: bottom; text-align: right">&#8212;</td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr style="background-color: white">
    <td style="vertical-align: bottom">Stock-based compensation expense</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right">&#8212;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">$</td>
    <td id="xdx_98F_ecustom--AllocatedShareBasedCompensationExpense1_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zqjwJjn6fyn5" style="vertical-align: bottom; text-align: right" title="Stock-based compensation expense"><span style="-sec-ix-hidden: xdx2ixbrl0953">&#8212;</span></td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right">&#8212;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">$</td>
    <td id="xdx_98E_ecustom--AllocatedShareBasedCompensationExpense1_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_z665Xj26ZrH" style="vertical-align: bottom; text-align: right" title="Stock-based compensation expense">(408,747</td>
    <td style="vertical-align: bottom">)</td></tr>
  </table>
<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock', window );">The following table summarizes the activities for our unvested restricted stock awards for the twelve months ended December 31, 2022, and 2021.</a></td>
<td class="text"><p id="xdx_890_eus-gaap--ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock_zpEioGXC9xR6" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_8B5_zCprAPbF5XI5" style="display: none; visibility: hidden">The following table summarizes the activities for our unvested
restricted stock awards for the twelve months ended December 31, 2022, and 2021.</span>&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 7.5in; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="9" style="border-bottom: black 1pt solid; text-align: center"><b>Twelve Months Ended December 31,</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="4" style="border-bottom: black 1pt solid; text-align: center"><b>2022</b></td>
    <td>&#160;</td>
    <td colspan="4" style="border-bottom: black 1pt solid; text-align: center"><b>2021</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: center"><b>Shares</b></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>Weighted<br/>
Average<br/>
Grant-Date Fair Value</b></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: center"><b>Shares</b></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>Weighted<br/>
Average<br/>
Grant-Date Fair Value</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="width: 201.15pt">Unvested at January 1</td>
    <td style="width: 9.65pt">&#160;</td>
    <td id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberUnvested_iS_pid_uShares_c20220101__20221231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zhacb022pAR" style="width: 53.1pt; text-align: right" title="Outstanding at beginning">1,000,000</td>
    <td style="width: 11pt">&#160;</td>
    <td style="width: 17.4pt">$</td>
    <td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceUnvested_iS_pid_uUSDPShares_c20220101__20221231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zKfcDQ74lxb8" style="width: 72.75pt; text-align: right" title="Outstanding at beginning">3.01</td>
    <td style="width: 11pt">&#160;</td>
    <td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberUnvested_iS_pid_uShares_c20210101__20211231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zMTMI0RJsFsg" style="width: 54.75pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0970">&#8212;</span></td>
    <td style="width: 11.35pt">&#160;</td>
    <td style="width: 16.9pt">$</td>
    <td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceUnvested_iS_pid_uUSDPShares_c20210101__20211231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_z8pULxd4p7f9" style="width: 73.25pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0971">&#8212;</span></td>
    <td style="width: 8pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Granted</td>
    <td>&#160;</td>
    <td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrossUnvested_pid_uShares_c20220101__20221231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_ztlm5zGVoigh" style="text-align: right" title="Granted"><span style="-sec-ix-hidden: xdx2ixbrl0973">&#8212;</span></td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_982_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePriceUnvested_pid_uUSDPShares_c20220101__20221231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_z3Ak3vyzIfta" style="text-align: right" title="Granted"><span style="-sec-ix-hidden: xdx2ixbrl0975">&#8212;</span></td>
    <td>&#160;</td>
    <td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrossUnvested_pid_uShares_c20210101__20211231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zWfQXlJPCfea" style="text-align: right">1,000,000</td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_98C_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePriceUnvested_pid_uUSDPShares_c20210101__20211231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zQmCl6uVkqmf" style="text-align: right">3.01</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Vested</td>
    <td>&#160;</td>
    <td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodGross_pid_uShares_c20220101__20221231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zu2SxkYyxad1" style="text-align: right" title="Vested">50,000</td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_984_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice_pid_uUSDPShares_c20220101__20221231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_z6jQd1eofYIj" style="text-align: right" title="Vested">3.31</td>
    <td>&#160;</td>
    <td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodGross_pid_uShares_c20210101__20211231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_z31UL0x5WW0l" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0982">&#8212;</span></td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_98C_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice_pid_uUSDPShares_c20210101__20211231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zBgpDsQZkXHl" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0983">&#8212;</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Forfeited/canceled</td>
    <td>&#160;</td>
    <td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodUnvested_pid_uShares_c20220101__20221231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zAeoBmoI2qF" style="text-align: right" title="Forfeited/canceled"><span style="-sec-ix-hidden: xdx2ixbrl0985">&#8212;</span></td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_980_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePriceUnvested_pid_uUSDPShares_c20220101__20221231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zXhpyyJIFlC4" style="text-align: right" title="Forfeited/canceled"><span style="-sec-ix-hidden: xdx2ixbrl0987">&#8212;</span></td>
    <td>&#160;</td>
    <td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodUnvested_pid_uShares_c20210101__20211231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zAq3e72xb4f6" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0988">&#8212;</span></td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_98C_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePriceUnvested_pid_uUSDPShares_c20210101__20211231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zQ9q8QPPkiJ9" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0989">&#8212;</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Unvested at December 31</td>
    <td>&#160;</td>
    <td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberUnvested_iE_pid_uShares_c20220101__20221231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zrVougvelbUa" style="text-align: right" title="Outstanding at ending">950,000</td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceUnvested_iE_pid_uUSDPShares_c20220101__20221231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zMh3yFi4kWh8" style="text-align: right" title="Outstanding at ending">3.04</td>
    <td>&#160;</td>
    <td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberUnvested_iE_pid_uShares_c20210101__20211231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zmbmg5YV0JTe" style="text-align: right">1,000,000</td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceUnvested_iE_pid_uUSDPShares_c20210101__20211231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zFQfz3vv3JR5" style="text-align: right">3.01</td>
    <td>&#160;</td></tr>
  </table>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krmd_ScheduleOfShareBasedCompensationStockOptionsActivityAmendedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The element represents schedule of share based compensation stock options activity amended table text block.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krmd_ScheduleOfShareBasedCompensationStockOptionsActivityAmendedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krmd_ScheduleOfShareBasedCompensationtaxBenefitsAssociatedWithRestrictedStockAwardCompensationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The element represents schedule of share based compensationtax benefits associated with restricted stock award compensation table text block.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krmd_ScheduleOfShareBasedCompensationtaxBenefitsAssociatedWithRestrictedStockAwardCompensationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfOtherShareBasedCompensationActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of activity for outstanding award under share-based payment arrangement excluding share and unit options and nonvested award.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfOtherShareBasedCompensationActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of option exercise prices, by grouped ranges, including the upper and lower limits of the price range, the number of shares under option, weighted average exercise price and remaining contractual option terms.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the change in restricted stock units (RSUs).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the number and weighted-average grant date fair value for outstanding performance shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139621722300912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LEASES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Schedule of components of lease expense</a></td>
<td class="text"><p id="xdx_890_eus-gaap--LeaseCostTableTextBlock_z1LTQGqoqzE1" style="font: 10pt Times New Roman, Times, Serif; margin: 0">The components of lease expense were as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_8BF_zHnufYvIrM98" style="display: none; visibility: hidden">Schedule of components of lease expense</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 4.75in; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="width: 187.95pt">&#160;</td>
    <td style="width: 7.15pt">&#160;</td>
    <td style="width: 0.1in; text-align: center">&#160;</td>
    <td id="xdx_494_20220101__20221231_z2p5lB62SXuh" style="width: 56.8pt; text-align: center">&#160;</td>
    <td style="width: 11.15pt; text-align: center">&#160;</td>
    <td style="width: 0.1in; text-align: center">&#160;</td>
    <td id="xdx_49B_20210101__20211231_zjrgEIxHcU5c" style="width: 57.4pt; text-align: center">&#160;</td>
    <td style="width: 7.15pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="5" style="text-align: center"><b>Years Ended</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="5" style="border-bottom: black 1pt solid; text-align: center"><b>December 31,</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>2022</b></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>2021</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--OperatingLeaseCost_maLCzGTc_zUsXlNVmwuB6" style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Operating lease cost</td>
    <td>&#160;</td>
    <td>$</td>
    <td style="text-align: right">514,294</td>
    <td>&#160;</td>
    <td>$</td>
    <td style="text-align: right">149,476</td>
    <td>&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--ShortTermLeaseCost_maLCzGTc_zSAnfqySRBt5" style="vertical-align: bottom">
    <td>Short-term lease cost</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">131,490</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">146,604</td>
    <td>&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--LeaseCost_zvUJoX9MAcG7" style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Total lease cost</td>
    <td>&#160;</td>
    <td style="border-top: black 1pt solid; border-bottom: black 2.25pt double">$</td>
    <td style="border-top: black 1pt solid; border-bottom: black 2.25pt double; text-align: right">645,784</td>
    <td>&#160;</td>
    <td style="border-top: black 1pt solid; border-bottom: black 2.25pt double">$</td>
    <td style="border-top: black 1pt solid; border-bottom: black 2.25pt double; text-align: right">296,080</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_40F_ecustom--FinanceLeaseCost1Abstract_iB_zWFaUUVzptO8" style="vertical-align: bottom">
    <td style="padding-left: 9.1pt; text-indent: -9.1pt">Finance lease cost:</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--FinanceLeaseRightOfUseAssetAmortization_i01_maFLCzAT2_zftg6rMSJ8Qg" style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="padding-left: 27.5pt; text-indent: -9.1pt">Amortization of right-of-use assets</td>
    <td>&#160;</td>
    <td>$</td>
    <td style="text-align: right">50,895</td>
    <td>&#160;</td>
    <td>$</td>
    <td style="text-align: right">2,586</td>
    <td>&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--FinanceLeaseInterestExpense_i01_maFLCzAT2_zDR8tEDw9AQ5" style="vertical-align: bottom">
    <td style="padding-left: 27.5pt; text-indent: -9.1pt">Interest on lease liabilities</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">5,393</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">60</td>
    <td>&#160;</td></tr>
  <tr id="xdx_40A_ecustom--FinanceLeaseCost_i01_zD2FyidY27S9" style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Total finance lease cost</td>
    <td>&#160;</td>
    <td style="border-top: black 1pt solid; border-bottom: black 2.25pt double">$</td>
    <td style="border-top: black 1pt solid; border-bottom: black 2.25pt double; text-align: right">56,288</td>
    <td>&#160;</td>
    <td style="border-top: black 1pt solid; border-bottom: black 2.25pt double">$</td>
    <td style="border-top: black 1pt solid; border-bottom: black 2.25pt double; text-align: right">2,646</td>
    <td>&#160;</td></tr>
  </table>
<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLeaseIncomeTableTextBlock', window );">Schedule of cash flow information related to leases</a></td>
<td class="text"><p id="xdx_899_eus-gaap--OperatingLeaseLeaseIncomeTableTextBlock_zEHge4wXvGc" style="font: 10pt Times New Roman, Times, Serif; margin: 0">Supplemental cash flow information related to leases was as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_8BB_zz98rsQUoiYj" style="display: none; visibility: hidden">Schedule of cash flow information related to leases</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 4.75in; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="width: 190pt">&#160;</td>
    <td style="width: 6.8pt">&#160;</td>
    <td style="width: 7.1pt; text-align: center">&#160;</td>
    <td id="xdx_49D_20220101__20221231_zvEQSh5ueQsi" style="width: 56.1pt; text-align: center">&#160;</td>
    <td style="width: 12pt; text-align: center">&#160;</td>
    <td style="width: 7.1pt; text-align: center">&#160;</td>
    <td id="xdx_491_20210101__20211231_zqBJ41jFceVb" style="width: 55.9pt; text-align: center">&#160;</td>
    <td style="width: 6.8pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="5" style="text-align: center"><b>Years Ended</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="5" style="border-bottom: black 1pt solid; text-align: center"><b>December 31,</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>2022</b></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>2021</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--CashFlowOperatingActivitiesLesseeAbstract_iB" style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="padding-left: 9.45pt; text-indent: -9.45pt">Cash paid for amounts included in the measurement of lease liabilities:</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--OperatingLeasePayments_i01_z2KIYtKYcSo1" style="vertical-align: bottom">
    <td>Operating cash flows from operating leases</td>
    <td>&#160;</td>
    <td>$</td>
    <td style="text-align: right">247,504</td>
    <td>&#160;</td>
    <td>$</td>
    <td style="text-align: right">141,293</td>
    <td>&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--FinanceLeaseInterestPaymentOnLiability_i01_zqOSMHTnsu29" style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Financing cash flows from finance leases</td>
    <td>&#160;</td>
    <td>$</td>
    <td style="text-align: right">57,243</td>
    <td>&#160;</td>
    <td>$</td>
    <td style="text-align: right">2,646</td>
    <td>&#160;</td></tr>
  </table>
<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock', window );">Schdeule of balance sheet information related to leases</a></td>
<td class="text"><p id="xdx_899_eus-gaap--OperatingLeasesOfLesseeDisclosureTextBlock_zBDoScivKUk9" style="font: 10pt Times New Roman, Times, Serif; margin: 0">Supplemental balance sheet information related to leases was as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_8B9_zhDohtT1ePmd" style="display: none; visibility: hidden">Schdeule of balance sheet information related to leases</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 5.5in; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" id="xdx_49B_20221231_z8ahI5LaIsN6" style="border-bottom: black 1pt solid; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td colspan="2" id="xdx_498_20211231_zerdUjqQqiPc" style="border-bottom: black 1pt solid; text-align: center">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>December 31,<br/>
2022</b></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>December 31,<br/>
2021</b></td>
    <td>&#160;</td></tr>
  <tr id="xdx_402_ecustom--AssetsAndLiabilitiesOperatingLesseeAbstract_iB_zY2BfEyxuXfl" style="vertical-align: bottom">
    <td style="width: 217.3pt; padding-left: 9.1pt; text-indent: -9.1pt"><b>Operating Leases</b></td>
    <td style="width: 9.8pt">&#160;</td>
    <td style="width: 11.25pt">&#160;</td>
    <td style="width: 63pt">&#160;</td>
    <td style="width: 12.8pt">&#160;</td>
    <td style="width: 9.75pt">&#160;</td>
    <td style="width: 64.5pt">&#160;</td>
    <td style="width: 0.1in">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--OperatingLeaseRightOfUseAsset_i01I_zf5monxP8L92" style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="padding-left: 28.25pt; text-indent: -9.45pt">Operating lease right-of-use assets</td>
    <td>&#160;</td>
    <td>$</td>
    <td style="text-align: right">3,786,545</td>
    <td>&#160;</td>
    <td>$</td>
    <td style="text-align: right">95,553</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 28.25pt; text-indent: -9.45pt">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--OperatingLeaseLiabilityCurrent_i01I_zQ08LsJOEJi5" style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="padding-left: 28.25pt; text-indent: -9.45pt">Operating lease liability &#8211; current</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">345,834</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">95,553</td>
    <td>&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--OperatingLeaseLiabilityNoncurrent_i01I_zfJUy2reio28" style="vertical-align: bottom">
    <td style="padding-left: 28.25pt; text-indent: -9.45pt">Operating lease liability, net of current portion</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right">3,653,257</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1057">&#8212;</span></td>
    <td>&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--OperatingLeaseLiability_i01I_ziKLJsgAbEh5" style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="padding-left: 9.1pt; text-indent: -9.1pt">Total operating lease liabilities</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right">3,999,091</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right">95,553</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 9.1pt; text-indent: -9.1pt">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_40F_ecustom--AssetsAndLiabilitiesLesseeFinanceAbstract_iB_z86pRnOO118" style="vertical-align: bottom">
    <td style="padding-left: 9.1pt; text-indent: -9.1pt"><b>Finance Leases</b></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--PropertyPlantAndEquipmentOther_i01I_zkshvzRWwsV7" style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="padding-left: 28.25pt; text-indent: -9.45pt">Property and equipment, at cost</td>
    <td>&#160;</td>
    <td>$</td>
    <td style="text-align: right">544,468</td>
    <td>&#160;</td>
    <td>$</td>
    <td style="text-align: right">12,725</td>
    <td>&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--PropertyPlantAndEquipmentOtherAccumulatedDepreciation_i01NI_di_zgPCpK3uctT4" style="vertical-align: bottom">
    <td style="padding-left: 28.25pt; text-indent: -9.45pt">Accumulated depreciation</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right">(50,895</td>
    <td>)</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right">(12,725</td>
    <td>)</td></tr>
  <tr id="xdx_407_eus-gaap--PropertyPlantAndEquipmentOtherNet_i01I_zow00fF4O8Z" style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="padding-left: 28.25pt; text-indent: -9.45pt">Property and equipment, net</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right">493,573</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1072">&#8212;</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--FinanceLeaseLiabilityCurrent_iI_ztoM1PT0aWsc" style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="padding-left: 28.25pt; text-indent: -9.45pt">Finance lease liability &#8211; current</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">98,335</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1075">&#8212;</span></td>
    <td>&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--FinanceLeaseLiabilityNoncurrent_iI_z0GlI9AHfFLh" style="vertical-align: bottom">
    <td style="padding-left: 28.25pt; text-indent: -9.45pt">Finance lease liability, net of current portion</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right">394,283</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1078">&#8212;</span></td>
    <td>&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--FinanceLeaseLiability_iI_zlJaUSV2xXHj" style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="padding-left: 9.1pt; text-indent: -9.1pt">Total finance lease liabilities</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right">492,618</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1081">&#8212;</span></td>
    <td>&#160;</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 5.5in; border-collapse: collapse">
  <tr style="background-color: white">
    <td style="vertical-align: bottom; width: 218.25pt">&#160;</td>
    <td style="vertical-align: bottom; width: 9.75pt">&#160;</td>
    <td style="border-bottom: black 1pt solid; vertical-align: bottom; width: 74.25pt; text-align: center"><b>December 31,<br/>
2022</b></td>
    <td style="vertical-align: bottom; width: 11.25pt">&#160;</td>
    <td style="border-bottom: black 1pt solid; vertical-align: top; width: 74.25pt; text-align: center"><b>December 31,<br/>
2021</b></td>
    <td style="vertical-align: top; width: 0.1in">&#160;</td></tr>
  <tr>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top">&#160;</td></tr>
  <tr style="background-color: #E6E6E6">
    <td style="vertical-align: bottom"><b>Weighted Average Remaining Lease Term</b></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top">&#160;</td></tr>
  <tr style="background-color: white">
    <td style="vertical-align: bottom; padding-left: 28.25pt; text-indent: -9.45pt">Operating leases</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="text-align: right"><span id="xdx_908_eus-gaap--LesseeOperatingLeaseRenewalTerm_iI_dxL_c20221231_zArCYc8v9ij" title="Operating leases::XDX::P9Y8M12D"><span style="-sec-ix-hidden: xdx2ixbrl1083">9.7</span></span> Years</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: right"><span id="xdx_90F_eus-gaap--LesseeOperatingLeaseRenewalTerm_iI_dxL_c20211231_zTyjDwcAZdKf" title="Operating leases::XDX::P0Y7M6D"><span style="-sec-ix-hidden: xdx2ixbrl1085">0.6</span></span> Years</td>
    <td style="vertical-align: top">&#160;</td></tr>
  <tr style="background-color: #E6E6E6">
    <td style="vertical-align: bottom; padding-left: 28.25pt; text-indent: -9.45pt">Finance leases</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="text-align: right"><span id="xdx_90D_eus-gaap--LesseeFinanceLeaseRenewalTerm1_iI_dxL_c20221231_zGKlAStG3FY" title="Finance leases::XDX::P4Y0M22D"><span style="-sec-ix-hidden: xdx2ixbrl1087">4.6</span></span> Years</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: right"><span id="xdx_90A_eus-gaap--LesseeFinanceLeaseRenewalTerm1_iI_dxL_c20211231_zrQaTiaSzknd" title="Finance leases::XDX::P0Y0M0D"><span style="-sec-ix-hidden: xdx2ixbrl1089">0</span></span> Years</td>
    <td style="vertical-align: top">&#160;</td></tr>
  <tr style="background-color: white">
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top">&#160;</td></tr>
  <tr style="background-color: #E6E6E6">
    <td style="vertical-align: bottom"><b>Weighted Average Discount Rate</b></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top">&#160;</td></tr>
  <tr style="background-color: white">
    <td style="vertical-align: bottom; padding-left: 28.25pt; text-indent: -9.45pt">Operating leases</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span id="xdx_90C_eus-gaap--LesseeOperatingLeaseDiscountRate_iI_pid_dp_uPure_c20221231_zg4uFdZV446l" title="Operating leases">4.00</span>%</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: right"><span id="xdx_90C_eus-gaap--LesseeOperatingLeaseDiscountRate_iI_pid_dp_uPure_c20211231_zJtJWBxHewic" title="Operating leases">4.75</span>%</td>
    <td style="vertical-align: top">&#160;</td></tr>
  <tr style="background-color: #E6E6E6">
    <td style="vertical-align: bottom; padding-left: 28.25pt; text-indent: -9.45pt">Finance leases</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span id="xdx_90A_eus-gaap--LesseeFinanceLeaseDiscountRate_iI_pid_dp_uPure_c20221231_zwKlu2rO5mQl" title="Finance leases">4.25</span>%</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: right"><span id="xdx_90F_eus-gaap--LesseeFinanceLeaseDiscountRate_iI_pid_dp_uPure_c20211231_z89nbAXUapO4" title="Finance leases">4.75</span>%</td>
    <td style="vertical-align: top">&#160;</td></tr>
  </table>
<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of maturities of lease liabilities</a></td>
<td class="text"><p id="xdx_894_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_zJzeWiAT4h1l" style="font: 10pt Times New Roman, Times, Serif; margin: 0">Maturities of lease liabilities are as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_8B0_zPfztqAP7W4f" style="display: none; visibility: hidden">Schedule of maturities of lease liabilities</span>&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"/>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 5.5in; border-collapse: collapse">
  <tr>
    <td style="border-bottom: black 1pt solid; vertical-align: bottom"><b>Year Ending December 31,</b></td>
    <td style="vertical-align: top">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: center"><b>Operating Leases</b></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: center"><b>Finance Leases</b></td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="width: 210.7pt">2023</td>
    <td style="width: 7pt">&#160;</td>
    <td style="width: 13.95pt">&#160;</td>
    <td id="xdx_98C_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_c20221231_zbdREWlyjfga" style="width: 67.6pt; text-align: right" title="2023">499,503</td>
    <td style="width: 10.2pt">&#160;</td>
    <td style="width: 7pt">&#160;</td>
    <td id="xdx_98E_eus-gaap--FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_iI_c20221231_zDBrss7U5qb" style="width: 62.05pt; text-align: right" title="2023">123,200</td>
    <td style="width: 8.75pt">&#160;</td></tr>
  <tr>
    <td style="vertical-align: bottom">2024</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td id="xdx_984_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_c20221231_zfrLp93TJoi7" style="vertical-align: bottom; text-align: right" title="2024">499,503</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td id="xdx_98D_eus-gaap--FinanceLeaseLiabilityPaymentsDueYearTwo_iI_c20221231_zqwZr9c5qS4c" style="vertical-align: bottom; text-align: right" title="2024">123,200</td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr style="background-color: #E6E6E6">
    <td style="vertical-align: bottom">2025</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td id="xdx_98F_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_c20221231_z6e6Jx5PulYk" style="vertical-align: bottom; text-align: right" title="2025">499,503</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td id="xdx_988_eus-gaap--FinanceLeaseLiabilityPaymentsDueYearThree_iI_c20221231_zfR57toQFVqh" style="vertical-align: bottom; text-align: right" title="2025">123,200</td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr>
    <td style="vertical-align: bottom">2026</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td id="xdx_985_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFour_iI_c20221231_znlIyIwgCNF8" style="vertical-align: bottom; text-align: right" title="2026">499,503</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td id="xdx_98E_eus-gaap--FinanceLeaseLiabilityPaymentsDueYearFour_iI_c20221231_zDrWXBFtwpB7" style="vertical-align: bottom; text-align: right" title="2026">123,200</td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr style="background-color: #E6E6E6">
    <td style="vertical-align: bottom">2027</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td id="xdx_98F_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFive_iI_c20221231_zW6ywYksJDz3" style="vertical-align: bottom; text-align: right" title="2027">499,503</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td id="xdx_983_eus-gaap--FinanceLeaseLiabilityPaymentsDueYearFive_iI_c20221231_zFhCRsXANDZ4" style="vertical-align: bottom; text-align: right" title="2027">65,957</td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr>
    <td style="vertical-align: bottom">Thereafter</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="border-bottom: black 1pt solid; vertical-align: bottom">&#160;</td>
    <td id="xdx_987_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_iI_c20221231_zbg3rVA8sdA3" style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: right" title="Thereafter">2,331,015</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="border-bottom: black 1pt solid; vertical-align: bottom">&#160;</td>
    <td id="xdx_98B_eus-gaap--FinanceLeaseLiabilityPaymentsDueAfterYearFive_iI_c20221231_zQFXPu2ksYAf" style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: right" title="Thereafter"><span style="-sec-ix-hidden: xdx2ixbrl1123">&#8212;</span></td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr style="background-color: #E6E6E6">
    <td style="vertical-align: bottom">Total undiscounted lease payments</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td id="xdx_980_ecustom--LesseeOperatingLeaseLiabilityPaymentsDueTotal_iI_c20221231_zLPcSKlSzTzc" style="vertical-align: bottom; text-align: right" title="Total undiscounted lease payments">4,828,530</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td id="xdx_98B_ecustom--LesseeFinancingLeaseLeaseLiabilityPaymentsDueTotal_iI_c20221231_z5kCzifwgWPj" style="vertical-align: bottom; text-align: right" title="Total undiscounted lease payments">558,757</td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr>
    <td style="vertical-align: bottom; padding-left: 18.8pt">Less: imputed interest</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="border-bottom: black 1pt solid; vertical-align: bottom">&#160;</td>
    <td id="xdx_98B_ecustom--LesseeOperatingLeaseImputedInterest_iNI_di_c20221231_zODxEvreSjwd" style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: right" title="Less: imputed interest">(829,439</td>
    <td style="vertical-align: bottom">)</td>
    <td style="border-bottom: black 1pt solid; vertical-align: bottom">&#160;</td>
    <td id="xdx_985_ecustom--LesseeFinancingLeaseImputedInterest_iNI_di_c20221231_zAhvBU1ADOQc" style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: right" title="Less: imputed interest">(66,139</td>
    <td style="vertical-align: bottom">)</td></tr>
  <tr style="background-color: #E6E6E6">
    <td style="vertical-align: bottom">Total lease liabilities</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="border-bottom: black 2.25pt double; vertical-align: bottom">$</td>
    <td id="xdx_98C_eus-gaap--OperatingLeaseLiability_iI_c20221231_zbVRBidywo6k" style="border-bottom: black 2.25pt double; vertical-align: bottom; text-align: right" title="Total lease liabilities">3,999,091</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="border-bottom: black 2.25pt double; vertical-align: bottom">$</td>
    <td id="xdx_981_eus-gaap--FinanceLeaseLiability_iI_c20221231_zHnd4FjVhccl" style="border-bottom: black 2.25pt double; vertical-align: bottom; text-align: right" title="Total lease liabilities">492,618</td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  </table>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLeaseIncomeTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of components of income from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 30<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124258985&amp;loc=SL77919372-209981<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6A<br> -URI https://asc.fasb.org/extlink&amp;oid=126900988&amp;loc=SL77927221-108306<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLeaseIncomeTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for lessee's operating leases. Includes, but is not limited to, description of lessee's operating lease, existence and terms of renewal or purchase options and escalation clauses, restrictions imposed by lease, such as those concerning dividends, additional debt, and further leasing, rent holidays, rent concessions, or leasehold improvement incentives and unusual provisions or conditions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123406913&amp;loc=d3e41499-112717<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124440162&amp;loc=d3e12069-110248<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=123406913&amp;loc=d3e41502-112717<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=123389372&amp;loc=d3e36991-112694<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI https://asc.fasb.org/extlink&amp;oid=123403562&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139621728809888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FEDERAL AND STATE INCOME TAXES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">Schedule of provision for income taxes</a></td>
<td class="text"><p id="xdx_899_eus-gaap--ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_zglEySmcueM1" style="font: 10pt Times New Roman, Times, Serif; margin: 0">Income tax expense consisted of the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_8BE_zsMQiuMp5bRh" style="display: none; visibility: hidden">Schedule of provision for income taxes</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 4.5in; border-collapse: collapse">
  <tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" id="xdx_496_20220101__20221231_zuCjSxBaV0T6" style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td colspan="2" id="xdx_49E_20210101__20211231_z9VxYzvHVC4f" style="text-align: center">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>Year Ended<br/>
December 31,<br/>
2022</b></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>Year Ended<br/>
December 31,<br/>
2021</b></td>
    <td>&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--StateAndLocalIncomeTaxExpenseBenefitContinuingOperationsAbstract_iB_zpVHNQEH2yh8" style="vertical-align: bottom; background-color: white">
    <td>State income tax:</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--CurrentStateAndLocalTaxExpenseBenefit_zuRz3QqK79eg" style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="width: 145.15pt; padding-left: 21.8pt">Current, net of refund</td>
    <td style="width: 8.25pt">&#160;</td>
    <td style="width: 8.25pt">$</td>
    <td style="width: 63.75pt; text-align: right">0</td>
    <td style="width: 17.3pt">&#160;</td>
    <td style="width: 8.25pt">$</td>
    <td style="width: 64.5pt; text-align: right">(12,800</td>
    <td style="width: 8.25pt">)</td></tr>
  <tr id="xdx_409_eus-gaap--FederalIncomeTaxExpenseBenefitContinuingOperationsAbstract_iB_zgNMkE8zBaDc" style="vertical-align: bottom; background-color: white">
    <td>Federal income tax:</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--DeferredFederalIncomeTaxExpenseBenefit_zuGwJOXBnkO" style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="padding-left: 21.8pt">Deferred</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">2,014,018</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">1,814,418</td>
    <td>&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--CurrentFederalTaxExpenseBenefit_zR3uewbkPO6l" style="vertical-align: bottom; background-color: white">
    <td style="padding-left: 21.8pt">Current</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1153">&#8212;</span></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1154">&#8212;</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Income tax benefit/(expense)</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td id="xdx_987_eus-gaap--IncomeTaxExpenseBenefit_iN_dixL_c20220101__20221231_z0H20cITsBPk" style="border-bottom: black 2.25pt double; text-align: right" title="Income tax benefit/(expense)::XDX::2014018"><span style="-sec-ix-hidden: xdx2ixbrl1156">2,014,018</span></td>
    <td style="border-bottom: white 2.25pt double">&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td id="xdx_98E_eus-gaap--IncomeTaxExpenseBenefit_iN_di_c20210101__20211231_zwg8wpJI77sk" style="border-bottom: black 2.25pt double; text-align: right" title="Income tax benefit/(expense)">1,801,618</td>
    <td style="border-bottom: white 2.25pt double">&#160;</td></tr>
  </table>
<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of reconciliation of income taxes</a></td>
<td class="text"><p id="xdx_898_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zUMt6iPfMcs4" style="font: 10pt Times New Roman, Times, Serif; margin: 0">The reconciliation of income taxes shown in the financial statements and
amounts computed by applying the Federal expected tax rate of 21% for year 2022 and 2021 is as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_8BF_zfXXktFPaDB4" style="display: none; visibility: hidden">Schedule of reconciliation of income taxes</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 5.5in; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" id="xdx_497_20220101__20221231_zZfBG566rN03" style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td colspan="2" id="xdx_49D_20210101__20211231_zbbvnlqEnBN7" style="text-align: center">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>Year Ended<br/>
December 31,<br/>
2022</b></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>Year Ended<br/>
December 31,<br/>
2021</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_zkkH8IRj2kNg" style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="width: 217.2pt">Loss before taxes</td>
    <td style="width: 8.3pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double; width: 8.25pt">$</td>
    <td style="border-bottom: black 2.25pt double; width: 65.25pt; text-align: right">(10,675,160</td>
    <td style="border-bottom: white 2.25pt double; width: 17.3pt">)</td>
    <td style="border-bottom: black 2.25pt double; width: 7.5pt">$</td>
    <td style="border-bottom: black 2.25pt double; width: 63.75pt; text-align: right">(6,364,441</td>
    <td style="border-bottom: white 2.25pt double; width: 8.25pt">)</td></tr>
  <tr id="xdx_407_eus-gaap--IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_zFpk8I5fX0u3" style="vertical-align: bottom">
    <td>Income taxes computed at the federal statutory rate</td>
    <td>&#160;</td>
    <td>$</td>
    <td style="text-align: right">2,241,784</td>
    <td>&#160;</td>
    <td>$</td>
    <td style="text-align: right">1,336,533</td>
    <td>&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--IncomeTaxReconciliationStateAndLocalIncomeTaxes_zYOmqgxXiNCd" style="vertical-align: bottom; background-color: #E6E6E6">
    <td>State income and franchise tax</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">(0</td>
    <td>)</td>
    <td>&#160;</td>
    <td style="text-align: right">(12,800</td>
    <td>)</td></tr>
  <tr id="xdx_400_eus-gaap--IncomeTaxReconciliationOtherAdjustments_znIbNnOLWCgd" style="vertical-align: bottom">
    <td>Permanent differences and other</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right">(227,766</td>
    <td>)</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right">477,885</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Income tax benefit/(expense)</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td id="xdx_987_eus-gaap--IncomeTaxExpenseBenefit_iN_dixL_c20220101__20221231_zX2yburYThGc" style="border-bottom: black 2.25pt double; text-align: right" title="Income tax benefit/(expense)::XDX::2014018"><span style="-sec-ix-hidden: xdx2ixbrl1175">2,014,018</span></td>
    <td style="border-bottom: white 1.5pt double">&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td id="xdx_980_eus-gaap--IncomeTaxExpenseBenefit_iN_di_c20210101__20211231_zvntdnqNBLhj" style="border-bottom: black 2.25pt double; text-align: right" title="Income tax benefit/(expense)">1,801,618</td>
    <td style="border-bottom: white 1.5pt double">&#160;</td></tr>
  </table>
<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of components of deferred tax assets</a></td>
<td class="text"><p id="xdx_894_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zlffzBYaydZ" style="font: 10pt Times New Roman, Times, Serif; margin: 0">The significant components of deferred income tax assets, net are as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_8B0_za0gIlKRnn84" style="display: none; visibility: hidden">Schedule of components of deferred tax assets</span>&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 5.5in; border-collapse: collapse">
  <tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" id="xdx_493_20221231_z7Xum9LAfpOi" style="border-bottom: black 1pt solid; text-align: center"><b>December 31,<br/>
2022</b></td>
    <td>&#160;</td>
    <td colspan="2" id="xdx_49E_20211231_z1A44rbmRDqc" style="border-bottom: black 1pt solid; text-align: center"><b>December 31,<br/>
2021</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--DeferredCompensationPlanAssets_iI_zt6hAbjnyePh" style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="width: 207.9pt">Deferred compensation cost</td>
    <td style="width: 0.1in">&#160;</td>
    <td style="width: 7.35pt">$</td>
    <td style="width: 80pt; text-align: right">557,931</td>
    <td style="width: 17.15pt">&#160;</td>
    <td style="width: 8.05pt">$</td>
    <td style="width: 61.1pt; text-align: right">389,981</td>
    <td style="width: 7.25pt">&#160;</td></tr>
  <tr id="xdx_40F_ecustom--DepreciationDepletionAndAmortization1_iI_zhEmxRj9hFYd" style="vertical-align: bottom; background-color: white">
    <td>Depreciation and amortization</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">(624,184</td>
    <td>)</td>
    <td>&#160;</td>
    <td style="text-align: right">(116,911</td>
    <td>)</td></tr>
  <tr id="xdx_403_ecustom--RdCredit_zgXcDJvczNKj" style="vertical-align: bottom; background-color: #E6E6E6">
    <td>R&amp;D credit</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">142,030</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">142,538</td>
    <td>&#160;</td></tr>
  <tr id="xdx_40D_ecustom--Nol_zhcYeQUIMA8" style="vertical-align: bottom; background-color: white">
    <td>NOL</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">2,956,685</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">1,507,982</td>
    <td>&#160;</td></tr>
  <tr id="xdx_40D_ecustom--AllowanceForDoubtfulOtherReceivables1Current_zuvcrVoDDgo4" style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Allowance for bad debts and other</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right">935,018</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right">17,664</td>
    <td>&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--DeferredTaxAssetsNet_iI_zNZ0sJT5k5o5" style="vertical-align: bottom; background-color: white">
    <td>Deferred income tax assets, net</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right">3,967,480</td>
    <td style="border-bottom: white 2.25pt double">&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right">1,941,254</td>
    <td style="border-bottom: white 2.25pt double">&#160;</td></tr>
  </table>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139621726512128">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Schedule of amortization expense (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths', window );">2023</a></td>
<td class="nump">$ 62,982<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">2024</a></td>
<td class="nump">62,982<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree', window );">2025</a></td>
<td class="nump">62,842<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour', window );">2026</a></td>
<td class="nump">61,787<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive', window );">2027</a></td>
<td class="nump">61,356<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive', window );">Thereafter</a></td>
<td class="nump">475,233<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Total amortization expense</a></td>
<td class="nump">$ 787,182<span></span>
</td>
<td class="nump">$ 808,813<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for asset, excluding financial asset and goodwill, lacking physical substance with finite life expected to be recognized after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139621726767152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of net income per common share (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (8,661,142)<span></span>
</td>
<td class="num">$ (4,562,823)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract', window );"><strong>Weighted Average Outstanding Shares:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Outstanding shares</a></td>
<td class="nump">45,002,074<span></span>
</td>
<td class="nump">44,385,032<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants', window );">Option shares includable</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krmd_IncrementalCommonSharesAttributableToRestrictedStock', window );">Restricted stock includable</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krmd_WeightedAverageNumberOfSharesOutstanding', window );">&#160;Total</a></td>
<td class="nump">45,002,074<span></span>
</td>
<td class="nump">44,385,032<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Net loss per share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic</a></td>
<td class="num">$ (0.19)<span></span>
</td>
<td class="num">$ (0.10)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted</a></td>
<td class="num">$ (0.19)<span></span>
</td>
<td class="num">$ (0.10)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_EmployeeStockMember', window );">Employee Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Net loss per share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Option shares excluded</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">273,110<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krmd_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount1', window );">Restricted stock shares excluded</a></td>
<td class="nump">950,000<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract', window );"><strong>Weighted Average Outstanding Shares:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Outstanding shares</a></td>
<td class="nump">45,002,074<span></span>
</td>
<td class="nump">44,385,032<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krmd_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krmd_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krmd_IncrementalCommonSharesAttributableToRestrictedStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krmd_IncrementalCommonSharesAttributableToRestrictedStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krmd_WeightedAverageNumberOfSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The element represents weighted average number of shares outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krmd_WeightedAverageNumberOfSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of call options and warrants using the treasury stock method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 26<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1828-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1757-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1707-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139621727573296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of net revenues by geography (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">$ 27,896,037<span></span>
</td>
<td class="nump">$ 23,490,175<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">UNITED STATES</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">23,586,254<span></span>
</td>
<td class="nump">19,488,685<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">Non-US [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">$ 4,309,783<span></span>
</td>
<td class="nump">$ 4,001,490<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=us-gaap_NonUsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139621722376064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>Number</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfReportableSegments', window );">Number of segments | Number</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashUninsuredAmount', window );">FDIC cash uninsured amount</a></td>
<td class="nump">$ 250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krmd_AmortizationOfIntangibleAssets1', window );">AmortizationOfIntangibleAssets1</a></td>
<td class="nump">62,143<span></span>
</td>
<td class="nump">$ 63,830<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">587,137<span></span>
</td>
<td class="nump">463,130<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_PropertyPlantAndEquipmentMember', window );">Property, Plant and Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">$ 524,994<span></span>
</td>
<td class="nump">$ 399,300<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | Furniture And Office Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives of property and equipment</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | Equipment and tooling [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives of property and equipment</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | Furniture And Office Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives of property and equipment</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | Equipment and tooling [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives of property and equipment</a></td>
<td class="text">12 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=krmd_PatentsAndTrademarksMember', window );">Patents And Trademarks [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">6 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=krmd_PatentsAndTrademarksMember', window );">Patents And Trademarks [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">20 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krmd_AmortizationOfIntangibleAssets1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The element represents amortization of intangible assets1.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krmd_AmortizationOfIntangibleAssets1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashUninsuredAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash as of the balance sheet date that is not insured by the Federal Deposit Insurance Corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashUninsuredAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportableSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportableSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_PropertyPlantAndEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_PropertyPlantAndEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=krmd_FurnitureAndOfficeEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=krmd_FurnitureAndOfficeEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=krmd_EquipmentAndToolingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=krmd_EquipmentAndToolingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=krmd_PatentsAndTrademarksMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=krmd_PatentsAndTrademarksMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139621726447520">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Inventory consists of: (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcessAndRawMaterials', window );">Raw materials and work-in-process</a></td>
<td class="nump">$ 3,853,034<span></span>
</td>
<td class="nump">$ 2,997,807<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoods', window );">Finished goods</a></td>
<td class="nump">2,611,951<span></span>
</td>
<td class="nump">3,176,836<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryGross', window );">Inventory, Gross</a></td>
<td class="nump">6,464,985<span></span>
</td>
<td class="nump">6,174,643<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryValuationReserves', window );">Less: reserve for obsolete inventory</a></td>
<td class="num">(60,118)<span></span>
</td>
<td class="num">(68,305)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory</a></td>
<td class="nump">$ 6,404,867<span></span>
</td>
<td class="nump">$ 6,106,338<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoods">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoods</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross amount, as of the balance sheet date, of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryValuationReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of valuation reserve for inventory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 5.BB)<br> -URI https://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryValuationReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcessAndRawMaterials">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate carrying amount as of the balance sheet date of items held by the entity which are partially completed at the time of measurement and unprocessed items that will go through the production process and become part of the final product. Includes supplies used directly or indirectly in the manufacturing or production process. This element may be used when the reporting entity combines work in process and raw materials into an aggregate amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcessAndRawMaterials</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139621726863504">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Schedule of property and equipment (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">$ 6,681,378<span></span>
</td>
<td class="nump">$ 3,418,479<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: accumulated depreciation and amortization</a></td>
<td class="num">(2,794,403)<span></span>
</td>
<td class="num">(2,312,034)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">3,886,975<span></span>
</td>
<td class="nump">1,106,445<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=krmd_FurnitureAndOfficeEquipmentMember', window );">Furniture And Office Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">1,456,745<span></span>
</td>
<td class="nump">818,897<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold Improvements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">2,413,820<span></span>
</td>
<td class="nump">556,907<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=krmd_ManufacturingEquipmentAndToolingMember', window );">Manufacturing Equipment And Tooling [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">$ 2,810,813<span></span>
</td>
<td class="nump">$ 2,042,675<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=krmd_FurnitureAndOfficeEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=krmd_FurnitureAndOfficeEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=krmd_ManufacturingEquipmentAndToolingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=krmd_ManufacturingEquipmentAndToolingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139621726239984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of time based stock options (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate', window );">Weighted-average volatility</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=krmd_StockOptionPlan2015Member', window );">Stock Option Plan 2015 [Member] | Time Based Shares Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate', window );">Weighted-average volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments', window );">Expected dividends</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=krmd_StockOptionPlan2015Member', window );">Stock Option Plan 2015 [Member] | Time Based Shares Options [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">65.29%<span></span>
</td>
<td class="nump">74.01%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free rate</a></td>
<td class="nump">1.81%<span></span>
</td>
<td class="nump">1.20%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=krmd_StockOptionPlan2015Member', window );">Stock Option Plan 2015 [Member] | Time Based Shares Options [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">77.50%<span></span>
</td>
<td class="nump">77.91%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free rate</a></td>
<td class="nump">4.02%<span></span>
</td>
<td class="nump">1.62%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=krmd_StockOptionPlan2021Member', window );">Stock Option Plan 2021 [Member] | Time Based Shares Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">65.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate', window );">Weighted-average volatility</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments', window );">Expected dividends</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">0 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free rate</a></td>
<td class="nump">2.99%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=krmd_StockOptionPlan2021Member', window );">Stock Option Plan 2021 [Member] | Time Based Shares Options [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=krmd_StockOptionPlan2021Member', window );">Stock Option Plan 2021 [Member] | Time Based Shares Options [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated amount of dividends to be paid to holders of the underlying shares (expected dividends) over the option's term. Dividends are taken into account because payment of dividends to shareholders reduces the fair value of the underlying shares, and option holders generally do not receive dividends.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Rate of weighted-average expected volatility for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=krmd_StockOptionPlan2015Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=krmd_StockOptionPlan2015Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=krmd_TimeBasedSharesOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=krmd_TimeBasedSharesOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=krmd_StockOptionPlan2021Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=krmd_StockOptionPlan2021Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139621726896208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of status of time based stock options (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 3,079,427<span></span>
</td>
<td class="nump">$ 2,707,554<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=krmd_StockOptionPlan2015Member', window );">Stock Option Plan 2015 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding at beginning</a></td>
<td class="nump">3,672,500<span></span>
</td>
<td class="nump">2,922,494<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding at beginning</a></td>
<td class="nump">$ 3.42<span></span>
</td>
<td class="nump">$ 2.46<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted</a></td>
<td class="nump">445,000<span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted</a></td>
<td class="nump">$ 2.57<span></span>
</td>
<td class="nump">$ 3.64<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised</a></td>
<td class="nump">1,031,250<span></span>
</td>
<td class="nump">1,062,500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised</a></td>
<td class="nump">$ 1.57<span></span>
</td>
<td class="nump">$ 1.19<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Forfeited</a></td>
<td class="nump">526,250<span></span>
</td>
<td class="nump">187,494<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Forfeited</a></td>
<td class="nump">$ 2.73<span></span>
</td>
<td class="nump">$ 3.36<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding at ending</a></td>
<td class="nump">2,560,000<span></span>
</td>
<td class="nump">3,672,500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding at ending</a></td>
<td class="nump">$ 4.15<span></span>
</td>
<td class="nump">$ 3.42<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Options exercisable at ending</a></td>
<td class="nump">737,500<span></span>
</td>
<td class="nump">983,750<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Options exercisable</a></td>
<td class="nump">$ 4.93<span></span>
</td>
<td class="nump">$ 2.73<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average fair value of options granted during the period</a></td>
<td class="nump">$ 1.98<span></span>
</td>
<td class="nump">$ 2.85<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 1,925,861<span></span>
</td>
<td class="nump">$ 2,457,788<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=krmd_StockOptionPlan2021Member', window );">Stock Option Plan 2021 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Options exercisable at ending</a></td>
<td class="nump">0<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber2', window );">Outstanding at beginning</a></td>
<td class="nump">0<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice2', window );">Outstanding at beginning</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross2', window );">Granted</a></td>
<td class="nump">475,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice2', window );">Granted</a></td>
<td class="nump">$ 2.67<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krmd_StockIssuedDuringPeriodSharesStockOptionsExercised2', window );">Exercised</a></td>
<td class="nump">0<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice2', window );">Exercised</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod2', window );">Forfeited</a></td>
<td class="nump">0<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice2', window );">Forfeited</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber2', window );">Outstanding at ending</a></td>
<td class="nump">475,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice2', window );">Outstanding at ending</a></td>
<td class="nump">$ 2.67<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice2', window );">Options exercisable at ending</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue2', window );">Weighted average fair value of options granted during the period</a></td>
<td class="nump">$ 1.99<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 157,536<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The element represents share based compensation arrangement by share based payment award options exercisable weighted average exercise price2.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The element represents share based compensation arrangement by share based payment award options forfeitures in period2.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The element represents share based compensation arrangement by share based payment award options grants in period gross2.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The element represents share based compensation arrangement by share based payment award options grants in period weighted average grant date fair value2.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The element represents share based compensation arrangement by share based payment award options outstanding number2.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The element represents share based compensation arrangement by share based payment award options outstanding weighted average exercise price2.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The element represents share based compensation arrangements by share based payment award options exercises in period weighted average exercise price2.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The element represents share based compensation arrangements by share based payment award options forfeitures in period weighted average exercise price2.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The element represents share based compensation arrangements by share based payment award options grants in period weighted average exercise price2.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krmd_StockIssuedDuringPeriodSharesStockOptionsExercised2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The element represents stock issued during period shares stock options exercised2.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krmd_StockIssuedDuringPeriodSharesStockOptionsExercised2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=krmd_StockOptionPlan2015Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=krmd_StockOptionPlan2015Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=krmd_StockOptionPlan2021Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=krmd_StockOptionPlan2021Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139621726759728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of information pertaining to options outstanding (Details) - Time Based Shares Options [Member] - Exercise Price1 [Member]<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2022 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=krmd_StockOptionPlan2015Member', window );">Stock Option Plan 2015 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Number outstanding | shares</a></td>
<td class="nump">2,560,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life</a></td>
<td class="text">8 years 9 months 18 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Weighted average exercise price | $ / shares</a></td>
<td class="nump">$ 4.15<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Number exercisable | shares</a></td>
<td class="nump">737,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Weighted average exercise price | $ / shares</a></td>
<td class="nump">$ 4.93<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=krmd_StockOptionPlan2021Member', window );">Stock Option Plan 2021 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Number outstanding | shares</a></td>
<td class="nump">475,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life</a></td>
<td class="text">9 years 3 months 19 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Weighted average exercise price | $ / shares</a></td>
<td class="nump">$ 2.67<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Number exercisable | shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Weighted average exercise price | $ / shares</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares reserved for issuance pertaining to the outstanding exercisable stock options as of the balance sheet date in the customized range of exercise prices for which the market and performance vesting condition has been satisfied.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares reserved for issuance pertaining to the outstanding stock options as of the balance sheet date for all option plans in the customized range of exercise prices.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average exercise price as of the balance sheet date for those equity-based payment arrangements exercisable and outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average price as of the balance sheet date at which grantees could acquire the underlying shares with respect to all outstanding stock options which are in the customized range of exercise prices.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term of outstanding stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=krmd_StockOptionPlan2015Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=krmd_StockOptionPlan2015Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=krmd_TimeBasedSharesOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=krmd_TimeBasedSharesOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=krmd_ExercisePrice1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=krmd_ExercisePrice1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=krmd_StockOptionPlan2021Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=krmd_StockOptionPlan2021Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139621726353584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of performance base options outstanding (Details) - Performance Shares [Member] - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber1', window );">Outstanding at beginning</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice1', window );">Outstanding at beginning</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 1.70<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross1', window );">Options exercisable at ending</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice1', window );">Granted</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krmd_StockIssuedDuringPeriodSharesStockOptionsExercised1', window );">Exercised</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice1', window );">Exercised</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod1', window );">Forfeited</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice1', window );">Forfeited</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding at ending</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding at ending</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 1.70<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice1', window );">Options exercisable at ending</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Weighted average fair value of options granted during the period</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue1', window );">Weighted average fair value of options granted during the period</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krmd_AllocatedShareBasedCompensationExpense1', window );">Stock-based compensation expense</a></td>
<td class="text"> <span></span>
</td>
<td class="num">$ (408,747)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krmd_AllocatedShareBasedCompensationExpense1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The element represents allocated share based compensation expense1.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krmd_AllocatedShareBasedCompensationExpense1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The element represents share based compensation arrangement by share based payment award options exercisable weighted average exercise price1.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The element represents share based compensation arrangement by share based payment award options forfeitures in period1.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The element represents share based compensation arrangement by share based payment award options grants in period gross1.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The element represents share based compensation arrangement by share based payment award options grants in period weighted average grant date fair value1.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The element represents share based compensation arrangement by share based payment award options outstanding number1.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The element represents share based compensation arrangement by share based payment award options outstanding weighted average exercise price1.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The element represents share based compensation arrangements by share based payment award options exercises in period weighted average exercise price1.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The element represents share based compensation arrangements by share based payment award options forfeitures in period weighted average exercise price1.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The element represents share based compensation arrangements by share based payment award options grants in period weighted average exercise price1..</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krmd_StockIssuedDuringPeriodSharesStockOptionsExercised1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The element represents stock issued during period shares stock options exercised1.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krmd_StockIssuedDuringPeriodSharesStockOptionsExercised1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139621726350256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>The following table summarizes the activities for our unvested restricted stock awards for the twelve months ended December 31, 2022, and 2021. (Details) - Restricted Stock Awards [Member] - Stock Option Plan 2021 [Member] - $ / shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberUnvested', window );">Outstanding at beginning</a></td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceUnvested', window );">Outstanding at beginning</a></td>
<td class="nump">$ 3.01<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrossUnvested', window );">Granted</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePriceUnvested', window );">Granted</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 3.01<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodGross', window );">Vested</a></td>
<td class="nump">50,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice', window );">Vested</a></td>
<td class="nump">$ 3.31<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodUnvested', window );">Forfeited/canceled</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePriceUnvested', window );">Forfeited/canceled</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberUnvested', window );">Outstanding at ending</a></td>
<td class="nump">950,000<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceUnvested', window );">Outstanding at ending</a></td>
<td class="nump">$ 3.04<span></span>
</td>
<td class="nump">$ 3.01<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodUnvested">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The element represents share based compensation arrangement by share based payment award options forfeitures in period unvested.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodUnvested</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrossUnvested">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The element represents share based compensation arrangement by share based payment award options grants in period gross unvested.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrossUnvested</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberUnvested">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The element represents share based compensation arrangement by share based payment award options outstanding number unvested.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberUnvested</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceUnvested">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The element represents share based compensation arrangement by share based payment award options outstanding weighted average exercise price unvested.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceUnvested</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The element represents share based compensation arrangement by share based payment award options vested in period gross.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePriceUnvested">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The element represents share based compensation arrangements by share based payment award options forfeitures in period weighted average exercise price unvested.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePriceUnvested</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePriceUnvested">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The element represents share based compensation arrangements by share based payment award options grants in period weighted average exercise price unvested.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePriceUnvested</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The element represents share based compensation arrangements by share based payment award options vested in period weighted average exercise price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=krmd_RestrictedStockAwardsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=krmd_RestrictedStockAwardsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=krmd_StockOptionPlan2021Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=krmd_StockOptionPlan2021Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139621722628992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK-BASED COMPENSATION (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>May 18, 2021</div></th>
<th class="th"><div>Apr. 12, 2021</div></th>
<th class="th"><div>Jan. 02, 2021</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Tax benefit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (2,014,018)<span></span>
</td>
<td class="num">$ (1,801,618)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,079,427<span></span>
</td>
<td class="nump">$ 2,707,554<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock issued, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">48,861,891<span></span>
</td>
<td class="nump">48,044,162<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Aggregate stock price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 488,619<span></span>
</td>
<td class="nump">$ 480,441<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=krmd_ChiefExecutiveOfficerLindaTharbyMember', window );">Chief Executive Officer Linda Tharby [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan', window );">Common stock issued, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan', window );">Aggregate stock price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,310,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=krmd_NonEmployeeDirectorAndBoardAdvisorMember', window );">Non Employee Director And Board Advisor [Member[</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krmd_NonemployeeServicesTransactionCost', window );">Nonemployee services transaction cost</a></td>
<td class="nump">110,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransaction', window );">Share-based goods and nonemployee services transaction</a></td>
<td class="text">to be paid quarterly $12,500 in cash and $15,000 in common stock<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">to be paid quarterly $12,500 in cash and
$6,250 in common stock<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=srt_BoardOfDirectorsChairmanMember', window );">Board of Directors Chairman [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krmd_NonemployeeServicesTransactionCost', window );">Nonemployee services transaction cost</a></td>
<td class="nump">140,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransaction', window );">Share-based goods and nonemployee services transaction</a></td>
<td class="text">to be paid quarterly $12,500 in cash and $22,500 in common stock<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">to be paid quarterly $12,500 in cash
and $12,500 in common stock<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=srt_ChiefExecutiveOfficerMember', window );">Chief Executive Officer [Member] | Employment Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock issued, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Aggregate stock price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,310,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=krmd_StockOptionPlan2015Member', window );">Stock Option Plan 2015 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Available for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue', window );">Stock options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.98<span></span>
</td>
<td class="nump">$ 2.85<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Tax benefit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 198,258<span></span>
</td>
<td class="nump">$ 175,257<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=krmd_StockOptionPlan2015Member', window );">Stock Option Plan 2015 [Member] | Time Based Shares Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Tax benefit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">103,319<span></span>
</td>
<td class="nump">665,700<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures', window );">Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,925,861<span></span>
</td>
<td class="nump">2,457,788<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from Stock Options Exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 406,623<span></span>
</td>
<td class="nump">$ 1,261,251<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average grant-date fair value options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">881,428<span></span>
</td>
<td class="nump">5,699,986<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krmd_StockIssuedDuringPeriodSharesStockOptionsExercised1', window );">Options exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,150,203<span></span>
</td>
<td class="nump">697,920<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Total unrecognized compensation cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,299,070<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted-average period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">45 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue', window );">Fair value of shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,703,002<span></span>
</td>
<td class="nump">$ 1,923,179<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=krmd_StockOptionPlan2015Member', window );">Stock Option Plan 2015 [Member] | Executiveskey Employees And Consultants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Common stock, shares, outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,560,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krmd_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan2015', window );">Stock issued during period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">445,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=krmd_StockOptionPlan2021Member', window );">Stock Option Plan 2021 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Available for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue', window );">Stock options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.99<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Tax benefit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 33,083<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue', window );">Fair value of shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">157,536<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=krmd_StockOptionPlan2021Member', window );">Stock Option Plan 2021 [Member] | Equity Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">$ (408,747)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=krmd_StockOptionPlan2021Member', window );">Stock Option Plan 2021 [Member] | Time Based Shares Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average grant-date fair value options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">945,215<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krmd_CompensationCost', window );">Unrecognized compensation cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 787,679<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krmd_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm3', window );">Weighted-average period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">48 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=krmd_StockOptionPlan2021Member', window );">Stock Option Plan 2021 [Member] | Restricted Stock Awards [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Tax benefit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 101,419<span></span>
</td>
<td class="nump">$ 47,220<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krmd_UnrecognizedCompensationCost', window );">Unrecognized compensation cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,618,177<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krmd_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm4', window );">Weighted-average period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">21 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=krmd_StockOptionPlan2021Member', window );">Stock Option Plan 2021 [Member] | Director [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan', window );">Common stock issued, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">97,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=krmd_StockOptionPlan2021Member', window );">Stock Option Plan 2021 [Member] | Executive [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan', window );">Common stock issued, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">475,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krmd_CompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The element represents compensation cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krmd_CompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krmd_NonemployeeServicesTransactionCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The element represents nonemployee services transaction cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krmd_NonemployeeServicesTransactionCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The element represents share based compensation arrangement by share based payment award grants in period weighted average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krmd_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm3">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krmd_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm3</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krmd_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm4">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krmd_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm4</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krmd_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan2015">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The element represents stock issued during period shares employee stock ownership plan2015.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krmd_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan2015</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krmd_StockIssuedDuringPeriodSharesStockOptionsExercised1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The element represents stock issued during period shares stock options exercised1.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krmd_StockIssuedDuringPeriodSharesStockOptionsExercised1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krmd_UnrecognizedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The element represents unrecognized compensation cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krmd_UnrecognizedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares reserved for issuance pertaining to the outstanding stock options as of the balance sheet date for all option plans in the customized range of exercise prices.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of transactions in which an entity acquires goods or services other than employee services in exchange for equity securities of the company, including the purpose of the transaction, identification and quantity of the securities issued, the accounting method used for valuing the transaction, disclosure of amounts by which report lines were affected, and noncash effects on the statement of cash flows.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedGoodsAndNonemployeeServicesTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average grant-date fair value of options vested.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of capital stock issued (purchased by employees) in connection with an employee stock ownership plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 40<br> -Section 25<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=109244457&amp;loc=d3e16649-113920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate value of stock issued during the period as a result of employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 40<br> -Section 25<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=109244457&amp;loc=d3e16649-113920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock related to Restricted Stock Awards issued during the period, net of the stock value of such awards forfeited.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=krmd_ChiefExecutiveOfficerLindaTharbyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=krmd_ChiefExecutiveOfficerLindaTharbyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=krmd_NonEmployeeDirectorAndBoardAdvisorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=krmd_NonEmployeeDirectorAndBoardAdvisorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_BoardOfDirectorsChairmanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_BoardOfDirectorsChairmanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_ChiefExecutiveOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_ChiefExecutiveOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=krmd_EmploymentAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=krmd_EmploymentAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=krmd_StockOptionPlan2015Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=krmd_StockOptionPlan2015Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=krmd_TimeBasedSharesOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=krmd_TimeBasedSharesOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=krmd_ExecutiveskeyEmployeesAndConsultantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=krmd_ExecutiveskeyEmployeesAndConsultantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=krmd_StockOptionPlan2021Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=krmd_StockOptionPlan2021Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_StockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_StockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=krmd_RestrictedStockAwardsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=krmd_RestrictedStockAwardsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_DirectorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_DirectorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=krmd_ExecutiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=krmd_ExecutiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139621726433248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of components of lease expense (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease cost</a></td>
<td class="nump">$ 514,294<span></span>
</td>
<td class="nump">$ 149,476<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermLeaseCost', window );">Short-term lease cost</a></td>
<td class="nump">131,490<span></span>
</td>
<td class="nump">146,604<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Total lease cost</a></td>
<td class="nump">645,784<span></span>
</td>
<td class="nump">296,080<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krmd_FinanceLeaseCost1Abstract', window );"><strong>Finance lease cost:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAssetAmortization', window );">Amortization of right-of-use assets</a></td>
<td class="nump">50,895<span></span>
</td>
<td class="nump">2,586<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseInterestExpense', window );">Interest on lease liabilities</a></td>
<td class="nump">5,393<span></span>
</td>
<td class="nump">60<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krmd_FinanceLeaseCost', window );">Total finance lease cost</a></td>
<td class="nump">$ 56,288<span></span>
</td>
<td class="nump">$ 2,646<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krmd_FinanceLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The element represents finance lease cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krmd_FinanceLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krmd_FinanceLeaseCost1Abstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The element represents finance lease cost1 abstract.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krmd_FinanceLeaseCost1Abstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense on finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918638-209977<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAssetAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918638-209977<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAssetAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term lease cost, excluding expense for lease with term of one month or less.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139621726781488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of cash flow information related to leases (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFlowOperatingActivitiesLesseeAbstract', window );"><strong>Cash paid for amounts included in the measurement of lease liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Operating cash flows from operating leases</a></td>
<td class="nump">$ 247,504<span></span>
</td>
<td class="nump">$ 141,293<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseInterestPaymentOnLiability', window );">Financing cash flows from finance leases</a></td>
<td class="nump">$ 57,243<span></span>
</td>
<td class="nump">$ 2,646<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowOperatingActivitiesLesseeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowOperatingActivitiesLesseeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseInterestPaymentOnLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest paid on finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918643-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseInterestPaymentOnLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139621722404688">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Schdeule of balance sheet information related to leases (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krmd_AssetsAndLiabilitiesOperatingLesseeAbstract', window );"><strong>Operating Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">$ 3,786,545<span></span>
</td>
<td class="nump">$ 95,553<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liability &#8211; current</a></td>
<td class="nump">345,834<span></span>
</td>
<td class="nump">95,553<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liability, net of current portion</a></td>
<td class="nump">3,653,257<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total operating lease liabilities</a></td>
<td class="nump">3,999,091<span></span>
</td>
<td class="nump">95,553<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krmd_AssetsAndLiabilitiesLesseeFinanceAbstract', window );"><strong>Finance Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentOther', window );">Property and equipment, at cost</a></td>
<td class="nump">544,468<span></span>
</td>
<td class="nump">12,725<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentOtherAccumulatedDepreciation', window );">Accumulated depreciation</a></td>
<td class="num">(50,895)<span></span>
</td>
<td class="num">(12,725)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentOtherNet', window );">Property and equipment, net</a></td>
<td class="nump">493,573<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityCurrent', window );">Finance lease liability &#8211; current</a></td>
<td class="nump">98,335<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityNoncurrent', window );">Finance lease liability, net of current portion</a></td>
<td class="nump">394,283<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiability', window );">Total finance lease liabilities</a></td>
<td class="nump">$ 492,618<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Operating leases</a></td>
<td class="text">9 years 8 months 12 days<span></span>
</td>
<td class="text">7 months 6 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeFinanceLeaseRenewalTerm1', window );">Finance leases</a></td>
<td class="text">4 years 22 days<span></span>
</td>
<td class="text">0 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseDiscountRate', window );">Operating leases</a></td>
<td class="nump">4.00%<span></span>
</td>
<td class="nump">4.75%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeFinanceLeaseDiscountRate', window );">Finance leases</a></td>
<td class="nump">4.25%<span></span>
</td>
<td class="nump">4.75%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krmd_AssetsAndLiabilitiesLesseeFinanceAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The element represents assets and liabilities lessee finance abstract.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krmd_AssetsAndLiabilitiesLesseeFinanceAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krmd_AssetsAndLiabilitiesOperatingLesseeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The element represents assets and liabilities operating lessee abstract.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krmd_AssetsAndLiabilitiesOperatingLesseeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeFinanceLeaseDiscountRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Discount rate used by lessee to determine present value of finance lease payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeFinanceLeaseDiscountRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeFinanceLeaseRenewalTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's finance lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeFinanceLeaseRenewalTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseDiscountRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Discount rate used by lessee to determine present value of operating lease payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseDiscountRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of other physical assets used in the normal conduct of business to produce goods and services and not intended for resale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentOtherAccumulatedDepreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation of long-lived, physical assets used to produce goods and services and not intended for resale, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentOtherAccumulatedDepreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentOtherNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after depreciation of long-lived, physical assets used to produce goods and services and not intended for resale, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentOtherNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139621722360096">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Schedule of maturities of lease liabilities (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2023</a></td>
<td class="nump">$ 499,503<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2023</a></td>
<td class="nump">123,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2024</a></td>
<td class="nump">499,503<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo', window );">2024</a></td>
<td class="nump">123,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2025</a></td>
<td class="nump">499,503<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree', window );">2025</a></td>
<td class="nump">123,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2026</a></td>
<td class="nump">499,503<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour', window );">2026</a></td>
<td class="nump">123,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive', window );">2027</a></td>
<td class="nump">499,503<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive', window );">2027</a></td>
<td class="nump">65,957<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive', window );">Thereafter</a></td>
<td class="nump">2,331,015<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive', window );">Thereafter</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krmd_LesseeOperatingLeaseLiabilityPaymentsDueTotal', window );">Total undiscounted lease payments</a></td>
<td class="nump">4,828,530<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krmd_LesseeFinancingLeaseLeaseLiabilityPaymentsDueTotal', window );">Total undiscounted lease payments</a></td>
<td class="nump">558,757<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krmd_LesseeOperatingLeaseImputedInterest', window );">Less: imputed interest</a></td>
<td class="num">(829,439)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krmd_LesseeFinancingLeaseImputedInterest', window );">Less: imputed interest</a></td>
<td class="num">(66,139)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total lease liabilities</a></td>
<td class="nump">3,999,091<span></span>
</td>
<td class="nump">$ 95,553<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiability', window );">Total lease liabilities</a></td>
<td class="nump">$ 492,618<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krmd_LesseeFinancingLeaseImputedInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The element represents lessee financing lease imputed interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krmd_LesseeFinancingLeaseImputedInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krmd_LesseeFinancingLeaseLeaseLiabilityPaymentsDueTotal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The element represents lessee financing lease lease liability payments due total.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krmd_LesseeFinancingLeaseLeaseLiabilityPaymentsDueTotal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krmd_LesseeOperatingLeaseImputedInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The element represents lessee operating lease imputed interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krmd_LesseeOperatingLeaseImputedInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krmd_LesseeOperatingLeaseLiabilityPaymentsDueTotal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The element represents lessee operating lease liability payments due total.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krmd_LesseeOperatingLeaseLiabilityPaymentsDueTotal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139621810471680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LEASES (Details Narrative)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krmd_DescriptionOfLessorOperatingLeaseTerm', window );">Description of lease term</a></td>
<td class="text">Our leases have remaining lease terms of 10, 5 years, and 3 months.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krmd_DescriptionOfLessorOperatingLeaseTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The element represents description of lessor operating lease term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krmd_DescriptionOfLessorOperatingLeaseTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139621722395392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of provision for income taxes (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>State income tax:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit', window );">Current, net of refund</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">$ (12,800)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Federal income tax:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit', window );">Deferred</a></td>
<td class="nump">2,014,018<span></span>
</td>
<td class="nump">1,814,418<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentFederalTaxExpenseBenefit', window );">Current</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax benefit/(expense)</a></td>
<td class="nump">$ 2,014,018<span></span>
</td>
<td class="nump">$ 1,801,618<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentFederalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentFederalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentStateAndLocalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFederalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139621726821408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of reconciliation of income taxes (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments', window );">Loss before taxes</a></td>
<td class="num">$ (10,675,160)<span></span>
</td>
<td class="num">$ (6,364,441)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate', window );">Income taxes computed at the federal statutory rate</a></td>
<td class="nump">2,241,784<span></span>
</td>
<td class="nump">1,336,533<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes', window );">State income and franchise tax</a></td>
<td class="nump">(0)<span></span>
</td>
<td class="num">(12,800)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationOtherAdjustments', window );">Permanent differences and other</a></td>
<td class="num">(227,766)<span></span>
</td>
<td class="nump">477,885<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax benefit/(expense)</a></td>
<td class="nump">$ 2,014,018<span></span>
</td>
<td class="nump">$ 1,801,618<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139621726867376">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Schedule of components of deferred tax assets (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCompensationPlanAssets', window );">Deferred compensation cost</a></td>
<td class="nump">$ 557,931<span></span>
</td>
<td class="nump">$ 389,981<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krmd_DepreciationDepletionAndAmortization1', window );">Depreciation and amortization</a></td>
<td class="num">(624,184)<span></span>
</td>
<td class="num">(116,911)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krmd_RdCredit', window );">R&amp;D credit</a></td>
<td class="nump">142,030<span></span>
</td>
<td class="nump">142,538<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krmd_Nol', window );">NOL</a></td>
<td class="nump">2,956,685<span></span>
</td>
<td class="nump">1,507,982<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krmd_AllowanceForDoubtfulOtherReceivables1Current', window );">Allowance for bad debts and other</a></td>
<td class="nump">935,018<span></span>
</td>
<td class="nump">17,664<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Deferred income tax assets, net</a></td>
<td class="nump">$ 3,967,480<span></span>
</td>
<td class="nump">$ 1,941,254<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krmd_AllowanceForDoubtfulOtherReceivables1Current">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The element represents allowance for doubtful other receivables1 current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krmd_AllowanceForDoubtfulOtherReceivables1Current</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krmd_DepreciationDepletionAndAmortization1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The element represents depreciation depletion and amortization1.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krmd_DepreciationDepletionAndAmortization1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krmd_Nol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The element represents nol.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krmd_Nol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krmd_RdCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The element represents rd credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krmd_RdCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCompensationPlanAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of assets held under deferred compensation agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCompensationPlanAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139621731320880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>MAJOR CUSTOMERS (Details Narrative)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember', window );">Revenue Benchmark [Member] | Customer Concentration Risk [Member] | Customer One [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="nump">64.00%<span></span>
</td>
<td class="nump">64.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13531-108611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13537-108611<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=krmd_CustomerOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=krmd_CustomerOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139621728838592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EMPLOYEE BENEFITS (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krmd_DescriptionOfMatchingContribution', window );">Description of matching contribution</a></td>
<td class="text">The Company makes safe harbor matching contributions in an amount
equal to 100% of the employee&#8217;s contribution, not to exceed 3% of employee&#8217;s compensation plus 50% of employee&#8217;s pay
contributed between 3% and 5% of employee&#8217;s compensation<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount', window );">Matching expense</a></td>
<td class="nump">$ 214,931<span></span>
</td>
<td class="nump">$ 166,014<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krmd_DescriptionOfMatchingContribution">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The element represents description of matching contribution.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krmd_DescriptionOfMatchingContribution</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of discretionary contributions made by an employer to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139621726797824">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>DEBT OBLIGATIONS (Details Narrative) - A O N Premium Finance L L C [Member] - Promissory Note [Member]<br></strong></div></th>
<th class="th">
<div>Aug. 05, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayable', window );">Notes payable</a></td>
<td class="nump">$ 800,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=krmd_AONPremiumFinanceLLCMember', window );">Line of Credit [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krmd_NotePayableTerms', window );">Note payable terms</a></td>
<td class="nump">6.50%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krmd_NotePayableTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The element represents note payable terms.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krmd_NotePayableTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=krmd_AONPremiumFinanceLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=krmd_AONPremiumFinanceLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=krmd_PromissoryNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=krmd_PromissoryNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_LineOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_LineOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>form_10-k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:country="http://xbrl.sec.gov/country/2022"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:krmd="http://korumedical.com/20221231"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2022"
  xmlns:us-gaap="http://fasb.org/us-gaap/2022"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="krmd-20221231.xsd" xlink:type="simple"/>
    <context id="From2022-01-01to2022-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="AsOf2023-03-08">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
        </entity>
        <period>
            <instant>2023-03-08</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="From2021-01-012021-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2020-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_us-gaap_TreasuryStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_TreasuryStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_us-gaap_TreasuryStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_TreasuryStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_TreasuryStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_PatentsAndTrademarksMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">krmd:PatentsAndTrademarksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_PatentsAndTrademarksMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">krmd:PatentsAndTrademarksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_srt_MinimumMember_custom_FurnitureAndOfficeEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">krmd:FurnitureAndOfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_srt_MaximumMember_custom_FurnitureAndOfficeEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">krmd:FurnitureAndOfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_srt_MinimumMember_custom_EquipmentAndToolingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">krmd:EquipmentAndToolingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_srt_MaximumMember_custom_EquipmentAndToolingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">krmd:EquipmentAndToolingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_PropertyPlantAndEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:PropertyPlantAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_us-gaap_PropertyPlantAndEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:PropertyPlantAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_EmployeeStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_us-gaap_EmployeeStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_country_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_country_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_NonUsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_us-gaap_NonUsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_FurnitureAndOfficeEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">krmd:FurnitureAndOfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_custom_FurnitureAndOfficeEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">krmd:FurnitureAndOfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_LeaseholdImprovementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_LeaseholdImprovementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_ManufacturingEquipmentAndToolingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">krmd:ManufacturingEquipmentAndToolingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_custom_ManufacturingEquipmentAndToolingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">krmd:ManufacturingEquipmentAndToolingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_StockOptionPlan2015Member_custom_ExecutiveskeyEmployeesAndConsultantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">krmd:ExecutiveskeyEmployeesAndConsultantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">krmd:StockOptionPlan2015Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_StockOptionPlan2015Member_custom_ExecutiveskeyEmployeesAndConsultantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">krmd:ExecutiveskeyEmployeesAndConsultantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">krmd:StockOptionPlan2015Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_StockOptionPlan2015Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">krmd:StockOptionPlan2015Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_StockOptionPlan2021Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">krmd:StockOptionPlan2021Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_StockOptionPlan2021Member_srt_DirectorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">krmd:StockOptionPlan2021Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_StockOptionPlan2021Member_custom_ExecutiveMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">krmd:ExecutiveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">krmd:StockOptionPlan2021Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2020-12-302021-01-02_custom_NonEmployeeDirectorAndBoardAdvisorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">krmd:NonEmployeeDirectorAndBoardAdvisorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-30</startDate>
            <endDate>2021-01-02</endDate>
        </period>
    </context>
    <context id="From2020-12-302021-01-02_srt_BoardOfDirectorsChairmanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-30</startDate>
            <endDate>2021-01-02</endDate>
        </period>
    </context>
    <context id="From2021-05-162021-05-18_custom_NonEmployeeDirectorAndBoardAdvisorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">krmd:NonEmployeeDirectorAndBoardAdvisorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-16</startDate>
            <endDate>2021-05-18</endDate>
        </period>
    </context>
    <context id="From2021-05-162021-05-18_srt_BoardOfDirectorsChairmanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-16</startDate>
            <endDate>2021-05-18</endDate>
        </period>
    </context>
    <context id="From2021-04-112021-04-12_custom_ChiefExecutiveOfficerLindaTharbyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">krmd:ChiefExecutiveOfficerLindaTharbyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-11</startDate>
            <endDate>2021-04-12</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_custom_StockOptionPlan2015Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">krmd:StockOptionPlan2015Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">krmd:TimeBasedSharesOptionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">krmd:StockOptionPlan2015Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">krmd:TimeBasedSharesOptionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">krmd:StockOptionPlan2015Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">krmd:TimeBasedSharesOptionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">krmd:StockOptionPlan2015Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">krmd:TimeBasedSharesOptionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">krmd:StockOptionPlan2015Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_custom_StockOptionPlan2021Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">krmd:StockOptionPlan2021Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_StockOptionPlan2021Member_custom_TimeBasedSharesOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">krmd:TimeBasedSharesOptionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">krmd:StockOptionPlan2021Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_custom_StockOptionPlan2021Member_custom_TimeBasedSharesOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">krmd:TimeBasedSharesOptionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">krmd:StockOptionPlan2021Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_StockOptionPlan2021Member_custom_TimeBasedSharesOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">krmd:TimeBasedSharesOptionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">krmd:StockOptionPlan2021Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_StockOptionPlan2021Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">krmd:StockOptionPlan2021Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_custom_StockOptionPlan2021Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">krmd:StockOptionPlan2021Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_StockOptionPlan2021Member_us-gaap_StockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">krmd:StockOptionPlan2021Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_custom_StockOptionPlan2021Member_us-gaap_StockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">krmd:StockOptionPlan2021Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2021-04-12_custom_EmploymentAgreementMember_srt_ChiefExecutiveOfficerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">krmd:EmploymentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-12</instant>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_StockOptionPlan2021Member_custom_RestrictedStockAwardsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">krmd:RestrictedStockAwardsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">krmd:StockOptionPlan2021Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_custom_RestrictedStockAwardsMember_custom_StockOptionPlan2021Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">krmd:RestrictedStockAwardsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">krmd:StockOptionPlan2021Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">krmd:TimeBasedSharesOptionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">krmd:StockOptionPlan2015Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">krmd:TimeBasedSharesOptionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">krmd:StockOptionPlan2015Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">krmd:TimeBasedSharesOptionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">krmd:StockOptionPlan2015Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">krmd:TimeBasedSharesOptionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">krmd:StockOptionPlan2015Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_custom_StockOptionPlan2021Member_custom_TimeBasedSharesOptionsMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">krmd:TimeBasedSharesOptionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">krmd:StockOptionPlan2021Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_StockOptionPlan2021Member_custom_TimeBasedSharesOptionsMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">krmd:TimeBasedSharesOptionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">krmd:StockOptionPlan2021Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2021-12-31_custom_StockOptionPlan2015Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">krmd:StockOptionPlan2015Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_custom_StockOptionPlan2015Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">krmd:StockOptionPlan2015Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_StockOptionPlan2015Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">krmd:StockOptionPlan2015Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_custom_StockOptionPlan2021Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">krmd:StockOptionPlan2021Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember_custom_ExercisePrice1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">krmd:TimeBasedSharesOptionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">krmd:StockOptionPlan2015Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">krmd:ExercisePrice1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember_custom_ExercisePrice1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">krmd:TimeBasedSharesOptionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">krmd:StockOptionPlan2015Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">krmd:ExercisePrice1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_StockOptionPlan2021Member_custom_TimeBasedSharesOptionsMember_custom_ExercisePrice1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">krmd:TimeBasedSharesOptionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">krmd:StockOptionPlan2021Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">krmd:ExercisePrice1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_StockOptionPlan2021Member_custom_TimeBasedSharesOptionsMember_custom_ExercisePrice1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">krmd:TimeBasedSharesOptionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">krmd:StockOptionPlan2021Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">krmd:ExercisePrice1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_PerformanceSharesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_us-gaap_PerformanceSharesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_PerformanceSharesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_us-gaap_PerformanceSharesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_PerformanceSharesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_custom_RestrictedStockAwardsMember_custom_StockOptionPlan2021Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">krmd:RestrictedStockAwardsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">krmd:StockOptionPlan2021Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_custom_RestrictedStockAwardsMember_custom_StockOptionPlan2021Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">krmd:RestrictedStockAwardsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">krmd:StockOptionPlan2021Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_RestrictedStockAwardsMember_custom_StockOptionPlan2021Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">krmd:RestrictedStockAwardsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">krmd:StockOptionPlan2021Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">krmd:CustomerOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">krmd:CustomerOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-08-05_custom_AONPremiumFinanceLLCMember_custom_PromissoryNoteMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">krmd:PromissoryNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">krmd:AONPremiumFinanceLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-08-05</instant>
        </period>
    </context>
    <context id="From2022-08-032022-08-05_custom_AONPremiumFinanceLLCMember_custom_PromissoryNoteMember_us-gaap_LineOfCreditMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">krmd:PromissoryNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">krmd:AONPremiumFinanceLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-08-03</startDate>
            <endDate>2022-08-05</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Pure">
        <measure>pure</measure>
    </unit>
    <unit id="N">
        <measure>krmd:Number</measure>
    </unit>
    <dei:EntityCentralIndexKey contextRef="From2022-01-01to2022-12-31">0000704440</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="From2022-01-01to2022-12-31">false</dei:AmendmentFlag>
    <dei:CurrentFiscalYearEndDate contextRef="From2022-01-01to2022-12-31">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus contextRef="From2022-01-01to2022-12-31">2022</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus contextRef="From2022-01-01to2022-12-31">FY</dei:DocumentFiscalPeriodFocus>
    <dei:EntityRegistrantName contextRef="From2022-01-01to2022-12-31" id="xdx2ixbrl0019">KORU MEDICAL SYSTEMS, INC</dei:EntityRegistrantName>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="AsOf2021-12-31"
      id="xdx2ixbrl0120"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:FinanceLeaseLiabilityNoncurrent
      contextRef="AsOf2021-12-31"
      id="xdx2ixbrl0129"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="AsOf2021-12-31"
      id="xdx2ixbrl0132"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment
      contextRef="From2022-01-01to2022-12-31"
      id="xdx2ixbrl0211"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherIncome
      contextRef="From2022-01-01to2022-12-31"
      id="xdx2ixbrl0214"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2021-01-012021-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0260"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2021-01-012021-12-31_us-gaap_TreasuryStockMember"
      id="xdx2ixbrl0261"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0266"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="From2021-01-012021-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0268"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="From2021-01-012021-12-31_us-gaap_TreasuryStockMember"
      id="xdx2ixbrl0269"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0272"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="From2021-01-012021-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0274"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="From2021-01-012021-12-31_us-gaap_TreasuryStockMember"
      id="xdx2ixbrl0275"
      unitRef="USD"
      xsi:nil="true"/>
    <krmd:NewIssuanceLitigationSettlementAmountIssuance
      contextRef="From2021-01-012021-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0280"
      unitRef="USD"
      xsi:nil="true"/>
    <krmd:NewIssuanceLitigationSettlementAmountIssuance
      contextRef="From2021-01-012021-12-31_us-gaap_TreasuryStockMember"
      id="xdx2ixbrl0281"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2021-01-012021-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0288"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2021-01-012021-12-31_us-gaap_TreasuryStockMember"
      id="xdx2ixbrl0289"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0294"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-01-012021-12-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0295"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-01-012021-12-31_us-gaap_TreasuryStockMember"
      id="xdx2ixbrl0297"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0310"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2022-01-012022-12-31_us-gaap_TreasuryStockMember"
      id="xdx2ixbrl0311"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0316"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0318"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="From2022-01-012022-12-31_us-gaap_TreasuryStockMember"
      id="xdx2ixbrl0319"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0324"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="From2022-01-012022-12-31_us-gaap_TreasuryStockMember"
      id="xdx2ixbrl0325"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0332"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2022-01-012022-12-31_us-gaap_TreasuryStockMember"
      id="xdx2ixbrl0333"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0338"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0339"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-01-012022-12-31_us-gaap_TreasuryStockMember"
      id="xdx2ixbrl0341"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:GainLossOnSaleOfOtherAssets
      contextRef="From2022-01-01to2022-12-31"
      id="xdx2ixbrl0367"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromSaleOfProductiveAssets
      contextRef="From2022-01-01to2022-12-31"
      id="xdx2ixbrl0415"
      unitRef="USD"
      xsi:nil="true"/>
    <krmd:CommonStockIssuanceAsSettlementForLitigation
      contextRef="From2022-01-01to2022-12-31"
      id="xdx2ixbrl0427"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="From2022-01-01to2022-12-31"
      id="xdx2ixbrl0460"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssued1
      contextRef="From2022-01-01to2022-12-31"
      id="xdx2ixbrl0469"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NumberOfReportableSegments
      contextRef="From2022-01-01to2022-12-31"
      decimals="INF"
      id="xdx2ixbrl0476"
      unitRef="N">1</us-gaap:NumberOfReportableSegments>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="From2022-01-012022-12-31_custom_PatentsAndTrademarksMember_srt_MinimumMember"
      id="xdx2ixbrl0488">P6Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="From2022-01-012022-12-31_custom_PatentsAndTrademarksMember_srt_MaximumMember"
      id="xdx2ixbrl0490">P20Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="From2022-01-012022-12-31_srt_MinimumMember_custom_FurnitureAndOfficeEquipmentMember"
      id="xdx2ixbrl0517">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="From2022-01-012022-12-31_srt_MaximumMember_custom_FurnitureAndOfficeEquipmentMember"
      id="xdx2ixbrl0518">P10Y0M0D</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="From2022-01-012022-12-31_srt_MinimumMember_custom_EquipmentAndToolingMember"
      id="xdx2ixbrl0519">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="From2022-01-012022-12-31_srt_MaximumMember_custom_EquipmentAndToolingMember"
      id="xdx2ixbrl0520">P12Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:IncrementalCommonSharesAttributableToCallOptionsAndWarrants
      contextRef="From2022-01-01to2022-12-31"
      id="xdx2ixbrl0541"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:IncrementalCommonSharesAttributableToCallOptionsAndWarrants
      contextRef="From2021-01-012021-12-31"
      id="xdx2ixbrl0542"
      unitRef="Shares"
      xsi:nil="true"/>
    <krmd:IncrementalCommonSharesAttributableToRestrictedStock
      contextRef="From2022-01-01to2022-12-31"
      id="xdx2ixbrl0544"
      unitRef="Shares"
      xsi:nil="true"/>
    <krmd:IncrementalCommonSharesAttributableToRestrictedStock
      contextRef="From2021-01-012021-12-31"
      id="xdx2ixbrl0545"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2022-01-012022-12-31_us-gaap_EmployeeStockMember"
      decimals="INF"
      id="xdx2ixbrl0560"
      unitRef="Shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="xdx2ixbrl0640"
      unitRef="USD">3886975</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
      contextRef="From2021-01-012021-12-31_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember"
      id="xdx2ixbrl0697"
      unitRef="Pure"
      xsi:nil="true"/>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="From2022-01-012022-12-31_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember"
      id="xdx2ixbrl0703">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="From2021-01-012021-12-31_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember"
      id="xdx2ixbrl0705">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
      contextRef="From2022-01-012022-12-31_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember_custom_ExercisePrice1Member"
      id="xdx2ixbrl0782">P8Y9M18D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="From2022-01-012022-12-31_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember"
      id="xdx2ixbrl0792">P45M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
      contextRef="From2022-01-012022-12-31_custom_StockOptionPlan2021Member_custom_TimeBasedSharesOptionsMember"
      id="xdx2ixbrl0817"
      unitRef="Pure"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
      contextRef="From2021-01-012021-12-31_custom_StockOptionPlan2021Member_custom_TimeBasedSharesOptionsMember"
      id="xdx2ixbrl0819"
      unitRef="Pure"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments
      contextRef="From2021-01-012021-12-31_custom_StockOptionPlan2021Member_custom_TimeBasedSharesOptionsMember"
      id="xdx2ixbrl0823"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="From2022-01-012022-12-31_custom_StockOptionPlan2021Member_custom_TimeBasedSharesOptionsMember"
      id="xdx2ixbrl0825">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="From2021-01-012021-12-31_custom_StockOptionPlan2021Member_custom_TimeBasedSharesOptionsMember"
      id="xdx2ixbrl0827">P0Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber2
      contextRef="AsOf2020-12-31_custom_StockOptionPlan2021Member"
      id="xdx2ixbrl0840"
      unitRef="Shares"
      xsi:nil="true"/>
    <krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice2
      contextRef="AsOf2020-12-31_custom_StockOptionPlan2021Member"
      id="xdx2ixbrl0841"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross2
      contextRef="From2021-01-012021-12-31_custom_StockOptionPlan2021Member"
      id="xdx2ixbrl0846"
      unitRef="Shares"
      xsi:nil="true"/>
    <krmd:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice2
      contextRef="From2021-01-012021-12-31_custom_StockOptionPlan2021Member"
      id="xdx2ixbrl0847"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <krmd:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice2
      contextRef="From2022-01-012022-12-31_custom_StockOptionPlan2021Member"
      id="xdx2ixbrl0851"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <krmd:StockIssuedDuringPeriodSharesStockOptionsExercised2
      contextRef="From2021-01-012021-12-31_custom_StockOptionPlan2021Member"
      id="xdx2ixbrl0852"
      unitRef="Shares"
      xsi:nil="true"/>
    <krmd:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice2
      contextRef="From2021-01-012021-12-31_custom_StockOptionPlan2021Member"
      id="xdx2ixbrl0853"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <krmd:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice2
      contextRef="From2022-01-012022-12-31_custom_StockOptionPlan2021Member"
      id="xdx2ixbrl0857"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod2
      contextRef="From2021-01-012021-12-31_custom_StockOptionPlan2021Member"
      id="xdx2ixbrl0858"
      unitRef="Shares"
      xsi:nil="true"/>
    <krmd:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice2
      contextRef="From2021-01-012021-12-31_custom_StockOptionPlan2021Member"
      id="xdx2ixbrl0859"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice2
      contextRef="AsOf2022-12-31_custom_StockOptionPlan2021Member"
      id="xdx2ixbrl0869"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="AsOf2021-12-31_custom_StockOptionPlan2021Member"
      id="xdx2ixbrl0870"
      unitRef="Shares"
      xsi:nil="true"/>
    <krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice2
      contextRef="AsOf2021-12-31_custom_StockOptionPlan2021Member"
      id="xdx2ixbrl0871"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue2
      contextRef="From2021-01-012021-12-31_custom_StockOptionPlan2021Member"
      id="xdx2ixbrl0874"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensation
      contextRef="From2021-01-012021-12-31_custom_StockOptionPlan2021Member"
      id="xdx2ixbrl0877"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensation
      contextRef="From2021-01-012021-12-31_custom_StockOptionPlan2021Member"
      id="xdx2ixbrl0881"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
      contextRef="From2022-01-012022-12-31_custom_StockOptionPlan2021Member_custom_TimeBasedSharesOptionsMember_custom_ExercisePrice1Member"
      id="xdx2ixbrl0891">P9Y3M19D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <krmd:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm3
      contextRef="From2022-01-012022-12-31_custom_StockOptionPlan2021Member_custom_TimeBasedSharesOptionsMember"
      id="xdx2ixbrl0901">P48M</krmd:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm3>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
      contextRef="AsOf2022-12-31_custom_StockOptionPlan2021Member"
      decimals="0"
      id="xdx2ixbrl0903"
      unitRef="USD">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
      contextRef="AsOf2021-12-31_custom_StockOptionPlan2021Member"
      decimals="0"
      id="xdx2ixbrl0905"
      unitRef="USD">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue>
    <krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber1
      contextRef="AsOf2021-12-31_us-gaap_PerformanceSharesMember"
      id="xdx2ixbrl0910"
      unitRef="Shares"
      xsi:nil="true"/>
    <krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice1
      contextRef="AsOf2021-12-31_us-gaap_PerformanceSharesMember"
      id="xdx2ixbrl0912"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <krmd:AllocatedShareBasedCompensationExpense1
      contextRef="From2022-01-012022-12-31_us-gaap_PerformanceSharesMember"
      id="xdx2ixbrl0953"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensation
      contextRef="From2022-01-012022-12-31_custom_StockOptionPlan2021Member_us-gaap_StockOptionMember"
      id="xdx2ixbrl0957"
      unitRef="USD"
      xsi:nil="true"/>
    <krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberUnvested
      contextRef="AsOf2020-12-31_custom_RestrictedStockAwardsMember_custom_StockOptionPlan2021Member"
      id="xdx2ixbrl0970"
      unitRef="Shares"
      xsi:nil="true"/>
    <krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceUnvested
      contextRef="AsOf2020-12-31_custom_RestrictedStockAwardsMember_custom_StockOptionPlan2021Member"
      id="xdx2ixbrl0971"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrossUnvested
      contextRef="From2022-01-012022-12-31_custom_StockOptionPlan2021Member_custom_RestrictedStockAwardsMember"
      id="xdx2ixbrl0973"
      unitRef="Shares"
      xsi:nil="true"/>
    <krmd:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePriceUnvested
      contextRef="From2022-01-012022-12-31_custom_StockOptionPlan2021Member_custom_RestrictedStockAwardsMember"
      id="xdx2ixbrl0975"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodGross
      contextRef="From2021-01-012021-12-31_custom_RestrictedStockAwardsMember_custom_StockOptionPlan2021Member"
      id="xdx2ixbrl0982"
      unitRef="Shares"
      xsi:nil="true"/>
    <krmd:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice
      contextRef="From2021-01-012021-12-31_custom_RestrictedStockAwardsMember_custom_StockOptionPlan2021Member"
      id="xdx2ixbrl0983"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodUnvested
      contextRef="From2022-01-012022-12-31_custom_StockOptionPlan2021Member_custom_RestrictedStockAwardsMember"
      id="xdx2ixbrl0985"
      unitRef="Shares"
      xsi:nil="true"/>
    <krmd:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePriceUnvested
      contextRef="From2022-01-012022-12-31_custom_StockOptionPlan2021Member_custom_RestrictedStockAwardsMember"
      id="xdx2ixbrl0987"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodUnvested
      contextRef="From2021-01-012021-12-31_custom_RestrictedStockAwardsMember_custom_StockOptionPlan2021Member"
      id="xdx2ixbrl0988"
      unitRef="Shares"
      xsi:nil="true"/>
    <krmd:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePriceUnvested
      contextRef="From2021-01-012021-12-31_custom_RestrictedStockAwardsMember_custom_StockOptionPlan2021Member"
      id="xdx2ixbrl0989"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <krmd:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm4
      contextRef="From2022-01-012022-12-31_custom_StockOptionPlan2021Member_custom_RestrictedStockAwardsMember"
      id="xdx2ixbrl0999">P21M</krmd:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm4>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="AsOf2021-12-31"
      id="xdx2ixbrl1057"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PropertyPlantAndEquipmentOtherNet
      contextRef="AsOf2021-12-31"
      id="xdx2ixbrl1072"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="AsOf2021-12-31"
      id="xdx2ixbrl1075"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:FinanceLeaseLiabilityNoncurrent
      contextRef="AsOf2021-12-31"
      id="xdx2ixbrl1078"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:FinanceLeaseLiability
      contextRef="AsOf2021-12-31"
      id="xdx2ixbrl1081"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:LesseeOperatingLeaseRenewalTerm contextRef="AsOf2022-12-31" id="xdx2ixbrl1083">P9Y8M12D</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <us-gaap:LesseeOperatingLeaseRenewalTerm contextRef="AsOf2021-12-31" id="xdx2ixbrl1085">P0Y7M6D</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <us-gaap:LesseeFinanceLeaseRenewalTerm1 contextRef="AsOf2022-12-31" id="xdx2ixbrl1087">P4Y0M22D</us-gaap:LesseeFinanceLeaseRenewalTerm1>
    <us-gaap:LesseeFinanceLeaseRenewalTerm1 contextRef="AsOf2021-12-31" id="xdx2ixbrl1089">P0Y0M0D</us-gaap:LesseeFinanceLeaseRenewalTerm1>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueAfterYearFive
      contextRef="AsOf2022-12-31"
      id="xdx2ixbrl1123"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="From2022-01-01to2022-12-31"
      id="xdx2ixbrl1153"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="From2021-01-012021-12-31"
      id="xdx2ixbrl1154"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      id="xdx2ixbrl1156"
      unitRef="USD">-2014018</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      id="xdx2ixbrl1175"
      unitRef="USD">-2014018</us-gaap:IncomeTaxExpenseBenefit>
    <dei:DocumentType contextRef="From2022-01-01to2022-12-31">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport contextRef="From2022-01-01to2022-12-31">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate contextRef="From2022-01-01to2022-12-31">2022-12-31</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport contextRef="From2022-01-01to2022-12-31">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="From2022-01-01to2022-12-31">0-12305</dei:EntityFileNumber>
    <dei:EntityIncorporationStateCountryCode contextRef="From2022-01-01to2022-12-31">NY</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="From2022-01-01to2022-12-31">13-3044880</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="From2022-01-01to2022-12-31">100 Corporate Drive</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="From2022-01-01to2022-12-31">Mahwah</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="From2022-01-01to2022-12-31">NJ</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="From2022-01-01to2022-12-31">07430</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="From2022-01-01to2022-12-31">845</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="From2022-01-01to2022-12-31">469-2042</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="From2022-01-01to2022-12-31">common stock, $0.01 par value</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="From2022-01-01to2022-12-31">KRMD</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="From2022-01-01to2022-12-31">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer contextRef="From2022-01-01to2022-12-31">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers contextRef="From2022-01-01to2022-12-31">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus contextRef="From2022-01-01to2022-12-31">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="From2022-01-01to2022-12-31">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="From2022-01-01to2022-12-31">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="From2022-01-01to2022-12-31">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="From2022-01-01to2022-12-31">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany contextRef="From2022-01-01to2022-12-31">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat contextRef="AsOf2022-06-30" decimals="0" unitRef="USD">71872771</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding contextRef="AsOf2023-03-08" decimals="INF" unitRef="Shares">45519164</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:TreasuryStockCommonShares contextRef="AsOf2023-03-08" decimals="INF" unitRef="Shares">3420502</us-gaap:TreasuryStockCommonShares>
    <dei:AuditorFirmId contextRef="From2022-01-01to2022-12-31">256</dei:AuditorFirmId>
    <dei:AuditorName contextRef="From2022-01-01to2022-12-31">McGrail Merkel Quinn &amp; Associates, P.C.</dei:AuditorName>
    <dei:AuditorLocation contextRef="From2022-01-01to2022-12-31">Scranton, Pennsylvania</dei:AuditorLocation>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">17408257</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">25334889</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">21459</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">24271</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:AccountsReceivableNetCurrent contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">3558884</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">3592886</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:InventoryNet contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">6404867</us-gaap:InventoryNet>
    <us-gaap:InventoryNet contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">6106338</us-gaap:InventoryNet>
    <us-gaap:OtherReceivables contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">972396</us-gaap:OtherReceivables>
    <us-gaap:OtherReceivables contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">718220</us-gaap:OtherReceivables>
    <us-gaap:PrepaidExpenseCurrent contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">1457232</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseCurrent contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">1568821</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:AssetsCurrent contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">29801636</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">37321154</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">3886975</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">1106445</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">325872</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">263729</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">787182</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">808813</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">3786545</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">95553</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:DeferredIncomeTaxAssetsNet contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">3967480</us-gaap:DeferredIncomeTaxAssetsNet>
    <us-gaap:DeferredIncomeTaxAssetsNet contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">1941254</us-gaap:DeferredIncomeTaxAssetsNet>
    <us-gaap:OtherAssetsNoncurrent contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">102625</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">19812</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">42332443</us-gaap:Assets>
    <us-gaap:Assets contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">41293031</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">2391799</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">1227533</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">2889941</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">2709704</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:NotesPayableCurrent contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">433295</us-gaap:NotesPayableCurrent>
    <us-gaap:NotesPayableCurrent contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">508583</us-gaap:NotesPayableCurrent>
    <us-gaap:OtherLiabilitiesCurrent contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">257337</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">90000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">542399</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">160603</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">98335</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">345834</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">95553</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">6958940</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">4791976</us-gaap:LiabilitiesCurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">394283</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">3653257</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:Liabilities contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">11006480</us-gaap:Liabilities>
    <us-gaap:Liabilities contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">4791976</us-gaap:Liabilities>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2022-12-31"
      decimals="INF"
      unitRef="USDPShares">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2021-12-31"
      decimals="INF"
      unitRef="USDPShares">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized contextRef="AsOf2022-12-31" decimals="INF" unitRef="Shares">75000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized contextRef="AsOf2021-12-31" decimals="INF" unitRef="Shares">75000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued contextRef="AsOf2022-12-31" decimals="INF" unitRef="Shares">48861891</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued contextRef="AsOf2021-12-31" decimals="INF" unitRef="Shares">48044162</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="AsOf2022-12-31" decimals="INF" unitRef="Shares">45441389</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding contextRef="AsOf2021-12-31" decimals="INF" unitRef="Shares">44623660</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">488619</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">480441</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">44252117</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">40774245</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:TreasuryStockShares contextRef="AsOf2022-12-31" decimals="INF" unitRef="Shares">3420502</us-gaap:TreasuryStockShares>
    <us-gaap:TreasuryStockShares contextRef="AsOf2021-12-31" decimals="INF" unitRef="Shares">3420502</us-gaap:TreasuryStockShares>
    <us-gaap:TreasuryStockValue contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">3843562</us-gaap:TreasuryStockValue>
    <us-gaap:TreasuryStockValue contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">3843562</us-gaap:TreasuryStockValue>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">-9571211</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">-910069</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">31325963</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">36501055</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">42332443</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">41293031</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:Revenues
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">27896037</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">23490175</us-gaap:Revenues>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">12527051</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">9720597</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:GrossProfit
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">15368986</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">13769578</us-gaap:GrossProfit>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">20606507</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">17862314</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">4956215</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">2473669</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">587137</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">463130</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:OperatingExpenses
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">26149859</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">20799113</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">-10780873</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">-7029535</us-gaap:OperatingIncomeLoss>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">-39874</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">-28905</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">1009</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:OtherIncome
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">679907</us-gaap:OtherIncome>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">145587</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">13083</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">105713</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">665094</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">-10675160</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">-6364441</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">-2014018</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">-1801618</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">-8661142</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">-4562823</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2022-01-01to2022-12-31"
      decimals="INF"
      unitRef="USDPShares">-0.19</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2021-01-012021-12-31"
      decimals="INF"
      unitRef="USDPShares">-0.10</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2022-01-01to2022-12-31"
      decimals="INF"
      unitRef="USDPShares">-0.19</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2021-01-012021-12-31"
      decimals="INF"
      unitRef="USDPShares">-0.10</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2022-01-01to2022-12-31"
      decimals="INF"
      unitRef="Shares">45002074</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2021-01-012021-12-31"
      decimals="INF"
      unitRef="Shares">44385032</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2022-01-01to2022-12-31"
      decimals="INF"
      unitRef="Shares">45002074</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2021-01-012021-12-31"
      decimals="INF"
      unitRef="Shares">44385032</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2020-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">46680119</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-12-31_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">466801</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">35880986</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">3652754</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-12-31_us-gaap_TreasuryStockMember"
      decimals="0"
      unitRef="USD">-3843562</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">36156979</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">95725</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">958</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2021-01-012021-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">432696</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">433654</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="From2021-01-012021-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">2049041</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">2049041</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="From2021-01-012021-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">224859</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">224859</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <krmd:NewIssuanceLitigationSettlementShareIssuance
      contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">95238</krmd:NewIssuanceLitigationSettlementShareIssuance>
    <krmd:NewIssuanceLitigationSettlementAmountIssuance
      contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">952</krmd:NewIssuanceLitigationSettlementAmountIssuance>
    <krmd:NewIssuanceLitigationSettlementAmountIssuance
      contextRef="From2021-01-012021-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">937142</krmd:NewIssuanceLitigationSettlementAmountIssuance>
    <krmd:NewIssuanceLitigationSettlementAmountIssuance
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">938094</krmd:NewIssuanceLitigationSettlementAmountIssuance>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">1173080</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">11730</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2021-01-012021-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">1249521</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">1261251</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-01-012021-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-4562823</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">-4562823</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2021-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">48044162</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">480441</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">40774245</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-910069</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31_us-gaap_TreasuryStockMember"
      decimals="0"
      unitRef="USD">-3843562</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">36501055</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">206570</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">2066</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">511016</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">513082</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">2083396</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">2083396</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <krmd:Compensationexpenserelatedtorestrictedstockawards
      contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">50000</krmd:Compensationexpenserelatedtorestrictedstockawards>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">500</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">482449</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">482949</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">561159</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">5612</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">401011</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">406623</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-8661142</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">-8661142</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2022-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">48861891</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">488619</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">44252117</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-9571211</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_TreasuryStockMember"
      decimals="0"
      unitRef="USD">-3843562</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">31325963</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">-8661142</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">-4562823</us-gaap:NetIncomeLoss>
    <us-gaap:ShareBasedCompensation
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">3079427</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">2707554</us-gaap:ShareBasedCompensation>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">587137</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">463130</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:GainLossOnSaleOfOtherAssets
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">1009</us-gaap:GainLossOnSaleOfOtherAssets>
    <us-gaap:DeferredIncomeTaxesAndTaxCredits
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">-2026226</us-gaap:DeferredIncomeTaxesAndTaxCredits>
    <us-gaap:DeferredIncomeTaxesAndTaxCredits
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">-1815980</us-gaap:DeferredIncomeTaxesAndTaxCredits>
    <krmd:RouLandlordCredit
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">212546</krmd:RouLandlordCredit>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">-34002</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">1019932</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">298529</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">-723434</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInOtherReceivables
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">254176</us-gaap:IncreaseDecreaseInOtherReceivables>
    <us-gaap:IncreaseDecreaseInOtherReceivables
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">718220</us-gaap:IncreaseDecreaseInOtherReceivables>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">-28776</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">761041</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">1164266</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">602613</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">381796</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
    <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">-126527</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
    <us-gaap:IncreaseDecreaseInOtherCurrentLiabilities
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">167337</us-gaap:IncreaseDecreaseInOtherCurrentLiabilities>
    <us-gaap:IncreaseDecreaseInOtherCurrentLiabilities
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">90000</us-gaap:IncreaseDecreaseInOtherCurrentLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">180237</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">99291</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">-5404549</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">-4319510</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquireProductiveAssets
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">2761056</us-gaap:PaymentsToAcquireProductiveAssets>
    <us-gaap:PaymentsToAcquireProductiveAssets
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">346178</us-gaap:PaymentsToAcquireProductiveAssets>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">40512</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">29056</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:ProceedsFromSaleOfProductiveAssets
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">9065</us-gaap:ProceedsFromSaleOfProductiveAssets>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">-2801568</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">-366169</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">406623</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">1261251</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <krmd:CommonStockIssuanceAsSettlementForLitigation
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">938094</krmd:CommonStockIssuanceAsSettlementForLitigation>
    <krmd:BorrowingsFromIndebtedness
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">783799</krmd:BorrowingsFromIndebtedness>
    <krmd:BorrowingsFromIndebtedness
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">924389</krmd:BorrowingsFromIndebtedness>
    <krmd:PaymentsOnIndebtedness
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">859087</krmd:PaymentsOnIndebtedness>
    <krmd:PaymentsOnIndebtedness
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">415806</krmd:PaymentsOnIndebtedness>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">51850</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">2646</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">279485</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">2705282</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">-7926632</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">-1980397</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">25334889</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">27315286</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">17408257</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">25334889</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:InterestPaidNet
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">28490</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">13241</us-gaap:InterestPaidNet>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">1903</us-gaap:IncomeTaxesPaidNet>
    <krmd:IssuanceOfCommonStockCompensation
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">513082</krmd:IssuanceOfCommonStockCompensation>
    <krmd:IssuanceOfCommonStockCompensation
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">433654</krmd:IssuanceOfCommonStockCompensation>
    <us-gaap:StockIssued1
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">938094</us-gaap:StockIssued1>
    <us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_803_eus-gaap--OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock_zGNfMJCk2tF6" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;span&gt;NOTE 1 &#x2014; &lt;span id="xdx_820_z74Qsx9zc2m7"&gt;NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING
POLICIES&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_84C_eus-gaap--NatureOfOperations_zdnVGPzndT5i" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span id="xdx_86B_z8TcbrjdtGD7"&gt;NATURE OF OPERATIONS&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;KORU MEDICAL SYSTEMS, INC. (the &#x201c;Company,&#x201d; &#x201c;KORU Medical,&#x201d;
&#x201c;KORU,&#x201d; &#x201c;we,&#x201d; &#x201c;us&#x201d; or &#x201c;our&#x201d;) develops, manufactures and markets proprietary portable and
innovative medical devices primarily for the ambulatory infusion market as governed by the United States Food and Drug Administration
(the &#x201c;FDA&#x201d;) quality and regulatory system and international standards for quality system management. &#160;The Company operates
as &lt;span id="xdx_907_eus-gaap--NumberOfReportableSegments_dxH_uN_c20220101__20221231_zp0YK2i0Lpfd" title="Number of segments::XDX::1"&gt;one&lt;/span&gt; segment.&lt;/p&gt;

&lt;p id="xdx_85C_zTv1vbyJcMOa" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_842_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zS9HDKwxKkD4" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span id="xdx_862_za4Wlr4TVcUi"&gt;BASIS OF PRESENTATION&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;We prepare our financial statements and accompanying
notes in accordance with accounting principles generally accepted in the United States of America (&#x201c;GAAP&#x201d;). &#160;Certain
prior year amounts have been reclassified to conform to the current year presentation in our Financial Statements.&lt;/p&gt;

&lt;p id="xdx_85F_zecxaotkjRZj" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_844_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zohP6xbtb9c3" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span id="xdx_868_zilxnUanv4tl"&gt;CASH AND CASH EQUIVALENTS&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;For purposes of the statement of cash flows, the Company considers all
short-term investments with an original maturity of three months or less to be cash equivalents. &#160;The Company holds cash in excess
of $&lt;span id="xdx_902_eus-gaap--CashUninsuredAmount_iI_c20221231_zRZKlxgJI0Ih" title="FDIC cash uninsured amount"&gt;250,000&lt;/span&gt; at its depository, which exceeds the FDIC insurance limits and is, therefore, uninsured.&lt;/p&gt;

&lt;p id="xdx_85A_zCLiQhLKJEA1" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_840_eus-gaap--InventoryPolicyTextBlock_zxzLjs6dGw8k" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span id="xdx_86A_zvP96g8ATew6"&gt;INVENTORY&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;Inventories of raw materials are stated at the lower of standard cost,
which approximates average cost, or market value including allocable overhead. &#160;Work-in-process and finished goods are stated at
the lower of standard cost or market value and include direct labor and allocable overhead.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;We maintain reserves for excess and obsolete inventory resulting from the
potential inability to sell certain products at prices in excess of current carrying costs. &#160;We make estimates regarding the future
recoverability of the costs of these products and record provisions based on historical experience, expiration of sterilization dates
and expected future trends. &#160;If actual product life cycles, product demand or acceptance of new product introductions are less favorable
than projected by management, additional inventory write downs may be required, which could unfavorably affect future operating results.&lt;/p&gt;

&lt;p id="xdx_851_zCJPGSQM6xEj" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_841_eus-gaap--IntangibleAssetsFiniteLivedPolicy_zFAchVM8szJb" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span id="xdx_867_zJ95rXxkf8S2"&gt;INTANGIBLE ASSETS&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;Certain of our identifiable intangible assets, including patents and trademarks,
are amortized using the straight-line method over their estimated useful lives which range from &lt;span id="xdx_905_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dxL_c20220101__20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentsAndTrademarksMember__srt--RangeAxis__srt--MinimumMember_zMgMbxBk72M1" title="Estimated useful lives::XDX::P6Y"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0488"&gt;6&lt;/span&gt;&lt;/span&gt; to &lt;span id="xdx_906_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dxL_c20220101__20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentsAndTrademarksMember__srt--RangeAxis__srt--MaximumMember_zsMBX7xYZM4" title="Estimated useful lives::XDX::P20Y"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0490"&gt;20&lt;/span&gt;&lt;/span&gt; years. &#160;All of our intangible
assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be
recoverable. &#160;Our management is responsible for determining if impairment exists and considers various factors when making these
determinations. &#160;Amortization expense related to intangible assets for the years ended December 31, 2022 and 2021 was $&lt;span id="xdx_90A_ecustom--AmortizationOfIntangibleAssets1_c20220101__20221231_zdaQyFTk8Rnc" title="AmortizationOfIntangibleAssets1"&gt;62,143&lt;/span&gt; and
$&lt;span id="xdx_907_ecustom--AmortizationOfIntangibleAssets1_c20210101__20211231_zleXm3JB0R5c" title="AmortizationOfIntangibleAssets1"&gt;63,830&lt;/span&gt;, respectively.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_898_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock_zgEH8iPnMqul" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The estimated amortization expense for the succeeding
years for the intangible assets is approximately:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span&gt;&lt;span id="xdx_8B1_zMmeOzpV9qQa" style="display: none; visibility: hidden"&gt;Schedule of amortization expense&lt;/span&gt;&lt;/span&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 3in; border-collapse: collapse"&gt;
  &lt;tr style="background-color: white"&gt;
    &lt;td style="border-bottom: black 1pt solid; vertical-align: bottom"&gt;&lt;b&gt;Year Ending December 31,&lt;/b&gt;&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_49C_20221231_zZxBsRzkCe58" style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_iI_zkTn0Qh4EZ05" style="background-color: #E6E6E6"&gt;
    &lt;td style="vertical-align: bottom; width: 150pt"&gt;2023&lt;/td&gt;
    &lt;td style="vertical-align: top; width: 10.4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; width: 10pt"&gt;$&lt;/td&gt;
    &lt;td style="vertical-align: bottom; width: 56.65pt; text-align: right"&gt;62,982&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_iI_zq1eV71T9gLc" style="vertical-align: bottom"&gt;
    &lt;td&gt;2024&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;62,982&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_iI_zHCqqdyxmXMa" style="background-color: #E6E6E6"&gt;
    &lt;td style="vertical-align: bottom"&gt;2025&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; text-align: right"&gt;62,842&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_iI_zj8WKS3ZyaX8" style="background-color: white"&gt;
    &lt;td style="vertical-align: bottom"&gt;2026&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; text-align: right"&gt;61,787&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_iI_zw0Gtw4DlTPe" style="background-color: #E6E6E6"&gt;
    &lt;td style="vertical-align: bottom"&gt;2027&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; text-align: right"&gt;61,356&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_iI_zCI3c5sQsljc" style="background-color: white"&gt;
    &lt;td style="vertical-align: bottom"&gt;Thereafter&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: right"&gt;475,233&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_zCRJMlJKZMk6" style="background-color: #E6E6E6"&gt;
    &lt;td style="vertical-align: bottom"&gt;Total amortization expense&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; vertical-align: bottom"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; vertical-align: bottom; text-align: right"&gt;787,182&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p id="xdx_8AC_zS8cA14RTjLd" style="font: 10pt Times New Roman, Times, Serif; margin: 0"/&gt;

&lt;p id="xdx_856_zUAUDDQnci0k" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;



&lt;p id="xdx_840_eus-gaap--IncomeTaxPolicyTextBlock_zPneQ0ZgQzgh" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span id="xdx_86A_zurAya66UGVf"&gt;INCOME TAXES&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;Deferred income taxes are provided using the liability method whereby deferred
tax assets are recognized for deductible temporary differences and operating loss and tax credit carry forwards and deferred tax liabilities
are recognized for taxable temporary differences.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;The Company believes that it has no uncertain tax positions requiring disclosure
or adjustment.&lt;/p&gt;

&lt;p id="xdx_85D_zUiO08rNX3Rk" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_841_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zOBbEIpyGmd6" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span id="xdx_862_zPYpLF37xpxc"&gt;PROPERTY AND EQUIPMENT&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;Property and equipment are stated at original acquisition cost less accumulated
depreciation. &#160;Additions and improvements are capitalized which increase the value or extend the life of an asset, while maintenance
and repair costs are expensed as incurred. &#160;When assets are retired or otherwise disposed, the cost and related accumulated depreciation
or amortization is removed from the respective accounts and any resulting gain or loss is included in income. &#160;Depreciation and amortization
are calculated on the straight-line basis over the estimated useful lives of the assets which generally range from &lt;span id="xdx_904_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dxL_c20220101__20221231__srt--RangeAxis__srt--MinimumMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--FurnitureAndOfficeEquipmentMember_zzKLaTSM3CF7" title="Estimated useful lives of property and equipment::XDX::P3Y"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0517"&gt;3&lt;/span&gt;&lt;/span&gt;-&lt;span id="xdx_905_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dxL_c20220101__20221231__srt--RangeAxis__srt--MaximumMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--FurnitureAndOfficeEquipmentMember_zR5ZBROcRTS8" title="::XDX::P10Y0M0D"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0518"&gt;10&lt;/span&gt;&lt;/span&gt; years for furniture
and office equipment, &lt;span id="xdx_902_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dxL_c20220101__20221231__srt--RangeAxis__srt--MinimumMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--EquipmentAndToolingMember_zp39ZMDYg8O5" title="::XDX::P3Y"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0519"&gt;3&lt;/span&gt;&lt;/span&gt;-&lt;span id="xdx_90E_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dxL_c20220101__20221231__srt--RangeAxis__srt--MaximumMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--EquipmentAndToolingMember_z00VDHNAeUH6" title="::XDX::P12Y"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0520"&gt;12&lt;/span&gt;&lt;/span&gt; years for manufacturing equipment and tooling and shorter of the lease term or their estimated useful lives
for leasehold improvements. Depreciation and amortization expense related to property and equipment for the years ended December 31, 2022
and 2021 was $&lt;span id="xdx_905_eus-gaap--DepreciationDepletionAndAmortization_c20220101__20221231__us-gaap--FairValueByAssetClassAxis__us-gaap--PropertyPlantAndEquipmentMember_zRMvqTTkVI79" title="Depreciation and amortization"&gt;524,994&lt;/span&gt; and $&lt;span id="xdx_908_eus-gaap--DepreciationDepletionAndAmortization_c20210101__20211231__us-gaap--FairValueByAssetClassAxis__us-gaap--PropertyPlantAndEquipmentMember_zK3zQHuOPHwj" title="Depreciation and amortization"&gt;399,300&lt;/span&gt;, respectively.&lt;/p&gt;

&lt;p id="xdx_859_z5gLhjvKiRff" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_84A_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_z4r5Vzf2AITb" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span id="xdx_863_zR62l6wfRBAe"&gt;STOCK-BASED COMPENSATION&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;The Company maintains a stock option plan and omnibus equity incentive
plan under which it grants stock options to certain executives, key employees and consultants. The fair value of each option grant is
estimated on the date of the grant using the Black-Scholes option-pricing model. &#160;All options are charged against income at their
fair value. &#160;The entire compensation expense of the award is recognized over the vesting period.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;Shares of stock granted for director fees under the non-employee director
compensation plan are recorded at the fair value of the shares at the grant date.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;The Company has also issued shares of stock for director fees under its
omnibus equity incentive plan. Those shares of stock granted are recorded at the fair value of the shares at the grant date.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;The Company issues restricted stock awards. Restricted stock awards are
equity classified and measured at the fair market value of the underlying stock at the grant date. The fair value of restricted stock
awards vesting at certain market capitalization thresholds were estimated on the date of grant using the Brownian Motion Monte Carlo lattice
model. The fair value of restricted stock awards with time-based vesting were estimated on the date of grant at the current stock price.
We recognize restricted stock expense using the straight-line attribution method over the requisite service period and account for forfeitures
as they occur.&lt;/p&gt;

&lt;p id="xdx_85F_zC9odunTWveb" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_845_eus-gaap--EarningsPerSharePolicyTextBlock_zZYuIlFBcHfk" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span id="xdx_86C_zhho2Pw2uBn1"&gt;NET LOSS PER COMMON SHARE&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_89E_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_zMG1jKvSqsWe" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;Basic earnings per share are computed on the weighted average of common
shares outstanding during each year. &#160;Diluted earnings per share includes only an increase in the weighted average shares by the
common shares issuable upon exercise of stock options. &#160;See &#x201c;NOTE 4 &#x2014; STOCK-BASED COMPENSATION&#x201d; for further detail.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span&gt;&lt;span id="xdx_8BC_zlnjQ0R1CBk9" style="display: none; visibility: hidden"&gt;Schedule of net income per common share&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 5.5in; border-collapse: collapse"&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 167.8pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; width: 6.95pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; width: 7.1pt; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_493_20220101__20221231_zzvMb6BBNmGj" style="vertical-align: top; width: 85.9pt; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; width: 14.1pt; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; width: 9.35pt; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; width: 7.1pt; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_496_20210101__20211231_zL1n95ZSVts2" style="vertical-align: top; width: 82.5pt; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; width: 15.1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: black 1pt solid; vertical-align: top; text-align: center"&gt;&lt;b&gt;Years Ended&lt;/b&gt;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: center"&gt;&lt;b&gt;December 31, 2022&lt;/b&gt;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: center"&gt;&lt;b&gt;December 31, 2021&lt;/b&gt;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--NetIncomeLoss_zY35B8ztZ5e8" style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td&gt;Net loss&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;(8,661,142&lt;/td&gt;
    &lt;td&gt;)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;(4,562,823&lt;/td&gt;
    &lt;td&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasicAbstract_iB_zJKQih5XQNV7" style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td&gt;Weighted Average Outstanding Shares:&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pid_hus-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zIQ1UMkP0mOc" style="vertical-align: bottom"&gt;
    &lt;td style="padding-left: 21.8pt"&gt;Outstanding shares&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;45,002,074&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;44,385,032&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--IncrementalCommonSharesAttributableToCallOptionsAndWarrants_pid_zm8oNBHXFS0c" style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td style="padding-left: 21.8pt"&gt;Option shares includable&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0541"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_F51_zXnO0VQ3fCd8"&gt;(a)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0542"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_F56_z8suocOMxah"&gt;(a)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_ecustom--IncrementalCommonSharesAttributableToRestrictedStock_pid_ztoKP1mn4Bw" style="vertical-align: bottom"&gt;
    &lt;td style="padding-left: 21.8pt"&gt;Restricted stock includable&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0544"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_F52_zmpyjNDtJ7Ea"&gt;(b)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0545"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_F5F_z4nwfjQAj7la"&gt;(b)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_ecustom--WeightedAverageNumberOfSharesOutstanding_zjf5cgBKhkY3" style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;&lt;b style="display: none; visibility: hidden"&gt;&#160;Total&lt;/b&gt;&lt;/p&gt;
        &lt;p style="margin-top: 0; margin-bottom: 0"/&gt;&lt;/td&gt;
    &lt;td/&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;45,002,074&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;44,385,032&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--EarningsPerShareAbstract_iB_zGOHyByYtat1" style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td&gt;Net loss per share&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--EarningsPerShareBasic_pid_uUSDPShares_zk4hYMtkkq2j" style="vertical-align: bottom"&gt;
    &lt;td style="padding-left: 21.8pt"&gt;Basic&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;(0.19&lt;/td&gt;
    &lt;td style="border-bottom: white 2.25pt double"&gt;)&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;(0.10&lt;/td&gt;
    &lt;td style="border-bottom: white 2.25pt double"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--EarningsPerShareDiluted_pid_uUSDPShares_zoNdyVgzpB1k" style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td style="padding-left: 21.8pt"&gt;Diluted&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;(0.19&lt;/td&gt;
    &lt;td style="border-bottom: white 2.25pt double"&gt;)&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;(0.10&lt;/td&gt;
    &lt;td style="border-bottom: white 2.25pt double"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;__________&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td id="xdx_F07_zpjRlU1tokg5" style="width: 0.5in"&gt;(a)&lt;/td&gt;
    &lt;td id="xdx_F13_zJ7k0c2TJW51" style="width: 7in"&gt;Option shares of &lt;span id="xdx_90B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_dxL_uShares_c20220101__20221231__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--EmployeeStockMember_zJscHJ6nJh08" title="Option shares excluded::XDX::0"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0560"&gt;zero&lt;/span&gt;&lt;/span&gt; and &lt;span id="xdx_906_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_uShares_c20210101__20211231__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--EmployeeStockMember_zOXokNhUvBRh" title="Option shares excluded"&gt;273,110&lt;/span&gt; for 2022 and 2021, respectively were not included as the impact is anti-dilutive.&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td id="xdx_F05_zQfISkekUjdj" style="width: 0.5in"&gt;(b)&lt;/td&gt;
    &lt;td id="xdx_F12_zj23i9XZITAh" style="width: 7in"&gt;Linda Tharby's Restricted Stock award shares of &lt;span id="xdx_90D_ecustom--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount1_pid_uShares_c20220101__20221231__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--EmployeeStockMember_zQe25yGQAtl2" title="Restricted stock shares excluded"&gt;950,000&lt;/span&gt; and &lt;span id="xdx_900_ecustom--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount1_pid_uShares_c20210101__20211231__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--EmployeeStockMember_zQeAAvWnACzb" title="Restricted stock shares excluded"&gt;1,000,000&lt;/span&gt; that are unvested for 2022 and 2021, respectively were not included as the impact is anti-dilutive.&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AD_z74ojCDpPbsk" style="margin-top: 0; margin-bottom: 0"&gt;&#160;&lt;/p&gt;
&lt;p id="xdx_855_zDA565EElgn3" style="font: 10pt Times New Roman, Times, Serif; margin: 0"/&gt;



&lt;p id="xdx_844_eus-gaap--UseOfEstimates_z6LaBImte0K4" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span id="xdx_869_z4A7A2mqJ7X9"&gt;USE OF ESTIMATES IN THE FINANCIAL STATEMENTS&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;The preparation of financial statements in conformity with GAAP requires
management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. &#160;Actual
results could differ from those estimates. &#160;Important estimates include but are not limited to asset lives, valuation allowances,
inventory valuation, and accruals.&lt;/p&gt;

&lt;p id="xdx_850_zNIRuhMWrZQ6" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_84F_eus-gaap--RevenueFromContractWithCustomerPolicyTextBlock_zpLpzc1GZBG4" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span id="xdx_860_zt5Gey8twc2c"&gt;REVENUE RECOGNITION&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;The Financial Accounting Standards Board (&#x201c;FASB&#x201d;) issued Accounting
Standards Update (&#x201c;ASU&#x201d;) No. 2014-09, &lt;i&gt;Revenue from Contracts with Customers&lt;/i&gt;, which provides a single comprehensive
model for entities to use in accounting for revenue arising from contracts with customers.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;The Company&#x2019;s revenues result from the sale of assembled products.
&#160;We recognize revenues when shipment occurs, and at which point the customer obtains control and ownership of the goods. &#160;Shipping
costs generally are billed to customers and are included in sales.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;The Company generally does not accept return of goods shipped unless it
is a Company error. &#160;The only credits provided to customers are for defective merchandise. &#160;The Company warrants the syringe
driver from defects in materials and workmanship under normal use and the warranty does not include a performance obligation. &#160;The
costs under the warranty are expensed as incurred.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;Provisions for distributor pricing and annual customer growth rebates are
variable consideration and are recorded as a reduction of revenue in the same period the related sales are recorded or when it is probable
the annual growth target will be achieved. &#160;Rebates are provided to distributors for the difference in selling price to distributor
and pricing specified to select customers.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;The Company established an allowance for charging off uncollectible trade
accounts receivable that have both of the following characteristics: (a) They have a contractual maturity of one year or less, (b) They
arose from the sale of goods or services.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_89E_ecustom--ScheduleOfNetRevenuesByGeography_z3BIpuyfVG4d" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;The following table summarizes net revenues by geography for the years ended
December 31, 2022 and 2021:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span id="xdx_8BD_z3C9ZxreeIk3" style="display: none; visibility: hidden"&gt;Schedule of net revenues by geography&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 3.5in; border-collapse: collapse"&gt;
  &lt;tr style="background-color: white"&gt;
    &lt;td style="vertical-align: bottom; width: 93.35pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; width: 8.3pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; width: 8.25pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; width: 53.4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; width: 18.05pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; width: 8.25pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; width: 54.15pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; width: 8.25pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="background-color: white"&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="5" style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: center"&gt;&lt;b&gt;Years Ended December 31,&lt;/b&gt;&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="background-color: white"&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: center"&gt;&lt;b&gt;2022&lt;/b&gt;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: center"&gt;&lt;b&gt;2021&lt;/b&gt;&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="background-color: white"&gt;
    &lt;td style="vertical-align: bottom"&gt;&lt;b&gt;Net Revenues&lt;/b&gt;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="background-color: #E6E6E6"&gt;
    &lt;td style="vertical-align: bottom; padding-left: 9.45pt"&gt;Domestic&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_98D_eus-gaap--Revenues_c20220101__20221231__srt--StatementGeographicalAxis__country--US_zZ4uQjTcgfJc" style="text-align: right" title="Net Revenue"&gt;23,586,254&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_98C_eus-gaap--Revenues_c20210101__20211231__srt--StatementGeographicalAxis__country--US_zmQIeI78tUyl" style="text-align: right" title="Net Revenue"&gt;19,488,685&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="background-color: white"&gt;
    &lt;td style="vertical-align: bottom; padding-left: 9.45pt"&gt;International&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_987_eus-gaap--Revenues_c20220101__20221231__srt--StatementGeographicalAxis__us-gaap--NonUsMember_zfGG2aByPLz" style="border-bottom: black 1pt solid; text-align: right" title="Net Revenues"&gt;4,309,783&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_981_eus-gaap--Revenues_c20210101__20211231__srt--StatementGeographicalAxis__us-gaap--NonUsMember_zRtFKssVTgme" style="border-bottom: black 1pt solid; text-align: right" title="Net Revenues"&gt;4,001,490&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="background-color: #E6E6E6"&gt;
    &lt;td style="vertical-align: bottom"&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;$&lt;/td&gt;
    &lt;td id="xdx_988_eus-gaap--Revenues_c20220101__20221231_zbAfS3LpNBGe" style="border-bottom: black 2.25pt double; text-align: right" title="Revenues"&gt;27,896,037&lt;/td&gt;
    &lt;td style="border-bottom: white 2.25pt double; vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;$&lt;/td&gt;
    &lt;td id="xdx_980_eus-gaap--Revenues_c20210101__20211231_zn8OKcUznKZg" style="border-bottom: black 2.25pt double; text-align: right" title="Revenues"&gt;23,490,175&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p id="xdx_8A4_zRN68oI0ioGe" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_85B_zjcwB7y4KIdf" style="font: 10pt Times New Roman, Times, Serif; margin: 0"/&gt;

&lt;p id="xdx_846_eus-gaap--LesseeLeasesPolicyTextBlock_zipKrI5L2i54" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span id="xdx_863_zGMa0N0Ww7ef"&gt;LEASES&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;In February 2016, the FASB issued a standard related to leases to increase
transparency and comparability among organizations by requiring the recognition of right-of-use (&#x201c;ROU&#x201d;) assets and lease liabilities
on the balance sheet. &#160;Most prominent among the changes in the standard is the recognition of ROU assets and lease liabilities by
the Company for those leases classified as operating leases under current GAAP, while our accounting for capital leases remains substantially
unchanged. &#160;Under the standard, disclosures are required to meet the objective of enabling users of financial statements to assess
the amount, timing, and uncertainty of cash flows arising from leases. &#160;The standard became effective for us on January 1, 2019.
&#160;The standard had a material impact on our balance sheets but did not have a material impact on our statements of operations. &#160;See
&#x201c;NOTE 5 &lt;b&gt;&#x2014; &lt;/b&gt;LEASES&#x201d; for further detail.&lt;/p&gt;

&lt;p id="xdx_859_zEKH0xo3rpFk" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_844_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zyR5yhkl0mx3" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span id="xdx_86D_zfWO34kCXJPi"&gt;ACCOUNTING PRONOUNCEMENTS RECENTLY ADOPTED&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;In December 2019, the FASB issued ASU No. 2019-12, &lt;i&gt;Income Taxes (Topic
740): Simplifying the Accounting for Income Taxes&lt;/i&gt;. The amendments in this ASU simplify the accounting for income taxes by removing
several exceptions including the exception to the general methodology for calculating income taxes in an interim period when a year-to-date
loss exceeds the anticipated loss for the year. &#160;The amendments also improve consistent application of and simplify GAAP for other
areas of Topic 740 by clarifying and amending existing guidance. &#160;The amendments in this ASU are effective for fiscal years, and
interim periods within those fiscal years, beginning after December 15, 2020. &#160;The Company adopted this standard on January 1, 2021,
and it had no impact on our financial statement disclosures.&lt;/p&gt;

&lt;p id="xdx_853_zmuLohV68dSk" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;



&lt;p id="xdx_846_ecustom--AccountingPronouncementsNotYetAdopted_zMJECMpJBn7j" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span id="xdx_865_z8maNI0cLQ6c"&gt;ACCOUNTING PRONOUNCEMENTS NOT YET ADOPTED&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;In June 2016, the FASB issued ASU No. 2016-13, &lt;i&gt;Financial Instruments
&#x2013; Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments&lt;/i&gt;, which amends guidance on reporting credit
losses for assets held at amortized cost basis and available for sale debt securities. &#160;For assets held at amortized cost basis,
Topic 326 eliminates the probable initial recognition threshold in current GAAP and, instead, requires an entity to reflect its current
estimate of all expected credit losses. &#160;The allowance for credit losses is a valuation account that is deducted from the amortized
cost basis of the financial assets to present the net amount expected to be collected. &#160;For available for sale debt securities, credit
losses should be measured in a manner similar to current GAAP, however Topic 326 will require that credit losses be presented as an allowance
rather than as a write-down. &#160;This ASU affects entities holding financial assets and net investment in leases that are not accounted
for at fair value through net income. &#160;The amendments affect loans, debt securities, trade receivables, net investments in leases,
off balance sheet credit exposures, reinsurance receivables, and any other financial assets not excluded from the scope that have the
contractual right to receive cash. &#160;The amendments in this update are effective for fiscal years beginning after December 15, 2022,
including interim periods within those fiscal years. &#160;The Company is assessing the impact of the adoption of the ASU on its financial
statements, disclosure requirements and methods of adoption.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;The Company considers the applicability and impact of all recently issued
accounting pronouncements. &#160;Recent accounting pronouncements not specifically identified in our disclosures are either not applicable
to the Company or are not expected to have a material effect on our financial condition or results of operations.&lt;/p&gt;

&lt;p id="xdx_854_z7Zkuvx9a9Pl" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_844_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_zB3qn80oaFa5" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span id="xdx_866_z5Y75OK0JD5g"&gt;FAIR VALUE MEASUREMENTS&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;Fair value is the exit price that would be received to sell an asset or
paid to transfer a liability. &#160;Fair value is a market-based measurement that should be determined using assumptions that market participants
would use in pricing an asset or liability. Valuation techniques used to measure fair value should maximize the use of observable inputs
and minimize the use of unobservable inputs. &#160;To measure fair value, the Company uses the following fair value hierarchy based on
three levels of inputs, of which the first two are considered observable and the last unobservable:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 7.5in; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.5in; text-align: center"&gt;&#x2022;&lt;/td&gt;
    &lt;td style="width: 7in"&gt;Level 1 &#x2013; Quoted prices in active markets for identical assets or liabilities.&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="text-align: center"&gt;&#x2022;&lt;/td&gt;
    &lt;td&gt;Level 2 &#x2013; Inputs other than Level 1 that are observable for the asset or liability, either directly or indirectly, such as quoted prices for similar assets and liabilities in active markets; quoted prices for identical or similar assets or liabilities in markets that are not active; or other inputs that are observable or can be corroborated by observable market data by correlation or other means.&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="text-align: center"&gt;&#x2022;&lt;/td&gt;
    &lt;td&gt;Level 3 &#x2013; Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. &#160;Value is determined using pricing models, discounted cash flow methodologies, or similar techniques and includes instruments for which the determination of fair value requires significant judgment or estimation.&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;The carrying amounts of cash and cash equivalents, accounts receivable,
prepaid expenses, accounts payable and accrued expenses are considered to be representative of their fair values because of the short-term
nature of those instruments. &#160;There were no transfers between levels in the fair value hierarchy during the year ended December 31,
2022.&lt;/p&gt;

&lt;p id="xdx_85B_zAUJFESrAdS1" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_849_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_zQZbDx9rQ7We" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span id="xdx_86D_zRmizrHnN8ef"&gt;IMPAIRMENT OF LONG-LIVED ASSETS&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;The Company reviews long-lived assets for impairment whenever events or
changes in circumstances indicate that the carrying amount of the assets may not be fully recoverable. &#160;An impairment loss would
be recognized when estimated undiscounted future cash flows expected to result from the use of the asset and its eventual disposition
are less than the carrying amount. &#160;The impairment loss, if recognized, would be based on the excess of the carrying value of the
impaired asset over its respective fair value. &#160;No impairment losses have been recorded through December 31, 2022.&lt;/p&gt;

&lt;p id="xdx_85E_zyBIgsY1g1i8" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

</us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock>
    <us-gaap:NatureOfOperations contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_84C_eus-gaap--NatureOfOperations_zdnVGPzndT5i" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span id="xdx_86B_z8TcbrjdtGD7"&gt;NATURE OF OPERATIONS&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;KORU MEDICAL SYSTEMS, INC. (the &#x201c;Company,&#x201d; &#x201c;KORU Medical,&#x201d;
&#x201c;KORU,&#x201d; &#x201c;we,&#x201d; &#x201c;us&#x201d; or &#x201c;our&#x201d;) develops, manufactures and markets proprietary portable and
innovative medical devices primarily for the ambulatory infusion market as governed by the United States Food and Drug Administration
(the &#x201c;FDA&#x201d;) quality and regulatory system and international standards for quality system management. &#160;The Company operates
as &lt;span id="xdx_907_eus-gaap--NumberOfReportableSegments_dxH_uN_c20220101__20221231_zp0YK2i0Lpfd" title="Number of segments::XDX::1"&gt;one&lt;/span&gt; segment.&lt;/p&gt;

</us-gaap:NatureOfOperations>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_842_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zS9HDKwxKkD4" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span id="xdx_862_za4Wlr4TVcUi"&gt;BASIS OF PRESENTATION&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;We prepare our financial statements and accompanying
notes in accordance with accounting principles generally accepted in the United States of America (&#x201c;GAAP&#x201d;). &#160;Certain
prior year amounts have been reclassified to conform to the current year presentation in our Financial Statements.&lt;/p&gt;

</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_844_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zohP6xbtb9c3" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span id="xdx_868_zilxnUanv4tl"&gt;CASH AND CASH EQUIVALENTS&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;For purposes of the statement of cash flows, the Company considers all
short-term investments with an original maturity of three months or less to be cash equivalents. &#160;The Company holds cash in excess
of $&lt;span id="xdx_902_eus-gaap--CashUninsuredAmount_iI_c20221231_zRZKlxgJI0Ih" title="FDIC cash uninsured amount"&gt;250,000&lt;/span&gt; at its depository, which exceeds the FDIC insurance limits and is, therefore, uninsured.&lt;/p&gt;

</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:CashUninsuredAmount contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">250000</us-gaap:CashUninsuredAmount>
    <us-gaap:InventoryPolicyTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_840_eus-gaap--InventoryPolicyTextBlock_zxzLjs6dGw8k" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span id="xdx_86A_zvP96g8ATew6"&gt;INVENTORY&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;Inventories of raw materials are stated at the lower of standard cost,
which approximates average cost, or market value including allocable overhead. &#160;Work-in-process and finished goods are stated at
the lower of standard cost or market value and include direct labor and allocable overhead.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;We maintain reserves for excess and obsolete inventory resulting from the
potential inability to sell certain products at prices in excess of current carrying costs. &#160;We make estimates regarding the future
recoverability of the costs of these products and record provisions based on historical experience, expiration of sterilization dates
and expected future trends. &#160;If actual product life cycles, product demand or acceptance of new product introductions are less favorable
than projected by management, additional inventory write downs may be required, which could unfavorably affect future operating results.&lt;/p&gt;

</us-gaap:InventoryPolicyTextBlock>
    <us-gaap:IntangibleAssetsFiniteLivedPolicy contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_841_eus-gaap--IntangibleAssetsFiniteLivedPolicy_zFAchVM8szJb" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span id="xdx_867_zJ95rXxkf8S2"&gt;INTANGIBLE ASSETS&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;Certain of our identifiable intangible assets, including patents and trademarks,
are amortized using the straight-line method over their estimated useful lives which range from &lt;span id="xdx_905_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dxL_c20220101__20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentsAndTrademarksMember__srt--RangeAxis__srt--MinimumMember_zMgMbxBk72M1" title="Estimated useful lives::XDX::P6Y"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0488"&gt;6&lt;/span&gt;&lt;/span&gt; to &lt;span id="xdx_906_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dxL_c20220101__20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentsAndTrademarksMember__srt--RangeAxis__srt--MaximumMember_zsMBX7xYZM4" title="Estimated useful lives::XDX::P20Y"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0490"&gt;20&lt;/span&gt;&lt;/span&gt; years. &#160;All of our intangible
assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be
recoverable. &#160;Our management is responsible for determining if impairment exists and considers various factors when making these
determinations. &#160;Amortization expense related to intangible assets for the years ended December 31, 2022 and 2021 was $&lt;span id="xdx_90A_ecustom--AmortizationOfIntangibleAssets1_c20220101__20221231_zdaQyFTk8Rnc" title="AmortizationOfIntangibleAssets1"&gt;62,143&lt;/span&gt; and
$&lt;span id="xdx_907_ecustom--AmortizationOfIntangibleAssets1_c20210101__20211231_zleXm3JB0R5c" title="AmortizationOfIntangibleAssets1"&gt;63,830&lt;/span&gt;, respectively.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_898_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock_zgEH8iPnMqul" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The estimated amortization expense for the succeeding
years for the intangible assets is approximately:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span&gt;&lt;span id="xdx_8B1_zMmeOzpV9qQa" style="display: none; visibility: hidden"&gt;Schedule of amortization expense&lt;/span&gt;&lt;/span&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 3in; border-collapse: collapse"&gt;
  &lt;tr style="background-color: white"&gt;
    &lt;td style="border-bottom: black 1pt solid; vertical-align: bottom"&gt;&lt;b&gt;Year Ending December 31,&lt;/b&gt;&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_49C_20221231_zZxBsRzkCe58" style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_iI_zkTn0Qh4EZ05" style="background-color: #E6E6E6"&gt;
    &lt;td style="vertical-align: bottom; width: 150pt"&gt;2023&lt;/td&gt;
    &lt;td style="vertical-align: top; width: 10.4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; width: 10pt"&gt;$&lt;/td&gt;
    &lt;td style="vertical-align: bottom; width: 56.65pt; text-align: right"&gt;62,982&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_iI_zq1eV71T9gLc" style="vertical-align: bottom"&gt;
    &lt;td&gt;2024&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;62,982&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_iI_zHCqqdyxmXMa" style="background-color: #E6E6E6"&gt;
    &lt;td style="vertical-align: bottom"&gt;2025&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; text-align: right"&gt;62,842&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_iI_zj8WKS3ZyaX8" style="background-color: white"&gt;
    &lt;td style="vertical-align: bottom"&gt;2026&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; text-align: right"&gt;61,787&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_iI_zw0Gtw4DlTPe" style="background-color: #E6E6E6"&gt;
    &lt;td style="vertical-align: bottom"&gt;2027&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; text-align: right"&gt;61,356&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_iI_zCI3c5sQsljc" style="background-color: white"&gt;
    &lt;td style="vertical-align: bottom"&gt;Thereafter&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: right"&gt;475,233&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_zCRJMlJKZMk6" style="background-color: #E6E6E6"&gt;
    &lt;td style="vertical-align: bottom"&gt;Total amortization expense&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; vertical-align: bottom"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; vertical-align: bottom; text-align: right"&gt;787,182&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p id="xdx_8AC_zS8cA14RTjLd" style="font: 10pt Times New Roman, Times, Serif; margin: 0"/&gt;

</us-gaap:IntangibleAssetsFiniteLivedPolicy>
    <krmd:AmortizationOfIntangibleAssets1
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">62143</krmd:AmortizationOfIntangibleAssets1>
    <krmd:AmortizationOfIntangibleAssets1
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">63830</krmd:AmortizationOfIntangibleAssets1>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_898_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock_zgEH8iPnMqul" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The estimated amortization expense for the succeeding
years for the intangible assets is approximately:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span&gt;&lt;span id="xdx_8B1_zMmeOzpV9qQa" style="display: none; visibility: hidden"&gt;Schedule of amortization expense&lt;/span&gt;&lt;/span&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 3in; border-collapse: collapse"&gt;
  &lt;tr style="background-color: white"&gt;
    &lt;td style="border-bottom: black 1pt solid; vertical-align: bottom"&gt;&lt;b&gt;Year Ending December 31,&lt;/b&gt;&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_49C_20221231_zZxBsRzkCe58" style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_iI_zkTn0Qh4EZ05" style="background-color: #E6E6E6"&gt;
    &lt;td style="vertical-align: bottom; width: 150pt"&gt;2023&lt;/td&gt;
    &lt;td style="vertical-align: top; width: 10.4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; width: 10pt"&gt;$&lt;/td&gt;
    &lt;td style="vertical-align: bottom; width: 56.65pt; text-align: right"&gt;62,982&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_iI_zq1eV71T9gLc" style="vertical-align: bottom"&gt;
    &lt;td&gt;2024&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;62,982&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_iI_zHCqqdyxmXMa" style="background-color: #E6E6E6"&gt;
    &lt;td style="vertical-align: bottom"&gt;2025&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; text-align: right"&gt;62,842&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_iI_zj8WKS3ZyaX8" style="background-color: white"&gt;
    &lt;td style="vertical-align: bottom"&gt;2026&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; text-align: right"&gt;61,787&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_iI_zw0Gtw4DlTPe" style="background-color: #E6E6E6"&gt;
    &lt;td style="vertical-align: bottom"&gt;2027&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; text-align: right"&gt;61,356&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_iI_zCI3c5sQsljc" style="background-color: white"&gt;
    &lt;td style="vertical-align: bottom"&gt;Thereafter&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: right"&gt;475,233&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_zCRJMlJKZMk6" style="background-color: #E6E6E6"&gt;
    &lt;td style="vertical-align: bottom"&gt;Total amortization expense&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; vertical-align: bottom"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; vertical-align: bottom; text-align: right"&gt;787,182&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">62982</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">62982</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">62842</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">61787</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">61356</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">475233</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">787182</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_840_eus-gaap--IncomeTaxPolicyTextBlock_zPneQ0ZgQzgh" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span id="xdx_86A_zurAya66UGVf"&gt;INCOME TAXES&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;Deferred income taxes are provided using the liability method whereby deferred
tax assets are recognized for deductible temporary differences and operating loss and tax credit carry forwards and deferred tax liabilities
are recognized for taxable temporary differences.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;The Company believes that it has no uncertain tax positions requiring disclosure
or adjustment.&lt;/p&gt;

</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_841_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zOBbEIpyGmd6" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span id="xdx_862_zPYpLF37xpxc"&gt;PROPERTY AND EQUIPMENT&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;Property and equipment are stated at original acquisition cost less accumulated
depreciation. &#160;Additions and improvements are capitalized which increase the value or extend the life of an asset, while maintenance
and repair costs are expensed as incurred. &#160;When assets are retired or otherwise disposed, the cost and related accumulated depreciation
or amortization is removed from the respective accounts and any resulting gain or loss is included in income. &#160;Depreciation and amortization
are calculated on the straight-line basis over the estimated useful lives of the assets which generally range from &lt;span id="xdx_904_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dxL_c20220101__20221231__srt--RangeAxis__srt--MinimumMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--FurnitureAndOfficeEquipmentMember_zzKLaTSM3CF7" title="Estimated useful lives of property and equipment::XDX::P3Y"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0517"&gt;3&lt;/span&gt;&lt;/span&gt;-&lt;span id="xdx_905_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dxL_c20220101__20221231__srt--RangeAxis__srt--MaximumMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--FurnitureAndOfficeEquipmentMember_zR5ZBROcRTS8" title="::XDX::P10Y0M0D"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0518"&gt;10&lt;/span&gt;&lt;/span&gt; years for furniture
and office equipment, &lt;span id="xdx_902_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dxL_c20220101__20221231__srt--RangeAxis__srt--MinimumMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--EquipmentAndToolingMember_zp39ZMDYg8O5" title="::XDX::P3Y"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0519"&gt;3&lt;/span&gt;&lt;/span&gt;-&lt;span id="xdx_90E_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dxL_c20220101__20221231__srt--RangeAxis__srt--MaximumMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--EquipmentAndToolingMember_z00VDHNAeUH6" title="::XDX::P12Y"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0520"&gt;12&lt;/span&gt;&lt;/span&gt; years for manufacturing equipment and tooling and shorter of the lease term or their estimated useful lives
for leasehold improvements. Depreciation and amortization expense related to property and equipment for the years ended December 31, 2022
and 2021 was $&lt;span id="xdx_905_eus-gaap--DepreciationDepletionAndAmortization_c20220101__20221231__us-gaap--FairValueByAssetClassAxis__us-gaap--PropertyPlantAndEquipmentMember_zRMvqTTkVI79" title="Depreciation and amortization"&gt;524,994&lt;/span&gt; and $&lt;span id="xdx_908_eus-gaap--DepreciationDepletionAndAmortization_c20210101__20211231__us-gaap--FairValueByAssetClassAxis__us-gaap--PropertyPlantAndEquipmentMember_zK3zQHuOPHwj" title="Depreciation and amortization"&gt;399,300&lt;/span&gt;, respectively.&lt;/p&gt;

</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="From2022-01-012022-12-31_us-gaap_PropertyPlantAndEquipmentMember"
      decimals="0"
      unitRef="USD">524994</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="From2021-01-012021-12-31_us-gaap_PropertyPlantAndEquipmentMember"
      decimals="0"
      unitRef="USD">399300</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_84A_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_z4r5Vzf2AITb" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span id="xdx_863_zR62l6wfRBAe"&gt;STOCK-BASED COMPENSATION&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;The Company maintains a stock option plan and omnibus equity incentive
plan under which it grants stock options to certain executives, key employees and consultants. The fair value of each option grant is
estimated on the date of the grant using the Black-Scholes option-pricing model. &#160;All options are charged against income at their
fair value. &#160;The entire compensation expense of the award is recognized over the vesting period.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;Shares of stock granted for director fees under the non-employee director
compensation plan are recorded at the fair value of the shares at the grant date.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;The Company has also issued shares of stock for director fees under its
omnibus equity incentive plan. Those shares of stock granted are recorded at the fair value of the shares at the grant date.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;The Company issues restricted stock awards. Restricted stock awards are
equity classified and measured at the fair market value of the underlying stock at the grant date. The fair value of restricted stock
awards vesting at certain market capitalization thresholds were estimated on the date of grant using the Brownian Motion Monte Carlo lattice
model. The fair value of restricted stock awards with time-based vesting were estimated on the date of grant at the current stock price.
We recognize restricted stock expense using the straight-line attribution method over the requisite service period and account for forfeitures
as they occur.&lt;/p&gt;

</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_845_eus-gaap--EarningsPerSharePolicyTextBlock_zZYuIlFBcHfk" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span id="xdx_86C_zhho2Pw2uBn1"&gt;NET LOSS PER COMMON SHARE&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_89E_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_zMG1jKvSqsWe" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;Basic earnings per share are computed on the weighted average of common
shares outstanding during each year. &#160;Diluted earnings per share includes only an increase in the weighted average shares by the
common shares issuable upon exercise of stock options. &#160;See &#x201c;NOTE 4 &#x2014; STOCK-BASED COMPENSATION&#x201d; for further detail.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span&gt;&lt;span id="xdx_8BC_zlnjQ0R1CBk9" style="display: none; visibility: hidden"&gt;Schedule of net income per common share&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 5.5in; border-collapse: collapse"&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 167.8pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; width: 6.95pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; width: 7.1pt; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_493_20220101__20221231_zzvMb6BBNmGj" style="vertical-align: top; width: 85.9pt; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; width: 14.1pt; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; width: 9.35pt; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; width: 7.1pt; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_496_20210101__20211231_zL1n95ZSVts2" style="vertical-align: top; width: 82.5pt; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; width: 15.1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: black 1pt solid; vertical-align: top; text-align: center"&gt;&lt;b&gt;Years Ended&lt;/b&gt;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: center"&gt;&lt;b&gt;December 31, 2022&lt;/b&gt;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: center"&gt;&lt;b&gt;December 31, 2021&lt;/b&gt;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--NetIncomeLoss_zY35B8ztZ5e8" style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td&gt;Net loss&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;(8,661,142&lt;/td&gt;
    &lt;td&gt;)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;(4,562,823&lt;/td&gt;
    &lt;td&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasicAbstract_iB_zJKQih5XQNV7" style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td&gt;Weighted Average Outstanding Shares:&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pid_hus-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zIQ1UMkP0mOc" style="vertical-align: bottom"&gt;
    &lt;td style="padding-left: 21.8pt"&gt;Outstanding shares&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;45,002,074&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;44,385,032&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--IncrementalCommonSharesAttributableToCallOptionsAndWarrants_pid_zm8oNBHXFS0c" style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td style="padding-left: 21.8pt"&gt;Option shares includable&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0541"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_F51_zXnO0VQ3fCd8"&gt;(a)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0542"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_F56_z8suocOMxah"&gt;(a)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_ecustom--IncrementalCommonSharesAttributableToRestrictedStock_pid_ztoKP1mn4Bw" style="vertical-align: bottom"&gt;
    &lt;td style="padding-left: 21.8pt"&gt;Restricted stock includable&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0544"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_F52_zmpyjNDtJ7Ea"&gt;(b)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0545"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_F5F_z4nwfjQAj7la"&gt;(b)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_ecustom--WeightedAverageNumberOfSharesOutstanding_zjf5cgBKhkY3" style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;&lt;b style="display: none; visibility: hidden"&gt;&#160;Total&lt;/b&gt;&lt;/p&gt;
        &lt;p style="margin-top: 0; margin-bottom: 0"/&gt;&lt;/td&gt;
    &lt;td/&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;45,002,074&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;44,385,032&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--EarningsPerShareAbstract_iB_zGOHyByYtat1" style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td&gt;Net loss per share&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--EarningsPerShareBasic_pid_uUSDPShares_zk4hYMtkkq2j" style="vertical-align: bottom"&gt;
    &lt;td style="padding-left: 21.8pt"&gt;Basic&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;(0.19&lt;/td&gt;
    &lt;td style="border-bottom: white 2.25pt double"&gt;)&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;(0.10&lt;/td&gt;
    &lt;td style="border-bottom: white 2.25pt double"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--EarningsPerShareDiluted_pid_uUSDPShares_zoNdyVgzpB1k" style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td style="padding-left: 21.8pt"&gt;Diluted&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;(0.19&lt;/td&gt;
    &lt;td style="border-bottom: white 2.25pt double"&gt;)&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;(0.10&lt;/td&gt;
    &lt;td style="border-bottom: white 2.25pt double"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;__________&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td id="xdx_F07_zpjRlU1tokg5" style="width: 0.5in"&gt;(a)&lt;/td&gt;
    &lt;td id="xdx_F13_zJ7k0c2TJW51" style="width: 7in"&gt;Option shares of &lt;span id="xdx_90B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_dxL_uShares_c20220101__20221231__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--EmployeeStockMember_zJscHJ6nJh08" title="Option shares excluded::XDX::0"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0560"&gt;zero&lt;/span&gt;&lt;/span&gt; and &lt;span id="xdx_906_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_uShares_c20210101__20211231__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--EmployeeStockMember_zOXokNhUvBRh" title="Option shares excluded"&gt;273,110&lt;/span&gt; for 2022 and 2021, respectively were not included as the impact is anti-dilutive.&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td id="xdx_F05_zQfISkekUjdj" style="width: 0.5in"&gt;(b)&lt;/td&gt;
    &lt;td id="xdx_F12_zj23i9XZITAh" style="width: 7in"&gt;Linda Tharby's Restricted Stock award shares of &lt;span id="xdx_90D_ecustom--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount1_pid_uShares_c20220101__20221231__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--EmployeeStockMember_zQe25yGQAtl2" title="Restricted stock shares excluded"&gt;950,000&lt;/span&gt; and &lt;span id="xdx_900_ecustom--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount1_pid_uShares_c20210101__20211231__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--EmployeeStockMember_zQeAAvWnACzb" title="Restricted stock shares excluded"&gt;1,000,000&lt;/span&gt; that are unvested for 2022 and 2021, respectively were not included as the impact is anti-dilutive.&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AD_z74ojCDpPbsk" style="margin-top: 0; margin-bottom: 0"&gt;&#160;&lt;/p&gt;
</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_89E_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_zMG1jKvSqsWe" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;Basic earnings per share are computed on the weighted average of common
shares outstanding during each year. &#160;Diluted earnings per share includes only an increase in the weighted average shares by the
common shares issuable upon exercise of stock options. &#160;See &#x201c;NOTE 4 &#x2014; STOCK-BASED COMPENSATION&#x201d; for further detail.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span&gt;&lt;span id="xdx_8BC_zlnjQ0R1CBk9" style="display: none; visibility: hidden"&gt;Schedule of net income per common share&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 5.5in; border-collapse: collapse"&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 167.8pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; width: 6.95pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; width: 7.1pt; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_493_20220101__20221231_zzvMb6BBNmGj" style="vertical-align: top; width: 85.9pt; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; width: 14.1pt; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; width: 9.35pt; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; width: 7.1pt; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_496_20210101__20211231_zL1n95ZSVts2" style="vertical-align: top; width: 82.5pt; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; width: 15.1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: black 1pt solid; vertical-align: top; text-align: center"&gt;&lt;b&gt;Years Ended&lt;/b&gt;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: center"&gt;&lt;b&gt;December 31, 2022&lt;/b&gt;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: center"&gt;&lt;b&gt;December 31, 2021&lt;/b&gt;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--NetIncomeLoss_zY35B8ztZ5e8" style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td&gt;Net loss&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;(8,661,142&lt;/td&gt;
    &lt;td&gt;)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;(4,562,823&lt;/td&gt;
    &lt;td&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasicAbstract_iB_zJKQih5XQNV7" style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td&gt;Weighted Average Outstanding Shares:&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pid_hus-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zIQ1UMkP0mOc" style="vertical-align: bottom"&gt;
    &lt;td style="padding-left: 21.8pt"&gt;Outstanding shares&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;45,002,074&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;44,385,032&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--IncrementalCommonSharesAttributableToCallOptionsAndWarrants_pid_zm8oNBHXFS0c" style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td style="padding-left: 21.8pt"&gt;Option shares includable&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0541"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_F51_zXnO0VQ3fCd8"&gt;(a)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0542"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_F56_z8suocOMxah"&gt;(a)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_ecustom--IncrementalCommonSharesAttributableToRestrictedStock_pid_ztoKP1mn4Bw" style="vertical-align: bottom"&gt;
    &lt;td style="padding-left: 21.8pt"&gt;Restricted stock includable&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0544"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_F52_zmpyjNDtJ7Ea"&gt;(b)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0545"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_F5F_z4nwfjQAj7la"&gt;(b)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_ecustom--WeightedAverageNumberOfSharesOutstanding_zjf5cgBKhkY3" style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;&lt;b style="display: none; visibility: hidden"&gt;&#160;Total&lt;/b&gt;&lt;/p&gt;
        &lt;p style="margin-top: 0; margin-bottom: 0"/&gt;&lt;/td&gt;
    &lt;td/&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;45,002,074&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;44,385,032&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--EarningsPerShareAbstract_iB_zGOHyByYtat1" style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td&gt;Net loss per share&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--EarningsPerShareBasic_pid_uUSDPShares_zk4hYMtkkq2j" style="vertical-align: bottom"&gt;
    &lt;td style="padding-left: 21.8pt"&gt;Basic&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;(0.19&lt;/td&gt;
    &lt;td style="border-bottom: white 2.25pt double"&gt;)&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;(0.10&lt;/td&gt;
    &lt;td style="border-bottom: white 2.25pt double"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--EarningsPerShareDiluted_pid_uUSDPShares_zoNdyVgzpB1k" style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td style="padding-left: 21.8pt"&gt;Diluted&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;(0.19&lt;/td&gt;
    &lt;td style="border-bottom: white 2.25pt double"&gt;)&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;(0.10&lt;/td&gt;
    &lt;td style="border-bottom: white 2.25pt double"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;__________&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td id="xdx_F07_zpjRlU1tokg5" style="width: 0.5in"&gt;(a)&lt;/td&gt;
    &lt;td id="xdx_F13_zJ7k0c2TJW51" style="width: 7in"&gt;Option shares of &lt;span id="xdx_90B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_dxL_uShares_c20220101__20221231__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--EmployeeStockMember_zJscHJ6nJh08" title="Option shares excluded::XDX::0"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0560"&gt;zero&lt;/span&gt;&lt;/span&gt; and &lt;span id="xdx_906_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_uShares_c20210101__20211231__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--EmployeeStockMember_zOXokNhUvBRh" title="Option shares excluded"&gt;273,110&lt;/span&gt; for 2022 and 2021, respectively were not included as the impact is anti-dilutive.&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td id="xdx_F05_zQfISkekUjdj" style="width: 0.5in"&gt;(b)&lt;/td&gt;
    &lt;td id="xdx_F12_zj23i9XZITAh" style="width: 7in"&gt;Linda Tharby's Restricted Stock award shares of &lt;span id="xdx_90D_ecustom--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount1_pid_uShares_c20220101__20221231__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--EmployeeStockMember_zQe25yGQAtl2" title="Restricted stock shares excluded"&gt;950,000&lt;/span&gt; and &lt;span id="xdx_900_ecustom--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount1_pid_uShares_c20210101__20211231__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--EmployeeStockMember_zQeAAvWnACzb" title="Restricted stock shares excluded"&gt;1,000,000&lt;/span&gt; that are unvested for 2022 and 2021, respectively were not included as the impact is anti-dilutive.&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">-8661142</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">-4562823</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">45002074</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">44385032</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <krmd:WeightedAverageNumberOfSharesOutstanding
      contextRef="From2022-01-01to2022-12-31"
      decimals="INF"
      unitRef="Shares">45002074</krmd:WeightedAverageNumberOfSharesOutstanding>
    <krmd:WeightedAverageNumberOfSharesOutstanding
      contextRef="From2021-01-012021-12-31"
      decimals="INF"
      unitRef="Shares">44385032</krmd:WeightedAverageNumberOfSharesOutstanding>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2022-01-01to2022-12-31"
      decimals="INF"
      unitRef="USDPShares">-0.19</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2021-01-012021-12-31"
      decimals="INF"
      unitRef="USDPShares">-0.10</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2022-01-01to2022-12-31"
      decimals="INF"
      unitRef="USDPShares">-0.19</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2021-01-012021-12-31"
      decimals="INF"
      unitRef="USDPShares">-0.10</us-gaap:EarningsPerShareDiluted>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2021-01-012021-12-31_us-gaap_EmployeeStockMember"
      decimals="INF"
      unitRef="Shares">273110</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <krmd:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount1
      contextRef="From2022-01-012022-12-31_us-gaap_EmployeeStockMember"
      decimals="INF"
      unitRef="Shares">950000</krmd:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount1>
    <krmd:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount1
      contextRef="From2021-01-012021-12-31_us-gaap_EmployeeStockMember"
      decimals="INF"
      unitRef="Shares">1000000</krmd:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount1>
    <us-gaap:UseOfEstimates contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_844_eus-gaap--UseOfEstimates_z6LaBImte0K4" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span id="xdx_869_z4A7A2mqJ7X9"&gt;USE OF ESTIMATES IN THE FINANCIAL STATEMENTS&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;The preparation of financial statements in conformity with GAAP requires
management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. &#160;Actual
results could differ from those estimates. &#160;Important estimates include but are not limited to asset lives, valuation allowances,
inventory valuation, and accruals.&lt;/p&gt;

</us-gaap:UseOfEstimates>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_84F_eus-gaap--RevenueFromContractWithCustomerPolicyTextBlock_zpLpzc1GZBG4" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span id="xdx_860_zt5Gey8twc2c"&gt;REVENUE RECOGNITION&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;The Financial Accounting Standards Board (&#x201c;FASB&#x201d;) issued Accounting
Standards Update (&#x201c;ASU&#x201d;) No. 2014-09, &lt;i&gt;Revenue from Contracts with Customers&lt;/i&gt;, which provides a single comprehensive
model for entities to use in accounting for revenue arising from contracts with customers.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;The Company&#x2019;s revenues result from the sale of assembled products.
&#160;We recognize revenues when shipment occurs, and at which point the customer obtains control and ownership of the goods. &#160;Shipping
costs generally are billed to customers and are included in sales.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;The Company generally does not accept return of goods shipped unless it
is a Company error. &#160;The only credits provided to customers are for defective merchandise. &#160;The Company warrants the syringe
driver from defects in materials and workmanship under normal use and the warranty does not include a performance obligation. &#160;The
costs under the warranty are expensed as incurred.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;Provisions for distributor pricing and annual customer growth rebates are
variable consideration and are recorded as a reduction of revenue in the same period the related sales are recorded or when it is probable
the annual growth target will be achieved. &#160;Rebates are provided to distributors for the difference in selling price to distributor
and pricing specified to select customers.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;The Company established an allowance for charging off uncollectible trade
accounts receivable that have both of the following characteristics: (a) They have a contractual maturity of one year or less, (b) They
arose from the sale of goods or services.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_89E_ecustom--ScheduleOfNetRevenuesByGeography_z3BIpuyfVG4d" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;The following table summarizes net revenues by geography for the years ended
December 31, 2022 and 2021:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span id="xdx_8BD_z3C9ZxreeIk3" style="display: none; visibility: hidden"&gt;Schedule of net revenues by geography&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 3.5in; border-collapse: collapse"&gt;
  &lt;tr style="background-color: white"&gt;
    &lt;td style="vertical-align: bottom; width: 93.35pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; width: 8.3pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; width: 8.25pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; width: 53.4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; width: 18.05pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; width: 8.25pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; width: 54.15pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; width: 8.25pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="background-color: white"&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="5" style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: center"&gt;&lt;b&gt;Years Ended December 31,&lt;/b&gt;&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="background-color: white"&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: center"&gt;&lt;b&gt;2022&lt;/b&gt;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: center"&gt;&lt;b&gt;2021&lt;/b&gt;&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="background-color: white"&gt;
    &lt;td style="vertical-align: bottom"&gt;&lt;b&gt;Net Revenues&lt;/b&gt;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="background-color: #E6E6E6"&gt;
    &lt;td style="vertical-align: bottom; padding-left: 9.45pt"&gt;Domestic&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_98D_eus-gaap--Revenues_c20220101__20221231__srt--StatementGeographicalAxis__country--US_zZ4uQjTcgfJc" style="text-align: right" title="Net Revenue"&gt;23,586,254&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_98C_eus-gaap--Revenues_c20210101__20211231__srt--StatementGeographicalAxis__country--US_zmQIeI78tUyl" style="text-align: right" title="Net Revenue"&gt;19,488,685&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="background-color: white"&gt;
    &lt;td style="vertical-align: bottom; padding-left: 9.45pt"&gt;International&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_987_eus-gaap--Revenues_c20220101__20221231__srt--StatementGeographicalAxis__us-gaap--NonUsMember_zfGG2aByPLz" style="border-bottom: black 1pt solid; text-align: right" title="Net Revenues"&gt;4,309,783&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_981_eus-gaap--Revenues_c20210101__20211231__srt--StatementGeographicalAxis__us-gaap--NonUsMember_zRtFKssVTgme" style="border-bottom: black 1pt solid; text-align: right" title="Net Revenues"&gt;4,001,490&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="background-color: #E6E6E6"&gt;
    &lt;td style="vertical-align: bottom"&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;$&lt;/td&gt;
    &lt;td id="xdx_988_eus-gaap--Revenues_c20220101__20221231_zbAfS3LpNBGe" style="border-bottom: black 2.25pt double; text-align: right" title="Revenues"&gt;27,896,037&lt;/td&gt;
    &lt;td style="border-bottom: white 2.25pt double; vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;$&lt;/td&gt;
    &lt;td id="xdx_980_eus-gaap--Revenues_c20210101__20211231_zn8OKcUznKZg" style="border-bottom: black 2.25pt double; text-align: right" title="Revenues"&gt;23,490,175&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p id="xdx_8A4_zRN68oI0ioGe" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <krmd:ScheduleOfNetRevenuesByGeography contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_89E_ecustom--ScheduleOfNetRevenuesByGeography_z3BIpuyfVG4d" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;The following table summarizes net revenues by geography for the years ended
December 31, 2022 and 2021:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span id="xdx_8BD_z3C9ZxreeIk3" style="display: none; visibility: hidden"&gt;Schedule of net revenues by geography&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 3.5in; border-collapse: collapse"&gt;
  &lt;tr style="background-color: white"&gt;
    &lt;td style="vertical-align: bottom; width: 93.35pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; width: 8.3pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; width: 8.25pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; width: 53.4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; width: 18.05pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; width: 8.25pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; width: 54.15pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; width: 8.25pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="background-color: white"&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="5" style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: center"&gt;&lt;b&gt;Years Ended December 31,&lt;/b&gt;&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="background-color: white"&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: center"&gt;&lt;b&gt;2022&lt;/b&gt;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: center"&gt;&lt;b&gt;2021&lt;/b&gt;&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="background-color: white"&gt;
    &lt;td style="vertical-align: bottom"&gt;&lt;b&gt;Net Revenues&lt;/b&gt;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="background-color: #E6E6E6"&gt;
    &lt;td style="vertical-align: bottom; padding-left: 9.45pt"&gt;Domestic&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_98D_eus-gaap--Revenues_c20220101__20221231__srt--StatementGeographicalAxis__country--US_zZ4uQjTcgfJc" style="text-align: right" title="Net Revenue"&gt;23,586,254&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_98C_eus-gaap--Revenues_c20210101__20211231__srt--StatementGeographicalAxis__country--US_zmQIeI78tUyl" style="text-align: right" title="Net Revenue"&gt;19,488,685&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="background-color: white"&gt;
    &lt;td style="vertical-align: bottom; padding-left: 9.45pt"&gt;International&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_987_eus-gaap--Revenues_c20220101__20221231__srt--StatementGeographicalAxis__us-gaap--NonUsMember_zfGG2aByPLz" style="border-bottom: black 1pt solid; text-align: right" title="Net Revenues"&gt;4,309,783&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_981_eus-gaap--Revenues_c20210101__20211231__srt--StatementGeographicalAxis__us-gaap--NonUsMember_zRtFKssVTgme" style="border-bottom: black 1pt solid; text-align: right" title="Net Revenues"&gt;4,001,490&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="background-color: #E6E6E6"&gt;
    &lt;td style="vertical-align: bottom"&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;$&lt;/td&gt;
    &lt;td id="xdx_988_eus-gaap--Revenues_c20220101__20221231_zbAfS3LpNBGe" style="border-bottom: black 2.25pt double; text-align: right" title="Revenues"&gt;27,896,037&lt;/td&gt;
    &lt;td style="border-bottom: white 2.25pt double; vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;$&lt;/td&gt;
    &lt;td id="xdx_980_eus-gaap--Revenues_c20210101__20211231_zn8OKcUznKZg" style="border-bottom: black 2.25pt double; text-align: right" title="Revenues"&gt;23,490,175&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
</krmd:ScheduleOfNetRevenuesByGeography>
    <us-gaap:Revenues
      contextRef="From2022-01-012022-12-31_country_US"
      decimals="0"
      unitRef="USD">23586254</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2021-01-012021-12-31_country_US"
      decimals="0"
      unitRef="USD">19488685</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2022-01-012022-12-31_us-gaap_NonUsMember"
      decimals="0"
      unitRef="USD">4309783</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2021-01-012021-12-31_us-gaap_NonUsMember"
      decimals="0"
      unitRef="USD">4001490</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">27896037</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">23490175</us-gaap:Revenues>
    <us-gaap:LesseeLeasesPolicyTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_846_eus-gaap--LesseeLeasesPolicyTextBlock_zipKrI5L2i54" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span id="xdx_863_zGMa0N0Ww7ef"&gt;LEASES&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;In February 2016, the FASB issued a standard related to leases to increase
transparency and comparability among organizations by requiring the recognition of right-of-use (&#x201c;ROU&#x201d;) assets and lease liabilities
on the balance sheet. &#160;Most prominent among the changes in the standard is the recognition of ROU assets and lease liabilities by
the Company for those leases classified as operating leases under current GAAP, while our accounting for capital leases remains substantially
unchanged. &#160;Under the standard, disclosures are required to meet the objective of enabling users of financial statements to assess
the amount, timing, and uncertainty of cash flows arising from leases. &#160;The standard became effective for us on January 1, 2019.
&#160;The standard had a material impact on our balance sheets but did not have a material impact on our statements of operations. &#160;See
&#x201c;NOTE 5 &lt;b&gt;&#x2014; &lt;/b&gt;LEASES&#x201d; for further detail.&lt;/p&gt;

</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_844_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zyR5yhkl0mx3" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span id="xdx_86D_zfWO34kCXJPi"&gt;ACCOUNTING PRONOUNCEMENTS RECENTLY ADOPTED&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;In December 2019, the FASB issued ASU No. 2019-12, &lt;i&gt;Income Taxes (Topic
740): Simplifying the Accounting for Income Taxes&lt;/i&gt;. The amendments in this ASU simplify the accounting for income taxes by removing
several exceptions including the exception to the general methodology for calculating income taxes in an interim period when a year-to-date
loss exceeds the anticipated loss for the year. &#160;The amendments also improve consistent application of and simplify GAAP for other
areas of Topic 740 by clarifying and amending existing guidance. &#160;The amendments in this ASU are effective for fiscal years, and
interim periods within those fiscal years, beginning after December 15, 2020. &#160;The Company adopted this standard on January 1, 2021,
and it had no impact on our financial statement disclosures.&lt;/p&gt;

</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <krmd:AccountingPronouncementsNotYetAdopted contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_846_ecustom--AccountingPronouncementsNotYetAdopted_zMJECMpJBn7j" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span id="xdx_865_z8maNI0cLQ6c"&gt;ACCOUNTING PRONOUNCEMENTS NOT YET ADOPTED&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;In June 2016, the FASB issued ASU No. 2016-13, &lt;i&gt;Financial Instruments
&#x2013; Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments&lt;/i&gt;, which amends guidance on reporting credit
losses for assets held at amortized cost basis and available for sale debt securities. &#160;For assets held at amortized cost basis,
Topic 326 eliminates the probable initial recognition threshold in current GAAP and, instead, requires an entity to reflect its current
estimate of all expected credit losses. &#160;The allowance for credit losses is a valuation account that is deducted from the amortized
cost basis of the financial assets to present the net amount expected to be collected. &#160;For available for sale debt securities, credit
losses should be measured in a manner similar to current GAAP, however Topic 326 will require that credit losses be presented as an allowance
rather than as a write-down. &#160;This ASU affects entities holding financial assets and net investment in leases that are not accounted
for at fair value through net income. &#160;The amendments affect loans, debt securities, trade receivables, net investments in leases,
off balance sheet credit exposures, reinsurance receivables, and any other financial assets not excluded from the scope that have the
contractual right to receive cash. &#160;The amendments in this update are effective for fiscal years beginning after December 15, 2022,
including interim periods within those fiscal years. &#160;The Company is assessing the impact of the adoption of the ASU on its financial
statements, disclosure requirements and methods of adoption.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;The Company considers the applicability and impact of all recently issued
accounting pronouncements. &#160;Recent accounting pronouncements not specifically identified in our disclosures are either not applicable
to the Company or are not expected to have a material effect on our financial condition or results of operations.&lt;/p&gt;

</krmd:AccountingPronouncementsNotYetAdopted>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_844_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_zB3qn80oaFa5" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span id="xdx_866_z5Y75OK0JD5g"&gt;FAIR VALUE MEASUREMENTS&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;Fair value is the exit price that would be received to sell an asset or
paid to transfer a liability. &#160;Fair value is a market-based measurement that should be determined using assumptions that market participants
would use in pricing an asset or liability. Valuation techniques used to measure fair value should maximize the use of observable inputs
and minimize the use of unobservable inputs. &#160;To measure fair value, the Company uses the following fair value hierarchy based on
three levels of inputs, of which the first two are considered observable and the last unobservable:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 7.5in; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.5in; text-align: center"&gt;&#x2022;&lt;/td&gt;
    &lt;td style="width: 7in"&gt;Level 1 &#x2013; Quoted prices in active markets for identical assets or liabilities.&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="text-align: center"&gt;&#x2022;&lt;/td&gt;
    &lt;td&gt;Level 2 &#x2013; Inputs other than Level 1 that are observable for the asset or liability, either directly or indirectly, such as quoted prices for similar assets and liabilities in active markets; quoted prices for identical or similar assets or liabilities in markets that are not active; or other inputs that are observable or can be corroborated by observable market data by correlation or other means.&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="text-align: center"&gt;&#x2022;&lt;/td&gt;
    &lt;td&gt;Level 3 &#x2013; Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. &#160;Value is determined using pricing models, discounted cash flow methodologies, or similar techniques and includes instruments for which the determination of fair value requires significant judgment or estimation.&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;The carrying amounts of cash and cash equivalents, accounts receivable,
prepaid expenses, accounts payable and accrued expenses are considered to be representative of their fair values because of the short-term
nature of those instruments. &#160;There were no transfers between levels in the fair value hierarchy during the year ended December 31,
2022.&lt;/p&gt;

</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_849_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_zQZbDx9rQ7We" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span id="xdx_86D_zRmizrHnN8ef"&gt;IMPAIRMENT OF LONG-LIVED ASSETS&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;The Company reviews long-lived assets for impairment whenever events or
changes in circumstances indicate that the carrying amount of the assets may not be fully recoverable. &#160;An impairment loss would
be recognized when estimated undiscounted future cash flows expected to result from the use of the asset and its eventual disposition
are less than the carrying amount. &#160;The impairment loss, if recognized, would be based on the excess of the carrying value of the
impaired asset over its respective fair value. &#160;No impairment losses have been recorded through December 31, 2022.&lt;/p&gt;

</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <us-gaap:InventoryDisclosureTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_80D_eus-gaap--InventoryDisclosureTextBlock_zBZWP51yiEx8" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;NOTE 2 &#x2014; &lt;span id="xdx_82C_zIfPFE30WoU5"&gt;INVENTORY&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_892_eus-gaap--ScheduleOfInventoryCurrentTableTextBlock_zSfOlZuewx4c" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span id="xdx_8B5_zEiwQCi3QSQc"&gt;Inventory consists of:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 5.75in; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;December 31, 2022&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;December 31, 2021&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="width: 208.35pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 0.1in"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 8.25pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 79.7pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 14.3pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 7.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 80.45pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 8.25pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td&gt;Raw materials and work-in-process&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_98A_eus-gaap--InventoryWorkInProcessAndRawMaterials_iI_c20221231_zQs9SGHLFSIl" style="text-align: right" title="Raw materials and work-in-process"&gt;3,853,034&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_98F_eus-gaap--InventoryWorkInProcessAndRawMaterials_iI_c20211231_zwPKqJbgVxHb" style="text-align: right" title="Raw materials and work-in-process"&gt;2,997,807&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;Finished goods&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_981_eus-gaap--InventoryFinishedGoods_iI_c20221231_zCjgaLgmr7nf" style="border-bottom: black 1pt solid; text-align: right" title="Finished goods"&gt;2,611,951&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98B_eus-gaap--InventoryFinishedGoods_iI_c20211231_z4OyKjNY8Aod" style="border-bottom: black 1pt solid; text-align: right" title="Finished goods"&gt;3,176,836&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td&gt;&#160;&#160;&#160;Total&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_988_eus-gaap--InventoryGross_iI_c20221231_zNa94DcM4pi" style="text-align: right" title="Inventory, Gross"&gt;6,464,985&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98B_eus-gaap--InventoryGross_iI_c20211231_zOtHtSUoLgv8" style="text-align: right" title="Inventory, Gross"&gt;6,174,643&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;Less: reserve for obsolete inventory&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98A_eus-gaap--InventoryValuationReserves_iNI_di_c20221231_zw26NTqXKrF8" style="border-bottom: black 1pt solid; text-align: right" title="Less: reserve for obsolete inventory"&gt;(60,118&lt;/td&gt;
    &lt;td&gt;)&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_985_eus-gaap--InventoryValuationReserves_iNI_di_c20211231_z65Ll2xB7sj7" style="border-bottom: black 1pt solid; text-align: right"&gt;(68,305&lt;/td&gt;
    &lt;td&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td&gt;Inventory, net&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;$&lt;/td&gt;
    &lt;td id="xdx_983_eus-gaap--InventoryNet_iI_c20221231_zTtndi3ifpb8" style="border-bottom: black 2.25pt double; text-align: right" title="Inventory"&gt;6,404,867&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;$&lt;/td&gt;
    &lt;td id="xdx_98A_eus-gaap--InventoryNet_iI_c20211231_zgsk9QWKuCD" style="border-bottom: black 2.25pt double; text-align: right" title="Inventory"&gt;6,106,338&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A0_zysOCcAhhAX5" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

</us-gaap:InventoryDisclosureTextBlock>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_892_eus-gaap--ScheduleOfInventoryCurrentTableTextBlock_zSfOlZuewx4c" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span id="xdx_8B5_zEiwQCi3QSQc"&gt;Inventory consists of:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 5.75in; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;December 31, 2022&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;December 31, 2021&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="width: 208.35pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 0.1in"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 8.25pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 79.7pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 14.3pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 7.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 80.45pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 8.25pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td&gt;Raw materials and work-in-process&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_98A_eus-gaap--InventoryWorkInProcessAndRawMaterials_iI_c20221231_zQs9SGHLFSIl" style="text-align: right" title="Raw materials and work-in-process"&gt;3,853,034&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_98F_eus-gaap--InventoryWorkInProcessAndRawMaterials_iI_c20211231_zwPKqJbgVxHb" style="text-align: right" title="Raw materials and work-in-process"&gt;2,997,807&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;Finished goods&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_981_eus-gaap--InventoryFinishedGoods_iI_c20221231_zCjgaLgmr7nf" style="border-bottom: black 1pt solid; text-align: right" title="Finished goods"&gt;2,611,951&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98B_eus-gaap--InventoryFinishedGoods_iI_c20211231_z4OyKjNY8Aod" style="border-bottom: black 1pt solid; text-align: right" title="Finished goods"&gt;3,176,836&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td&gt;&#160;&#160;&#160;Total&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_988_eus-gaap--InventoryGross_iI_c20221231_zNa94DcM4pi" style="text-align: right" title="Inventory, Gross"&gt;6,464,985&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98B_eus-gaap--InventoryGross_iI_c20211231_zOtHtSUoLgv8" style="text-align: right" title="Inventory, Gross"&gt;6,174,643&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;Less: reserve for obsolete inventory&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98A_eus-gaap--InventoryValuationReserves_iNI_di_c20221231_zw26NTqXKrF8" style="border-bottom: black 1pt solid; text-align: right" title="Less: reserve for obsolete inventory"&gt;(60,118&lt;/td&gt;
    &lt;td&gt;)&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_985_eus-gaap--InventoryValuationReserves_iNI_di_c20211231_z65Ll2xB7sj7" style="border-bottom: black 1pt solid; text-align: right"&gt;(68,305&lt;/td&gt;
    &lt;td&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td&gt;Inventory, net&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;$&lt;/td&gt;
    &lt;td id="xdx_983_eus-gaap--InventoryNet_iI_c20221231_zTtndi3ifpb8" style="border-bottom: black 2.25pt double; text-align: right" title="Inventory"&gt;6,404,867&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;$&lt;/td&gt;
    &lt;td id="xdx_98A_eus-gaap--InventoryNet_iI_c20211231_zgsk9QWKuCD" style="border-bottom: black 2.25pt double; text-align: right" title="Inventory"&gt;6,106,338&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:InventoryWorkInProcessAndRawMaterials contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">3853034</us-gaap:InventoryWorkInProcessAndRawMaterials>
    <us-gaap:InventoryWorkInProcessAndRawMaterials contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">2997807</us-gaap:InventoryWorkInProcessAndRawMaterials>
    <us-gaap:InventoryFinishedGoods contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">2611951</us-gaap:InventoryFinishedGoods>
    <us-gaap:InventoryFinishedGoods contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">3176836</us-gaap:InventoryFinishedGoods>
    <us-gaap:InventoryGross contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">6464985</us-gaap:InventoryGross>
    <us-gaap:InventoryGross contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">6174643</us-gaap:InventoryGross>
    <us-gaap:InventoryValuationReserves contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">60118</us-gaap:InventoryValuationReserves>
    <us-gaap:InventoryValuationReserves contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">68305</us-gaap:InventoryValuationReserves>
    <us-gaap:InventoryNet contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">6404867</us-gaap:InventoryNet>
    <us-gaap:InventoryNet contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">6106338</us-gaap:InventoryNet>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_80A_eus-gaap--PropertyPlantAndEquipmentDisclosureTextBlock_zdR6NODU7928" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;NOTE 3 &#x2014; &lt;span id="xdx_828_zjpD9hEUjx1"&gt;PROPERTY AND EQUIPMENT&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_895_eus-gaap--PropertyPlantAndEquipmentTextBlock_zaoyxblUiHw7" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span&gt;Property and equipment consists of the following at:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span id="xdx_8BD_zWKiA8IJzf19" style="display: none; visibility: hidden"&gt;Schedule of property and equipment&lt;/span&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 5.75in; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;December 31, 2022&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;December 31, 2021&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td style="width: 203.85pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 0.1in"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 8.25pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 79.7pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 14.3pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 8.25pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 79.7pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 8.25pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td&gt;Furniture and office equipment&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_98A_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--FurnitureAndOfficeEquipmentMember_zWHnBNx3xFe5" style="text-align: right"&gt;1,456,745&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_987_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20211231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--FurnitureAndOfficeEquipmentMember_zECbEcrxcYZa" style="text-align: right"&gt;818,897&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;Leasehold improvements&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_984_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zW5Uhbm2OpUg" style="text-align: right"&gt;2,413,820&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_984_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20211231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zUBg8Aip0597" style="text-align: right"&gt;556,907&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td&gt;Manufacturing equipment and tooling&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98C_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ManufacturingEquipmentAndToolingMember_zT0quWrrXv3" style="border-bottom: black 1pt solid; text-align: right"&gt;2,810,813&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_988_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20211231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ManufacturingEquipmentAndToolingMember_zNTYU2zCQITe" style="border-bottom: black 1pt solid; text-align: right"&gt;2,042,675&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&#160;&#160;Total property and equipment&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98C_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20221231_zZxEzqn5ixH1" style="text-align: right" title="Total property and equipment"&gt;6,681,378&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_983_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20211231_zR6JnYT1Bkpa" style="text-align: right" title="Total property and equipment"&gt;3,418,479&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td&gt;Less: accumulated depreciation and amortization&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_989_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_di_c20221231_zELaZxCyfw6b" style="border-bottom: black 1pt solid; text-align: right" title="Less: accumulated depreciation and amortization"&gt;(2,794,403&lt;/td&gt;
    &lt;td&gt;)&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98B_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_di_c20211231_zfIeWTTvng2a" style="border-bottom: black 1pt solid; text-align: right" title="Less: accumulated depreciation and amortization"&gt;(2,312,034&lt;/td&gt;
    &lt;td&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;Property and equipment, net&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;$&lt;/td&gt;
    &lt;td id="xdx_985_eus-gaap--PropertyPlantAndEquipmentNet_iI_dxL_c20221231_zTlhecAMheBg" style="border-bottom: black 2.25pt double; text-align: right" title="Property and equipment, net::XDX::3886975"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0640"&gt;3,886,975&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;$&lt;/td&gt;
    &lt;td id="xdx_989_eus-gaap--PropertyPlantAndEquipmentNet_iI_c20211231_zsbI0O4sKC4e" style="border-bottom: black 2.25pt double; text-align: right" title="Property and equipment, net"&gt;1,106,445&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p id="xdx_8AA_z9ktPti7bLjc" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_895_eus-gaap--PropertyPlantAndEquipmentTextBlock_zaoyxblUiHw7" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span&gt;Property and equipment consists of the following at:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span id="xdx_8BD_zWKiA8IJzf19" style="display: none; visibility: hidden"&gt;Schedule of property and equipment&lt;/span&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 5.75in; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;December 31, 2022&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;December 31, 2021&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td style="width: 203.85pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 0.1in"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 8.25pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 79.7pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 14.3pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 8.25pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 79.7pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 8.25pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td&gt;Furniture and office equipment&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_98A_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--FurnitureAndOfficeEquipmentMember_zWHnBNx3xFe5" style="text-align: right"&gt;1,456,745&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_987_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20211231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--FurnitureAndOfficeEquipmentMember_zECbEcrxcYZa" style="text-align: right"&gt;818,897&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;Leasehold improvements&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_984_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zW5Uhbm2OpUg" style="text-align: right"&gt;2,413,820&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_984_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20211231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zUBg8Aip0597" style="text-align: right"&gt;556,907&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td&gt;Manufacturing equipment and tooling&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98C_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ManufacturingEquipmentAndToolingMember_zT0quWrrXv3" style="border-bottom: black 1pt solid; text-align: right"&gt;2,810,813&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_988_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20211231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ManufacturingEquipmentAndToolingMember_zNTYU2zCQITe" style="border-bottom: black 1pt solid; text-align: right"&gt;2,042,675&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&#160;&#160;Total property and equipment&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98C_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20221231_zZxEzqn5ixH1" style="text-align: right" title="Total property and equipment"&gt;6,681,378&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_983_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20211231_zR6JnYT1Bkpa" style="text-align: right" title="Total property and equipment"&gt;3,418,479&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td&gt;Less: accumulated depreciation and amortization&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_989_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_di_c20221231_zELaZxCyfw6b" style="border-bottom: black 1pt solid; text-align: right" title="Less: accumulated depreciation and amortization"&gt;(2,794,403&lt;/td&gt;
    &lt;td&gt;)&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98B_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_di_c20211231_zfIeWTTvng2a" style="border-bottom: black 1pt solid; text-align: right" title="Less: accumulated depreciation and amortization"&gt;(2,312,034&lt;/td&gt;
    &lt;td&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;Property and equipment, net&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;$&lt;/td&gt;
    &lt;td id="xdx_985_eus-gaap--PropertyPlantAndEquipmentNet_iI_dxL_c20221231_zTlhecAMheBg" style="border-bottom: black 2.25pt double; text-align: right" title="Property and equipment, net::XDX::3886975"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0640"&gt;3,886,975&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;$&lt;/td&gt;
    &lt;td id="xdx_989_eus-gaap--PropertyPlantAndEquipmentNet_iI_c20211231_zsbI0O4sKC4e" style="border-bottom: black 2.25pt double; text-align: right" title="Property and equipment, net"&gt;1,106,445&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2022-12-31_custom_FurnitureAndOfficeEquipmentMember"
      decimals="0"
      unitRef="USD">1456745</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2021-12-31_custom_FurnitureAndOfficeEquipmentMember"
      decimals="0"
      unitRef="USD">818897</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2022-12-31_us-gaap_LeaseholdImprovementsMember"
      decimals="0"
      unitRef="USD">2413820</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2021-12-31_us-gaap_LeaseholdImprovementsMember"
      decimals="0"
      unitRef="USD">556907</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2022-12-31_custom_ManufacturingEquipmentAndToolingMember"
      decimals="0"
      unitRef="USD">2810813</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2021-12-31_custom_ManufacturingEquipmentAndToolingMember"
      decimals="0"
      unitRef="USD">2042675</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">6681378</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">3418479</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">2794403</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">2312034</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">1106445</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_80D_eus-gaap--DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_z4k1HyoJ39Lj" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;NOTE 4 &#x2014; &lt;span id="xdx_82F_z6Rf2R9VgmR9"&gt;STOCK-BASED COMPENSATION&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;The Company has three equity incentive plans: the 2015 Stock Option Plan,
as amended (the &#x201c;2015 Plan&#x201d;), the 2021 Omnibus Equity Incentive Plan (the &#x201c;2021 Plan&#x201d;), and the Non-Employee Director
Compensation Plan. The Company has also issued restricted stock as employment inducement awards to its Chief Executive Officer.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;As of December 31, 2022, there were options to purchase &lt;span id="xdx_907_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pid_uShares_c20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__srt--TitleOfIndividualAxis__custom--ExecutiveskeyEmployeesAndConsultantsMember_zbccPmTX67T6" title="Common stock, shares, outstanding"&gt;2,560,000&lt;/span&gt; shares
of the Company&#x2019;s common stock outstanding to certain executives, key employees and consultants under the 2015 Plan, of which &lt;span id="xdx_903_ecustom--StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan2015_pid_uShares_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__srt--TitleOfIndividualAxis__custom--ExecutiveskeyEmployeesAndConsultantsMember_zvBJcDgeisBj" title="Stock issued during period"&gt;445,000&lt;/span&gt;
were issued during the twelve months ended December 31, 2022. Additional options may be issued under the 2015 Plan as outstanding options
are forfeited, subject to a maximum &lt;span id="xdx_901_eus-gaap--StockIssuedDuringPeriodSharesShareBasedCompensation_pid_uShares_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zYVVvbGfdUUj" title="Available for issuance"&gt;6,000,000&lt;/span&gt; available for issuance under the 2015 Plan.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;The 2021 Plan provides for the grant of up to &lt;span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodSharesShareBasedCompensation_pid_uShares_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zL3V1K5nBYe3" title="Available for issuance"&gt;1,000,000&lt;/span&gt; incentive stock
options, nonqualified stock options, stock awards, restricted stock awards, restricted stock units and/or stock appreciation rights to
employees, consultants and directors. During the twelve months ended December 31, 2022, there were issued &lt;span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan_pid_uShares_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member__srt--TitleOfIndividualAxis__srt--DirectorMember_zkklXmZ8w7si" title="Stock issued during period"&gt;97,100&lt;/span&gt; shares of common stock, as director compensation and &lt;span id="xdx_904_eus-gaap--StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan_pid_uShares_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member__srt--TitleOfIndividualAxis__custom--ExecutiveMember_zmwBFQCY0xb6" title="Stock issued during period"&gt;475,000&lt;/span&gt; options to purchase shares of common stock as executive compensation under the 2021 Plan.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;Effective January 1, 2021, each non-employee director of the Company (other
than the Chairman of the Board) and Board advisor were eligible to receive of $&lt;span id="xdx_900_ecustom--NonemployeeServicesTransactionCost_pid_uShares_c20201230__20210102__srt--TitleOfIndividualAxis__custom--NonEmployeeDirectorAndBoardAdvisorMember_zIkhJX6VVOoa" title="Nonemployee services transaction cost"&gt;75,000&lt;/span&gt; annually, &lt;span id="xdx_902_eus-gaap--ShareBasedGoodsAndNonemployeeServicesTransaction_c20201230__20210102__srt--TitleOfIndividualAxis__custom--NonEmployeeDirectorAndBoardAdvisorMember_zBE02q8YweT2" title="Share-based goods and nonemployee services transaction"&gt;to be paid quarterly $12,500 in cash and
$6,250 in common stock&lt;/span&gt;. &#160;The Chairman of the Board is eligible to receive $&lt;span id="xdx_900_ecustom--NonemployeeServicesTransactionCost_pid_uShares_c20201230__20210102__srt--TitleOfIndividualAxis__srt--BoardOfDirectorsChairmanMember_z6PgXGpsFKYb" title="Non-employee director compensation"&gt;100,000&lt;/span&gt; annually, &lt;span id="xdx_908_eus-gaap--ShareBasedGoodsAndNonemployeeServicesTransaction_c20201230__20210102__srt--TitleOfIndividualAxis__srt--BoardOfDirectorsChairmanMember_zULEuO57yx1a" title="Share-based goods and nonemployee services transaction"&gt;to be paid quarterly $12,500 in cash
and $12,500 in common stock&lt;/span&gt;. Effective May 18, 2021, each non-employee director of the Company (other than the Chairman of the Board)
and Board advisor are eligible to receive of $&lt;span id="xdx_90B_ecustom--NonemployeeServicesTransactionCost_pid_uShares_c20210516__20210518__srt--TitleOfIndividualAxis__custom--NonEmployeeDirectorAndBoardAdvisorMember_zep2nfzAEid" title="Nonemployee services transaction cost"&gt;110,000&lt;/span&gt; annually, &lt;span id="xdx_90C_eus-gaap--ShareBasedGoodsAndNonemployeeServicesTransaction_c20210516__20210518__srt--TitleOfIndividualAxis__custom--NonEmployeeDirectorAndBoardAdvisorMember_zxq0BxHtClyc" title="Share-based goods and nonemployee services transaction"&gt;to be paid quarterly $12,500 in cash and $15,000 in common stock&lt;/span&gt;. &#160;The
Chairman of the Board is eligible to receive $&lt;span id="xdx_90F_ecustom--NonemployeeServicesTransactionCost_pid_uShares_c20210516__20210518__srt--TitleOfIndividualAxis__srt--BoardOfDirectorsChairmanMember_z0I2jjkpupL5"&gt;140,000&lt;/span&gt; annually, &lt;span id="xdx_90F_eus-gaap--ShareBasedGoodsAndNonemployeeServicesTransaction_c20210516__20210518__srt--TitleOfIndividualAxis__srt--BoardOfDirectorsChairmanMember_zoxWQpIP97N1" title="Share-based goods and nonemployee services transaction"&gt;to be paid quarterly $12,500 in cash and $22,500 in common stock&lt;/span&gt;. From
May 18, 2021 to May 6, 2022, non-employee director compensation was paid pursuant to the 2021 Plan. Since May 6, 2022, non-employee director
compensation has been paid pursuant to the Non-Employee Director Compensation Plan. All payments were and are pro-rated for partial service.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;On April 12, 2021, pursuant to an employment agreement entered into on
March 15, 2021, with Linda Tharby, the Company&#x2019;s President and Chief Executive Officer, the Company issued three restricted stock
awards for an aggregate &lt;span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan_pid_uShares_c20210411__20210412__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ChiefExecutiveOfficerLindaTharbyMember_zKxuJPWmyrXe" title="Common stock issued, shares"&gt;1,000,000&lt;/span&gt; shares of common stock for an aggregate stock price of $&lt;span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan_c20210411__20210412__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ChiefExecutiveOfficerLindaTharbyMember_zTls4M7CGjLf" title="Aggregate stock price"&gt;3,310,000&lt;/span&gt; and each vesting subject to employment
on the respective vesting date. These awards were issued as an inducement employment.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;2015 STOCK OPTION PLAN, as amended&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;Time-Based Stock Options&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;The per share weighted average fair value of stock options granted during
the years ended December 31, 2022, and December 31, 2021 was $&lt;span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_pid_uUSDPShares_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zbbDGR8bAfyg" title="Stock options granted"&gt;1.98&lt;/span&gt; and $&lt;span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_pid_uUSDPShares_c20210101__20211231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zvwWSiUkZFM2"&gt;2.85&lt;/span&gt;, respectively. &#160;The fair value of each award is estimated
on the grant date using the Black-Scholes option pricing model with the following weighted average assumptions used for grants in the
years ended December 31, 2022, and December 31, 2021. &#160;Historical information was the primary basis for the selection of the expected
volatility, expected dividend yield and the expected lives of the options. &#160;The risk-free interest rate was selected based upon yields
of the U.S. Treasury issues with a term equal to the expected life of the option being valued. &#160;The following table summarizes the
assumptions used in determining fair value. These assumptions are subjective and generally require significant analysis and judgment to
develop. We have recognized tax benefits associated with stock-based compensation of $&lt;span id="xdx_900_eus-gaap--IncomeTaxExpenseBenefit_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zRVLB861j9Cl" title="Tax benefit"&gt;198,258&lt;/span&gt; and $&lt;span id="xdx_90B_eus-gaap--IncomeTaxExpenseBenefit_c20210101__20211231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zw662DENIShk" title="Tax benefit"&gt;175,257&lt;/span&gt; for the years ended December
31, 2022 and 2021, respectively.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;



&lt;p id="xdx_898_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zMJTgRo09HFf" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span id="xdx_8B3_zNIQLyoNSWk4" style="display: none; visibility: hidden"&gt;Schedule of time based stock options&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 5.25in; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;December 31, 2022&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;December 31, 2021&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td style="width: 161.1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9.75pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 7.25pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 89.15pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 10.55pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9.05pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 82.85pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 8.3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td&gt;Dividend yield&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_z9I9JarWYZVl" title="Dividend yield"&gt;0.00&lt;/span&gt;%&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20210101__20211231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zwjPMQzkzhQc" title="Dividend yield"&gt;0.00&lt;/span&gt;%&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;Expected volatility&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember__srt--RangeAxis__srt--MinimumMember_z6mvehlaByMj"&gt;65.29&lt;/span&gt;% &#x2013; &lt;span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember__srt--RangeAxis__srt--MaximumMember_zGJbo5iW8TI1"&gt;77.5&lt;/span&gt;%&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20210101__20211231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember__srt--RangeAxis__srt--MinimumMember_zfzDfqq1wrRf"&gt;74.01&lt;/span&gt; &#x2013; &lt;span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20210101__20211231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember__srt--RangeAxis__srt--MaximumMember_zKyuNYz9KZ8h"&gt;77.91&lt;/span&gt;%&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td&gt;Weighted-average volatility&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_pid_dp0_uPure_c20220101__20221231_zlXJAsd0BLe" title="Weighted-average volatility"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_pid_dp_uPure_c20210101__20211231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zFG8DozU7zW4" title="Weighted-average volatility"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0697"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;Expected dividends&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments_d0_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zs1BAQmLx361" title="Expected dividends"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments_d0_c20210101__20211231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zAH1DVyaDcb6" title="Expected dividends"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td&gt;Expected term (in years)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dxL_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_ztG1LJY5HuX" title="Expected term (in years)::XDX::P10Y"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0703"&gt;10&lt;/span&gt;&lt;/span&gt; Years&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dxL_c20210101__20211231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zn7GgykVhqw7" title="Expected term (in years)::XDX::P10Y"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0705"&gt;10&lt;/span&gt;&lt;/span&gt; Years&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;Risk-free rate&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember__srt--RangeAxis__srt--MinimumMember_zhBrKaFMEtph" title="Risk-free rate"&gt;1.81&lt;/span&gt; &#x2013; &lt;span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember__srt--RangeAxis__srt--MaximumMember_zc1gVFzsSI62" title="Risk-free rate"&gt;4.02&lt;/span&gt;%&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20210101__20211231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember__srt--RangeAxis__srt--MinimumMember_zCY0GYklx5Sl" title="Risk-free rate"&gt;1.20&lt;/span&gt; &#x2013; &lt;span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20210101__20211231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember__srt--RangeAxis__srt--MaximumMember_zZufVf0If4Ui" title="Risk-free rate"&gt;1.62&lt;/span&gt;%&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p id="xdx_8A5_zQNZNQ0vEXaa" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_899_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_z1TmxFWsn1u9" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;The following table summarizes the status of the Company&#x2019;s stock
option plan:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span id="xdx_8B4_z3SmpQTP4fk1" style="display: none; visibility: hidden"&gt;Schedule of status of time based stock options&lt;/span&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 7.5in; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="5" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;December 31, 2022&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="5" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;December 31, 2021&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;Shares&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;Weighted&lt;br/&gt;
Average&lt;br/&gt;
Exercise&lt;br/&gt;
Price&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;Shares&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;Weighted&lt;br/&gt;
Average&lt;br/&gt;
Exercise&lt;br/&gt;
Price&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td style="width: 273.25pt"&gt;Outstanding at January 1&lt;/td&gt;
    &lt;td style="width: 0.1in"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 0.1in"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_uShares_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zO2vPnRHQxz" style="width: 49.5pt; text-align: right" title="Outstanding at beginning"&gt;3,672,500&lt;/td&gt;
    &lt;td style="width: 11.3pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9.75pt"&gt;$&lt;/td&gt;
    &lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_uUSDPShares_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zG4oARPUgMA1" style="width: 43.8pt; text-align: right" title="Outstanding at beginning"&gt;3.42&lt;/td&gt;
    &lt;td style="width: 11.3pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 0.1in"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_uShares_c20210101__20211231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zlSM4Nm3iOT6" style="width: 48.75pt; text-align: right"&gt;2,922,494&lt;/td&gt;
    &lt;td style="width: 11.3pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 7.5pt"&gt;$&lt;/td&gt;
    &lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_uUSDPShares_c20210101__20211231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zACFEiklGXXj" style="width: 43.8pt; text-align: right" title="Outstanding at beginning"&gt;2.46&lt;/td&gt;
    &lt;td style="width: 7.25pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;Granted&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_uShares_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_z2exdIa3IfIg" style="text-align: right" title="Granted"&gt;445,000&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_uUSDPShares_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zM61B6j8h4rd" style="text-align: right" title="Granted"&gt;2.57&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_uShares_c20210101__20211231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zAtBDtQDZi9f" style="text-align: right"&gt;2,000,000&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_uUSDPShares_c20210101__20211231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zaDavxuGXPuj" style="text-align: right" title="Granted"&gt;3.64&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td&gt;Exercised&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98C_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pid_uShares_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zRSnnZVL4Ky" style="text-align: right" title="Exercised"&gt;1,031,250&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_uUSDPShares_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zw3P2KzfQM26" style="text-align: right" title="Exercised"&gt;1.57&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_989_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pid_uShares_c20210101__20211231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zy56Oc1yEai" style="text-align: right"&gt;1,062,500&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_uUSDPShares_c20210101__20211231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zGPwU22jiHA2" style="text-align: right" title="Exercised"&gt;1.19&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;Forfeited&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_pid_uShares_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zZUUVkZxAPQ1" style="text-align: right" title="Forfeited"&gt;526,250&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_uUSDPShares_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zBhDcTK1lSae" style="text-align: right" title="Forfeited"&gt;2.73&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_pid_uShares_c20210101__20211231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zyrwK7iZFf47" style="text-align: right"&gt;187,494&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_uUSDPShares_c20210101__20211231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zM5BVIvfBCm1" style="text-align: right"&gt;3.36&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td&gt;Outstanding at year end&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_uShares_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zSQ0QcHFXhTi" style="text-align: right" title="Outstanding at ending"&gt;2,560,000&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_uUSDPShares_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zdvsy8XZx6q8" style="text-align: right" title="Outstanding at ending"&gt;4.15&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_uShares_c20210101__20211231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zIHVknGiXgH6" style="text-align: right"&gt;3,672,500&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_uUSDPShares_c20210101__20211231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zFOcStvlapl5" style="text-align: right" title="Outstanding at ending"&gt;3.42&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;Options exercisable&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pid_uShares_c20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zOhbICZVlq04" style="text-align: right" title="Options exercisable"&gt;737,500&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_pid_uUSDPShares_c20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zUJmsNslmS74" style="text-align: right" title="Options exercisable"&gt;4.93&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pid_uShares_c20211231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zyPqqxDV8A6k" style="text-align: right"&gt;983,750&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_pid_uUSDPShares_c20211231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zqxiXWdfvja3" style="text-align: right"&gt;2.73&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td style="padding-left: 19.05pt; text-indent: -19.05pt"&gt;Weighted average fair value of options granted during the period&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_uUSDPShares_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zjy3QMIiTGn2" style="text-align: right" title="Weighted average fair value of options granted during the period"&gt;1.98&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_uUSDPShares_c20210101__20211231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zJ7nUsbGN3G5" style="text-align: right" title="Weighted average fair value of options granted during the period"&gt;2.85&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;Stock-based compensation expense&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_980_eus-gaap--AllocatedShareBasedCompensationExpense_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zfLR5zcx3wL6" style="text-align: right" title="Stock-based compensation expense"&gt;1,925,861&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_982_eus-gaap--AllocatedShareBasedCompensationExpense_c20210101__20211231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zrV2bdvx9Ojb" style="text-align: right" title="Stock-based compensation expense"&gt;2,457,788&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p id="xdx_8A6_zuEGKYhqlmKd" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;Total stock-based compensation expense, net of forfeitures, for stock
option awards totaled $&lt;span id="xdx_902_eus-gaap--StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zoEgBwBSX584"&gt;1,925,861&lt;/span&gt;
and $&lt;span id="xdx_907_eus-gaap--StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_c20210101__20211231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zK3zxZX4H1xd"&gt;2,457,788&lt;/span&gt;
for the years ended December 31, 2022, and 2021, respectively. &#160;Net cash received from option exercises for the years ended
December 31, 2022, and 2021 was $&lt;span id="xdx_909_eus-gaap--ProceedsFromStockOptionsExercised_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zVHfzAS0Osof"&gt;406,623&lt;/span&gt;
and $&lt;span id="xdx_90C_eus-gaap--ProceedsFromStockOptionsExercised_pp0p0_c20210101__20211231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_z6b29HqngqGf"&gt;1,261,251&lt;/span&gt;,
respectively. We have recognized tax benefits associated with options exercised of &lt;span id="xdx_90F_eus-gaap--IncomeTaxExpenseBenefit_pp0p0_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zSRtStmfjh8k"&gt;103,319&lt;/span&gt;
and $&lt;span id="xdx_908_eus-gaap--IncomeTaxExpenseBenefit_pp0p0_c20210101__20211231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_z19jgYcVFgEk"&gt;665,700&lt;/span&gt;
for the years ended December 31, 2022 and 2021, respectively.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;The weighted-average grant-date fair value of options granted during the
years ended December 31, 2022, and 2021, was $&lt;span id="xdx_908_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriodWeightedAverageGrantDateFairValue_uShares_c20220101__20221231__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zS4bMBfKMhif" title="Weighted-average grant-date fair value options granted"&gt;881,428&lt;/span&gt; and $&lt;span id="xdx_903_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriodWeightedAverageGrantDateFairValue_uShares_c20210101__20211231__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_z4r7pCd3Liuf" title="Weighted-average grant-date fair value options granted"&gt;5,699,986&lt;/span&gt;, respectively. &#160;The total intrinsic value of options exercised
during the years ended December 31, 2022, and 2021, was $&lt;span id="xdx_909_ecustom--StockIssuedDuringPeriodSharesStockOptionsExercised1_pid_uShares_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zSHIr6N3f1D1" title="Options exercised"&gt;1,150,203&lt;/span&gt; and $&lt;span id="xdx_90D_ecustom--StockIssuedDuringPeriodSharesStockOptionsExercised1_pid_uShares_c20210101__20211231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zumE46frju5"&gt;697,920&lt;/span&gt;, respectively.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_89D_ecustom--ScheduleOfShareBasedCompensationStockOptionsActivityAmendedTableTextBlock_zz8RJ2Ki4uS8" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;The following table presents information pertaining to options outstanding
as of December 31, 2022:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span id="xdx_8B3_zdHY4FCcHVjd" style="display: none; visibility: hidden"&gt;Schedule of information pertaining to options outstanding&lt;/span&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 7.5in; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&lt;b&gt;Range of Exercise Price&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;Number&lt;br/&gt;
Outstanding&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;Weighted&lt;br/&gt;
Average&lt;br/&gt;
Remaining&lt;br/&gt;
Contractual&lt;br/&gt;
Life&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;Weighted&lt;br/&gt;
Average&lt;br/&gt;
Exercise&lt;br/&gt;
Price&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;Number&lt;br/&gt;
Exercisable&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;Weighted&lt;br/&gt;
Average&lt;br/&gt;
Exercise&lt;br/&gt;
Price&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td style="width: 131.2pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 8.25pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 64.85pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 14.35pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 64.85pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 13.6pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 7.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 63pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 13.6pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 64.85pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 14.35pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 8.25pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 63pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 7.55pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td&gt;$2.25 - $9.49&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_985_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pid_uShares_c20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice1Member_zE9AiaUVP7N1" style="text-align: right" title="Number outstanding"&gt;2,560,000&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span id="xdx_906_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dxL_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice1Member_zm6fxm2yXdlj" title="Weighted average remaining contractual life::XDX::P8Y9M18D"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0782"&gt;8.8&lt;/span&gt;&lt;/span&gt; years&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_988_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pid_uUSDPShares_c20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice1Member_ze4YPaf8jUGe" style="text-align: right" title="Weighted average exercise price"&gt;4.15&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_uShares_c20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice1Member_zVzOB3aHfG61" style="text-align: right" title="Number exercisable"&gt;737,500&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_98F_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_pid_uUSDPShares_c20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice1Member_z1agaJApbVVc" style="text-align: right" title="Weighted average exercise price"&gt;4.93&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p id="xdx_8A2_zcTIeuFTe1Ed" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;As of December 31, 2022, there was $&lt;span id="xdx_90C_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_iI_c20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_z63JWR8opn1" title="Total unrecognized compensation cost"&gt;4,299,070&lt;/span&gt; of total unrecognized compensation
cost related to non-vested share-based compensation arrangements granted under the 2015 Plan. &#160;That cost is expected to be recognized
over a weighted-average period of &lt;span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dxL_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_z7aL5B4O0RVk" title="Weighted-average period::XDX::P45M"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0792"&gt;45&lt;/span&gt;&lt;/span&gt; months. &#160;The total fair value of shares vested was $&lt;span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_iI_c20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zj9RxtkaEKf7" title="Fair value of shares"&gt;2,703,002&lt;/span&gt; and $&lt;span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_iI_c20211231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_z2d9sp2yP0pk"&gt;1,923,179&lt;/span&gt; at December 31,
2022, and December 31, 2021, respectively.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;2021 STOCK OPTION PLAN, as amended&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;Time Based Stock Options&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;The per share weighted average fair value of stock options granted during
the years ended December 31, 2022 and December 31, 2021 was $&lt;span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_pid_uUSDPShares_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_z6QrnwW63uv4" title="Stock options granted"&gt;1.99&lt;/span&gt; and $&lt;span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_pid_uUSDPShares_c20210101__20211231__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zUZ1vKVeb5hg" title="Stock options granted"&gt;0&lt;/span&gt; respectively. &#160;The fair value of each award is estimated
on the grant date using the Black-Scholes option pricing model with the following weighted average assumptions used for grants in the
years ended December 31, 2022 and December 31, 2021. Historical information was the primary basis for the selection of the expected volatility,
expected dividend yield and the expected lives of the options. &#160;The risk-free interest rate was selected based upon yields of the
U.S. Treasury issues with a term equal to the expected life of the option being valued. We have recognized tax benefits associated with
stock-based compensation of $&lt;span id="xdx_900_eus-gaap--IncomeTaxExpenseBenefit_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zbekZFstSbci" title="Tax benefit"&gt;33,083&lt;/span&gt; and $&lt;span id="xdx_908_eus-gaap--IncomeTaxExpenseBenefit_c20210101__20211231__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zi6mxkU83IU2" title="Tax benefit"&gt;0&lt;/span&gt; for the years ended December 31, 2022 and 2021, respectively.&lt;/p&gt;

&lt;p id="xdx_893_eus-gaap--ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_z1c7sldhvJtd" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span&gt;&lt;span id="xdx_8B8_zmgyVB3Zl42e" style="display: none; visibility: hidden"&gt;Schedule of time based stock options&lt;/span&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 4.5in; border-collapse: collapse"&gt;
  &lt;tr&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="5" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;December 31,&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;2022&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;2021&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="width: 136.7pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 0.1in"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 0.1in"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 71.6pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 14.25pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 0.1in"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 72.35pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 7.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td&gt;Dividend yield&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zJwoESfRyAab" title="Dividend yield"&gt;0.00&lt;/span&gt;%&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zhWeaToWIlj8" title="Dividend yield"&gt;0.00&lt;/span&gt;%&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;Expected Volatility&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zlzsSWsvcP8k" title="Expected volatility"&gt;65.9&lt;/span&gt;%&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20210101__20211231__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember__srt--RangeAxis__srt--MinimumMember_zUmPwsUZYfZd"&gt;0&lt;/span&gt;% &#x2013; &lt;span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember__srt--RangeAxis__srt--MaximumMember_zTwmV5AIzBm2" title="Expected volatility"&gt;0&lt;/span&gt;%&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td&gt;Weighted-average volatility&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_pid_dp_uPure_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zbPtw0LX5FZ7" title="Weighted-average volatility"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0817"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_pid_dp_uPure_c20210101__20211231__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zdGMNi9skWj6" title="Weighted-average volatility"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0819"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;Expected dividends&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments_d0_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_z50YwJiVy8o3" title="Expected dividends"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments_c20210101__20211231__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_z28VpsVDQRCc" title="Expected dividends"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0823"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td&gt;Expected term (in years)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dxL_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_ziwAuYv74Xbh" title="Expected term (in years)::XDX::P10Y"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0825"&gt;10&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dxL_c20210101__20211231__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zLo14Du90Qd" title="Expected term (in years)::XDX::P0Y"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0827"&gt;0&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;Risk-free rate&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zVSeOdzf4oMf" title="Risk-free rate"&gt;2.99&lt;/span&gt;%&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20210101__20211231__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember__srt--RangeAxis__srt--MinimumMember_zaFr9qzZvIm9" title="Risk-free rate"&gt;0&lt;/span&gt;% &#x2013; &lt;span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20210101__20211231__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember__srt--RangeAxis__srt--MinimumMember_zB2vYAeILLq4" title="Risk-free rate"&gt;0&lt;/span&gt;%&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p id="xdx_8A1_zDsLo233sWhe" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_890_eus-gaap--ScheduleOfOtherShareBasedCompensationActivityTableTextBlock_zgKL1plP0rec" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;The following table summarizes the status of the 2021 Plan with respect
to time based stock options:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span id="xdx_8BA_zduzcPjGX2fi" style="display: none; visibility: hidden"&gt;Schedule of status of time based stock options&lt;/span&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 7.5in; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;Year Ended December 31,&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="4" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;2022&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="5" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;2021&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;Shares&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;Weighted&lt;br/&gt;
Average&lt;br/&gt;
Exercise&lt;br/&gt;
Price&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;Shares&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;Weighted&lt;br/&gt;
Average&lt;br/&gt;
Exercise&lt;br/&gt;
Price&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td style="width: 264.6pt"&gt;Outstanding at January 1&lt;/td&gt;
    &lt;td style="width: 0.1in"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber2_iS_pid_uShares_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zJn084UMm3Hb" style="width: 49.2pt; text-align: right" title="Outstanding at beginning"&gt;0&lt;/td&gt;
    &lt;td style="width: 0.2in"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 0.1in"&gt;$&lt;/td&gt;
    &lt;td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice2_iS_pid_uUSDPShares_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zdyPJ6msQb84" style="width: 49.15pt; text-align: right" title="Outstanding at beginning"&gt;0&lt;/td&gt;
    &lt;td style="width: 14.7pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 0.1in"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber2_iS_pid_uShares_c20210101__20211231__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zBv9XV56t6of" style="width: 48.85pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0840"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 14.55pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 0.1in"&gt;$&lt;/td&gt;
    &lt;td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice2_iS_pid_uUSDPShares_c20210101__20211231__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zw2MZhDPuTi2" style="width: 48.55pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0841"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 0.1in"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;Granted&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross2_pid_uShares_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zUhpTJ7MfqGa" style="text-align: right" title="Granted"&gt;475,000&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_984_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice2_pid_uUSDPShares_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_z4finuiR92Wl" style="text-align: right" title="Granted"&gt;2.67&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross2_pid_uShares_c20210101__20211231__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zXjFEbRNUM6g" style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0846"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_98E_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice2_pid_uUSDPShares_c20210101__20211231__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_ztMaUpOvkv6g" style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0847"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td&gt;Exercised&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_989_ecustom--StockIssuedDuringPeriodSharesStockOptionsExercised2_pid_uShares_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zQLVCQI05zL1" style="text-align: right" title="Exercised"&gt;0&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_980_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice2_pid_uUSDPShares_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zpglE3WdXyxa" style="text-align: right" title="Exercised"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0851"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_980_ecustom--StockIssuedDuringPeriodSharesStockOptionsExercised2_pid_uShares_c20210101__20211231__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zzU0EQfxTLNb" style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0852"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_985_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice2_pid_uUSDPShares_c20210101__20211231__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zfke8nRT0Ql6" style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0853"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;Forfeited&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod2_pid_uShares_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zud5mcwUwd5f" style="text-align: right" title="Forfeited"&gt;0&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_981_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice2_pid_uUSDPShares_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zFTArLr4LvO" style="text-align: right" title="Forfeited"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0857"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod2_pid_uShares_c20210101__20211231__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_ztP0z42eq7g6" style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0858"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_98C_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice2_pid_uUSDPShares_c20210101__20211231__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zJtGJk5gjWid" style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0859"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td&gt;Outstanding at year end&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber2_iE_pid_uShares_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zzSNeNun6ka7" style="text-align: right" title="Outstanding at ending"&gt;475,000&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice2_iE_pid_uUSDPShares_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_z9U1aKMLdD7k" style="text-align: right" title="Outstanding at ending"&gt;2.67&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber2_iE_pid_d0_uShares_c20210101__20211231__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_z3TSrOrdfbhd" style="text-align: right"&gt;&#x2014;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice2_iE_pid_d0_uUSDPShares_c20210101__20211231__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_z25ZkGVljTM7" style="text-align: right"&gt;&#x2014;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;Options exercisable&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pid_uShares_c20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zEmdFXL5jX8k" style="text-align: right" title="Options exercisable at ending"&gt;0&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_984_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice2_iI_pid_uUSDPShares_c20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zPUtOEBvfuQk" style="text-align: right" title="Options exercisable at ending"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0869"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pid_uShares_c20211231__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zurkgefKQTu8" style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0870"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_982_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice2_iI_pid_uUSDPShares_c20211231__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zkcGJynuGkA" style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0871"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td style="padding-left: 0.1in; text-indent: -0.1in"&gt;Weighted average fair value of options granted during the period&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue2_pid_uUSDPShares_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zPiZtEGtaR89" style="text-align: right" title="Weighted average fair value of options granted during the period"&gt;1.99&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue2_pid_uUSDPShares_c20210101__20211231__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zg2K9XA8FE8k" style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0874"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;Stock-based compensation expense&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_98C_eus-gaap--ShareBasedCompensation_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zMR0a556MYe4" style="text-align: right" title="Stock-based compensation expense"&gt;157,536&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_98B_eus-gaap--ShareBasedCompensation_c20210101__20211231__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zhI0JtDcVzbl" style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0877"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p id="xdx_8AA_zqOtN3bblshd" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;Total stock-based compensation expense was $&lt;span id="xdx_906_eus-gaap--ShareBasedCompensation_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zZJxsmXDlR32" title="Stock-based compensation expense"&gt;157,536&lt;/span&gt; and $&lt;span id="xdx_905_eus-gaap--ShareBasedCompensation_dxL_c20210101__20211231__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zP5H5JfGBqG1" title="Stock-based compensation expense::XDX::-"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0881"&gt;0&lt;/span&gt;&lt;/span&gt; for the years
ended December 31, 2022, and 2021, respectively. There were no options exercised during the years ended December 31, 2022 and December
31, 2021.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;The weighted-average grant-date fair value of options granted during the
years ended December 31, 2022, and 2021 was $&lt;span id="xdx_90B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriodWeightedAverageGrantDateFairValue_uShares_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zVFu5SIxjIKh" title="Weighted-average grant-date fair value options granted"&gt;945,215&lt;/span&gt; and $&lt;span id="xdx_90E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriodWeightedAverageGrantDateFairValue_uShares_c20210101__20211231__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zBXjZmNM2RF8" title="Weighted-average grant-date fair value options granted"&gt;0&lt;/span&gt;, respectively.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_893_ecustom--ScheduleOfShareBasedCompensationtaxBenefitsAssociatedWithRestrictedStockAwardCompensationTableTextBlock_zPKPQIQxyncf" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;The following table presents information pertaining to options outstanding
at December 31, 2022:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span id="xdx_8B1_zPPZmpjvZHPa" style="display: none; visibility: hidden"&gt;Schedule of information pertaining to options outstanding&lt;/span&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 7.5in; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&lt;b&gt;Range of Exercise Price&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;Number&lt;br/&gt;
Outstanding&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;Weighted&lt;br/&gt;
Average&lt;br/&gt;
Remaining&lt;br/&gt;
Contractual&lt;br/&gt;
Life&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;Weighted&lt;br/&gt;
Average&lt;br/&gt;
Exercise&lt;br/&gt;
Price&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;Number&lt;br/&gt;
Exercisable&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;Weighted&lt;br/&gt;
Average&lt;br/&gt;
Exercise&lt;br/&gt;
Price&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="width: 131.2pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 8.25pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 64.85pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 14.35pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 64.85pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 13.6pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 7.55pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 63.35pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 13.6pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 64.85pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 14.35pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 8.3pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 55.8pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 15.1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td&gt;$2.67&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pid_uShares_c20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice1Member_zsRCclyBqdal" style="text-align: right" title="Number outstanding"&gt;475,000&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span id="xdx_90A_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dxL_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice1Member_zXOIgQYORYWa" title="Weighted average remaining contractual life::XDX::P9Y3M19D"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0891"&gt;9.3&lt;/span&gt;&lt;/span&gt; years&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_98F_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_c20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice1Member_zpulwXJjCC2j" style="text-align: center" title="Weighted average exercise price"&gt;2.67&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_984_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_uShares_c20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice1Member_zWpe3SyNSA6a" style="text-align: right" title="Number exercisable"&gt;0&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_982_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_pid_uUSDPShares_c20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice1Member_z3h6UfDDpwme" style="text-align: right" title="Weighted average exercise price"&gt;0&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p id="xdx_8AE_zMK3ItcFGRXd" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;As of December 31, 2022, there was $&lt;span id="xdx_908_ecustom--CompensationCost_iI_c20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zqickrqe2Qyd" title="Unrecognized compensation cost"&gt;787,679&lt;/span&gt; of total unrecognized compensation
cost related to non-vested share-based compensation arrangements granted under the 2021 Plan. &#160;That cost is expected to be recognized
over a weighted-average period of &lt;span id="xdx_90B_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm3_dxL_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zHRqLGthcSqk" title="Weighted-average period::XDX::P48M"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0901"&gt;48&lt;/span&gt;&lt;/span&gt; months. &#160;The total fair value of shares vested as of December 31, 2022, and December 31, 2021,
was &lt;span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_iI_dxL_c20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zS2FHeIBBrlg" title="Fair value of shares::XDX::0"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0903"&gt;zero&lt;/span&gt;&lt;/span&gt; and &lt;span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_iI_dxL_c20211231__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zsLWGRmOKFSb" title="Fair value of shares::XDX::0"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0905"&gt;zero&lt;/span&gt;&lt;/span&gt;, respectively.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;Performance-Based Stock Options&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;There were no performance-based stock options granted during the twelve
months ended December 31, 2022, and 2021.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_89A_eus-gaap--ShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock_ziaATDPStcpg" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;The following table summarizes the status of the 2015 Plan with respect
to performance-based stock options as of December 31, 2022 and 2021:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span id="xdx_8B0_zFmIDLEsG1N" style="display: none; visibility: hidden"&gt;Schedule of performance base options outstanding&lt;/span&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 7.5in; border-collapse: collapse"&gt;
  &lt;tr style="background-color: white"&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="4" style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: center"&gt;&lt;b&gt;December 31, 2022&lt;/b&gt;&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="5" style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: center"&gt;&lt;b&gt;December 31, 2021&lt;/b&gt;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="background-color: white"&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: center"&gt;&lt;b&gt;Shares&lt;/b&gt;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: center"&gt;&lt;b&gt;Weighted&lt;br/&gt;
Average&lt;br/&gt;
Exercise&lt;br/&gt;
Price&lt;/b&gt;&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: center"&gt;&lt;b&gt;Shares&lt;/b&gt;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: center"&gt;&lt;b&gt;Weighted&lt;br/&gt;
Average&lt;br/&gt;
Exercise&lt;br/&gt;
Price&lt;/b&gt;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="background-color: white"&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="background-color: #E6E6E6"&gt;
    &lt;td style="vertical-align: bottom; width: 257.75pt"&gt;Outstanding at January 1&lt;/td&gt;
    &lt;td style="vertical-align: bottom; width: 7.15pt"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber1_iS_pid_dxL_uShares_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_z0M2W59pO8fk" style="vertical-align: bottom; width: 47.8pt; text-align: right" title="Outstanding at beginning::XDX::1000000"&gt;&lt;b style="display: none; visibility: hidden"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0910"&gt;&#x2014;&lt;/span&gt;&lt;/b&gt;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; width: 15.15pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; width: 0.1in"&gt;$&lt;/td&gt;
    &lt;td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice1_iS_pid_dxL_uUSDPShares_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zz6GEJl9i7X2" style="vertical-align: bottom; width: 48.5pt; text-align: right" title="Outstanding at beginning::XDX::1.70"&gt;&lt;b style="display: none; visibility: hidden"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0912"&gt;&#x2014;&lt;/span&gt;&lt;/b&gt;&lt;/td&gt;
    &lt;td style="vertical-align: top; width: 12.9pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; width: 12.95pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; width: 0.1in"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_982_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber1_iS_pid_uShares_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zNrjDxCN5cw6" style="vertical-align: bottom; width: 48pt; text-align: right" title="Outstanding at beginning"&gt;1,000,000&lt;/td&gt;
    &lt;td style="vertical-align: bottom; width: 11.55pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; width: 0.1in"&gt;$&lt;/td&gt;
    &lt;td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice1_iS_pid_uUSDPShares_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zv9YzAaCKyV2" style="vertical-align: bottom; width: 49.95pt; text-align: right"&gt;1.70&lt;/td&gt;
    &lt;td style="vertical-align: bottom; width: 7.15pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="background-color: white"&gt;
    &lt;td style="vertical-align: bottom"&gt;Granted&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross1_pid_d0_uShares_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_znMigeF3Cy4c" style="vertical-align: bottom; text-align: right" title="Granted"&gt;&#x2014;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;$&lt;/td&gt;
    &lt;td id="xdx_980_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice1_pid_d0_uUSDPShares_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zw1sSZzmgc77" style="vertical-align: bottom; text-align: right" title="Granted"&gt;&#x2014;&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross1_pid_d0_uShares_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zajKijFVkUp7" style="vertical-align: bottom; text-align: right"&gt;&#x2014;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;$&lt;/td&gt;
    &lt;td id="xdx_98B_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice1_pid_d0_uUSDPShares_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zQMolxBiscE7" style="vertical-align: bottom; text-align: right"&gt;&#x2014;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="background-color: #E6E6E6"&gt;
    &lt;td style="vertical-align: bottom"&gt;Exercised&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_989_ecustom--StockIssuedDuringPeriodSharesStockOptionsExercised1_pid_d0_uShares_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_z8CXWSE0Ujvh" style="vertical-align: bottom; text-align: right" title="Exercised"&gt;&#x2014;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;$&lt;/td&gt;
    &lt;td id="xdx_98B_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice1_pid_d0_uUSDPShares_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zKoVOB1QkUB5" style="vertical-align: bottom; text-align: right" title="Exercised"&gt;&#x2014;&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_980_ecustom--StockIssuedDuringPeriodSharesStockOptionsExercised1_pid_d0_uShares_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zFYgOcOG6Jl" style="vertical-align: bottom; text-align: right"&gt;&#x2014;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;$&lt;/td&gt;
    &lt;td id="xdx_98E_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice1_pid_d0_uUSDPShares_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zNZK1HJv0i7" style="vertical-align: bottom; text-align: right"&gt;&#x2014;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="background-color: white"&gt;
    &lt;td style="vertical-align: bottom"&gt;Forfeited&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod1_pid_d0_uShares_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zsEACKSpxZni" style="vertical-align: bottom; text-align: right" title="Forfeited"&gt;&#x2014;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;$&lt;/td&gt;
    &lt;td id="xdx_982_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice1_pid_d0_uUSDPShares_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zpMOG22IlwOk" style="vertical-align: bottom; text-align: right" title="Forfeited"&gt;&#x2014;&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_984_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod1_pid_d0_uShares_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zD9qTNpJmza" style="vertical-align: bottom; text-align: right"&gt;&#x2014;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;$&lt;/td&gt;
    &lt;td id="xdx_988_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice1_pid_d0_uUSDPShares_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zMbPSxP2Exd" style="vertical-align: bottom; text-align: right"&gt;&#x2014;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="background-color: #E6E6E6"&gt;
    &lt;td style="vertical-align: bottom"&gt;Outstanding at year end&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_d0_uShares_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zyKbhzgvNtke" style="vertical-align: bottom; text-align: right" title="Outstanding at ending"&gt;&#x2014;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;$&lt;/td&gt;
    &lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_d0_uUSDPShares_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zfZBqFlaW2Oc" style="vertical-align: bottom; text-align: right" title="Outstanding at ending"&gt;&#x2014;&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_uShares_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zgDB6RDXRAB5" style="vertical-align: bottom; text-align: right"&gt;1,000,000&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;$&lt;/td&gt;
    &lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_uUSDPShares_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zm1JZlstwHTg" style="vertical-align: bottom; text-align: right"&gt;1.70&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="background-color: white"&gt;
    &lt;td style="vertical-align: bottom"&gt;Options exercisable&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross1_pid_d0_uShares_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zjmL7oDnQJf" style="vertical-align: bottom; text-align: right" title="Options exercisable at ending"&gt;&#x2014;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;$&lt;/td&gt;
    &lt;td id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice1_iI_pid_d0_uUSDPShares_c20221231__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zhqy6DeuJT83" style="vertical-align: bottom; text-align: right" title="Options exercisable at ending"&gt;&#x2014;&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross1_pid_d0_uShares_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zOE2NUXibFT7" style="vertical-align: bottom; text-align: right"&gt;&#x2014;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;$&lt;/td&gt;
    &lt;td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice1_iI_pid_d0_uUSDPShares_c20211231__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zQkYAvK8aRva" style="vertical-align: bottom; text-align: right"&gt;&#x2014;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="background-color: #E6E6E6"&gt;
    &lt;td style="vertical-align: bottom; padding-left: 7.4pt; text-indent: -7.4pt"&gt;Weighted average fair value of options granted during the period&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_d0_uShares_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zcmhAcGr65Dg" style="vertical-align: bottom; text-align: right" title="Weighted average fair value of options granted during the period"&gt;&#x2014;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;$&lt;/td&gt;
    &lt;td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue1_pid_d0_uUSDPShares_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zLfM1tdYCCYj" style="vertical-align: bottom; text-align: right" title="Weighted average fair value of options granted during the period"&gt;&#x2014;&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_d0_uShares_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zTRtxzr0EcSj" style="vertical-align: bottom; text-align: right"&gt;&#x2014;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;$&lt;/td&gt;
    &lt;td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue1_pid_d0_uUSDPShares_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zkU8GGqbg8be" style="vertical-align: bottom; text-align: right"&gt;&#x2014;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="background-color: white"&gt;
    &lt;td style="vertical-align: bottom"&gt;Stock-based compensation expense&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; text-align: right"&gt;&#x2014;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;$&lt;/td&gt;
    &lt;td id="xdx_98F_ecustom--AllocatedShareBasedCompensationExpense1_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zqjwJjn6fyn5" style="vertical-align: bottom; text-align: right" title="Stock-based compensation expense"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0953"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; text-align: right"&gt;&#x2014;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;$&lt;/td&gt;
    &lt;td id="xdx_98E_ecustom--AllocatedShareBasedCompensationExpense1_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_z665Xj26ZrH" style="vertical-align: bottom; text-align: right" title="Stock-based compensation expense"&gt;(408,747&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p id="xdx_8AC_zfrYdCNQQwNl" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;Total performance stock-based compensation expense totaled &lt;span id="xdx_90F_eus-gaap--ShareBasedCompensation_dxL_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member__us-gaap--FinancialInstrumentAxis__us-gaap--StockOptionMember_zDfz9QbPcIt1" title="Stock-based compensation expense::XDX::-"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0957"&gt;zero&lt;/span&gt;&lt;/span&gt; and $&lt;span id="xdx_907_eus-gaap--ShareBasedCompensation_c20210101__20211231__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member__us-gaap--FinancialInstrumentAxis__us-gaap--StockOptionMember_zgrTu7lmcx0h" title="Stock-based compensation expense"&gt;(408,747)&lt;/span&gt;
for the years ended December 2022 and 2021, respectively. All performance-based stock options were forfeited as of December 31, 2021,
and there was no unrecognized compensation cost remaining.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;RESTRICTED STOCK AWARDS&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;On April 12, 2021, pursuant to an employment agreement entered into on
March 15, 2021, with Linda Tharby, the Company&#x2019;s President and Chief Executive Officer and as an inducement to her employment, the
Company issued three restricted stock awards for an aggregate &lt;span id="xdx_909_eus-gaap--CommonStockSharesIssued_iI_pid_uShares_c20210412__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_zsVr6wmj1a2l" title="Common stock issued, shares"&gt;1,000,000&lt;/span&gt; shares of common stock for an aggregate stock price of $&lt;span id="xdx_906_eus-gaap--CommonStockValue_iI_c20210412__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_z8fSaic3WZ23" title="Aggregate stock price"&gt;3,310,000&lt;/span&gt;
and each vesting subject to employment on the respective vesting date.&#160;The following table summarizes the activities for our unvested
restricted stock awards for the twelve months ended December 31, 2022, and 2021.&lt;/p&gt;

&lt;p id="xdx_890_eus-gaap--ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock_zpEioGXC9xR6" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span id="xdx_8B5_zCprAPbF5XI5" style="display: none; visibility: hidden"&gt;The following table summarizes the activities for our unvested
restricted stock awards for the twelve months ended December 31, 2022, and 2021.&lt;/span&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 7.5in; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="9" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;Twelve Months Ended December 31,&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="4" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;2022&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="4" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;2021&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;Shares&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;Weighted&lt;br/&gt;
Average&lt;br/&gt;
Grant-Date Fair Value&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;Shares&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;Weighted&lt;br/&gt;
Average&lt;br/&gt;
Grant-Date Fair Value&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td style="width: 201.15pt"&gt;Unvested at January 1&lt;/td&gt;
    &lt;td style="width: 9.65pt"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberUnvested_iS_pid_uShares_c20220101__20221231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zhacb022pAR" style="width: 53.1pt; text-align: right" title="Outstanding at beginning"&gt;1,000,000&lt;/td&gt;
    &lt;td style="width: 11pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 17.4pt"&gt;$&lt;/td&gt;
    &lt;td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceUnvested_iS_pid_uUSDPShares_c20220101__20221231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zKfcDQ74lxb8" style="width: 72.75pt; text-align: right" title="Outstanding at beginning"&gt;3.01&lt;/td&gt;
    &lt;td style="width: 11pt"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberUnvested_iS_pid_uShares_c20210101__20211231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zMTMI0RJsFsg" style="width: 54.75pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0970"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 11.35pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 16.9pt"&gt;$&lt;/td&gt;
    &lt;td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceUnvested_iS_pid_uUSDPShares_c20210101__20211231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_z8pULxd4p7f9" style="width: 73.25pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0971"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 8pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;Granted&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrossUnvested_pid_uShares_c20220101__20221231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_ztlm5zGVoigh" style="text-align: right" title="Granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0973"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_982_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePriceUnvested_pid_uUSDPShares_c20220101__20221231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_z3Ak3vyzIfta" style="text-align: right" title="Granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0975"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrossUnvested_pid_uShares_c20210101__20211231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zWfQXlJPCfea" style="text-align: right"&gt;1,000,000&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_98C_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePriceUnvested_pid_uUSDPShares_c20210101__20211231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zQmCl6uVkqmf" style="text-align: right"&gt;3.01&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td&gt;Vested&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodGross_pid_uShares_c20220101__20221231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zu2SxkYyxad1" style="text-align: right" title="Vested"&gt;50,000&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_984_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice_pid_uUSDPShares_c20220101__20221231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_z6jQd1eofYIj" style="text-align: right" title="Vested"&gt;3.31&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodGross_pid_uShares_c20210101__20211231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_z31UL0x5WW0l" style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0982"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_98C_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice_pid_uUSDPShares_c20210101__20211231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zBgpDsQZkXHl" style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0983"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;Forfeited/canceled&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodUnvested_pid_uShares_c20220101__20221231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zAeoBmoI2qF" style="text-align: right" title="Forfeited/canceled"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0985"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_980_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePriceUnvested_pid_uUSDPShares_c20220101__20221231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zXhpyyJIFlC4" style="text-align: right" title="Forfeited/canceled"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0987"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodUnvested_pid_uShares_c20210101__20211231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zAq3e72xb4f6" style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0988"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_98C_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePriceUnvested_pid_uUSDPShares_c20210101__20211231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zQ9q8QPPkiJ9" style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0989"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td&gt;Unvested at December 31&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberUnvested_iE_pid_uShares_c20220101__20221231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zrVougvelbUa" style="text-align: right" title="Outstanding at ending"&gt;950,000&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceUnvested_iE_pid_uUSDPShares_c20220101__20221231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zMh3yFi4kWh8" style="text-align: right" title="Outstanding at ending"&gt;3.04&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberUnvested_iE_pid_uShares_c20210101__20211231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zmbmg5YV0JTe" style="text-align: right"&gt;1,000,000&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceUnvested_iE_pid_uUSDPShares_c20210101__20211231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zFQfz3vv3JR5" style="text-align: right"&gt;3.01&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p id="xdx_8AC_zNaCS3qlyOHg" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;As of December 31, 2022, there was $&lt;span id="xdx_904_ecustom--UnrecognizedCompensationCost_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember_zZusQLPMoQN7" title="Unrecognized compensation cost"&gt;1,618,177&lt;/span&gt; of unrecognized compensation
cost related to unvested employee restricted shares. This amount is expected to be recognized over a weighted-average period of &lt;span id="xdx_905_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm4_dxL_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember_zSeTpzd1QTA8" title="Weighted-average period::XDX::P21M"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0999"&gt;21&lt;/span&gt;&lt;/span&gt; months.
We have recognized tax benefits associated with restricted stock award compensation of $&lt;span id="xdx_903_eus-gaap--IncomeTaxExpenseBenefit_c20220101__20221231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zASlgyxk8Cj4"&gt;101,419&lt;/span&gt; and $&lt;span id="xdx_902_eus-gaap--IncomeTaxExpenseBenefit_c20210101__20211231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zv7gaoOBESw7"&gt;47,220&lt;/span&gt; for the twelve months ended
December 31, 2022 and 2021, respectively.&lt;/p&gt;

</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="AsOf2022-12-31_custom_StockOptionPlan2015Member_custom_ExecutiveskeyEmployeesAndConsultantsMember"
      decimals="INF"
      unitRef="Shares">2560000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <krmd:StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan2015
      contextRef="From2022-01-012022-12-31_custom_StockOptionPlan2015Member_custom_ExecutiveskeyEmployeesAndConsultantsMember"
      decimals="INF"
      unitRef="Shares">445000</krmd:StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan2015>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="From2022-01-012022-12-31_custom_StockOptionPlan2015Member"
      decimals="INF"
      unitRef="Shares">6000000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="From2022-01-012022-12-31_custom_StockOptionPlan2021Member"
      decimals="INF"
      unitRef="Shares">1000000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan
      contextRef="From2022-01-012022-12-31_custom_StockOptionPlan2021Member_srt_DirectorMember"
      decimals="INF"
      unitRef="Shares">97100</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan
      contextRef="From2022-01-012022-12-31_custom_StockOptionPlan2021Member_custom_ExecutiveMember"
      decimals="INF"
      unitRef="Shares">475000</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan>
    <krmd:NonemployeeServicesTransactionCost
      contextRef="From2020-12-302021-01-02_custom_NonEmployeeDirectorAndBoardAdvisorMember"
      decimals="INF"
      unitRef="Shares">75000</krmd:NonemployeeServicesTransactionCost>
    <us-gaap:ShareBasedGoodsAndNonemployeeServicesTransaction contextRef="From2020-12-302021-01-02_custom_NonEmployeeDirectorAndBoardAdvisorMember">to be paid quarterly $12,500 in cash and
$6,250 in common stock</us-gaap:ShareBasedGoodsAndNonemployeeServicesTransaction>
    <krmd:NonemployeeServicesTransactionCost
      contextRef="From2020-12-302021-01-02_srt_BoardOfDirectorsChairmanMember"
      decimals="INF"
      unitRef="Shares">100000</krmd:NonemployeeServicesTransactionCost>
    <us-gaap:ShareBasedGoodsAndNonemployeeServicesTransaction contextRef="From2020-12-302021-01-02_srt_BoardOfDirectorsChairmanMember">to be paid quarterly $12,500 in cash
and $12,500 in common stock</us-gaap:ShareBasedGoodsAndNonemployeeServicesTransaction>
    <krmd:NonemployeeServicesTransactionCost
      contextRef="From2021-05-162021-05-18_custom_NonEmployeeDirectorAndBoardAdvisorMember"
      decimals="INF"
      unitRef="Shares">110000</krmd:NonemployeeServicesTransactionCost>
    <us-gaap:ShareBasedGoodsAndNonemployeeServicesTransaction contextRef="From2021-05-162021-05-18_custom_NonEmployeeDirectorAndBoardAdvisorMember">to be paid quarterly $12,500 in cash and $15,000 in common stock</us-gaap:ShareBasedGoodsAndNonemployeeServicesTransaction>
    <krmd:NonemployeeServicesTransactionCost
      contextRef="From2021-05-162021-05-18_srt_BoardOfDirectorsChairmanMember"
      decimals="INF"
      unitRef="Shares">140000</krmd:NonemployeeServicesTransactionCost>
    <us-gaap:ShareBasedGoodsAndNonemployeeServicesTransaction contextRef="From2021-05-162021-05-18_srt_BoardOfDirectorsChairmanMember">to be paid quarterly $12,500 in cash and $22,500 in common stock</us-gaap:ShareBasedGoodsAndNonemployeeServicesTransaction>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan
      contextRef="From2021-04-112021-04-12_custom_ChiefExecutiveOfficerLindaTharbyMember"
      decimals="INF"
      unitRef="Shares">1000000</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan
      contextRef="From2021-04-112021-04-12_custom_ChiefExecutiveOfficerLindaTharbyMember"
      decimals="0"
      unitRef="USD">3310000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue
      contextRef="From2022-01-012022-12-31_custom_StockOptionPlan2015Member"
      decimals="INF"
      unitRef="USDPShares">1.98</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue
      contextRef="From2021-01-012021-12-31_custom_StockOptionPlan2015Member"
      decimals="INF"
      unitRef="USDPShares">2.85</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2022-01-012022-12-31_custom_StockOptionPlan2015Member"
      decimals="0"
      unitRef="USD">198258</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2021-01-012021-12-31_custom_StockOptionPlan2015Member"
      decimals="0"
      unitRef="USD">175257</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_898_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zMJTgRo09HFf" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span id="xdx_8B3_zNIQLyoNSWk4" style="display: none; visibility: hidden"&gt;Schedule of time based stock options&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 5.25in; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;December 31, 2022&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;December 31, 2021&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td style="width: 161.1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9.75pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 7.25pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 89.15pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 10.55pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9.05pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 82.85pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 8.3pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td&gt;Dividend yield&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_z9I9JarWYZVl" title="Dividend yield"&gt;0.00&lt;/span&gt;%&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20210101__20211231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zwjPMQzkzhQc" title="Dividend yield"&gt;0.00&lt;/span&gt;%&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;Expected volatility&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember__srt--RangeAxis__srt--MinimumMember_z6mvehlaByMj"&gt;65.29&lt;/span&gt;% &#x2013; &lt;span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember__srt--RangeAxis__srt--MaximumMember_zGJbo5iW8TI1"&gt;77.5&lt;/span&gt;%&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20210101__20211231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember__srt--RangeAxis__srt--MinimumMember_zfzDfqq1wrRf"&gt;74.01&lt;/span&gt; &#x2013; &lt;span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20210101__20211231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember__srt--RangeAxis__srt--MaximumMember_zKyuNYz9KZ8h"&gt;77.91&lt;/span&gt;%&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td&gt;Weighted-average volatility&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_pid_dp0_uPure_c20220101__20221231_zlXJAsd0BLe" title="Weighted-average volatility"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_pid_dp_uPure_c20210101__20211231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zFG8DozU7zW4" title="Weighted-average volatility"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0697"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;Expected dividends&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments_d0_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zs1BAQmLx361" title="Expected dividends"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments_d0_c20210101__20211231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zAH1DVyaDcb6" title="Expected dividends"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td&gt;Expected term (in years)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dxL_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_ztG1LJY5HuX" title="Expected term (in years)::XDX::P10Y"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0703"&gt;10&lt;/span&gt;&lt;/span&gt; Years&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dxL_c20210101__20211231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zn7GgykVhqw7" title="Expected term (in years)::XDX::P10Y"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0705"&gt;10&lt;/span&gt;&lt;/span&gt; Years&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;Risk-free rate&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember__srt--RangeAxis__srt--MinimumMember_zhBrKaFMEtph" title="Risk-free rate"&gt;1.81&lt;/span&gt; &#x2013; &lt;span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember__srt--RangeAxis__srt--MaximumMember_zc1gVFzsSI62" title="Risk-free rate"&gt;4.02&lt;/span&gt;%&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20210101__20211231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember__srt--RangeAxis__srt--MinimumMember_zCY0GYklx5Sl" title="Risk-free rate"&gt;1.20&lt;/span&gt; &#x2013; &lt;span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20210101__20211231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember__srt--RangeAxis__srt--MaximumMember_zZufVf0If4Ui" title="Risk-free rate"&gt;1.62&lt;/span&gt;%&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="From2022-01-012022-12-31_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember"
      decimals="INF"
      unitRef="Pure">0.0000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="From2021-01-012021-12-31_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember"
      decimals="INF"
      unitRef="Pure">0.0000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="From2022-01-012022-12-31_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember_srt_MinimumMember"
      decimals="INF"
      unitRef="Pure">0.6529</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="From2022-01-012022-12-31_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember_srt_MaximumMember"
      decimals="INF"
      unitRef="Pure">0.775</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="From2021-01-012021-12-31_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember_srt_MinimumMember"
      decimals="INF"
      unitRef="Pure">0.7401</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="From2021-01-012021-12-31_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember_srt_MaximumMember"
      decimals="INF"
      unitRef="Pure">0.7791</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
      contextRef="From2022-01-01to2022-12-31"
      decimals="INF"
      unitRef="Pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments
      contextRef="From2022-01-012022-12-31_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember"
      decimals="0"
      unitRef="USD">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments
      contextRef="From2021-01-012021-12-31_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember"
      decimals="0"
      unitRef="USD">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="From2022-01-012022-12-31_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember_srt_MinimumMember"
      decimals="INF"
      unitRef="Pure">0.0181</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="From2022-01-012022-12-31_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember_srt_MaximumMember"
      decimals="INF"
      unitRef="Pure">0.0402</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="From2021-01-012021-12-31_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember_srt_MinimumMember"
      decimals="INF"
      unitRef="Pure">0.0120</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="From2021-01-012021-12-31_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember_srt_MaximumMember"
      decimals="INF"
      unitRef="Pure">0.0162</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_899_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_z1TmxFWsn1u9" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;The following table summarizes the status of the Company&#x2019;s stock
option plan:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span id="xdx_8B4_z3SmpQTP4fk1" style="display: none; visibility: hidden"&gt;Schedule of status of time based stock options&lt;/span&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 7.5in; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="5" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;December 31, 2022&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="5" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;December 31, 2021&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;Shares&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;Weighted&lt;br/&gt;
Average&lt;br/&gt;
Exercise&lt;br/&gt;
Price&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;Shares&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;Weighted&lt;br/&gt;
Average&lt;br/&gt;
Exercise&lt;br/&gt;
Price&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td style="width: 273.25pt"&gt;Outstanding at January 1&lt;/td&gt;
    &lt;td style="width: 0.1in"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 0.1in"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_uShares_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zO2vPnRHQxz" style="width: 49.5pt; text-align: right" title="Outstanding at beginning"&gt;3,672,500&lt;/td&gt;
    &lt;td style="width: 11.3pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9.75pt"&gt;$&lt;/td&gt;
    &lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_uUSDPShares_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zG4oARPUgMA1" style="width: 43.8pt; text-align: right" title="Outstanding at beginning"&gt;3.42&lt;/td&gt;
    &lt;td style="width: 11.3pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 0.1in"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_uShares_c20210101__20211231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zlSM4Nm3iOT6" style="width: 48.75pt; text-align: right"&gt;2,922,494&lt;/td&gt;
    &lt;td style="width: 11.3pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 7.5pt"&gt;$&lt;/td&gt;
    &lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_uUSDPShares_c20210101__20211231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zACFEiklGXXj" style="width: 43.8pt; text-align: right" title="Outstanding at beginning"&gt;2.46&lt;/td&gt;
    &lt;td style="width: 7.25pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;Granted&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_uShares_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_z2exdIa3IfIg" style="text-align: right" title="Granted"&gt;445,000&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_uUSDPShares_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zM61B6j8h4rd" style="text-align: right" title="Granted"&gt;2.57&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_uShares_c20210101__20211231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zAtBDtQDZi9f" style="text-align: right"&gt;2,000,000&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_uUSDPShares_c20210101__20211231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zaDavxuGXPuj" style="text-align: right" title="Granted"&gt;3.64&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td&gt;Exercised&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98C_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pid_uShares_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zRSnnZVL4Ky" style="text-align: right" title="Exercised"&gt;1,031,250&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_uUSDPShares_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zw3P2KzfQM26" style="text-align: right" title="Exercised"&gt;1.57&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_989_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pid_uShares_c20210101__20211231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zy56Oc1yEai" style="text-align: right"&gt;1,062,500&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_uUSDPShares_c20210101__20211231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zGPwU22jiHA2" style="text-align: right" title="Exercised"&gt;1.19&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;Forfeited&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_pid_uShares_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zZUUVkZxAPQ1" style="text-align: right" title="Forfeited"&gt;526,250&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_uUSDPShares_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zBhDcTK1lSae" style="text-align: right" title="Forfeited"&gt;2.73&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_pid_uShares_c20210101__20211231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zyrwK7iZFf47" style="text-align: right"&gt;187,494&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_uUSDPShares_c20210101__20211231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zM5BVIvfBCm1" style="text-align: right"&gt;3.36&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td&gt;Outstanding at year end&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_uShares_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zSQ0QcHFXhTi" style="text-align: right" title="Outstanding at ending"&gt;2,560,000&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_uUSDPShares_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zdvsy8XZx6q8" style="text-align: right" title="Outstanding at ending"&gt;4.15&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_uShares_c20210101__20211231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zIHVknGiXgH6" style="text-align: right"&gt;3,672,500&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_uUSDPShares_c20210101__20211231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zFOcStvlapl5" style="text-align: right" title="Outstanding at ending"&gt;3.42&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;Options exercisable&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pid_uShares_c20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zOhbICZVlq04" style="text-align: right" title="Options exercisable"&gt;737,500&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_pid_uUSDPShares_c20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zUJmsNslmS74" style="text-align: right" title="Options exercisable"&gt;4.93&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pid_uShares_c20211231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zyPqqxDV8A6k" style="text-align: right"&gt;983,750&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_pid_uUSDPShares_c20211231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zqxiXWdfvja3" style="text-align: right"&gt;2.73&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td style="padding-left: 19.05pt; text-indent: -19.05pt"&gt;Weighted average fair value of options granted during the period&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_uUSDPShares_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zjy3QMIiTGn2" style="text-align: right" title="Weighted average fair value of options granted during the period"&gt;1.98&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_uUSDPShares_c20210101__20211231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zJ7nUsbGN3G5" style="text-align: right" title="Weighted average fair value of options granted during the period"&gt;2.85&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;Stock-based compensation expense&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_980_eus-gaap--AllocatedShareBasedCompensationExpense_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zfLR5zcx3wL6" style="text-align: right" title="Stock-based compensation expense"&gt;1,925,861&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_982_eus-gaap--AllocatedShareBasedCompensationExpense_c20210101__20211231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zrV2bdvx9Ojb" style="text-align: right" title="Stock-based compensation expense"&gt;2,457,788&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2021-12-31_custom_StockOptionPlan2015Member"
      decimals="INF"
      unitRef="Shares">3672500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2021-12-31_custom_StockOptionPlan2015Member"
      decimals="INF"
      unitRef="USDPShares">3.42</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2020-12-31_custom_StockOptionPlan2015Member"
      decimals="INF"
      unitRef="Shares">2922494</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2020-12-31_custom_StockOptionPlan2015Member"
      decimals="INF"
      unitRef="USDPShares">2.46</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2022-01-012022-12-31_custom_StockOptionPlan2015Member"
      decimals="INF"
      unitRef="Shares">445000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="From2022-01-012022-12-31_custom_StockOptionPlan2015Member"
      decimals="INF"
      unitRef="USDPShares">2.57</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2021-01-012021-12-31_custom_StockOptionPlan2015Member"
      decimals="INF"
      unitRef="Shares">2000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="From2021-01-012021-12-31_custom_StockOptionPlan2015Member"
      decimals="INF"
      unitRef="USDPShares">3.64</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="From2022-01-012022-12-31_custom_StockOptionPlan2015Member"
      decimals="INF"
      unitRef="Shares">1031250</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="From2022-01-012022-12-31_custom_StockOptionPlan2015Member"
      decimals="INF"
      unitRef="USDPShares">1.57</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="From2021-01-012021-12-31_custom_StockOptionPlan2015Member"
      decimals="INF"
      unitRef="Shares">1062500</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="From2021-01-012021-12-31_custom_StockOptionPlan2015Member"
      decimals="INF"
      unitRef="USDPShares">1.19</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="From2022-01-012022-12-31_custom_StockOptionPlan2015Member"
      decimals="INF"
      unitRef="Shares">526250</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="From2022-01-012022-12-31_custom_StockOptionPlan2015Member"
      decimals="INF"
      unitRef="USDPShares">2.73</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="From2021-01-012021-12-31_custom_StockOptionPlan2015Member"
      decimals="INF"
      unitRef="Shares">187494</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="From2021-01-012021-12-31_custom_StockOptionPlan2015Member"
      decimals="INF"
      unitRef="USDPShares">3.36</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2022-12-31_custom_StockOptionPlan2015Member"
      decimals="INF"
      unitRef="Shares">2560000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2022-12-31_custom_StockOptionPlan2015Member"
      decimals="INF"
      unitRef="USDPShares">4.15</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2021-12-31_custom_StockOptionPlan2015Member"
      decimals="INF"
      unitRef="Shares">3672500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2021-12-31_custom_StockOptionPlan2015Member"
      decimals="INF"
      unitRef="USDPShares">3.42</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="AsOf2022-12-31_custom_StockOptionPlan2015Member"
      decimals="INF"
      unitRef="Shares">737500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="AsOf2022-12-31_custom_StockOptionPlan2015Member"
      decimals="INF"
      unitRef="USDPShares">4.93</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="AsOf2021-12-31_custom_StockOptionPlan2015Member"
      decimals="INF"
      unitRef="Shares">983750</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="AsOf2021-12-31_custom_StockOptionPlan2015Member"
      decimals="INF"
      unitRef="USDPShares">2.73</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2022-01-012022-12-31_custom_StockOptionPlan2015Member"
      decimals="INF"
      unitRef="USDPShares">1.98</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2021-01-012021-12-31_custom_StockOptionPlan2015Member"
      decimals="INF"
      unitRef="USDPShares">2.85</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2022-01-012022-12-31_custom_StockOptionPlan2015Member"
      decimals="0"
      unitRef="USD">1925861</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2021-01-012021-12-31_custom_StockOptionPlan2015Member"
      decimals="0"
      unitRef="USD">2457788</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="From2022-01-012022-12-31_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember"
      decimals="0"
      unitRef="USD">1925861</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="From2021-01-012021-12-31_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember"
      decimals="0"
      unitRef="USD">2457788</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="From2022-01-012022-12-31_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember"
      decimals="0"
      unitRef="USD">406623</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="From2021-01-012021-12-31_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember"
      decimals="0"
      unitRef="USD">1261251</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2022-01-012022-12-31_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember"
      decimals="0"
      unitRef="USD">103319</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2021-01-012021-12-31_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember"
      decimals="0"
      unitRef="USD">665700</us-gaap:IncomeTaxExpenseBenefit>
    <krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2022-01-012022-12-31_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember"
      decimals="INF"
      unitRef="Shares">881428</krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriodWeightedAverageGrantDateFairValue>
    <krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2021-01-012021-12-31_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember"
      decimals="INF"
      unitRef="Shares">5699986</krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriodWeightedAverageGrantDateFairValue>
    <krmd:StockIssuedDuringPeriodSharesStockOptionsExercised1
      contextRef="From2022-01-012022-12-31_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember"
      decimals="INF"
      unitRef="Shares">1150203</krmd:StockIssuedDuringPeriodSharesStockOptionsExercised1>
    <krmd:StockIssuedDuringPeriodSharesStockOptionsExercised1
      contextRef="From2021-01-012021-12-31_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember"
      decimals="INF"
      unitRef="Shares">697920</krmd:StockIssuedDuringPeriodSharesStockOptionsExercised1>
    <krmd:ScheduleOfShareBasedCompensationStockOptionsActivityAmendedTableTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_89D_ecustom--ScheduleOfShareBasedCompensationStockOptionsActivityAmendedTableTextBlock_zz8RJ2Ki4uS8" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;The following table presents information pertaining to options outstanding
as of December 31, 2022:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span id="xdx_8B3_zdHY4FCcHVjd" style="display: none; visibility: hidden"&gt;Schedule of information pertaining to options outstanding&lt;/span&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 7.5in; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&lt;b&gt;Range of Exercise Price&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;Number&lt;br/&gt;
Outstanding&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;Weighted&lt;br/&gt;
Average&lt;br/&gt;
Remaining&lt;br/&gt;
Contractual&lt;br/&gt;
Life&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;Weighted&lt;br/&gt;
Average&lt;br/&gt;
Exercise&lt;br/&gt;
Price&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;Number&lt;br/&gt;
Exercisable&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;Weighted&lt;br/&gt;
Average&lt;br/&gt;
Exercise&lt;br/&gt;
Price&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td style="width: 131.2pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 8.25pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 64.85pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 14.35pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 64.85pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 13.6pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 7.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 63pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 13.6pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 64.85pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 14.35pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 8.25pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 63pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 7.55pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td&gt;$2.25 - $9.49&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_985_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pid_uShares_c20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice1Member_zE9AiaUVP7N1" style="text-align: right" title="Number outstanding"&gt;2,560,000&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span id="xdx_906_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dxL_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice1Member_zm6fxm2yXdlj" title="Weighted average remaining contractual life::XDX::P8Y9M18D"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0782"&gt;8.8&lt;/span&gt;&lt;/span&gt; years&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_988_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pid_uUSDPShares_c20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice1Member_ze4YPaf8jUGe" style="text-align: right" title="Weighted average exercise price"&gt;4.15&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_uShares_c20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice1Member_zVzOB3aHfG61" style="text-align: right" title="Number exercisable"&gt;737,500&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_98F_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_pid_uUSDPShares_c20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice1Member_z1agaJApbVVc" style="text-align: right" title="Weighted average exercise price"&gt;4.93&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
</krmd:ScheduleOfShareBasedCompensationStockOptionsActivityAmendedTableTextBlock>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="AsOf2022-12-31_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember_custom_ExercisePrice1Member"
      decimals="INF"
      unitRef="Shares">2560000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
      contextRef="AsOf2022-12-31_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember_custom_ExercisePrice1Member"
      decimals="INF"
      unitRef="USDPShares">4.15</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="AsOf2022-12-31_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember_custom_ExercisePrice1Member"
      decimals="INF"
      unitRef="Shares">737500</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
      contextRef="AsOf2022-12-31_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember_custom_ExercisePrice1Member"
      decimals="INF"
      unitRef="USDPShares">4.93</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="AsOf2022-12-31_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember"
      decimals="0"
      unitRef="USD">4299070</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
      contextRef="AsOf2022-12-31_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember"
      decimals="0"
      unitRef="USD">2703002</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
      contextRef="AsOf2021-12-31_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember"
      decimals="0"
      unitRef="USD">1923179</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue
      contextRef="From2022-01-012022-12-31_custom_StockOptionPlan2021Member"
      decimals="INF"
      unitRef="USDPShares">1.99</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue
      contextRef="From2021-01-012021-12-31_custom_StockOptionPlan2021Member"
      decimals="INF"
      unitRef="USDPShares">0</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2022-01-012022-12-31_custom_StockOptionPlan2021Member"
      decimals="0"
      unitRef="USD">33083</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2021-01-012021-12-31_custom_StockOptionPlan2021Member"
      decimals="0"
      unitRef="USD">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_893_eus-gaap--ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_z1c7sldhvJtd" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span&gt;&lt;span id="xdx_8B8_zmgyVB3Zl42e" style="display: none; visibility: hidden"&gt;Schedule of time based stock options&lt;/span&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 4.5in; border-collapse: collapse"&gt;
  &lt;tr&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="5" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;December 31,&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;2022&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;2021&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="width: 136.7pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 0.1in"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 0.1in"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 71.6pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 14.25pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 0.1in"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 72.35pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 7.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td&gt;Dividend yield&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zJwoESfRyAab" title="Dividend yield"&gt;0.00&lt;/span&gt;%&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zhWeaToWIlj8" title="Dividend yield"&gt;0.00&lt;/span&gt;%&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;Expected Volatility&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zlzsSWsvcP8k" title="Expected volatility"&gt;65.9&lt;/span&gt;%&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20210101__20211231__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember__srt--RangeAxis__srt--MinimumMember_zUmPwsUZYfZd"&gt;0&lt;/span&gt;% &#x2013; &lt;span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember__srt--RangeAxis__srt--MaximumMember_zTwmV5AIzBm2" title="Expected volatility"&gt;0&lt;/span&gt;%&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td&gt;Weighted-average volatility&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_pid_dp_uPure_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zbPtw0LX5FZ7" title="Weighted-average volatility"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0817"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_pid_dp_uPure_c20210101__20211231__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zdGMNi9skWj6" title="Weighted-average volatility"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0819"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;Expected dividends&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments_d0_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_z50YwJiVy8o3" title="Expected dividends"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments_c20210101__20211231__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_z28VpsVDQRCc" title="Expected dividends"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0823"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td&gt;Expected term (in years)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dxL_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_ziwAuYv74Xbh" title="Expected term (in years)::XDX::P10Y"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0825"&gt;10&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dxL_c20210101__20211231__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zLo14Du90Qd" title="Expected term (in years)::XDX::P0Y"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0827"&gt;0&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;Risk-free rate&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember_zVSeOdzf4oMf" title="Risk-free rate"&gt;2.99&lt;/span&gt;%&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20210101__20211231__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember__srt--RangeAxis__srt--MinimumMember_zaFr9qzZvIm9" title="Risk-free rate"&gt;0&lt;/span&gt;% &#x2013; &lt;span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20210101__20211231__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember__srt--RangeAxis__srt--MinimumMember_zB2vYAeILLq4" title="Risk-free rate"&gt;0&lt;/span&gt;%&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
</us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="From2022-01-012022-12-31_custom_StockOptionPlan2021Member_custom_TimeBasedSharesOptionsMember"
      decimals="INF"
      unitRef="Pure">0.0000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="From2022-01-012022-12-31_custom_StockOptionPlan2021Member_custom_TimeBasedSharesOptionsMember"
      decimals="INF"
      unitRef="Pure">0.0000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="From2022-01-012022-12-31_custom_StockOptionPlan2021Member_custom_TimeBasedSharesOptionsMember"
      decimals="INF"
      unitRef="Pure">0.659</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="From2021-01-012021-12-31_custom_StockOptionPlan2021Member_custom_TimeBasedSharesOptionsMember_srt_MinimumMember"
      decimals="INF"
      unitRef="Pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="From2022-01-012022-12-31_custom_StockOptionPlan2021Member_custom_TimeBasedSharesOptionsMember_srt_MaximumMember"
      decimals="INF"
      unitRef="Pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments
      contextRef="From2022-01-012022-12-31_custom_StockOptionPlan2021Member_custom_TimeBasedSharesOptionsMember"
      decimals="0"
      unitRef="USD">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="From2022-01-012022-12-31_custom_StockOptionPlan2021Member_custom_TimeBasedSharesOptionsMember"
      decimals="INF"
      unitRef="Pure">0.0299</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="From2021-01-012021-12-31_custom_StockOptionPlan2021Member_custom_TimeBasedSharesOptionsMember_srt_MinimumMember"
      decimals="INF"
      unitRef="Pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="From2021-01-012021-12-31_custom_StockOptionPlan2021Member_custom_TimeBasedSharesOptionsMember_srt_MinimumMember"
      decimals="INF"
      unitRef="Pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ScheduleOfOtherShareBasedCompensationActivityTableTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_890_eus-gaap--ScheduleOfOtherShareBasedCompensationActivityTableTextBlock_zgKL1plP0rec" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;The following table summarizes the status of the 2021 Plan with respect
to time based stock options:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span id="xdx_8BA_zduzcPjGX2fi" style="display: none; visibility: hidden"&gt;Schedule of status of time based stock options&lt;/span&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 7.5in; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;Year Ended December 31,&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="4" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;2022&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="5" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;2021&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;Shares&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;Weighted&lt;br/&gt;
Average&lt;br/&gt;
Exercise&lt;br/&gt;
Price&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;Shares&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;Weighted&lt;br/&gt;
Average&lt;br/&gt;
Exercise&lt;br/&gt;
Price&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td style="width: 264.6pt"&gt;Outstanding at January 1&lt;/td&gt;
    &lt;td style="width: 0.1in"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber2_iS_pid_uShares_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zJn084UMm3Hb" style="width: 49.2pt; text-align: right" title="Outstanding at beginning"&gt;0&lt;/td&gt;
    &lt;td style="width: 0.2in"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 0.1in"&gt;$&lt;/td&gt;
    &lt;td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice2_iS_pid_uUSDPShares_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zdyPJ6msQb84" style="width: 49.15pt; text-align: right" title="Outstanding at beginning"&gt;0&lt;/td&gt;
    &lt;td style="width: 14.7pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 0.1in"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber2_iS_pid_uShares_c20210101__20211231__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zBv9XV56t6of" style="width: 48.85pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0840"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 14.55pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 0.1in"&gt;$&lt;/td&gt;
    &lt;td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice2_iS_pid_uUSDPShares_c20210101__20211231__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zw2MZhDPuTi2" style="width: 48.55pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0841"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 0.1in"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;Granted&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross2_pid_uShares_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zUhpTJ7MfqGa" style="text-align: right" title="Granted"&gt;475,000&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_984_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice2_pid_uUSDPShares_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_z4finuiR92Wl" style="text-align: right" title="Granted"&gt;2.67&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross2_pid_uShares_c20210101__20211231__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zXjFEbRNUM6g" style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0846"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_98E_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice2_pid_uUSDPShares_c20210101__20211231__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_ztMaUpOvkv6g" style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0847"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td&gt;Exercised&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_989_ecustom--StockIssuedDuringPeriodSharesStockOptionsExercised2_pid_uShares_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zQLVCQI05zL1" style="text-align: right" title="Exercised"&gt;0&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_980_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice2_pid_uUSDPShares_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zpglE3WdXyxa" style="text-align: right" title="Exercised"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0851"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_980_ecustom--StockIssuedDuringPeriodSharesStockOptionsExercised2_pid_uShares_c20210101__20211231__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zzU0EQfxTLNb" style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0852"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_985_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice2_pid_uUSDPShares_c20210101__20211231__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zfke8nRT0Ql6" style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0853"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;Forfeited&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod2_pid_uShares_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zud5mcwUwd5f" style="text-align: right" title="Forfeited"&gt;0&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_981_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice2_pid_uUSDPShares_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zFTArLr4LvO" style="text-align: right" title="Forfeited"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0857"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod2_pid_uShares_c20210101__20211231__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_ztP0z42eq7g6" style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0858"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_98C_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice2_pid_uUSDPShares_c20210101__20211231__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zJtGJk5gjWid" style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0859"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td&gt;Outstanding at year end&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber2_iE_pid_uShares_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zzSNeNun6ka7" style="text-align: right" title="Outstanding at ending"&gt;475,000&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice2_iE_pid_uUSDPShares_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_z9U1aKMLdD7k" style="text-align: right" title="Outstanding at ending"&gt;2.67&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber2_iE_pid_d0_uShares_c20210101__20211231__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_z3TSrOrdfbhd" style="text-align: right"&gt;&#x2014;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice2_iE_pid_d0_uUSDPShares_c20210101__20211231__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_z25ZkGVljTM7" style="text-align: right"&gt;&#x2014;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;Options exercisable&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pid_uShares_c20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zEmdFXL5jX8k" style="text-align: right" title="Options exercisable at ending"&gt;0&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_984_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice2_iI_pid_uUSDPShares_c20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zPUtOEBvfuQk" style="text-align: right" title="Options exercisable at ending"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0869"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pid_uShares_c20211231__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zurkgefKQTu8" style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0870"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_982_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice2_iI_pid_uUSDPShares_c20211231__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zkcGJynuGkA" style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0871"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td style="padding-left: 0.1in; text-indent: -0.1in"&gt;Weighted average fair value of options granted during the period&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue2_pid_uUSDPShares_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zPiZtEGtaR89" style="text-align: right" title="Weighted average fair value of options granted during the period"&gt;1.99&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue2_pid_uUSDPShares_c20210101__20211231__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zg2K9XA8FE8k" style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0874"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;Stock-based compensation expense&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_98C_eus-gaap--ShareBasedCompensation_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zMR0a556MYe4" style="text-align: right" title="Stock-based compensation expense"&gt;157,536&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_98B_eus-gaap--ShareBasedCompensation_c20210101__20211231__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zhI0JtDcVzbl" style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0877"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
</us-gaap:ScheduleOfOtherShareBasedCompensationActivityTableTextBlock>
    <krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber2
      contextRef="AsOf2021-12-31_custom_StockOptionPlan2021Member"
      decimals="INF"
      unitRef="Shares">0</krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber2>
    <krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice2
      contextRef="AsOf2021-12-31_custom_StockOptionPlan2021Member"
      decimals="INF"
      unitRef="USDPShares">0</krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice2>
    <krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross2
      contextRef="From2022-01-012022-12-31_custom_StockOptionPlan2021Member"
      decimals="INF"
      unitRef="Shares">475000</krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross2>
    <krmd:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice2
      contextRef="From2022-01-012022-12-31_custom_StockOptionPlan2021Member"
      decimals="INF"
      unitRef="USDPShares">2.67</krmd:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice2>
    <krmd:StockIssuedDuringPeriodSharesStockOptionsExercised2
      contextRef="From2022-01-012022-12-31_custom_StockOptionPlan2021Member"
      decimals="INF"
      unitRef="Shares">0</krmd:StockIssuedDuringPeriodSharesStockOptionsExercised2>
    <krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod2
      contextRef="From2022-01-012022-12-31_custom_StockOptionPlan2021Member"
      decimals="INF"
      unitRef="Shares">0</krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod2>
    <krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber2
      contextRef="AsOf2022-12-31_custom_StockOptionPlan2021Member"
      decimals="INF"
      unitRef="Shares">475000</krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber2>
    <krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice2
      contextRef="AsOf2022-12-31_custom_StockOptionPlan2021Member"
      decimals="INF"
      unitRef="USDPShares">2.67</krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice2>
    <krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber2
      contextRef="AsOf2021-12-31_custom_StockOptionPlan2021Member"
      decimals="INF"
      unitRef="Shares">0</krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber2>
    <krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice2
      contextRef="AsOf2021-12-31_custom_StockOptionPlan2021Member"
      decimals="INF"
      unitRef="USDPShares">0</krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="AsOf2022-12-31_custom_StockOptionPlan2021Member"
      decimals="INF"
      unitRef="Shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue2
      contextRef="From2022-01-012022-12-31_custom_StockOptionPlan2021Member"
      decimals="INF"
      unitRef="USDPShares">1.99</krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue2>
    <us-gaap:ShareBasedCompensation
      contextRef="From2022-01-012022-12-31_custom_StockOptionPlan2021Member"
      decimals="0"
      unitRef="USD">157536</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2022-01-012022-12-31_custom_StockOptionPlan2021Member"
      decimals="0"
      unitRef="USD">157536</us-gaap:ShareBasedCompensation>
    <krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2022-01-012022-12-31_custom_StockOptionPlan2021Member_custom_TimeBasedSharesOptionsMember"
      decimals="INF"
      unitRef="Shares">945215</krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriodWeightedAverageGrantDateFairValue>
    <krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2021-01-012021-12-31_custom_StockOptionPlan2021Member_custom_TimeBasedSharesOptionsMember"
      decimals="INF"
      unitRef="Shares">0</krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriodWeightedAverageGrantDateFairValue>
    <krmd:ScheduleOfShareBasedCompensationtaxBenefitsAssociatedWithRestrictedStockAwardCompensationTableTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_893_ecustom--ScheduleOfShareBasedCompensationtaxBenefitsAssociatedWithRestrictedStockAwardCompensationTableTextBlock_zPKPQIQxyncf" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;The following table presents information pertaining to options outstanding
at December 31, 2022:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span id="xdx_8B1_zPPZmpjvZHPa" style="display: none; visibility: hidden"&gt;Schedule of information pertaining to options outstanding&lt;/span&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 7.5in; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&lt;b&gt;Range of Exercise Price&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;Number&lt;br/&gt;
Outstanding&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;Weighted&lt;br/&gt;
Average&lt;br/&gt;
Remaining&lt;br/&gt;
Contractual&lt;br/&gt;
Life&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;Weighted&lt;br/&gt;
Average&lt;br/&gt;
Exercise&lt;br/&gt;
Price&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;Number&lt;br/&gt;
Exercisable&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;Weighted&lt;br/&gt;
Average&lt;br/&gt;
Exercise&lt;br/&gt;
Price&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="width: 131.2pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 8.25pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 64.85pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 14.35pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 64.85pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 13.6pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 7.55pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 63.35pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 13.6pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 64.85pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 14.35pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 8.3pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 55.8pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 15.1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td&gt;$2.67&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pid_uShares_c20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice1Member_zsRCclyBqdal" style="text-align: right" title="Number outstanding"&gt;475,000&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span id="xdx_90A_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dxL_c20220101__20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice1Member_zXOIgQYORYWa" title="Weighted average remaining contractual life::XDX::P9Y3M19D"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0891"&gt;9.3&lt;/span&gt;&lt;/span&gt; years&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_98F_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_c20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice1Member_zpulwXJjCC2j" style="text-align: center" title="Weighted average exercise price"&gt;2.67&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_984_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_uShares_c20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice1Member_zWpe3SyNSA6a" style="text-align: right" title="Number exercisable"&gt;0&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_982_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_pid_uUSDPShares_c20221231__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member__us-gaap--AwardTypeAxis__custom--TimeBasedSharesOptionsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice1Member_z3h6UfDDpwme" style="text-align: right" title="Weighted average exercise price"&gt;0&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
</krmd:ScheduleOfShareBasedCompensationtaxBenefitsAssociatedWithRestrictedStockAwardCompensationTableTextBlock>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="AsOf2022-12-31_custom_StockOptionPlan2021Member_custom_TimeBasedSharesOptionsMember_custom_ExercisePrice1Member"
      decimals="INF"
      unitRef="Shares">475000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
      contextRef="AsOf2022-12-31_custom_StockOptionPlan2021Member_custom_TimeBasedSharesOptionsMember_custom_ExercisePrice1Member"
      decimals="INF"
      unitRef="USDPShares">2.67</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="AsOf2022-12-31_custom_StockOptionPlan2021Member_custom_TimeBasedSharesOptionsMember_custom_ExercisePrice1Member"
      decimals="INF"
      unitRef="Shares">0</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
      contextRef="AsOf2022-12-31_custom_StockOptionPlan2021Member_custom_TimeBasedSharesOptionsMember_custom_ExercisePrice1Member"
      decimals="INF"
      unitRef="USDPShares">0</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
    <krmd:CompensationCost
      contextRef="AsOf2022-12-31_custom_StockOptionPlan2021Member_custom_TimeBasedSharesOptionsMember"
      decimals="0"
      unitRef="USD">787679</krmd:CompensationCost>
    <us-gaap:ShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_89A_eus-gaap--ShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock_ziaATDPStcpg" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;The following table summarizes the status of the 2015 Plan with respect
to performance-based stock options as of December 31, 2022 and 2021:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span id="xdx_8B0_zFmIDLEsG1N" style="display: none; visibility: hidden"&gt;Schedule of performance base options outstanding&lt;/span&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 7.5in; border-collapse: collapse"&gt;
  &lt;tr style="background-color: white"&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="4" style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: center"&gt;&lt;b&gt;December 31, 2022&lt;/b&gt;&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="5" style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: center"&gt;&lt;b&gt;December 31, 2021&lt;/b&gt;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="background-color: white"&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: center"&gt;&lt;b&gt;Shares&lt;/b&gt;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: center"&gt;&lt;b&gt;Weighted&lt;br/&gt;
Average&lt;br/&gt;
Exercise&lt;br/&gt;
Price&lt;/b&gt;&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: center"&gt;&lt;b&gt;Shares&lt;/b&gt;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: center"&gt;&lt;b&gt;Weighted&lt;br/&gt;
Average&lt;br/&gt;
Exercise&lt;br/&gt;
Price&lt;/b&gt;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="background-color: white"&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="background-color: #E6E6E6"&gt;
    &lt;td style="vertical-align: bottom; width: 257.75pt"&gt;Outstanding at January 1&lt;/td&gt;
    &lt;td style="vertical-align: bottom; width: 7.15pt"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber1_iS_pid_dxL_uShares_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_z0M2W59pO8fk" style="vertical-align: bottom; width: 47.8pt; text-align: right" title="Outstanding at beginning::XDX::1000000"&gt;&lt;b style="display: none; visibility: hidden"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0910"&gt;&#x2014;&lt;/span&gt;&lt;/b&gt;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; width: 15.15pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; width: 0.1in"&gt;$&lt;/td&gt;
    &lt;td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice1_iS_pid_dxL_uUSDPShares_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zz6GEJl9i7X2" style="vertical-align: bottom; width: 48.5pt; text-align: right" title="Outstanding at beginning::XDX::1.70"&gt;&lt;b style="display: none; visibility: hidden"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0912"&gt;&#x2014;&lt;/span&gt;&lt;/b&gt;&lt;/td&gt;
    &lt;td style="vertical-align: top; width: 12.9pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; width: 12.95pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; width: 0.1in"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_982_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber1_iS_pid_uShares_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zNrjDxCN5cw6" style="vertical-align: bottom; width: 48pt; text-align: right" title="Outstanding at beginning"&gt;1,000,000&lt;/td&gt;
    &lt;td style="vertical-align: bottom; width: 11.55pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; width: 0.1in"&gt;$&lt;/td&gt;
    &lt;td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice1_iS_pid_uUSDPShares_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zv9YzAaCKyV2" style="vertical-align: bottom; width: 49.95pt; text-align: right"&gt;1.70&lt;/td&gt;
    &lt;td style="vertical-align: bottom; width: 7.15pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="background-color: white"&gt;
    &lt;td style="vertical-align: bottom"&gt;Granted&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross1_pid_d0_uShares_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_znMigeF3Cy4c" style="vertical-align: bottom; text-align: right" title="Granted"&gt;&#x2014;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;$&lt;/td&gt;
    &lt;td id="xdx_980_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice1_pid_d0_uUSDPShares_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zw1sSZzmgc77" style="vertical-align: bottom; text-align: right" title="Granted"&gt;&#x2014;&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross1_pid_d0_uShares_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zajKijFVkUp7" style="vertical-align: bottom; text-align: right"&gt;&#x2014;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;$&lt;/td&gt;
    &lt;td id="xdx_98B_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice1_pid_d0_uUSDPShares_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zQMolxBiscE7" style="vertical-align: bottom; text-align: right"&gt;&#x2014;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="background-color: #E6E6E6"&gt;
    &lt;td style="vertical-align: bottom"&gt;Exercised&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_989_ecustom--StockIssuedDuringPeriodSharesStockOptionsExercised1_pid_d0_uShares_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_z8CXWSE0Ujvh" style="vertical-align: bottom; text-align: right" title="Exercised"&gt;&#x2014;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;$&lt;/td&gt;
    &lt;td id="xdx_98B_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice1_pid_d0_uUSDPShares_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zKoVOB1QkUB5" style="vertical-align: bottom; text-align: right" title="Exercised"&gt;&#x2014;&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_980_ecustom--StockIssuedDuringPeriodSharesStockOptionsExercised1_pid_d0_uShares_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zFYgOcOG6Jl" style="vertical-align: bottom; text-align: right"&gt;&#x2014;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;$&lt;/td&gt;
    &lt;td id="xdx_98E_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice1_pid_d0_uUSDPShares_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zNZK1HJv0i7" style="vertical-align: bottom; text-align: right"&gt;&#x2014;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="background-color: white"&gt;
    &lt;td style="vertical-align: bottom"&gt;Forfeited&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod1_pid_d0_uShares_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zsEACKSpxZni" style="vertical-align: bottom; text-align: right" title="Forfeited"&gt;&#x2014;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;$&lt;/td&gt;
    &lt;td id="xdx_982_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice1_pid_d0_uUSDPShares_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zpMOG22IlwOk" style="vertical-align: bottom; text-align: right" title="Forfeited"&gt;&#x2014;&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_984_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod1_pid_d0_uShares_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zD9qTNpJmza" style="vertical-align: bottom; text-align: right"&gt;&#x2014;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;$&lt;/td&gt;
    &lt;td id="xdx_988_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice1_pid_d0_uUSDPShares_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zMbPSxP2Exd" style="vertical-align: bottom; text-align: right"&gt;&#x2014;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="background-color: #E6E6E6"&gt;
    &lt;td style="vertical-align: bottom"&gt;Outstanding at year end&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_d0_uShares_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zyKbhzgvNtke" style="vertical-align: bottom; text-align: right" title="Outstanding at ending"&gt;&#x2014;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;$&lt;/td&gt;
    &lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_d0_uUSDPShares_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zfZBqFlaW2Oc" style="vertical-align: bottom; text-align: right" title="Outstanding at ending"&gt;&#x2014;&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_uShares_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zgDB6RDXRAB5" style="vertical-align: bottom; text-align: right"&gt;1,000,000&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;$&lt;/td&gt;
    &lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_uUSDPShares_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zm1JZlstwHTg" style="vertical-align: bottom; text-align: right"&gt;1.70&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="background-color: white"&gt;
    &lt;td style="vertical-align: bottom"&gt;Options exercisable&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross1_pid_d0_uShares_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zjmL7oDnQJf" style="vertical-align: bottom; text-align: right" title="Options exercisable at ending"&gt;&#x2014;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;$&lt;/td&gt;
    &lt;td id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice1_iI_pid_d0_uUSDPShares_c20221231__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zhqy6DeuJT83" style="vertical-align: bottom; text-align: right" title="Options exercisable at ending"&gt;&#x2014;&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross1_pid_d0_uShares_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zOE2NUXibFT7" style="vertical-align: bottom; text-align: right"&gt;&#x2014;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;$&lt;/td&gt;
    &lt;td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice1_iI_pid_d0_uUSDPShares_c20211231__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zQkYAvK8aRva" style="vertical-align: bottom; text-align: right"&gt;&#x2014;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="background-color: #E6E6E6"&gt;
    &lt;td style="vertical-align: bottom; padding-left: 7.4pt; text-indent: -7.4pt"&gt;Weighted average fair value of options granted during the period&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_d0_uShares_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zcmhAcGr65Dg" style="vertical-align: bottom; text-align: right" title="Weighted average fair value of options granted during the period"&gt;&#x2014;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;$&lt;/td&gt;
    &lt;td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue1_pid_d0_uUSDPShares_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zLfM1tdYCCYj" style="vertical-align: bottom; text-align: right" title="Weighted average fair value of options granted during the period"&gt;&#x2014;&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_d0_uShares_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zTRtxzr0EcSj" style="vertical-align: bottom; text-align: right"&gt;&#x2014;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;$&lt;/td&gt;
    &lt;td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue1_pid_d0_uUSDPShares_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zkU8GGqbg8be" style="vertical-align: bottom; text-align: right"&gt;&#x2014;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="background-color: white"&gt;
    &lt;td style="vertical-align: bottom"&gt;Stock-based compensation expense&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; text-align: right"&gt;&#x2014;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;$&lt;/td&gt;
    &lt;td id="xdx_98F_ecustom--AllocatedShareBasedCompensationExpense1_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zqjwJjn6fyn5" style="vertical-align: bottom; text-align: right" title="Stock-based compensation expense"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0953"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; text-align: right"&gt;&#x2014;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;$&lt;/td&gt;
    &lt;td id="xdx_98E_ecustom--AllocatedShareBasedCompensationExpense1_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_z665Xj26ZrH" style="vertical-align: bottom; text-align: right" title="Stock-based compensation expense"&gt;(408,747&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
</us-gaap:ShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock>
    <krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber1
      contextRef="AsOf2020-12-31_us-gaap_PerformanceSharesMember"
      decimals="INF"
      unitRef="Shares">1000000</krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber1>
    <krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice1
      contextRef="AsOf2020-12-31_us-gaap_PerformanceSharesMember"
      decimals="INF"
      unitRef="USDPShares">1.70</krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice1>
    <krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross1
      contextRef="From2022-01-012022-12-31_us-gaap_PerformanceSharesMember"
      decimals="INF"
      unitRef="Shares">0</krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross1>
    <krmd:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice1
      contextRef="From2022-01-012022-12-31_us-gaap_PerformanceSharesMember"
      decimals="INF"
      unitRef="USDPShares">0</krmd:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice1>
    <krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross1
      contextRef="From2021-01-012021-12-31_us-gaap_PerformanceSharesMember"
      decimals="INF"
      unitRef="Shares">0</krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross1>
    <krmd:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice1
      contextRef="From2021-01-012021-12-31_us-gaap_PerformanceSharesMember"
      decimals="INF"
      unitRef="USDPShares">0</krmd:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice1>
    <krmd:StockIssuedDuringPeriodSharesStockOptionsExercised1
      contextRef="From2022-01-012022-12-31_us-gaap_PerformanceSharesMember"
      decimals="INF"
      unitRef="Shares">0</krmd:StockIssuedDuringPeriodSharesStockOptionsExercised1>
    <krmd:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice1
      contextRef="From2022-01-012022-12-31_us-gaap_PerformanceSharesMember"
      decimals="INF"
      unitRef="USDPShares">0</krmd:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice1>
    <krmd:StockIssuedDuringPeriodSharesStockOptionsExercised1
      contextRef="From2021-01-012021-12-31_us-gaap_PerformanceSharesMember"
      decimals="INF"
      unitRef="Shares">0</krmd:StockIssuedDuringPeriodSharesStockOptionsExercised1>
    <krmd:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice1
      contextRef="From2021-01-012021-12-31_us-gaap_PerformanceSharesMember"
      decimals="INF"
      unitRef="USDPShares">0</krmd:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice1>
    <krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod1
      contextRef="From2022-01-012022-12-31_us-gaap_PerformanceSharesMember"
      decimals="INF"
      unitRef="Shares">0</krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod1>
    <krmd:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice1
      contextRef="From2022-01-012022-12-31_us-gaap_PerformanceSharesMember"
      decimals="INF"
      unitRef="USDPShares">0</krmd:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice1>
    <krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod1
      contextRef="From2021-01-012021-12-31_us-gaap_PerformanceSharesMember"
      decimals="INF"
      unitRef="Shares">0</krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod1>
    <krmd:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice1
      contextRef="From2021-01-012021-12-31_us-gaap_PerformanceSharesMember"
      decimals="INF"
      unitRef="USDPShares">0</krmd:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2022-12-31_us-gaap_PerformanceSharesMember"
      decimals="INF"
      unitRef="Shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2022-12-31_us-gaap_PerformanceSharesMember"
      decimals="INF"
      unitRef="USDPShares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2021-12-31_us-gaap_PerformanceSharesMember"
      decimals="INF"
      unitRef="Shares">1000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2021-12-31_us-gaap_PerformanceSharesMember"
      decimals="INF"
      unitRef="USDPShares">1.70</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross1
      contextRef="From2022-01-012022-12-31_us-gaap_PerformanceSharesMember"
      decimals="INF"
      unitRef="Shares">0</krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross1>
    <krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice1
      contextRef="AsOf2022-12-31_us-gaap_PerformanceSharesMember"
      decimals="INF"
      unitRef="USDPShares">0</krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice1>
    <krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross1
      contextRef="From2021-01-012021-12-31_us-gaap_PerformanceSharesMember"
      decimals="INF"
      unitRef="Shares">0</krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross1>
    <krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice1
      contextRef="AsOf2021-12-31_us-gaap_PerformanceSharesMember"
      decimals="INF"
      unitRef="USDPShares">0</krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2022-01-012022-12-31_us-gaap_PerformanceSharesMember"
      decimals="INF"
      unitRef="Shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue1
      contextRef="From2022-01-012022-12-31_us-gaap_PerformanceSharesMember"
      decimals="INF"
      unitRef="USDPShares">0</krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2021-01-012021-12-31_us-gaap_PerformanceSharesMember"
      decimals="INF"
      unitRef="Shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue1
      contextRef="From2021-01-012021-12-31_us-gaap_PerformanceSharesMember"
      decimals="INF"
      unitRef="USDPShares">0</krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue1>
    <krmd:AllocatedShareBasedCompensationExpense1
      contextRef="From2021-01-012021-12-31_us-gaap_PerformanceSharesMember"
      decimals="0"
      unitRef="USD">-408747</krmd:AllocatedShareBasedCompensationExpense1>
    <us-gaap:ShareBasedCompensation
      contextRef="From2021-01-012021-12-31_custom_StockOptionPlan2021Member_us-gaap_StockOptionMember"
      decimals="0"
      unitRef="USD">-408747</us-gaap:ShareBasedCompensation>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2021-04-12_custom_EmploymentAgreementMember_srt_ChiefExecutiveOfficerMember"
      decimals="INF"
      unitRef="Shares">1000000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValue
      contextRef="AsOf2021-04-12_custom_EmploymentAgreementMember_srt_ChiefExecutiveOfficerMember"
      decimals="0"
      unitRef="USD">3310000</us-gaap:CommonStockValue>
    <us-gaap:ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_890_eus-gaap--ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock_zpEioGXC9xR6" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span id="xdx_8B5_zCprAPbF5XI5" style="display: none; visibility: hidden"&gt;The following table summarizes the activities for our unvested
restricted stock awards for the twelve months ended December 31, 2022, and 2021.&lt;/span&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 7.5in; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="9" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;Twelve Months Ended December 31,&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="4" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;2022&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="4" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;2021&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;Shares&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;Weighted&lt;br/&gt;
Average&lt;br/&gt;
Grant-Date Fair Value&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;Shares&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;Weighted&lt;br/&gt;
Average&lt;br/&gt;
Grant-Date Fair Value&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td style="width: 201.15pt"&gt;Unvested at January 1&lt;/td&gt;
    &lt;td style="width: 9.65pt"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberUnvested_iS_pid_uShares_c20220101__20221231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zhacb022pAR" style="width: 53.1pt; text-align: right" title="Outstanding at beginning"&gt;1,000,000&lt;/td&gt;
    &lt;td style="width: 11pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 17.4pt"&gt;$&lt;/td&gt;
    &lt;td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceUnvested_iS_pid_uUSDPShares_c20220101__20221231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zKfcDQ74lxb8" style="width: 72.75pt; text-align: right" title="Outstanding at beginning"&gt;3.01&lt;/td&gt;
    &lt;td style="width: 11pt"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberUnvested_iS_pid_uShares_c20210101__20211231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zMTMI0RJsFsg" style="width: 54.75pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0970"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 11.35pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 16.9pt"&gt;$&lt;/td&gt;
    &lt;td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceUnvested_iS_pid_uUSDPShares_c20210101__20211231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_z8pULxd4p7f9" style="width: 73.25pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0971"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 8pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;Granted&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrossUnvested_pid_uShares_c20220101__20221231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_ztlm5zGVoigh" style="text-align: right" title="Granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0973"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_982_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePriceUnvested_pid_uUSDPShares_c20220101__20221231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_z3Ak3vyzIfta" style="text-align: right" title="Granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0975"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrossUnvested_pid_uShares_c20210101__20211231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zWfQXlJPCfea" style="text-align: right"&gt;1,000,000&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_98C_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePriceUnvested_pid_uUSDPShares_c20210101__20211231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zQmCl6uVkqmf" style="text-align: right"&gt;3.01&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td&gt;Vested&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodGross_pid_uShares_c20220101__20221231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zu2SxkYyxad1" style="text-align: right" title="Vested"&gt;50,000&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_984_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice_pid_uUSDPShares_c20220101__20221231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_z6jQd1eofYIj" style="text-align: right" title="Vested"&gt;3.31&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodGross_pid_uShares_c20210101__20211231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_z31UL0x5WW0l" style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0982"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_98C_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice_pid_uUSDPShares_c20210101__20211231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zBgpDsQZkXHl" style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0983"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;Forfeited/canceled&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodUnvested_pid_uShares_c20220101__20221231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zAeoBmoI2qF" style="text-align: right" title="Forfeited/canceled"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0985"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_980_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePriceUnvested_pid_uUSDPShares_c20220101__20221231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zXhpyyJIFlC4" style="text-align: right" title="Forfeited/canceled"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0987"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodUnvested_pid_uShares_c20210101__20211231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zAq3e72xb4f6" style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0988"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_98C_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePriceUnvested_pid_uUSDPShares_c20210101__20211231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zQ9q8QPPkiJ9" style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0989"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td&gt;Unvested at December 31&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberUnvested_iE_pid_uShares_c20220101__20221231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zrVougvelbUa" style="text-align: right" title="Outstanding at ending"&gt;950,000&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceUnvested_iE_pid_uUSDPShares_c20220101__20221231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zMh3yFi4kWh8" style="text-align: right" title="Outstanding at ending"&gt;3.04&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberUnvested_iE_pid_uShares_c20210101__20211231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zmbmg5YV0JTe" style="text-align: right"&gt;1,000,000&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceUnvested_iE_pid_uUSDPShares_c20210101__20211231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember__us-gaap--PlanNameAxis__custom--StockOptionPlan2021Member_zFQfz3vv3JR5" style="text-align: right"&gt;3.01&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
</us-gaap:ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock>
    <krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberUnvested
      contextRef="AsOf2021-12-31_custom_RestrictedStockAwardsMember_custom_StockOptionPlan2021Member"
      decimals="INF"
      unitRef="Shares">1000000</krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberUnvested>
    <krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceUnvested
      contextRef="AsOf2021-12-31_custom_RestrictedStockAwardsMember_custom_StockOptionPlan2021Member"
      decimals="INF"
      unitRef="USDPShares">3.01</krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceUnvested>
    <krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrossUnvested
      contextRef="From2021-01-012021-12-31_custom_RestrictedStockAwardsMember_custom_StockOptionPlan2021Member"
      decimals="INF"
      unitRef="Shares">1000000</krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrossUnvested>
    <krmd:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePriceUnvested
      contextRef="From2021-01-012021-12-31_custom_RestrictedStockAwardsMember_custom_StockOptionPlan2021Member"
      decimals="INF"
      unitRef="USDPShares">3.01</krmd:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePriceUnvested>
    <krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodGross
      contextRef="From2022-01-012022-12-31_custom_StockOptionPlan2021Member_custom_RestrictedStockAwardsMember"
      decimals="INF"
      unitRef="Shares">50000</krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodGross>
    <krmd:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice
      contextRef="From2022-01-012022-12-31_custom_StockOptionPlan2021Member_custom_RestrictedStockAwardsMember"
      decimals="INF"
      unitRef="USDPShares">3.31</krmd:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice>
    <krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberUnvested
      contextRef="AsOf2022-12-31_custom_RestrictedStockAwardsMember_custom_StockOptionPlan2021Member"
      decimals="INF"
      unitRef="Shares">950000</krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberUnvested>
    <krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceUnvested
      contextRef="AsOf2022-12-31_custom_RestrictedStockAwardsMember_custom_StockOptionPlan2021Member"
      decimals="INF"
      unitRef="USDPShares">3.04</krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceUnvested>
    <krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberUnvested
      contextRef="AsOf2021-12-31_custom_RestrictedStockAwardsMember_custom_StockOptionPlan2021Member"
      decimals="INF"
      unitRef="Shares">1000000</krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberUnvested>
    <krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceUnvested
      contextRef="AsOf2021-12-31_custom_RestrictedStockAwardsMember_custom_StockOptionPlan2021Member"
      decimals="INF"
      unitRef="USDPShares">3.01</krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceUnvested>
    <krmd:UnrecognizedCompensationCost
      contextRef="From2022-01-012022-12-31_custom_StockOptionPlan2021Member_custom_RestrictedStockAwardsMember"
      decimals="0"
      unitRef="USD">1618177</krmd:UnrecognizedCompensationCost>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2022-01-012022-12-31_custom_StockOptionPlan2021Member_custom_RestrictedStockAwardsMember"
      decimals="0"
      unitRef="USD">101419</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2021-01-012021-12-31_custom_RestrictedStockAwardsMember_custom_StockOptionPlan2021Member"
      decimals="0"
      unitRef="USD">47220</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:LeasesOfLesseeDisclosureTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_80A_eus-gaap--LeasesOfLesseeDisclosureTextBlock_zktF80J4F7ih" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;NOTE 5 &#x2014; &lt;span id="xdx_82F_zRVinPaaV2Y3"&gt;LEASES&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;We have finance and operating leases for our corporate office and certain
office and computer equipment. &#160;&lt;span id="xdx_900_ecustom--DescriptionOfLessorOperatingLeaseTerm_c20220101__20221231_z0WCfOOTFkO4" title="Description of lease term"&gt;Our leases have remaining lease terms of 10, 5 years, and 3 months.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;At contract inception, we evaluate whether an arrangement is or contains
a lease for which we are the lessee (that is, arrangements which provide us with the right to control a physical asset for a period of
time). &#160;Operating leases are accounted for on the balance sheets with ROU assets being recognized in &#x201c;Operating lease right-of-use
assets&#x201d; and lease liabilities recognized in &#x201c;Operating lease liability &#x2013; current&#x201d; and &#x201c;Operating lease liability,
net of current portion.&#x201d; Finance leases are accounted for on the balance sheets recognized in &#x201c;Property and equipment, net&#x201d;
and lease liabilities recognized in &#x201c;Finance lease liability &#x2013; current&#x201d; and &#x201c;Finance lease liability, net of current
portion.&#x201d;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;Operating lease expenses are recognized on a straight-line basis over the
lease term. &#160;With respect to finance leases, amortization of the ROU asset is presented separately from interest expense related
to the finance lease liability.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;We have elected to combine lease and non-lease components for all lease
contracts where we are the lessee. &#160;Additionally, for arrangements with lease terms of 12 months or less, we do not recognize ROU
assets and lease liabilities and lease payments are recognized on a straight-line basis over the lease term with variable lease payments
recognized in the period in which the obligation is incurred. &#160;ROU assets are measured for impairment when a triggering event occurs.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_890_eus-gaap--LeaseCostTableTextBlock_z1LTQGqoqzE1" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;The components of lease expense were as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span id="xdx_8BF_zHnufYvIrM98" style="display: none; visibility: hidden"&gt;Schedule of components of lease expense&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 4.75in; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="width: 187.95pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 7.15pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 0.1in; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_494_20220101__20221231_z2p5lB62SXuh" style="width: 56.8pt; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 11.15pt; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 0.1in; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_49B_20210101__20211231_zjrgEIxHcU5c" style="width: 57.4pt; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 7.15pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="5" style="text-align: center"&gt;&lt;b&gt;Years Ended&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="5" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;December 31,&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;2022&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;2021&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--OperatingLeaseCost_maLCzGTc_zUsXlNVmwuB6" style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td&gt;Operating lease cost&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;514,294&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;149,476&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--ShortTermLeaseCost_maLCzGTc_zSAnfqySRBt5" style="vertical-align: bottom"&gt;
    &lt;td&gt;Short-term lease cost&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;131,490&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;146,604&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--LeaseCost_zvUJoX9MAcG7" style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td&gt;Total lease cost&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-top: black 1pt solid; border-bottom: black 2.25pt double"&gt;$&lt;/td&gt;
    &lt;td style="border-top: black 1pt solid; border-bottom: black 2.25pt double; text-align: right"&gt;645,784&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-top: black 1pt solid; border-bottom: black 2.25pt double"&gt;$&lt;/td&gt;
    &lt;td style="border-top: black 1pt solid; border-bottom: black 2.25pt double; text-align: right"&gt;296,080&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_ecustom--FinanceLeaseCost1Abstract_iB_zWFaUUVzptO8" style="vertical-align: bottom"&gt;
    &lt;td style="padding-left: 9.1pt; text-indent: -9.1pt"&gt;Finance lease cost:&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--FinanceLeaseRightOfUseAssetAmortization_i01_maFLCzAT2_zftg6rMSJ8Qg" style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td style="padding-left: 27.5pt; text-indent: -9.1pt"&gt;Amortization of right-of-use assets&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;50,895&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;2,586&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--FinanceLeaseInterestExpense_i01_maFLCzAT2_zDR8tEDw9AQ5" style="vertical-align: bottom"&gt;
    &lt;td style="padding-left: 27.5pt; text-indent: -9.1pt"&gt;Interest on lease liabilities&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;5,393&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;60&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_ecustom--FinanceLeaseCost_i01_zD2FyidY27S9" style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td&gt;Total finance lease cost&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-top: black 1pt solid; border-bottom: black 2.25pt double"&gt;$&lt;/td&gt;
    &lt;td style="border-top: black 1pt solid; border-bottom: black 2.25pt double; text-align: right"&gt;56,288&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-top: black 1pt solid; border-bottom: black 2.25pt double"&gt;$&lt;/td&gt;
    &lt;td style="border-top: black 1pt solid; border-bottom: black 2.25pt double; text-align: right"&gt;2,646&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p id="xdx_8A9_zcHQw6kJMYhl" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_899_eus-gaap--OperatingLeaseLeaseIncomeTableTextBlock_zEHge4wXvGc" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;Supplemental cash flow information related to leases was as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span id="xdx_8BB_zz98rsQUoiYj" style="display: none; visibility: hidden"&gt;Schedule of cash flow information related to leases&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 4.75in; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="width: 190pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 6.8pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 7.1pt; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_49D_20220101__20221231_zvEQSh5ueQsi" style="width: 56.1pt; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 12pt; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 7.1pt; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_491_20210101__20211231_zqBJ41jFceVb" style="width: 55.9pt; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 6.8pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="5" style="text-align: center"&gt;&lt;b&gt;Years Ended&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="5" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;December 31,&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;2022&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;2021&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--CashFlowOperatingActivitiesLesseeAbstract_iB" style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td style="padding-left: 9.45pt; text-indent: -9.45pt"&gt;Cash paid for amounts included in the measurement of lease liabilities:&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--OperatingLeasePayments_i01_z2KIYtKYcSo1" style="vertical-align: bottom"&gt;
    &lt;td&gt;Operating cash flows from operating leases&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;247,504&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;141,293&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--FinanceLeaseInterestPaymentOnLiability_i01_zqOSMHTnsu29" style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td&gt;Financing cash flows from finance leases&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;57,243&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;2,646&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p id="xdx_8A8_zPqTb9StI1w3" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;



&lt;p id="xdx_899_eus-gaap--OperatingLeasesOfLesseeDisclosureTextBlock_zBDoScivKUk9" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;Supplemental balance sheet information related to leases was as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span id="xdx_8B9_zhDohtT1ePmd" style="display: none; visibility: hidden"&gt;Schdeule of balance sheet information related to leases&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 5.5in; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49B_20221231_z8ahI5LaIsN6" style="border-bottom: black 1pt solid; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_498_20211231_zerdUjqQqiPc" style="border-bottom: black 1pt solid; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;December 31,&lt;br/&gt;
2022&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;December 31,&lt;br/&gt;
2021&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_ecustom--AssetsAndLiabilitiesOperatingLesseeAbstract_iB_zY2BfEyxuXfl" style="vertical-align: bottom"&gt;
    &lt;td style="width: 217.3pt; padding-left: 9.1pt; text-indent: -9.1pt"&gt;&lt;b&gt;Operating Leases&lt;/b&gt;&lt;/td&gt;
    &lt;td style="width: 9.8pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 11.25pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 63pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 12.8pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9.75pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 64.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 0.1in"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--OperatingLeaseRightOfUseAsset_i01I_zf5monxP8L92" style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td style="padding-left: 28.25pt; text-indent: -9.45pt"&gt;Operating lease right-of-use assets&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;3,786,545&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;95,553&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-left: 28.25pt; text-indent: -9.45pt"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--OperatingLeaseLiabilityCurrent_i01I_zQ08LsJOEJi5" style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td style="padding-left: 28.25pt; text-indent: -9.45pt"&gt;Operating lease liability &#x2013; current&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;345,834&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;95,553&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--OperatingLeaseLiabilityNoncurrent_i01I_zfJUy2reio28" style="vertical-align: bottom"&gt;
    &lt;td style="padding-left: 28.25pt; text-indent: -9.45pt"&gt;Operating lease liability, net of current portion&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;3,653,257&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1057"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--OperatingLeaseLiability_i01I_ziKLJsgAbEh5" style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td style="padding-left: 9.1pt; text-indent: -9.1pt"&gt;Total operating lease liabilities&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;3,999,091&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;95,553&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-left: 9.1pt; text-indent: -9.1pt"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_ecustom--AssetsAndLiabilitiesLesseeFinanceAbstract_iB_z86pRnOO118" style="vertical-align: bottom"&gt;
    &lt;td style="padding-left: 9.1pt; text-indent: -9.1pt"&gt;&lt;b&gt;Finance Leases&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--PropertyPlantAndEquipmentOther_i01I_zkshvzRWwsV7" style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td style="padding-left: 28.25pt; text-indent: -9.45pt"&gt;Property and equipment, at cost&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;544,468&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;12,725&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--PropertyPlantAndEquipmentOtherAccumulatedDepreciation_i01NI_di_zgPCpK3uctT4" style="vertical-align: bottom"&gt;
    &lt;td style="padding-left: 28.25pt; text-indent: -9.45pt"&gt;Accumulated depreciation&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;(50,895&lt;/td&gt;
    &lt;td&gt;)&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;(12,725&lt;/td&gt;
    &lt;td&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--PropertyPlantAndEquipmentOtherNet_i01I_zow00fF4O8Z" style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td style="padding-left: 28.25pt; text-indent: -9.45pt"&gt;Property and equipment, net&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;493,573&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1072"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--FinanceLeaseLiabilityCurrent_iI_ztoM1PT0aWsc" style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td style="padding-left: 28.25pt; text-indent: -9.45pt"&gt;Finance lease liability &#x2013; current&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;98,335&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1075"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--FinanceLeaseLiabilityNoncurrent_iI_z0GlI9AHfFLh" style="vertical-align: bottom"&gt;
    &lt;td style="padding-left: 28.25pt; text-indent: -9.45pt"&gt;Finance lease liability, net of current portion&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;394,283&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1078"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--FinanceLeaseLiability_iI_zlJaUSV2xXHj" style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td style="padding-left: 9.1pt; text-indent: -9.1pt"&gt;Total finance lease liabilities&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;492,618&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1081"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 5.5in; border-collapse: collapse"&gt;
  &lt;tr style="background-color: white"&gt;
    &lt;td style="vertical-align: bottom; width: 218.25pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; width: 9.75pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; vertical-align: bottom; width: 74.25pt; text-align: center"&gt;&lt;b&gt;December 31,&lt;br/&gt;
2022&lt;/b&gt;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; width: 11.25pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; vertical-align: top; width: 74.25pt; text-align: center"&gt;&lt;b&gt;December 31,&lt;br/&gt;
2021&lt;/b&gt;&lt;/td&gt;
    &lt;td style="vertical-align: top; width: 0.1in"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="background-color: #E6E6E6"&gt;
    &lt;td style="vertical-align: bottom"&gt;&lt;b&gt;Weighted Average Remaining Lease Term&lt;/b&gt;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="background-color: white"&gt;
    &lt;td style="vertical-align: bottom; padding-left: 28.25pt; text-indent: -9.45pt"&gt;Operating leases&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_908_eus-gaap--LesseeOperatingLeaseRenewalTerm_iI_dxL_c20221231_zArCYc8v9ij" title="Operating leases::XDX::P9Y8M12D"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1083"&gt;9.7&lt;/span&gt;&lt;/span&gt; Years&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--LesseeOperatingLeaseRenewalTerm_iI_dxL_c20211231_zTyjDwcAZdKf" title="Operating leases::XDX::P0Y7M6D"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1085"&gt;0.6&lt;/span&gt;&lt;/span&gt; Years&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="background-color: #E6E6E6"&gt;
    &lt;td style="vertical-align: bottom; padding-left: 28.25pt; text-indent: -9.45pt"&gt;Finance leases&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_90D_eus-gaap--LesseeFinanceLeaseRenewalTerm1_iI_dxL_c20221231_zGKlAStG3FY" title="Finance leases::XDX::P4Y0M22D"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1087"&gt;4.6&lt;/span&gt;&lt;/span&gt; Years&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: right"&gt;&lt;span id="xdx_90A_eus-gaap--LesseeFinanceLeaseRenewalTerm1_iI_dxL_c20211231_zrQaTiaSzknd" title="Finance leases::XDX::P0Y0M0D"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1089"&gt;0&lt;/span&gt;&lt;/span&gt; Years&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="background-color: white"&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="background-color: #E6E6E6"&gt;
    &lt;td style="vertical-align: bottom"&gt;&lt;b&gt;Weighted Average Discount Rate&lt;/b&gt;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="background-color: white"&gt;
    &lt;td style="vertical-align: bottom; padding-left: 28.25pt; text-indent: -9.45pt"&gt;Operating leases&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; text-align: right"&gt;&lt;span id="xdx_90C_eus-gaap--LesseeOperatingLeaseDiscountRate_iI_pid_dp_uPure_c20221231_zg4uFdZV446l" title="Operating leases"&gt;4.00&lt;/span&gt;%&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: right"&gt;&lt;span id="xdx_90C_eus-gaap--LesseeOperatingLeaseDiscountRate_iI_pid_dp_uPure_c20211231_zJtJWBxHewic" title="Operating leases"&gt;4.75&lt;/span&gt;%&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="background-color: #E6E6E6"&gt;
    &lt;td style="vertical-align: bottom; padding-left: 28.25pt; text-indent: -9.45pt"&gt;Finance leases&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; text-align: right"&gt;&lt;span id="xdx_90A_eus-gaap--LesseeFinanceLeaseDiscountRate_iI_pid_dp_uPure_c20221231_zwKlu2rO5mQl" title="Finance leases"&gt;4.25&lt;/span&gt;%&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--LesseeFinanceLeaseDiscountRate_iI_pid_dp_uPure_c20211231_z89nbAXUapO4" title="Finance leases"&gt;4.75&lt;/span&gt;%&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p id="xdx_8A8_zJsGcKQZ7H0b" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_894_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_zJzeWiAT4h1l" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;Maturities of lease liabilities are as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span id="xdx_8B0_zPfztqAP7W4f" style="display: none; visibility: hidden"&gt;Schedule of maturities of lease liabilities&lt;/span&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"/&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 5.5in; border-collapse: collapse"&gt;
  &lt;tr&gt;
    &lt;td style="border-bottom: black 1pt solid; vertical-align: bottom"&gt;&lt;b&gt;Year Ending December 31,&lt;/b&gt;&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: center"&gt;&lt;b&gt;Operating Leases&lt;/b&gt;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: center"&gt;&lt;b&gt;Finance Leases&lt;/b&gt;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td style="width: 210.7pt"&gt;2023&lt;/td&gt;
    &lt;td style="width: 7pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 13.95pt"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98C_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_c20221231_zbdREWlyjfga" style="width: 67.6pt; text-align: right" title="2023"&gt;499,503&lt;/td&gt;
    &lt;td style="width: 10.2pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 7pt"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98E_eus-gaap--FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_iI_c20221231_zDBrss7U5qb" style="width: 62.05pt; text-align: right" title="2023"&gt;123,200&lt;/td&gt;
    &lt;td style="width: 8.75pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom"&gt;2024&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_984_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_c20221231_zfrLp93TJoi7" style="vertical-align: bottom; text-align: right" title="2024"&gt;499,503&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98D_eus-gaap--FinanceLeaseLiabilityPaymentsDueYearTwo_iI_c20221231_zqwZr9c5qS4c" style="vertical-align: bottom; text-align: right" title="2024"&gt;123,200&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="background-color: #E6E6E6"&gt;
    &lt;td style="vertical-align: bottom"&gt;2025&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98F_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_c20221231_z6e6Jx5PulYk" style="vertical-align: bottom; text-align: right" title="2025"&gt;499,503&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_988_eus-gaap--FinanceLeaseLiabilityPaymentsDueYearThree_iI_c20221231_zfR57toQFVqh" style="vertical-align: bottom; text-align: right" title="2025"&gt;123,200&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom"&gt;2026&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_985_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFour_iI_c20221231_znlIyIwgCNF8" style="vertical-align: bottom; text-align: right" title="2026"&gt;499,503&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98E_eus-gaap--FinanceLeaseLiabilityPaymentsDueYearFour_iI_c20221231_zDrWXBFtwpB7" style="vertical-align: bottom; text-align: right" title="2026"&gt;123,200&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="background-color: #E6E6E6"&gt;
    &lt;td style="vertical-align: bottom"&gt;2027&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98F_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFive_iI_c20221231_zW6ywYksJDz3" style="vertical-align: bottom; text-align: right" title="2027"&gt;499,503&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_983_eus-gaap--FinanceLeaseLiabilityPaymentsDueYearFive_iI_c20221231_zFhCRsXANDZ4" style="vertical-align: bottom; text-align: right" title="2027"&gt;65,957&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom"&gt;Thereafter&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_987_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_iI_c20221231_zbg3rVA8sdA3" style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: right" title="Thereafter"&gt;2,331,015&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98B_eus-gaap--FinanceLeaseLiabilityPaymentsDueAfterYearFive_iI_c20221231_zQFXPu2ksYAf" style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: right" title="Thereafter"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1123"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="background-color: #E6E6E6"&gt;
    &lt;td style="vertical-align: bottom"&gt;Total undiscounted lease payments&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_980_ecustom--LesseeOperatingLeaseLiabilityPaymentsDueTotal_iI_c20221231_zLPcSKlSzTzc" style="vertical-align: bottom; text-align: right" title="Total undiscounted lease payments"&gt;4,828,530&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98B_ecustom--LesseeFinancingLeaseLeaseLiabilityPaymentsDueTotal_iI_c20221231_z5kCzifwgWPj" style="vertical-align: bottom; text-align: right" title="Total undiscounted lease payments"&gt;558,757&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; padding-left: 18.8pt"&gt;Less: imputed interest&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98B_ecustom--LesseeOperatingLeaseImputedInterest_iNI_di_c20221231_zODxEvreSjwd" style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: right" title="Less: imputed interest"&gt;(829,439&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;)&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_985_ecustom--LesseeFinancingLeaseImputedInterest_iNI_di_c20221231_zAhvBU1ADOQc" style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: right" title="Less: imputed interest"&gt;(66,139&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="background-color: #E6E6E6"&gt;
    &lt;td style="vertical-align: bottom"&gt;Total lease liabilities&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; vertical-align: bottom"&gt;$&lt;/td&gt;
    &lt;td id="xdx_98C_eus-gaap--OperatingLeaseLiability_iI_c20221231_zbVRBidywo6k" style="border-bottom: black 2.25pt double; vertical-align: bottom; text-align: right" title="Total lease liabilities"&gt;3,999,091&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; vertical-align: bottom"&gt;$&lt;/td&gt;
    &lt;td id="xdx_981_eus-gaap--FinanceLeaseLiability_iI_c20221231_zHnd4FjVhccl" style="border-bottom: black 2.25pt double; vertical-align: bottom; text-align: right" title="Total lease liabilities"&gt;492,618&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p id="xdx_8A8_zkXgyaoYOY7h" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

</us-gaap:LeasesOfLesseeDisclosureTextBlock>
    <krmd:DescriptionOfLessorOperatingLeaseTerm contextRef="From2022-01-01to2022-12-31">Our leases have remaining lease terms of 10, 5 years, and 3 months.</krmd:DescriptionOfLessorOperatingLeaseTerm>
    <us-gaap:LeaseCostTableTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_890_eus-gaap--LeaseCostTableTextBlock_z1LTQGqoqzE1" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;The components of lease expense were as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span id="xdx_8BF_zHnufYvIrM98" style="display: none; visibility: hidden"&gt;Schedule of components of lease expense&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 4.75in; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="width: 187.95pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 7.15pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 0.1in; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_494_20220101__20221231_z2p5lB62SXuh" style="width: 56.8pt; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 11.15pt; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 0.1in; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_49B_20210101__20211231_zjrgEIxHcU5c" style="width: 57.4pt; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 7.15pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="5" style="text-align: center"&gt;&lt;b&gt;Years Ended&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="5" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;December 31,&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;2022&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;2021&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--OperatingLeaseCost_maLCzGTc_zUsXlNVmwuB6" style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td&gt;Operating lease cost&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;514,294&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;149,476&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--ShortTermLeaseCost_maLCzGTc_zSAnfqySRBt5" style="vertical-align: bottom"&gt;
    &lt;td&gt;Short-term lease cost&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;131,490&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;146,604&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--LeaseCost_zvUJoX9MAcG7" style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td&gt;Total lease cost&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-top: black 1pt solid; border-bottom: black 2.25pt double"&gt;$&lt;/td&gt;
    &lt;td style="border-top: black 1pt solid; border-bottom: black 2.25pt double; text-align: right"&gt;645,784&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-top: black 1pt solid; border-bottom: black 2.25pt double"&gt;$&lt;/td&gt;
    &lt;td style="border-top: black 1pt solid; border-bottom: black 2.25pt double; text-align: right"&gt;296,080&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_ecustom--FinanceLeaseCost1Abstract_iB_zWFaUUVzptO8" style="vertical-align: bottom"&gt;
    &lt;td style="padding-left: 9.1pt; text-indent: -9.1pt"&gt;Finance lease cost:&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--FinanceLeaseRightOfUseAssetAmortization_i01_maFLCzAT2_zftg6rMSJ8Qg" style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td style="padding-left: 27.5pt; text-indent: -9.1pt"&gt;Amortization of right-of-use assets&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;50,895&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;2,586&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--FinanceLeaseInterestExpense_i01_maFLCzAT2_zDR8tEDw9AQ5" style="vertical-align: bottom"&gt;
    &lt;td style="padding-left: 27.5pt; text-indent: -9.1pt"&gt;Interest on lease liabilities&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;5,393&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;60&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_ecustom--FinanceLeaseCost_i01_zD2FyidY27S9" style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td&gt;Total finance lease cost&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-top: black 1pt solid; border-bottom: black 2.25pt double"&gt;$&lt;/td&gt;
    &lt;td style="border-top: black 1pt solid; border-bottom: black 2.25pt double; text-align: right"&gt;56,288&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-top: black 1pt solid; border-bottom: black 2.25pt double"&gt;$&lt;/td&gt;
    &lt;td style="border-top: black 1pt solid; border-bottom: black 2.25pt double; text-align: right"&gt;2,646&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseCost
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">514294</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">149476</us-gaap:OperatingLeaseCost>
    <us-gaap:ShortTermLeaseCost
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">131490</us-gaap:ShortTermLeaseCost>
    <us-gaap:ShortTermLeaseCost
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">146604</us-gaap:ShortTermLeaseCost>
    <us-gaap:LeaseCost
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">645784</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">296080</us-gaap:LeaseCost>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">50895</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">2586</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <us-gaap:FinanceLeaseInterestExpense
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">5393</us-gaap:FinanceLeaseInterestExpense>
    <us-gaap:FinanceLeaseInterestExpense
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">60</us-gaap:FinanceLeaseInterestExpense>
    <krmd:FinanceLeaseCost
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">56288</krmd:FinanceLeaseCost>
    <krmd:FinanceLeaseCost
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">2646</krmd:FinanceLeaseCost>
    <us-gaap:OperatingLeaseLeaseIncomeTableTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_899_eus-gaap--OperatingLeaseLeaseIncomeTableTextBlock_zEHge4wXvGc" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;Supplemental cash flow information related to leases was as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span id="xdx_8BB_zz98rsQUoiYj" style="display: none; visibility: hidden"&gt;Schedule of cash flow information related to leases&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 4.75in; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="width: 190pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 6.8pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 7.1pt; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_49D_20220101__20221231_zvEQSh5ueQsi" style="width: 56.1pt; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 12pt; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 7.1pt; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_491_20210101__20211231_zqBJ41jFceVb" style="width: 55.9pt; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 6.8pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="5" style="text-align: center"&gt;&lt;b&gt;Years Ended&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="5" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;December 31,&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;2022&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;2021&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--CashFlowOperatingActivitiesLesseeAbstract_iB" style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td style="padding-left: 9.45pt; text-indent: -9.45pt"&gt;Cash paid for amounts included in the measurement of lease liabilities:&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--OperatingLeasePayments_i01_z2KIYtKYcSo1" style="vertical-align: bottom"&gt;
    &lt;td&gt;Operating cash flows from operating leases&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;247,504&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;141,293&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--FinanceLeaseInterestPaymentOnLiability_i01_zqOSMHTnsu29" style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td&gt;Financing cash flows from finance leases&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;57,243&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;2,646&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
</us-gaap:OperatingLeaseLeaseIncomeTableTextBlock>
    <us-gaap:OperatingLeasePayments
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">247504</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">141293</us-gaap:OperatingLeasePayments>
    <us-gaap:FinanceLeaseInterestPaymentOnLiability
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">57243</us-gaap:FinanceLeaseInterestPaymentOnLiability>
    <us-gaap:FinanceLeaseInterestPaymentOnLiability
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">2646</us-gaap:FinanceLeaseInterestPaymentOnLiability>
    <us-gaap:OperatingLeasesOfLesseeDisclosureTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_899_eus-gaap--OperatingLeasesOfLesseeDisclosureTextBlock_zBDoScivKUk9" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;Supplemental balance sheet information related to leases was as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span id="xdx_8B9_zhDohtT1ePmd" style="display: none; visibility: hidden"&gt;Schdeule of balance sheet information related to leases&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 5.5in; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49B_20221231_z8ahI5LaIsN6" style="border-bottom: black 1pt solid; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_498_20211231_zerdUjqQqiPc" style="border-bottom: black 1pt solid; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;December 31,&lt;br/&gt;
2022&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;December 31,&lt;br/&gt;
2021&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_ecustom--AssetsAndLiabilitiesOperatingLesseeAbstract_iB_zY2BfEyxuXfl" style="vertical-align: bottom"&gt;
    &lt;td style="width: 217.3pt; padding-left: 9.1pt; text-indent: -9.1pt"&gt;&lt;b&gt;Operating Leases&lt;/b&gt;&lt;/td&gt;
    &lt;td style="width: 9.8pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 11.25pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 63pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 12.8pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9.75pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 64.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 0.1in"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--OperatingLeaseRightOfUseAsset_i01I_zf5monxP8L92" style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td style="padding-left: 28.25pt; text-indent: -9.45pt"&gt;Operating lease right-of-use assets&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;3,786,545&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;95,553&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-left: 28.25pt; text-indent: -9.45pt"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--OperatingLeaseLiabilityCurrent_i01I_zQ08LsJOEJi5" style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td style="padding-left: 28.25pt; text-indent: -9.45pt"&gt;Operating lease liability &#x2013; current&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;345,834&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;95,553&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--OperatingLeaseLiabilityNoncurrent_i01I_zfJUy2reio28" style="vertical-align: bottom"&gt;
    &lt;td style="padding-left: 28.25pt; text-indent: -9.45pt"&gt;Operating lease liability, net of current portion&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;3,653,257&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1057"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--OperatingLeaseLiability_i01I_ziKLJsgAbEh5" style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td style="padding-left: 9.1pt; text-indent: -9.1pt"&gt;Total operating lease liabilities&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;3,999,091&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;95,553&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-left: 9.1pt; text-indent: -9.1pt"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_ecustom--AssetsAndLiabilitiesLesseeFinanceAbstract_iB_z86pRnOO118" style="vertical-align: bottom"&gt;
    &lt;td style="padding-left: 9.1pt; text-indent: -9.1pt"&gt;&lt;b&gt;Finance Leases&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--PropertyPlantAndEquipmentOther_i01I_zkshvzRWwsV7" style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td style="padding-left: 28.25pt; text-indent: -9.45pt"&gt;Property and equipment, at cost&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;544,468&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;12,725&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--PropertyPlantAndEquipmentOtherAccumulatedDepreciation_i01NI_di_zgPCpK3uctT4" style="vertical-align: bottom"&gt;
    &lt;td style="padding-left: 28.25pt; text-indent: -9.45pt"&gt;Accumulated depreciation&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;(50,895&lt;/td&gt;
    &lt;td&gt;)&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;(12,725&lt;/td&gt;
    &lt;td&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--PropertyPlantAndEquipmentOtherNet_i01I_zow00fF4O8Z" style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td style="padding-left: 28.25pt; text-indent: -9.45pt"&gt;Property and equipment, net&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;493,573&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1072"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--FinanceLeaseLiabilityCurrent_iI_ztoM1PT0aWsc" style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td style="padding-left: 28.25pt; text-indent: -9.45pt"&gt;Finance lease liability &#x2013; current&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;98,335&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1075"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--FinanceLeaseLiabilityNoncurrent_iI_z0GlI9AHfFLh" style="vertical-align: bottom"&gt;
    &lt;td style="padding-left: 28.25pt; text-indent: -9.45pt"&gt;Finance lease liability, net of current portion&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;394,283&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1078"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--FinanceLeaseLiability_iI_zlJaUSV2xXHj" style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td style="padding-left: 9.1pt; text-indent: -9.1pt"&gt;Total finance lease liabilities&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;492,618&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1081"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 5.5in; border-collapse: collapse"&gt;
  &lt;tr style="background-color: white"&gt;
    &lt;td style="vertical-align: bottom; width: 218.25pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; width: 9.75pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; vertical-align: bottom; width: 74.25pt; text-align: center"&gt;&lt;b&gt;December 31,&lt;br/&gt;
2022&lt;/b&gt;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; width: 11.25pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; vertical-align: top; width: 74.25pt; text-align: center"&gt;&lt;b&gt;December 31,&lt;br/&gt;
2021&lt;/b&gt;&lt;/td&gt;
    &lt;td style="vertical-align: top; width: 0.1in"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="background-color: #E6E6E6"&gt;
    &lt;td style="vertical-align: bottom"&gt;&lt;b&gt;Weighted Average Remaining Lease Term&lt;/b&gt;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="background-color: white"&gt;
    &lt;td style="vertical-align: bottom; padding-left: 28.25pt; text-indent: -9.45pt"&gt;Operating leases&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_908_eus-gaap--LesseeOperatingLeaseRenewalTerm_iI_dxL_c20221231_zArCYc8v9ij" title="Operating leases::XDX::P9Y8M12D"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1083"&gt;9.7&lt;/span&gt;&lt;/span&gt; Years&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--LesseeOperatingLeaseRenewalTerm_iI_dxL_c20211231_zTyjDwcAZdKf" title="Operating leases::XDX::P0Y7M6D"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1085"&gt;0.6&lt;/span&gt;&lt;/span&gt; Years&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="background-color: #E6E6E6"&gt;
    &lt;td style="vertical-align: bottom; padding-left: 28.25pt; text-indent: -9.45pt"&gt;Finance leases&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_90D_eus-gaap--LesseeFinanceLeaseRenewalTerm1_iI_dxL_c20221231_zGKlAStG3FY" title="Finance leases::XDX::P4Y0M22D"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1087"&gt;4.6&lt;/span&gt;&lt;/span&gt; Years&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: right"&gt;&lt;span id="xdx_90A_eus-gaap--LesseeFinanceLeaseRenewalTerm1_iI_dxL_c20211231_zrQaTiaSzknd" title="Finance leases::XDX::P0Y0M0D"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1089"&gt;0&lt;/span&gt;&lt;/span&gt; Years&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="background-color: white"&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="background-color: #E6E6E6"&gt;
    &lt;td style="vertical-align: bottom"&gt;&lt;b&gt;Weighted Average Discount Rate&lt;/b&gt;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="background-color: white"&gt;
    &lt;td style="vertical-align: bottom; padding-left: 28.25pt; text-indent: -9.45pt"&gt;Operating leases&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; text-align: right"&gt;&lt;span id="xdx_90C_eus-gaap--LesseeOperatingLeaseDiscountRate_iI_pid_dp_uPure_c20221231_zg4uFdZV446l" title="Operating leases"&gt;4.00&lt;/span&gt;%&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: right"&gt;&lt;span id="xdx_90C_eus-gaap--LesseeOperatingLeaseDiscountRate_iI_pid_dp_uPure_c20211231_zJtJWBxHewic" title="Operating leases"&gt;4.75&lt;/span&gt;%&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="background-color: #E6E6E6"&gt;
    &lt;td style="vertical-align: bottom; padding-left: 28.25pt; text-indent: -9.45pt"&gt;Finance leases&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; text-align: right"&gt;&lt;span id="xdx_90A_eus-gaap--LesseeFinanceLeaseDiscountRate_iI_pid_dp_uPure_c20221231_zwKlu2rO5mQl" title="Finance leases"&gt;4.25&lt;/span&gt;%&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--LesseeFinanceLeaseDiscountRate_iI_pid_dp_uPure_c20211231_z89nbAXUapO4" title="Finance leases"&gt;4.75&lt;/span&gt;%&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
</us-gaap:OperatingLeasesOfLesseeDisclosureTextBlock>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">3786545</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">95553</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">345834</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">95553</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">3653257</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiability contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">3999091</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiability contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">95553</us-gaap:OperatingLeaseLiability>
    <us-gaap:PropertyPlantAndEquipmentOther contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">544468</us-gaap:PropertyPlantAndEquipmentOther>
    <us-gaap:PropertyPlantAndEquipmentOther contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">12725</us-gaap:PropertyPlantAndEquipmentOther>
    <us-gaap:PropertyPlantAndEquipmentOtherAccumulatedDepreciation contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">50895</us-gaap:PropertyPlantAndEquipmentOtherAccumulatedDepreciation>
    <us-gaap:PropertyPlantAndEquipmentOtherAccumulatedDepreciation contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">12725</us-gaap:PropertyPlantAndEquipmentOtherAccumulatedDepreciation>
    <us-gaap:PropertyPlantAndEquipmentOtherNet contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">493573</us-gaap:PropertyPlantAndEquipmentOtherNet>
    <us-gaap:FinanceLeaseLiabilityCurrent contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">98335</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">394283</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:FinanceLeaseLiability contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">492618</us-gaap:FinanceLeaseLiability>
    <us-gaap:LesseeOperatingLeaseDiscountRate contextRef="AsOf2022-12-31" decimals="INF" unitRef="Pure">0.0400</us-gaap:LesseeOperatingLeaseDiscountRate>
    <us-gaap:LesseeOperatingLeaseDiscountRate contextRef="AsOf2021-12-31" decimals="INF" unitRef="Pure">0.0475</us-gaap:LesseeOperatingLeaseDiscountRate>
    <us-gaap:LesseeFinanceLeaseDiscountRate contextRef="AsOf2022-12-31" decimals="INF" unitRef="Pure">0.0425</us-gaap:LesseeFinanceLeaseDiscountRate>
    <us-gaap:LesseeFinanceLeaseDiscountRate contextRef="AsOf2021-12-31" decimals="INF" unitRef="Pure">0.0475</us-gaap:LesseeFinanceLeaseDiscountRate>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_894_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_zJzeWiAT4h1l" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;Maturities of lease liabilities are as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span id="xdx_8B0_zPfztqAP7W4f" style="display: none; visibility: hidden"&gt;Schedule of maturities of lease liabilities&lt;/span&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"/&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 5.5in; border-collapse: collapse"&gt;
  &lt;tr&gt;
    &lt;td style="border-bottom: black 1pt solid; vertical-align: bottom"&gt;&lt;b&gt;Year Ending December 31,&lt;/b&gt;&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: center"&gt;&lt;b&gt;Operating Leases&lt;/b&gt;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: center"&gt;&lt;b&gt;Finance Leases&lt;/b&gt;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td style="width: 210.7pt"&gt;2023&lt;/td&gt;
    &lt;td style="width: 7pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 13.95pt"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98C_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_c20221231_zbdREWlyjfga" style="width: 67.6pt; text-align: right" title="2023"&gt;499,503&lt;/td&gt;
    &lt;td style="width: 10.2pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 7pt"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98E_eus-gaap--FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_iI_c20221231_zDBrss7U5qb" style="width: 62.05pt; text-align: right" title="2023"&gt;123,200&lt;/td&gt;
    &lt;td style="width: 8.75pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom"&gt;2024&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_984_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_c20221231_zfrLp93TJoi7" style="vertical-align: bottom; text-align: right" title="2024"&gt;499,503&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98D_eus-gaap--FinanceLeaseLiabilityPaymentsDueYearTwo_iI_c20221231_zqwZr9c5qS4c" style="vertical-align: bottom; text-align: right" title="2024"&gt;123,200&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="background-color: #E6E6E6"&gt;
    &lt;td style="vertical-align: bottom"&gt;2025&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98F_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_c20221231_z6e6Jx5PulYk" style="vertical-align: bottom; text-align: right" title="2025"&gt;499,503&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_988_eus-gaap--FinanceLeaseLiabilityPaymentsDueYearThree_iI_c20221231_zfR57toQFVqh" style="vertical-align: bottom; text-align: right" title="2025"&gt;123,200&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom"&gt;2026&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_985_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFour_iI_c20221231_znlIyIwgCNF8" style="vertical-align: bottom; text-align: right" title="2026"&gt;499,503&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98E_eus-gaap--FinanceLeaseLiabilityPaymentsDueYearFour_iI_c20221231_zDrWXBFtwpB7" style="vertical-align: bottom; text-align: right" title="2026"&gt;123,200&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="background-color: #E6E6E6"&gt;
    &lt;td style="vertical-align: bottom"&gt;2027&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98F_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFive_iI_c20221231_zW6ywYksJDz3" style="vertical-align: bottom; text-align: right" title="2027"&gt;499,503&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_983_eus-gaap--FinanceLeaseLiabilityPaymentsDueYearFive_iI_c20221231_zFhCRsXANDZ4" style="vertical-align: bottom; text-align: right" title="2027"&gt;65,957&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom"&gt;Thereafter&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_987_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_iI_c20221231_zbg3rVA8sdA3" style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: right" title="Thereafter"&gt;2,331,015&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98B_eus-gaap--FinanceLeaseLiabilityPaymentsDueAfterYearFive_iI_c20221231_zQFXPu2ksYAf" style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: right" title="Thereafter"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1123"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="background-color: #E6E6E6"&gt;
    &lt;td style="vertical-align: bottom"&gt;Total undiscounted lease payments&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_980_ecustom--LesseeOperatingLeaseLiabilityPaymentsDueTotal_iI_c20221231_zLPcSKlSzTzc" style="vertical-align: bottom; text-align: right" title="Total undiscounted lease payments"&gt;4,828,530&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98B_ecustom--LesseeFinancingLeaseLeaseLiabilityPaymentsDueTotal_iI_c20221231_z5kCzifwgWPj" style="vertical-align: bottom; text-align: right" title="Total undiscounted lease payments"&gt;558,757&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; padding-left: 18.8pt"&gt;Less: imputed interest&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98B_ecustom--LesseeOperatingLeaseImputedInterest_iNI_di_c20221231_zODxEvreSjwd" style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: right" title="Less: imputed interest"&gt;(829,439&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;)&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_985_ecustom--LesseeFinancingLeaseImputedInterest_iNI_di_c20221231_zAhvBU1ADOQc" style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: right" title="Less: imputed interest"&gt;(66,139&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="background-color: #E6E6E6"&gt;
    &lt;td style="vertical-align: bottom"&gt;Total lease liabilities&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; vertical-align: bottom"&gt;$&lt;/td&gt;
    &lt;td id="xdx_98C_eus-gaap--OperatingLeaseLiability_iI_c20221231_zbVRBidywo6k" style="border-bottom: black 2.25pt double; vertical-align: bottom; text-align: right" title="Total lease liabilities"&gt;3,999,091&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; vertical-align: bottom"&gt;$&lt;/td&gt;
    &lt;td id="xdx_981_eus-gaap--FinanceLeaseLiability_iI_c20221231_zHnd4FjVhccl" style="border-bottom: black 2.25pt double; vertical-align: bottom; text-align: right" title="Total lease liabilities"&gt;492,618&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">499503</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">123200</us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">499503</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">123200</us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">499503</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearThree contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">123200</us-gaap:FinanceLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">499503</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearFour contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">123200</us-gaap:FinanceLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">499503</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearFive contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">65957</us-gaap:FinanceLeaseLiabilityPaymentsDueYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">2331015</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive>
    <krmd:LesseeOperatingLeaseLiabilityPaymentsDueTotal contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">4828530</krmd:LesseeOperatingLeaseLiabilityPaymentsDueTotal>
    <krmd:LesseeFinancingLeaseLeaseLiabilityPaymentsDueTotal contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">558757</krmd:LesseeFinancingLeaseLeaseLiabilityPaymentsDueTotal>
    <krmd:LesseeOperatingLeaseImputedInterest contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">829439</krmd:LesseeOperatingLeaseImputedInterest>
    <krmd:LesseeFinancingLeaseImputedInterest contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">66139</krmd:LesseeFinancingLeaseImputedInterest>
    <us-gaap:OperatingLeaseLiability contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">3999091</us-gaap:OperatingLeaseLiability>
    <us-gaap:FinanceLeaseLiability contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">492618</us-gaap:FinanceLeaseLiability>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_801_eus-gaap--IncomeTaxDisclosureTextBlock_zlWt42gbfGN2" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;NOTE 6 &#x2014; &lt;span id="xdx_822_zaj4n2rmGLn4"&gt;FEDERAL AND STATE INCOME TAXES&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_899_eus-gaap--ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_zglEySmcueM1" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;Income tax expense consisted of the following:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span id="xdx_8BE_zsMQiuMp5bRh" style="display: none; visibility: hidden"&gt;Schedule of provision for income taxes&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 4.5in; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_496_20220101__20221231_zuCjSxBaV0T6" style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49E_20210101__20211231_z9VxYzvHVC4f" style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;Year Ended&lt;br/&gt;
December 31,&lt;br/&gt;
2022&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;Year Ended&lt;br/&gt;
December 31,&lt;br/&gt;
2021&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--StateAndLocalIncomeTaxExpenseBenefitContinuingOperationsAbstract_iB_zpVHNQEH2yh8" style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;State income tax:&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--CurrentStateAndLocalTaxExpenseBenefit_zuRz3QqK79eg" style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td style="width: 145.15pt; padding-left: 21.8pt"&gt;Current, net of refund&lt;/td&gt;
    &lt;td style="width: 8.25pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 8.25pt"&gt;$&lt;/td&gt;
    &lt;td style="width: 63.75pt; text-align: right"&gt;0&lt;/td&gt;
    &lt;td style="width: 17.3pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 8.25pt"&gt;$&lt;/td&gt;
    &lt;td style="width: 64.5pt; text-align: right"&gt;(12,800&lt;/td&gt;
    &lt;td style="width: 8.25pt"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--FederalIncomeTaxExpenseBenefitContinuingOperationsAbstract_iB_zgNMkE8zBaDc" style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;Federal income tax:&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--DeferredFederalIncomeTaxExpenseBenefit_zuGwJOXBnkO" style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td style="padding-left: 21.8pt"&gt;Deferred&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;2,014,018&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;1,814,418&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--CurrentFederalTaxExpenseBenefit_zR3uewbkPO6l" style="vertical-align: bottom; background-color: white"&gt;
    &lt;td style="padding-left: 21.8pt"&gt;Current&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1153"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1154"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td&gt;Income tax benefit/(expense)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;$&lt;/td&gt;
    &lt;td id="xdx_987_eus-gaap--IncomeTaxExpenseBenefit_iN_dixL_c20220101__20221231_z0H20cITsBPk" style="border-bottom: black 2.25pt double; text-align: right" title="Income tax benefit/(expense)::XDX::2014018"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1156"&gt;2,014,018&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: white 2.25pt double"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;$&lt;/td&gt;
    &lt;td id="xdx_98E_eus-gaap--IncomeTaxExpenseBenefit_iN_di_c20210101__20211231_zwg8wpJI77sk" style="border-bottom: black 2.25pt double; text-align: right" title="Income tax benefit/(expense)"&gt;1,801,618&lt;/td&gt;
    &lt;td style="border-bottom: white 2.25pt double"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p id="xdx_8A4_z9Z1GHVHUYtg" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;



&lt;p id="xdx_898_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zUMt6iPfMcs4" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;The reconciliation of income taxes shown in the financial statements and
amounts computed by applying the Federal expected tax rate of 21% for year 2022 and 2021 is as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span id="xdx_8BF_zfXXktFPaDB4" style="display: none; visibility: hidden"&gt;Schedule of reconciliation of income taxes&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 5.5in; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_497_20220101__20221231_zZfBG566rN03" style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49D_20210101__20211231_zbbvnlqEnBN7" style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;Year Ended&lt;br/&gt;
December 31,&lt;br/&gt;
2022&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;Year Ended&lt;br/&gt;
December 31,&lt;br/&gt;
2021&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_zkkH8IRj2kNg" style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td style="width: 217.2pt"&gt;Loss before taxes&lt;/td&gt;
    &lt;td style="width: 8.3pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; width: 8.25pt"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; width: 65.25pt; text-align: right"&gt;(10,675,160&lt;/td&gt;
    &lt;td style="border-bottom: white 2.25pt double; width: 17.3pt"&gt;)&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; width: 7.5pt"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; width: 63.75pt; text-align: right"&gt;(6,364,441&lt;/td&gt;
    &lt;td style="border-bottom: white 2.25pt double; width: 8.25pt"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_zFpk8I5fX0u3" style="vertical-align: bottom"&gt;
    &lt;td&gt;Income taxes computed at the federal statutory rate&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;2,241,784&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;1,336,533&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--IncomeTaxReconciliationStateAndLocalIncomeTaxes_zYOmqgxXiNCd" style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td&gt;State income and franchise tax&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(0&lt;/td&gt;
    &lt;td&gt;)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(12,800&lt;/td&gt;
    &lt;td&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--IncomeTaxReconciliationOtherAdjustments_znIbNnOLWCgd" style="vertical-align: bottom"&gt;
    &lt;td&gt;Permanent differences and other&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;(227,766&lt;/td&gt;
    &lt;td&gt;)&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;477,885&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td&gt;Income tax benefit/(expense)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;$&lt;/td&gt;
    &lt;td id="xdx_987_eus-gaap--IncomeTaxExpenseBenefit_iN_dixL_c20220101__20221231_zX2yburYThGc" style="border-bottom: black 2.25pt double; text-align: right" title="Income tax benefit/(expense)::XDX::2014018"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1175"&gt;2,014,018&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: white 1.5pt double"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;$&lt;/td&gt;
    &lt;td id="xdx_980_eus-gaap--IncomeTaxExpenseBenefit_iN_di_c20210101__20211231_zvntdnqNBLhj" style="border-bottom: black 2.25pt double; text-align: right" title="Income tax benefit/(expense)"&gt;1,801,618&lt;/td&gt;
    &lt;td style="border-bottom: white 1.5pt double"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p id="xdx_8AF_zMjx34GGqG33" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_894_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zlffzBYaydZ" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;The significant components of deferred income tax assets, net are as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span id="xdx_8B0_za0gIlKRnn84" style="display: none; visibility: hidden"&gt;Schedule of components of deferred tax assets&lt;/span&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 5.5in; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_493_20221231_z7Xum9LAfpOi" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;December 31,&lt;br/&gt;
2022&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49E_20211231_z1A44rbmRDqc" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;December 31,&lt;br/&gt;
2021&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--DeferredCompensationPlanAssets_iI_zt6hAbjnyePh" style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td style="width: 207.9pt"&gt;Deferred compensation cost&lt;/td&gt;
    &lt;td style="width: 0.1in"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 7.35pt"&gt;$&lt;/td&gt;
    &lt;td style="width: 80pt; text-align: right"&gt;557,931&lt;/td&gt;
    &lt;td style="width: 17.15pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 8.05pt"&gt;$&lt;/td&gt;
    &lt;td style="width: 61.1pt; text-align: right"&gt;389,981&lt;/td&gt;
    &lt;td style="width: 7.25pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_ecustom--DepreciationDepletionAndAmortization1_iI_zhEmxRj9hFYd" style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;Depreciation and amortization&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(624,184&lt;/td&gt;
    &lt;td&gt;)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(116,911&lt;/td&gt;
    &lt;td&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_ecustom--RdCredit_zgXcDJvczNKj" style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td&gt;R&amp;amp;D credit&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;142,030&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;142,538&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_ecustom--Nol_zhcYeQUIMA8" style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;NOL&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;2,956,685&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;1,507,982&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_ecustom--AllowanceForDoubtfulOtherReceivables1Current_zuvcrVoDDgo4" style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td&gt;Allowance for bad debts and other&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;935,018&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;17,664&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--DeferredTaxAssetsNet_iI_zNZ0sJT5k5o5" style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;Deferred income tax assets, net&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;3,967,480&lt;/td&gt;
    &lt;td style="border-bottom: white 2.25pt double"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;1,941,254&lt;/td&gt;
    &lt;td style="border-bottom: white 2.25pt double"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p id="xdx_8AF_zunDjj9Fxttg" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;Our U.S. federal and state income tax returns remain open to examination
for the tax years 2019 through 2021.&lt;/p&gt;

</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_899_eus-gaap--ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_zglEySmcueM1" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;Income tax expense consisted of the following:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span id="xdx_8BE_zsMQiuMp5bRh" style="display: none; visibility: hidden"&gt;Schedule of provision for income taxes&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 4.5in; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_496_20220101__20221231_zuCjSxBaV0T6" style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49E_20210101__20211231_z9VxYzvHVC4f" style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;Year Ended&lt;br/&gt;
December 31,&lt;br/&gt;
2022&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;Year Ended&lt;br/&gt;
December 31,&lt;br/&gt;
2021&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--StateAndLocalIncomeTaxExpenseBenefitContinuingOperationsAbstract_iB_zpVHNQEH2yh8" style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;State income tax:&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--CurrentStateAndLocalTaxExpenseBenefit_zuRz3QqK79eg" style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td style="width: 145.15pt; padding-left: 21.8pt"&gt;Current, net of refund&lt;/td&gt;
    &lt;td style="width: 8.25pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 8.25pt"&gt;$&lt;/td&gt;
    &lt;td style="width: 63.75pt; text-align: right"&gt;0&lt;/td&gt;
    &lt;td style="width: 17.3pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 8.25pt"&gt;$&lt;/td&gt;
    &lt;td style="width: 64.5pt; text-align: right"&gt;(12,800&lt;/td&gt;
    &lt;td style="width: 8.25pt"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--FederalIncomeTaxExpenseBenefitContinuingOperationsAbstract_iB_zgNMkE8zBaDc" style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;Federal income tax:&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--DeferredFederalIncomeTaxExpenseBenefit_zuGwJOXBnkO" style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td style="padding-left: 21.8pt"&gt;Deferred&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;2,014,018&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;1,814,418&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--CurrentFederalTaxExpenseBenefit_zR3uewbkPO6l" style="vertical-align: bottom; background-color: white"&gt;
    &lt;td style="padding-left: 21.8pt"&gt;Current&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1153"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1154"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td&gt;Income tax benefit/(expense)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;$&lt;/td&gt;
    &lt;td id="xdx_987_eus-gaap--IncomeTaxExpenseBenefit_iN_dixL_c20220101__20221231_z0H20cITsBPk" style="border-bottom: black 2.25pt double; text-align: right" title="Income tax benefit/(expense)::XDX::2014018"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1156"&gt;2,014,018&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: white 2.25pt double"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;$&lt;/td&gt;
    &lt;td id="xdx_98E_eus-gaap--IncomeTaxExpenseBenefit_iN_di_c20210101__20211231_zwg8wpJI77sk" style="border-bottom: black 2.25pt double; text-align: right" title="Income tax benefit/(expense)"&gt;1,801,618&lt;/td&gt;
    &lt;td style="border-bottom: white 2.25pt double"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">0</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">-12800</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">2014018</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">1814418</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">-1801618</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_898_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zUMt6iPfMcs4" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;The reconciliation of income taxes shown in the financial statements and
amounts computed by applying the Federal expected tax rate of 21% for year 2022 and 2021 is as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span id="xdx_8BF_zfXXktFPaDB4" style="display: none; visibility: hidden"&gt;Schedule of reconciliation of income taxes&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 5.5in; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_497_20220101__20221231_zZfBG566rN03" style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49D_20210101__20211231_zbbvnlqEnBN7" style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;Year Ended&lt;br/&gt;
December 31,&lt;br/&gt;
2022&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;Year Ended&lt;br/&gt;
December 31,&lt;br/&gt;
2021&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_zkkH8IRj2kNg" style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td style="width: 217.2pt"&gt;Loss before taxes&lt;/td&gt;
    &lt;td style="width: 8.3pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; width: 8.25pt"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; width: 65.25pt; text-align: right"&gt;(10,675,160&lt;/td&gt;
    &lt;td style="border-bottom: white 2.25pt double; width: 17.3pt"&gt;)&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; width: 7.5pt"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; width: 63.75pt; text-align: right"&gt;(6,364,441&lt;/td&gt;
    &lt;td style="border-bottom: white 2.25pt double; width: 8.25pt"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_zFpk8I5fX0u3" style="vertical-align: bottom"&gt;
    &lt;td&gt;Income taxes computed at the federal statutory rate&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;2,241,784&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;1,336,533&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--IncomeTaxReconciliationStateAndLocalIncomeTaxes_zYOmqgxXiNCd" style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td&gt;State income and franchise tax&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(0&lt;/td&gt;
    &lt;td&gt;)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(12,800&lt;/td&gt;
    &lt;td&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--IncomeTaxReconciliationOtherAdjustments_znIbNnOLWCgd" style="vertical-align: bottom"&gt;
    &lt;td&gt;Permanent differences and other&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;(227,766&lt;/td&gt;
    &lt;td&gt;)&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;477,885&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td&gt;Income tax benefit/(expense)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;$&lt;/td&gt;
    &lt;td id="xdx_987_eus-gaap--IncomeTaxExpenseBenefit_iN_dixL_c20220101__20221231_zX2yburYThGc" style="border-bottom: black 2.25pt double; text-align: right" title="Income tax benefit/(expense)::XDX::2014018"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1175"&gt;2,014,018&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: white 1.5pt double"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;$&lt;/td&gt;
    &lt;td id="xdx_980_eus-gaap--IncomeTaxExpenseBenefit_iN_di_c20210101__20211231_zvntdnqNBLhj" style="border-bottom: black 2.25pt double; text-align: right" title="Income tax benefit/(expense)"&gt;1,801,618&lt;/td&gt;
    &lt;td style="border-bottom: white 1.5pt double"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">-10675160</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">-6364441</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">2241784</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">1336533</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">-0</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">-12800</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">-227766</us-gaap:IncomeTaxReconciliationOtherAdjustments>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">477885</us-gaap:IncomeTaxReconciliationOtherAdjustments>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">-1801618</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_894_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zlffzBYaydZ" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;The significant components of deferred income tax assets, net are as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span id="xdx_8B0_za0gIlKRnn84" style="display: none; visibility: hidden"&gt;Schedule of components of deferred tax assets&lt;/span&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 5.5in; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_493_20221231_z7Xum9LAfpOi" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;December 31,&lt;br/&gt;
2022&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49E_20211231_z1A44rbmRDqc" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;December 31,&lt;br/&gt;
2021&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--DeferredCompensationPlanAssets_iI_zt6hAbjnyePh" style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td style="width: 207.9pt"&gt;Deferred compensation cost&lt;/td&gt;
    &lt;td style="width: 0.1in"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 7.35pt"&gt;$&lt;/td&gt;
    &lt;td style="width: 80pt; text-align: right"&gt;557,931&lt;/td&gt;
    &lt;td style="width: 17.15pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 8.05pt"&gt;$&lt;/td&gt;
    &lt;td style="width: 61.1pt; text-align: right"&gt;389,981&lt;/td&gt;
    &lt;td style="width: 7.25pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_ecustom--DepreciationDepletionAndAmortization1_iI_zhEmxRj9hFYd" style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;Depreciation and amortization&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(624,184&lt;/td&gt;
    &lt;td&gt;)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(116,911&lt;/td&gt;
    &lt;td&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_ecustom--RdCredit_zgXcDJvczNKj" style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td&gt;R&amp;amp;D credit&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;142,030&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;142,538&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_ecustom--Nol_zhcYeQUIMA8" style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;NOL&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;2,956,685&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;1,507,982&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_ecustom--AllowanceForDoubtfulOtherReceivables1Current_zuvcrVoDDgo4" style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td&gt;Allowance for bad debts and other&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;935,018&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;17,664&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--DeferredTaxAssetsNet_iI_zNZ0sJT5k5o5" style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;Deferred income tax assets, net&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;3,967,480&lt;/td&gt;
    &lt;td style="border-bottom: white 2.25pt double"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;1,941,254&lt;/td&gt;
    &lt;td style="border-bottom: white 2.25pt double"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredCompensationPlanAssets contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">557931</us-gaap:DeferredCompensationPlanAssets>
    <us-gaap:DeferredCompensationPlanAssets contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">389981</us-gaap:DeferredCompensationPlanAssets>
    <krmd:DepreciationDepletionAndAmortization1 contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">-624184</krmd:DepreciationDepletionAndAmortization1>
    <krmd:DepreciationDepletionAndAmortization1 contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">-116911</krmd:DepreciationDepletionAndAmortization1>
    <krmd:RdCredit contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">142030</krmd:RdCredit>
    <krmd:RdCredit contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">142538</krmd:RdCredit>
    <krmd:Nol contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">2956685</krmd:Nol>
    <krmd:Nol contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">1507982</krmd:Nol>
    <krmd:AllowanceForDoubtfulOtherReceivables1Current contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">935018</krmd:AllowanceForDoubtfulOtherReceivables1Current>
    <krmd:AllowanceForDoubtfulOtherReceivables1Current contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">17664</krmd:AllowanceForDoubtfulOtherReceivables1Current>
    <us-gaap:DeferredTaxAssetsNet contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">3967480</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsNet contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">1941254</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:ConcentrationRiskDisclosureTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_807_eus-gaap--ConcentrationRiskDisclosureTextBlock_zp9zL7iFsihl" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;NOTE 7 &#x2014; &lt;span id="xdx_823_zAAZm5feetge"&gt;MAJOR CUSTOMERS&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;For the years ended December 31, 2022 and December 31, 2021,
approximately &lt;span id="xdx_902_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20221231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerOneMember_zQguANDOkgv8" title="Concentration risk, percentage"&gt;64&lt;/span&gt;%
and &lt;span id="xdx_90C_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20210101__20211231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerOneMember_zmwq5IkLWFw9"&gt;64&lt;/span&gt;%,
respectively, of the Company&#x2019;s net product revenues were derived from three major customers that are distributors. &#160;As of
December 31, 2022 and December 31, 2021, accounts receivable due from the three major customers was $2.2 million and $2.1 million,
respectively.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;The largest customer in both years is a domestic medical products and supplies
distributor. &#160;Although, a number of larger infusion customers have elected to consolidate their purchases through one or more distributors
in recent years, we continue to maintain strong direct relationships with them. &#160;We do not believe that their continued purchase
of FREEDOM System products and related supplies is contingent upon the distributor.&lt;/p&gt;

</us-gaap:ConcentrationRiskDisclosureTextBlock>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2022-01-012022-12-31_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerOneMember"
      decimals="INF"
      unitRef="Pure">0.64</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2021-01-012021-12-31_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerOneMember"
      decimals="INF"
      unitRef="Pure">0.64</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_80A_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_zwUo59jiRuq5" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;NOTE 8 &#x2014; &lt;span id="xdx_827_zDSZ7RSQs8rb"&gt;COMMITMENTS AND CONTINGENCIES&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;LEGAL PROCEEDINGS&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;The Company has been and may again become involved in legal proceedings,
claims and litigation arising in the ordinary course of business. &#160;KORU Medical is not presently a party to any litigation or other
legal proceeding that is believed to be material to its financial condition.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;OTHER&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;On November 11, 2020, the Company entered into a Manufacturing and Supply
Agreement with Command Medical Products, Inc. (&#x201c;Command&#x201d;), pursuant to which Command has agreed to manufacture and supply
the Company&#x2019;s subassemblies, needle sets and tubing products pursuant to the Company&#x2019;s specifications and purchase orders.
&#160;The first binding purchase order pursuant to the Manufacturing and Supply Agreement was made on November 17, 2020 (the &#x201c;Effective
Date&#x201d;).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;The Manufacturing and Supply Agreement provides for a term of five years
from the Effective Date. &#160;Either party may terminate the Manufacturing and Supply Agreement upon a material breach by the other Party
that has not been cured within 90 days, upon the bankruptcy or insolvency of the other Party or as expressly set forth elsewhere in the
Agreement. &#160;If the Company terminates the Manufacturing and Supply Agreement other than for those reasons within the first three
years from the Effective Date, the Company is obligated to pay an early termination fee to Command.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;The Manufacturing and Supply Agreement also includes customary provisions
relating to, among other things, delivery, inspection procedures, warranties, quality management, business continuity plans, handling
and transport, intellectual property, confidentiality and indemnification.&lt;/p&gt;

</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_803_eus-gaap--PensionAndOtherPostretirementBenefitsDisclosureTextBlock_z9c2bq4t4VWh" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;NOTE 9 &#x2014;&lt;span id="xdx_82E_z9PnJ8HC491j"&gt; EMPLOYEE BENEFITS&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;We provide a safe harbor 401(k) plan for our employees that allows for
employee elective contributions, Company matching contributions and discretionary profit-sharing contributions. &#160;Employee elective
contributions are funded through voluntary payroll deductions. &#160;&lt;span id="xdx_90D_ecustom--DescriptionOfMatchingContribution_c20220101__20221231_ziktIA9RrVP2" title="Description of matching contribution"&gt;The Company makes safe harbor matching contributions in an amount
equal to 100% of the employee&#x2019;s contribution, not to exceed 3% of employee&#x2019;s compensation plus 50% of employee&#x2019;s pay
contributed between 3% and 5% of employee&#x2019;s compensation&lt;/span&gt;. &#160;Company matching expense for the years ended December 31, 2022 and
December 31, 2021 was $&lt;span id="xdx_904_eus-gaap--DefinedContributionPlanEmployerDiscretionaryContributionAmount_c20220101__20221231_zx16SqhdblOc" title="Matching expense"&gt;214,931&lt;/span&gt; and $&lt;span id="xdx_901_eus-gaap--DefinedContributionPlanEmployerDiscretionaryContributionAmount_c20210101__20211231_zV7fv98IDyha" title="Matching expense"&gt;166,014&lt;/span&gt;, respectively. &#160;The Company has not provided for a discretionary profit-sharing contribution.&lt;/p&gt;

</us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock>
    <krmd:DescriptionOfMatchingContribution contextRef="From2022-01-01to2022-12-31">The Company makes safe harbor matching contributions in an amount
equal to 100% of the employee&#x2019;s contribution, not to exceed 3% of employee&#x2019;s compensation plus 50% of employee&#x2019;s pay
contributed between 3% and 5% of employee&#x2019;s compensation</krmd:DescriptionOfMatchingContribution>
    <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">214931</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
    <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">166014</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
    <us-gaap:DebtDisclosureTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_80C_eus-gaap--DebtDisclosureTextBlock_zWXV1QzCJny8" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;NOTE 10 &#x2014; &lt;span id="xdx_827_zNtvDGCyZBni"&gt;DEBT OBLIGATIONS&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;On June 29, 2022, the Company entered into a Loan Modification Extension
Agreement (the &#x201c;Modification Agreement&#x201d;) with Keybank National Association (&#x201c;Lender&#x201d;) to modify its revolving
line of credit with Lender in the amount of $3,500,000 (the &#x201c;Loan&#x201d;) that was originally made available on April 14, 2020 and
renewed on June 24, 2021. Among other things, the Modification Agreement: (i) extends the maturity date of the Loan from June 1, 2022
to June 1, 2023; (ii) changes the interest rate applicable to the Loan from Prime &#x2013; 1.50% to Prime + 0%; (iii) releases the Company
from its obligations under a certain security agreement dated June 24, 2021 pursuant to which the Company had previously granted the Lender
a first priority security interest in all equipment, inventory, accounts, instruments, chattel paper and general intangibles of the Company
(the &#x201c;Security Agreement&#x201d;); and (iv) replaces the Security Agreement with a new pledge security agreement dated June 29, 2022
by and between the Company and Lender (the &#x201c;Pledge Agreement&#x201d;), which Pledge Agreement grants Lender a first priority security
interest in certain of the Company&#x2019;s bank accounts as collateral security for the Loan. The Company had zero outstanding against
the line of credit as of December 31, 2022.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;On August 5, 2022, the Company entered into a commercial insurance premium
finance and security agreement with AON Premium Finance, LLC in the aggregate principal amount of $&lt;span id="xdx_909_eus-gaap--NotesPayable_iI_dm_c20220805__dei--LegalEntityAxis__custom--AONPremiumFinanceLLCMember__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember_z0Knt7TLj9Wd" title="Notes payable"&gt;0.8 million&lt;/span&gt; bearing an annual percentage
rate of &lt;span id="xdx_903_ecustom--NotePayableTerms_pid_dp_uPure_c20220803__20220805__dei--LegalEntityAxis__custom--AONPremiumFinanceLLCMember__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember__us-gaap--CreditFacilityAxis__us-gaap--LineOfCreditMember_zjnelyJAHTq6" title="Note payable terms"&gt;6.5&lt;/span&gt;%, to finance its insurance premiums. Monthly payments are due on the first of each month beginning August 1, 2022 through
June 1, 2023.&lt;/p&gt;

</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:NotesPayable
      contextRef="AsOf2022-08-05_custom_AONPremiumFinanceLLCMember_custom_PromissoryNoteMember"
      decimals="0"
      unitRef="USD">800000</us-gaap:NotesPayable>
    <krmd:NotePayableTerms
      contextRef="From2022-08-032022-08-05_custom_AONPremiumFinanceLLCMember_custom_PromissoryNoteMember_us-gaap_LineOfCreditMember"
      decimals="INF"
      unitRef="Pure">0.065</krmd:NotePayableTerms>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>60
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MLOKE1LF5*@T /E\7,/[L+\SCHO;QX.Q_4$L#!!0    ( ,F$:%;M/4K%1P,
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M")0-P.=K*<U#PQZV_;=5]B]02P,$%     @ R81H5OL+7*:H!0  )Q8  !@
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MB@POS'=96K$V>FV4+!$*Q5J;,IGGD@9$JBCT4T+!2JP<CT1.I9+F*$Q7^8M
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MA[V=3E6$=B&E 8YDU($,];N-FN*?(-%6.X7#!?QB%4 3%26^L'=]9@=;P0@
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M(F$A\ZHUX?#(<5RY3E,#7&MFVYQ]K8O-4J;+0OU!,*"R(7XR9^U&I.=ME?Q
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M+*:;=0<9UH#=R3X!>=U2+DWE!9&1L(:"LP)T"%1VA^,B!R"HZ;?EEJ] RJU
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ML '!CH\K;+_L1 #WN;5A>Q #NWUZ_"]02P,$%     @ R81H5FP.[74$ P
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MX%(QA"@*0(9RLC7)$PD "IOD$)OQDH:ME"Q:"%D:>C#@"(1LRSAZFJD48EP
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MH1FEZFX?@&J/S][=7./UN<^Z$%CC[^57T?]T<SL>?-J(('\5<0*4&G9)ZNN
M@I@[Q-IGN]U>C"5<X1AST_;56"]4&IT<=EX#\B'<7$V? SSTE]6^O7";$)N1
MJ.[VP::7SXDK$U\'XZTR_(MHDPC_4<$U;\;CEOB.=[L'<2M1&A:(7BK6/E:U
M;O>M.'<=YTM-)NBE*PYZQY#NE:M,ASFXY2>ASQL)+\4ZS8@<F_8"EY76>.\Z
MHVP;4PJ#.*0IRMP7V;-H:312%YI@P,T6PCVG#,XO/<&6Z(.RE/.,,%SB4A(R
MQ55 DXKK;)R+>$XIT-1+0W_4V_2)>#UAA$=6C=[!33#Z!O8@D,R["!/&<U:
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M [5SH/>54O:HN 3C)VCU#U!+ P04    " #)A&A6!\F%.?$%   [&   &0
M 'AL+W=O<FMS:&5E=',O<VAE970R,2YX;6S-65EOVT80?N>O&"A!D0 R12YO
MQQ;@JVU:)#9L)T%1]&$MKB3"/-3E2K+[ZSN[/$1;%$.[=E# D/:8<V>^F=7Z
M8)WQVWS.F("[)$[SP\%<B,7^:)1/YBRAN9XM6(H[TXPG5."4ST;Y@C,:*J8D
M'A'#<$<)C=+!^$"M7?#Q0;84<92R"P[Y,DDHOS]F<;8^')B#:N$RFLV%7!B-
M#Q9TQJZ8^+*XX#@;U5+"*&%I'F4I<#8]'!R9^\>F8E 47R.VSAMCD*[<9-FM
MG'P,#P>&M(C%;"*D"(I?*W;"XEA*0CO^+H4.:IV2L3FNI/^LG$=G;FC.3K+X
M6Q2*^>' 'T#(IG09B\ML_2LK'7*DO$D6Y^H3UB6M,8#),A=94C*C!4F4%M_T
MKCR(/@RD9"#*[D*1LO*4"CH^X-D:N*1&:7*@7%7<:%R4RJA<"8Z[$?*)\=7U
M^<GO>\='5V>G<'+^Z>+L\]71]<?SS_#NFM[$+']_,!*H1A*/)J7(XT(DV2'2
M)/ I2\4\A[,T9.%# 2.TKS:25$8>DTZ)IVRB@V4.@1B$=,BS:J<M)<_:Y?2<
M<K9WC,$,X8+>8Y()..*<IC.FQG\>W>2"8\+\U>9](=MNERU1M)\OZ(0=#A F
M.>,K-AC_],9TC0\=EMNUY7:7]/$5HC)<Q@RR*0A$A\K($#!-)K>0+62BYVTV
M=TIMM[F/*@TCPY(;QNOHP.,54SN-5E'(TA#N(Q:'8.B&H3ZTL[L%8A-EKK*8
MBBB.Q#VXCDX"\#S= <_6#5,. U/[IM#%PCVZ8ARK19/EIS<^,<F'ZGLC-BP5
MY[M)!.,)O(M2N&>4Y^_!-/!/NXSRV[TI9PPX%0Q,W3<!C2$X(DB@NP0Z8NG4
ML71ZQS(75"SSIT:U4WY[5*_G#*99C,4X2F<@),;+BAS]PW(0N-VP!6<G6;*@
MZ;TZ.>]#7ABE%4;!(J;I/CS-D5XYHQ":0Q5V>#37SI<"-:6A=((*^(VF2^PI
M8((U=#TR=##%WH*EVP3(,"!D: <V+A#==K5?$.=2I&T[0T/1$=WQD XGY8*E
MNS;F"..32)IO#@TTC#ARRY2TN.!62DS=##1L$%,62:D.<4M*HGL6F+Y7ZK9T
MRWULMDPZD,A 86ZEW-9-9\L-[;PX/&"%52INGN65)+8>6!#XUM"K5=>0@0HR
M4QIQ6-%XJ0)51@-FY7&$2ZXR D.^8#S*PAHTTL? ;TR)[CO:E8SI7A'?">8(
M-FJJ<H+=R3%KLF,(G*'OFDT90]OQAI[O=R')K9'D]D92E!97%96>C N\F"B_
MLMKC;!.$-E!UJNH/*K6;BOQI!FE486<+(@]!]C21E[*O2;8JH^&"1Q,&GY=*
M19TG]>#1AO:6Z,2!/7@;Z';0R%5?]ZM\?92*'3'UZIAZK]+I.J6^4*?35-7J
MV=R^/FAN >#^CVQG6]V,Z($RHBM(?ATD_Y5;6*?\%VIA,E!P@:T*[]9BCK\E
M<GE<&L)EEZ5/[FE_R$JNKKNP(U&>W=$DJ(Q&Y:R"7O<Q;]/'7*^%<-/(C,UJ
M"]VFB773[6IBWS6DK8=UJWK9'A:T:'A*&\.&Y5CNMI N) 4UDH(?U\(Z5;U^
M"Q/_O_Z%^5BE9Z!;58H6T.J(GFEL?D8;O>.'+BG_TDE1+/J&[3LJGE'WL#.W
MUKV&A7LMY0QVW$* RKLJ5K.'X>SC[^O>^K<A:3:N\Z;N&76YW";MJIA]J#=U
MLP_UKNK9PX6V^ME'Y0M6T=U*GE!(MX6\LPU_Z-D>O.\"8^--R_RO2%&O@9&(
M<(JYBYG*89FN6"X/ '-.8(41-2SHFO*P()2\8LWB%8.D>.1B6UU?I?>P!HO>
MBO5.#YY]\>EP2WMIM[3K@J'YV/?<V\^7ZNP?P-I\\)O<:,%Y!ZP?,VM?"PW.
M9M%JDUC#>321%2WNB>NF!XU#@*"AS["W76I+^%'C/3=A?*9>K7.$U3(5Q=-N
MO5J_C!\5[\$;\N)9_1/ELPC!';,ILAJZYPR %R_5Q41D"_4Z?),)D25J.&<T
M9%P2X/XTRT0UD0KJ_Q>,_P502P,$%     @ R81H5@N&L:(J!0  $0\  !D
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M&TD)U17>DOH\_@_V:5O' LN("QJDP3*#P N37_R2"G$4@-IG E :@$X#T)D
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MS94Y/D': O-^(83>=>P.W1W(Z5]02P,$%     @ R81H5D]-$$*( P  R0X
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M"!JKRR7! 6%I _G[G%+Q=I,Z*/[R,/H/4$L#!!0    ( ,F$:%89)6+MH04
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MV%G>R'13G!<^I%*F<7&YYBS@(C=0OR_35+[<Y /41\[S_P!02P,$%     @
MR81H5IN.,.2/ P  W P  !D   !X;"]W;W)K<VAE971S+W-H965T,S(N>&UL
MQ5=M;]LV$/XK!VT8-F"U1/D]LPW$28L56#:CV=8/Q3[0TMD60HD:2=LQL!^_
M(RG+*FHKR=IB^1")%._A<\_Q[NC)7JH'O4$T\)B+0D^#C3'E51CJ9(,YUQU9
M8D%?5E+EW-!0K4-=*N2I,\I%&$?1(,QY5@2SB9M;J-E$;HW("EPHT-L\Y^HP
M1R'WTX %QXEWV7IC[$0XFY1\C?=H_B@7BD9AC9)F.18ZDP4H7$V#:W8U9P-K
MX%;\F>%>-][!NK*4\L$.WJ;3(+*,4&!B+ 2GQPYO4 B+1#S^KD"#>D]KV'P_
MHK]QSI,S2Z[Q1HKW66HVTV 40(HKOA7FG=S_C)5#?8N72*'=?]A7:Z, DJTV
M,J^,B4&>%?[)'RLA&@;=^()!7!G$CK??R+&\Y8;/)DKN0=G5A&9?G*O.FLAE
MA8W*O5'T-2,[,[NG,*=;@2!7D!4^RE:M$I6AF&;%&HP$6=I)#116;7B1VNGO
M;Y%6"/T#O(+?*5 P)W%2N-]PA1I^JRP^W&&^1/47+7K]B"K)-,)"90FR^M,D
M-.2(I1,F%>FY)QU?(,UBN).%V6AX7:28?@P0D@*U#/%1AGG<BGB+20>Z[$>(
MHSB&;R$$[?WPCY8=NK707;=#[Y+01B8/E2RP$+R@K5B_58160)NN5[KD"4X#
MRD>-:H?![+MOV"#ZJ85NKZ;;<^C=2W2MWZ]\2&]D3D5 ^X-QK10OUDB):6!Y
M@.:Z!3^XZ>L]5RE\^(4@X:W!7)_UKO<5O.O7WO5;@_'KUHK^T7'^YVRH/54/
M-G!@MLSM9G%_$-'?)-R=83&H60Q:6;QW)8.$XSM45 *IRN55SB5TO!55K"T7
M(+(5GF/5#CZ" W*E80RY3Q4V@I0?VH[RL.8]?!EO/&9V:3.;I#PET#GB'GW8
MD+/78?WS6HYJ3J/G1+1BPI<"6R,Z^B2BP^ZP?RF@XYK$^*L*,SXCS+A[GA.+
M3A4^>G'EB9\HOZV(_S$Y6:,GL?^Y^%0$OK"#\<G!^$O6GPJM>5Q[]K1>.*[L
MU)-8>U/ZS KT!/JX*D'=N@2-GRI![-2?6&N#^.Q<J^";R19W!L,+BIX:"WM6
M9WEN'6*?MI9+03UU%?;"MO)293Q\OX53V+APYJC6[EJMZ<QL"^/OGO5L?76_
M]A?6TW)_[[_C:IW115'@BDRCSI#V5?XJ[0=&EN[ZNI2&+L/N=4,_/U#9!?1]
M):4Y#NP&]0^:V;]02P,$%     @ R81H5L[ZY"_( P  R0X  !D   !X;"]W
M;W)K<VAE971S+W-H965T,S,N>&ULM5==;]LV%/TKA#8,+=!$HOR9S!80.]U6
MH,&,&ET?BC[0TK4E1!(]DK:3?[]+2M9'(M/UUN4A%J5[C\XY(GEY)P<N'F4,
MH,A3EN9RZL1*;6]=5X8Q9$Q>\RWD^&3-1<84#L7&E5L!+#))6>KZGC=T,Y;D
M3C Q]Q8BF/"=2I,<%H+(798Q\3R#E!^F#G6.-SXEFUCI&VXPV;(-+$%]WBX$
MCMP*)4HRR&7"<R)@/77NZ.V<CG2"B?@K@8-L7!,M9<7YHQY\B*:.IQE!"J'2
M$ Q_]C"'--5(R./O$M2IWJD3F]=']-^,>!2S8A+F//V21"J>.F.'1+!FNU1]
MXH<_H!0TT'@A3Z7Y3PYEK.>0<"<5S\ID9) E>?'+GDHC&@ET>"+!+Q/\EPG]
M$PF],J%GA!;,C*Q[IE@P$?Q A(Y&-'UAO#'9J";)]6=<*H%/$\Q3P1+G1;1+
M@? UV8(P\R(/P5A#^%9;+0E^?JE8'B7YAKRY!\625+XE5V312%C&3( D7Q\@
M6X'XAD\_+^_)FY_?3ER%//7;W+#D-"LX^2<X49\\\%S%DKS/(XC: "X*K%3Z
M1Y4SWXIX#^$UZ=%WQ/=\OX/0_/O3J85.KS*]9_!ZITS77EW-T.*(S'F&2U(R
M,ZGOA&#Y!G"9*+)Z)LVX!7LVM^\.3$3DZT>$)!\49/);E\'%^_O=[]=;PZW<
MLA"F#JY]"6(/3O#+3W3H_=IES@\":UG5KZSJV]"#/QM3CZ$IL$GR' ==HJU(
MW3Q)E]X"9VAP]#:X#ZAG_B;NOD/*H)(R^&%2K$@72"EP1DTIUZ-N&<-*QM N
MH]P4X E$F$BVPLT#Y8 1UJ5E^,K.VLB"I2VBQ7%4<1Q9.?Z.RTB]W#D*-D7B
MP,+&%M%B,Z[8C*ULWA=.=?,9GW7'%M'B<U/QN?GW?&[.^F.+:/&A7EV$/"LC
MK,AK2$Y\L3+79I$UI,VI41CI?^!$S]ID#6ES\FM._B5;R.DU5^)8/7L=8MWF
M:%W=J+4B7,"R=][%WO?O8+0N*O1,5;ET#ROQK$QM(6V>=<6@]I+QQ9Q"L?JS
M/0@\59,U2P39LW1G#FS'\]FFV.Y(M!/:<Q6#/LLEO'OJ#LY/#5M(6TI=-:B]
M;/PO4H;GOXHMI"VE+B[47EV6BH>/5RMS+ N;QS=XTM?02=4*>4%%IZ_+TU7?
M&X_Z+Q>%VV@*,A ;TRM))+S+57%RKNY6_=B=Z4)>W)_I/LTT&S5,T>0],(%G
M&$E26".D=SU"5J+HFXJ!XEO3>JRXPD;&7,;8:X+0 ?A\S;DZ#O0+JNXU^ =0
M2P,$%     @ R81H5MHX!AV: P  ?0T  !D   !X;"]W;W)K<VAE971S+W-H
M965T,S0N>&ULK5?;;MLX$/T50BT66Z"U;HZ=I+: V.D-:! CV<T^%'V@I;%%
M1")=DK:;_?H=4HHLNPJW;I.'F*1F#L\YO&@TV@IYKW( 3;Z7!5=C+]=Z=>[[
M*LVAI*HG5L#QR4+(DFKLRJ6O5A)H9I/*PH^"8."7E'$O&=FQF4Q&8JT+QF$F
MB5J7)94/$RC$=NR%WN/ #5OFV@SXR6A%EW +^N_53&+/;U R5@)73' B83'V
M+L+S:1B;!!MQQV"K6FUBI,R%N#>=3]G8"PPC*"#5!H+BSP:F4!0&"7E\JT&]
M9DZ3V&X_HK^WXE',G"J8BN(?ENE\[)UZ)(,%71?Z1FP_0BWHQ."EHE#V/]G6
ML8%'TK72HJR3D4')>/5+O]=&M!+"P1,)49T0'2;TGTB(ZP3KG%\QL[(NJ:;)
M2(HMD28:T4S#>F.S40WC9AEOM<2G#/-T\E<.9"$*7$W&ET33>0'UDK)_01&-
MCZW33#/LXK8A8BW)FF] :<AP(966+#5-I)K>$[JE,JL"3:[>0K$!4@JN<T6
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MW'(@MF6)^>-'4K#=W('._L4WNMY(_<)=S&J\)G=$?J]ON1JY/4I.2U()RBK
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MN@DVCQMU62=<&ZCO*\;D?J"O@_WU?_$74$L#!!0    ( ,F$:%8X6CE'F@,
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MU5GORG(":4D]$[38;[[N-XX__0M02P,$%     @ R81H5OTLU:6N 0  P1L
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MDN,>) <?HP1!(2I'02I'82I'@2I'H2I'P2I'X2I' 2M'(:M (:M (:M (:M
M(:M (:M (:M (:M (:M (:M (:M$(:M$(:M$(:M$(:M$(:M$(:M$(:M$(:M$
M(:M$(6N"0M8$A:P)"ED3%+(F*&1-4,B:_"=9W[5>_?7_IG:-:U4V1W_6_=2;
M?P)02P$"% ,4    " #)A&A6!T%-8H$   "Q    $               @ $
M    9&]C4')O<',O87!P+GAM;%!+ 0(4 Q0    ( ,F$:%;_ZDH [@   "L"
M   1              "  :\   !D;V-0<F]P<R]C;W)E+GAM;%!+ 0(4 Q0
M   ( ,F$:%:97)PC$ 8  )PG   3              "  <P!  !X;"]T:&5M
M92]T:&5M93$N>&UL4$L! A0#%     @ R81H5JQY7))W!P  G#   !@
M         ("!#0@  'AL+W=O<FMS:&5E=',O<VAE970Q+GAM;%!+ 0(4 Q0
M   ( ,F$:%:L _5I @<  "H<   8              " @;H/  !X;"]W;W)K
M<VAE971S+W-H965T,BYX;6Q02P$"% ,4    " #)A&A6[3U*Q4<#  !G"0
M&               @('R%@  >&PO=V]R:W-H965T<R]S:&5E=#,N>&UL4$L!
M A0#%     @ R81H5OL+7*:H!0  )Q8  !@              ("!;QH  'AL
M+W=O<FMS:&5E=',O<VAE970T+GAM;%!+ 0(4 Q0    ( ,F$:%:W[3)<8@8
M %LI   8              " @4T@  !X;"]W;W)K<VAE971S+W-H965T-2YX
M;6Q02P$"% ,4    " #)A&A6S<^,A0X(   #(P  &               @('E
M)@  >&PO=V]R:W-H965T<R]S:&5E=#8N>&UL4$L! A0#%     @ R81H5@H'
MO*W@%   >S0  !@              ("!*2\  'AL+W=O<FMS:&5E=',O<VAE
M970W+GAM;%!+ 0(4 Q0    ( ,F$:%9CWC6ZN (  , %   8
M  " @3]$  !X;"]W;W)K<VAE971S+W-H965T."YX;6Q02P$"% ,4    " #)
MA&A6RL#-FA4#  "?!@  &               @($M1P  >&PO=V]R:W-H965T
M<R]S:&5E=#DN>&UL4$L! A0#%     @ R81H5M#RJMS "   [AT  !D
M         ("!>$H  'AL+W=O<FMS:&5E=',O<VAE970Q,"YX;6Q02P$"% ,4
M    " #)A&A61'?MK/\&  !+$P  &0              @(%O4P  >&PO=V]R
M:W-H965T<R]S:&5E=#$Q+GAM;%!+ 0(4 Q0    ( ,F$:%9;( )\B 0   <*
M   9              " @:5:  !X;"]W;W)K<VAE971S+W-H965T,3(N>&UL
M4$L! A0#%     @ R81H5ATXI9T< P  JP8  !D              ("!9%\
M 'AL+W=O<FMS:&5E=',O<VAE970Q,RYX;6Q02P$"% ,4    " #)A&A6:B:R
M9@P%  !;"P  &0              @(&W8@  >&PO=V]R:W-H965T<R]S:&5E
M=#$T+GAM;%!+ 0(4 Q0    ( ,F$:%9L#NUU! ,  ,\&   9
M  " @?IG  !X;"]W;W)K<VAE971S+W-H965T,34N>&UL4$L! A0#%     @
MR81H5B&"2H*\!   L H  !D              ("!-6L  'AL+W=O<FMS:&5E
M=',O<VAE970Q-BYX;6Q02P$"% ,4    " #)A&A6GA3C^^05  "$/   &0
M            @($H<   >&PO=V]R:W-H965T<R]S:&5E=#$W+GAM;%!+ 0(4
M Q0    ( ,F$:%8I]3,%\P0  +4+   9              " @4.&  !X;"]W
M;W)K<VAE971S+W-H965T,3@N>&UL4$L! A0#%     @ R81H5A(]-".R @
MO04  !D              ("!;8L  'AL+W=O<FMS:&5E=',O<VAE970Q.2YX
M;6Q02P$"% ,4    " #)A&A6R?RDSP\#  ".!@  &0              @(%6
MC@  >&PO=V]R:W-H965T<R]S:&5E=#(P+GAM;%!+ 0(4 Q0    ( ,F$:%8'
MR84Y\04  #L8   9              " @9R1  !X;"]W;W)K<VAE971S+W-H
M965T,C$N>&UL4$L! A0#%     @ R81H5@N&L:(J!0  $0\  !D
M     ("!Q)<  'AL+W=O<FMS:&5E=',O<VAE970R,BYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( ,F$:%:@R)6L_ 0  'T=   9              "
M@<"K  !X;"]W;W)K<VAE971S+W-H965T,C<N>&UL4$L! A0#%     @ R81H
M5B3G _Z] @  G <  !D              ("!\[   'AL+W=O<FMS:&5E=',O
M<VAE970R."YX;6Q02P$"% ,4    " #)A&A63TT00H@#  #)#@  &0
M        @('GLP  >&PO=V]R:W-H965T<R]S:&5E=#(Y+GAM;%!+ 0(4 Q0
M   ( ,F$:%:QL7)7!04  /X@   9              " @::W  !X;"]W;W)K
M<VAE971S+W-H965T,S N>&UL4$L! A0#%     @ R81H5ADE8NVA!0  ?AX
M !D              ("!XKP  'AL+W=O<FMS:&5E=',O<VAE970S,2YX;6Q0
M2P$"% ,4    " #)A&A6FXXPY(\#  #<#   &0              @(&ZP@
M>&PO=V]R:W-H965T<R]S:&5E=#,R+GAM;%!+ 0(4 Q0    ( ,F$:%;.^N0O
MR ,  ,D.   9              " @8#&  !X;"]W;W)K<VAE971S+W-H965T
M,S,N>&UL4$L! A0#%     @ R81H5MHX!AV: P  ?0T  !D
M ("!?\H  'AL+W=O<FMS:&5E=',O<VAE970S-"YX;6Q02P$"% ,4    " #)
MA&A672,<E#H,  !(?P  &0              @(%0S@  >&PO=V]R:W-H965T
M<R]S:&5E=#,U+GAM;%!+ 0(4 Q0    ( ,F$:%:A_Y3T+ ,  -L)   9
M          " @<':  !X;"]W;W)K<VAE971S+W-H965T,S8N>&UL4$L! A0#
M%     @ R81H5C,;0NFG @  K@8  !D              ("!)-X  'AL+W=O
M<FMS:&5E=',O<VAE970S-RYX;6Q02P$"% ,4    " #)A&A6W8/)'>H#   *
M$   &0              @($"X0  >&PO=V]R:W-H965T<R]S:&5E=#,X+GAM
M;%!+ 0(4 Q0    ( ,F$:%8X6CE'F@,  #42   9              " @2/E
M  !X;"]W;W)K<VAE971S+W-H965T,SDN>&UL4$L! A0#%     @ R81H5B3B
M;H4S @  U@0  !D              ("!].@  'AL+W=O<FMS:&5E=',O<VAE
M970T,"YX;6Q02P$"% ,4    " #)A&A6-?4+L\H"  "P"   &0
M    @(%>ZP  >&PO=V]R:W-H965T<R]S:&5E=#0Q+GAM;%!+ 0(4 Q0    (
M ,F$:%8_9_2-(@,  (0(   9              " @5_N  !X;"]W;W)K<VAE
M971S+W-H965T-#(N>&UL4$L! A0#%     @ R81H5M-S1OS\ @  7@@  !D
M             ("!N/$  'AL+W=O<FMS:&5E=',O<VAE970T,RYX;6Q02P$"
M% ,4    " #)A&A61$SN]'\"  #2!@  &0              @('K]   >&PO
M=V]R:W-H965T<R]S:&5E=#0T+GAM;%!+ 0(4 Q0    ( ,F$:%8(4ZDU] (
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M<F5L<R\N<F5L<U!+ 0(4 Q0    ( ,F$:%9^ ??&B00  +P>   /
M      "  :(! 0!X;"]W;W)K8F]O:RYX;6Q02P$"% ,4    " #)A&A6_2S5
MI:X!  #!&P  &@              @ %8!@$ >&PO7W)E;',O=V]R:V)O;VLN
M>&UL+G)E;'-02P$"% ,4    " #)A&A6)OJ'I[4!  #<&P  $P
M    @ $^" $ 6T-O;G1E;G1?5'EP97-=+GAM;%!+!08     -@ V +$.   D
%"@$    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.4</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>100</ContextCount>
  <ElementCount>316</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>36</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>5</UnitCount>
  <MyReports>
    <Report instance="form_10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://korumedical.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="form_10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>00000002 - Statement - BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://korumedical.com/role/BalanceSheets</Role>
      <ShortName>BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="form_10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>00000003 - Statement - BALANCE SHEETS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://korumedical.com/role/BalanceSheetsParenthetical</Role>
      <ShortName>BALANCE SHEETS (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="form_10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>00000004 - Statement - STATEMENTS OF OPERATIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://korumedical.com/role/StatementsOfOperations</Role>
      <ShortName>STATEMENTS OF OPERATIONS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="form_10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>00000005 - Statement - STATEMENTS OF STOCKHOLDERS' EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://korumedical.com/role/StatementsOfStockholdersEquity</Role>
      <ShortName>STATEMENTS OF STOCKHOLDERS' EQUITY</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="form_10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>00000006 - Statement - STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://korumedical.com/role/StatementsOfCashFlows</Role>
      <ShortName>STATEMENTS OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="form_10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>00000007 - Disclosure - NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://korumedical.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPolicies</Role>
      <ShortName>NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="form_10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>00000008 - Disclosure - INVENTORY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://korumedical.com/role/Inventory</Role>
      <ShortName>INVENTORY</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="form_10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>00000009 - Disclosure - PROPERTY AND EQUIPMENT</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://korumedical.com/role/PropertyAndEquipment</Role>
      <ShortName>PROPERTY AND EQUIPMENT</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="form_10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>00000010 - Disclosure - STOCK-BASED COMPENSATION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://korumedical.com/role/Stock-basedCompensation</Role>
      <ShortName>STOCK-BASED COMPENSATION</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="form_10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>00000011 - Disclosure - LEASES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://korumedical.com/role/Leases</Role>
      <ShortName>LEASES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="form_10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>00000012 - Disclosure - FEDERAL AND STATE INCOME TAXES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://korumedical.com/role/FederalAndStateIncomeTaxes</Role>
      <ShortName>FEDERAL AND STATE INCOME TAXES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="form_10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>00000013 - Disclosure - MAJOR CUSTOMERS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://korumedical.com/role/MajorCustomers</Role>
      <ShortName>MAJOR CUSTOMERS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="form_10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>00000014 - Disclosure - COMMITMENTS AND CONTINGENCIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://korumedical.com/role/CommitmentsAndContingencies</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="form_10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>00000015 - Disclosure - EMPLOYEE BENEFITS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://korumedical.com/role/EmployeeBenefits</Role>
      <ShortName>EMPLOYEE BENEFITS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="form_10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>00000016 - Disclosure - DEBT OBLIGATIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://korumedical.com/role/DebtObligations</Role>
      <ShortName>DEBT OBLIGATIONS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="form_10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>00000017 - Disclosure - NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://korumedical.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="form_10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>00000018 - Disclosure - NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://korumedical.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesTables</Role>
      <ShortName>NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://korumedical.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>18</Position>
    </Report>
    <Report instance="form_10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>00000019 - Disclosure - INVENTORY (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://korumedical.com/role/InventoryTables</Role>
      <ShortName>INVENTORY (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://korumedical.com/role/Inventory</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="form_10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>00000020 - Disclosure - PROPERTY AND EQUIPMENT (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://korumedical.com/role/PropertyAndEquipmentTables</Role>
      <ShortName>PROPERTY AND EQUIPMENT (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://korumedical.com/role/PropertyAndEquipment</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="form_10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>00000021 - Disclosure - STOCK-BASED COMPENSATION (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://korumedical.com/role/Stock-basedCompensationTables</Role>
      <ShortName>STOCK-BASED COMPENSATION (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://korumedical.com/role/Stock-basedCompensation</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="form_10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>00000022 - Disclosure - LEASES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://korumedical.com/role/LeasesTables</Role>
      <ShortName>LEASES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://korumedical.com/role/Leases</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="form_10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>00000023 - Disclosure - FEDERAL AND STATE INCOME TAXES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://korumedical.com/role/FederalAndStateIncomeTaxesTables</Role>
      <ShortName>FEDERAL AND STATE INCOME TAXES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://korumedical.com/role/FederalAndStateIncomeTaxes</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="form_10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>00000024 - Disclosure - Schedule of amortization expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://korumedical.com/role/ScheduleOfAmortizationExpenseDetails</Role>
      <ShortName>Schedule of amortization expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="form_10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>00000025 - Disclosure - Schedule of net income per common share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://korumedical.com/role/ScheduleOfNetIncomePerCommonShareDetails</Role>
      <ShortName>Schedule of net income per common share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="form_10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>00000026 - Disclosure - Schedule of net revenues by geography (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://korumedical.com/role/ScheduleOfNetRevenuesByGeographyDetails</Role>
      <ShortName>Schedule of net revenues by geography (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="form_10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>00000027 - Disclosure - NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://korumedical.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesDetailsNarrative</Role>
      <ShortName>NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://korumedical.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesTables</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="form_10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>00000028 - Disclosure - Inventory consists of: (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://korumedical.com/role/InventoryConsistsOfDetails</Role>
      <ShortName>Inventory consists of: (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="form_10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>00000029 - Disclosure - Schedule of property and equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://korumedical.com/role/ScheduleOfPropertyAndEquipmentDetails</Role>
      <ShortName>Schedule of property and equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="form_10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>00000030 - Disclosure - Schedule of time based stock options (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://korumedical.com/role/ScheduleOfTimeBasedStockOptionsDetails</Role>
      <ShortName>Schedule of time based stock options (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="form_10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>00000031 - Disclosure - Schedule of status of time based stock options (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://korumedical.com/role/ScheduleOfStatusOfTimeBasedStockOptionsDetails</Role>
      <ShortName>Schedule of status of time based stock options (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="form_10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>00000032 - Disclosure - Schedule of information pertaining to options outstanding (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://korumedical.com/role/ScheduleOfInformationPertainingToOptionsOutstandingDetails</Role>
      <ShortName>Schedule of information pertaining to options outstanding (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="form_10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>00000033 - Disclosure - Schedule of performance base options outstanding (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://korumedical.com/role/ScheduleOfPerformanceBaseOptionsOutstandingDetails</Role>
      <ShortName>Schedule of performance base options outstanding (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="form_10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>00000034 - Disclosure - The following table summarizes the activities for our unvested restricted stock awards for the twelve months ended December 31, 2022, and 2021. (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://korumedical.com/role/FollowingTableSummarizesActivitiesForOurUnvestedRestrictedStockAwardsForTwelveMonthsEndedDecember312022And2021.Details</Role>
      <ShortName>The following table summarizes the activities for our unvested restricted stock awards for the twelve months ended December 31, 2022, and 2021. (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="form_10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>00000035 - Disclosure - STOCK-BASED COMPENSATION (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://korumedical.com/role/Stock-basedCompensationDetailsNarrative</Role>
      <ShortName>STOCK-BASED COMPENSATION (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://korumedical.com/role/Stock-basedCompensationTables</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="form_10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>00000036 - Disclosure - Schedule of components of lease expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://korumedical.com/role/ScheduleOfComponentsOfLeaseExpenseDetails</Role>
      <ShortName>Schedule of components of lease expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="form_10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>00000037 - Disclosure - Schedule of cash flow information related to leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://korumedical.com/role/ScheduleOfCashFlowInformationRelatedToLeasesDetails</Role>
      <ShortName>Schedule of cash flow information related to leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="form_10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>00000038 - Disclosure - Schdeule of balance sheet information related to leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://korumedical.com/role/SchdeuleOfBalanceSheetInformationRelatedToLeasesDetails</Role>
      <ShortName>Schdeule of balance sheet information related to leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="form_10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>00000039 - Disclosure - Schedule of maturities of lease liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://korumedical.com/role/ScheduleOfMaturitiesOfLeaseLiabilitiesDetails</Role>
      <ShortName>Schedule of maturities of lease liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="form_10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>00000040 - Disclosure - LEASES (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://korumedical.com/role/LeasesDetailsNarrative</Role>
      <ShortName>LEASES (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://korumedical.com/role/LeasesTables</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="form_10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>00000041 - Disclosure - Schedule of provision for income taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://korumedical.com/role/ScheduleOfProvisionForIncomeTaxesDetails</Role>
      <ShortName>Schedule of provision for income taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="form_10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>00000042 - Disclosure - Schedule of reconciliation of income taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://korumedical.com/role/ScheduleOfReconciliationOfIncomeTaxesDetails</Role>
      <ShortName>Schedule of reconciliation of income taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="form_10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>00000043 - Disclosure - Schedule of components of deferred tax assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://korumedical.com/role/ScheduleOfComponentsOfDeferredTaxAssetsDetails</Role>
      <ShortName>Schedule of components of deferred tax assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="form_10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>00000044 - Disclosure - MAJOR CUSTOMERS (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://korumedical.com/role/MajorCustomersDetailsNarrative</Role>
      <ShortName>MAJOR CUSTOMERS (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://korumedical.com/role/MajorCustomers</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="form_10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>00000045 - Disclosure - EMPLOYEE BENEFITS (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://korumedical.com/role/EmployeeBenefitsDetailsNarrative</Role>
      <ShortName>EMPLOYEE BENEFITS (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://korumedical.com/role/EmployeeBenefits</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="form_10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>00000046 - Disclosure - DEBT OBLIGATIONS (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://korumedical.com/role/DebtObligationsDetailsNarrative</Role>
      <ShortName>DEBT OBLIGATIONS (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://korumedical.com/role/DebtObligations</ParentRole>
      <Position>46</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Warning">[ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 28 fact(s) appearing in ix:hidden were eligible for transformation: dei:CurrentFiscalYearEndDate, dei:EntityRegistrantName, krmd:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm3, krmd:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm4, us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount, us-gaap:FiniteLivedIntangibleAssetUsefulLife, us-gaap:IncomeTaxExpenseBenefit, us-gaap:LesseeFinanceLeaseRenewalTerm1, us-gaap:LesseeOperatingLeaseRenewalTerm, us-gaap:NumberOfReportableSegments, us-gaap:PropertyPlantAndEquipmentNet, us-gaap:PropertyPlantAndEquipmentUsefulLife, us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue, us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1, us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2, us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2 -  form_10-k.htm 27, 30, 68, 69, 70, 71, 72, 73, 74, 79, 80, 82, 83, 84, 85, 89, 90, 107, 108, 109, 110, 125, 131, 132, 133, 134, 138, 139</Log>
  </Logs>
  <InputFiles>
    <File doctype="10-K" original="form_10-k.htm">form_10-k.htm</File>
    <File>ex_10-15.htm</File>
    <File>ex_23-1.htm</File>
    <File>ex_31-1.htm</File>
    <File>ex_31-2.htm</File>
    <File>ex_32-1.htm</File>
    <File>ex_32-2.htm</File>
    <File>krmd-20221231.xsd</File>
    <File>krmd-20221231_cal.xml</File>
    <File>krmd-20221231_def.xml</File>
    <File>krmd-20221231_lab.xml</File>
    <File>krmd-20221231_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="538">http://fasb.org/us-gaap/2022</BaseTaxonomy>
    <BaseTaxonomy items="35">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>66
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "form_10-k.htm": {
   "axisCustom": 0,
   "axisStandard": 20,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2022": 538,
    "http://xbrl.sec.gov/dei/2022": 35
   },
   "contextCount": 100,
   "dts": {
    "calculationLink": {
     "local": [
      "krmd-20221231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "krmd-20221231_def.xml"
     ]
    },
    "inline": {
     "local": [
      "form_10-k.htm"
     ]
    },
    "labelLink": {
     "local": [
      "krmd-20221231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "krmd-20221231_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "krmd-20221231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd",
      "https://xbrl.fasb.org/srt/2022q3/srt-sup-2022q3.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022q3/us-gaap-sup-2022q3.xsd",
      "https://xbrl.sec.gov/country/2022/country-2022.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd"
     ]
    }
   },
   "elementCount": 467,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2022": 76,
    "http://korumedical.com/20221231": 33,
    "http://xbrl.sec.gov/dei/2022": 6,
    "total": 115
   },
   "keyCustom": 64,
   "keyStandard": 252,
   "memberCustom": 17,
   "memberStandard": 19,
   "nsprefix": "krmd",
   "nsuri": "http://korumedical.com/20221231",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "b",
       "p",
       "div",
       "body",
       "html"
      ],
      "baseRef": "form_10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "00000001 - Document - Cover",
     "menuCat": "Cover",
     "order": "1",
     "role": "http://korumedical.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "b",
       "p",
       "div",
       "body",
       "html"
      ],
      "baseRef": "form_10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "form_10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000010 - Disclosure - STOCK-BASED COMPENSATION",
     "menuCat": "Notes",
     "order": "10",
     "role": "http://korumedical.com/role/Stock-basedCompensation",
     "shortName": "STOCK-BASED COMPENSATION",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "form_10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "form_10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeasesOfLesseeDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000011 - Disclosure - LEASES",
     "menuCat": "Notes",
     "order": "11",
     "role": "http://korumedical.com/role/Leases",
     "shortName": "LEASES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "form_10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeasesOfLesseeDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "form_10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000012 - Disclosure - FEDERAL AND STATE INCOME TAXES",
     "menuCat": "Notes",
     "order": "12",
     "role": "http://korumedical.com/role/FederalAndStateIncomeTaxes",
     "shortName": "FEDERAL AND STATE INCOME TAXES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "form_10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "form_10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConcentrationRiskDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000013 - Disclosure - MAJOR CUSTOMERS",
     "menuCat": "Notes",
     "order": "13",
     "role": "http://korumedical.com/role/MajorCustomers",
     "shortName": "MAJOR CUSTOMERS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "form_10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConcentrationRiskDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "form_10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000014 - Disclosure - COMMITMENTS AND CONTINGENCIES",
     "menuCat": "Notes",
     "order": "14",
     "role": "http://korumedical.com/role/CommitmentsAndContingencies",
     "shortName": "COMMITMENTS AND CONTINGENCIES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "form_10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "form_10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000015 - Disclosure - EMPLOYEE BENEFITS",
     "menuCat": "Notes",
     "order": "15",
     "role": "http://korumedical.com/role/EmployeeBenefits",
     "shortName": "EMPLOYEE BENEFITS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "form_10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "form_10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000016 - Disclosure - DEBT OBLIGATIONS",
     "menuCat": "Notes",
     "order": "16",
     "role": "http://korumedical.com/role/DebtObligations",
     "shortName": "DEBT OBLIGATIONS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "form_10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "form_10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NatureOfOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000017 - Disclosure - NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "menuCat": "Policies",
     "order": "17",
     "role": "http://korumedical.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies",
     "shortName": "NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "form_10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NatureOfOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:IntangibleAssetsFiniteLivedPolicy",
       "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "form_10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000018 - Disclosure - NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)",
     "menuCat": "Tables",
     "order": "18",
     "role": "http://korumedical.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesTables",
     "shortName": "NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:IntangibleAssetsFiniteLivedPolicy",
       "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "form_10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:InventoryDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "form_10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000019 - Disclosure - INVENTORY (Tables)",
     "menuCat": "Tables",
     "order": "19",
     "role": "http://korumedical.com/role/InventoryTables",
     "shortName": "INVENTORY (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:InventoryDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "form_10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "form_10-k.htm",
      "contextRef": "AsOf2022-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00000002 - Statement - BALANCE SHEETS",
     "menuCat": "Statements",
     "order": "2",
     "role": "http://korumedical.com/role/BalanceSheets",
     "shortName": "BALANCE SHEETS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "form_10-k.htm",
      "contextRef": "AsOf2022-12-31",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:AccountsReceivableNetCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "form_10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000020 - Disclosure - PROPERTY AND EQUIPMENT (Tables)",
     "menuCat": "Tables",
     "order": "20",
     "role": "http://korumedical.com/role/PropertyAndEquipmentTables",
     "shortName": "PROPERTY AND EQUIPMENT (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "form_10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "form_10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000021 - Disclosure - STOCK-BASED COMPENSATION (Tables)",
     "menuCat": "Tables",
     "order": "21",
     "role": "http://korumedical.com/role/Stock-basedCompensationTables",
     "shortName": "STOCK-BASED COMPENSATION (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "form_10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:LeasesOfLesseeDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "form_10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000022 - Disclosure - LEASES (Tables)",
     "menuCat": "Tables",
     "order": "22",
     "role": "http://korumedical.com/role/LeasesTables",
     "shortName": "LEASES (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:LeasesOfLesseeDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "form_10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "form_10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000023 - Disclosure - FEDERAL AND STATE INCOME TAXES (Tables)",
     "menuCat": "Tables",
     "order": "23",
     "role": "http://korumedical.com/role/FederalAndStateIncomeTaxesTables",
     "shortName": "FEDERAL AND STATE INCOME TAXES (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "form_10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock",
       "us-gaap:IntangibleAssetsFiniteLivedPolicy",
       "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "form_10-k.htm",
      "contextRef": "AsOf2022-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000024 - Disclosure - Schedule of amortization expense (Details)",
     "menuCat": "Details",
     "order": "24",
     "role": "http://korumedical.com/role/ScheduleOfAmortizationExpenseDetails",
     "shortName": "Schedule of amortization expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock",
       "us-gaap:IntangibleAssetsFiniteLivedPolicy",
       "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "form_10-k.htm",
      "contextRef": "AsOf2022-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "form_10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000025 - Disclosure - Schedule of net income per common share (Details)",
     "menuCat": "Details",
     "order": "25",
     "role": "http://korumedical.com/role/ScheduleOfNetIncomePerCommonShareDetails",
     "shortName": "Schedule of net income per common share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "form_10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": "INF",
      "lang": null,
      "name": "krmd:WeightedAverageNumberOfSharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "form_10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000026 - Disclosure - Schedule of net revenues by geography (Details)",
     "menuCat": "Details",
     "order": "26",
     "role": "http://korumedical.com/role/ScheduleOfNetRevenuesByGeographyDetails",
     "shortName": "Schedule of net revenues by geography (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "krmd:ScheduleOfNetRevenuesByGeography",
       "us-gaap:RevenueFromContractWithCustomerPolicyTextBlock",
       "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "form_10-k.htm",
      "contextRef": "From2022-01-012022-12-31_country_US",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:CashAndCashEquivalentsPolicyTextBlock",
       "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "form_10-k.htm",
      "contextRef": "AsOf2022-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashUninsuredAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000027 - Disclosure - NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)",
     "menuCat": "Details",
     "order": "27",
     "role": "http://korumedical.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesDetailsNarrative",
     "shortName": "NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:CashAndCashEquivalentsPolicyTextBlock",
       "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "form_10-k.htm",
      "contextRef": "AsOf2022-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashUninsuredAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "us-gaap:InventoryDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "form_10-k.htm",
      "contextRef": "AsOf2022-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:InventoryWorkInProcessAndRawMaterials",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000028 - Disclosure - Inventory consists of: (Details)",
     "menuCat": "Details",
     "order": "28",
     "role": "http://korumedical.com/role/InventoryConsistsOfDetails",
     "shortName": "Inventory consists of: (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "us-gaap:InventoryDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "form_10-k.htm",
      "contextRef": "AsOf2022-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:InventoryWorkInProcessAndRawMaterials",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "form_10-k.htm",
      "contextRef": "AsOf2022-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000029 - Disclosure - Schedule of property and equipment (Details)",
     "menuCat": "Details",
     "order": "29",
     "role": "http://korumedical.com/role/ScheduleOfPropertyAndEquipmentDetails",
     "shortName": "Schedule of property and equipment (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "form_10-k.htm",
      "contextRef": "AsOf2022-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "form_10-k.htm",
      "contextRef": "AsOf2022-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00000003 - Statement - BALANCE SHEETS (Parenthetical)",
     "menuCat": "Statements",
     "order": "3",
     "role": "http://korumedical.com/role/BalanceSheetsParenthetical",
     "shortName": "BALANCE SHEETS (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "form_10-k.htm",
      "contextRef": "AsOf2022-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "form_10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000030 - Disclosure - Schedule of time based stock options (Details)",
     "menuCat": "Details",
     "order": "30",
     "role": "http://korumedical.com/role/ScheduleOfTimeBasedStockOptionsDetails",
     "shortName": "Schedule of time based stock options (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "form_10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Pure",
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "form_10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensation",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000031 - Disclosure - Schedule of status of time based stock options (Details)",
     "menuCat": "Details",
     "order": "31",
     "role": "http://korumedical.com/role/ScheduleOfStatusOfTimeBasedStockOptionsDetails",
     "shortName": "Schedule of status of time based stock options (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "form_10-k.htm",
      "contextRef": "AsOf2020-12-31_custom_StockOptionPlan2015Member",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "krmd:ScheduleOfShareBasedCompensationStockOptionsActivityAmendedTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "form_10-k.htm",
      "contextRef": "AsOf2022-12-31_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember_custom_ExercisePrice1Member",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000032 - Disclosure - Schedule of information pertaining to options outstanding (Details)",
     "menuCat": "Details",
     "order": "32",
     "role": "http://korumedical.com/role/ScheduleOfInformationPertainingToOptionsOutstandingDetails",
     "shortName": "Schedule of information pertaining to options outstanding (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "krmd:ScheduleOfShareBasedCompensationStockOptionsActivityAmendedTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "form_10-k.htm",
      "contextRef": "AsOf2022-12-31_custom_StockOptionPlan2015Member_custom_TimeBasedSharesOptionsMember_custom_ExercisePrice1Member",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "form_10-k.htm",
      "contextRef": "AsOf2020-12-31_us-gaap_PerformanceSharesMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000033 - Disclosure - Schedule of performance base options outstanding (Details)",
     "menuCat": "Details",
     "order": "33",
     "role": "http://korumedical.com/role/ScheduleOfPerformanceBaseOptionsOutstandingDetails",
     "shortName": "Schedule of performance base options outstanding (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "form_10-k.htm",
      "contextRef": "AsOf2020-12-31_us-gaap_PerformanceSharesMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "form_10-k.htm",
      "contextRef": "AsOf2021-12-31_custom_RestrictedStockAwardsMember_custom_StockOptionPlan2021Member",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberUnvested",
      "reportCount": 1,
      "unitRef": "Shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000034 - Disclosure - The following table summarizes the activities for our unvested restricted stock awards for the twelve months ended December 31, 2022, and 2021. (Details)",
     "menuCat": "Details",
     "order": "34",
     "role": "http://korumedical.com/role/FollowingTableSummarizesActivitiesForOurUnvestedRestrictedStockAwardsForTwelveMonthsEndedDecember312022And2021.Details",
     "shortName": "The following table summarizes the activities for our unvested restricted stock awards for the twelve months ended December 31, 2022, and 2021. (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "form_10-k.htm",
      "contextRef": "From2021-01-012021-12-31_custom_RestrictedStockAwardsMember_custom_StockOptionPlan2021Member",
      "decimals": "INF",
      "lang": null,
      "name": "krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrossUnvested",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "form_10-k.htm",
      "contextRef": "From2021-01-012021-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:IncomeTaxExpenseBenefit",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000035 - Disclosure - STOCK-BASED COMPENSATION (Details Narrative)",
     "menuCat": "Details",
     "order": "35",
     "role": "http://korumedical.com/role/Stock-basedCompensationDetailsNarrative",
     "shortName": "STOCK-BASED COMPENSATION (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "form_10-k.htm",
      "contextRef": "From2021-04-112021-04-12_custom_ChiefExecutiveOfficerLindaTharbyMember",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "us-gaap:LeasesOfLesseeDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "form_10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000036 - Disclosure - Schedule of components of lease expense (Details)",
     "menuCat": "Details",
     "order": "36",
     "role": "http://korumedical.com/role/ScheduleOfComponentsOfLeaseExpenseDetails",
     "shortName": "Schedule of components of lease expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "us-gaap:LeasesOfLesseeDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "form_10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:OperatingLeaseLeaseIncomeTableTextBlock",
       "us-gaap:LeasesOfLesseeDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "form_10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeasePayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000037 - Disclosure - Schedule of cash flow information related to leases (Details)",
     "menuCat": "Details",
     "order": "37",
     "role": "http://korumedical.com/role/ScheduleOfCashFlowInformationRelatedToLeasesDetails",
     "shortName": "Schedule of cash flow information related to leases (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:OperatingLeaseLeaseIncomeTableTextBlock",
       "us-gaap:LeasesOfLesseeDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "form_10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeasePayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "form_10-k.htm",
      "contextRef": "AsOf2022-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000038 - Disclosure - Schdeule of balance sheet information related to leases (Details)",
     "menuCat": "Details",
     "order": "38",
     "role": "http://korumedical.com/role/SchdeuleOfBalanceSheetInformationRelatedToLeasesDetails",
     "shortName": "Schdeule of balance sheet information related to leases (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:OperatingLeasesOfLesseeDisclosureTextBlock",
       "us-gaap:LeasesOfLesseeDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "form_10-k.htm",
      "contextRef": "AsOf2022-12-31",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentOther",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "us-gaap:LeasesOfLesseeDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "form_10-k.htm",
      "contextRef": "AsOf2022-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000039 - Disclosure - Schedule of maturities of lease liabilities (Details)",
     "menuCat": "Details",
     "order": "39",
     "role": "http://korumedical.com/role/ScheduleOfMaturitiesOfLeaseLiabilitiesDetails",
     "shortName": "Schedule of maturities of lease liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "us-gaap:LeasesOfLesseeDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "form_10-k.htm",
      "contextRef": "AsOf2022-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "form_10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00000004 - Statement - STATEMENTS OF OPERATIONS",
     "menuCat": "Statements",
     "order": "4",
     "role": "http://korumedical.com/role/StatementsOfOperations",
     "shortName": "STATEMENTS OF OPERATIONS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "form_10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:CostOfGoodsAndServicesSold",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:LeasesOfLesseeDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "form_10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "krmd:DescriptionOfLessorOperatingLeaseTerm",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000040 - Disclosure - LEASES (Details Narrative)",
     "menuCat": "Details",
     "order": "40",
     "role": "http://korumedical.com/role/LeasesDetailsNarrative",
     "shortName": "LEASES (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:LeasesOfLesseeDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "form_10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "krmd:DescriptionOfLessorOperatingLeaseTerm",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "form_10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:CurrentStateAndLocalTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000041 - Disclosure - Schedule of provision for income taxes (Details)",
     "menuCat": "Details",
     "order": "41",
     "role": "http://korumedical.com/role/ScheduleOfProvisionForIncomeTaxesDetails",
     "shortName": "Schedule of provision for income taxes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "form_10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:CurrentStateAndLocalTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "form_10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000042 - Disclosure - Schedule of reconciliation of income taxes (Details)",
     "menuCat": "Details",
     "order": "42",
     "role": "http://korumedical.com/role/ScheduleOfReconciliationOfIncomeTaxesDetails",
     "shortName": "Schedule of reconciliation of income taxes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "form_10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "form_10-k.htm",
      "contextRef": "AsOf2022-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredCompensationPlanAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000043 - Disclosure - Schedule of components of deferred tax assets (Details)",
     "menuCat": "Details",
     "order": "43",
     "role": "http://korumedical.com/role/ScheduleOfComponentsOfDeferredTaxAssetsDetails",
     "shortName": "Schedule of components of deferred tax assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "form_10-k.htm",
      "contextRef": "AsOf2022-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredCompensationPlanAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:ConcentrationRiskDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "form_10-k.htm",
      "contextRef": "From2022-01-012022-12-31_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerOneMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000044 - Disclosure - MAJOR CUSTOMERS (Details Narrative)",
     "menuCat": "Details",
     "order": "44",
     "role": "http://korumedical.com/role/MajorCustomersDetailsNarrative",
     "shortName": "MAJOR CUSTOMERS (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:ConcentrationRiskDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "form_10-k.htm",
      "contextRef": "From2022-01-012022-12-31_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerOneMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Pure",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "form_10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "krmd:DescriptionOfMatchingContribution",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000045 - Disclosure - EMPLOYEE BENEFITS (Details Narrative)",
     "menuCat": "Details",
     "order": "45",
     "role": "http://korumedical.com/role/EmployeeBenefitsDetailsNarrative",
     "shortName": "EMPLOYEE BENEFITS (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "form_10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "krmd:DescriptionOfMatchingContribution",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:DebtDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "form_10-k.htm",
      "contextRef": "AsOf2022-08-05_custom_AONPremiumFinanceLLCMember_custom_PromissoryNoteMember",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:NotesPayable",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000046 - Disclosure - DEBT OBLIGATIONS (Details Narrative)",
     "menuCat": "Details",
     "order": "46",
     "role": "http://korumedical.com/role/DebtObligationsDetailsNarrative",
     "shortName": "DEBT OBLIGATIONS (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:DebtDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "form_10-k.htm",
      "contextRef": "AsOf2022-08-05_custom_AONPremiumFinanceLLCMember_custom_PromissoryNoteMember",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:NotesPayable",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "form_10-k.htm",
      "contextRef": "AsOf2020-12-31_us-gaap_CommonStockMember",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00000005 - Statement - STATEMENTS OF STOCKHOLDERS' EQUITY",
     "menuCat": "Statements",
     "order": "5",
     "role": "http://korumedical.com/role/StatementsOfStockholdersEquity",
     "shortName": "STATEMENTS OF STOCKHOLDERS' EQUITY",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "form_10-k.htm",
      "contextRef": "AsOf2020-12-31_us-gaap_CommonStockMember",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "form_10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00000006 - Statement - STATEMENTS OF CASH FLOWS",
     "menuCat": "Statements",
     "order": "6",
     "role": "http://korumedical.com/role/StatementsOfCashFlows",
     "shortName": "STATEMENTS OF CASH FLOWS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "form_10-k.htm",
      "contextRef": "From2021-01-012021-12-31",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:GainLossOnSaleOfOtherAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "form_10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000007 - Disclosure - NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
     "menuCat": "Notes",
     "order": "7",
     "role": "http://korumedical.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPolicies",
     "shortName": "NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "form_10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "form_10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000008 - Disclosure - INVENTORY",
     "menuCat": "Notes",
     "order": "8",
     "role": "http://korumedical.com/role/Inventory",
     "shortName": "INVENTORY",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "form_10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "form_10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000009 - Disclosure - PROPERTY AND EQUIPMENT",
     "menuCat": "Notes",
     "order": "9",
     "role": "http://korumedical.com/role/PropertyAndEquipment",
     "shortName": "PROPERTY AND EQUIPMENT",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "form_10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 36,
   "tag": {
    "country_US": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "UNITED STATES"
       }
      }
     },
     "localname": "US",
     "nsuri": "http://xbrl.sec.gov/country/2022",
     "presentation": [
      "http://korumedical.com/role/ScheduleOfNetRevenuesByGeographyDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of changes contained within amended document.",
        "label": "Amendment Description"
       }
      }
     },
     "localname": "AmendmentDescription",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://korumedical.com/role/Cover"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://korumedical.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AnnualInformationForm": {
     "auth_ref": [
      "r521"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.",
        "label": "Annual Information Form"
       }
      }
     },
     "localname": "AnnualInformationForm",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://korumedical.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditedAnnualFinancialStatements": {
     "auth_ref": [
      "r521"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.",
        "label": "Audited Annual Financial Statements"
       }
      }
     },
     "localname": "AuditedAnnualFinancialStatements",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://korumedical.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditorFirmId": {
     "auth_ref": [
      "r518",
      "r520",
      "r521"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "PCAOB issued Audit Firm Identifier",
        "label": "Auditor Firm ID"
       }
      }
     },
     "localname": "AuditorFirmId",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://korumedical.com/role/Cover"
     ],
     "xbrltype": "nonemptySequenceNumberItemType"
    },
    "dei_AuditorLocation": {
     "auth_ref": [
      "r518",
      "r520",
      "r521"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location"
       }
      }
     },
     "localname": "AuditorLocation",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://korumedical.com/role/Cover"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_AuditorName": {
     "auth_ref": [
      "r518",
      "r520",
      "r521"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name"
       }
      }
     },
     "localname": "AuditorName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://korumedical.com/role/Cover"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://korumedical.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CountryRegion": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Region code of country",
        "label": "Country Region"
       }
      }
     },
     "localname": "CountryRegion",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://korumedical.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://korumedical.com/role/Cover"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAccountingStandard": {
     "auth_ref": [
      "r520"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.",
        "label": "Document Accounting Standard"
       }
      }
     },
     "localname": "DocumentAccountingStandard",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://korumedical.com/role/Cover"
     ],
     "xbrltype": "accountingStandardItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r518",
      "r520",
      "r521"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://korumedical.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://korumedical.com/role/Cover"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://korumedical.com/role/Cover"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://korumedical.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentPeriodStartDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.",
        "label": "Document Period Start Date"
       }
      }
     },
     "localname": "DocumentPeriodStartDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://korumedical.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r519"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://korumedical.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentRegistrationStatement": {
     "auth_ref": [
      "r507"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a registration statement.",
        "label": "Document Registration Statement"
       }
      }
     },
     "localname": "DocumentRegistrationStatement",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://korumedical.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentShellCompanyEventDate": {
     "auth_ref": [
      "r520"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date of event requiring a shell company report.",
        "label": "Document Shell Company Event Date"
       }
      }
     },
     "localname": "DocumentShellCompanyEventDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://korumedical.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentShellCompanyReport": {
     "auth_ref": [
      "r520"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.",
        "label": "Document Shell Company Report"
       }
      }
     },
     "localname": "DocumentShellCompanyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://korumedical.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r522"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://korumedical.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://korumedical.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "auth_ref": [
      "r510"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Documents incorporated by reference.",
        "label": "Documents Incorporated by Reference [Text Block]"
       }
      }
     },
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://korumedical.com/role/Cover"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://korumedical.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://korumedical.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine3": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 3 such as an Office Park",
        "label": "Entity Address, Address Line Three"
       }
      }
     },
     "localname": "EntityAddressAddressLine3",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://korumedical.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://korumedical.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCountry": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ISO 3166-1 alpha-2 country code.",
        "label": "Entity Address, Country"
       }
      }
     },
     "localname": "EntityAddressCountry",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://korumedical.com/role/Cover"
     ],
     "xbrltype": "countryCodeItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://korumedical.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://korumedical.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "auth_ref": [
      "r513"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not.  Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.",
        "label": "Entity Bankruptcy Proceedings, Reporting Current"
       }
      }
     },
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://korumedical.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r509"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://korumedical.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://korumedical.com/role/Cover"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://korumedical.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains."
       }
      }
     },
     "localname": "EntityDomain",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://korumedical.com/role/DebtObligationsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r509"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://korumedical.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r526"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Elected Not To Use the Extended Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://korumedical.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://korumedical.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r509"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://korumedical.com/role/Cover"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://korumedical.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r523"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://korumedical.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPrimarySicNumber": {
     "auth_ref": [
      "r521"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.",
        "label": "Entity Primary SIC Number"
       }
      }
     },
     "localname": "EntityPrimarySicNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://korumedical.com/role/Cover"
     ],
     "xbrltype": "sicNumberItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://korumedical.com/role/Cover"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r509"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://korumedical.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r509"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://korumedical.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r509"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://korumedical.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r509"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://korumedical.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://korumedical.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [
      "r524"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://korumedical.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_Extension": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Extension number for local phone number.",
        "label": "Extension"
       }
      }
     },
     "localname": "Extension",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://korumedical.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_LegalEntityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The set of legal entities associated with a report.",
        "label": "Legal Entity [Axis]"
       }
      }
     },
     "localname": "LegalEntityAxis",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://korumedical.com/role/DebtObligationsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://korumedical.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_NoTradingSymbolFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a security having no trading symbol.",
        "label": "No Trading Symbol Flag"
       }
      }
     },
     "localname": "NoTradingSymbolFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://korumedical.com/role/Cover"
     ],
     "xbrltype": "trueItemType"
    },
    "dei_OtherReportingStandardItemNumber": {
     "auth_ref": [
      "r520"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.",
        "label": "Other Reporting Standard Item Number"
       }
      }
     },
     "localname": "OtherReportingStandardItemNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://korumedical.com/role/Cover"
     ],
     "xbrltype": "otherReportingStandardItemNumberItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r514"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://korumedical.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r515"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://korumedical.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r508"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://korumedical.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_Security12gTitle": {
     "auth_ref": [
      "r512"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(g) registered security.",
        "label": "Title of 12(g) Security"
       }
      }
     },
     "localname": "Security12gTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://korumedical.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r511"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://korumedical.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SecurityReportingObligation": {
     "auth_ref": [
      "r516"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.",
        "label": "Security Reporting Obligation"
       }
      }
     },
     "localname": "SecurityReportingObligation",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://korumedical.com/role/Cover"
     ],
     "xbrltype": "securityReportingObligationItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r517"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://korumedical.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://korumedical.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r525"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://korumedical.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "krmd_AONPremiumFinanceLLCMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The element represents a o n premium finance l l c member.",
        "label": "A O N Premium Finance L L C [Member]"
       }
      }
     },
     "localname": "AONPremiumFinanceLLCMember",
     "nsuri": "http://korumedical.com/20221231",
     "presentation": [
      "http://korumedical.com/role/DebtObligationsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "krmd_AccountingPronouncementsNotYetAdopted": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The element represents accounting pronouncements not yet adopted.",
        "label": "ACCOUNTING PRONOUNCEMENTS NOT YET ADOPTED"
       }
      }
     },
     "localname": "AccountingPronouncementsNotYetAdopted",
     "nsuri": "http://korumedical.com/20221231",
     "presentation": [
      "http://korumedical.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "krmd_AllocatedShareBasedCompensationExpense1": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The element represents allocated share based compensation expense1.",
        "label": "Allocated Share Based Compensation Expense1",
        "verboseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense1",
     "nsuri": "http://korumedical.com/20221231",
     "presentation": [
      "http://korumedical.com/role/ScheduleOfPerformanceBaseOptionsOutstandingDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "krmd_AllowanceForDoubtfulOtherReceivables1Current": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The element represents allowance for doubtful other receivables1 current.",
        "label": "Allowance for bad debts and other"
       }
      }
     },
     "localname": "AllowanceForDoubtfulOtherReceivables1Current",
     "nsuri": "http://korumedical.com/20221231",
     "presentation": [
      "http://korumedical.com/role/ScheduleOfComponentsOfDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "krmd_AmortizationOfIntangibleAssets1": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The element represents amortization of intangible assets1.",
        "label": "AmortizationOfIntangibleAssets1"
       }
      }
     },
     "localname": "AmortizationOfIntangibleAssets1",
     "nsuri": "http://korumedical.com/20221231",
     "presentation": [
      "http://korumedical.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "krmd_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted stock shares excluded"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount1",
     "nsuri": "http://korumedical.com/20221231",
     "presentation": [
      "http://korumedical.com/role/ScheduleOfNetIncomePerCommonShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "krmd_AssetsAndLiabilitiesLesseeFinanceAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The element represents assets and liabilities lessee finance abstract.",
        "label": "Finance Leases"
       }
      }
     },
     "localname": "AssetsAndLiabilitiesLesseeFinanceAbstract",
     "nsuri": "http://korumedical.com/20221231",
     "presentation": [
      "http://korumedical.com/role/SchdeuleOfBalanceSheetInformationRelatedToLeasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "krmd_AssetsAndLiabilitiesOperatingLesseeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The element represents assets and liabilities operating lessee abstract.",
        "label": "Operating Leases"
       }
      }
     },
     "localname": "AssetsAndLiabilitiesOperatingLesseeAbstract",
     "nsuri": "http://korumedical.com/20221231",
     "presentation": [
      "http://korumedical.com/role/SchdeuleOfBalanceSheetInformationRelatedToLeasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "krmd_BorrowingsFromIndebtedness": {
     "auth_ref": [],
     "calculation": {
      "http://korumedical.com/role/StatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The element represents borrowings from indebtedness.",
        "label": "Borrowings from indebtedness"
       }
      }
     },
     "localname": "BorrowingsFromIndebtedness",
     "nsuri": "http://korumedical.com/20221231",
     "presentation": [
      "http://korumedical.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "krmd_CashPaidDuringPeriodsForAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The element represents cash paid during periods for abstract.",
        "label": "Cash paid during the years for:"
       }
      }
     },
     "localname": "CashPaidDuringPeriodsForAbstract",
     "nsuri": "http://korumedical.com/20221231",
     "presentation": [
      "http://korumedical.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "krmd_ChiefExecutiveOfficerLindaTharbyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The element represents chief executive officer linda tharby member.",
        "label": "Chief Executive Officer Linda Tharby [Member]"
       }
      }
     },
     "localname": "ChiefExecutiveOfficerLindaTharbyMember",
     "nsuri": "http://korumedical.com/20221231",
     "presentation": [
      "http://korumedical.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "krmd_CommonStockIssuanceAsSettlementForLitigation": {
     "auth_ref": [],
     "calculation": {
      "http://korumedical.com/role/StatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The element represents common stock issuance as settlement for litigation.",
        "label": "Common stock issuance settlement of litigation"
       }
      }
     },
     "localname": "CommonStockIssuanceAsSettlementForLitigation",
     "nsuri": "http://korumedical.com/20221231",
     "presentation": [
      "http://korumedical.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "krmd_CompensationCost": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The element represents compensation cost.",
        "label": "Unrecognized compensation cost"
       }
      }
     },
     "localname": "CompensationCost",
     "nsuri": "http://korumedical.com/20221231",
     "presentation": [
      "http://korumedical.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "krmd_Compensationexpenserelatedtorestrictedstockawards": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The element represents compensationexpenserelatedtorestrictedstockawards.",
        "label": "Compensation expense related to restricted stock awards (in shares)"
       }
      }
     },
     "localname": "Compensationexpenserelatedtorestrictedstockawards",
     "nsuri": "http://korumedical.com/20221231",
     "presentation": [
      "http://korumedical.com/role/StatementsOfStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "krmd_CustomerOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer One [Member]"
       }
      }
     },
     "localname": "CustomerOneMember",
     "nsuri": "http://korumedical.com/20221231",
     "presentation": [
      "http://korumedical.com/role/MajorCustomersDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "krmd_DepreciationDepletionAndAmortization1": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The element represents depreciation depletion and amortization1.",
        "label": "Depreciation Depletion and Amortization1",
        "verboseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization1",
     "nsuri": "http://korumedical.com/20221231",
     "presentation": [
      "http://korumedical.com/role/ScheduleOfComponentsOfDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "krmd_DescriptionOfLessorOperatingLeaseTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The element represents description of lessor operating lease term.",
        "label": "Description of lease term"
       }
      }
     },
     "localname": "DescriptionOfLessorOperatingLeaseTerm",
     "nsuri": "http://korumedical.com/20221231",
     "presentation": [
      "http://korumedical.com/role/LeasesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "krmd_DescriptionOfMatchingContribution": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The element represents description of matching contribution.",
        "label": "Description of matching contribution"
       }
      }
     },
     "localname": "DescriptionOfMatchingContribution",
     "nsuri": "http://korumedical.com/20221231",
     "presentation": [
      "http://korumedical.com/role/EmployeeBenefitsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "krmd_EmploymentAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The element represents employment agreement member.",
        "label": "Employment Agreement [Member]"
       }
      }
     },
     "localname": "EmploymentAgreementMember",
     "nsuri": "http://korumedical.com/20221231",
     "presentation": [
      "http://korumedical.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "krmd_EquipmentAndToolingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The element represents equipment and tooling member.",
        "label": "Equipment and tooling [Member]"
       }
      }
     },
     "localname": "EquipmentAndToolingMember",
     "nsuri": "http://korumedical.com/20221231",
     "presentation": [
      "http://korumedical.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "krmd_ExecutiveMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Executive [Member]"
       }
      }
     },
     "localname": "ExecutiveMember",
     "nsuri": "http://korumedical.com/20221231",
     "presentation": [
      "http://korumedical.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "krmd_ExecutiveskeyEmployeesAndConsultantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The element represents executiveskey employees and consultants member.",
        "label": "Executiveskey Employees And Consultants [Member]"
       }
      }
     },
     "localname": "ExecutiveskeyEmployeesAndConsultantsMember",
     "nsuri": "http://korumedical.com/20221231",
     "presentation": [
      "http://korumedical.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "krmd_ExercisePrice1Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The element represents exercise price1 member.",
        "label": "Exercise Price1 [Member]"
       }
      }
     },
     "localname": "ExercisePrice1Member",
     "nsuri": "http://korumedical.com/20221231",
     "presentation": [
      "http://korumedical.com/role/ScheduleOfInformationPertainingToOptionsOutstandingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "krmd_FinanceLeaseCost": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The element represents finance lease cost.",
        "label": "Total finance lease cost"
       }
      }
     },
     "localname": "FinanceLeaseCost",
     "nsuri": "http://korumedical.com/20221231",
     "presentation": [
      "http://korumedical.com/role/ScheduleOfComponentsOfLeaseExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "krmd_FinanceLeaseCost1Abstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The element represents finance lease cost1 abstract.",
        "label": "Finance lease cost:"
       }
      }
     },
     "localname": "FinanceLeaseCost1Abstract",
     "nsuri": "http://korumedical.com/20221231",
     "presentation": [
      "http://korumedical.com/role/ScheduleOfComponentsOfLeaseExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "krmd_FurnitureAndOfficeEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The element represents furniture and office equipment member.",
        "label": "Furniture And Office Equipment [Member]"
       }
      }
     },
     "localname": "FurnitureAndOfficeEquipmentMember",
     "nsuri": "http://korumedical.com/20221231",
     "presentation": [
      "http://korumedical.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesDetailsNarrative",
      "http://korumedical.com/role/ScheduleOfPropertyAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "krmd_IncrementalCommonSharesAttributableToRestrictedStock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted stock includable"
       }
      }
     },
     "localname": "IncrementalCommonSharesAttributableToRestrictedStock",
     "nsuri": "http://korumedical.com/20221231",
     "presentation": [
      "http://korumedical.com/role/ScheduleOfNetIncomePerCommonShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "krmd_IssuanceOfCommonStockCompensation": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The element represents issuance of common stock compensation.",
        "label": "Issuance of common stock as compensation"
       }
      }
     },
     "localname": "IssuanceOfCommonStockCompensation",
     "nsuri": "http://korumedical.com/20221231",
     "presentation": [
      "http://korumedical.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "krmd_LesseeFinancingLeaseImputedInterest": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The element represents lessee financing lease imputed interest.",
        "label": "Lessee Financing Lease Imputed Interest",
        "negatedLabel": "Less: imputed interest"
       }
      }
     },
     "localname": "LesseeFinancingLeaseImputedInterest",
     "nsuri": "http://korumedical.com/20221231",
     "presentation": [
      "http://korumedical.com/role/ScheduleOfMaturitiesOfLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "krmd_LesseeFinancingLeaseLeaseLiabilityPaymentsDueTotal": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The element represents lessee financing lease lease liability payments due total.",
        "label": "Lessee Financing Lease Lease Liability Payments Due Total",
        "verboseLabel": "Total undiscounted lease payments"
       }
      }
     },
     "localname": "LesseeFinancingLeaseLeaseLiabilityPaymentsDueTotal",
     "nsuri": "http://korumedical.com/20221231",
     "presentation": [
      "http://korumedical.com/role/ScheduleOfMaturitiesOfLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "krmd_LesseeOperatingLeaseImputedInterest": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The element represents lessee operating lease imputed interest.",
        "label": "Lessee Operating Lease Imputed Interest",
        "negatedLabel": "Less: imputed interest"
       }
      }
     },
     "localname": "LesseeOperatingLeaseImputedInterest",
     "nsuri": "http://korumedical.com/20221231",
     "presentation": [
      "http://korumedical.com/role/ScheduleOfMaturitiesOfLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "krmd_LesseeOperatingLeaseLiabilityPaymentsDueTotal": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The element represents lessee operating lease liability payments due total.",
        "label": "Total undiscounted lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueTotal",
     "nsuri": "http://korumedical.com/20221231",
     "presentation": [
      "http://korumedical.com/role/ScheduleOfMaturitiesOfLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "krmd_ManufacturingEquipmentAndToolingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The element represents manufacturing equipment and tooling member.",
        "label": "Manufacturing Equipment And Tooling [Member]"
       }
      }
     },
     "localname": "ManufacturingEquipmentAndToolingMember",
     "nsuri": "http://korumedical.com/20221231",
     "presentation": [
      "http://korumedical.com/role/ScheduleOfPropertyAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "krmd_NewIssuanceLitigationSettlementAmountIssuance": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The element represents new issuance litigation settlement amount issuance.",
        "label": "Litigation settlement share issuance"
       }
      }
     },
     "localname": "NewIssuanceLitigationSettlementAmountIssuance",
     "nsuri": "http://korumedical.com/20221231",
     "presentation": [
      "http://korumedical.com/role/StatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "krmd_NewIssuanceLitigationSettlementShareIssuance": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The element represents new issuance litigation settlement share issuance.",
        "label": "Litigation settlement share issuance (in shares)"
       }
      }
     },
     "localname": "NewIssuanceLitigationSettlementShareIssuance",
     "nsuri": "http://korumedical.com/20221231",
     "presentation": [
      "http://korumedical.com/role/StatementsOfStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "krmd_Nol": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The element represents nol.",
        "label": "NOL"
       }
      }
     },
     "localname": "Nol",
     "nsuri": "http://korumedical.com/20221231",
     "presentation": [
      "http://korumedical.com/role/ScheduleOfComponentsOfDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "krmd_NonEmployeeDirectorAndBoardAdvisorMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The element represents non employee director and board advisor member.",
        "label": "Non Employee Director And Board Advisor [Member["
       }
      }
     },
     "localname": "NonEmployeeDirectorAndBoardAdvisorMember",
     "nsuri": "http://korumedical.com/20221231",
     "presentation": [
      "http://korumedical.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "krmd_NonemployeeServicesTransactionCost": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The element represents nonemployee services transaction cost.",
        "label": "Nonemployee services transaction cost"
       }
      }
     },
     "localname": "NonemployeeServicesTransactionCost",
     "nsuri": "http://korumedical.com/20221231",
     "presentation": [
      "http://korumedical.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "krmd_NotePayableTerms": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The element represents note payable terms.",
        "label": "Note payable terms"
       }
      }
     },
     "localname": "NotePayableTerms",
     "nsuri": "http://korumedical.com/20221231",
     "presentation": [
      "http://korumedical.com/role/DebtObligationsDetailsNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "krmd_PatentsAndTrademarksMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Patents And Trademarks [Member]"
       }
      }
     },
     "localname": "PatentsAndTrademarksMember",
     "nsuri": "http://korumedical.com/20221231",
     "presentation": [
      "http://korumedical.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "krmd_PaymentsOnIndebtedness": {
     "auth_ref": [],
     "calculation": {
      "http://korumedical.com/role/StatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The element represents payments on indebtedness.",
        "label": "Payments On Indebtedness",
        "negatedLabel": "Payments on indebtedness"
       }
      }
     },
     "localname": "PaymentsOnIndebtedness",
     "nsuri": "http://korumedical.com/20221231",
     "presentation": [
      "http://korumedical.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "krmd_PromissoryNoteMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The element represents promissory note member.",
        "label": "Promissory Note [Member]"
       }
      }
     },
     "localname": "PromissoryNoteMember",
     "nsuri": "http://korumedical.com/20221231",
     "presentation": [
      "http://korumedical.com/role/DebtObligationsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "krmd_RdCredit": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The element represents rd credit.",
        "label": "R&amp;D credit"
       }
      }
     },
     "localname": "RdCredit",
     "nsuri": "http://korumedical.com/20221231",
     "presentation": [
      "http://korumedical.com/role/ScheduleOfComponentsOfDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "krmd_RestrictedStockAwardsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The element represents restricted stock awards member.",
        "label": "Restricted Stock Awards [Member]"
       }
      }
     },
     "localname": "RestrictedStockAwardsMember",
     "nsuri": "http://korumedical.com/20221231",
     "presentation": [
      "http://korumedical.com/role/FollowingTableSummarizesActivitiesForOurUnvestedRestrictedStockAwardsForTwelveMonthsEndedDecember312022And2021.Details",
      "http://korumedical.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "krmd_RouLandlordCredit": {
     "auth_ref": [],
     "calculation": {
      "http://korumedical.com/role/StatementsOfCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The element represents rou landlord credit.",
        "label": "ROU landlord credit"
       }
      }
     },
     "localname": "RouLandlordCredit",
     "nsuri": "http://korumedical.com/20221231",
     "presentation": [
      "http://korumedical.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "krmd_ScheduleOfNetRevenuesByGeography": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of net revenues by geography"
       }
      }
     },
     "localname": "ScheduleOfNetRevenuesByGeography",
     "nsuri": "http://korumedical.com/20221231",
     "presentation": [
      "http://korumedical.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "krmd_ScheduleOfShareBasedCompensationStockOptionsActivityAmendedTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The element represents schedule of share based compensation stock options activity amended table text block.",
        "label": "Schedule of information pertaining to options outstanding"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityAmendedTableTextBlock",
     "nsuri": "http://korumedical.com/20221231",
     "presentation": [
      "http://korumedical.com/role/Stock-basedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "krmd_ScheduleOfShareBasedCompensationtaxBenefitsAssociatedWithRestrictedStockAwardCompensationTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The element represents schedule of share based compensationtax benefits associated with restricted stock award compensation table text block.",
        "label": "Schedule Of Share Based Compensationtax Benefits Associated With Restricted Stock Award Compensation Table Text Block",
        "verboseLabel": "Schedule of information pertaining to options outstanding"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationtaxBenefitsAssociatedWithRestrictedStockAwardCompensationTableTextBlock",
     "nsuri": "http://korumedical.com/20221231",
     "presentation": [
      "http://korumedical.com/role/Stock-basedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The element represents share based compensation arrangement by share based payment award grants in period weighted average grant date fair value.",
        "label": "Weighted-average grant-date fair value options granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://korumedical.com/20221231",
     "presentation": [
      "http://korumedical.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The element represents share based compensation arrangement by share based payment award options exercisable weighted average exercise price1.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price1",
        "verboseLabel": "Options exercisable at ending"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice1",
     "nsuri": "http://korumedical.com/20221231",
     "presentation": [
      "http://korumedical.com/role/ScheduleOfPerformanceBaseOptionsOutstandingDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The element represents share based compensation arrangement by share based payment award options exercisable weighted average exercise price2.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price2",
        "verboseLabel": "Options exercisable at ending"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice2",
     "nsuri": "http://korumedical.com/20221231",
     "presentation": [
      "http://korumedical.com/role/ScheduleOfStatusOfTimeBasedStockOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The element represents share based compensation arrangement by share based payment award options forfeitures in period1.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period 1",
        "verboseLabel": "Forfeited"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod1",
     "nsuri": "http://korumedical.com/20221231",
     "presentation": [
      "http://korumedical.com/role/ScheduleOfPerformanceBaseOptionsOutstandingDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The element represents share based compensation arrangement by share based payment award options forfeitures in period2.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period2",
        "verboseLabel": "Forfeited"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod2",
     "nsuri": "http://korumedical.com/20221231",
     "presentation": [
      "http://korumedical.com/role/ScheduleOfStatusOfTimeBasedStockOptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodUnvested": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The element represents share based compensation arrangement by share based payment award options forfeitures in period unvested.",
        "label": "Forfeited/canceled"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodUnvested",
     "nsuri": "http://korumedical.com/20221231",
     "presentation": [
      "http://korumedical.com/role/FollowingTableSummarizesActivitiesForOurUnvestedRestrictedStockAwardsForTwelveMonthsEndedDecember312022And2021.Details"
     ],
     "xbrltype": "sharesItemType"
    },
    "krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The element represents share based compensation arrangement by share based payment award options grants in period gross1.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Option Grants In Period Gross1",
        "verboseLabel": "Options exercisable at ending"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross1",
     "nsuri": "http://korumedical.com/20221231",
     "presentation": [
      "http://korumedical.com/role/ScheduleOfPerformanceBaseOptionsOutstandingDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The element represents share based compensation arrangement by share based payment award options grants in period gross2.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross2",
        "verboseLabel": "Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross2",
     "nsuri": "http://korumedical.com/20221231",
     "presentation": [
      "http://korumedical.com/role/ScheduleOfStatusOfTimeBasedStockOptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrossUnvested": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The element represents share based compensation arrangement by share based payment award options grants in period gross unvested.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross Unvested",
        "verboseLabel": "Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrossUnvested",
     "nsuri": "http://korumedical.com/20221231",
     "presentation": [
      "http://korumedical.com/role/FollowingTableSummarizesActivitiesForOurUnvestedRestrictedStockAwardsForTwelveMonthsEndedDecember312022And2021.Details"
     ],
     "xbrltype": "sharesItemType"
    },
    "krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The element represents share based compensation arrangement by share based payment award options grants in period weighted average grant date fair value1.",
        "label": "ShareBasedCompensationArrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value1",
        "verboseLabel": "Weighted average fair value of options granted during the period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue1",
     "nsuri": "http://korumedical.com/20221231",
     "presentation": [
      "http://korumedical.com/role/ScheduleOfPerformanceBaseOptionsOutstandingDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The element represents share based compensation arrangement by share based payment award options grants in period weighted average grant date fair value2.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value2",
        "verboseLabel": "Weighted average fair value of options granted during the period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue2",
     "nsuri": "http://korumedical.com/20221231",
     "presentation": [
      "http://korumedical.com/role/ScheduleOfStatusOfTimeBasedStockOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The element represents share based compensation arrangement by share based payment award options outstanding number1.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number1",
        "periodStartLabel": "Outstanding at beginning"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber1",
     "nsuri": "http://korumedical.com/20221231",
     "presentation": [
      "http://korumedical.com/role/ScheduleOfPerformanceBaseOptionsOutstandingDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The element represents share based compensation arrangement by share based payment award options outstanding number2.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number2",
        "periodEndLabel": "Outstanding at ending",
        "periodStartLabel": "Outstanding at beginning"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber2",
     "nsuri": "http://korumedical.com/20221231",
     "presentation": [
      "http://korumedical.com/role/ScheduleOfStatusOfTimeBasedStockOptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberUnvested": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The element represents share based compensation arrangement by share based payment award options outstanding number unvested.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number Unvested",
        "periodEndLabel": "Outstanding at ending",
        "periodStartLabel": "Outstanding at beginning"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberUnvested",
     "nsuri": "http://korumedical.com/20221231",
     "presentation": [
      "http://korumedical.com/role/FollowingTableSummarizesActivitiesForOurUnvestedRestrictedStockAwardsForTwelveMonthsEndedDecember312022And2021.Details"
     ],
     "xbrltype": "sharesItemType"
    },
    "krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The element represents share based compensation arrangement by share based payment award options outstanding weighted average exercise price1.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price1",
        "periodStartLabel": "Outstanding at beginning"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice1",
     "nsuri": "http://korumedical.com/20221231",
     "presentation": [
      "http://korumedical.com/role/ScheduleOfPerformanceBaseOptionsOutstandingDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The element represents share based compensation arrangement by share based payment award options outstanding weighted average exercise price2.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price2",
        "periodEndLabel": "Outstanding at ending",
        "periodStartLabel": "Outstanding at beginning"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice2",
     "nsuri": "http://korumedical.com/20221231",
     "presentation": [
      "http://korumedical.com/role/ScheduleOfStatusOfTimeBasedStockOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceUnvested": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The element represents share based compensation arrangement by share based payment award options outstanding weighted average exercise price unvested.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price Unvested",
        "periodEndLabel": "Outstanding at ending",
        "periodStartLabel": "Outstanding at beginning"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceUnvested",
     "nsuri": "http://korumedical.com/20221231",
     "presentation": [
      "http://korumedical.com/role/FollowingTableSummarizesActivitiesForOurUnvestedRestrictedStockAwardsForTwelveMonthsEndedDecember312022And2021.Details"
     ],
     "xbrltype": "perShareItemType"
    },
    "krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodGross": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The element represents share based compensation arrangement by share based payment award options vested in period gross.",
        "label": "Vested"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodGross",
     "nsuri": "http://korumedical.com/20221231",
     "presentation": [
      "http://korumedical.com/role/FollowingTableSummarizesActivitiesForOurUnvestedRestrictedStockAwardsForTwelveMonthsEndedDecember312022And2021.Details"
     ],
     "xbrltype": "sharesItemType"
    },
    "krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The element represents share based compensation arrangements by share based payment award options exercises in period weighted average exercise price1.",
        "label": "Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price1",
        "verboseLabel": "Exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice1",
     "nsuri": "http://korumedical.com/20221231",
     "presentation": [
      "http://korumedical.com/role/ScheduleOfPerformanceBaseOptionsOutstandingDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The element represents share based compensation arrangements by share based payment award options exercises in period weighted average exercise price2.",
        "label": "Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price2",
        "verboseLabel": "Exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice2",
     "nsuri": "http://korumedical.com/20221231",
     "presentation": [
      "http://korumedical.com/role/ScheduleOfStatusOfTimeBasedStockOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The element represents share based compensation arrangements by share based payment award options forfeitures in period weighted average exercise price1.",
        "label": "ShareBased Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price1",
        "verboseLabel": "Forfeited"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice1",
     "nsuri": "http://korumedical.com/20221231",
     "presentation": [
      "http://korumedical.com/role/ScheduleOfPerformanceBaseOptionsOutstandingDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The element represents share based compensation arrangements by share based payment award options forfeitures in period weighted average exercise price2.",
        "label": "Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price2",
        "verboseLabel": "Forfeited"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice2",
     "nsuri": "http://korumedical.com/20221231",
     "presentation": [
      "http://korumedical.com/role/ScheduleOfStatusOfTimeBasedStockOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePriceUnvested": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The element represents share based compensation arrangements by share based payment award options forfeitures in period weighted average exercise price unvested.",
        "label": "Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price Unvested",
        "verboseLabel": "Forfeited/canceled"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePriceUnvested",
     "nsuri": "http://korumedical.com/20221231",
     "presentation": [
      "http://korumedical.com/role/FollowingTableSummarizesActivitiesForOurUnvestedRestrictedStockAwardsForTwelveMonthsEndedDecember312022And2021.Details"
     ],
     "xbrltype": "perShareItemType"
    },
    "krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The element represents share based compensation arrangements by share based payment award options grants in period weighted average exercise price1..",
        "label": "Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price1",
        "verboseLabel": "Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice1",
     "nsuri": "http://korumedical.com/20221231",
     "presentation": [
      "http://korumedical.com/role/ScheduleOfPerformanceBaseOptionsOutstandingDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The element represents share based compensation arrangements by share based payment award options grants in period weighted average exercise price2.",
        "label": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice2",
        "verboseLabel": "Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice2",
     "nsuri": "http://korumedical.com/20221231",
     "presentation": [
      "http://korumedical.com/role/ScheduleOfStatusOfTimeBasedStockOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePriceUnvested": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The element represents share based compensation arrangements by share based payment award options grants in period weighted average exercise price unvested.",
        "label": "Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price Unvested",
        "verboseLabel": "Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePriceUnvested",
     "nsuri": "http://korumedical.com/20221231",
     "presentation": [
      "http://korumedical.com/role/FollowingTableSummarizesActivitiesForOurUnvestedRestrictedStockAwardsForTwelveMonthsEndedDecember312022And2021.Details"
     ],
     "xbrltype": "perShareItemType"
    },
    "krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The element represents share based compensation arrangements by share based payment award options vested in period weighted average exercise price.",
        "label": "Share Based Compensation Arrangements By Share Based Payment Award Options Vested In Period Weighted Average Exercise Price",
        "verboseLabel": "Vested"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://korumedical.com/20221231",
     "presentation": [
      "http://korumedical.com/role/FollowingTableSummarizesActivitiesForOurUnvestedRestrictedStockAwardsForTwelveMonthsEndedDecember312022And2021.Details"
     ],
     "xbrltype": "perShareItemType"
    },
    "krmd_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm3": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm3",
        "verboseLabel": "Weighted-average period"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm3",
     "nsuri": "http://korumedical.com/20221231",
     "presentation": [
      "http://korumedical.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "durationItemType"
    },
    "krmd_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm4": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm4",
        "verboseLabel": "Weighted-average period"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm4",
     "nsuri": "http://korumedical.com/20221231",
     "presentation": [
      "http://korumedical.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "durationItemType"
    },
    "krmd_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan2015": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The element represents stock issued during period shares employee stock ownership plan2015.",
        "label": "Stock issued during period"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan2015",
     "nsuri": "http://korumedical.com/20221231",
     "presentation": [
      "http://korumedical.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "krmd_StockIssuedDuringPeriodSharesStockOptionsExercised1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The element represents stock issued during period shares stock options exercised1.",
        "label": "Options exercised",
        "verboseLabel": "Exercised"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised1",
     "nsuri": "http://korumedical.com/20221231",
     "presentation": [
      "http://korumedical.com/role/ScheduleOfPerformanceBaseOptionsOutstandingDetails",
      "http://korumedical.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "krmd_StockIssuedDuringPeriodSharesStockOptionsExercised2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The element represents stock issued during period shares stock options exercised2.",
        "label": "Stock Issued During Period Shares Stock Options Exercised2",
        "verboseLabel": "Exercised"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised2",
     "nsuri": "http://korumedical.com/20221231",
     "presentation": [
      "http://korumedical.com/role/ScheduleOfStatusOfTimeBasedStockOptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "krmd_StockOptionPlan2015Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The element represents stock option plan2015 member.",
        "label": "Stock Option Plan 2015 [Member]"
       }
      }
     },
     "localname": "StockOptionPlan2015Member",
     "nsuri": "http://korumedical.com/20221231",
     "presentation": [
      "http://korumedical.com/role/ScheduleOfInformationPertainingToOptionsOutstandingDetails",
      "http://korumedical.com/role/ScheduleOfStatusOfTimeBasedStockOptionsDetails",
      "http://korumedical.com/role/ScheduleOfTimeBasedStockOptionsDetails",
      "http://korumedical.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "krmd_StockOptionPlan2021Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The element represents stock option plan2021 member.",
        "label": "Stock Option Plan 2021 [Member]"
       }
      }
     },
     "localname": "StockOptionPlan2021Member",
     "nsuri": "http://korumedical.com/20221231",
     "presentation": [
      "http://korumedical.com/role/FollowingTableSummarizesActivitiesForOurUnvestedRestrictedStockAwardsForTwelveMonthsEndedDecember312022And2021.Details",
      "http://korumedical.com/role/ScheduleOfInformationPertainingToOptionsOutstandingDetails",
      "http://korumedical.com/role/ScheduleOfStatusOfTimeBasedStockOptionsDetails",
      "http://korumedical.com/role/ScheduleOfTimeBasedStockOptionsDetails",
      "http://korumedical.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "krmd_TimeBasedSharesOptionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The element represents time based shares options member.",
        "label": "Time Based Shares Options [Member]"
       }
      }
     },
     "localname": "TimeBasedSharesOptionsMember",
     "nsuri": "http://korumedical.com/20221231",
     "presentation": [
      "http://korumedical.com/role/ScheduleOfInformationPertainingToOptionsOutstandingDetails",
      "http://korumedical.com/role/ScheduleOfTimeBasedStockOptionsDetails",
      "http://korumedical.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "krmd_UnrecognizedCompensationCost": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The element represents unrecognized compensation cost.",
        "label": "Unrecognized Compensation Cost",
        "verboseLabel": "Unrecognized compensation cost"
       }
      }
     },
     "localname": "UnrecognizedCompensationCost",
     "nsuri": "http://korumedical.com/20221231",
     "presentation": [
      "http://korumedical.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "krmd_WeightedAverageNumberOfSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The element represents weighted average number of shares outstanding.",
        "label": "Total"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstanding",
     "nsuri": "http://korumedical.com/20221231",
     "presentation": [
      "http://korumedical.com/role/ScheduleOfNetIncomePerCommonShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "srt_BoardOfDirectorsChairmanMember": {
     "auth_ref": [
      "r541"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Board of Directors Chairman [Member]"
       }
      }
     },
     "localname": "BoardOfDirectorsChairmanMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://korumedical.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ChiefExecutiveOfficerMember": {
     "auth_ref": [
      "r541"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Chief Executive Officer [Member]"
       }
      }
     },
     "localname": "ChiefExecutiveOfficerMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://korumedical.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_DirectorMember": {
     "auth_ref": [
      "r541"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Director [Member]"
       }
      }
     },
     "localname": "DirectorMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://korumedical.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MajorCustomersAxis": {
     "auth_ref": [
      "r208",
      "r498",
      "r551",
      "r604"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Axis]"
       }
      }
     },
     "localname": "MajorCustomersAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://korumedical.com/role/MajorCustomersDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r236",
      "r237",
      "r238",
      "r239",
      "r300",
      "r432",
      "r457",
      "r479",
      "r480",
      "r496",
      "r500",
      "r506",
      "r550",
      "r597",
      "r598",
      "r599",
      "r600",
      "r601",
      "r602"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://korumedical.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesDetailsNarrative",
      "http://korumedical.com/role/ScheduleOfTimeBasedStockOptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r236",
      "r237",
      "r238",
      "r239",
      "r300",
      "r432",
      "r457",
      "r479",
      "r480",
      "r496",
      "r500",
      "r506",
      "r550",
      "r597",
      "r598",
      "r599",
      "r600",
      "r601",
      "r602"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://korumedical.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesDetailsNarrative",
      "http://korumedical.com/role/ScheduleOfTimeBasedStockOptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_NameOfMajorCustomerDomain": {
     "auth_ref": [
      "r208",
      "r498",
      "r551",
      "r604"
     ],
     "localname": "NameOfMajorCustomerDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://korumedical.com/role/MajorCustomersDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r236",
      "r237",
      "r238",
      "r239",
      "r287",
      "r300",
      "r330",
      "r331",
      "r332",
      "r408",
      "r432",
      "r457",
      "r479",
      "r480",
      "r496",
      "r500",
      "r506",
      "r546",
      "r550",
      "r598",
      "r599",
      "r600",
      "r601",
      "r602"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://korumedical.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesDetailsNarrative",
      "http://korumedical.com/role/ScheduleOfTimeBasedStockOptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r236",
      "r237",
      "r238",
      "r239",
      "r287",
      "r300",
      "r330",
      "r331",
      "r332",
      "r408",
      "r432",
      "r457",
      "r479",
      "r480",
      "r496",
      "r500",
      "r506",
      "r546",
      "r550",
      "r598",
      "r599",
      "r600",
      "r601",
      "r602"
     ],
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://korumedical.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesDetailsNarrative",
      "http://korumedical.com/role/ScheduleOfTimeBasedStockOptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [
      "r206",
      "r207",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r497",
      "r505",
      "r551"
     ],
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://korumedical.com/role/ScheduleOfNetRevenuesByGeographyDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [
      "r206",
      "r207",
      "r464",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r497",
      "r505",
      "r551"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://korumedical.com/role/ScheduleOfNetRevenuesByGeographyDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualAxis": {
     "auth_ref": [
      "r541",
      "r593"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Axis]"
       }
      }
     },
     "localname": "TitleOfIndividualAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://korumedical.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "auth_ref": [],
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://korumedical.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r14",
      "r504"
     ],
     "calculation": {
      "http://korumedical.com/role/BalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://korumedical.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r209",
      "r210"
     ],
     "calculation": {
      "http://korumedical.com/role/BalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts receivable less allowance for doubtful accounts of $21,459 and $24,271 for December 31, 2022, and December 31, 2021, respectively"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://korumedical.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r18"
     ],
     "calculation": {
      "http://korumedical.com/role/BalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued expenses"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://korumedical.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r64",
      "r130"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "negatedLabel": "Less: accumulated depreciation and amortization"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://korumedical.com/role/ScheduleOfPropertyAndEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "auth_ref": [
      "r6"
     ],
     "calculation": {
      "http://korumedical.com/role/BalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.",
        "label": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://korumedical.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r339",
      "r340",
      "r341",
      "r535",
      "r536",
      "r537",
      "r587"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://korumedical.com/role/StatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://korumedical.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for option under share-based payment arrangement.",
        "label": "Compensation expense related to stock options"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://korumedical.com/role/StatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts": {
     "auth_ref": [
      "r70",
      "r71"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.",
        "label": "Compensation expense related to restricted stock awards"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://korumedical.com/role/StatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r334"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-Based Payment Arrangement, Expense",
        "verboseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://korumedical.com/role/ScheduleOfStatusOfTimeBasedStockOptionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent": {
     "auth_ref": [
      "r135",
      "r211",
      "r216"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of allowance for credit loss on accounts receivable, classified as current.",
        "label": "Accounts receivable, allowance for credit loss, current"
       }
      }
     },
     "localname": "AllowanceForDoubtfulAccountsReceivableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://korumedical.com/role/BalanceSheetsParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r181"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Option shares excluded"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://korumedical.com/role/ScheduleOfNetIncomePerCommonShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://korumedical.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r103",
      "r109",
      "r133",
      "r154",
      "r196",
      "r199",
      "r203",
      "r214",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r365",
      "r367",
      "r373",
      "r504",
      "r548",
      "r549",
      "r595"
     ],
     "calculation": {
      "http://korumedical.com/role/BalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "TOTAL ASSETS"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://korumedical.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "ASSETS"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://korumedical.com/role/BalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r125",
      "r139",
      "r154",
      "r214",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r365",
      "r367",
      "r373",
      "r504",
      "r548",
      "r549",
      "r595"
     ],
     "calculation": {
      "http://korumedical.com/role/BalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "TOTAL CURRENT ASSETS"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://korumedical.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CURRENT ASSETS"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://korumedical.com/role/BalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r305",
      "r306",
      "r307",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://korumedical.com/role/FollowingTableSummarizesActivitiesForOurUnvestedRestrictedStockAwardsForTwelveMonthsEndedDecember312022And2021.Details",
      "http://korumedical.com/role/ScheduleOfInformationPertainingToOptionsOutstandingDetails",
      "http://korumedical.com/role/ScheduleOfPerformanceBaseOptionsOutstandingDetails",
      "http://korumedical.com/role/ScheduleOfTimeBasedStockOptionsDetails",
      "http://korumedical.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "BASIS OF PRESENTATION"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://korumedical.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r37",
      "r128",
      "r481"
     ],
     "calculation": {
      "http://korumedical.com/role/BalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and cash equivalents",
        "periodEndLabel": "CASH AND CASH EQUIVALENTS, END OF YEAR",
        "periodStartLabel": "CASH AND CASH EQUIVALENTS, BEGINNING OF YEAR"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://korumedical.com/role/BalanceSheets",
      "http://korumedical.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "auth_ref": [
      "r38"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.",
        "label": "CASH AND CASH EQUIVALENTS"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://korumedical.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r32",
      "r102"
     ],
     "calculation": {
      "http://korumedical.com/role/StatementsOfCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "NET DECREASE IN CASH AND CASH EQUIVALENTS"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://korumedical.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Non-Cash Operating, Investing and Financing Activities:"
       }
      }
     },
     "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://korumedical.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashFlowOperatingActivitiesLesseeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash paid for amounts included in the measurement of lease liabilities:"
       }
      }
     },
     "localname": "CashFlowOperatingActivitiesLesseeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://korumedical.com/role/ScheduleOfCashFlowInformationRelatedToLeasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashUninsuredAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash as of the balance sheet date that is not insured by the Federal Deposit Insurance Corporation.",
        "label": "FDIC cash uninsured amount"
       }
      }
     },
     "localname": "CashUninsuredAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://korumedical.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r68",
      "r234",
      "r235",
      "r466",
      "r547"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "COMMITMENTS AND CONTINGENCIES"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://korumedical.com/role/CommitmentsAndContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r535",
      "r536",
      "r587"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://korumedical.com/role/ScheduleOfNetIncomePerCommonShareDetails",
      "http://korumedical.com/role/StatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common stock, par or stated value per share"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://korumedical.com/role/BalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common stock, shares authorized"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://korumedical.com/role/BalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common stock, shares, issued",
        "verboseLabel": "Common stock issued, shares"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://korumedical.com/role/BalanceSheetsParenthetical",
      "http://korumedical.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r5",
      "r70"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common stock, shares, outstanding"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://korumedical.com/role/BalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r5",
      "r504"
     ],
     "calculation": {
      "http://korumedical.com/role/BalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common stock, $0.01 par value, 75,000,000 shares authorized, 48,861,891 and 48,044,162 shares issued; 45,441,389 and 44,623,660 shares outstanding at December 31, 2022, and December 31, 2021, respectively",
        "verboseLabel": "Aggregate stock price"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://korumedical.com/role/BalanceSheets",
      "http://korumedical.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CompensationAndRetirementDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retirement Benefits [Abstract]"
       }
      }
     },
     "localname": "CompensationAndRetirementDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "auth_ref": [
      "r49",
      "r50",
      "r99",
      "r100",
      "r208",
      "r465"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage."
       }
      }
     },
     "localname": "ConcentrationRiskBenchmarkDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://korumedical.com/role/MajorCustomersDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "auth_ref": [
      "r49",
      "r50",
      "r99",
      "r100",
      "r208",
      "r463",
      "r465"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by benchmark of concentration risk.",
        "label": "Concentration Risk Benchmark [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://korumedical.com/role/MajorCustomersDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskByTypeAxis": {
     "auth_ref": [
      "r49",
      "r50",
      "r99",
      "r100",
      "r208",
      "r465",
      "r605"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.",
        "label": "Concentration Risk Type [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://korumedical.com/role/MajorCustomersDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskDisclosureTextBlock": {
     "auth_ref": [
      "r55"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for any concentrations existing at the date of the financial statements that make an entity vulnerable to a reasonably possible, near-term, severe impact. This disclosure informs financial statement users about the general nature of the risk associated with the concentration, and may indicate the percentage of concentration risk as of the balance sheet date.",
        "label": "MAJOR CUSTOMERS"
       }
      }
     },
     "localname": "ConcentrationRiskDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://korumedical.com/role/MajorCustomers"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConcentrationRiskLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Concentration Risk [Line Items]"
       }
      }
     },
     "localname": "ConcentrationRiskLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://korumedical.com/role/MajorCustomersDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskPercentage1": {
     "auth_ref": [
      "r49",
      "r50",
      "r99",
      "r100",
      "r208"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.",
        "label": "Concentration risk, percentage"
       }
      }
     },
     "localname": "ConcentrationRiskPercentage1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://korumedical.com/role/MajorCustomersDetailsNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ConcentrationRiskTable": {
     "auth_ref": [
      "r47",
      "r49",
      "r50",
      "r51",
      "r99",
      "r101",
      "r465"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Describes the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.",
        "label": "Concentration Risk [Table]"
       }
      }
     },
     "localname": "ConcentrationRiskTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://korumedical.com/role/MajorCustomersDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskTypeDomain": {
     "auth_ref": [
      "r49",
      "r50",
      "r99",
      "r100",
      "r208",
      "r465"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration."
       }
      }
     },
     "localname": "ConcentrationRiskTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://korumedical.com/role/MajorCustomersDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "auth_ref": [
      "r25",
      "r437"
     ],
     "calculation": {
      "http://korumedical.com/role/StatementsOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_GrossProfit",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.",
        "label": "Cost of goods sold"
       }
      }
     },
     "localname": "CostOfGoodsAndServicesSold",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://korumedical.com/role/StatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CreditFacilityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Axis]"
       }
      }
     },
     "localname": "CreditFacilityAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://korumedical.com/role/DebtObligationsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CreditFacilityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing."
       }
      }
     },
     "localname": "CreditFacilityDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://korumedical.com/role/DebtObligationsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CurrentFederalTaxExpenseBenefit": {
     "auth_ref": [
      "r534",
      "r580",
      "r582"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction.",
        "label": "Current"
       }
      }
     },
     "localname": "CurrentFederalTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://korumedical.com/role/ScheduleOfProvisionForIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentStateAndLocalTaxExpenseBenefit": {
     "auth_ref": [
      "r534",
      "r580",
      "r582"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.",
        "label": "Current, net of refund"
       }
      }
     },
     "localname": "CurrentStateAndLocalTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://korumedical.com/role/ScheduleOfProvisionForIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CustomerConcentrationRiskMember": {
     "auth_ref": [
      "r48",
      "r208"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.",
        "label": "Customer Concentration Risk [Member]"
       }
      }
     },
     "localname": "CustomerConcentrationRiskMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://korumedical.com/role/MajorCustomersDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]"
       }
      }
     },
     "localname": "DebtDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "auth_ref": [
      "r69",
      "r153",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r265",
      "r272",
      "r273",
      "r275"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.",
        "label": "DEBT OBLIGATIONS"
       }
      }
     },
     "localname": "DebtDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://korumedical.com/role/DebtObligations"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r1",
      "r2",
      "r3",
      "r104",
      "r105",
      "r108",
      "r157",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r255",
      "r261",
      "r262",
      "r263",
      "r264",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r384",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r532"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://korumedical.com/role/DebtObligationsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r20",
      "r157",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r255",
      "r261",
      "r262",
      "r263",
      "r264",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r384",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r532"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities."
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://korumedical.com/role/DebtObligationsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DeferredCompensationPlanAssets": {
     "auth_ref": [
      "r527"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of assets held under deferred compensation agreements.",
        "label": "Deferred compensation cost"
       }
      }
     },
     "localname": "DeferredCompensationPlanAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://korumedical.com/role/ScheduleOfComponentsOfDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredFederalIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r534",
      "r581",
      "r582"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction.",
        "label": "Deferred"
       }
      }
     },
     "localname": "DeferredFederalIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://korumedical.com/role/ScheduleOfProvisionForIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxAssetsNet": {
     "auth_ref": [
      "r346",
      "r347"
     ],
     "calculation": {
      "http://korumedical.com/role/BalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.",
        "label": "Deferred income tax assets, net"
       }
      }
     },
     "localname": "DeferredIncomeTaxAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://korumedical.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxesAndTaxCredits": {
     "auth_ref": [
      "r36"
     ],
     "calculation": {
      "http://korumedical.com/role/StatementsOfCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income tax expense (benefit) and income tax credits.",
        "label": "Deferred income taxes"
       }
      }
     },
     "localname": "DeferredIncomeTaxesAndTaxCredits",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://korumedical.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "auth_ref": [
      "r579"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Net of Valuation Allowance",
        "verboseLabel": "Deferred income tax assets, net"
       }
      }
     },
     "localname": "DeferredTaxAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://korumedical.com/role/ScheduleOfComponentsOfDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of discretionary contributions made by an employer to a defined contribution plan.",
        "label": "Matching expense"
       }
      }
     },
     "localname": "DefinedContributionPlanEmployerDiscretionaryContributionAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://korumedical.com/role/EmployeeBenefitsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r35",
      "r194"
     ],
     "calculation": {
      "http://korumedical.com/role/StatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://korumedical.com/role/StatementsOfOperations": {
       "order": 3.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation and amortization"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://korumedical.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesDetailsNarrative",
      "http://korumedical.com/role/StatementsOfCashFlows",
      "http://korumedical.com/role/StatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r304",
      "r335",
      "r336",
      "r338",
      "r343",
      "r501"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "STOCK-BASED COMPENSATION"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://korumedical.com/role/Stock-basedCompensation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "NET LOSS PER SHARE",
        "verboseLabel": "Net loss per share"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://korumedical.com/role/ScheduleOfNetIncomePerCommonShareDetails",
      "http://korumedical.com/role/StatementsOfOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r147",
      "r163",
      "r164",
      "r165",
      "r166",
      "r167",
      "r171",
      "r173",
      "r178",
      "r179",
      "r180",
      "r182",
      "r371",
      "r372",
      "r452",
      "r455",
      "r487"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Basic"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://korumedical.com/role/ScheduleOfNetIncomePerCommonShareDetails",
      "http://korumedical.com/role/StatementsOfOperations"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r147",
      "r163",
      "r164",
      "r165",
      "r166",
      "r167",
      "r173",
      "r178",
      "r179",
      "r180",
      "r182",
      "r371",
      "r372",
      "r452",
      "r455",
      "r487"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Diluted"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://korumedical.com/role/ScheduleOfNetIncomePerCommonShareDetails",
      "http://korumedical.com/role/StatementsOfOperations"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r45",
      "r46"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "NET LOSS PER COMMON SHARE"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://korumedical.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r18"
     ],
     "calculation": {
      "http://korumedical.com/role/BalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued payroll and related taxes"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://korumedical.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "auth_ref": [
      "r337"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.",
        "label": "Total unrecognized compensation cost"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://korumedical.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock.",
        "label": "Employee Stock [Member]"
       }
      }
     },
     "localname": "EmployeeStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://korumedical.com/role/ScheduleOfNetIncomePerCommonShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r70",
      "r123",
      "r143",
      "r144",
      "r145",
      "r158",
      "r159",
      "r160",
      "r162",
      "r168",
      "r170",
      "r185",
      "r215",
      "r277",
      "r339",
      "r340",
      "r341",
      "r356",
      "r357",
      "r370",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r399",
      "r458",
      "r459",
      "r460"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://korumedical.com/role/ScheduleOfNetIncomePerCommonShareDetails",
      "http://korumedical.com/role/StatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": {
     "auth_ref": [
      "r97"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class of asset."
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://korumedical.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueByAssetClassAxis": {
     "auth_ref": [
      "r96",
      "r98"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by class of asset.",
        "label": "Asset Class [Axis]"
       }
      }
     },
     "localname": "FairValueByAssetClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://korumedical.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.",
        "label": "FAIR VALUE MEASUREMENTS"
       }
      }
     },
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://korumedical.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Federal income tax:"
       }
      }
     },
     "localname": "FederalIncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://korumedical.com/role/ScheduleOfProvisionForIncomeTaxesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FinanceLeaseInterestExpense": {
     "auth_ref": [
      "r387",
      "r392",
      "r503"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of interest expense on finance lease liability.",
        "label": "Interest on lease liabilities"
       }
      }
     },
     "localname": "FinanceLeaseInterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://korumedical.com/role/ScheduleOfComponentsOfLeaseExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseInterestPaymentOnLiability": {
     "auth_ref": [
      "r389",
      "r395"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of interest paid on finance lease liability.",
        "label": "Financing cash flows from finance leases"
       }
      }
     },
     "localname": "FinanceLeaseInterestPaymentOnLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://korumedical.com/role/ScheduleOfCashFlowInformationRelatedToLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiability": {
     "auth_ref": [
      "r386",
      "r397"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease.",
        "label": "Total finance lease liabilities",
        "verboseLabel": "Total lease liabilities"
       }
      }
     },
     "localname": "FinanceLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://korumedical.com/role/SchdeuleOfBalanceSheetInformationRelatedToLeasesDetails",
      "http://korumedical.com/role/ScheduleOfMaturitiesOfLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityCurrent": {
     "auth_ref": [
      "r386"
     ],
     "calculation": {
      "http://korumedical.com/role/BalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.",
        "label": "Finance lease liability \u2013 current"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://korumedical.com/role/BalanceSheets",
      "http://korumedical.com/role/SchdeuleOfBalanceSheetInformationRelatedToLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r386"
     ],
     "calculation": {
      "http://korumedical.com/role/BalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.",
        "label": "Finance lease liability, net current portion",
        "verboseLabel": "Finance lease liability, net of current portion"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://korumedical.com/role/BalanceSheets",
      "http://korumedical.com/role/SchdeuleOfBalanceSheetInformationRelatedToLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive": {
     "auth_ref": [
      "r397"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finance Lease, Liability, to be Paid, after Year Five",
        "verboseLabel": "Thereafter"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDueAfterYearFive",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://korumedical.com/role/ScheduleOfMaturitiesOfLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r397"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finance Lease, Liability, to be Paid, Year One",
        "verboseLabel": "2023"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://korumedical.com/role/ScheduleOfMaturitiesOfLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive": {
     "auth_ref": [
      "r397"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finance Lease, Liability, to be Paid, Year Five",
        "verboseLabel": "2027"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDueYearFive",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://korumedical.com/role/ScheduleOfMaturitiesOfLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r397"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finance Lease, Liability, to be Paid, Year Four",
        "verboseLabel": "2026"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://korumedical.com/role/ScheduleOfMaturitiesOfLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r397"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finance Lease, Liability, to be Paid, Year Three",
        "verboseLabel": "2025"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://korumedical.com/role/ScheduleOfMaturitiesOfLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r397"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finance Lease, Liability, to be Paid, Year Two",
        "verboseLabel": "2024"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://korumedical.com/role/ScheduleOfMaturitiesOfLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeasePrincipalPayments": {
     "auth_ref": [
      "r388",
      "r395"
     ],
     "calculation": {
      "http://korumedical.com/role/StatementsOfCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow for principal payment on finance lease.",
        "label": "Finance Lease, Principal Payments",
        "negatedLabel": "Payments on finance lease liability"
       }
      }
     },
     "localname": "FinanceLeasePrincipalPayments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://korumedical.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseRightOfUseAssetAmortization": {
     "auth_ref": [
      "r387",
      "r392",
      "r503"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense attributable to right-of-use asset from finance lease.",
        "label": "Amortization of right-of-use assets"
       }
      }
     },
     "localname": "FinanceLeaseRightOfUseAssetAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://korumedical.com/role/ScheduleOfComponentsOfLeaseExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinancialInstrumentAxis": {
     "auth_ref": [
      "r212",
      "r213",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r274",
      "r276",
      "r369",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r490",
      "r542",
      "r543",
      "r544",
      "r606",
      "r607",
      "r608",
      "r609",
      "r610",
      "r611",
      "r612"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of financial instrument.",
        "label": "Financial Instrument [Axis]"
       }
      }
     },
     "localname": "FinancialInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://korumedical.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Estimated useful lives"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://korumedical.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
     "auth_ref": [
      "r131",
      "r232"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-lived intangible assets, accumulated amortization"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://korumedical.com/role/BalanceSheetsParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for asset, excluding financial asset and goodwill, lacking physical substance with finite life expected to be recognized after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Thereafter"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://korumedical.com/role/ScheduleOfAmortizationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": {
     "auth_ref": [
      "r61"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "2023"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://korumedical.com/role/ScheduleOfAmortizationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of amortization expense of assets, excluding financial assets, that lack physical substance, having a limited useful life.",
        "label": "Schedule of amortization expense"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://korumedical.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive": {
     "auth_ref": [
      "r61"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "2027"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFive",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://korumedical.com/role/ScheduleOfAmortizationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": {
     "auth_ref": [
      "r61"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "2026"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://korumedical.com/role/ScheduleOfAmortizationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": {
     "auth_ref": [
      "r61"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "2025"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://korumedical.com/role/ScheduleOfAmortizationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": {
     "auth_ref": [
      "r61"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "2024"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://korumedical.com/role/ScheduleOfAmortizationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r230",
      "r231",
      "r232",
      "r233",
      "r438",
      "r439"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by major type or class of finite-lived intangible assets.",
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://korumedical.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r58",
      "r59"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company."
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://korumedical.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "auth_ref": [
      "r60",
      "r438"
     ],
     "calculation": {
      "http://korumedical.com/role/BalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Intangible assets, net of accumulated amortization of $325,872 and $263,729 at December 31, 2022 and December 31, 2021, respectively",
        "verboseLabel": "Total amortization expense"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://korumedical.com/role/BalanceSheets",
      "http://korumedical.com/role/ScheduleOfAmortizationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ForeignCurrencyTransactionGainLossBeforeTax": {
     "auth_ref": [
      "r374",
      "r375",
      "r376",
      "r377"
     ],
     "calculation": {
      "http://korumedical.com/role/StatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.",
        "label": "Loss on foreign currency exchange"
       }
      }
     },
     "localname": "ForeignCurrencyTransactionGainLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://korumedical.com/role/StatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainLossOnSaleOfOtherAssets": {
     "auth_ref": [
      "r531"
     ],
     "calculation": {
      "http://korumedical.com/role/StatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) on sale or disposal of other assets.",
        "label": "Gain (Loss) on Disposition of Other Assets",
        "negatedLabel": "Loss on disposal of fixed assets"
       }
      }
     },
     "localname": "GainLossOnSaleOfOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://korumedical.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainLossOnSaleOfPropertyPlantEquipment": {
     "auth_ref": [
      "r35"
     ],
     "calculation": {
      "http://korumedical.com/role/StatementsOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.",
        "label": "Gain on disposal of fixed assets"
       }
      }
     },
     "localname": "GainLossOnSaleOfPropertyPlantEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://korumedical.com/role/StatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GrossProfit": {
     "auth_ref": [
      "r24",
      "r154",
      "r196",
      "r198",
      "r202",
      "r204",
      "r214",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r373",
      "r489",
      "r548"
     ],
     "calculation": {
      "http://korumedical.com/role/StatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.",
        "label": "Gross Profit",
        "totalLabel": "Gross Profit"
       }
      }
     },
     "localname": "GrossProfit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://korumedical.com/role/StatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": {
     "auth_ref": [
      "r62",
      "r66"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.",
        "label": "IMPAIRMENT OF LONG-LIVED ASSETS"
       }
      }
     },
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://korumedical.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments": {
     "auth_ref": [
      "r196",
      "r198",
      "r202",
      "r204",
      "r489"
     ],
     "calculation": {
      "http://korumedical.com/role/StatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.",
        "label": "Loss before taxes",
        "totalLabel": "LOSS BEFORE TAXES"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://korumedical.com/role/ScheduleOfReconciliationOfIncomeTaxesDetails",
      "http://korumedical.com/role/StatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r155",
      "r350",
      "r351",
      "r354",
      "r358",
      "r360",
      "r362",
      "r363",
      "r364"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "FEDERAL AND STATE INCOME TAXES"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://korumedical.com/role/FederalAndStateIncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r156",
      "r169",
      "r170",
      "r195",
      "r348",
      "r359",
      "r361",
      "r456"
     ],
     "calculation": {
      "http://korumedical.com/role/StatementsOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Tax benefit",
        "negatedLabel": "Income tax benefit",
        "negatedTerseLabel": "Income tax benefit/(expense)"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://korumedical.com/role/ScheduleOfProvisionForIncomeTaxesDetails",
      "http://korumedical.com/role/ScheduleOfReconciliationOfIncomeTaxesDetails",
      "http://korumedical.com/role/StatementsOfOperations",
      "http://korumedical.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r142",
      "r344",
      "r345",
      "r351",
      "r352",
      "r353",
      "r355"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "INCOME TAXES"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://korumedical.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r349"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Income taxes computed at the federal statutory rate"
       }
      }
     },
     "localname": "IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://korumedical.com/role/ScheduleOfReconciliationOfIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationOtherAdjustments": {
     "auth_ref": [
      "r578"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.",
        "label": "Permanent differences and other"
       }
      }
     },
     "localname": "IncomeTaxReconciliationOtherAdjustments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://korumedical.com/role/ScheduleOfReconciliationOfIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes": {
     "auth_ref": [
      "r578"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit).",
        "label": "State income and franchise tax"
       }
      }
     },
     "localname": "IncomeTaxReconciliationStateAndLocalIncomeTaxes",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://korumedical.com/role/ScheduleOfReconciliationOfIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxesPaidNet": {
     "auth_ref": [
      "r39"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.",
        "label": "Income taxes"
       }
      }
     },
     "localname": "IncomeTaxesPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://korumedical.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r34"
     ],
     "calculation": {
      "http://korumedical.com/role/StatementsOfCashFlows": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase in accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://korumedical.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r34"
     ],
     "calculation": {
      "http://korumedical.com/role/StatementsOfCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedLabel": "Decrease/(Increase)\u00a0in accounts receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://korumedical.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities": {
     "auth_ref": [
      "r530"
     ],
     "calculation": {
      "http://korumedical.com/role/StatementsOfCashFlows": {
       "order": 14.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in accrued expenses, and obligations classified as other.",
        "label": "Increase in accrued expenses"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://korumedical.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities": {
     "auth_ref": [
      "r34"
     ],
     "calculation": {
      "http://korumedical.com/role/StatementsOfCashFlows": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits.",
        "label": "Increase/(Decrease) in accrued payroll and related taxes"
       }
      }
     },
     "localname": "IncreaseDecreaseInEmployeeRelatedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://korumedical.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "auth_ref": [
      "r34"
     ],
     "calculation": {
      "http://korumedical.com/role/StatementsOfCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.",
        "label": "Increase (Decrease) in Inventories",
        "negatedLabel": "(Increase)/Decrease in inventory"
       }
      }
     },
     "localname": "IncreaseDecreaseInInventories",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://korumedical.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://korumedical.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherCurrentLiabilities": {
     "auth_ref": [
      "r530"
     ],
     "calculation": {
      "http://korumedical.com/role/StatementsOfCashFlows": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in current liabilities classified as other.",
        "label": "Increase in other liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherCurrentLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://korumedical.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherReceivables": {
     "auth_ref": [
      "r34"
     ],
     "calculation": {
      "http://korumedical.com/role/StatementsOfCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in receivables classified as other.",
        "label": "Increase (Decrease) in Other Receivables",
        "negatedLabel": "Increase in other receivables"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherReceivables",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://korumedical.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r34"
     ],
     "calculation": {
      "http://korumedical.com/role/StatementsOfCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Decrease/(Increase) in prepaid expenses and other assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://korumedical.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants": {
     "auth_ref": [
      "r174",
      "r175",
      "r176",
      "r180"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of call options and warrants using the treasury stock method.",
        "label": "Option shares includable"
       }
      }
     },
     "localname": "IncrementalCommonSharesAttributableToCallOptionsAndWarrants",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://korumedical.com/role/ScheduleOfNetIncomePerCommonShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_IntangibleAssetsFiniteLivedPolicy": {
     "auth_ref": [
      "r59",
      "r434",
      "r435",
      "r436",
      "r438",
      "r484"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for finite-lived intangible assets. This accounting policy also might address: (1) the amortization method used; (2) the useful lives of such assets; and (3) how the entity assesses and measures impairment of such assets.",
        "label": "INTANGIBLE ASSETS"
       }
      }
     },
     "localname": "IntangibleAssetsFiniteLivedPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://korumedical.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InterestPaidNet": {
     "auth_ref": [
      "r149",
      "r151",
      "r152"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.",
        "label": "Interest"
       }
      }
     },
     "localname": "InterestPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://korumedical.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory Disclosure [Abstract]"
       }
      }
     },
     "localname": "InventoryDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryDisclosureTextBlock": {
     "auth_ref": [
      "r227"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.",
        "label": "INVENTORY"
       }
      }
     },
     "localname": "InventoryDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://korumedical.com/role/Inventory"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InventoryFinishedGoods": {
     "auth_ref": [
      "r528"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.",
        "label": "Finished goods"
       }
      }
     },
     "localname": "InventoryFinishedGoods",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://korumedical.com/role/InventoryConsistsOfDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryGross": {
     "auth_ref": [
      "r529"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross amount, as of the balance sheet date, of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.",
        "label": "Inventory, Gross"
       }
      }
     },
     "localname": "InventoryGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://korumedical.com/role/InventoryConsistsOfDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryNet": {
     "auth_ref": [
      "r137",
      "r482",
      "r504"
     ],
     "calculation": {
      "http://korumedical.com/role/BalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory"
       }
      }
     },
     "localname": "InventoryNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://korumedical.com/role/BalanceSheets",
      "http://korumedical.com/role/InventoryConsistsOfDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryPolicyTextBlock": {
     "auth_ref": [
      "r127",
      "r136",
      "r183",
      "r225",
      "r226",
      "r227",
      "r433",
      "r485"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.",
        "label": "Inventory, Policy [Policy Text Block]",
        "verboseLabel": "INVENTORY"
       }
      }
     },
     "localname": "InventoryPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://korumedical.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InventoryValuationReserves": {
     "auth_ref": [
      "r57",
      "r529"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of valuation reserve for inventory.",
        "label": "Inventory Valuation Reserves",
        "negatedLabel": "Less: reserve for obsolete inventory"
       }
      }
     },
     "localname": "InventoryValuationReserves",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://korumedical.com/role/InventoryConsistsOfDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryWorkInProcessAndRawMaterials": {
     "auth_ref": [
      "r529"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate carrying amount as of the balance sheet date of items held by the entity which are partially completed at the time of measurement and unprocessed items that will go through the production process and become part of the final product. Includes supplies used directly or indirectly in the manufacturing or production process. This element may be used when the reporting entity combines work in process and raw materials into an aggregate amount.",
        "label": "Raw materials and work-in-process"
       }
      }
     },
     "localname": "InventoryWorkInProcessAndRawMaterials",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://korumedical.com/role/InventoryConsistsOfDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseCost": {
     "auth_ref": [
      "r396",
      "r503"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lease cost recognized by lessee for lease contract.",
        "label": "Total lease cost"
       }
      }
     },
     "localname": "LeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://korumedical.com/role/ScheduleOfComponentsOfLeaseExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "auth_ref": [
      "r591"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.",
        "label": "Schedule of components of lease expense"
       }
      }
     },
     "localname": "LeaseCostTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://korumedical.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "auth_ref": [
      "r63"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additions or improvements to assets held under a lease arrangement.",
        "label": "Leasehold Improvements [Member]"
       }
      }
     },
     "localname": "LeaseholdImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://korumedical.com/role/ScheduleOfPropertyAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Abstract]"
       }
      }
     },
     "localname": "LeasesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LeasesOfLesseeDisclosureTextBlock": {
     "auth_ref": [
      "r122"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for lessee entity's leasing arrangements including, but not limited to, all of the following: (a.) The basis on which contingent rental payments are determined, (b.) The existence and terms of renewal or purchase options and escalation clauses, (c.) Restrictions imposed by lease agreements, such as those concerning dividends, additional debt, and further leasing.",
        "label": "LEASES"
       }
      }
     },
     "localname": "LeasesOfLesseeDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://korumedical.com/role/Leases"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeFinanceLeaseDiscountRate": {
     "auth_ref": [
      "r590"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discount rate used by lessee to determine present value of finance lease payments.",
        "label": "Lessee, Finance Lease, Discount Rate",
        "verboseLabel": "Finance leases"
       }
      }
     },
     "localname": "LesseeFinanceLeaseDiscountRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://korumedical.com/role/SchdeuleOfBalanceSheetInformationRelatedToLeasesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_LesseeFinanceLeaseRenewalTerm1": {
     "auth_ref": [
      "r589"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's finance lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Finance leases"
       }
      }
     },
     "localname": "LesseeFinanceLeaseRenewalTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://korumedical.com/role/SchdeuleOfBalanceSheetInformationRelatedToLeasesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "auth_ref": [
      "r391"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.",
        "label": "Lessee, Leases [Policy Text Block]",
        "verboseLabel": "LEASES"
       }
      }
     },
     "localname": "LesseeLeasesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://korumedical.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseDiscountRate": {
     "auth_ref": [
      "r502"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discount rate used by lessee to determine present value of operating lease payments.",
        "label": "Lessee, Operating Lease, Discount Rate",
        "verboseLabel": "Operating leases"
       }
      }
     },
     "localname": "LesseeOperatingLeaseDiscountRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://korumedical.com/role/SchdeuleOfBalanceSheetInformationRelatedToLeasesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r592"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Schedule of maturities of lease liabilities"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://korumedical.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": {
     "auth_ref": [
      "r397"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, after Year Five",
        "verboseLabel": "Thereafter"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://korumedical.com/role/ScheduleOfMaturitiesOfLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r397"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "verboseLabel": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://korumedical.com/role/ScheduleOfMaturitiesOfLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": {
     "auth_ref": [
      "r397"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Five",
        "verboseLabel": "2027"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://korumedical.com/role/ScheduleOfMaturitiesOfLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r397"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "verboseLabel": "2026"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://korumedical.com/role/ScheduleOfMaturitiesOfLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r397"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "verboseLabel": "2025"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://korumedical.com/role/ScheduleOfMaturitiesOfLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r397"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "verboseLabel": "2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://korumedical.com/role/ScheduleOfMaturitiesOfLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseRenewalTerm": {
     "auth_ref": [
      "r589"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating leases"
       }
      }
     },
     "localname": "LesseeOperatingLeaseRenewalTerm",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://korumedical.com/role/SchdeuleOfBalanceSheetInformationRelatedToLeasesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r17",
      "r154",
      "r214",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r366",
      "r367",
      "r368",
      "r373",
      "r488",
      "r548",
      "r595",
      "r596"
     ],
     "calculation": {
      "http://korumedical.com/role/BalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "TOTAL LIABILITIES"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://korumedical.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r10",
      "r106",
      "r112",
      "r504",
      "r533",
      "r545",
      "r588"
     ],
     "calculation": {
      "http://korumedical.com/role/BalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "TOTAL LIABILITIES AND STOCKHOLDERS\u2019 EQUITY"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://korumedical.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "LIABILITIES AND STOCKHOLDERS\u2019 EQUITY"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://korumedical.com/role/BalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r19",
      "r126",
      "r154",
      "r214",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r366",
      "r367",
      "r368",
      "r373",
      "r504",
      "r548",
      "r595",
      "r596"
     ],
     "calculation": {
      "http://korumedical.com/role/BalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "TOTAL CURRENT LIABILITIES"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://korumedical.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CURRENT LIABILITIES"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://korumedical.com/role/BalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LineOfCreditMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A contractual arrangement with a lender under which borrowings can be made up to a specific amount at any point in time, and under which borrowings outstanding may be either short-term or long-term, depending upon the particulars.",
        "label": "Line of Credit [Member]"
       }
      }
     },
     "localname": "LineOfCreditMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://korumedical.com/role/DebtObligationsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NatureOfOperations": {
     "auth_ref": [
      "r186",
      "r191"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.",
        "label": "NATURE OF OPERATIONS"
       }
      }
     },
     "localname": "NatureOfOperations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://korumedical.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r150"
     ],
     "calculation": {
      "http://korumedical.com/role/StatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "NET CASH PROVIDED BY FINANCING ACTIVITIES"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://korumedical.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CASH FLOWS FROM FINANCING ACTIVITIES"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://korumedical.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r150"
     ],
     "calculation": {
      "http://korumedical.com/role/StatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "NET CASH USED IN INVESTING ACTIVITIES"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://korumedical.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CASH FLOWS FROM INVESTING ACTIVITIES"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://korumedical.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r32",
      "r33",
      "r36"
     ],
     "calculation": {
      "http://korumedical.com/role/StatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "NET CASH USED IN OPERATING ACTIVITIES"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://korumedical.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CASH FLOWS FROM OPERATING ACTIVITIES"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://korumedical.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r23",
      "r36",
      "r107",
      "r114",
      "r124",
      "r140",
      "r141",
      "r145",
      "r154",
      "r161",
      "r163",
      "r164",
      "r165",
      "r166",
      "r169",
      "r170",
      "r177",
      "r196",
      "r198",
      "r202",
      "r204",
      "r214",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r372",
      "r373",
      "r489",
      "r548"
     ],
     "calculation": {
      "http://korumedical.com/role/StatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://korumedical.com/role/StatementsOfOperations": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net loss",
        "totalLabel": "NET LOSS",
        "verboseLabel": "Net Loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://korumedical.com/role/ScheduleOfNetIncomePerCommonShareDetails",
      "http://korumedical.com/role/StatementsOfCashFlows",
      "http://korumedical.com/role/StatementsOfOperations",
      "http://korumedical.com/role/StatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "ACCOUNTING PRONOUNCEMENTS RECENTLY ADOPTED"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://korumedical.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NonUsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Countries excluding the United States of America (US).",
        "label": "Non-US [Member]"
       }
      }
     },
     "localname": "NonUsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://korumedical.com/role/ScheduleOfNetRevenuesByGeographyDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "auth_ref": [
      "r27"
     ],
     "calculation": {
      "http://korumedical.com/role/StatementsOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).",
        "label": "Nonoperating Income (Expense)",
        "totalLabel": "TOTAL OTHER INCOME"
       }
      }
     },
     "localname": "NonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://korumedical.com/role/StatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Operating Income"
       }
      }
     },
     "localname": "NonoperatingIncomeExpenseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://korumedical.com/role/StatementsOfOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NotesPayable": {
     "auth_ref": [
      "r3",
      "r105",
      "r110"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Including the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer.",
        "label": "Notes payable"
       }
      }
     },
     "localname": "NotesPayable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://korumedical.com/role/DebtObligationsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NotesPayableCurrent": {
     "auth_ref": [
      "r16"
     ],
     "calculation": {
      "http://korumedical.com/role/BalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.",
        "label": "Note Payable"
       }
      }
     },
     "localname": "NotesPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://korumedical.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NumberOfReportableSegments": {
     "auth_ref": [
      "r540"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.",
        "label": "Number of segments"
       }
      }
     },
     "localname": "NumberOfReportableSegments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://korumedical.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://korumedical.com/role/StatementsOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "totalLabel": "Total Operating Expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://korumedical.com/role/StatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "OPERATING EXPENSES"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://korumedical.com/role/StatementsOfOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r196",
      "r198",
      "r202",
      "r204",
      "r489"
     ],
     "calculation": {
      "http://korumedical.com/role/StatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Net Operating Loss"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://korumedical.com/role/StatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseCost": {
     "auth_ref": [
      "r393",
      "r503"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.",
        "label": "Operating lease cost"
       }
      }
     },
     "localname": "OperatingLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://korumedical.com/role/ScheduleOfComponentsOfLeaseExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLeaseIncomeTableTextBlock": {
     "auth_ref": [
      "r184",
      "r398"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of components of income from operating lease.",
        "label": "Schedule of cash flow information related to leases"
       }
      }
     },
     "localname": "OperatingLeaseLeaseIncomeTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://korumedical.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r386"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Total operating lease liabilities",
        "verboseLabel": "Total lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://korumedical.com/role/SchdeuleOfBalanceSheetInformationRelatedToLeasesDetails",
      "http://korumedical.com/role/ScheduleOfMaturitiesOfLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r386"
     ],
     "calculation": {
      "http://korumedical.com/role/BalanceSheets": {
       "order": 7.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating lease liability \u2013 current"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://korumedical.com/role/BalanceSheets",
      "http://korumedical.com/role/SchdeuleOfBalanceSheetInformationRelatedToLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r386"
     ],
     "calculation": {
      "http://korumedical.com/role/BalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating lease liability, net of current portion"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://korumedical.com/role/BalanceSheets",
      "http://korumedical.com/role/SchdeuleOfBalanceSheetInformationRelatedToLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasePayments": {
     "auth_ref": [
      "r390",
      "r395"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.",
        "label": "Operating cash flows from operating leases"
       }
      }
     },
     "localname": "OperatingLeasePayments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://korumedical.com/role/ScheduleOfCashFlowInformationRelatedToLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r385"
     ],
     "calculation": {
      "http://korumedical.com/role/BalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating lease right-of-use assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://korumedical.com/role/BalanceSheets",
      "http://korumedical.com/role/SchdeuleOfBalanceSheetInformationRelatedToLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock": {
     "auth_ref": [
      "r117",
      "r118",
      "r119",
      "r120",
      "r121"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for lessee's operating leases. Includes, but is not limited to, description of lessee's operating lease, existence and terms of renewal or purchase options and escalation clauses, restrictions imposed by lease, such as those concerning dividends, additional debt, and further leasing, rent holidays, rent concessions, or leasehold improvement incentives and unusual provisions or conditions.",
        "label": "Schdeule of balance sheet information related to leases"
       }
      }
     },
     "localname": "OperatingLeasesOfLesseeDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://korumedical.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r43",
      "r44",
      "r55",
      "r95"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the general note to the financial statements for the reporting entity which may include, descriptions of the basis of presentation, business description, significant accounting policies, consolidations, reclassifications, new pronouncements not yet adopted and changes in accounting principles.",
        "label": "NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES"
       }
      }
     },
     "localname": "OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://korumedical.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r132"
     ],
     "calculation": {
      "http://korumedical.com/role/BalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://korumedical.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherIncome": {
     "auth_ref": [
      "r115"
     ],
     "calculation": {
      "http://korumedical.com/role/StatementsOfOperations": {
       "order": 3.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue and income classified as other.",
        "label": "Other Income"
       }
      }
     },
     "localname": "OtherIncome",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://korumedical.com/role/StatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesCurrent": {
     "auth_ref": [
      "r18",
      "r504"
     ],
     "calculation": {
      "http://korumedical.com/role/BalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://korumedical.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r28"
     ],
     "calculation": {
      "http://korumedical.com/role/StatementsOfOperations": {
       "order": 4.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Interest income, net"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://korumedical.com/role/StatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherReceivables": {
     "auth_ref": [
      "r134"
     ],
     "calculation": {
      "http://korumedical.com/role/BalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount due from parties in nontrade transactions, classified as other.",
        "label": "Other receivables"
       }
      }
     },
     "localname": "OtherReceivables",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://korumedical.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireIntangibleAssets": {
     "auth_ref": [
      "r30"
     ],
     "calculation": {
      "http://korumedical.com/role/StatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.",
        "label": "Payments to Acquire Intangible Assets",
        "negatedLabel": "Purchases of intangible assets"
       }
      }
     },
     "localname": "PaymentsToAcquireIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://korumedical.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireProductiveAssets": {
     "auth_ref": [
      "r148",
      "r583",
      "r584",
      "r585"
     ],
     "calculation": {
      "http://korumedical.com/role/StatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for purchases of and capital improvements on property, plant and equipment (capital expenditures), software, and other intangible assets.",
        "label": "Payments to Acquire Productive Assets",
        "negatedLabel": "Purchases of property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquireProductiveAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://korumedical.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock": {
     "auth_ref": [
      "r287",
      "r288",
      "r289",
      "r290",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r301",
      "r499"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for retirement benefits.",
        "label": "EMPLOYEE BENEFITS"
       }
      }
     },
     "localname": "PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://korumedical.com/role/EmployeeBenefits"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PerformanceSharesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement awarded for meeting performance target.",
        "label": "Performance Shares [Member]"
       }
      }
     },
     "localname": "PerformanceSharesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://korumedical.com/role/ScheduleOfPerformanceBaseOptionsOutstandingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r552",
      "r553",
      "r554",
      "r555",
      "r556",
      "r557",
      "r558",
      "r559",
      "r560",
      "r561",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r567",
      "r568",
      "r569",
      "r570",
      "r571",
      "r572",
      "r573",
      "r574",
      "r575",
      "r576",
      "r577"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://korumedical.com/role/FollowingTableSummarizesActivitiesForOurUnvestedRestrictedStockAwardsForTwelveMonthsEndedDecember312022And2021.Details",
      "http://korumedical.com/role/ScheduleOfInformationPertainingToOptionsOutstandingDetails",
      "http://korumedical.com/role/ScheduleOfStatusOfTimeBasedStockOptionsDetails",
      "http://korumedical.com/role/ScheduleOfTimeBasedStockOptionsDetails",
      "http://korumedical.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [
      "r552",
      "r553",
      "r554",
      "r555",
      "r556",
      "r557",
      "r558",
      "r559",
      "r560",
      "r561",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r567",
      "r568",
      "r569",
      "r570",
      "r571",
      "r572",
      "r573",
      "r574",
      "r575",
      "r576",
      "r577"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://korumedical.com/role/FollowingTableSummarizesActivitiesForOurUnvestedRestrictedStockAwardsForTwelveMonthsEndedDecember312022And2021.Details",
      "http://korumedical.com/role/ScheduleOfInformationPertainingToOptionsOutstandingDetails",
      "http://korumedical.com/role/ScheduleOfStatusOfTimeBasedStockOptionsDetails",
      "http://korumedical.com/role/ScheduleOfTimeBasedStockOptionsDetails",
      "http://korumedical.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PrepaidExpenseCurrent": {
     "auth_ref": [
      "r138",
      "r228",
      "r229",
      "r483"
     ],
     "calculation": {
      "http://korumedical.com/role/BalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.",
        "label": "Prepaid expenses and other"
       }
      }
     },
     "localname": "PrepaidExpenseCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://korumedical.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r31"
     ],
     "calculation": {
      "http://korumedical.com/role/StatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds from issuance of equity"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://korumedical.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleOfProductiveAssets": {
     "auth_ref": [
      "r29"
     ],
     "calculation": {
      "http://korumedical.com/role/StatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the sale of property, plant and equipment (capital expenditures), software, and other intangible assets.",
        "label": "Proceeds from disposal of property and equipment"
       }
      }
     },
     "localname": "ProceedsFromSaleOfProductiveAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://korumedical.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "auth_ref": [
      "r31",
      "r89"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.",
        "label": "Proceeds from Stock Options Exercised"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://korumedical.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r65"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Long-Lived Tangible Asset [Axis]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://korumedical.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesDetailsNarrative",
      "http://korumedical.com/role/ScheduleOfPropertyAndEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "auth_ref": [
      "r67",
      "r467",
      "r468",
      "r469"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "PROPERTY AND EQUIPMENT"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://korumedical.com/role/PropertyAndEquipment"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r63",
      "r129"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Total property and equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://korumedical.com/role/ScheduleOfPropertyAndEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property, Plant and Equipment [Line Items]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://korumedical.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesDetailsNarrative",
      "http://korumedical.com/role/ScheduleOfPropertyAndEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment [Member]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://korumedical.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r65",
      "r113",
      "r454",
      "r504"
     ],
     "calculation": {
      "http://korumedical.com/role/BalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://korumedical.com/role/BalanceSheets",
      "http://korumedical.com/role/ScheduleOfPropertyAndEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentOther": {
     "auth_ref": [
      "r65"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of other physical assets used in the normal conduct of business to produce goods and services and not intended for resale.",
        "label": "Property and equipment, at cost"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentOther",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://korumedical.com/role/SchdeuleOfBalanceSheetInformationRelatedToLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentOtherAccumulatedDepreciation": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation of long-lived, physical assets used to produce goods and services and not intended for resale, classified as other.",
        "label": "Property, Plant and Equipment, Other, Accumulated Depreciation",
        "negatedLabel": "Accumulated depreciation"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentOtherAccumulatedDepreciation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://korumedical.com/role/SchdeuleOfBalanceSheetInformationRelatedToLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentOtherNet": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after depreciation of long-lived, physical assets used to produce goods and services and not intended for resale, classified as other.",
        "label": "Property, Plant and Equipment, Other, Net",
        "verboseLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentOtherNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://korumedical.com/role/SchdeuleOfBalanceSheetInformationRelatedToLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "auth_ref": [
      "r65",
      "r467",
      "r468"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "verboseLabel": "PROPERTY AND EQUIPMENT"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://korumedical.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r65"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Schedule of property and equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://korumedical.com/role/PropertyAndEquipmentTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r63"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software."
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://korumedical.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesDetailsNarrative",
      "http://korumedical.com/role/ScheduleOfPropertyAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.",
        "label": "Estimated useful lives of property and equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://korumedical.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_RelatedPartyDomain": {
     "auth_ref": [
      "r291",
      "r400",
      "r401"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests."
       }
      }
     },
     "localname": "RelatedPartyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://korumedical.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "auth_ref": [
      "r291",
      "r400",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r594"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://korumedical.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r91",
      "r116",
      "r603"
     ],
     "calculation": {
      "http://korumedical.com/role/StatementsOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://korumedical.com/role/StatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r7",
      "r71",
      "r111",
      "r461",
      "r462",
      "r504"
     ],
     "calculation": {
      "http://korumedical.com/role/BalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://korumedical.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r123",
      "r158",
      "r159",
      "r160",
      "r162",
      "r168",
      "r170",
      "r215",
      "r339",
      "r340",
      "r341",
      "r356",
      "r357",
      "r370",
      "r458",
      "r460"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://korumedical.com/role/StatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": {
     "auth_ref": [
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r486"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue from contract with customer.",
        "label": "REVENUE RECOGNITION"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://korumedical.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Revenues": {
     "auth_ref": [
      "r146",
      "r154",
      "r192",
      "r193",
      "r197",
      "r200",
      "r201",
      "r205",
      "r206",
      "r208",
      "r214",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r373",
      "r453",
      "r548"
     ],
     "calculation": {
      "http://korumedical.com/role/StatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_GrossProfit",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).",
        "label": "NET REVENUES",
        "verboseLabel": "Revenues"
       }
      }
     },
     "localname": "Revenues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://korumedical.com/role/ScheduleOfNetRevenuesByGeographyDetails",
      "http://korumedical.com/role/StatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RisksAndUncertaintiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Risks and Uncertainties [Abstract]"
       }
      }
     },
     "localname": "RisksAndUncertaintiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement."
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://korumedical.com/role/ScheduleOfNetIncomePerCommonShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SalesRevenueNetMember": {
     "auth_ref": [
      "r208",
      "r539"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation.",
        "label": "Revenue Benchmark [Member]"
       }
      }
     },
     "localname": "SalesRevenueNetMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://korumedical.com/role/MajorCustomersDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": {
     "auth_ref": [
      "r94"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.",
        "label": "Schedule of provision for income taxes"
       }
      }
     },
     "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://korumedical.com/role/FederalAndStateIncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "auth_ref": [
      "r93"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.",
        "label": "Schedule of components of deferred tax assets"
       }
      }
     },
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://korumedical.com/role/FederalAndStateIncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [
      "r538"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
        "label": "Schedule of net income per common share"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://korumedical.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "auth_ref": [
      "r92"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Schedule of reconciliation of income taxes"
       }
      }
     },
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://korumedical.com/role/FederalAndStateIncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": {
     "auth_ref": [
      "r0",
      "r11",
      "r12",
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.",
        "label": "Inventory consists of:"
       }
      }
     },
     "localname": "ScheduleOfInventoryCurrentTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://korumedical.com/role/InventoryTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfOtherShareBasedCompensationActivityTableTextBlock": {
     "auth_ref": [
      "r79"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of activity for outstanding award under share-based payment arrangement excluding share and unit options and nonvested award.",
        "label": "Share-Based Payment Arrangement, Outstanding Award, Activity, Excluding Option [Table Text Block]",
        "verboseLabel": "Schedule of status of time based stock options"
       }
      }
     },
     "localname": "ScheduleOfOtherShareBasedCompensationActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://korumedical.com/role/Stock-basedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r65"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://korumedical.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesDetailsNarrative",
      "http://korumedical.com/role/ScheduleOfPropertyAndEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r302",
      "r303",
      "r305",
      "r306",
      "r307",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://korumedical.com/role/FollowingTableSummarizesActivitiesForOurUnvestedRestrictedStockAwardsForTwelveMonthsEndedDecember312022And2021.Details",
      "http://korumedical.com/role/ScheduleOfInformationPertainingToOptionsOutstandingDetails",
      "http://korumedical.com/role/ScheduleOfPerformanceBaseOptionsOutstandingDetails",
      "http://korumedical.com/role/ScheduleOfStatusOfTimeBasedStockOptionsDetails",
      "http://korumedical.com/role/ScheduleOfTimeBasedStockOptionsDetails",
      "http://korumedical.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock": {
     "auth_ref": [
      "r88"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of option exercise prices, by grouped ranges, including the upper and lower limits of the price range, the number of shares under option, weighted average exercise price and remaining contractual option terms.",
        "label": "Share-Based Payment Arrangement, Option, Exercise Price Range [Table Text Block]",
        "verboseLabel": "Schedule of time based stock options"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://korumedical.com/role/Stock-basedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r76",
      "r81",
      "r83"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Schedule of status of time based stock options"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://korumedical.com/role/Stock-basedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r86"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of time based stock options"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://korumedical.com/role/Stock-basedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShortTermDebtTable": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to borrowings under which repayment was required in less than twelve months (or normal operating cycle, if longer) after its issuance. It may include: (1) description of the short-term debt arrangement; (2) identification of the lender or type of lender; (3) repayment terms; (4) weighted average interest rate; (5) carrying amount of funds borrowed under the specified short-term debt arrangement as of the balance sheet date and measures of the maximum and average amount outstanding during the period; (6) description of the refinancing of a short-term obligation when that obligation is excluded from current liabilities in the balance sheet; and (7) amount of a short-term obligation that has been excluded from current liabilities in the balance sheet because of a refinancing of the obligation.",
        "label": "Schedule of Short-Term Debt [Table]"
       }
      }
     },
     "localname": "ScheduleOfShortTermDebtTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://korumedical.com/role/DebtObligationsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the change in restricted stock units (RSUs).",
        "label": "The following table summarizes the activities for our unvested restricted stock awards for the twelve months ended December 31, 2022, and 2021."
       }
      }
     },
     "localname": "ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://korumedical.com/role/Stock-basedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r26"
     ],
     "calculation": {
      "http://korumedical.com/role/StatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.",
        "label": "Selling, general and administrative"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://korumedical.com/role/StatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r34"
     ],
     "calculation": {
      "http://korumedical.com/role/StatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Stock-based compensation expense"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://korumedical.com/role/ScheduleOfStatusOfTimeBasedStockOptionsDetails",
      "http://korumedical.com/role/StatementsOfCashFlows",
      "http://korumedical.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments": {
     "auth_ref": [
      "r331"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated amount of dividends to be paid to holders of the underlying shares (expected dividends) over the option's term. Dividends are taken into account because payment of dividends to shareholders reduces the fair value of the underlying shares, and option holders generally do not receive dividends.",
        "label": "Expected dividends"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://korumedical.com/role/ScheduleOfTimeBasedStockOptionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r331"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Dividend yield"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://korumedical.com/role/ScheduleOfTimeBasedStockOptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r330"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Expected volatility"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://korumedical.com/role/ScheduleOfTimeBasedStockOptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r332"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Risk-free rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://korumedical.com/role/ScheduleOfTimeBasedStockOptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate": {
     "auth_ref": [
      "r330"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rate of weighted-average expected volatility for award under share-based payment arrangement.",
        "label": "Weighted-average volatility"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://korumedical.com/role/ScheduleOfTimeBasedStockOptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://korumedical.com/role/FollowingTableSummarizesActivitiesForOurUnvestedRestrictedStockAwardsForTwelveMonthsEndedDecember312022And2021.Details",
      "http://korumedical.com/role/ScheduleOfInformationPertainingToOptionsOutstandingDetails",
      "http://korumedical.com/role/ScheduleOfPerformanceBaseOptionsOutstandingDetails",
      "http://korumedical.com/role/ScheduleOfStatusOfTimeBasedStockOptionsDetails",
      "http://korumedical.com/role/ScheduleOfTimeBasedStockOptionsDetails",
      "http://korumedical.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r311"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Options exercisable at ending"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://korumedical.com/role/ScheduleOfStatusOfTimeBasedStockOptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r311"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Options exercisable"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://korumedical.com/role/ScheduleOfStatusOfTimeBasedStockOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "auth_ref": [
      "r315"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Forfeited"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://korumedical.com/role/ScheduleOfStatusOfTimeBasedStockOptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [
      "r313"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Granted",
        "verboseLabel": "Weighted average fair value of options granted during the period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://korumedical.com/role/ScheduleOfPerformanceBaseOptionsOutstandingDetails",
      "http://korumedical.com/role/ScheduleOfStatusOfTimeBasedStockOptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r323"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Weighted average fair value of options granted during the period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://korumedical.com/role/ScheduleOfStatusOfTimeBasedStockOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r309",
      "r310"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Outstanding at ending",
        "periodStartLabel": "Outstanding at beginning"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://korumedical.com/role/ScheduleOfPerformanceBaseOptionsOutstandingDetails",
      "http://korumedical.com/role/ScheduleOfStatusOfTimeBasedStockOptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r309",
      "r310"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Outstanding at ending",
        "periodStartLabel": "Outstanding at beginning"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://korumedical.com/role/ScheduleOfPerformanceBaseOptionsOutstandingDetails",
      "http://korumedical.com/role/ScheduleOfStatusOfTimeBasedStockOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue": {
     "auth_ref": [
      "r326"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Fair value of shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://korumedical.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r305",
      "r306",
      "r307",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://korumedical.com/role/FollowingTableSummarizesActivitiesForOurUnvestedRestrictedStockAwardsForTwelveMonthsEndedDecember312022And2021.Details",
      "http://korumedical.com/role/ScheduleOfInformationPertainingToOptionsOutstandingDetails",
      "http://korumedical.com/role/ScheduleOfPerformanceBaseOptionsOutstandingDetails",
      "http://korumedical.com/role/ScheduleOfTimeBasedStockOptionsDetails",
      "http://korumedical.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r314"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://korumedical.com/role/ScheduleOfStatusOfTimeBasedStockOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r315"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "verboseLabel": "Forfeited"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://korumedical.com/role/ScheduleOfStatusOfTimeBasedStockOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r313"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "verboseLabel": "Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://korumedical.com/role/ScheduleOfStatusOfTimeBasedStockOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "auth_ref": [
      "r308",
      "r327",
      "r328",
      "r329",
      "r330",
      "r333",
      "r342",
      "r343"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.",
        "label": "Share-Based Payment Arrangement [Policy Text Block]",
        "verboseLabel": "STOCK-BASED COMPENSATION"
       }
      }
     },
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://korumedical.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock": {
     "auth_ref": [
      "r75"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the number and weighted-average grant date fair value for outstanding performance shares.",
        "label": "Schedule of performance base options outstanding"
       }
      }
     },
     "localname": "ShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://korumedical.com/role/Stock-basedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis": {
     "auth_ref": [
      "r85"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by range of option prices pertaining to options granted.",
        "label": "Exercise Price Range [Axis]"
       }
      }
     },
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://korumedical.com/role/ScheduleOfInformationPertainingToOptionsOutstandingDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain": {
     "auth_ref": [
      "r87"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Supplementary information on outstanding and exercisable share awards as of the balance sheet date which stratifies outstanding options by ranges of exercise prices."
       }
      }
     },
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://korumedical.com/role/ScheduleOfInformationPertainingToOptionsOutstandingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions": {
     "auth_ref": [
      "r80"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares reserved for issuance pertaining to the outstanding exercisable stock options as of the balance sheet date in the customized range of exercise prices for which the market and performance vesting condition has been satisfied.",
        "label": "Number exercisable"
       }
      }
     },
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://korumedical.com/role/ScheduleOfInformationPertainingToOptionsOutstandingDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions": {
     "auth_ref": [
      "r77"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares reserved for issuance pertaining to the outstanding stock options as of the balance sheet date for all option plans in the customized range of exercise prices.",
        "label": "Number outstanding",
        "verboseLabel": "Common stock, shares, outstanding"
       }
      }
     },
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://korumedical.com/role/ScheduleOfInformationPertainingToOptionsOutstandingDetails",
      "http://korumedical.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedGoodsAndNonemployeeServicesTransaction": {
     "auth_ref": [
      "r74",
      "r88"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of transactions in which an entity acquires goods or services other than employee services in exchange for equity securities of the company, including the purpose of the transaction, identification and quantity of the securities issued, the accounting method used for valuing the transaction, disclosure of amounts by which report lines were affected, and noncash effects on the statement of cash flows.",
        "label": "Share-based goods and nonemployee services transaction"
       }
      }
     },
     "localname": "ShareBasedGoodsAndNonemployeeServicesTransaction",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://korumedical.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r329"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Expected term (in years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://korumedical.com/role/ScheduleOfTimeBasedStockOptionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r84"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Weighted-average period"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://korumedical.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average grant-date fair value of options vested.",
        "label": "Stock options granted"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://korumedical.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1": {
     "auth_ref": [
      "r78"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average exercise price as of the balance sheet date for those equity-based payment arrangements exercisable and outstanding.",
        "label": "Share-Based Payment Arrangement, Option, Exercise Price Range, Exercisable, Weighted Average Exercise Price",
        "verboseLabel": "Weighted average exercise price"
       }
      }
     },
     "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://korumedical.com/role/ScheduleOfInformationPertainingToOptionsOutstandingDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1": {
     "auth_ref": [
      "r77"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average price as of the balance sheet date at which grantees could acquire the underlying shares with respect to all outstanding stock options which are in the customized range of exercise prices.",
        "label": "Weighted average exercise price"
       }
      }
     },
     "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://korumedical.com/role/ScheduleOfInformationPertainingToOptionsOutstandingDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r84"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term of outstanding stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Weighted average remaining contractual life"
       }
      }
     },
     "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://korumedical.com/role/ScheduleOfInformationPertainingToOptionsOutstandingDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
        "label": "Shares, Outstanding",
        "periodEndLabel": "Balance ending (in shares)",
        "periodStartLabel": "Balance beginning (in shares)"
       }
      }
     },
     "localname": "SharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://korumedical.com/role/StatementsOfStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShortTermDebtLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Short-Term Debt [Line Items]"
       }
      }
     },
     "localname": "ShortTermDebtLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://korumedical.com/role/DebtObligationsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShortTermLeaseCost": {
     "auth_ref": [
      "r394",
      "r503"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of short-term lease cost, excluding expense for lease with term of one month or less.",
        "label": "Short-term lease cost"
       }
      }
     },
     "localname": "ShortTermLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://korumedical.com/role/ScheduleOfComponentsOfLeaseExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "State income tax:"
       }
      }
     },
     "localname": "StateAndLocalIncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://korumedical.com/role/ScheduleOfProvisionForIncomeTaxesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r22",
      "r70",
      "r123",
      "r143",
      "r144",
      "r145",
      "r158",
      "r159",
      "r160",
      "r162",
      "r168",
      "r170",
      "r185",
      "r215",
      "r277",
      "r339",
      "r340",
      "r341",
      "r356",
      "r357",
      "r370",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r399",
      "r458",
      "r459",
      "r460"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://korumedical.com/role/ScheduleOfNetIncomePerCommonShareDetails",
      "http://korumedical.com/role/StatementsOfStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://korumedical.com/role/ScheduleOfNetIncomePerCommonShareDetails",
      "http://korumedical.com/role/ScheduleOfNetRevenuesByGeographyDetails",
      "http://korumedical.com/role/StatementsOfStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r158",
      "r159",
      "r160",
      "r185",
      "r437"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://korumedical.com/role/ScheduleOfNetIncomePerCommonShareDetails",
      "http://korumedical.com/role/ScheduleOfNetRevenuesByGeographyDetails",
      "http://korumedical.com/role/StatementsOfStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssued1": {
     "auth_ref": [
      "r40",
      "r41",
      "r42"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The fair value of stock issued in noncash financing activities.",
        "label": "Issuance of common stock as settlement for litigation"
       }
      }
     },
     "localname": "StockIssued1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://korumedical.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan": {
     "auth_ref": [
      "r4",
      "r5",
      "r70",
      "r71",
      "r90"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of capital stock issued (purchased by employees) in connection with an employee stock ownership plan.",
        "label": "Common stock issued, shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://korumedical.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": {
     "auth_ref": [
      "r4",
      "r5",
      "r70",
      "r71"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).",
        "label": "Issuance of stock-based compensation (in shares)",
        "verboseLabel": "Available for issuance"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://korumedical.com/role/StatementsOfStockholdersEquity",
      "http://korumedical.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r4",
      "r5",
      "r70",
      "r71",
      "r314"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Issuance upon options exercised (in shares)",
        "verboseLabel": "Exercised"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://korumedical.com/role/ScheduleOfStatusOfTimeBasedStockOptionsDetails",
      "http://korumedical.com/role/StatementsOfStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan": {
     "auth_ref": [
      "r4",
      "r5",
      "r70",
      "r71",
      "r90"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate value of stock issued during the period as a result of employee stock ownership plan (ESOP).",
        "label": "Aggregate stock price"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://korumedical.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures": {
     "auth_ref": [
      "r70",
      "r71"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock related to Restricted Stock Awards issued during the period, net of the stock value of such awards forfeited.",
        "label": "Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://korumedical.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": {
     "auth_ref": [
      "r4",
      "r5",
      "r71",
      "r82"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).",
        "label": "Issuance of stock-based compensation"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://korumedical.com/role/StatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r22",
      "r70",
      "r71"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Issuance upon options exercised"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://korumedical.com/role/StatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contracts conveying rights, but not obligations, to buy or sell a specific quantity of stock at a specified price during a specified period (an American option) or at a specified date (a European option).",
        "label": "Equity Option [Member]"
       }
      }
     },
     "localname": "StockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://korumedical.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r5",
      "r8",
      "r9",
      "r56",
      "r504",
      "r533",
      "r545",
      "r588"
     ],
     "calculation": {
      "http://korumedical.com/role/BalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Ending balance, value",
        "periodStartLabel": "Beginning balance, value",
        "totalLabel": "TOTAL STOCKHOLDERS\u2019 EQUITY"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://korumedical.com/role/BalanceSheets",
      "http://korumedical.com/role/StatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "STOCKHOLDERS\u2019 EQUITY"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://korumedical.com/role/BalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Sale of Stock [Axis]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://korumedical.com/role/ScheduleOfNetIncomePerCommonShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Information"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://korumedical.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "auth_ref": [
      "r212",
      "r213",
      "r274",
      "r276",
      "r369",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r542",
      "r543",
      "r544",
      "r606",
      "r607",
      "r608",
      "r609",
      "r610",
      "r611",
      "r612"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms."
       }
      }
     },
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://korumedical.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TreasuryStockCommonShares": {
     "auth_ref": [
      "r72"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of previously issued common shares repurchased by the issuing entity and held in treasury.",
        "label": "Treasury Stock, Common, Shares"
       }
      }
     },
     "localname": "TreasuryStockCommonShares",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://korumedical.com/role/Cover"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TreasuryStockMember": {
     "auth_ref": [
      "r21",
      "r72"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares of an entity that have been repurchased by the entity. This stock has no voting rights and receives no dividends. Note that treasury stock may be recorded at its total cost or separately as par (or stated) value and additional paid in capital. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.",
        "label": "Treasury Stock [Member]"
       }
      }
     },
     "localname": "TreasuryStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://korumedical.com/role/StatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TreasuryStockShares": {
     "auth_ref": [
      "r21",
      "r72"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of common and preferred shares that were previously issued and that were repurchased by the issuing entity and held in treasury on the financial statement date. This stock has no voting rights and receives no dividends.",
        "label": "Treasury stock, shares"
       }
      }
     },
     "localname": "TreasuryStockShares",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://korumedical.com/role/BalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TreasuryStockValue": {
     "auth_ref": [
      "r21",
      "r72",
      "r73"
     ],
     "calculation": {
      "http://korumedical.com/role/BalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.",
        "label": "Treasury Stock, Value",
        "negatedLabel": "Treasury stock, 3,420,502 shares at December 31, 2022 and December 31, 2021, at cost"
       }
      }
     },
     "localname": "TreasuryStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://korumedical.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r586"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://korumedical.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r52",
      "r53",
      "r54",
      "r187",
      "r188",
      "r189",
      "r190"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "USE OF ESTIMATES IN THE FINANCIAL STATEMENTS"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://korumedical.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r172",
      "r180"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Outstanding shares",
        "verboseLabel": "Diluted"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://korumedical.com/role/ScheduleOfNetIncomePerCommonShareDetails",
      "http://korumedical.com/role/StatementsOfOperations"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "WEIGHTED AVERAGE COMMON SHARES OUTSTANDING"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://korumedical.com/role/StatementsOfOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r171",
      "r180"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "verboseLabel": "Basic"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://korumedical.com/role/StatementsOfOperations"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Outstanding Shares:"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasicAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://korumedical.com/role/ScheduleOfNetIncomePerCommonShareDetails"
     ],
     "xbrltype": "stringItemType"
    }
   },
   "unitCount": 5
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04.4)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "https://asc.fasb.org/extlink&oid=124440162&loc=d3e12069-110248",
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "840",
   "URI": "https://asc.fasb.org/extlink&oid=123389372&loc=d3e36991-112694",
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(Note 3)",
   "Topic": "840",
   "URI": "https://asc.fasb.org/extlink&oid=123403562&loc=d3e38371-112697",
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "840",
   "URI": "https://asc.fasb.org/extlink&oid=123406913&loc=d3e41499-112717",
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "840",
   "URI": "https://asc.fasb.org/extlink&oid=123406913&loc=d3e41502-112717",
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "840",
   "URI": "https://asc.fasb.org/topic&trid=2208923",
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(c))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(16))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(18))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3)(a)(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(1))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3367-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4297-108586",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(c))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19,20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1707-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1757-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "26",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1828-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "270",
   "URI": "https://asc.fasb.org/extlink&oid=126900757&loc=d3e543-108305",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "270",
   "URI": "https://asc.fasb.org/extlink&oid=126900988&loc=SL77927221-108306",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "https://asc.fasb.org/topic&trid=2134479",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29,30)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5074-111524",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27232-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=SL120269820-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255206&loc=SL82895884-210446",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919258-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "https://asc.fasb.org/extlink&oid=116847112&loc=d3e4492-108314",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "https://asc.fasb.org/extlink&oid=116847112&loc=d3e4556-108314",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "330",
   "URI": "https://asc.fasb.org/topic&trid=2126998",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "https://asc.fasb.org/extlink&oid=126905020&loc=d3e5879-108316",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "https://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.1,2)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2(a),(d))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(i)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130561-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130563-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130563-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130564-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "606",
   "URI": "https://asc.fasb.org/topic&trid=49130388",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(l)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(o)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(p)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(q)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(r)(1)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(r)(2)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=21916913&loc=d3e273930-122802",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "60",
   "Subparagraph": "(c)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=6414203&loc=d3e39689-114964",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "70",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=49170846&loc=d3e28014-114942",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "715",
   "URI": "https://asc.fasb.org/topic&trid=2235017",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=SL116886442-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4549-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(l)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "https://asc.fasb.org/topic&trid=2228938",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e31917-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e31931-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "https://asc.fasb.org/topic&trid=2144680",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=d3e90205-114008",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=126980362&loc=d3e28228-110885",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123602790&loc=d3e30226-110892",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=125521441&loc=d3e30690-110894",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=124440516&loc=d3e30840-110895",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4273-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918638-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4297-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918666-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=124258985&loc=SL77919372-209981",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4304-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(i)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(ii)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4313-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4332-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)(i)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(5)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(6)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(7)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(b)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "https://asc.fasb.org/topic&trid=2122369",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "330",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=6471895&loc=d3e55923-109411",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "350",
   "Subparagraph": "(a)",
   "Topic": "920",
   "URI": "https://asc.fasb.org/extlink&oid=120155617&loc=SL120155628-234783",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "350",
   "Subparagraph": "(b)",
   "Topic": "920",
   "URI": "https://asc.fasb.org/extlink&oid=120155617&loc=SL120155628-234783",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "350",
   "Subparagraph": "(a)",
   "Topic": "920",
   "URI": "https://asc.fasb.org/extlink&oid=120155617&loc=SL120155638-234783",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "340",
   "Topic": "928",
   "URI": "https://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "250",
   "URI": "https://asc.fasb.org/topic&trid=2122394",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(1)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(2)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "https://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=126942805&loc=d3e3115-115594",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Subparagraph": "(d)",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99779-112916",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99893-112916",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=SL120174063-112916",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6327-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r507": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r508": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r509": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6442-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r510": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-23",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r511": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r512": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "g",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r513": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12, 13, 15d",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r514": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r515": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r516": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "15",
   "Subsection": "d",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r517": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r518": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r519": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r520": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r521": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r522": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r523": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r524": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r525": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r526": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r527": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r528": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r529": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r530": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r531": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r532": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(f))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r533": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r534": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r535": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r536": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r537": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r538": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r539": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r540": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8672-108599",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r541": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4647-111522",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r542": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r543": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r544": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r545": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r546": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "410",
   "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r547": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "https://asc.fasb.org/topic&trid=2127136",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r548": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r549": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "https://asc.fasb.org/topic&trid=2134479",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r550": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r551": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r552": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r553": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r554": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r555": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r556": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r557": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r558": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r559": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r560": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r561": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r562": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r563": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r564": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r565": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r566": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r567": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r568": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r569": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 5.BB)",
   "Topic": "330",
   "URI": "https://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r570": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r571": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r572": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r573": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r574": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r575": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r576": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r577": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r578": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r579": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r580": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r581": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r582": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r583": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "50",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=127000608&loc=d3e9135-128495",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r584": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "50",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126928898&loc=d3e9212-128498",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r585": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "50",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126928898&loc=d3e9215-128498",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r586": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r587": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r588": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r589": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r590": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r591": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r592": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r593": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r594": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r595": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r596": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r597": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r598": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r599": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r600": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r601": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r602": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r603": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r604": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r605": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r606": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r607": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(1)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r608": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r609": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(3)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(3)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r610": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(i)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r611": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(ii)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r612": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(iii)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226317&loc=d3e202-110218",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.CC)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=27011434&loc=d3e125687-122742",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "360",
   "URI": "https://asc.fasb.org/topic&trid=2155823",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "https://asc.fasb.org/topic&trid=2144648",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "https://asc.fasb.org/topic&trid=2208564",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=6405834&loc=d3e23315-112656",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5047-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)-(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=SL79508275-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "40",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=109244457&loc=d3e16649-113920",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "https://asc.fasb.org/topic&trid=2197479",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13531-108611",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  }
 },
 "version": "2.2"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>67
<FILENAME>0001161697-23-000158-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001161697-23-000158-xbrl.zip
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M/6D3^ 2\6Y1BXU$D _D1_,VS##?T-QG O@2W:/('\'@+NL,8A*5.R"'4'4@
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MI6.ZB&05/R3J4A<.JLPAQKF]:*B!748QM=YV;Q$C83)I7#'&][U2L#*X2(G
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M*MPFJ]@]UKF?G:"LJ!"$W/=3%<YV$:_73DQB#@N?M0>^]"Y*N:!L?:JEAL'
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MV1O8*AE'*H;#/W")DJ;*U.5V=E58D>'9<.B.L!/!9&Z+>G#_^ES@K)Z*>4W
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M[BT32^! L U"ZSY0P7:1]QYNZ':NTOA3G<^,/"L(/UR)9G4-&/0N%QG"ZG^
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MQW"%PRQ+TM%ADC_Q^Q6H\,U'U?.C75JO@SW3X3#;R[2CVOEXP3=:0!68OZF
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M;M77&AO3;9A?0^&R^NC__L_KM>:KMQD\%JDA+E0L#S44@*("-1[/![@O+W4
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M%\84PT+M1I*@Z&"INN$P&M5X[! -BNR#VST'*.R<U-PR'C(I)IX1R (L#E'
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MPTA>F.[$'7*-CE0F1L*I4,XGOQB]KE/EZ3(YHY247W@I3(7SHLZ*11",>Z,
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MVM;+PU, YAS")6%<N49<;*RNT?-5H=]WG/D:P156T^I]U<5H(!Q+H(7WPON
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M@&T4YK0TVK#2Z%2;L".1:N%,PF+<AG(P H5D,^T9^%$T5AR8*S9+>.N>Y$N
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M+:"K/T[/S>VGCA?=;GA%U>QTR@_F.6*0:CX2EQ_G?%.B.O<5U$Y7$SQIPZE
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M6T#PEMF<,49P2P9F7>@7,)%*C]CKY4>%+_TLW$M$94QSF_U*M,*Y!UF17BA
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MSWKU$P[?<MZ5TS1,RK&-).,K&I$/0#*'-$=<7JJ F]6L4(RD9C&XPDO,2I?
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M<T6)C&<[E_3<E18%>+':U>V0(:,"WTXM&O.F5.-XVBPQQP/-L&%1XAL&+Z<
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MLV3V'._\7$2$[%)R5E*R='1!1ZAT.6A4R\&+QD^4 1I790?"#6/,5\A8RU9
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MZ#% ^TZO&.==#H,?NLBNR%H9.YS(GGG<?8$4!#-PD_(3'^&5EM9<:U2LDG-
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M-2@TNA R&/_5</6FB)4B<-DM.S*$$?&63D&[-$WPZ$),$402IV'&25)EE;V
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M!N/,'!R_?!8.PN.7ZVOTH>"<O?GU%)^AB'&?_K*Z9R37?"*9*-5,%Y"N8I@
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M*>'*N<<P)O-FD>9;*:6\Y1K,!=<B6B#L?-%GW,/FG/ALRE&SJ.;II=RCKB0
M9IE#N63Y[Z;@-;@3NOR9I?Y^Z_]N\-K !MA*5Q%17"VFK-5+,H#N&[)>PM/P
MTE>85-)F'ZZWE5YOV7Y:VM(_<%W^< HNX[7AUT'VAU9L]PJD8<CD_Z)C*Q.V
MDJN,TZ;/2""=:AG&[WE)XH9,B+#*.='G]V*G&-_U>CH]9*]L/VW&18C]M/T8
M8-#[[A+9&RP[B/4GY9F$!TAI=7H$0.MK;35?Y?5"+MJO=?N9B0M6)!]\7]#
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MT.\X!VZ7PI*W4B=([B&T6;@H$Z^"+&/@67DJ01\9?"% JUUQ;W!TMBR=E3E
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M1Z'1Q1(8/_EPV;ATAM^89"(29,2HTL2U#-QK$<88J[*=@- ?DSD)[FB>AKL
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MW\=-+?_^WM-V:997D2V/?(%71("++4G)/OL,7RZLR4CF$7FG.#:5W$K>T59
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MF^)X-K$3/O](J< QO(IL+5]N.X+I]?95+6F%ZD.6#Z^\$2RD0SDATB8H6TR
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ME&XU3-95@\W3W:<B8.<X9;"7A-_<.R"'I/<)C)W[GO:)KYUH3^%W00XMX?;
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MO);>%T6*G!!?UY^>J'S)8A1T'EUD8Y@*V#PL,QDHG0'&&W3Q@+/%N\2@DK)
M9:A0&:R0TS=PB(1UD1!,*F5:\UQ9N1^4;V\*&?[,I9(]<W"+T; X+-;_*ZWY
M=%Y^-1/=JTGJ+5S9@U#Z44LG^JE,4YXDOOV OE^59K7^<L:RQC/-$=C?D"8@
M#M!CB*09, .PX.D"K0(U(IE#;5EJA*/C-2WVZQ="N-((>2%398C5-U*]!K+%
MR1,@2Z@;\0$YE# PGE02@*S2.]A; >=B($M=6[(\Z<;;A:)=C*!WBDFHO@<^
MQ0!!U$?.QA*(7[^LAW$% .)8 ! RTU60>6 QJM1&3V'[9A6F<SP]9*X-)6A&
MJH"!8\H&DO+8*R*2ETRX:YNZ*ENR.T85'AVKV"K#7240TI#QA&PX9*DA=8!T
M JDY!KEORJK*=(B%!2XF= 8T@1J0L=4A1A]]%^@E:D1U:+8L1KRC)S"P;S(#
M%^Z$0I"WAX['SK#KC<&I_?H%'04@W0:"*D"\%/W%E#V@8*\1S$[X[$,!A]5D
MVI*)* ()_@%R0'4#^[PP\ +1.9*B+/RL$+^4$ KZ@TK#9DR7>H@:F9$!M3$4
M-L9"V^LZ&RKU&'#$T=(4&B2=>PC264>%X[(_[,I#? X&-7?MNS,-';#]##I#
MVG41H >BQHJW)WWH!I A4+:$#^"5 (3\;]?591FXOJ/NL7O,$Z34$6WK$[3D
M4)J!#C=DW":U:VL:9)ZK7:0Z[!<ADQP7\]@;=D>0$YH):/(BC9V[J5TU[N\2
MT\*YF[S+/6.1I8_P5E8^Y"[1'4M:9G%:V9;OMN;%3&?P>)<RYS?M<-5-LC6_
M2<>-Y^E;+]400-TT,Y6K4K9<8#*-1N&L35SJLP$;@'.EP!4S<LVPQ%UIKLQZ
ME,5(LAPGU#(DX"WCS40*"'@&67^&I<P1>T!HNT\-9T."^Z8+5=$@_F4-]"X6
MZO!7Q7"D$7Q'[HU5Q,,@1 E[&%#B1H3DLOT:7^P[89_Z$D$\X#7+2"RTNM.R
M;]"H%6 9,SN[DUYU(P<N;&:JF*V6V\P%(P3Y7$T''7<RA)Q:+1.9_Q=UV /Y
M#O[]#KUE.![29^9W_;OV-/N6%.YXQ[(N^.*$AJUJB9?@-^:IU+<?B<6 .VB5
M960F/BTRI:D7F>9=]CDY??EY%PN(2X'; 9EIQ#@P]7<!FS@OW=9(&55U6,K9
M- 0[8=M8K1CRAR)/0*,A?:0@ITTQL%<Y&<B:#%PA?Y!.) 9#"CRQBN\H1F<\
M-+'J@@\@B(Q4"]))Q"QT%#[QOP &M"/\6JQY--U"VL>CVE79!KDZ-CR:##DU
MH&E&X,B"   HNS*XL.@XT?I*SPNTC Z"R@+7]?V0#$4?@^[L("UHXIV!X4$%
M@HG L%<DUR(.\HCT($8 G8[ESFC45^62$S,GM0'(-$ /YN4.)@9&Y%D&Z!*#
M!TD4S$0R5_U@3WLR+P#5WC+5\OXAYZYT/RLVWU)UK>/0W):%-B9*;?MNQ'EG
M"8'E8W[YI]1EAON,%1PF=\,A[^"0)SA4Y>>A>)/EZO'3X3"\J:PBFQ+7!AU8
MS%XR;N^MSB)R:L*WT39(<R^RZ1SH)@B8-4&"="J0KMF^;&O>+URGE)IV]SY6
M#['LUH3B(:SF&B>2GW"RY8\Y[D# ",?BG3HE_)=5F84$K,=+5V??H[Q.('?\
M2X9K%G'<W5"NSD>/Z?=[]_8*Y@:HTNP[TA::_"\#KAQQ ;\S1!E^6TCG]L/(
MHFY<HDIR(]I!#BWZ*V1Y8^:!WVGV(VD[L"L.: :3"-,7:4)41U=5:63*WQG[
MIV_+99JKR5'(XK1DG]3,;47DZW(\_VO_>('+C(*&#6>O7B(Y#WZ9ALN+6?IH
M<XG[NK?[?L=)8TWG/!KLYS1KUN=O.3F^?89+H.ZT>[)W!5%P<R*K'_(=#G]#
M"'K^UM2X^T&L\)-S6S[LDM2^+C'>SGN+<Y!2BY A!CX03]+<96RT)NL_Z/OQ
MZ]>DG6[Y;CQQF7#+BG9)/3WL7*((U2.S([TNVWT-H>VO1X MFQ,=T]<[+S\F
M^6:Z7]ZEK0':<"R"\I$P3XUN\DP.JWC88<&E&#ZNZ]S[>W<V'3[?22&* RP
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M$-'ETN!@7.)IFN.AW;4 BV4RN1:7Z0])OS@$"70%ZMK58+ZPV/6BN!@94LQ
M\+I3 ?&$7QA=B.??THFYI FGW:P.:K<=X)SIP-"P$_HC>."VYTVWQT2+@%[
M$]U)[R R,%$E+1>@9I=V7U%5?8)'+[)?O[CC?9T'6'L+!H(TX(1>KC6OE.KC
MP=V3\?/^P$Z0D1=2UF$HY5@F5H2&+[Z>$,GDL-DE&YMK7+W7:+LMU)J/RJ-Y
MA[_ZF;T*F?T1^JWXE3Q+69..T/GVHUYX+%0>"DR]D*M>54J?H"N)JRDRI-8:
MY]+2B>LFD]7!:?J+5D<6,XTL+7W\VVZ?X'[MZQ?W>P\C7%QN?S'3>'"^5]$O
MD8'%QRZX-,L@748/DS"A?9RTE-T^41,4ESWLFK8(QOU3T&M54K!JR -9,W&7
M%%PV3^:G(\# @ 6N')-J4LG=)CQAT+=+AF(ZD]0[BU!T;"C.O04#3N!)_FO:
MNS)IATVW&Z<IT:E[2$0-D0G:=2:P7W[]0EN&+I;ZTX7P^%5S0-N@X;)[DPHL
MRSX77='L'@($88S>)IUN,$)UE72WF6@(E6@EIV&,KKO#V!OH#R-,3*3!J=MQ
M$P1M6U%5(F.=,R$PN#7$6$G -L_^M#Q[Z^JRB;4(&2T/;5K'!E:[&#D8\2-H
M>*?A]K2*A10(T+^]DFP8NN'M@8/KJ$GO:M/MJ;V(-\.>R]NC_5G1QS LN*N8
M"_UT[)=,:-XJ(:09%'G#$%Y#^;!5*%D*FP6@* TD5LCY3'3C#>$%GSKIIJ*!
M>Z=BII1H!URZO@<;MIZ5((,!.X1(>R*B0O;^0C?>)BD!!WIQ^]TXRZWMD7N.
M]%&#LS*Q-40:T9@DTQ/];/=,(MUS-60DN(R&W)8)DE2&W":&%;14@0G*Y#J#
M#E7V-(%;Z$0#E&20'NG$UK.%(C6W3&GH=.4@+3M(FT3,98MKZ0:1% KVB!'A
MM24\NAI;<P1F"JH%O9V0Z$ <S;2A-_  6HP[C8OK[DX6Z->#$'<\JMM+'3._
MK.)VDKAWR=)W2&M&&Y/@WY-F,^@I]#6P.S^-L =[%"%7,0>X68YK7F*TX-Y9
ML$>]UX,^[;H*NR,]\&$F.D*$W8T9'9ZL?)#V]&" #R0D"]HZ.B,JH'LZ+ V+
MP:I(+R*PD"W<,;\S?TE_0WN:&?F2Y&A..&@D B!^-,.CS#72,Q/W>$8BC&7^
M:I-O0LMF,+Q75!21?.AYVA<FJ@,)S\[%$32WMT=%MJAM8V9G5[+>-Z318+;:
M%L0..V[[9FLN9DNC\:SW>!4[<&I+<^%4R:4G<L/0$TCIF[A!A*/YVZ"H* A^
M_4^_?ED_*SV<J<0K=G<VCW"12_^<&K)<>G/#5GOTP?#=YG';7XA!VU\XD:8#
M)X>Y+1=$W'/AH%X$J4OQX!6$0X&(BX>/T$U=<H?CXO"=Q"[Y@]J-^,#@=]EW
M^/2Y\+LBQ*-J%>!I'Q'2 .W/@M+(NB^$V%OB*,#NT!WB.&>-P(+\;%O/1]NG
MXUC?.>(XTL, "W:FN\^#7\P,35_&L"S.(X<"#.;#][>23NA<8*?RJP'2-6D'
M>+" <S%DVY<  AT; 'Z!,;NX>&BTYC]CX_O79J??N^DX5\P>PG58=N?J81O&
M@+D"%*C60V/?'N&"R,93"5:(;ZL:VIFZ-YQ*;MVIK&0#['0JP_N27$JFK(>9
M>L136;W"/_Q4^#0;2Z781"H>TJE$(:[7,78)5(R&XRI0&AB6]-JK1M2EN61H
MDL!M$J1K#Z:===*[NA*D[*Q6GOO1GAE8BT<M,NS\$@_P>T_S944NS293VQK(
M[*T8#SQR/C0QXW_D=:MX:YJ/S?Y0/J<S7Y]3%,J9<QS/QM)!4]E/8W-@2])3
MFARI#-I2V^#28RJH")JW,[V&6!Y5LE>R)X4M"%7M6U6[BS39KZ_7DMV19%/I
M!,N)R=!J(GR[)T9YGEQ0^3+74M7;SL-<N_W9/Z?S/*"GV(H5B40"RR?#MU>"
M3>^.(6E<2:3T$J?H5P>V@5X*A6_*-,FVYJ^=238YB]V6N@>.PXDPQZ0LFZ8L
MEZ%WM+DYH<1;2;'A6ZVY,KHU2O&RH,1#SAX16_.K.XFK<$^3I-S[]J-<R#3.
M>FQS26.*<ML8P_QB),@39& H9(78V2 PTH;D@'B'J>&I;#@)P^[K_?6+94@:
MVBC<VLWH))HAY)O14<_24(?+*Z,O:736 @[1NY.%R44DSE-PKBWQQ &]=P&W
MRG;J2;WJII[8@U#1V\A@N86QS;3;>5M2\2V:.9!ER[Z.O(.AJ"-$DXJ&I]9A
MZ'"JPP &]IG.5:F]>\7T@Q !LQ$(M$5R5VK?\9'[%K@?HSCT#L@PO4.KR9_)
M];<]PP%R\>PYLOK86,Y]H;,L[.\:\A G:YCC-FS#4B UX>N7L4;VZ%S-/CA7
M[/9N6<^<9_M"&"< XM,?(CSBQ_7V*\TT@,E"&EQ>(DC081GFV@Q#FDYGFO0.
M&6<$LC#C GV7)* X4ZC)56-',@=,3]4GYF)2#]FE-['!.:RVW($K;KEG9T(
M=L;0C9ZYD31,[OAFBT\[63(+WQ](0/EVRH.=$@Y'CI"^0$\FSAGL*EV<WT O
M3==\T8,%N$$=T0M\;]MZ@,;M6Q]GD"EHMZX':Y (E"#-ZK<,0BO<7G-3731&
MQ7,?PHV <#/2:H:NZ4 >&(M$L&]6"K&%QKB[+=6:S^KQV>!-Y8;30U/IES1%
M'CG=3U4Q]I9[OJDIWWYD<KGJ0Z59JEPQM7JU@G[.D9QBR#Q$_Y9?F$R^6FL6
M\N>M39S+&."M56V2:3S8Z8)I=/@X79#TCF6:TA2]YJ^F/E(Z7[\D8]S?WYD&
MXA]5Z<UL]9!9%'?>;T(^(1FL@ZA'ZSK9S-8 "6YXK4G7(GG(BPO1V0D6!@$K
MI:'^@7/63!F:]*A0:R/3G&:2PV2#Y/P!!!M.?B,Y8'0L#G(!^S,JF\D,:_CB
MPOL@A1'F8X#(&-I9.3CG1L*W\A>6?@&YEU^_X-8O\$*Y2Y01R/2.,L):&?_1
M>YOO%8P>G)!)6626*DDD,BVL 4<(/1TG.QR/;K51AE/ >_:(<3R36\(R#)\6
M@PX+L(8TF4$/B\REE$EG4'FJD*%%_;'2!<FY!C+O:>$4KP7IW4,*":$5YRE@
M-0$IUUZ<D=Q.O A./UEXOBTC(M4P:#V81NO0*1_'&0Z<7WZ<U-5'V. !J!S=
ML*Q#!)XE24B*A?6&IB^)?1\UZ%6OP60V,BV'X[(^>$RDNHW09?::ZIYD:YZ\
MJ17FM9_7G>P@NNJ>Y)_JGE^INH<4'J[1M!7=>I&M#&&M50_.*=D,\O76_.ZF
MD+L;W62UY&NX"CK>FJ>&4J7$=<KWB<XF!8TL->:ET/P<^OEFK,EK/#V/;DY<
M\"+6S2YAEC03'3$^ F*C\L@ S>%\9 ;ZOCNZFQ&%!%+==V30'TDN[RT]B02C
M[\K>H@"L&$Q'9\!W2-403EO$RQ&-*!.U1[VP@:SB#'8Z%5D&-Q1Y>FW)5&AF
M^0>RDW'Z%WP+YR9VY;;%F$YQK*T*BL%61=+?V3@C0]60AA-=+5QR1?)ED6Y3
MP/U:<!^=48.XZLKCX0&<+ ,34F6IRSJU5V FX/J'&<@,)$]P>BOD@],ONW-<
ML09759PEC0N'"<(8@J\%_;N89.I]#)? >LN=Z.P^G%.*_M;%&<90:FMG>CKH
M(<G;%.MVTJESXA2I>"B[;,JTQ@"2]X@WZ(*-'FG+#,UU=1U6?#);SY%=)A.$
M;*@1:\ON&$HPOF"4O08-]=#1(1.&)-5[_>V!/@$SD'&/&2<YTW,A^%C$7%NV
MMT;3L3W9O%^_(+=O@!UN^!AP/$$ RQ==?>))@+<-H1[)P'<*7X!@L-VZC$X@
M;C((#"J@,>.AW=F1&KL^FM8D )KAF##G6-YAE(@J]7%_X)DIMLZ0)&5]JBYI
M"-4KN,=)R9Y49/31(G2F"QYB(<AJ7G"L;8PB6B!V$C "XHFQ@9]96)@DT,^(
M>;J*&=BS72SO24ON( _<DR!-Q\ZYZ<XX^D18#=XEXT#$%MMU3,JD-INO6ZU1
M =<3VFY&8#/7SX8%'L;A%MMAL6U3.C>Y2V=!T]^!Y'0-"Q4'C<@+<JP2;V#(
M9@"W6I/X/)CC[87//NG>KJ6@'A7Q@NR8)5CU#KXDS/-@MJIT-F[72;HGY0E>
M0\6M>^A@]VK=<Y@Z:=U"!]<.(6C0@S@BJ! /8CD8)RN8T#$O4X!Q30;Q0.V=
M 6M3CO<*U.48%:'356<%(:9+XYP&8U?9+L:M GDN,>1$_'P;?TS34KJFGGFT
MJ8@$X2/(08_]LFN8*? :K7E6?-=2G"X5I7BXYFNB-8^_)./56^XF'^]_^U',
ME.K,8Z;\4&#N"HC)ZV=?L5YT51(-O<M3Q;)K@$!J3VQM3N6S7?2C8G6+2[:A
M/F@D*?@O^'X"BL,E)T _<PR*A9=)=#8TG;D\])BR^,6N'=&5$1/!%4*7CDI>
M*7ZG4Z9'DD%"-=A^)I#3^E6W"LP!V@O@HV-_67)GH"GO4-LP-NU(/ ;-J[\I
M<$-IBLR9N4R&:9-9J7H;*F^H/3H: R18:B/C=/G1L;;RL*-=_%[++DB>L4GM
M7[<DQ0/A0$$"Q.@,9@S!+TR=!5L8KD0^9!4+&?)*%GXD[@"Q( UD5%H3G0ZU
M)8(;5G!AM6L/50D]ZMU%6)4K2T0>;25)<M=*DBTMOWP:>ZV;99D2A,2:S -O
M6Z\R'!G#,[9+>#_6+9D4Y-'8)BU%Q7Q 7#6BX#JN@>:A> 4'Q/9J:+9;_^F=
M$!88110?@H./$B9D:IEBB]_&F&.2>ZC7CM^N"@+65OI=9'%UP +!<6O[-Y8Q
MQ^ TF\S[P@%@WXCZ-=Y[2L\-Y<H9_>NSAGMDJPLNGAZI%2:'O>1UP$O^9>PP
M,N5Q7SS@>+E&?#\#^="Z@6/<[9GW(2I:D<$MX? S>A)NJ*G%0MZ!))7V*Q"4
MZ!#4PZID=E%HCD>TL0I""#H/B^!2TVUDX4.P35OW:P@.;'Z2IBY8UKKRVG85
M?'F5*H5'6W>N:$1;O>$>#M1_(-ZG>['KN2S!OJ.'QCQ*#UOC]EQQQ8T:80)U
MM80-@=OHQMV*$TKQ[OAUW.V3.)5AMX0ACDLD/6I#=V0ZDF&02Q?:7,>^,L<Y
M&/ #;!KMG_AO/E7"R-O$O8&0G43+ZKW/C:29HUEQ+QO9?6Q9$9-X#5J+!#\D
M.S< G0LZ _<@3'Q#3VT-[(P/$-E>P,%]_:)!F3']BXYM).>H/1ZN(=LMW!S+
M#E:U)K*LV8:$W5W(S_:@0^WMVS)2^KI03/;U"W@-P9R<;&N>>;@I%AI&IMO@
MS]S)*2$K33$ H54CKY@CW934:J^L:_TRF-$9S.B;_9VT=V+:'LNUYO<_V_EI
MVKA//AV8\N9SM5Y'YJQQK552D(15NJLAYP?<'6CD5:Y6KB[*I<="GLDT&H6S
M=H&\80I#_E#DB<FH.M0L8&^'"F2LGITCP#?'.%H)R9-87G_]XLEIZBA&9SR$
MRTQBGW7ASI<Z5-:J-%D2_D-IAG4Y8O+>&&(5$,^&&W(D()S&7)H7''PMC?V=
MKU_:GD8T](K;#EA#TH]',_3&6 1X,G^\$8SE'C@>.4(,)W(;:Q(40"BOB\D2
M1S/P[35N64#,,9]->^-H2UMA&:7GV03K.J&V+^-D!9A.Y-M9WJM/OWXA2]L'
MR0 >,=1NFTJ/Y+)AJNC+($%,&#=X ,'G].VPP[@KI?S!Y%FA-9]E2WWSA>_S
M2NI8.:G01SC3$9[CD]KULZ:<;4YJR>[UEG<"<VL$)9=?&"VY_FNM>?;G4RW.
MSY3"]$!\0R$J9(]1)P12QQ9%I)!KS4N]6K$@<D_Z0QR)R,HC$H_5^HLC#-L1
M"<3PS\)MLN&@-T=N;YIXF*+_N:0%S[D$7:(U;_2JZL^Q/)G&.J$JK6R\-2\H
MD_N<(MXW[CMP56MW$Z0I.B!,OD>JJZ*-9,0ODP>&,M;/=5DN_=MA2-P>I>IK
M2M)7!.UJ]<ZQ0? ID3]XCMM2#$C@4@$ZCCCQ)E[1 CT9I.^&'85*7R8#/LK'
MMK<V<0-O 9],<;1T=+]M!3^$@#/BZM+$IU?;A:)=C P=K)(@0]O6UPUE_/39
M$WI#2:N1]3-:%\%P9X/04DJD3HQ4$]V;Z<;5=;G8*+EUSEM!WK_Z.1"(B_5%
M&;/:.[Q&3&13<9'EQ/T&6J['?W%?_--JKDGM]OVFW7^<7K?/&_^'5G6QZ722
M37';2O3"X\45+514--++#3<^.W2*V'ZEPP[^;6"N )8EGLR]]J5R?V@DM9Y#
M$XO 1U<-[ ]@%!PIL F>9]-Q?A^.#.EHLH&/AK)KK#J[?:V\I#)Z]YR/YD!F
M%5D^F6!38N)HS.JC.,G:WO^E1=C;Q?664T_YG?J5@7SW)4:L2.E8OG,7&RG.
M83O/LPS^1@BBF*X3/H<EV%@BQJ:W-O[8"XF^K+. 1,HR5>O::CSHY?Y'ZC18
M/) 9$H@98FPBMJTS182:"ZIGOT,<2C9H^IK>1E)$ALE-]OZ/)S1]34XG+:).
MH$144"FUNHJ7G29"HM)\?[XUBBXE!-G:(2)URSS']?!'PI <R_.I;72TRRS-
MX*<6W_G4*/\FXF55F&:3YFOR? [B4)Y.L2*W52SZS,L-0[%YA)\F6X?R;> .
M$Z(? 51D:TGG-2VMJXA*;]3V$=?1]I?P0A61/N1B;"JQBP\2\B'XRD[/(5">
MZYMOZ?NGVW$N?W9G<+@VY1*L*&Z5@IL;>&QIX<&UYC.SFNMD!H/,\X&IG#M<
MEQ1;\[Q^5Q]>*W$Q<>"MLZ< +Y(:O]2?&K_CU?A%=-=2,R#YVYK55$FS,EJW
M\#XF\T.VWX-Y!=$NR[3FW7JB4LT_)--"2/=BXMI[L51K_CK*IP>%A]<I_^U'
MK5ZM%>K-%R93R3.%^X=2#;((/N$=V5J$K[L=BP<Y+<\92?ILVE8?E.M),H1[
ML1_V*W$L4K;?Y[T*6\HNEOX_>V_:G*C:+HQ^3U7^ ]5[/:?6JF-<@#CUZM-5
MCHF)4]2,7RQ45"*"87#Z]><>F%104%#2W6^]>^_51N&^KWF^U(!S8P[SZ5\>
M^%RF<K\>4MECY]//'.^EG_Q/.NY/.BXXH._DZ1+QS"^8IPOG .?(TY4U&1BJ
ML,H)[= :#F%?BTTF!)6D<Q7?#@'([N%?Y5>=U8S3!QCKO?KF5< 7&^@BYM>-
M<:,O=V*^ODPLRUSR^-C;_JOL\^#THW8/GO3HH<<Q)IF*I9GC0I_NF$S[QN3V
M*NJ@,5DJ]$I]>=E_>V?/BDGJ3)C,4)E8)AM.VG SQLHJ'.[^Q\-X=(_@Y$ Y
M<Q[FMXU:U"]2L=W#Y/ODT[@WI1NSI]%%^-Z8'KSGD,?G$QDJ$<O0AZ8)GPF)
M1_&]-R0^Y4>9'#\CD]GT15@^1"0F@=3.GK%(P,$0J+&B-H0C!U _@N7MH X=
M28(C%<^7:RF<UW+8N+OY3?"K#KZX08$=\E-[D>77>2*\=/?IUH6WVQPO;S(4
M"?['3UXP:/+(G-<<\4H>]<[;$[TN/%8Z7*3H@SHO?9 ,'4L='&-]NNGB4BGA
M&MXX61L>*Y76[\O2^E-,\LL[RDQL[#OK)6R4XS,;J0P52Z3]9#8\0SQQ)*.O
M6ZE[\:U#Y2<S-GH0/[E,B0'. 9/.7M)<P 4,;+^O334\CWL VRW[O&T9,![#
MA3XXGVZPMP3FK.,5;:<#_RUP\#\ NG*V0[JBTJ&HHU1EWY>%U7"1ZFT5=7B&
M28AE!4%=/)P"R'26B3'D00,BG(*0?,CTH0N@885[Z73FXHAF?S?Z.+ED.D'1
M7DK6_=:IV,67<VKGO)4IGK);>I'$8%G=J%81QEP_5QMS>6L9RIXK??_^6GS]
M_CV1R:2RZ0/;4#U44J"DE/Z,&X7KW_#+&YQG^DZ J]'\LB<+9(HA4?]!!KBV
MT!K4\V)G F[6!W!M;*OT*F2#41X*#.<%L.$6I>P[=QB<1Z$B%<97]-BA2&5O
MB4JNN\Y.U*;*IWO5CQ.[%_V5J%127&K27Y*-S(G3WVSU(\'GR*W:@\80-MUS
MHJ*7!2)I79 456F/69G+PT;O)KM"T2<O;;\G/KF[9B;4W4JZ3V2KIPXYUBL@
M&-<*"("N5&M(M[+/HVDK^^UGN],H/-SD<^U2D2@T:LU2O9WK5!KUT(L@@IN<
M,&85 H\7@R($2!->A$E:V%X_ _P-# -82T"35))HJP#>1 -/Q(3,#R>[*WC.
M)S :_H9?U/=SH._#KQB[:&+Z8VB*:$Q%OJ<I1 F_KV*^#WY_ZRG@ZYM/,0:8
MU27QIC2="=(*G+R(QCS!40YV D*_Q$L/[)?%$_[Q4&>94U3 (=#D4=#EP-\Y
M]%1]0.Q PW,H"7;!R@.\TD=5B,*8YX9$:<GU-71RG&*1(SG-,X<*0G82_@@A
MQI08R9C))Q$S3>Z/X9J>3=K/DO9<F\6/=H"C3Y6<IHXE&8Y_0(MS$-%@FH'X
M4 #0Y#ZO<$TX/:L%!V\ ,04.UA@V-!5M$>#%$?X^<IYG_*"KX2<[!U3!0^N
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MA9S-KF/BE-,PV6!#^^>06P&JXLK=\T2\Y5]'=ZE(4,]7J?_U*YE"TFW'2*8
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M6;GRQ2ANXR=Y8W9>G@6/ P"'"N W%_HS35B\WG\4"O2'.ZT9V0C@Z(/?.FH
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MJ+!F1Q)ZV$YZL$?4+9B0B%PP87W7^JS>JN-^^W/B7JJ P6DX[TRFYMEQSY+
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M79Y6BM62<DO5CZTQLUT.+:/\LJ5ENRIE,>95SJ&>Q:WP95^JT]=OCECXZ%8
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M9FCT]=_WX _,=TESV+1/+'2Q<F/,\\1C.N'1M@ERVPKO'99K/=]RK67,CB@
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MGH+B@%T^WUV_E-FGI^?U3&UDO.L_XXN;6^FSMLFSYE9Z].&WGYM1<2B0OD<
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MB9W9MD&'CJ:O(QD\3SVY5V[[#X_OZ3NR%_34D\"W5N[*<C/'4V-530;_=^\
M5>: 9CKP- "L-??"YSK,F#IQPJS^ K@KU6GD&=ZB'/J<"[*[;@[7ZF>NF7YA
MAL<.3IWNOXM.T5OD<>)%(I8<"BKI8@[$A/,PH96S?Y*D?S_DB*D+7A2R+7GB
M?1:!+YT3_L$/-2OX.+;WDC1_&7XS<TC&T] & Y(SX7Q((]/E=2!#8M\.5U-U
M9PZ9]J8 ->;@%36N#L#=67#"G*NAW=)0J=O,K=Z@57H15A_#$6OJ<7BO[0FX
MJ70\M9VS\[C(Z+ASAE,UD(TER4/5,]O((>.TU\'+'G!8.E2DXAUWQ;RL*.FG
MY&=O/^KH.+F3;SV^G./,. -7C=&.#O<>1&1V\_+'97W!^9F0@D][Y:U%+YZ-
M)AM>H KK+*0M<AG*U5DVT;F7^+2=7@YUAX3(\_HY+\_JH<>O+7P6??"_,QX_
M%^]RMI_\;#/]D/'H\7R79_LCC8(@PNW@JLG+2HA#^5M7S(UECMNBK127NE\F
MFYKP-K'3UN&^^7!E!#SI;R4E#K8:>,#EL)5,J])C^?ES'#(N/9_PRTD*7W(@
M=5DYD#Q2#I0E3=XB'5&HK"J+4:%>SMA)Y_ :\E#% #SH;R4%_/@*+I@LRB^O
M^;*ZF.73(6/2ZP&_G P(V%I(?TUKH<S/MQ7,2VJU>)LH]\5UPDY;AT<OA"LE
MP$%_*RF1\"LE=C%9'A=:RFNN7GQG0L:DUP.&@<%4,I8].$TK=$.A,^9DCAVJ
MG!R0(#@VUGV K-)'"(H<O)8+C?5&"?DYEU$&.4M:6+ (-*P<J$S9N%,89$G'
M$@DJ1E*'^E-/$2TAT4C>A^C91QN/Y=>F1D^4M]SP7+3AK<P2'&]_+U8$; K<
M3@@>H:?/N8&>!9SIP+^LP4%:<[*\LARZT1:)5)O]]H/07G?65M3KX,V#TU]H
M9:NO\X=B@\0R=":63 1HZ0:%YOPVFLV=0M:*5*^X3DX*:WZX&+TT/RZ,:S^7
M"&4 4#(32U_:9MDN3:,R>'X\!-%W@I_.-!6MD\.KB:)MU>R0Z28W5_!EC#5+
M71X/T[+19J.X+,UEKOVQL"KZG0$1AMIR&;+D*IVV[A,&B6;H;(Q)9$\DT:-F
M6!U-!<G]PNHP%>3&\_P3E2LV'ON1I(*]]PG%MTK%J("((%P[Z<"XA6#EU=9,
M +>3;8\9<*[X<!URO.EF/;?R_&"UD%*3+=VY<_/]I.GI[+_&O.# /:N3\7YP
MML\6UN_$ 5/^>![W^T(TL1ZQR2!'64R>BWHGKZ,5*[TUWM+C0(MZMU\;?)%O
M1>Q+4Z[#+@]NL=L8/[7O9]VU\*(R]*@WO*W3IX'C1^]GO=$I$2E"=\F)K9):
MFNZNV0]&I.7I;55DOOTLEXJE5JY*Y.I%HMW)@=]6ZH5&K41T<J^EMNG1]X+?
M0QA2%;91^=L8%J3I3!*A ](8FO O+6><J'!Y3N2&O+JW&MN^A?"$IW;7(Z&T
M:D_[&E>C3D,O?A^ALDN"PV^$(%-X!=I3TA!MJ\8EV4![A%647>JNE=HCK]5F
MR5YK?&Q1]DR6X%> &(2KMWGS8N?>-<@$LVO0J4YVNPW2Q_@\YX5_*;2$D*2
M9+&M(]0*'^UEGGTF.U;.,HQU@R6T;M!\N][FDGU>OJWG=\\%6WU^N(L%0P2U
M1T?$I4#;J(OG!L90GNCL(/1\MN.V$MKS\&B%+1SU+P'4N4C( F!37M0 \^K&
M+I!B&RL 9L]W]<?2';T:']H!X(D<T)EL4N:[3^@?1T_'CE&U&P[ZS,\-H.Z
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M?W8WJV:LFIYVJQ4EJMT!A(R$X#;QH)]TN22HRTCYEY#U5HX7$=>!"R""EYM
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M$S9\P;2_X=]#UWS%B_%\XK"+_P-02P,$%     @ R81H5NG0E0_Q$0  8,
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M]WT50!48R#QA&6=!#5(%)L#HJ6$Q/(1AXD9JX<IJJ\*P@Y<I R>QV&8U5&'
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M8-_K_"/N<#M)38_R[:7S:W*PY:2F2.D65+$>T1D-_@^O^N"3_P)02P,$%
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M6JV4C\^FIA> :"'&:_LD?D?N[5V$G-X#"NQ;-%I1RHFN;=_..;%#=]Z[":.
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M]I(CRN7CHVI<7K?7=B^G.IMSD"$^?]:VMB>VB7LRN-6LM9:XE!VJZVC(W,Z
M5+]0YCNBUD7-;'K<@G+)X@;H-<^[V'\M,MG3T:5IC3I,+^&CY%6J)-K#M.:L
M+IK<)J4?/!8GO1D[TZ;J6)+-OUCY++DIWUWY+%/9::1UZ<IGF5X^J]'EX565
MS])VUZ9VQ#][ZW:U3.S]X.D>T5=53]T'UT&^,[$CU@&*ZJFUW0Q1=XS2#,L@
M-35W/U>'[M^P1X;QW.A9@Y[F)^\TM3;3C#M,DDKYUDO)6E26B:'3W%UYMW\A
MV%V,3-I>1=))E>D[M=V!;<U$#ZIJ[ V?]ILJM,]0L"RK$I#EMY(Y6ZJ;"GD%
M*:2V6^]2/\:)&_X\"Q :^A$*4!@U:/K+IFZI>JIG&:2E^B[S9Z+-D1VMPCI)
MLT>LI-DP'K9+G^W29[OTV2Y]MDN?[=)G]>?)=.FS9AW[=>FS9N9U[G7ZK*['
M!79(GV6^'[!_T>QT[S!>1603X#NN?YN48%7@+D-371_)7^_V=*?*9E%[SON*
M=&Y%X =/Q*MS0W09N',5491J #H-W8EQQGG"NU+_G32,PJ%_B0(7.YSB$@HF
MZ_11F$G[=VP';CU+256T;LH#\0IU53;SS#O(H][Q, Q7R#F-"P4EE"1)Y=F0
M])H8AZ&*E<=JH4;5Y,'^':CQ/HTU@;K7MTHX6JB0&O@G<.YFF#)S>'"&@P6*
MJQ-NN*#.2RR9[!6J95TF0;KWR5C=XWV ):1J6DHK(GF%6JN$@Y!*?S96I<5,
M"CU_4QVB+$SU"I6R'HM8Q]9[KW9Z8I2" #H5W8EQH.*V)$BYQ8'XCZ=VA#:Y
M<4T%,+E .D66PD!0H;5%/GM>/&Y:?*# #YHP[(<,/13KWS[UJ4(W*/6ZL4(H
M!4#V"><QE#L@?:(6*8A*!H&:5#>XJ%Z36%:^ ?UB3M]IW0YL W6Q;FQ0D2Z6
MG$*JTKNRJ3H=$V01J$]UXWUU]4G>26%M/9,(X;7IGW36@7I9-VC'2N"L=-X(
MJE?UD=JF)74Y  K[%\,6H4IG><K6H6HHVJ9D.K@'*N@7L[RNDN,155Y7V52O
M3=5JLPA,Q9-]":3A\S9E2UY5'*]-$]7P#U13V;=HFCG>4+44BD[_VI12*MM
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M$HZJE*YLJD[!A#@D^X1&?S7-VDHF$<(K4S[9G)-] ".ME":H6]5':IF*U&2
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M_RH[^8VFD#O[\-NGWZ%*RW+UWR;+U O(D/BP6S\ED2#[%%?*%@DD$"L><$1
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M(.BD@U 0.D.53G^E6JA2*W?"G##IQR3:QKF7LKOD*:]G$LC998X 9ILQ'2%
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M$) +Z0I'-2^I"ZR 8?E@Z)S3.6+H-**64-B_V2ZZTNZ<ZXU=@CLO7:0LW6S
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MU@?297]C#C5_PZD?9L*PH@%V "R"U6YJ[^[PC#BG]:'(A<O?[88PO)SYDGE
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MT'JJ;KDJ=D;.TKX>M.F9 >;^:%FH?/W;RLCO_OTW9]]_\V?"6*\T0A>FI16
M'*7)-V/RH5#XXI)"QRTK.?#E=&PHP.=A'VR7@'O>?5VIT=XR+!5W !G'5C_[
MEJ5/N[ZBX]%;X(ABU.YHP6>A #$GOVK-OX0](K#O^-PO6/MNW:5XXX5!M>"I
M'AN* _6>R5!C;OEJXK"<PSJ6X//:P N-<9_2?E-8K'8#BTEJT1: [-N(YSIW
MWF[0#+76@S$][;BA-S<ME0 OG/A(95UP/?W<%"H J3=?;Z)DA_%]$3UWLU_-
M:9>+S(1;0JJ=DW-3K ^8IDK0(L9^_=O*R.]*\J9;'%#N$A3%\]QUC.48.Y)3
MS6N+)^+R(506Z@.8Y8K=TICL]I4!,UB.6#WG;6Q) >3HK&A7#<>JZ4Z],S>$
MNJ9FG4\5!A2"<B9A8!,P_P<YHIB'L*Z\FA,[;Q7Z(7H'Q_A!#;X\+.@2W$,?
M9KAY;SFP:,O'A_DENKXU#K5TR=KB[:010HBEA@"P6,-1#39+K(#IDP=#5X40
M7]_^.'^ QFNRH*U2COC_V(8I)GX'6^HBEF[!:>C99*VV&TV2*I6@[:'I NXR
M\8Y@>?'HAEBR0IOR>6*VJ,/5\\3PB'@=Y\2'\"DR)&)?SRD116Y(B=A5 D]$
M 6 I$<-:!\KN+&E./L8!>R&Q?LM;JS?44+3*0FU'6C14:H$9I+6A]AA8*B):
M8*WX3J#]HOYTY.#Y#-2)YF$3S*-8+HEQ*Y=+(*>5 C>OPMB+_1&62U)# %BL
MX:@&FR56P/3$@Z&KEDM7U[>SVPM@O&Z..U4NFL7J(EFORR2F&N.50,_5_$#J
MAFAZP%4"PTE=I/+)09T!CDP.,,MQ,5W2FPI8A7:6[3/9727I/E%=Q^,!^C93
MW1B[U<QRHZWLG'=#$7-RVZQI+D*6MZ:F7R,U(6%B5!N9B(WG29HF7^@CF:SY
MQ %^(JO!&/=>R%9*6V.:&G+-*[$H#!8I\?72N]0*9:_54)F((=7J?Q&KV"&2
MM,8,.=2:%7PQ*+LN:HB]@:P4IG<8QR3$P?.G8EJ(;^CIY%T:DAGBAJ:X+M *
M1G.%CLUYDQ;\YIQ)J@"%7R9@94Q;%?HH8F?/522&^QAX_27*P6L<J(O/PQ:=
M1[&%(L8MW$*YNU_\>'TYOT3G/\-<;E(_Z?_1%'NO7H39G:@JOR']818'[3\T
M)(L<J_T0$S_:TDQP\S>?7>^[)]W"?+7"PBT8VR!LMB W!=QLA781P&K)3GSG
M]0:7\XO[^>QA3O=36<\PN[TL_C'_S\?K'V<W\]NEJW1?93ETO)^1/C!-=\11
MEA9<Q"RE(LPW/,V@<W<2>35X@L[GGZYO;VDOO[A"/\]G]^^S4@%FC#4#;E"E
M<_)7C<JTDT9JN]D46S5>5.7/O(Y72;IF.S:JW*:ZVE8339FYU,H\I:?J?.-E
M&-Y>;JJ&-FJH3;5I3*? ]/I<(Y]^=I6D HYIZMC;'-:$O]\05B@X9Y$)RE[W
M1C/DL:N+ 5-$^0M&.^RE&2(\@I!;(\<TL3IUC2R_!.VG)V7WG@$78OO:0$O$
M.6/DN/I!_844 #+4&:U4?.@+6KYZ(@#:N4S2D0)$# $TSH6/T9*%C;)I08?.
M*A=I'=H2!YP]FLLP\Z,DVZ98,3LZW*SMC84Q"J$[]S_$)AA>C^1(;P;FO^!@
M&[$#>V+ZE(VJ]464$U1_AX7XU5]"^T\=/-(*)FO<( 1)IEE=)6O3-6T'ZOF:
M4L,Y&XU@RIX6]YO']E[6RDSKO#=N/+UU)EKWM$0</8QVQNOQFK\[YXL$E D[
M&N$<9&X_8CS'X9GNBY05=.&21*&OD:->HF UN[P2>"LOO% :#,64$'NYV&L%
M5&E >H!ED3Y[<?A/1O.+),X(Q(#]CW,O"S,:O(\SNG'"_K3-0AJK<(DS/PW9
M"W]D7M OD25^R\\C<<CEQ-^TR6\KQ==L(I-^$$PKL^%E[[1IMGR\G],-Z_*:
M\^+V@6UL/SQ^_CR[_YG^\G#]Z?;ZZOIB=KM$LXN+Q>,M"^^_6]Q<7T XE:[2
M(NZTUVY2#;M; DKH[;T!H3@8%JLQ]G<+2@VT5X$T6G \4G7V<A7'#)-VM3)Y
MR!Q3=73T6M+M<G'_LW,ZW947^^X(OIQTVO/J;I^BT]+0LWQG0\^-SIT-N1(8
MBNDBY=S98'HGB&FRK9U:%U*O)G10OY<S,P&"G)J]H(D^?,KJ]Y)W]W0:N/R9
M30%I6,/=9])K.N?JW@&V+U;O9I5Y!2^2+,_8PTWL*:8J!EC1GQYJU.K3-*,4
M0.OAFH,L@N'\*&[T-NZIPBE[! R5*FB6IC1\#UHOKNW_>=-_5<=^L%60;4->
M!(,:!]_D\;4.J1^]YK%<7/SM]'Q&+_Q?+#[?S6\?V,:!\\; ;HJHNOVND$VJ
M\@$VF=>6 $,D+JS>*W5,"%+O6"!:K&YPEF&L/['5T+-/&PTW^DR2* $CEQII
MCV\T1!["]F,9%6.P_2C1<!*1I+O]*!0'0R8U1D&P$E$!N__8<TF]_RA3<4PQ
MQ?ZC6!XRR52=U=7\<GX_NRG.5I:S);W;0R9/<[2<_1> 3NP^S'ZEJ9T?286F
MN1?&&KF0%#HV6:8%OTDSJ0(8GNF@[+WA2778MF-+"U*'=D$K-,[38BU"\.IW
M;'JJ5B,K#9QI14]JZ($AH@'8+A\_S_[?Q3VZ>"2KQL_S>_<]'8VK"_-B&R@F
M2V!V7(YCWRCVU\R&73H.<*_-2P,#@ AJCIJ7[JBTP?K/EA6@<T,MO]6=JID1
M<'Q6=+0F%HZ+T:K.E\PP/U\OZ1E.$=5SL6"Q._-;$($[S2U)=K4^#U/</K!2
M=\3Z%BS3UM2U#F=UU2$1UA!S;^I:JZ!S'.-5F(.:MMX1[PK?V ,X=PD!5B.N
M !N<G@\V9_4D_4"G6Z?J VV!H?B!#G3Y/O]\=[/X>3Y'Y_/;^=6U/*6'G>-$
M_*3?^8J$K1[^20&WSO2XDF"H)877?V_V*0<Z(6W[H3QH%DF[XY#\8)@O"I1%
MJO[G<GZ^1(OSF^M/1>"W<_+<>CD[JRXO22:Q, ,>1]!JICLAT%9&NYX4&*((
MH>E<$'#.D_)"1.>ZPZ[X3U6?HZMLDT]F#C4YIJ<)AG=&<'NYA6</UP^4BG?W
M\P>RIH41=<+/)*7'14U=VYD"M-U1IP*#2D03M-K9OYQSL;X8H4<_L;B3*RH:
M)!/)6N75*TZ?D@S?2$^(I3CAWD[IOIQV%<9ACF_"5QP4K@@=5NI93K^DYT8G
M(9-<"4SOI8NTS[/E[/;3]?G-',T>'N8@>JPRE$*WQQ*).PEJT>JQ^+* N"0%
MV*<0H+ 5X947/3;IJX.XO*3!-EU=:..E(>XCN;>TCZUO'HXLJNOZURRH@G3:
MU.M,.KP.LF0U=<YP5UL9=LS-0*/R<!>.YJ+%W$MC^L3/'4Z9MWJ]K5++)E\U
M76AR4Z$"9D#7P\G+.W^S>'A I".E;/N\N$4/?YW=SYVS[3'#B]4\R\.UEPO?
M1.D*V>02'V"3.FT),$SAPNH2X_&!;?_21UT_SY;S!_HHP?*O\^J%DME-$<_\
M&<0&R#TFZ^XMIH^5T9 9>B;V4YB_7&RSG$QR4[V.RM2(U4CG00ZV0I^-+(#A
MZB#8O0B3^8_SV\<YNI]?+#[=7H,83(MK3\4E*#U^2C7L7DQ30F]?21.*0YO$
MJ:$"O8UVB[\T#E?2)";_]%E\2F9R2&9NQNY#8\.<;#\W9F8#3$<X$'@O16,C
MD]O]XI;\^Z(8PVGG2/[[ABRF+Q=WR_GE1$F(14[<)OG/.)\%R2;'0:<,3!2M
M)2,V<J1.2*REY9QTQE#U:7:[6**?R:)C))8=W'->>6'*7OWY3'K];1'39])E
M&NA;?2/4U*W6>Z&ZRLZ).A1Q[Y[F[/H>_3B[(9/$SV1$?[P'LK"Y7F^(9]2;
M17H99ILD\Z+%ZB:)G]FI3W$,I'F&,LB4U?.5 YQMG;T,L .&R0> [YW9?+XC
MM*9$IBOYF\7MI].;ZQ_GEU . 1O'E]V3S=DZ2?,R*>[\C6ZGXJ5'?E7VQ@>9
MM/R(\\'.=]YX'FP/#/E'<$+V'(?7L(%P8<1Y*Z@ +E;='5P:->?/XN RC+9D
MJJ75  9;LWIJ=)C+K9.C8:; ,/XP_#*RQSA'89'D9(/3^@$(:GJBI=W>EUN<
MEQMWV?GN$TZ>4V_STCWDU-2QMJ#3A5^OY50*SDEF@E)%I;341$\[]%SI NH\
MZ]"[BVV:DG\9]I8J=3?=HYY3_/Y0KNN<FP,!B[/(DX+-PBS/"&'=/U4I#&P9
M')L$+2II6#P2//YI0Y5UD)O2"$L@@2L+SEFX;UN]=)^S+UX:L#>DBA"5C.Z>
M%)>XLVR[+OYFV(>.\Q$W/>V8!<3OC\?X IA6,XE;LA:6AV0>R[(YEV^8)84A
MD&VL&0'6+(GRB<?=X'9E:MAU6QI6$*KV8V85=)L9Y(JLG62YEV^S*5N,<O&G
M[]V,]!>!8F-C;.,.EI,C%0AGW7F@9>=-8Q)W9,TCC%=)NBXV #=%FD3VT'U2
MM0Z4;'/2AN* _!G^V$+_FLVV^4N2AO_$P2,ID[117"S6^'PW?\.I'V;X+@U]
M?$_?,SAX[!GAPZ#&IM$*TFCL.OBKT.*GK'E\Y%-%ED>(7T0#YX@#++II@(-=
MY[<L8W-PF\Q05XYR.IA[;U7F++(L3/R0ODQ"(WOO<9:39D_^%^L7V&JRJ7CX
M9'&T3X.92HY<F-H3S9&^"Z5).O#Y'<U5N:5UAU/F!.%W.?;38EGL<9L-=^-^
MP_U%R0.+1WV%<N 'G"\,I_1*NI&_M\P&2YA-K>ZB'N-7TNO@H-/W/,:D=[I/
MHN@J26G)&,XE!UIU,Y\\J CX<\I!)N$TF5'\Z#:2Y0M&*Z*3?&%C$%5!V7:]
M]N@Z+D-DZHJ\HM'1K.FD#9$6DZ)MB0"E-81R]NG1+Q>"5#?_@J-7C-9D?'W)
M$-O;09?8Q^LGG**/9R>(-H(3=KQ&_G7V>^=MD-T1HB_I:;4MH;3U]\3$D'NO
MB/5%P7!<CD_6P?MD&$EBENR?_*^(V@$3"5AF98R?F7OL/ZHL+1H<T]:VR3E#
MEYH<U%0%PTDSO%*.>MD+6I&NMK4$2(O7.^G\G]'6_7Y6V^,!#RZ:&'#'6M,G
M&/6U@7)WP*.,A+X!+NG[Y$5L_IR]8!:""IG"A9^=IAMZ3V%$5@^?:;9<W;7I
M($OV;VT/<K5_F]O(#!B:#\<NZZ[7A2*=]]93BJBT&@+@^'Y!<%%/?FBT99G_
MK;Q,46YJ&2X5!UATLTP<[#I_B6AL#DP;.-P'12#D:T@?RV KN_+Z0>Z]@6H&
M\]4*T[5J/3][NR?#TCVFA"*-5GW,,(Y)1S=N!CLON'9C; ]@4QCLA*PMI"WU
M8D<?9'NXQ"N<IC2:YJV\:Q<'-_L!S+ I&%ISTPH&N<QO $:F ')_"'[]'9:@
MM$Y)CSQFWSGSS6Z9WA+?EVQ[\C/;G104Z*%&X=X]%A7 \-O'78M@6L4H;G0;
M!^'?QR/C_,_82Y=?DE%*J;8%E^$==X<3NS1TI'QNH^?0^-MCI#'Y,AZO> IK
MP*G<=/E ,E-3QTSG!GX.H;\[0D)?D2(=K7P*8[#IW'3X,#932T=,Y@9\#I>_
M/T8N$]GQBH<9 \[EAL,'<IG('C.7]_ Y7/[#D7%YMLIQ.BJA.Q;ALIKK^G!J
MM\P=*;]Y/G#BJ5+L44$9U=W4\BWF/J4LU_CE Y0P;D.\O9I)<B^"F2KL)QP^
MO^0XF!'OO6=\NZ7A<66@>M8(?RU21\F?\1YHRV9'=)"[3>8.,@2F\SD$?9?<
ME2U4&D,-?518E";/L5_;9?JSGK<&]2PR8;G+&E#'2N3=^FU6)TOUYGZW_3KV
MBWR\7G3!<M"5(?MYGH9/6Q9)O$PNO"BJKGC'P4]>FGIQ+MIJ/\BBY0<##W6]
M\Z;@4'-@B'ZX#SW*,\&2[?2(-=H&U,Q$%QNU'.A$W'?*X@ [UJX<'N)F?7]P
MB!'G3#T4>>_QF>[5A\DIJCMAX#FNKVN-BJ;NU/33581!.4.T79K]^V_.OO_F
MSVSQXF@"UTU@*YN1BV3AK2*52'LOZN$<14F6L:R[HZ3;/7@*-HOS,*!32;(6
M?L!^&:TZ?Z/]$ Z*M[76&]*ML2<K>YF(9VOZ#HB@?$:R;7-:-FIQ-%D]BF'G
MO=$4WL@G;;BT.=630V,X<L;KL\>R;._1HE&+8O^JT2AFG3-_?%^4DT&#%C!A
MCUBE!>=U:M5O\(;F'K)^:1<"S@?@?;2E.-TP71 H@S55ZFZB:?6<XH?/RG6=
M=PD# ?=>JB^53A!38Q?9:T7T=Z;ZW\YI*G3M)HSQ=8[7HATY'4406<M[CFAE
M+:^UP-!1&ZHA$:DZ8OKNV5BM@._Q)DG9ELL#?F8O$ H*1:9@]9U2)?#6BZ1"
M:3!L4T+LK8&9 DM 5PHZ9].%E[T\DID:O<T<2%>T7$F;_)% ;1*'(P:&,6)L
MO9<7+Z\OBHP'VTJ>'KYO 3R?( X@>,SP:AO=A"OS8)^F*HRHGKXS>E$?>STP
MM#, V^7A/,O#-<M.L&6B*")6ILJ.V0P:HI=OV]$I_*T&E8J]/00]\/O- ;F\
M<_(8@.P]<RS7<MZ#":>)R@Y,2Q/$E%[>?6FH.2>@.5:]S@OPRT3ULUT_)>FO
MUS'QW,<9/>R_][Y\)HZDH1>)PS^T=.T&>ABXTP[IT% $0U 3M+V]..\+S912
MR# V?B%&3L/X=%.8@<-).HO(7G#P*4D")0D[PDY8QP7,I5E+$AZO>/!Z"X92
M!CU3(3BL^90FF9(MI9 3EK0 <MG!)."QH@E+^/[C"6)B</A0/WMVCS.<OF(E
M-S@*3G@B!,[E3$_:#G_^5/ GQL]TVB,[)5(B[5**9@G[@6:LI4)%*MNGC'PL
MQRBL;#FGF7"N*.N&5$H@YO/";DJN :;;TH+)OW0"=+(^\_WM>LM2-U[B38K]
M(J,1^3=I%/1UDCAH+H2%!2"*,QG-O-4@HI$+I15'-))M:%WQR'[Q.VYO_Q$4
M-+["&E7S6I?S=J5Z:F1&X]Z?61AR=K[C/[2J%S9PL'U(C[49%XO)FVS:QL&,
M-V-[),OMQ;1/F3IJ?@,U/X*>=BW!\D.(?0E,K(.RL$1E=:.(A1C#L/N7:884
MA/HY&A.K<!K86*[T6I9&:U(TIAM \1J#R^G*"U.Z.,.-!\+I57H:)GD9OH8!
MICN,N7"8F_Z[1]$>38MQE.:J^]'C;\V&GG8;>R6"=B&.#HYTA]E8?TS(M)LE
M4[?=7+M?/OH&RR_*R9ML^[/ON]%R?>V=K);"Z+66?E]MMW/MT'X35@ XVI:L
M5;"3-6CIU]]GN]9Q690/Y=0K\Z&\UV;>G:F4\J,O8LV^?;2-6U6<UN;6U8??
M9Y-6>"L<K(-2WOUQ,//U25T<3R;%L<3INALD:N.#UIOKI 77:Z.3? U6PYS2
M16%KS(D0^FT8HQWVTNQW,-KD6%W4?9C]>I5B?!T3-W&6VYHV\[][M .JK!@G
M&TQY'X757BUXV@O4)**G*R*+4B)TO(VU3"#6R)Q3W$H;N[C%WSF*QJ@JIE$:
MG^@C5AO;!J=A$CSD7IK+@A2F<E*6JM'+T1-^#F.:2>(]M;C.DGS^AE,_S/!=
M&OJC#Y*F7S_2UJE3I!.U6=FGWWE+UG#]7Z9]?V+9.*_C.U8+LGC32;YT3.U6
M4E1CME'.9XY_&JOTK=O@F.3A2<2F;U_","RNRU.,H6,B -4>QR]:HW8ZWN>A
MY=JR[_J YCTE\VBVMFNRH,;!Y38EPWCA!W,Y8S\NJIVQPI6 2R!C*_"RKAW@
M0W^'L)0X_CZ[<L5IMVT(XJAZ[D$%/&KG;83@>.9?4[A]Q U=41I72;K"8;Y-
M]^4QT<27^R50379X48VY^.%\YG@:WV#?>K?B"\EC:&&J#H?CM(O!U!@&J+8Y
M42&/.J :8@ W$7;C_Z"6#WB8<'3R9'==5>Q8SV/I]=CIG%3L36/VK^/G#]2S
MD??--2W7#V8@C+F+WEJ)WG"=--B \QU0LX^AQ31FX^Q]Y-VL"D2>\1]9H8]+
MU/+OLZTY"#/0_OJ1MDO;0ZGFI]]C&QX26]!OV4??GJ4'1.S'2R_'=7"CE>-F
M#13'U+X'%O%TH0I*".^FO0_S6_A\=W5=;444T"O5H.E9DK);>"Z.2E' SN=0
M_H)1L2APWDG,(F:W?-*Z5Y[TRD"<B=JVKK+5-&!&#K62?&EI0MOT,D+=2WA"
M3X=/V043Y#<3GN!";:)L^Z/OJWSH%,YD7[&6TW^Z(JJ? 1C_$Y!B3J=UT59L
MZ?0-2#;9G;I9*;Y]C(U-JSBG:(+2#[_GAJGC^)$W5T[([21-D_^=HVF&LF(:
MK<GQ/@)E3CBU@Q,%> ]M->-%N YK3:-^'TXKFZ!8]5O?B!\_KE8YON.66ZMQ
M%#*_T0TQ8Z_M#'=RWP3,;<!B\F#\DP6A3C6 &$7:3C.&F$(XGF%D6.&.-Y*8
M?1]6$W3B.[CF:Q[--\FJB?\=. WQ@&(:;=7$^\AQ-:GA#DX6&3[5L&<8!CO-
MP&<. DZ+FZJ QQO\3!$<5UN=R'LH@=Y'?$ $*/!V:A<AAGC_BYQVO&.6Z3EN
M);A[HFF[9B#>)%-Y_6_#F6R,7)RCM5;=#Q_7U&)<IZT&B%LYG%0&TEDXN-3!
M<#3M=VCQ3G3@J0;PKMKS0.??79@HOQR+/?_9-G])TO"?.'B, YPVC@#H.Z%9
MJ^.[I^5>S)07J\:LI"QNHUC?";[N/G9\LB)5QXR/_FG@L>)3^=MM_(4"2O;R
M,)KSTT@%TB^(3C]YC]=>2,.K+I(X3ST_WWH1S5/?G0J 0^?^>05G5:)^B\$Z
M-%C="9CR4,XUTLH \O<64!2N@%Q1LU:2+97S*N;SW"/F?&SV?(LKB.^W1]*K
M''?=DAS?OVC?I%4HR@ZJW.T@BQUJ!D:G-/9LL;$QY&"MP_OZT:]UQ$4Z^5JG
M_VE8'8 U?P5K'7#7X,?J$?L%(>L1K<PIC"$=[1QB8.%/-F<PQ -E8Q1065B>
M&MBZCMQM]Y-]Y6A.,<1%-%VTB=T&Y^0ZLJ@='=G]1LWXAJF;%8!QTTEQV@[0
M>=<-<\BP=V3-E7-#=)*FR?_.T31#63%->1T9S$1S:@>/(GIFO'N=P]K8J-^'
MT_8F*%87EY2/K*V.[SCT2\K\1C?$#.!+RIPF8&X#%I,'XP=WRW'4NYS3C"&F
M$(YG&!E6N(XN*0-K@DY\!]=\S:^B3;*6XG\'3D,\H)BFO*1\9$UJN(/O_9+R
M- .?.0@X+6ZJ G9V2?G(VNI$WH-KR./<F)ID4-3_-IQF.W)QVK[N=V2-=%RG
M1]NPM!ZJ==!^K7Y8UD&? ?@R]X1.0KMB!N-VJ85S*!T,1S-<#"U>5[=+W]?P
M,=#Y(VGZ>B]3<%NLMJJUAF;H3-T^-/5 T=H,\WM]4^0Q?L49*00K@5S[CQW-
MT*$LL.DB^ZHOO><X(JZG1QXXI!DF9:GEZ4$XQO9H4KBV@__^%=JN@?]'WJ(Y
M*]0I6Z_T<T?34C4*;<KX0"<MT$&8H**EO9O'2PYJ<%/ @-,0IRMD%\&"Q]EP
M)_,?6(-6N/DC@\[=%Q^S'^1^!DZ#'%Y(HXV(G&\XO[P]L6/=EE)(0AWYVG[H
MO'L_:G]D\GDX#6O\0AUOA-/_]OL:V8S]AM5.S>-3IESZ23\'IQT>7FA3AC,Z
MF4%.-N"I'10&0WWMTPQ%$=Q!T##Z:](UX& L<)KEQ,7M+.;Q?2X)#RN$PQH]
MU)$#PG';.WY70^#IO_HC+F!.B]XQ]8S\ATC(?Z&,YD<28CJ=XUW^D:^NDQAE
MU/8)RMAW3\;,=3[D)O=\O8F2'<:%QU]BG&8OX88Z_>&;L^^XS?D0<S!N=NLY
MK7?#6VX+R.KQ8 >XD6LH9":K*$EUA.24':KT%CNWY7,[1W,S #NZ YSH5O3L
MU0LC=MMBE:2LPNG"P'VFTF&,'E)@,FM6\X,>YK(VR\6FG'=FX^"7C<MEEU8-
MSQ.-R+=)C"N4.'TE<XIL26;#F>?3MGB19#FO%]?1LC:^ZKM0#Z-J%><$,\/9
MR^B\5T19J8GRO2KRB:[[KK,> #XE29#-XD#NL'(VK6O&319U,R?Y"R4]&\[9
M>R#PWAR/FBEO)SQ30X@L4U"L(+E[?O,'!W8M:*R9@=(8@(F!IL,:\P*%)3B\
M/P1^;^+[_)SB9R_'Y<0 T(,;3^J]M"?I.;OR^IRL8['Q=?=Y]R<K4G6*_=$_
M#:>!6O67OV?1N>+I:+OB.O:3-5YZ;^4-P7,<XU68\T@B$+6\[2"K5A7";D40
M2?14R+CO4"5CQCVA&^GUZ>U.*L68>(OSQ:IQZ#I@*-(S"V4&85((NG,)'9M@
MV#V2(_S>J+"+"L.HL'R"F.T3M+>."FEF_P21+]#+ZHUO.&]&=VGB8QQD5X17
MW)RA@L+5T+/9$+3=:#)=J02&RKI(NURM]! MK9*+54(>L%DC#3-&C'IR;?QM
M..%?(Q?GX5$0AA]VWMA<>"M*<W):I3EAL]W3@"YGFQE/G,Z%G6;@=C][/ABZ
M(D7:X3WRP;.">7O/D=\H;I,R<(?Q/ULFN1<U?Z<;[K=)_C/.[[&?/,<T2$,P
MODWX/9NSD,F+K3E[F>QCSAN8+0][RUNJB[9Q6@NVD_O .04Z8"M&')0G?(1]
MHDVA04B.:8/Q@*(><[-Q  PP78 [WY4SLW'RRDWTDK?IC=I9'- ]0+IEL4SH
MGQI97^L#E6M24&&<A;[RJ,$-'O>O?5LL]C$3S0X& ZN?<%@"O?LXK>R4D\8D
M=2<[O-5*7\;:OH4(7KT([ HXYY0,5;>>'R>=+,IVUJP.BA^%6R6V8=C=;W-3
MR.VM-[L8H(1$._9_A-G?A)./(O"5[3(5&T[%1A1O:B 0A1?[K@(Z4O"OG5H1
MSM2Z,J#KH8W02IR58,1K#K,Z\QVYO+4Q1 =VW=G+A*&01!?HO^@TZ5L8@]BW
M[WJ:]"V :=*WH!JD._^/99-L07"00HF?;S I \ZH(1.TN:TD!MJ<1?2EG"^:
ME=#ZAYZE((JH))3#E23-*<%5/.$)VMU^% %M[PMVI<#P1 BM?YF%")[F1!(2
M453\<$0+*1O@D4!5]\6!['C5+I@H7H4QO1M=HSF;/65LM.,-MA)A:Y,N)>!Z
M:B24=,X!+7B];?5"OD&)'YQW!4T?[NGT9[%ZS/ LRW ^6Y.^*_QG*VE!IPEH
M:]OL1@Q=:G8RFJK.Z3<,;V\/I"%"#WI2:N$T69UN"3T]:L1]A'?3P^N8#*3L
M7(O=]] HDYZ&*QX*H(NXUQ$'R3<^QB['*BE$*%;T>U'H/851F(>3G2EV^V6=
MOMOA^*<<]IQ7OPP5?]:SZ@UUSGN2"R][N8J2+_72;>;GX2OCX0TFG1T6S)L&
MZ-OL98S=:FWHZRH[I^!0Q+V#%Z*/-EX8L,1"WCK9QGF&PMB/M@$.R#_8JYMK
M0MMMRG:?Z,#8Z[C<S]O:.Q7EMICH6J!(V-W>4!>P>'^HD@3#0"D\\3Z13XFW
M(LPMKS,E[1TDF#.MTKM%?%-R?V<P,> INYY_B1U23<7ZFF 8:027ORCE,;0U
MAD\U5V-K%9HKYF;?NS9:F&1<-E>W]Q2QN5/[YXCU=9T3<"!@<2=Y Z,K;'?Q
MJKY/*.UN>)7V;@)1YVS2P\=?;W1&4PN+3![M"[:7W;%IMR50=MII21V2=EE<
M3><4&P17M(T+I+.Z2RGY\QU-*I73&/!_;,,-&_O)2B85M#&5DN7L!QH.=%(?
M2#2<L\P()B?I 5-B6>]PI7%"4\>#V$:1.S7S_>UZ&WDY#B[Q)L5^*#L^&&@+
M#CD5[NIS5F#(#I7_5% Y9O&0W <5QG"B=_JPET9!0QPXPV^Q:(-00P\.<QMN
MZ+.4*$$)'3,%K-O-QEC:Q5K:KJ@GO;=$;YNF!)IJGX*C B\\6Q>P_.2\FMSO
M6'71#=I2'VWH@2: +H3KITF9N-LIT]X8@[=PE*'3.:8:<=$X0H@679"TE\+W
M.,9?BA!684B20LMN.)>6"^T@+ZD*&*;IX50$C4(A62N(9._$F=1WL9)]BJD<
MZ#-,I &,8 J8TE$2"KO:C>0RS'QZY'I/IOT&;:NMYKH3XSFAZL6:.M!F99IX
MC[ [TZ:;6,EM=Z9'-9$&3*(IT!YAKU9/-JMH@,LMOL5O^?(+CE[QYR3.7T2A
M&</-N>X%39Q6]8XZMF"2>; ?79H3HGUT3F[N"LJ<U.9FG*]V#4EL:@,:>0?B
M!TE:W8;X,_;2Y9?DP.9<6X'8_W9<'-+MEB:@$788? Y?OW7.5U7;D_-46QM2
MERKAI:8J-#Z:P0;)0Z,F1;YILF!7V ';=S;='-Q[4B/0^#K4 0YSOW/.7*W&
M)V&L@3ZX7E3$4&UE:,PT!0Z2D2;-ZXJ4X@BMM# #M2=M.CFT(Z4VH+%U('X.
M:;]W3EJ=EB<AJ[XZM$Y41$Y=76BD-,0-DHQ&#2M\'6,R6I@!VX,VG!S<@Q(;
MT,@Z$#^'M']P3EJMAB<FJ[XZN!Y40$Y=76BD-,0-DHRZ#6NVRG$Z4C?:L06Q
M+^6Z.Z1#;1F"1N!#G.C%QKW@%'M4T#FG5>U2A\N&-B!UM4KN&AF QMDAX*?C
MJN">GV[#8@&E'4>'&+!VWV^08_6=/R-MYV%U@R&+'ED+RK@5')2QPYM2?U(6
MUG?U"^P#J6AFQ3(?A[C8(:6)"2A=XF'P8;&TW<*NUYLM 5#EI=!MF#TUI_VB
MP EI;]C1@7*5SQ!OEUI4\P<4%K(H+(4M]GK:?%*H.>W7]/@DU0'()QV\A_-I
MPNGX"$DTP%VY4P&592W6O!!E>X&DO1""5QMRF"/4Q0&][27._#1DCRHL5K1=
M)FF;/)R+9R:*UGI<(T?J/E=+"\9*Q@1JEU,-W7UJ0YJ@WOE>ST-.QAB:EH58
MCZYC/UGCI?=6II<]QS%>A3E]R2.,M\3/TN$DSA1Y.P\W:_5IA)$*H?60PH$V
MG9-^9$=ZCS10LS0'*+&'<N_-?7;/B^(^>\O?GJ>"0M+4M9JCUL2=5GY:'44P
M]#1!V\M+6^C6&0T(C\CZW3D1KW! &M&(O?$A!JWNS!_L>&MV.M@:&'(?[$+O
M7E]A$%2_>XE7F+3#0.ZLH(1TE6W2V,RA)F7U-,'0TPAN?TY<*#OG7SD*E$X8
MCOAB+0=CO<H%SB@O4@'#,3V<@I'=T0:*08L7M1E+KVJWMQK)"E:^DZ)"VW^(
MI!IFT%,A^O5O<:'Z.Z=U<Y-DV17Y.V\(/<>K),6UJSC[',9)&N:[:E>53#/;
M5FC^LWSW&><O"?GEE8@(\^Q;_+SEC3A9(W;A=6_3F^@1%M+/4$("R&I0>WN/
M*7'#J,C%*&ADLZH/I$N=+4&SV^N+,VV,_ V;@]HDQ</M>\?X +"V-JY7XGX=
M9^QQ;G:0Y.7L'9=5N<;(*HN(M/&#GWF?JK7QM[>P*,N"L14 +4;EHD:;$)F
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M@:Y)V18WB_Z(CC[E?U;FJZE@A@)'[UD61=#HD@F^Z_5FRY:4.:9GW((:E^I
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M%V&V\51EJJ(_D*52^P\-R2*)0G_1Y4?;@)U%^B_T?=![+\?SU0K[W(-KNP@
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M*_Y,1O@7[D-,0VV!J^ #7-!NJ;75$Y0GZ FC.R\,3M#/V$O1(G9%AR:UA]+
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M6?(2S]<31N>$B..3:#O: !LB8 -02A#WIU90X+@+LB<O1![J]-V+8F9RK=-
M6P]*#>8E3H#@2%90M+OH11:7ZZG([BK"%&;D/;[D'_JJ-XH U:'\H&84 L/0
M*$U++WI,A4JB#T^>]Y)Q18(XVOQD1UK^@]]GC'A1PM:I-A4>D9%MC?,ZFBI0
M<HZ_23;W'>_(A;(;GZV&B@U#J0@48I0ML50<'$C5@09[!<!IX1#A1 PKR'MP
MF[]=K05T5P@**LZ)JUPD";!__ECI_2W_09MII^4/7.^EG_[4^]#;'D_ROU_V
M;_NCJT'O_M\'@]G]X8FHZZPBV_Z,E]LCU G-O#.:C-5Y=5AMG/4Q2TIOEJ%<
M#BO-M16DTB52+C&ZH9)U*]]W0/FH%$?+EJT'5\: 0E1T(L0#,^(A8/Z'>$SM
MU0N$P=N/KSS&UGP'\C<O2&0K;UX?6!TM[3:( UI')$?XR_VW?"\_)[ROCP$9
MD5CMVMC@H:V%EJN[!EL0^=%)VKZUR/NF)F6_%%H"[QHDR.1#!SWWK6_40K,%
MKI9$2^A= WR5G.@$3!AY\?Q%_OR:<4Y2%$?+]%V#"JW$Z'SL20*TM1!3?M=9
M#&02%G#G?<_>I[K-I%;V,.U>3&,O2$OBC:#LI=M)(%X7+CQWJUU']+70<HC;
MV,P0P=''$]^*^3&Y]5_)8L@!#)]\/OUFXFGY,=5#RS=NPQ!,>'2.\C>[PZ?T
MN<.I__3,]] /4=93C46@KX:7I=R&(I#LZ QMG@S<OH (&$&Z.GCIS&VX,4N-
M3DQJ5^;=HN'<9#8HBN.E.K<:*CI9T9G(.F:RV#!SG-O[PT[ .BL\[<M-E/0,
M\ID&'.)(F"OQVNS6A+> EUK]<!>T+4[HXZW08;"'6E<'+V=[70:4!+KJQMZX
M 2?>6CA!P [0<GF\I.]PK.4.4+GD+A##$CZE5\32<J.J@I<F_@!Z]/*C,S2B
M,0&/&VEAO 3R=5G1R(S.1VJ+VHP7906\3/)U>3'(CL[-YB7V*0E$+* -2X"J
M>(GGZ_(%Q@.=N<QH):DK9-/-M9$T?2V\C/5U^8*@@$[5OM\*3I:I'EZF^]K3
M(0@)=,)LIL%#YKW6_!;6Q( FNJ[Y,Z23 \3U9ZR(EW6_T8G20=>@8H8 .6S-
M5?&R]S?CN "C@\YC05#0W(F9Y;]QI]()S)UUO+\-^'M;>&.@&78[X.4MW+LS
M!;E62N*]6 #'EQID<(2&_F*1'B)XP<3S%\/PRGOQ^6@N]%?C*034Q7L$H2Y5
M<$30R=N[@&<81;*R>&\JU"5'+;']ZO5SMGJ%Y"EUGF"N7U,2>WY(%@./A>)J
M>'\^3U9)ZM2Y)DN1EE]-+*0NWNL.=8F&(X(^"JNRV1@=F*]"U"5'+7&';4B3
MR54_C@#S&8K&=PM:;!JE'_O&Z"0%]IG$HLQ6PKWKHY^UUT=[_[37Q#^?KY,V
M;+L& 7T3?-U0=DV3QWB9!-4+2>8#;[MF.GP9M0Y>Z,NK)M2Y8!3T5R*7SC]4
M%^MW?D7KMK!ON1Y >'WHT%DO;+?X)#IF*0J+U.*?$):F&0%Y#-25L2_%'L"K
M!3@N$9DEA^DG\3-E_C]VZ[*6P&HE[/NQS1"G L,]PM*\\39D;2I@WZ%MDJA]
M$-PC29^N3255K61M7:"K[21N!WOKK/*"668$:^W,Z0"&-,*[D2QH]TC)>)D?
M7!8?&=W;]OU8VO;=S_JSP=U@Q+=\XYO>>#*8]F?#\0@I?U!VJ6G;/_,>3UD!
MRQGZ2L)$-SAV)9 W8P:H*S[-?<'09Z0K&O&A_(721>K6(>S5GY/HG@;:U5Y=
M!WNK9$>'67IT@KXP&D431I>Z X"]0MB[&CL*)/)UV(.\C7?),U  ,IUIJF!O
M<^R8-,J./I;N21"(IR5(R'L:\!'?7ZS\T!>]%._6Y/W6>$*!];%W/68F:"VY
M'*%QRM'DGQ<YPJ[Y>AK0-#&%D3U#->R]CRUI(!30N;HF'$>^21 H\K\')(4S
M!#IK8;6Q]T2VS-E@@DY@13B+E0P_=Y$M-4II3\$FR9;S6RI]IZL,0+$P=L:B
MFG9(5=X.LSBB(=T7+%=1LX4)J(J=\<B.83 6Z+/G#67$?PJS ]7Y.GUC2SR2
M2,,OGA\*U;PD2UYFYKUKCBQM&D'/C 0GA]:7TA%Z-ST;A_=>0,;+O:QIVY1I
MFGT[L#YZ2J6ZI-H!A,YG>OLYDT^S1!8+H6=7JLN,1%0WX%<*9&!$4P\]+=-!
M)!D!0>>M!F4-L-6:^Z0N6S9$=<W\W-G2-QRN*RH>K$RXG+MSLFQUWJ;3(]&=
M'U*V>1F:1"*+Z'XK6>#H'8F?Z4(DL([B]/#-=$IUI$Z@YXRRLXD1".J\.G,4
M\A%Z24*B/6%15D#/5U5'392"=_H*S8C$$!='J1AZ1BO+O:],R Z/Q,WMGDW4
MHMF=H:Z!G@;+CDJ3Z.AV7;F#EU[DS^'$Y,71DV 9<=;3LB>U<YQ<^T$2ZV(S
ME170DUT=R$M)<G1F?B4BP3=9]%^YQ?5$LO?#Q\M*-*)YAK-O"3T1EMW,5Q>J
MSG!LF"DMFT'/FU6;KWJTJV9<.]N&?^211@35NE%(G$]=%G';U@VAI_1J5V=,
M"#:L-<C1R)KKMGM1R3]IHY+O9^.KO_[[^/9Z,+W_/]X+C?ZU-_C/A^'L-_1;
MJ?62]X"J8R4$R#LW$_<I 4+DY4RCMJ+<K0Q=*V8JB0'V)2J>-R)SP0<E&?*_
M:GP#LK*.<;*G42KP"]TOFO'(!&0*=$57+S04$UO_W8=P(:_615KDDA1BXI'V
ME/O=NJ8KS]=$Y2F*.T:(3MG*.TNY0(6(3_0K?G=$V#UJ3B1%L:]BU&%"*3'Z
MSD^1$\S$BZ$:]EV-.AR!D$#GJYP]RD24JCSV'8PZ#.EE1Z=F[R*HB1=I8>P+
M%G5(T4B-SLB1\I>UO]143/SVTY:]$.;3!>\!BW$3X,*=20>XB_ 9;-SCXPR!
M0C>S)!/7">.23=*.I3E=-@=19"'F&A)&AHLS==IR9J4##>):0+DQT5:[GBEU
M0R3K&W-FZ:S),@0J=)K[B[\G>;#4C"KL9;D(J=3CES1@:TKX"A7Y,<DOIF<
M3,F</H6^7C6.U@'L6Y-@=3HR)=U0P=T0$_\5>0%%1@3=0[<'M8I]4;-993&
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MG23A KI8M/,U-S1'JO6V-EPM^=M9N78.A.R5JVR_KYU7]56PUZ\V5;TX04.
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MWW#.4K,YM%PD[3-M@- ^$N;G;#\=II<^%JAQFWK)1[JM!Z J6C:2]I5B)-V
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MA/W^2N/S0A&@3FL%9 SHM0'> O8;*(U-"B?#OI7*^Z\-&0M92]C/GS0_)Q0
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MW3QXM)6P'J_FYHVX*<=;#Q0O;8M$X'Z8< W,59&&@)GB\):1!RN XLJCU,V
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M,"TQ-2YH=&U02P$"% ,4    " #)A&A6[X9P1T<"  !Z!P  "P
M    @ &P-   97A?,C,M,2YH=&U02P$"% ,4    " #)A&A6Q ^4DY8&  "B
M&@  "P              @ $@-P  97A?,S$M,2YH=&U02P$"% ,4    " #)
MA&A61=CNA),&  "K&@  "P              @ '?/0  97A?,S$M,BYH=&U0
M2P$"% ,4    " #)A&A6S5$7-X0#  !U"@  "P              @ &;1
M97A?,S(M,2YH=&U02P$"% ,4    " #)A&A65=&L9X4#  ","@  "P
M        @ %(2   97A?,S(M,BYH=&U02P$"% ,4    " #)A&A6Y=D\H\>_
M 0 E?@P #0              @ 'V2P  9F]R;5\Q,"UK+FAT;5!+ 0(4 Q0
M   ( ,F$:%;IT)4/\1$  &#    1              "  >@+ @!K<FUD+3(P
M,C(Q,C,Q+GAS9%!+ 0(4 Q0    ( ,F$:%9=<(W701$  "3!   5
M      "  0@> @!K<FUD+3(P,C(Q,C,Q7V-A;"YX;6Q02P$"% ,4    " #)
MA&A6F]5,WE0B  "): ( %0              @ %\+P( :W)M9"TR,#(R,3(S
M,5]D968N>&UL4$L! A0#%     @ R81H5@.3*Z/49P  @&0& !4
M     ( ! U(" &MR;60M,C R,C$R,S%?;&%B+GAM;%!+ 0(4 Q0    ( ,F$
M:%9;Z-R<[C\  "%T!  5              "  0JZ @!K<FUD+3(P,C(Q,C,Q
>7W!R92YX;6Q02P4&      P # #= @  *_H"

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
